<SEC-DOCUMENT>0001564590-21-008860.txt : 20210225
<SEC-HEADER>0001564590-21-008860.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225162004
ACCESSION NUMBER:		0001564590-21-008860
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alector, Inc.
		CENTRAL INDEX KEY:			0001653087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				462702363
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38792
		FILM NUMBER:		21680631

	BUSINESS ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-231-5660

	MAIL ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alector LLC
		DATE OF NAME CHANGE:	20150915
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>alec-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;line-height:1pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;line-height:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><font style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-38792 </p>
<p style="text-align:center;line-height:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alector, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;line-height:1pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:29.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:3.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:31.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-38792</p></td>
<td valign="bottom"  style="width:2.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">82-2933343</p></td>
</tr>
<tr>
<td valign="top"  style="width:29.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation)</p></td>
<td valign="bottom"  style="width:3.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer<br />Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">131 Oyster Point Blvd, Suite&#160;600 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">South San Francisco, California 94080 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> <font style="letter-spacing:-0.1pt;font-weight:normal;">(Address of principal executive offices, including zip code)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(415) 231-5660 <br /><font style="font-size:8pt;letter-spacing:-0.1pt;font-weight:normal;">(Registrant&#8217;s telephone number, including area code)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Former name or former address, if changed since last report)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;line-height:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:3pt;margin-top:3pt;text-indent:4.99%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>Securities registered pursuant to Section 12(b) of the Exchange Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:34.24%;"></td>
<td style="width:26.8%;"></td>
<td style="width:41.16%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALEC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(The Nasdaq Global Select Market)</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font> NO&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font> </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;YES&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;NO&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font> </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;YES&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;NO&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font> </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;YES&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;NO&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font> </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></p></td>
</tr>
<tr style="height:3.75pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under section 404(b) of the Sarbanes-Oxley Act(15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report &#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;YES&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;NO&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font> </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2020 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $1,375.6 million, based on the closing price of the registrant&#8217;s common stock, as reported by the Nasdaq Global Select Market on June 30, 2020 of $24.44 per share.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of the registrant&#8217;s Common Stock outstanding as of February 15, 2021 was 79,584,442. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s 2020 fiscal year ended December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alector, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Signatures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:0.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements about: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our plans relating to the development and manufacturing of our product candidates and research programs;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing and focus of our future clinical trials, and the reporting of data from those trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of the coronavirus (COVID-19) pandemic on our business; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our estimates of the number of patients in the United States who suffer from the diseases we are targeting and the number of patients that will enroll in our clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the size of the market opportunity for our product candidates in each of the diseases we are targeting; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to expand our product candidates into additional indications and patient populations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of competing therapies that are or may become available; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such as orphan drug designation, for our product candidates for various diseases; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain and maintain regulatory approval of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our plans relating to the further development and manufacturing of our product candidates, including additional indications that we may pursue; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">existing regulations and regulatory developments in the United States and other jurisdictions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and the outcome of our ongoing arbitration proceedings; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the need to hire additional personnel and our ability to attract and retain such personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our financial performance; and</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:4pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:1pt;">&#160;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this report and are subject to a number of risks, uncertainties, and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Annual Report on Form 10-K, whether as a result of any new information, future events, or otherwise. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://investors.alector.com), Securities and Exchange Commission (SEC) filings, webcasts, press releases, and conference calls. We use these mediums, including our website, to communicate with our stockholders and public about our company, our products, and other issues. It is possible that the information that we make available may be deemed to be material information. We therefore encourage investors and others interested in our company to review the information that we make available on our website.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines. As a result, we have identified over 100 system targets, have advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development, and continue to develop our research pipeline.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL001, our first product candidate, modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and amyotrophic lateral sclerosis (ALS). AL001 is initially designed to treat FTD, a severe, rapidly progressing neurodegenerative disorder that affects 50,000 to 60,000 people in the United States and roughly 110,000 people in the European Union, with potentially higher prevalence in Asia and Latin America. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL001 is initially aimed at treating people with FTD who have a known genetic mutation that causes a deficiency in PGRN, which is called FTD-<font style="font-style:italic;">GRN</font>. Our AL001 program has successfully demonstrated safety, target engagement, and proof-of-mechanism with a well-tolerated safety profile in the central nervous systems of healthy volunteers and FTD patients in our Phase 1a, Phase 1b, and Phase 2 clinical trials. In July 2020, we advanced AL001 into a global pivotal Phase 3 trial, named INFRONT-3, in both pre-symptomatic and symptomatic participants with FTD-<font style="font-style:italic;">GRN</font>. We own worldwide rights to AL001. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL101, our second product candidate in our PGRN portfolio, is designed to treat people suffering from more prevalent neurodegenerative diseases including Alzheimer&#8217;s disease and Parkinson&#8217;s disease, in addition to FTD. In line with our therapeutic hypothesis for FTD, mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer&#8217;s disease and Parkinson&#8217;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. We initiated our AL101 clinical study in January 2020, and we expect to start receiving Phase 1a data in 2021. We also own worldwide rights for AL101. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our AL002 product candidate is aimed at treating patients with Alzheimer&#8217;s disease and is being developed in collaboration with AbbVie. Alzheimer&#8217;s disease is a chronic neurodegenerative&#160;disease that is the most common cause of dementia, affecting nearly six million people in 2020 and that number is projected to rise to nearly 14&#160;million by 2050. Alzheimer&#8217;s disease is the sixth leading cause of death in the United States. AL002 is focused on modulating check-point receptors on the brain&#8217;s immune cells, targeting Triggering Receptor Expressed on Myeloid cells&#160;2 (TREM2). AL002 has demonstrated a safety and tolerability profile that supports further development, target engagement, and proof-of-mechanism in the central nervous systems of healthy volunteers in a Phase 1 trial. We initiated a Phase 2 trial evaluating AL002 in patients with early Alzheimer&#8217;s disease in January 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL003 is another product candidate designed to treat patients with Alzheimer&#8217;s disease and is also being developed in collaboration with AbbVie. AL003 focuses on modulating check-point receptors on the brain&#8217;s immune cells, targeting sialic acid binding Ig-like lectin&#160;3 (SIGLEC&#160;3). AL003 has demonstrated a safety and tolerability profile that supports further development and peripheral target engagement in healthy volunteers in a Phase 1a study. AL003 has also completed enrollment of Alzheimer&#8217;s disease patients in a Phase1b study that continues to progress.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our newest development program, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4, is developing </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> latest prioritized product candidate that targets </font><font style="font-style:italic;">MS4A4A</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a major risk gene for Alzheimer&#8217;s disease that encodes a transmembrane receptor protein that is expressed selectively in microglia in the brain and is associated with control of microglia functionality and potential viability.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own worldwide rights </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 development program.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also expanding our discovery platform to other indications, such as the field of immuno-oncology. We believe that products focused on innate immune biology will complement and expand the efficacy of current immuno-oncology drugs that target the adaptive immune system.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Immune System is Central to Neurodegeneration </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loss of healthy immune function in the brain, due to cellular aging or mutations of genes that regulate key immune cells, underlies the onset and progression of multiple neurodegenerative disorders. Genomic analyses have shown that there is a strong correlation between genetic mutations that predispose individuals to neurodegeneration and dysfunction in the immune system. As a result of these genetic mutations, the brain&#8217;s immune function deteriorates and subsequently would fail to carry out critical activities, which include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clearing or counteracting pathological neurodegenerative proteins such as amyloid-beta, TAU, alpha-synuclein, and TDP-43; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">providing metabolic and functional support to nerve cells; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulating synaptic connections; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">protecting nerve cells by stimulating the regeneration of myelin sheaths around nerve fibers; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">controlling the neurotoxic activities of activated astrocytes and rogue microglia. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that restoring the immune system&#8217;s ability to perform all of these vital functions in the brain is crucial to addressing neurodegeneration given that past approaches focusing on single degenerative pathologies have proved inadequate to date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the early 20<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font> century, the root cause of neurodegeneration has been thought to be misfolded and aggregated pathological proteins. Other observable pathologies, including destruction of synapses, accelerated nerve cell death, and dysfunction of the brain support cells, were all thought to be consequences of these pathological misfolded proteins. As a result, attempts to develop therapies for neurodegeneration have been centered on blocking the synthesis of, and removing or dis-aggregating misfolded proteins. These attempts have been largely unsuccessful, as the disease continues to progress despite significant clearance of the misfolded protein. We believe that the multiple pathologies found in degenerative brain disorders become independent of the misfolded proteins, and each other, at early disease stages and are driven primarily by dysfunction of the brain&#8217;s immune system. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, the brain&#8217;s immune system undergoes gradual deterioration of functional characteristics as part of normal biological&#160;aging or due to harmful genetic mutations that are linked to neurodegeneration and are associated with accelerated senescence of the brain immune cells. These cells are no longer capable of executing their beneficial and protective roles and instead often become harmful and destructive to the brain. Based on our understanding of the role of genetic mutations in neurodegeneration, we have designed our product candidates to target the mutated genes linked to neurodegeneration, with the goal of slowing or reversing the deterioration of the brain&#8217;s immune cells to achieve therapeutic benefit. By restoring healthy immune function in the brain, we believe we can simultaneously counteract the multiple independent pathologies responsible for neurodegeneration. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to develop therapies that empower the immune system to cure neurodegeneration and other diseases. The key tenets of our business strategy to achieve this goal include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Building the leading, fully-integrated company focused on delivering innovative immuno-therapies, validated by human genetics, for the treatment of neurodegeneration. </font>We believe that building a fully integrated company will allow us to more rapidly and efficiently develop therapies for patients as </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">well as create value for our stakeholders. We are focused on building an independent research, development, clinical, and ultimately commercial organization in order to prosecute the full potential of our immuno-neurology approach and Discovery Platform. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Applying our proprietary development capabilities to rapidly advance our product candidates through clinical proof-of-concept studies and beyond.</font><font style="font-weight:bold;"> </font>We are focused on maximizing the probability of success of our product candidates by leveraging immunology, neurobiology, and human genetics, as well as our state-of-the-art bioinformatics, to enable better and earlier target selection. In addition, we are also focused on a biomarker-driven approach, including proprietary tools and assays, to confirm target engagement, inform patient selection, and follow clinical outcomes. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Maximizing the therapeutic potential of our existing targets and product candidates. </font>Given the central physiological roles played by the distinct targets of our product candidates, we believe that there is significant potential for us to address multiple indications with single targets. Our goal is to expand the therapeutic and commercial potential of our existing targets and product candidates to additional indications, such as immuno-oncology. However, we will remain disciplined about advancing this strategy, leveraging our Discovery Platform capabilities to inform expansion areas of maximum value and highest probability of success. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Continuing to focus on discovering new targets and product candidates, validated by human genetics, to prosecute the full power of our insights and platform. </font>Our Discovery Platform is central to our efforts to rapidly identify new product candidates with compelling clinical promise. We will continue to invest in our Discovery Platform, including evolving our proprietary analytical tools and assays, to further investigate several of our identified immune system targets as well as generate additional targets and product candidates.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Approach </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Role of the Innate Immune System and Microglia in Neurodegeneration </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant evidence in the last decade has shown that neurodegenerative diseases, such as Alzheimer&#8217;s disease, Parkinson&#8217;s disease, FTD, and ALS, are linked to a dysfunctional brain immune system. In contrast to the dual adaptive and innate components that characterize the broader human immune system, the brain&#8217;s immune system consists primarily of innate immune cells, known as microglia. These brain resident macrophages account for 10% to 15% of all cells found within the brain and are responsible for many aspects of brain health and maintenance. As the key innate immune cells in the brain, microglia respond to infection and damage, clear cell debris and pathological proteins, nurture neurons and the brain support cells, and control the number and functionality of inter-neuronal connections. Microglia have been our initial focus and new scientific advances have made it possible to understand how these key innate immune cells in the brain represent a crucial focal point for intervening, treating, or preventing neurodegenerative diseases (Figure&#160;1). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000001.jpg" title="" alt="" style="width:462px;height:286px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;1. Our antibody product candidates target microglia to harness their many potential beneficial roles in treating neurodegenerative diseases.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Scientific Data Support Our Hypothesis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Understanding how the brain&#8217;s immune cells affect its structure and function, in both normal and diseased states, is in our view, the key to understanding many neurological diseases. Human genetic evidence has supported the importance of the interactions between the brain and the innate immune system. For example, 22 of the top 29 risk genes for Alzheimer&#8217;s disease, identified using genetic linkage studies, candidate gene analysis, genome-wide association (GWAS) studies, and whole-genome or whole-exome sequencing, regulate immune function in the brain. Many of these risk genes have been shown to express predominantly in microglia and to control the function of these cells (Figure&#160;2). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000002.jpg" title="" alt="" style="width:584px;height:326px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;2. Expression of genes linked to Alzheimer&#8217;s disease is highly enriched in microglia.<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Microglia have been shown to be key cells in overall brain maintenance, health, and function and are the brain&#8217;s first line of immune defense. These innate immune cells are tooled with &#8220;microglial sensomes&#8221; which enable them to constantly survey brain cells to identify and respond to subtle signs of pathology or dysfunction. Microglia scavenge the brain for&#160;toxic misfolded proteins, cell debris, damaged or unnecessary nerve cells, dysfunctional or aged synapses, and infectious agents. In addition, microglia support the generation of new neurons and synapses and remodel neuronal circuits. Microglia also control the survival and function of astrocytes and oligodendrocytes, the main brain support cells which control brain metabolism and blood supply and replenish aged or damaged nerve fibers after injury. Further, microglia have been shown to modulate the permeability of the blood brain barrier allowing access to peripheral immune cells, to assist against infection or injury. Microglia can also change their morphology, functionality, and number in response to changing brain environment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Analysis of gene transcription at the single-cell level in microglia from normal and diseased brains revealed that multiple microglia subtypes exist which may respond to specific disease pathologies in the brain. Our product candidates are designed to recruit microglia subtypes by targeting microglia check-point proteins that control their survival, proliferation, migration, and function. This allows us to differentially modulate microglia activity as needed to counteract a given degenerative brain disorder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Findings in the fields of human genetics, immunology, and neuroscience have indicated that as a result of normal aging or genetic mutations, the beneficial functions of the microglia deteriorate leading to massive death of neurons and consequently to neurodegeneration. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Hansen, D., Hanson, J., Sheng, M. &#8220;Microglia in Alzheimer&#8217;s disease.&#8221; Journal of Cell Biology. Volume 217, Number 2, February 2018</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table outlines the key impact of functional and dysfunctional microglia: <font style="font-size:12pt;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:508.65pt;;">
<tr>
<td style="width:264.7pt;"></td>
<td style="width:243.95pt;"></td>
</tr>
<tr style="height:10.65pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:14.8pt;">
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Functional Microglia</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:94.3pt;;margin-right:20.09%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dysfunctional Microglia</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:74.15pt;;margin-right:15.81%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.8pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="border-top:none 0pt;padding-top:0pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;border-top:none 0pt;padding-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:5.65pt;">
<td valign="middle"  BGCOLOR="#D8D8D8">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#D8D8D8" style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:43.3pt;">
<td valign="top"  BGCOLOR="#D8D8D8">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Clear/counteract and form a barrier around pathological proteins such as amyloid-beta</p></td>
<td valign="top"  BGCOLOR="#D8D8D8" style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Reduced ability to remove, or to limit the damage caused by pathological proteins leading to dysfunction of neuronal connections and ultimately leading to neuronal cell death</p></td>
</tr>
<tr style="height:5.65pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:21.95pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Provide metabolic and functional support to nerve cells</p></td>
<td valign="top"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Reduced ability to provide nourishing factors to neurons leading to neuronal cell death</p></td>
</tr>
<tr style="height:5.65pt;">
<td valign="middle"  BGCOLOR="#D8D8D8">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#D8D8D8" style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:32.65pt;">
<td valign="top"  BGCOLOR="#D8D8D8">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Regulate healthy synaptic connections</p></td>
<td valign="top"  BGCOLOR="#D8D8D8" style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Indiscriminate destruction of synapses leading to reduced number of synapses and dysfunctional neuronal connections</p></td>
</tr>
<tr style="height:5.65pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:43.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Control the function of astrocytes, the brain&#8217;s star shaped support cells that help maintain the&#160;blood-brain barrier, provide nutrients to neurons, repair the nerve tissue following injury, and facilitate neurotransmission</p></td>
<td valign="top"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Inducement and conversion of beneficial astrocytes to toxic astrocytes leading to neuronal cell death</p></td>
</tr>
<tr style="height:5.65pt;">
<td valign="middle"  BGCOLOR="#D8D8D8">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#D8D8D8" style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:21.95pt;">
<td valign="top"  BGCOLOR="#D8D8D8">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Control the survival and function of oligodendrocytes that provide protective myelin sheaths around nerve fibers</p></td>
<td valign="top"  BGCOLOR="#D8D8D8" style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Failure to support oligodendrocytes, leading to neuronal dysfunction</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Discovery Platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Discovery Platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to: (1)&#160;identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases, and&#160;rapidly develop antibody therapeutics to these targets, (2)&#160;interrogate and prioritize those targets for activity using biomarkers and related proprietary assays and preclinical models, and (3)&#160;clinically test product candidates in genetically defined patient populations that are most likely to respond to treatment. We believe that these platform capabilities provide us with the tools to solve the conceptual and technical challenges associated with development of drug candidates for neurodegeneration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on proprietary immuno-neurology bioinformatics algorithms and methodologies to analyze large genetic datasets from diseased and healthy individuals, brain-based gene expression profiling, brain-based proteomics, and human pathology. These proprietary capabilities allow us to rapidly identify tractable targets, pharmacodynamic biomarkers, and patient populations associated with aberrant immune function which lead to neurodegeneration. Specifically, the three priorities of our platform efforts are: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Target Selection</font><font style="font-weight:bold;">. </font>Our target selection capabilities address a wide array of factors that we believe inform efficient, optimized therapeutic outcomes, including genetic and mechanistic rationale. We leverage our state-of-the-art bioinformatics to identify genetic mutations in the brain immune system that we believe are the root cause of neurodegeneration. We employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations. We then seek to engineer immune modulating antibody product candidates to functionally counteract the harmful consequence of these genetic mutations. We leverage <font style="font-style:italic;">in vitro </font>and <font style="font-style:italic;">in vivo </font>functional tools to validate the activity of our product candidates and their ability to cross the blood brain barrier at sufficient quantities to be therapeutically effective. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Biomarker Selection</font><font style="font-weight:bold;">. </font>We are able to identify and employ molecular biomarkers, assays, and imaging techniques that are tailored to our product candidates to confirm target engagement and quantify their therapeutic impact, allowing us to potentially obtain clinical data earlier than would be expected using traditional clinical measures. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Patient Selection</font><font style="font-weight:bold;">. </font>We utilize genetic screening and biomarkers to better align a patient&#8217;s specific diagnosis with the targeted intervention in our clinical studies. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ gene expression profiling, proteomics, brain imaging, and data on disease pathology as well as our own preclinical and clinical data to continually refine our proprietary immuno-neurology algorithms and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">methodologies. Using our Discovery Platform to identify targets that are validated by human genetics, disease biomarkers, and responsive patient populations, we believe that we are positioned for greater probability of technical success on more efficient timelines relative to historical drug development in neurodegeneration. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Pipeline Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 3. The following table highlights our clinical programs.<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000003.jpg" title="" alt="" style="width:619px;height:160px;"></p>
<p style="margin-bottom:0pt;margin-top:14pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our pre-clinical and clinical programs described above, we continue to expand the number of research programs in our pipeline focused on targeting Alzheimer&#8217;s disease, Parkinson&#8217;s disease, ALS, progressive multiple sclerosis, and oncology. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Progranulin Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first development program is focused on modulating levels of PGRN, a key regulator of microglia function in the brain with strong genetic links to FTD and other neurodegenerative disorders. Healthy individuals carry two copies of PGRN that function together to produce healthy levels of PGRN throughout the body. Mutations in both copies of the PGRN gene lead to a neurodegenerative disease called neuronal ceroid lipofuscinosis, which is typified by childhood dementia, vision loss, and epilepsy. Mutations in a single copy of PGRN lead to a drop of between 50% and 70% in the level of PGRN and consequently lead to development of FTD with about 90% penetrance by 75 years of age<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> with greater than 90% probability. Moreover, large scale human genetic studies have shown that mutations in the gene for PGRN, which leads to a more modest decrease in the level of PGRN, increases the risk for Alzheimer&#8217;s disease and Parkinson&#8217;s disease, making PGRN a significant risk gene for these disorders as well. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthy levels of PGRN are associated with many cellular processes that include, but are not limited to, normal microglial activities, neuronal survival, and lysosome function. As shown in the figure below (Figure&#160;4), PGRN deficiency disrupts microglia-neuronal homeostasis in the brain and promotes neurodegeneration through the release of cytotoxic cytokines and complement factors by dysfunctional microglia. Moreover, these microglia activate astrocytes, which in turn, damage neurons. Thus, lack of PGRN leads to disrupted health and function of both neurons and microglia and if not corrected, rapid neurodegeneration. </p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Cruts et al.<font style="Background-color:#FFFFFF;color:#303030;font-size:12pt;font-family:Trebuchet MS;"> </font><font style="Background-color:#FFFFFF;color:#303030;">Nature.&#160;2006;442:920&#8211;4.&#160;[</font><font style="Background-color:#FFFFFF;color:#2F4A8B;text-decoration:underline;">PubMed</font><font style="Background-color:#FFFFFF;color:#303030;">]</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000004.jpg" title="" alt="" style="width:345px;height:251px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;4. PGRN deficiency disrupts homeostasis between microglia and neurons, and promotes neurodegeneration during aging. <sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SORT1 Controls PGRN Levels in the Body </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human and mouse genetic studies have identified the neurotrophic factor PGRN degrading receptor Sortilin (SORT1) as a major negative regulator of PGRN levels in plasma and the brain. SORT1 is a sorting receptor on the cell surface and on the endoplasmic reticulum-Golgi apparatus within the cell. SORT1 binds to extracellular PGRN in the plasma and brain and transports it into the cells for degradation by the lysosome resulting in decreasing levels of extracellular PGRN. SORT1 deficiency increases PGRN plasma and brain levels by two to three-fold in mouse models, while variants that modestly reduce expression of SORT1 increase the level of PGRN in humans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, genetic loss of SORT1 in mice does not lead to the adverse effects associated with genetic loss of PGRN, and PGRN continue to function as expected in the absence of SORT1. These studies and others have indicated to us that blocking SORT1 with a pharmacological agent would be a safe and effective approach in increasing the level of functional PGRN in the brain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed two distinct product candidates that target SORT1, AL001 and AL101, designed to increase PGRN levels in the brain of patients to counteract the damage sustained due to low PGRN levels in neurodegenerative disorders. Our first product candidate, AL001, is initially intended to target orphan disorders, including genetic forms of FTD such as in patients that are missing a functional copy of the PGRN gene (FTD-<font style="font-style:italic;">GRN</font>). Our second PGRN product candidate, AL101, is intended to target widely prevalent neurodegenerative disorders such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease, in addition to FTD. We have worldwide development and commercial rights to our PGRN product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AL001 for the Treatment of FTD </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first product candidate, AL001, is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion to the blood stream to increase the levels of PGRN in the brains of FTD-<font style="font-style:italic;font-size:12pt;">GRN</font> patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018 as well as Fast Track designation for the treatment of patients with </p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Kao, A., McKay, A., Singh, P., Brunet, A., Huang, E. &#8220;Progranulin, lysosomal regulation and neurodegenerative disease.&#8221; <font style="font-style:italic;">Nature Reviews Neuroscience.</font> Volume&#160;18, Number&#160;6, June 2017.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:-0.01%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTD-<font style="font-style:italic;">GRN</font>. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity. This exclusivity precludes the FDA from approving another marketing application for the same indication for that time period, unless the later product is clinically superior. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Fast Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and additionally, a rolling submission of the marketing application.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview of FTD </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTD is a rapidly progressing and severe degenerative brain disease with no approved treatment. FTD is a form of dementia found most frequently in individuals less than 65&#160;years old at time of diagnosis. Patients with FTD exhibit a range of symptoms including personality changes including compulsive behavior, lack of restraint, apathy, and anxiety as well as language and behavioral problems. Average life expectancy in FTD patients is seven to 10&#160;years after the start of symptoms. FTD symptoms have an insidious onset with clinical symptoms usually appearing between 45 to 65&#160;years of age at an average age of 58. Hence, FTD is considered an early-onset dementia as compared to late-onset Alzheimer&#8217;s disease, and is more common than Alzheimer&#8217;s disease in early-onset dementia under the age of 60 years. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000005.jpg" title="" alt="" style="width:276px;height:236px;"></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 5. MRI of frontal and temporal atrophy in FTD. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although FTD was poorly understood and thought to be rare, over the past decade the scientific community has gained a knowledge about the biology of FTD as well as an awareness of disease prevalence. FTD affects roughly 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union. There are multiple heritable forms of FTD, and FTD-<font style="font-style:italic;">GRN</font>, and FTD-<font style="font-style:italic;">GRN</font> patients represent 5% to 10% of all people with FTD There are currently no approved treatments options available for FTD. Healthy individuals carry two copies of PGRN that function together to produce sufficient levels of PGRN throughout the body. Mutations in a single copy of PGRN lead to a drop of between 50% and 70% in the level of PGRN and consequently lead to development of FTD with about 90% penetrance by 75 years of age<sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> with greater than 90% probability. Researchers have identified over 70 inherited loss of function mutations in PGRN that lead to FTD to date.</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Cruts et al.<font style="Background-color:#FFFFFF;color:#303030;font-size:12pt;font-family:Trebuchet MS;"> </font><font style="Background-color:#FFFFFF;color:#303030;">Nature.&#160;2006;442:920&#8211;4.&#160;[</font><font style="Background-color:#FFFFFF;color:#2F4A8B;text-decoration:underline;">PubMed</font><font style="Background-color:#FFFFFF;color:#303030;">]</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000006.jpg" title="" alt="" style="width:590px;height:254px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;6. Mutations in a single copy of PGRN lead to a 50% or greater decrease in the level of PGRN and lead to development of FTD with a greater than 90% probability.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rate of disease progression in FTD is faster than in Alzheimer&#8217;s disease, suggesting that clinical trials with disease-modifying agents have the potential to obtain clinical data more quickly and with fewer subjects in FTD than in Alzheimer&#8217;s disease. For example, the median survival from symptom onset in FTD is shorter than in Alzheimer&#8217;s disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we can establish rapid clinical proof-of-concept in FTD-<font style="font-style:italic;">GRN</font> patients given its genetically-defined patient population, fast rate of disease progression, and our ability to leverage fluid and imaging biomarkers. In FTD-<font style="font-style:italic;">GRN</font> patients, inhibition of SORT1 through AL001 represents a potential mechanism to compensate for the over 50% reduction of PGRN. AL001 is intended to reduce the ability of SORT1 to bind to and degrade PGRN, leading to increases in the levels of PGRN through increasing its circulating half-life (Figure&#160;7). We have tested our PGRN program antibodies in various animal models, healthy volunteers, and FTD-<font style="font-style:italic;">GRN</font> patients and have achieved significantly elevated, long-lasting levels of PGRN in the brain after intravenous administration. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000007.jpg" title="" alt="" style="width:544px;height:257px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;7. Mechanism of action for our PGRN programs. AL001 binds to SORT1 and prevents degradation of PGRN, increasing its circulating half-life significantly. A similar mechanism of action is also applicable for AL101. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AL101 for the Treatment of Alzheimer&#8217;s Disease and Parkinson&#8217;s Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a second product candidate in our PGRN program, AL101, that targets SORT1 for large patient populations such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease. The FDA has granted orphan drug designation for the treatment of FTD to AL101, as well as Fast Track designation for the treatment of patients with FTD-<font style="font-style:italic;">GRN</font>.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutations that moderately reduce the amount of PGRN in the brain increase the risk for Alzheimer&#8217;s disease and Parkinson&#8217;s disease. Moreover, some Parkinson&#8217;s disease patients have been shown to have reduced levels of PGRN. In line with our therapeutic hypothesis, we plan to target PGRN as a potential disease modifying therapeutic for patients suffering from Alzheimer&#8217;s disease and/or Parkinson&#8217;s disease.<font style="font-size:8pt;"> </font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview of Alzheimer&#8217;s Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alzheimer&#8217;s disease is a chronic neurodegenerative&#160;disease that usually starts slowly in people over 65&#160;years of age and worsens over time.&#160;It is the most common cause of dementia, accounting for 60% to 70% of all cases. The most common early symptom of Alzheimer&#8217;s disease is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, failure to manage self-care, and behavioral issues. As a person&#8217;s condition declines, they often withdraw from family and society.&#160;Gradually, bodily functions are lost, leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is eight to ten years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While estimates of the prevalence of Alzheimer&#8217;s disease vary, the Alzheimer&#8217;s Association estimates that in 2020, there were more than five million Americans age 65+ suffering from Alzheimer&#8217;s disease and that number is projected to nearly triple by 2050. Alzheimer&#8217;s disease is the sixth leading cause of death in the United States and the fifth-leading cause of death for those ages 65 and older.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to its debilitating effect on patients&#8217; cognition and day-to-day functioning, Alzheimer&#8217;s disease places a significant burden on the healthcare system. According to the Alzheimer&#8217;s Association, the aggregate cost of care in 2020 for patients with Alzheimer&#8217;s disease and other types of dementia in the United States was estimated to be $305&#160;billion, with nearly two-thirds over half of which is borne by the Medicare system. Total payments for health care, long-term care and hospice care for people with Alzheimer&#8217;s and other dementias are projected to increase to more than $1.1 trillion in 2050.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview of Parkinson&#8217;s Disease </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parkinson&#8217;s disease is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. Early in the disease, the most obvious symptoms are shaking, rigidity, slowness of movement, and difficulty with walking. Cognitive and behavioral problems may also occur. Dementia becomes common in the advanced stages of the disease. Depression and anxiety are also common, occurring in more than a third of people with Parkinson&#8217;s disease. Other symptoms include sensory, sleep, and emotional problems. Parkinson&#8217;s disease typically occurs in people over the age of 60. The average life expectancy following diagnosis is between three to 10 years after the onset of symptoms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no disease modifying treatment for Parkinson&#8217;s disease, and the options for patients are limited to treatments that improve symptoms. Initial treatment is typically with the anti-Parkinson&#8217;s drug medication levodopa, with dopamine agonists being used once levodopa becomes less effective. As the disease progresses and neurons continue to be lost, these medications become less effective while at the same time they produce a complication marked by involuntary writhing movements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the Parkinson&#8217;s Foundation, more than 10&#160;million people worldwide are living with Parkinson&#8217;s disease. Approximately 60,000 Americans are diagnosed with Parkinson&#8217;s disease each year and an estimated one million Americans will be living with Parkinson&#8217;s disease by the year 2040. According to the Parkinson&#8217;s Foundation, the combined direct and indirect cost of Parkinson&#8217;s, including treatment, social security payments and lost income, is estimated to be nearly $52 billion per year in the United States alone. It is estimated that by 2040, over 12 million people globally will have Parkinson&#8217;s disease.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:bold;font-style:italic;">Our PGRN Product Candidates Development Plan </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated our AL001 Phase 1a clinical study in September 2018. Our AL001 product candidate has demonstrated target engagement and increases in the disease associated pharmacodynamic marker PGRN in the brains of primates, healthy volunteers, and FTD-<font style="font-style:italic;">GRN</font> patients. We initiated our AL101 Phase 1a clinical study in January 2020, and we expect to start receiving Phase 1a data in 2021. AL001 successfully demonstrated proof-of-mechanism in a Phase 1a study (n=50) in healthy volunteers and in the Phase 1b portion of the study (n=14) in FTD-<font style="font-style:italic;">GRN</font> patients by showing a statistically significant increase in PGRN levels relative to baseline when compared to pooled placebo in plasma and in CSF at the pre-specified follow-up time point. The primary endpoints of the study are safety and tolerability. The secondary endpoints include pharmacokinetic and pharmacodynamic measurements, including changes of PGRN in serum and the CSF. Pharmacodynamic characteristics include the biochemical and physiological effects of a product candidate, and pharmacokinetic characteristics describe the time course, for example, product candidate absorption, distribution, metabolism, and excretion.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000008.jpg" title="" alt="" style="width:567px;height:279px;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 8. AL001 restores PGRN levels back to normal range in healthy volunteers and symptomatic and asymptomatic FTD-<font style="font-style:italic;">GRN</font> patients.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results showed that AL001 was generally safe and well-tolerated, with no drug-related serious adverse events or dose-limiting adverse events reported in the study, achieving the primary objective of the study. There were no drug-related serious adverse events or dose limiting adverse events reported in the study, achieving the primary endpoint. Moreover, in our Phase 1a and 1b studies, statistically significant increases in plasma and CSF PGRN levels relative to baseline were also observed, and the magnitude and duration of the effect in plasma and CSF PGRN levels appeared to be dose dependent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2019, we advanced AL001 into a Phase&#160;2 study.  Our preliminary Phase 2 preliminary results similarly showed that there were no drug-related serious adverse events or dose limiting adverse events reported in the study and significant increases in plasma PGRN levels relative to baseline back to the normal range were also observed, and the magnitude and duration of the effect in plasma PGRN levels appeared to be dose dependent. The Phase 2 study also includes an additional genetic subset of FTD patients (FTD-<font style="font-style:italic;">C9orf72</font>).&#160;We plan to continue this 96-week open-label Phase 2 study and present additional data from the study participants in 2021.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000009.jpg" title="" alt="" style="width:555px;height:236px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 9. Phase 2 data shows plasma PGRN restored to normal in FTD-<font style="font-style:italic;">GRN</font> participants.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review and monitor biomarker data from these studies to confirm target engagement and quantify their therapeutic impact. In addition to reviewing PGRN levels in plasma and CSF, we evaluate </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disease-associated proteins, including inflammatory (i.e. SPP1, CHIT1) and lysosomal (i.e. CTSB) biomarkers</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">neurofilament light chain (</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NfL</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NfL</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has been associated with disease progression in FTD patients and identified as a marker of treatment effect in neurodegenerative diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and multiple sclerosis in peer-reviewed journals.</font><font style="font-weight:bold;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have previously reported results from our AL001 Phase 1b study and preliminary data from our AL002 study which showed </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">normalization in a number of disease-associated proteins</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, further validating our decision to progress AL001 into a Phase 3 study.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we advanced AL001 into a global pivotal Phase 3 trial in both pre-symptomatic and symptomatic participants with FTD-<font style="font-style:italic;">GRN</font>, named INFRONT-3. The randomized, double-blind, placebo-controlled trial will enroll up to 180 FTD-GRN mutation carriers across approximately 50 sites in the United States, Europe and Australia. Symptomatic and pre-symptomatic participants will be randomized to receive AL001 or placebo intravenously every four weeks. Participants will also be given the option to continue receiving treatment in an open-label extension study. The primary endpoint of the pivotal Phase 3 trial is to measure the effect of AL001 on clinical decline by utilizing the CDR&#174; plus NACC FTLD-SB assessment, which evaluates clinical impairments in behavior, language, memory, judgment, and functional activities in trial participants. In addition, the trial will assess secondary clinical endpoints, multiple biomarkers and safety.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000010.jpg" title="" alt="" style="width:609px;height:190px;"></p>
<p style="margin-bottom:12pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;10. Clinical plan for AL001 in FTD-<font style="font-style:italic;">GRN</font>. (Figure not to scale.)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential Additional Applications for Our PGRN Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial PGRN program is currently targeted only at patients with FTD-<font style="font-style:italic;">GRN</font>, which is a subset of the total FTD patient population. Beyond FTD-<font style="font-style:italic;">GRN</font>, we believe AL001 has the potential to treat other rare diseases </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that share pathological mechanisms with FTD-<font style="font-style:italic;">GRN</font>. In order to treat any other rare diseases and the broader FTD patient population, we will be required to conduct additional clinical studies in order to obtain the applicable approvals for that specific patient population. We are enrolling an additional genetic subset of FTD patients (FTD-<font style="font-style:italic;">C9orf72</font>) in our Phase 2 clinical trial of AL001 and may expand to additional FTD subpopulations in the future, and we will evaluate AL001 in patients with ALS caused by <font style="font-style:italic;">C9orf72</font> repeats, which share TDP-43 pathology with FTD-<font style="font-style:italic;">GRN</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, polymorphic mutations that moderately reduce the expression levels of PGRN have also been shown to increase the risk of developing Alzheimer&#8217;s disease and Parkinson&#8217;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. We are developing AL101 ultimately to target these large chronic neurodegenerative diseases (Figure&#160;11). The study is a randomized, double-blind, placebo-controlled Phase 1 trial expected to enroll up to 42 healthy volunteers at a single clinical study site in the United States. The study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and bioavailability profile of intravenously and subcutaneously administered doses of AL101. For our other programs, we anticipate following a similar development approach to expand into additional patient populations as appropriate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000011.jpg" title="" alt="" style="width:464px;height:330px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;11 Our PGRN programs have broad therapeutic potential, including FTD and other more prevalent neurodegenerative diseases. (Figure not to scale.)</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our TREM2 Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TREM2 is a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia in the brain. TREM2 on microglia cells is thought to promote improved cell migration to the site of injury, improved cell survival, increased phagocytosis, and increased cell proliferation. Rare individuals with homozygous TREM2 mutations, or mutations on both chromosomal copies, may develop neurodegeneration by the age of 40 with an average lifespan of 10&#160;years following diagnosis. A gene variant in one of the two copies of TREM2 is found to increase the risk of Alzheimer&#8217;s disease by threefold. Not only do mutations in a single copy of TREM2 increase the risk of Alzheimer&#8217;s disease significantly, but Alzheimer&#8217;s disease patients with TREM2 mutations exhibit an earlier onset of symptoms by three years and an increased rate of brain volume loss compared to individuals without such mutation. Evidence also suggests that gain of function mutation leading to increased extension of TREM2 confer a protective phenotype against Alzheimer&#8217;s disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discovery of strong genetic linkage of TREM2 to Alzheimer&#8217;s disease in 2013 was one of the first examples in which large scale genomic analyses were used to identify a rare gene variation and link it to an increase in the risk of late-onset Alzheimer&#8217;s disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TREM2 binds to membrane lipids and lipoproteins such as Apolipoprotein E (ApoE) which are normally found in the brain. Mutations in the gene for ApoE are also known to significantly increase the risk of development of Alzheimer&#8217;s disease and is the single highest risk factor for Alzheimer&#8217;s disease. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AL002 for the Treatment of Alzheimer&#8217;s Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidate, AL002, is a humanized, TREM2 activating, monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion into the blood stream (Figure&#160;12). AL002 is a microglia cell regulator that modulates the TREM2 receptor<font style="font-weight:bold;"> </font>and is being developed for the treatment of Alzheimer&#8217;s disease in collaboration with AbbVie. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000012.jpg" title="" alt="" style="width:232px;height:338px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;12. Mechanism of action of our TREM2 activating product candidate AL002. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no cures or approved disease-modifying therapies for Alzheimer&#8217;s disease, and there are only two classes of approved therapies for symptomatic treatment: acetylcholinesterase inhibitors and glutamatergic modulators. These drugs are designed to help preserve neuronal communication, but only provide temporary benefit and do not slow or halt neuronal death. In addition, antidepressants and antipsychotics are often prescribed off-label to treat the symptoms of severe Alzheimer&#8217;s disease in patients suffering from agitation, aggressive behaviors, psychosis, and depression. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent drug candidates under development for Alzheimer&#8217;s disease include those focused on blocking synthesis, enhancing clearance or disaggregating misfolded amyloid-beta or TAU proteins in the brain, reversing chronic inflammation, and repairing vascular dysfunction, metabolic dysregulation, as well as neurotoxicity. Almost all of these candidates were designed to target just one of the multiple Alzheimer&#8217;s disease pathologies, and most of these drug candidates have so far failed to demonstrate any significant benefit. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although amyloid-beta plaques and TAU protein in the brain represent physical pathologies of the disease and are believed to cause a loss of neuronal connectivity in the brain and neuronal death, recent scientific data paints a more complex picture. Therapeutic approaches that address only one of the multiple pathologies observed in Alzheimer&#8217;s disease, for example, pathology-directed therapies that clear amyloid-beta or TAU proteins, have had limited efficacy. More efficacious therapies will require addressing additional pathologies which we believe are associated with microglial failure. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our TREM2 Preclinical Data </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL002 binds to TREM2 on the surface of microglia and is designed to optimize microglial activity through the phosphorylation of Spleen Associated Tyrosine Kinase (Syk). With prominent academic collaborators, we have demonstrated that AL002s, an antibody that is functionally similar to AL002 but cross-reacts to the mouse TREM2, can normalize gene expression signature associated with Alzheimer&#8217;s disease and reduce pathology in a mouse model of Alzheimer&#8217;s disease. Furthermore, AL002 was shown to induce microglial proliferation, increase microglial survival and decrease dystrophic neurites associated with damaged neurons in an aggressive mouse model of Alzheimer&#8217;s disease that expresses either the normal or genetic risk variant of the human TREM2. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000013.jpg" title="" alt="" style="width:624px;height:198px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;13. AL002s statistically significantly increases the number of microglia around amyloid-beta plaques (left) and reduces the area occupied by amyloid-beta plaques<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> (right) in a mouse model of Alzheimer&#8217;s disease (**** indicates p&lt;0.001 by T-test). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000014.jpg" title="" alt="" style="width:272px;height:207px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;14. AL002s statistically significantly improves cognitive deficit in a mouse model of Alzheimer&#8217;s disease (**** indicates p&lt;0.0001 by T-test). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AL002 Development Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2019, we completed the Phase 1a portion (n=56) of a clinical trial in healthy volunteers with AL002. AL002 was generally safe and well-tolerated in the single ascending dose part of the Phase 1 study. In addition, a dose dependent and statistically significant change in both soluble TREM2 (sTREM2) and downstream biomarkers for microglia functionality in cerebrospinal fluid were observed upon treatment, indicating both target engagement and proof-of-mechanism in healthy volunteers.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Data generated by D. Wilcox, University of Kentucky.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000015.jpg" title="" alt="" style="width:615px;height:222px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 15. In healthy volunteers, a dose dependent decrease in sTREM2 and an increase in an immune activity biomarker was observed in the AL002 Phase 1a clinical study. CSF samples were taken from the five highest dose cohorts. The data shown are derived from analysis of CSF samples from 34 healthy volunteers (* denotes p&lt;0.05 by T-test, *** denotes p&lt;0.001 by T-test).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2019, based on the safety and tolerability observed in the Phase 1a healthy volunteer study, as well as encouraging biomarker data, we initiated the Phase 1b portion of the trial with AL002 in people with Alzheimer&#8217;s disease. Based on the data collected to date in preclinical studies as well as in healthy volunteers, and in alignment with our partner AbbVie, we have decided to close enrollment in the Phase 1b study, which was impacted by the COVID-19 pandemic.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, initiated our Phase 2 trial in Alzheimer&#8217;s disease patients in early stages of the disease. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 study will enroll approximately 265 participants with early AD at up to 90 sites globally. The primary endpoint of the Phase 2 study will measure disease progression utilizing the Clinical Dementia Rating Sum of Boxes (CDR-SB). The study will also measure multiple fluid and imaging biomarkers, and assess several secondary clinical, pharmacokinetic and pharmacodynamic endpoints, as well as safety to generate data enabling pivotal Phase 3 studies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000016.jpg" title="" alt="" style="width:612px;height:156px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;16. Clinical development plan for AL002 in Alzheimer&#8217;s disease. (Figure not to scale.)</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These clinical trials have been designed in close collaboration with AbbVie. Our desired outcome is to achieve informative endpoints to enable efficient Phase&#160;3 clinical trial design and a rapid advancement towards marketing approval. For more information on our collaboration with AbbVie see the section titled &#8220;Business&#8212;Strategic Alliance with AbbVie.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our SIGLEC&#160;3 Program </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large scale genomic profiling of datasets from Alzheimer&#8217;s disease patients has been used to identify the association between certain variants of SIGLEC&#160;3, also known as CD33, and increased risk to develop Alzheimer&#8217;s disease. SIGLEC&#160;3 is an inhibitory receptor expressed on microglia and acts as the brakes of the immune system in the brain, slowing down microglial activity. Excessive inhibition of the microglia by the disease risk variant of SIGLEC&#160;3, which increases expression of the inhibitory SIGLEC&#160;3 receptor on microglia, leads to reduced functionality of the myeloid cells, and consequently, increased deposition of amyloid-beta plaques and accelerated loss of tissue in the brain of Alzheimer&#8217;s disease patients that carry this risk variant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our analysis further showed that the natural inhibitory ligands for SIGLEC&#160;3, which are required for activation of SIGLEC&#160;3, are upregulated in the brain of Alzheimer&#8217;s disease patients, further reducing the functionality of the microglia. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with the genetic findings in humans, Alzheimer&#8217;s disease mouse models, in which the gene for SIGLEC&#160;3 was genetically ablated, have microglia with improved phagocytosis of beta amyloid and displayed fewer amyloid-beta plaques compared to the same Alzheimer&#8217;s disease model that expressed the mouse SIGLEC&#160;3 gene. In line with the findings that the presence of SIGLEC&#160;3 increased the severity of Alzheimer&#8217;s disease, a reduced number of certain disease associated microglia that are thought to counteract the progression of Alzheimer&#8217;s disease was observed when the human SIGLEC&#160;3 in Alzheimer&#8217;s disease mouse models was over-expressed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taken together, this data supports the hypothesis that blocking the function of SIGLEC&#160;3 would increase the number of beneficial microglia and elicit a therapeutic benefit in Alzheimer&#8217;s disease.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AL003 for Treatment of Alzheimer&#8217;s Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidate, AL003, is a SIGLEC&#160;3 blocking, monoclonal antibody (Figure&#160;17) that is intended to be delivered by intravenous, peripheral infusion into the blood stream. The function of SIGLEC&#160;3 on microglia is similar to the inhibitory function of PD-1 on T-cells. AL003 acts similarly to PD-1 inhibitors that have been employed successfully in immunotherapy of cancer. Both approaches aim to remove the &#8220;brakes&#8221; on the immune system to allow the system to work at its full capacity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000017.jpg" title="" alt="" style="width:397px;height:302px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;17. Mechanism of action of our SIGLEC&#160;3 blocking product candidate AL003. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our SIGLEC&#160;3 Preclinical Data </p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The activity of AL003 in mice was assessed in immunodeficient mice containing human immune cells to recapitulate the human immune system as closely as possible. AL003 injected into the bloodstream of these mice blocks SIGLEC 3 on immune cells. In addition, a single intraperitoneal injection of AL003 into mice that express the human SIGLEC 3 in microglia leads to a long-lasting, statistically significant blockade of SIGLEC 3 on the cell surface of microglia in the brain, indicating that AL003 is potentially able to cross the blood brain barrier and exert its desired activity (Figure&#160;18).</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000018.jpg" title="" alt="" style="width:196px;height:224px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;18. AL003 blocks SIGLEC 3 on microglia in mouse brain following injection to the blood stream (**** indicates p&lt;0.0001 by T-test). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AL003 Development Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2019, we completed the Phase 1a portion of our trial (n=38) in healthy volunteers with AL003 for the treatment of Alzheimer&#8217;s disease patients, and reported that the primary safety endpoint of the study </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had been achieved. Additionally, secondary PK and PD endpoints were also met. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the study, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthy </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">volunteers </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were dosed over eight dose cohorts in the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAD portion of the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL003 Phase 1a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">study. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A dose dependent </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and long-lasting change in SIGLEC 3 indicating </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">target engagement </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was observed upon a single dose treatment in these healthy volunteers.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the safety and tolerability observed in the Phase 1a study, we commenced dosing in January 2020 in Alzheimer&#8217;s disease patients in a Phase 1b study with AL003. We have completed enrollment of Alzheimer&#8217;s disease patients in this study which continues to progress with clinical data expected to be presented in 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000019.jpg" title="" alt="" style="width:624px;height:121px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;19. Clinical development plan for AL003 in Alzheimer&#8217;s disease. (Figure not to scale.)</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These clinical trials have been designed in close collaboration with AbbVie. Our desired outcome is to achieve informative endpoints to enable efficient Phase&#160;3 clinical trial design and a rapid advancement towards marketing approval. For more information on our collaboration with AbbVie see the section titled &#8220;Business&#8212;Strategic Alliance with AbbVie.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our MS4A4A Program</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">MS4A4A<font style="font-style:normal;"> is among the most prominent genetic risk clusters for late-onset Alzheimer&#8217;s disease. Risk variants of </font>MS4A4A<font style="font-style:normal;"> are&#160;associated with an increase in the prevalence of Alzheimer&#8217;s disease and a decrease in the age of onset</font>.<font style="font-style:normal;">&#160;</font>MS4A4A<font style="font-style:normal;"> is a transmembrane receptor protein that is expressed in a subset of innate immune cells, and selectively, in microglia in the brain. </font>MS4A4A<font style="font-style:normal;"> is thought to control microglia functionality and/or viability. Our AL044 product candidate was designed to counteract the risk variants of </font>MS4A4A<font style="font-style:normal;"> and to functionally convert the risk variants of </font>MS4A4A<font style="font-style:normal;"> to the protective variant. We expect that AL044 will mimic and exceed the beneficial activity of the protective </font>MS4A4A<font style="font-style:normal;"> variant, which we believe may potentially decrease the progression of Alzheimer&#8217;s disease.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000020.jpg" title="" alt="" style="width:537px;height:239px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;20. AL044 is designed to mimic and exceed the beneficial activity of the protective <font style="font-style:italic;">MS4A4A</font> variant, which we believe may stop or slow the progression of Alzheimer&#8217;s disease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">L</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">0</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">4 </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">for the Treatment of Alzheimer&#8217;s Disease</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="m_2865200430658234997_m_-716178206681664"></a>AL044 is a humanized, <font style="font-style:italic;">MS4A4A</font> function modulating monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion into the bloodstream. AL044 was designed to mimic and exceed the beneficial activities of the protective <font style="font-style:italic;">MS4A4A</font> gene variant in Alzheimer&#8217;s disease, as determined by AL044&#8217;s ability to partially phenocopy the gene expression signature of the protective <font style="font-style:italic;">MS4A4A</font> gene variant and to increase sTREM2 levels in the CSF of non-human primates in a dose-dependent manner. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expansion of Our Discovery Platform to Other Indications </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Immuno-oncology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also expanding our discovery platform to other indications, such as the field of immuno-oncology. We believe that products focused on innate immune biology will complement and expand the efficacy of current immuno-oncology drugs that target the adaptive immune system. Microglia display similar gene expression signature and function to the innate cells of the peripheral immune system. These peripheral innate cells such as macrophages, NK cells, and others, likely play a significant role in multiple chronic diseases including cancer, inflammation, and autoimmune disorders. We are leveraging our expertise in the innate immune system to develop additional innate immune&#160;check-point&#160;focused programs, including programs targeting the Siglec protein family and the SIRP protein family, for peripheral disorders, particularly cancer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into a licensing agreement with Innovent to develop and commercialize AL008, our novel antibody that non-competitively antagonizes combines inhibition of the CD47-SIRP-alpha (SIRP&#945;) pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a &#8220;don&#8217;t eat me signal&#8221;) while also engaging FcyR2A, an activating IgG Fc receptor to promote immune-stimulatory pathways that drive anti-tumor immunity. We believe that products focused on innate, a potent immune biology will complement and expand the efficacy of current immuno-oncology drugs that target the adaptive checkpoint pathway co-opted by tumors to evade the immune system. AL008 is a potential best-in-class SIRP-alpha inhibitor with a unique dual mechanism of action that non-competitively antagonizes the CD47-SIRP-alpha pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a "don't eat me signal") while also engaging Fc gamma receptors to promote immuno-stimulatory pathways that drive anti-tumor immunity.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL009, our latest prioritized investigational product candidate, is a first-in-class multi Siglec inhibitor that works to enhance both the innate and adaptive immune system response to tumors by blocking a critical glycan checkpoint pathway that drives immune inhibition. This product candidate is being developed in oncology and we believe it could also have potential therapeutic application to neurodegenerative disorders.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Combination Therapies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our therapies are also likely to act in conjunction with each other or with other experimental drugs that are designed to remove pathological proteins.&#160;Therapies such as antibodies against amyloid-beta, the TAU filaments or misfolded alpha-synuclein protein are designed to tag the pathological proteins and recruit microglia to dispose of the drug pathological protein complex. Aging microglia are less likely to perform this function effectively, and our&#160;immuno-neurology therapies could ameliorate this deficiency. We are continuing to explore various combination strategies in preclinical models and will, in the future, consider moving this strategy into the clinic based upon results from preclinical models. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strategic Alliance with AbbVie </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, we entered into the Co-Development and Option Agreement with AbbVie (AbbVie Agreement). The primary goal of our global strategic collaboration with AbbVie is to co-develop and commercialize therapeutics to treat Alzheimer&#8217;s and other neurodegenerative diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the AbbVie Agreement, we granted AbbVie an exclusive option to global development and commercialization for our TREM2 and SIGLEC&#160;3 programs. The terms of the AbbVie Agreement included initial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upfront payments of&#160;$205.0&#160;million and $20.0&#160;million from the sale of shares of our stock, and if AbbVie exercises its option for both programs, we are eligible for up to an additional $985.6&#160;million in option exercise and milestone payments. Following AbbVie&#8217;s exercise of its option, Alector and AbbVie will share the development costs and will split global profits after marketing approval. However, following AbbVie&#8217;s option exercise for a program, we may opt out of sharing in development costs and profits or losses from that program and instead receive a tiered royalty on sales of products from that program. We are responsible for the design and execution of Phase&#160;1 and Phase&#160;2 studies, taking advantage of our significant in-house expertise in running clinical trials in Alzheimer&#8217;s disease. Following its exercise of an option for a program, AbbVie will be responsible for certain development activities and global commercialization, taking advantage of its global clinical trial expertise and commercialization networks. Through this partnership, we aim to leverage the strengths of both organizations efficiently to best achieve the desired outcome. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exercise of options.<font style="font-weight:normal;font-style:normal;"> AbbVie may exercise its option for a program at any time until the expiration of an option term for that program. For each program, the option term ends following a fixed period after AbbVie&#8217;s receipt of the data package after completion of Phase 2 clinical trials that includes certain information relating to the applicable program&#8217;s research and development activities. If AbbVie fails to exercise its option during the option term for a product candidate, we will retain all rights to that program. If AbbVie exercises its option for a program, then AbbVie will lead development and commercialization activities worldwide. Once AbbVie opts in with respect to a given product candidate, AbbVie must use commercially reasonable efforts to develop and commercialize the corresponding product globally. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Governance.<font style="font-weight:normal;font-style:normal;"> The collaboration is governed by a joint steering committee (JSC). The JSC may establish additional subcommittees to oversee particular projects or activities. Subject to limitations specified in the AbbVie Agreement, if the applicable governance committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then the issue is escalated to an alternative dispute resolution subject to final decision-making rights retained by each party. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusivity.<font style="font-weight:normal;font-style:normal;"> During the term of the AbbVie Agreement, each of Alector and AbbVie are subject to exclusivity requirements prohibiting certain activities outside of the AbbVie Agreement directed to targets under the AbbVie Agreement. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual Property.<font style="font-weight:normal;font-style:normal;"> Ownership of intellectual property created in connection with the AbbVie Agreement is generally determined on the basis of inventorship. Generally, each party has the first right to prosecute and maintain its own patents. We generally have the first right to prosecute and maintain joint patents prior to AbbVie&#8217;s exercise of its option for the program relating to such patent, and AbbVie has the right following its exercise of such option. AbbVie has the first right to prosecute any infringement of jointly held patents developed under the AbbVie Agreement and our patents that are licensed under the AbbVie Agreement. Additionally, AbbVie has the sole right to prosecute its own patents. AbbVie has the first right to defend against claims that a product developed under either of the programs that are the subject of the AbbVie Agreement infringe third-party intellectual property rights. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Term and Termination.<font style="font-weight:normal;font-style:normal;"> At any point during the term of the AbbVie Agreement, including during the research, development, and clinical trial process, AbbVie can terminate the AbbVie Agreement in its entirety, or with respect to either program under the AbbVie Agreement, for convenience. In that event, all rights related to the applicable program revert to us. Additionally, AbbVie or we and can terminate the AbbVie Agreement in connection with a material breach of the AbbVie Agreement by the other party that remains uncured for a specified period of time.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adimab Collaboration Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2014, we entered into the 2014 Adimab Collaboration Agreement. Under the 2014 Adimab Agreement, we are required to fund, and we and Adimab LLC (Adimab) are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We are developing antibodies discovered by Adimab in our AL001 and AL101 product candidates, and we are developing antibodies optimized by Adimab in our AL002 and AL003 product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Governance.</font><font style="font-weight:normal;font-style:normal;"> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from each party. The research committee prioritizes among research programs and prepares and finalizes new proposed research plans, among other activities. If the research committee is unable to </font><font style="font-weight:normal;font-style:normal;">make a decision</font><font style="font-weight:normal;font-style:normal;"> by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then either party may seek arbitration of the matter. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusivity.<font style="font-weight:normal;font-style:normal;"> Pursuant to the 2014 Adimab Agreement, each party is subject to limitations on its ability to use information or material provided by the other outside the scope of the collaboration. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual Property.<font style="font-weight:normal;font-style:normal;"> Ownership of intellectual property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. For example, patent rights relating to improvements to Adimab&#8217;s background platform technology that are invented in the course of the research are assigned to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a non-exclusive license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research; and except for Adimab&#8217;s retained rights to continue using and licensing its own libraries, each party agrees not to practice or license the patents arising out of the research that it owns for any purpose other than to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exercise of Options.<font style="font-weight:normal;font-style:normal;"> The 2014 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extended to ownership of patent rights specifically covering the sequences of such antibodies, and the right to obtain worldwide, royalty-bearing, sublicensable licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. These licenses are exclusive, except as to Adimab background and platform technology and Adimab&#8217;s retained rights to continue using and licensing its own libraries, as to which the licenses are non-exclusive. We have confirmed with Adimab in writing that key patents we have filed relating to the programs partnered with AbbVie claim inventions owned solely by us, and do not include any such background or platform technology of Adimab. All of our options under the 2014 Adimab Agreement have either expired, are in the process of being exercised, or, with respect to multiple targets and hundreds of antibodies (including the target programs partnered with AbbVie), have already been exercised. Upon our exercise of the option with respect to a target, we are subject to an obligation to devote commercially reasonable efforts to commercialize products using the optioned rights to such target. The assigned and licensed patent rights we obtained from these option exercises are described in more detail above under the section titled &#8220;Business&#8212;Intellectual Property.&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financial terms.<font style="font-weight:normal;font-style:normal;"> We fund Adimab&#8217;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2014 Adimab Agreement. We also have potential milestone payments per program for use of antibodies and low- to mid-single digit royalty payments for commercial sales of products incorporating such antibodies. However, if we enter into any transaction granting rights to the inventions or sell products created as a result of a collaboration with a third party, we have a choice to pay a share of the resulting revenue instead of royalties from such sales. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Term and Termination.<font style="font-weight:normal;font-style:normal;"> We are able to terminate the 2014 Adimab Agreement, in its entirety or with respect to a products or antibodies directed to particular targets, on three months prior written notice to Adimab. In addition, either party can terminate the 2014 Adimab Agreement in its entirety, or, subject to certain limitations, with respect to specific optioned rights, for material breaches that remain uncured after 90 days&#8217; notice to the breaching party. In the case of a termination before expiration of the 2014 Adimab Agreement, we would have certain continuing payment obligations to Adimab, or would be required to adhere to certain restrictions as to the fruits of the collaboration. The 2014 Adimab Agreement expires on the twelfth anniversary of the first commercial sale of the products created under the collaboration, on a product-by-product and country-by-country basis. The licenses we and Adimab granted to each other do not survive, subject to certain limitations.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview&#8212;2019 Adimab Collaboration Agreement (2019 Adimab Agreement) </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we entered into another Adimab collaboration agreement. Under the 2019 Adimab Agreement, we are required to fund, and we and Adimab are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We have not yet identified any research programs under the 2019 Adimab Agreement. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Governance.<font style="font-weight:normal;font-style:normal;"> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from each party. The research committee facilitates communication regarding research under the 2019 Adimab Agreement and has the limited authority to amend a research plan in a manner not substantially affecting the resources required from a party. If the research committee is unable to make a decision by consensus, no decision will be taken. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusivity.<font style="font-weight:normal;font-style:normal;"> Pursuant to the 2019 Adimab Agreement, each party is subject to limitations on its ability to use information or material provided by the other outside the scope of the collaboration. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual Property.<font style="font-weight:normal;font-style:normal;"> Ownership of intellectual property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. Certain intellectual property relating to Adimab&#8217;s background platform technology including any improvements thereto that are invented in the course of the research are assigned to Adimab. Patents covering antibodies that are the subject of the collaboration are owned by us; however, prior to our exercise of the option described below, we are prohibited from practicing such patents for any purpose other than to perform our research obligations under the 2019 Adimab Agreement. Upon the expiration of the option term described below, in the event we elect not to exercise our option right with respect to an antibody, ownership of such patents is transferred to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a non-exclusive license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exercise of Options.<font style="font-weight:normal;font-style:normal;"> The 2019 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extends to ownership of the applicable optioned antibody, and the right to obtain worldwide, royalty-bearing, sublicensable non-exclusive licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. Upon our exercise of the option with respect to a target, we are subject to an obligation to devote commercially reasonable efforts to commercialize products using the optioned rights to such target. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financial terms.<font style="font-weight:normal;font-style:normal;"> We fund Adimab&#8217;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2019 Adimab Agreement. We are also responsible for certain development fees and, in the event we exercise the option right, we are obligated to pay an option fee. We also have potential milestone payments per product for use of antibodies, subject to certain limitations on total payments owed on any given target, and low-single digit royalty payments for commercial sales of products incorporating such antibodies. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Term and Termination.<font style="font-weight:normal;font-style:normal;"> We are able to terminate the 2019 Adimab Agreement, in its entirety or with respect to a products or antibodies directed to particular targets, on 60 days&#8217; prior written notice to Adimab. In addition, either party can terminate the 2019 Adimab Agreement in its entirety for material breaches that remain uncured after 90 days&#8217; notice to the breaching party. In the case of a termination before expiration of the 2019 Adimab Agreement, we would be prohibited from using the fruits of the collaboration. The 2019 Adimab Agreement expires, on a product-by-product and country-by-country basis, on the later of the twelfth anniversary of the first commercial sale of such product in such country and expiration of the last patent covering such product in such country, or, in the event no product is optioned under the 2019 Adimab Agreement, upon the last to expire option period. Upon expiration, the licenses Adimab granted to us with respect to products for which we have exercised our option will continue on a non-exclusive, royalty-free basis. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must manufacture our product candidates for clinical trial use in compliance with cGMP regulations. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and FDA or comparable foreign regulatory authority&#8217;s satisfaction before any product is approved for human clinical trial use. Our third-party manufacturers will also be subject to periodic inspections of their respective facilities for general cGMP compliance by the FDA and other foreign authorities. These inspections may include review of procedures and operations used in the testing and manufacture of our products to assess compliance with applicable regulations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have the infrastructure or internal capability to manufacture our product candidates for use in clinical trials and commercialization. We rely, and expect to continue to rely, on third-party cGMP manufacturers for the production of our products for human clinical trials in compliance with FDA and other foreign authority regulations for such products. We rely on CDMOs to manufacture and supply our preclinical and clinical materials to be used during the preclinical and clinical development of our product candidates. As part of our broad manufacturing strategy to expedite the manufacturing of our product candidates and minimize manufacturing risk, we currently have established relationships with several CDMOs for the manufacturing of our drug substance or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have long-term supply agreements and we purchase our required drug product on a development manufacturing services agreement or purchase order basis. We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We have personnel with significant technical, manufacturing, analytical, quality, regulatory, including cGMP, and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of our products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any approved drugs and we do not expect to have any approved drugs in the near term. Therefore, we have no sales, marketing or commercial product distribution capabilities and have no experience as a company in marketing drugs. When, and if any of our product candidates are approved for commercialization, we intend to develop a commercialization infrastructure for those products in the United States, Europe, Asia, and potentially in certain other key markets. We may also rely on partnerships, such as our AbbVie collaboration, to provide commercialization infrastructure, including sales and marketing and commercial distribution. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our strategy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates and related components, their methods of use and processes for their manufacture, our proprietary reagents and assays and any other inventions that are commercially important to our business. We also rely on trademarks as well as trade secret protection of our confidential information and know-how relating to our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proprietary technology, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">platforms</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and product candidates. We believe that we have substantial know-how and trade secrets relating to our technology and product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio contains over 40 families, and as of December 31, 2020, our patent portfolio includes 11 issued patents and over 300 pending patent applications, directed to over 20 different targets and/or technologies, that are solely owned or we have rights to exclusive licenses by us. For our product candidates, we generally pursue multilayered patent protection covering the composition of matter based on binding epitopes of the product candidates on the target protein, functional characteristics of the product candidates, degenerative sequence of the product candidates, and/or specific sequence of the product candidates. In addition to composition of matter coverage, we also generally pursue claims directed to methods of making, nucleic acids, formulations, and methods of use of the product candidates. The method of use claims further include claims directed to patient selection criteria, biomarkers, disease subgroups, pharmacodynamic and clinical end-points, and dosage regimes. As further described below, we intend to strengthen the patent protection of our product candidates and technologies through additional patent application filings. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PGRN Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own five patent families directed to our PGRN programs, AL001 and AL101, which include three issued U.S. patents, covering the compositions and uses of our PGRN program product candidates. The first two patent families are expected to expire in 2036, the third patent family is expected to expire in 2039, the fourth patent family is expected to expire in 2040, and the fifth patent family, assuming that the necessary non-provisional patent applications are timely filed and all other applicable requirements are satisfied for the U.S. provisional patent application, is expected to expire in 2041, in all cases excluding any patent term adjustments and any patent term extensions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">TREM2 Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own six patent families directed to the TREM2 program covering the compositions and uses of our TREM2 program product candidates. Four patent families are expected to expire in 2035, 2036, 2038, 2040, respectively, and two patent families, assuming that the necessary non-provisional patent applications are timely filed and all other applicable requirements are satisfied for the U.S. provisional patent application, are expected to expire in 2041, in all cases excluding any patent term adjustments and any patent term extensions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SIGLEC&#160;3 Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own five patent families directed to the SIGLEC&#160;3 program covering the compositions and uses of our SIGLEC&#160;3 program product candidates. Two patent families are expected to expire in 2036, the third patent family in 2038, the fourth patent family in 2039, and the fifth patent family in 2040, in all cases excluding any patent term adjustments and any patent term extensions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MS4A4A Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own two patent families directed to the <font style="font-style:italic;">MS4A4A</font> program covering the compositions and uses of our <font style="font-style:italic;">MS4A4A</font> program product candidates. The first patent family is expected to expire in 2039 and the second patent family in 2040.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent is in force. A patent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it, may be extended. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar provisions are available in the European Union and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and other factors. Expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be available to us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk2362091"></a>Competition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries, including in the neurodegenerative disease field, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Some of the pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the neurodegenerative disease indications for which we have research programs, including FTD, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and ALS, include large companies with significant financial resources, such as Biogen, Eli Lilly, GlaxoSmithKline, Merck and Roche Holding AG. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, method of administration, cost, level of promotional activity and intellectual property protection.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates will compete with current therapies approved for the treatment of neurodegenerative diseases, which to date have been primarily targeted at treating the symptoms of such diseases rather than halting or slowing the progression of the disease. However, in addition to such currently approved therapies, we believe that our product candidates, if approved, may also compete with other potential therapies intended to halt or slow the progression of neurodegenerative disease that are being developed by a number of companies and institutions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Drug Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA) and biologics under the FDCA and the Public Health Service Act (PHSA). Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any future product candidates must be approved by the FDA through either a biologics license application (BLA) or new drug application (NDA) process before they may be legally marketed in the United States. The process generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Submission to the FDA of an investigational new drug application (IND), which must become effective before human clinical trials may begin; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Approval by an independent Institutional Review Board (IRB), or ethics committee at each clinical trial site before each trial may be initiated; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (GCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Submission to the FDA of a NDA or BLA; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A determination by the FDA within 60 days of its receipt of an NDA or Biologics License Application (BLA) to accept the filing for review; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Satisfactory completion of a FDA pre-approval inspection of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality, and purity; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA or BLA; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The data required to support an NDA or BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all.  </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as<font style="font-style:italic;"> in vitro</font> and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Trials </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2, and Phase&#160;3, and may overlap. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Phase&#160;1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Phase&#160;2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Phase&#160;3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of an NDA or BLA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug or biologic, findings from animal or<font style="font-style:italic;"> in vitro</font> testing that suggest a significant risk for human </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">volunteers </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase&#160;1, Phase&#160;2, and Phase&#160;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the consequences of the COVID-19 pandemic, the FDA has issued various COVID-19 related guidance documents applicable to biopharmaceutical manufacturers and clinical trial sponsors. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the clinical trial, and any disruption of the clinical trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19-pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the clinical trial. The FDA also issued a guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug products manufacturing, including recommendations for manufacturing controls to prevent contamination of drugs; guidance on recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products; a guidance on drug and biologics manufacturing operations during the COVID-19 public health emergency; and a guidance on review timelines for applicant responses to Complete Response Letters when a facility assessment is needed during the COVID-19 public health emergency. These and future guidance documents and regulatory requirements, including future legislation, may require us to develop and implement new policies and procedures, make significant adjustments to our clinical trials, or increase the amount time and resources needed for regulatory compliance, which may impact our clinical development plans and timelines. The extent to which the COVID-19 public health emergency impacts our business, including non-clinical studies and clinical trials, will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NDA/BLA Review Process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity, and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#8217;s 2021 fee schedule for prescription drug user fees, which became effective on October&#160;1, 2020, and will remain in effect through September&#160;30, 2021, the user fee for an application requiring clinical data, such as an NDA or BLA, is approximately $2.9&#160;million. PDUFA also imposes an annual program fee for each marketed human drug or biologic ($336,432 in 2021) and an annual establishment fee on facilities used to manufacture prescription drugs and biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA or BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase&#160;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA or BLA approval, but ideally no later than the pre-NDA or pre-BLA meeting. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Abbreviated Licensure Pathway of Biological Products as Biosimilar or Interchangeable </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, or ACA, signed into law in 2010, includes the BPCIA, which created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">animal studies (including the assessment of toxicity); and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic) sufficient to demonstrate safety, purity, and potency in one or more conditions for which the reference product is licensed and intended to be used. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, an application must include information demonstrating that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for the reference product; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure, and potent. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. In addition, the law provides for a designation of &#8220;interchangeability&#8221; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the proposed product is biosimilar to the reference product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the proposed product is expected to produce the same clinical result as the reference product in any given patient; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA approval is required before a biosimilar may be marketed in the United States. However, complexities associated with the large and intricate structures of biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#8217;s implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion over the kind and amount of scientific evidence&#8212;laboratory, preclinical and/or clinical&#8212;required to demonstrate biosimilarity to a licensed biological product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA intends to consider the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity, and recommends that sponsors use a stepwise approach in the development of their biosimilar products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical and clinical testing used to establish the underlying safety and effectiveness of the reference product. However, the FDA may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate that any impurities or differences in active ingredients do not affect the safety, purity, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or potency of the biosimilar product. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure and preserve the biological product&#8217;s safety, purity</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and potency. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The submission of a biosimilar application does not guarantee that the FDA will accept the application for filing and review, as the FDA may refuse to accept applications that it finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose to conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for 12&#160;years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer undertakes, studies on the effect of its product in children, a so-called pediatric extension. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first biological product determined to be interchangeable with a branded product for any condition of use is also entitled to a period of exclusivity, during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use. This exclusivity period extends until the earlier of: one year after the first commercial marketing of the first interchangeable product; 18&#160;months after resolution of a patent infringement against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; 42&#160;months after approval of the first interchangeable product, if a patent infringement suit against the applicant that submitted the application for the first interchangeable product is still ongoing; or 18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known as &#8220;off-label use&#8221;, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fines, warning letters, or holds on post-approval clinical studies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal of the FDA to approve pending applications or supplements to approved applications; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">applications, or suspension or revocation of product license approvals; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of products; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other U.S. Regulatory Matters </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency, and state and local governments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">storage</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Patent-Term Restoration and Marketing Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office (USPTO), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA), or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union Drug Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA), and one or more Ethics Committees (ECs). Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. Recently enacted Clinical Trials Regulation EU No&#160;536/2014 ensures that the rules for conducting clinical trials in the EU will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the EU. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union Drug Review and Approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of marketing authorizations. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessment report, a draft summary of the product characteristics (SPC), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned). </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. The Centers for Medicare&#160;&amp; Medicaid Services (CMS), have proposed to expand Medicaid rebate liability to the territories of the United States as well. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Trump administration announced several executive orders designed to reduce prescription drug pricing. The FDA also released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada. In November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturer. In December 2020, the CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. It is unclear to what extent the new administration and these new regulations will impact our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA),</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> established the Medicare Part&#160;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part&#160;A and B, Part&#160;D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&#160;D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part&#160;B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Scientific Advisory Board </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled a highly qualified scientific advisory board comprised of advisors who have, collectively, deep expertise in neurodegenerative diseases, genomics, protein engineering, drug development, and drug discovery as well as translational medicine. Our scientists work in collaboration with these advisors to identify new disease targets, develop a biomarker strategy, and accelerate discovery and development. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:490.3pt;;">
<tr>
<td style="width:183.25pt;"></td>
<td style="width:307.05pt;"></td>
</tr>
<tr style="height:11.9pt;">
<td colspan="0" style="auto;"></td>
</tr>
<tr style="height:13.7pt;">
<td valign="bottom"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Affiliated Entity</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:11.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adam Boxer, M.D., Ph.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director of UCSF Neurosciences Clinical Research Unit</p></td>
</tr>
<tr style="height:11.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stephen Hauser, M.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chair of the Department of Neurology at UCSF</p></td>
</tr>
<tr style="height:23.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Heneka, M.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director of the Department of Neurodegenerative Diseases and Gerontopsychiatry at the University of Bonn</p></td>
</tr>
<tr style="height:11.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lewis Lanier, Ph.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chair of the Department of Microbiology and Immunology at UCSF</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:490.3pt;;">
<tr>
<td style="width:183.25pt;"></td>
<td style="width:307.05pt;"></td>
</tr>
<tr style="height:11.9pt;">
<td colspan="0" style="auto;"></td>
</tr>
<tr style="height:13.7pt;">
<td valign="bottom"  style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Affiliated Entity</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:11.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liqun</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Luo, Ph.D.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of National Academy of Sciences, Stanford University</p></td>
</tr>
<tr style="height:11.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Scheller, Ph.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of National Academy of Sciences</p></td>
</tr>
<tr style="height:11.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas&#160;Christian&#160;S&#252;dhof,&#160;M.D., Ph.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nobel Laureate, Stanford University</p></td>
</tr>
<tr style="height:11.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Vassar, Ph.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Northwestern University Feinberg School of Medicine</p></td>
</tr>
<tr style="height:23.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Berislav Zlokovic, M.D., Ph.D.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chair of the Department of Physiology&#160;&amp; Neuroscience at USC Keck School of Medicine</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 171 full-time employees, over 75% of whom were engaged in research and development activities. None of our employees are represented by a labor union or covered under a collective bargaining agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees, advisors, and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, we focused our health and safety efforts on protecting our employees and their families. We swiftly implemented changes that we determined were in the best interest of our employees and the communities in which we operate, and which are aligned with guidance from the Centers for Disease Control and Prevention and in compliance with state and local regulations. This includes having some of our employees work from home, while implementing additional safety measures for employees continuing critical on-site work. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were initially formed as a limited liability company in Delaware in May 2013 under the name Alector LLC and completed our restructuring to a Delaware corporation in October 2017 under the name Alector, Inc. Our principal executive offices are located at 131&#160;Oyster Point Boulevard, Suite&#160;600, South San Francisco, California 94080. Our telephone number is 415-231-5660. Our website address is www.alector.com. Information contained on, or that can be accessed through, our website is not incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the SEC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended (Exchange Act). These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use Alector, the Alector logo, and other marks as trademarks in the United States and other countries. This report contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report, including logos, artwork, and other visual displays, may appear without the <sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> or TM&#160;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary Risk Factors</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company<font style="color:#000000;">, as fully described below. The principal factors and uncertainties that make investing in our company risky include, among others</font>:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We are in the early stages of clinical drug development and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The market price of our common stock may continue to be volatile, which could result in substantial losses for investors.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Drug development is a highly uncertain undertaking and involves a substantial degree of risk.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Research and development of biopharmaceutical products is inherently risky, and our business is heavily dependent on the successful development of our product candidates, which are in the early stages of preclinical and clinical development, so we cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We may not be successful in our efforts to continue to create a pipeline of product candidates from our Discovery Platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our Discovery Platform, our commercial opportunity may be limited.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We may not be successful in our efforts to expand indications for approved product candidates.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk64671743"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_Hlk64671743"></a>We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our product candidates are based on new approaches and novel technology, and we must be able to identify and develop new biomarkers that are signs of a disease or condition and that can measure impact on disease progression of our product candidates, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Our operations and financial results could be adversely impacted by the COVID-19 pandemic in the United States and the rest of the world.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business, Financial Condition, and Capital Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are in the early stages of clinical drug development and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company with a limited operating history, focused initially on developing therapeutics for neurodegenerative diseases, including FTD, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and ALS. We commenced operations in May&#160;2013. To date, we have only generated revenue from our collaboration arrangements and a government grant. We have no products approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We are in Phase 2 and Phase 3 clinical trials for one product candidate, AL001, are in Phase 2 clinical trials for one product candidate, AL002, and are in Phase 1 clinical trials for two product candidates, AL003 and AL101. To date, we have not completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses in each reporting period since our inception, including net losses of $190.2 million, $105.4&#160;million, and $52.2&#160;million for the years ended December&#160;31, 2020, 2019, and 2018, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $410.0&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested significant financial resources in research and development activities, including for our preclinical and clinical product candidates. We do not expect to generate revenue from product sales for several years, if at all. The revenue we currently generate from our collaboration arrangement with AbbVie is variable and limited in amount. For our collaboration with AbbVie, we recognize collaboration revenue by measuring the progress towards complete satisfaction of the performance of obligation measured as the program costs are incurred. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </font></p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasingly higher operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">continue our research and discovery activities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">advance our Discovery Platform, including our target, patient, and biomarker selections; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">progress our current and any future product candidates through preclinical and clinical development; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiate and conduct additional preclinical, clinical, or other studies for our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">work with our contract development and manufacturing organizations (CDMOs) to scale up the manufacturing processes for our product candidates or, in the future, establish and operate a manufacturing facility; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">change or add additional contract manufacturers or suppliers; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek regulatory approvals and marketing authorizations for our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish sales, marketing, and distribution infrastructure to commercialize any products for which we obtain approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">make milestone, royalty, or other payments due under any license or collaboration agreements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">take steps to seek protection of our intellectual property and defend our intellectual property against challenges from third parties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property obtained through license agreements, including as a result of the arbitration proceeding that we have initiated against our former consulting co-founder;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">attract, hire, and retain qualified personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">experience any delays or encounter other issues related to our operations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">implement additional internal systems and infrastructure related to cybersecurity; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">meet the requirements and demands of being a public company; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">defend against any product liability claims or other lawsuits related to our products. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing therapies with significant commercial success. Our ability to generate revenue and achieve profitability depends on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">completing research and preclinical and clinical development of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">addressing any delays in our clinical trials or other impacts resulting from factors related to the COVID-19 pandemic;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">identifying, assessing, acquiring, and/or developing new product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing, and distribution infrastructure; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our products are commercialized; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining adequate reimbursement for our product candidates from payors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtaining market acceptance of our product candidates as viable treatment options; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">addressing any competing technological and market developments; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">receiving milestones and other payments under our current and any future collaboration arrangements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">attracting, hiring, and retaining qualified personnel. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#8217; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with launching and commercializing any approved product candidate and ongoing compliance efforts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have required substantial amounts of cash since inception, and we expect our expenses to increase significantly in the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities and upfront payments received in connection with our collaboration arrangement with AbbVie. Developing our product candidates and conducting clinical trials for the treatment of neurodegenerative diseases, including FTD, Alzheimer&#8217;s disease, and Parkinson&#8217;s disease, will require substantial amounts of capital. We will also require a significant amount of capital to commercialize any approved products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had cash, cash equivalents, and marketable securities of $413.3&#160;million. In February 2019, we received $168.2&#160;million of net proceeds from the issuance of common stock upon the completion of our initial public offering (IPO), net of underwriting discounts and commissions and offering expenses. In January 2020, we received $224.5 million of net proceeds from the issuance of common stock upon the completion of a follow-on offering, net of underwriting discounts and commissions and offering expenses. In May 2020, we established an &#8220;at-the-market&#8221; facility for the sale of up to $150 million worth of shares of common stock from time to time by entering into an equity distribution agreement with Morgan Stanley &amp; Co. LLC and Goldman Sachs &amp; Co. LLC, as sales agents. We have not issued any shares pursuant to any at-the-market offerings but may at a future date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our projected operations through at least the next 12&#160;months</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, subsequent to the filing date of this Annual Report on Form 10-K</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Our estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operations is based on assumptions that may be proved inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require additional capital for the further development and, if approved, commercialization of our product candidates. In recent months, global markets have experienced volatility in connection with continued concerns over the global impact of a novel strain of coronavirus, COVID-19. Our ability to raise money in the public markets may be severely impacted for the foreseeable future due to the impact of COVID-19. Additional capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back, or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we have identified over 100 immune system targets, have advanced four product candidates, AL001, AL002, AL003, and AL101 into clinical development, and continue to develop our research pipeline. We currently have four product candidates in clinical trials. Together, the development of these programs and product candidates require significant capital investment. Due to the significant resources required for the development of our programs and product candidates, we must focus our programs and product candidates on specific diseases and disease pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we will be able to quickly generate proof-of-concept data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication. However, even if our product candidates are able to gain regulatory approval in one indication, there is no guarantee that we will be able to expand to other indications, and we may expend significant resources in seeking such approvals. In addition, we may focus resources on pursuing indications outside of neurodegeneration based on the same genetic and mechanistic rationale we utilize in determining on which of our discovery programs to focus. Our decisions concerning the allocation of research, development, collaboration, management, and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate, or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurodegenerative diseases, our business, financial condition, and results of operations could be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on the successful development of our product candidates, which are in various stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are at the early stages of development of many of the product candidates currently in our programs. To date, we have invested substantially in our efforts and financial resources to identify, procure intellectual property for, and develop our programs, including conducting preclinical studies and clinical trials in our programs for our product candidates, AL001, AL002, AL003, AL101, and AL044, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our product candidates may not successfully complete preclinical studies or clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the product candidates that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the product candidates that we develop may be covered by third parties&#8217; patents or other intellectual property or exclusive rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be successful in our efforts to further develop our current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Most of our product candidates are in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never completed a clinical development program. We currently have one product candidate, AL001, in a pivotal Phase 3 clinical trial, one product candidate, AL002 in a Phase 2 clinical trial, and two product candidates, AL003 and AL101, in Phase&#160;1 clinical trials. Further, we cannot be certain that any of our product candidates will be successful in clinical trials. We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates successfully complete clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical trials, commercial sales, pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. For example, for our AL002 and AL003 product candidates, our collaboration arrangement with AbbVie provides that we are responsible for the execution of the Phase&#160;1 and Phase&#160;2 studies. We cannot be sure that our collaborators or partners will conduct these activities or do so within the timeframe we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment of neurodegenerative diseases or other diseases, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to continue to create a pipeline of product candidates from our Discovery Platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our Discovery Platform, our commercial opportunity may be limited. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk59542344"></a><a name="_Hlk59542344"></a>One of our strategies is to identify and pursue clinical development of additional product candidates. Identifying, developing, obtaining regulatory approval, and commercializing additional product candidates for the treatment of neurodegenerative diseases will require substantial additional funding and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop, or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to expand indications for approved product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we will be able to quickly generate proof-of-concept data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication. Conducting clinical trials for additional indications for our product candidates requires substantial technical, financial, and human resources and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successful in our effort to obtain regulatory approval for our product candidates for additional indications even if we obtain approval for an initial indication. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, our product candidate AL001 is initially targeting FTD-<font style="font-style:italic;">GRN</font> patients. In the third quarter of 2019, we advanced AL001 into a Phase&#160;2, which also includes an additional genetic subset of FTD patients (FTD-<font style="font-style:italic;">C9orf72</font>) and we will evaluate AL001 in patients with amyotrophic lateral sclerosis (ALS) caused by <font style="font-style:italic;">C9orf72</font> repeats, which share TDP-43 pathology with FTD-<font style="font-style:italic;">GRN</font>. If we are unable to expand indications for our product candidates, our commercial opportunity may be limited.&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our product candidates are based on new approaches and novel technology, and we must be able to identify and develop new biomarkers that are signs of a disease or condition and that can measure impact on disease progression of our product candidates, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have focused a substantial portion of our research and development efforts on addressing neurodegenerative diseases. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are few effective therapeutic options available for patients with FTD, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our product candidates for treating neurodegenerative diseases. Developing and, if approved, commercializing our product candidates for treatment of neurodegenerative diseases subjects us to a number of challenges, including obtaining disease modifying activity and efficacious dose in target tissue and obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our approach to the treatment of neurodegenerative diseases aims to identify and select targets enriched in microglia and other myeloid immune cells which are genetically associated with neurodegenerative diseases. We identify and develop product candidates that are designed to cross the blood brain barrier in sufficient quantity and potency to enable efficacious dosing in the brain and engage the intended target, and we must be able to identify and develop biomarkers and biomarker assays that can accurately identify signs of a disease or condition, assist us in selecting the right patient population, and demonstrate target engagement, pathway engagement, and measure the impact on disease progression of our product candidates. This strategy may not prove to be successful. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an IND or a clinical trial application (CTA) will result in the FDA or EMA, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in preclinical and clinical product candidate development; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in reaching a consensus with regulatory agencies on study design; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays in identifying, recruiting, and training suitable clinical </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigators;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in obtaining required IRB approval at each clinical trial site; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">imposition of delays to clinical trials, including as a result of temporary or permanent clinical hold by regulatory agencies for a number of reasons, including: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">as a result of a new safety finding that presents unreasonable risk to clinical trial participants; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">as a result of modifications to clinical trial protocols or related documentation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a negative finding from an inspection of our clinical trial operations or study sites; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the finding that the investigational protocol or plan is clearly deficient to meet its stated objectives; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials, or failing to return for post-treatment follow-up; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">difficulty collaborating with patient groups and investigators; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure by our CROs, other third parties, or us to adhere to clinical trial requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current good clinical practices (cGCPs) requirements, or applicable EMA or other regulatory guidelines in other countries; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of clinical trials of our product candidates being greater than we anticipate; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any and all of the events described above may be caused or exacerbated by factors related to the ongoing COVID-19 pandemic.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA, EMA, or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion, which could adversely affect our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the size and nature of the patient population; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the size of the study population required for analysis of the trial&#8217;s primary endpoints; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the proximity of patients to a trial site; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the design of the trial; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain and maintain patient consents; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the risk that patients enrolled in clinical trials will not complete such trials, for any reason. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment of patients in our clinical trials and maintaining patients in our ongoing clinical trials have been, and may continue to be, delayed or limited as certain of our clinical trial sites limit their onsite staff or temporarily close as a result of the COVID-19 pandemic. In addition, patients may not be able or willing to visit clinical trial sites for dosing or data collection purposes due to limitations on travel and physical distancing imposed or recommended by federal or state governments or patients&#8217; reluctance to visit the clinical trial sites during the pandemic. These factors resulting from the COVID-19 pandemic could delay or prevent the anticipated readouts from our clinical trials.<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials that our product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen, and other clinical trial protocols and the rate of dropout among clinical trial participants. Open-label extension studies may also extend the timing and cost of a clinical test substantially. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in neurodegenerative diseases, where failure rates historically have been higher than in many other disease areas. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operations and financial results could be adversely impacted by the COVID-19 pandemic in the United States and the rest of the world.<font style="font-size:12pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;"> </font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the World Health Organization declared the outbreak of&#160;COVID-19&#160;as a &#8220;Public Health Emergency of International Concern,&#8221; which continues to spread throughout the world and has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The&#160;COVID-19&#160;pandemic and government responses are creating disruption in global supply chains and adversely impacting many industries. The pandemic could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. We continue to monitor the impact of the&#160;COVID-19&#160;pandemic closely. The extent to which the&#160;COVID-19&#160;pandemic will impact its operations or financial results is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of&#160;COVID-19 and in compliance with local shelter-in-place regulations,&#160;we reduced the number of employees operating at our headquarters, which has altered our operations and processes. While the extent of the impact of the&#160;COVID-19&#160;pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the&#160;COVID-19&#160;pandemic could have a material adverse effect on our business, financial condition and results of operations.<font style="color:#000000;"> As the COVID-19 pandemic continues to spread around the globe, we may experience disruptions that could severely impact our business and clinical trials, including: </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the size and nature of the patient </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">population;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays or difficulties in recruiting, enrolling, and maintaining patients in our clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations in resources that would otherwise be focused on the conduct of our business or our clinical trials, including because of sickness or the desire to avoid contact with large groups of people or as a result of government-imposed &#8220;shelter in place&#8221; or similar working restrictions;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, or to discontinue the clinical trials altogether, or which may result in unexpected costs;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the&#160;COVID-19&#160;virus, which may delay our anticipated timelines for clinical studies and regulatory approval and increase our costs for clinical studies. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, that describes a number of considerations for sponsors of clinical trials impacted by the pandemic. In this guidance, pharmaceutical companies would be required to include in the clinical trial report contingency measures implemented to manage the clinical trial, and any disruption of the clinical trial as a result of the&#160;COVID-19&#160;pandemic; a list of all subjects affected by the&#160;COVID-19&#160;pandemic related study disruption (by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered); and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the <font style="color:#000000;">clinical trial. In June 2020, the FDA also issued a guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biological products manufacturing, including recommendations for manufacturing controls to prevent contamination of drugs and a guidance on resuming normal drug and biologics manufacturing operations during the COVID-19 public health emergency. To the extent our clinical studies are delayed or data from our clinical studies become compromised due to COVID-19 related factors, we may be required to expend additional resources to conduct additional studies and/or enroll more participants, which could adversely affect our business operations and delay regulatory approval. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The&#160;COVID-19&#160;pandemic continues to evolve rapidly, with the status of operations and government restrictions evolving weekly. The extent to which the outbreak impacts our business, preclinical studies, and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions, and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, certain third parties with whom we engage, including our collaborators, contract organizations, third party manufacturers, suppliers, clinical trial sites, regulators and other third parties with whom </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we conduct business are similarly adjusting their operations and assessing their capacity in light of the COVID-19 pandemic. If these third parties experience shutdowns or continued business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, certain of our clinical trial sites have experienced clinical trial visit delays, and we are aware that for a period of time, some participants in each of our ongoing trials did not received scheduled doses on time. These events could negatively impact the integrity, reliability, or robustness of the data from our clinical trials. We and our CROs have also made certain adjustments to the operation of such trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA, and we may be required to make further adjustments in the future. Many of these adjustments are new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. In addition, notwithstanding any adjustments, some trial participants may decline to visit clinical trial sites for dosing or data collection purposes due to limitations on travel and physical distancing imposed or recommended by federal or state governments or patients&#8217; reluctance to visit the clinical trial sites during the pandemic. We may not be successful in adding clinical trial sites, may experience delays in patient enrollment or in the progression of our clinical trials and collection and analysis of patient data, may need to suspend or abandon our clinical trials, and may encounter other negative impacts to our trials, due to the effects of the COVID-19 pandemic. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global outbreak of COVID-19 continues to rapidly evolve, with particularly significant case increases in the United States. While the extent of the impact of the current COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition and operating results. To the extent the COVID-19 pandemic adversely affects our operations and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of neurodegenerative diseases, including FTD and Alzheimer&#8217;s disease. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan drug exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-style:italic;font-size:10pt;">The manufacture of our product candidates is complex, and we may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The processes involved in manufacturing our drug and biological product candidates are complex, expensive, highly-regulated, and subject to multiple risks. Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in large quantities. Our CDMOs may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our CDMOs are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risk would apply to our internal manufacturing facilities, should we in the future decide to build internal manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design, and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the manufacturing process for any products that we may develop is subject to FDA, EMA, and foreign regulatory authority approval processes, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA, and foreign regulatory authority requirements, including complying with current good manufacturing practices (cGMPs) on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA, or other regulatory authorities, including recent FDA guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biological products manufacturing, as well as any future guidance and regulations, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CDMOs will be able to manufacture the approved product to specifications acceptable to the FDA, EMA, or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations, and growth prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize any approved product on our own include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">unforeseen costs and expenses associated with creating an independent commercialization organization. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the efficacy and safety of such product candidates as demonstrated in clinical trials and published in peer-reviewed journals; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential and perceived advantages compared to alternative treatments; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ability to offer our products for sale at competitive prices; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sufficient third-party coverage or reimbursement; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ability to offer appropriate patient access programs, such as co-pay assistance; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which physicians recommend our products to their patients; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">convenience and ease of dosing and administration compared to alternative treatments; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the clinical indications for which the product candidate is approved by FDA, EMA, or other regulatory agencies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product labeling or product insert requirements of the FDA, EMA, or other comparable foreign regulatory authorities, including any limitations, contraindications, or warnings contained in a product&#8217;s approved labeling; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on how the product is distributed; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing of market introduction of competitive products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">publicity concerning our products or competing products and treatments; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the strength of marketing and distribution support; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the prevalence and severity of any side effects. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any products we commercialize may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing, and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted or potential future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid, and Veterans Affairs hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA, or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates for which we intend to seek approval may face competition sooner than anticipated. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12&#160;years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to get it on the market until 10 years after the time of approval of the innovative product. This 10-year marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">decreased or interrupted demand for our products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injury to our reputation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">withdrawal of clinical trial participants and inability to continue clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiation of investigations by regulators; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">costs to defend the related litigation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a diversion of management&#8217;s time and our resources; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">substantial monetary awards to trial participants or patients; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product recalls, withdrawals or labeling, marketing, or promotional restrictions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">loss of revenue; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">exhaustion of any available insurance and our capital resources; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability to commercialize any product candidate. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approval and Other Legal Compliance Matters </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA, EMA, and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not submitted for, or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, the U.S. federal government has experienced and may in the future experience shutdown or budget sequestration, which could result in significant reductions to the FDA&#8217;s budget, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. To the extent FDA and other regulatory authorities experience any delays or limited resources in reviewing our regulatory applications or requests for meetings and/or guidance, and inspection of manufacturing facilities prior to regulatory approval due to the COVID-19 pandemic or other reasons, we may experience significant delays in our anticipated timelines for our clinical studies and/or seeking regulatory approvals, which could adversely affect our business. <font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design, implementation, or results of our clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA, EMA, or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio when compared to the standard of care is acceptable; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a NDA, BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be unable to demonstrate to the FDA, EMA, or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for a proposed indication is acceptable; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the approval policies or regulations of the FDA, EMA, or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, or other comparable foreign regulatory authorities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may withdraw approvals of such product and cause us to recall our products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may require additional warnings on the label; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements, such as boxed warning on the packaging, to assure safe use; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we could be sued and held liable for harm caused to patients; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our reputation may suffer. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, financial condition, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently are and may continue in the future to conduct clinical trials for our product candidates outside the United States, and the FDA, EMA, and applicable foreign regulatory authorities may not accept data from such trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently are and may continue in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe or Australia. The acceptance of study data from clinical trials conducted outside the United&#160;States or another jurisdiction by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates will be harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive requirements imposed by the FDA, EMA, and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA, or marketing authorization application (MAA). Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including the requirement to implement a Risk Evaluation and Mitigation Strategy), or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA, and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">issue warning letters that would result in adverse publicity; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">impose civil or criminal penalties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">suspend or withdraw regulatory approvals; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">suspend any of our ongoing clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refuse to approve pending applications or supplements to approved applications submitted by us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seize or detain products; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">require a product recall. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have received orphan drug designation from the FDA for AL001 and AL101 for treatment of FTD and plan to seek orphan drug designation for some of our other product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. While we have obtained orphan drug designation from the FDA for AL001 and AL101 for treatment of FTD, we may be unable to reap the benefits associated with orphan drug status. In addition, we plan to seek orphan drug designations for some of our other product candidates in the future but may be unable to obtain an orphan drug designation for any additional product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusivity, which means that the FDA may not approve any other NDA or BLA applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even though the FDA has approved orphan drug status for AL001 and AL101 for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have received Fast Track designation from the FDA for AL001 and AL101 for the treatment of patients with frontotemporal dementia carrying specific genetic mutation in the granulin gene, but we may be unable to obtain or maintain the benefits associated with the Fast Track designation.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product and the specific indication for which it is being studied.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FDA granted Fast Track designation for AL001 and in January 2020, the FDA granted Fast Track designation for AL101 for the treatment of patients with FTD carrying specific genetic mutations in the granulin gene. If our clinical development program does not continue to meet the criteria for Fast Track designation, or if our clinical trials are delayed, suspended, or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. In particular, in 2010, the ACA was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. The ACA has been subject to litigation and other efforts to repeal and replace the ACA. It is unclear how such efforts, including the Supreme Court&#8217;s ruling on the constitutionality of the ACA, and healthcare measures of the new administration will impact the ACA and our business. Complying with any new legislation or reversing changes implemented under the Trump administration could be time-intensive and expensive, resulting in a material adverse effect on our business. Until the ACA is fully implemented or there is more certainty concerning the future of the ACA, it will be difficult to predict its full impact and influence on our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. In 2020, the Trump administration announced several executive orders related to prescription drug pricing. The FDA also released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada. Further, in November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturer. It is unclear to what extent these new regulations and those of the new administration will affect these policies and what the effects will be on our business. In December 2020, the CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the demand for our product candidates, if we obtain regulatory approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to receive or set a price that we believe is fair for our products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to generate revenue and achieve or maintain profitability; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of taxes that we are required to pay; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of capital. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. Further, the governmental may take further action to address the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. This could lower the price that we receive for any approved product. The new administration and the states may pass further legislation and regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our product candidates, if approved. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">comply with the laws of the FDA, EMA, and other comparable foreign regulatory authorities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide true, complete, and accurate information to the FDA, EMA, and other comparable foreign regulatory authorities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">comply with manufacturing standards we have established; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">report financial information or data accurately or to disclose unauthorized activities to us. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be in compliance with</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations, and financial conditions could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The federal Anti-Kickback Statute, prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, or recommendation of any good, facility, </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.76%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, impose criminal and civil penalties, including through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease, or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of individually identifiable health information without appropriate authorization. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, require manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2022, these reporting obligations will extend to include payments and transfers of value made during the previous year to certain non-physician providers, such as physician assistants and nurse practitioners.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection, and unfair competition laws may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements, as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">State laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">State laws also require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration, and items of value provided to healthcare professionals and entities. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">State and foreign laws also govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development, and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to security, privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A wide variety of state, national, and international laws and regulations apply to security and cybersecurity requirements and the collection, use, retention, protection, disclosure, transfer, and other processing of personal data. These security and data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. We are working to comply with these laws, and we anticipate needing to devote significant additional resources to our compliance efforts. It is possible that the new legislation may impose new obligations and requirements on similarly situated companies, and these laws may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices. Our actual or perceived failure to adequately comply with applicable laws and regulations relating to security, privacy and data protection, or to protect our systems, personal data and other data we process or maintain, could result in regulatory fines, investigations and enforcement actions, penalties and other liabilities, claims for damages by affected individuals, and damage to our reputation, any of which could materially affect our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inadequate funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In the past, the U.S. government has experienced budgetary shutdowns and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business activities may be subject to the Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently use and expect to continue to use third-party collaborators for the research, development, and commercialization of certain of the product candidates we may develop, including our previously disclosed arrangements with AbbVie and Adimab. We have entered into a licensing agreement with Innovent Biologics to develop and commercialize our AL008 product, an anti-SIRP-alpha antibody for the treatment of oncology indications in China. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies, and academic institutions. Such arrangements with any third parties, generally provide us with shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our research programs, or any product candidates we may develop, pose the following risks to us: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights relating to our product candidates or research programs or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity, and enforceability of our intellectual property; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may own or co-own intellectual property covering our product candidates or research and development programs that results from our collaboration with them, and in such cases, we may not </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have the exclusive right to commercialize such intellectual property or such product candidates or research </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may control certain interactions with regulatory authorities, which may impact our ability to obtain and maintain regulatory approval of our product candidates; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities or collaborators may elect to fund or commercialize a competing product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may restrict us from researching, developing, or commercializing certain products or technologies without their involvement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control, and the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know-how, or intellectual property of the collaborator relating to our products, product candidates, or research programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">if our collaborators do not satisfy their obligations under our agreements with them, or if they terminate our collaborations with them, we may not be able to develop or commercialize product candidates as planned; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do not fully control, and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies; and </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed, diminished, or terminated. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not realize the benefit of collaborations if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this &#8220;Risk Factors&#8221; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue. </font></p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We contract with third parties for the manufacture of materials for our research programs, preclinical studies, clinical trials, and for commercialization of any product candidates that we may develop. This reliance on third parties carries and may increase the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any manufacturing facilities. We currently rely on CDMOs for the manufacture of our materials for preclinical studies and clinical trials and expect to continue to do so for preclinical studies, clinical trials, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing of our product candidates. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possible breach of the manufacturing agreement by the third party; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inability to produce required volume in a timely manner and to quality standards. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our CDMOs, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures, or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party suppliers for the supply of the raw materials required for the production of our product candidates, and we expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality, and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors who are larger than we are. We do not have long-term supply agreements, and we purchase our required drug product on a development manufacturing services </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement or purchase order basis. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad relating to our core programs and product candidates, as well as other technologies that are important to our business. Given that the development of many of our product candidates is at an early stage, our intellectual property portfolio with respect to certain aspects of many of our product candidates is also at an early stage. For example, we have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If any of our patent applications, or those of our collaborators, do not issue as patents in any jurisdiction, we may not be able to compete effectively. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents or those of our collaborators with respect to our product candidates. With respect to both our intellectual property and that of our collaborators related to our product candidates, we cannot predict whether the patent applications we and our collaborators are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive, time-consuming, and complex, and we or our collaborators may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our collaborators were the first to make the inventions claimed in any of our or our collaborators&#8217; patents or pending patent applications, or that we or our collaborators were the first to file for patent protection of such inventions. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our or our collaborators&#8217; pending and future patent applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we or our collaborators license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we or our collaborators have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our collaborators may be subject to a third-party preissuance submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, post-grant and <font style="font-style:italic;">inter partes </font>review, or interference proceedings or other similar proceedings challenging our or our collaborators&#8217; patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our collaborators, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our collaborators&#8217; priority of invention or other features of patentability with respect to our or our collaborators&#8217; patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our patents and patent applications may in the future be co-owned with third parties. In addition, collaborators or future licensors may co-own their patents and patent applications with other third parties with whom we do not have a direct relationship. Our rights to certain of these patents and patent applications may be dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our collaborators or future licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology to the extent such products and technology are not also covered by our intellectual property. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of agreements with others. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are heavily reliant upon option rights to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our product candidates and are subject to the terms and conditions of certain collaboration agreements with third parties. For example, in 2014 we entered into the Adimab Collaboration Agreement with Adimab. Under the Adimab Collaboration Agreement, we are developing antibodies discovered by Adimab in our AL001 and AL101 product candidates, and we are developing antibodies optimized by Adimab in our AL002 and AL003 product candidates. Additionally, in October&#160;2017, we entered into the AbbVie Agreement to co-develop and commercialize medicines with AbbVie to treat Alzheimer&#8217;s disease and other neurodegenerative diseases. In August 2019, we entered into a new Adimab collaboration agreement for development of antibodies for use in future programs. For additional information on the Adimab Collaboration Agreement and the AbbVie Agreement, see the sections titled &#8220;Business&#8212;Adimab Collaboration Agreements&#8221; and &#8220;Business&#8212;Strategic Alliance with AbbVie.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our agreements with Adimab and AbbVie and other agreements we enter into in the future may not provide exclusive rights to use certain intellectual property and technology retained by the collaborator in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that utilizes technology retained by such collaborators to the extent such products are not also covered by our intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, subject to the terms of any such agreements, we do not have the right to control the preparation, filing, prosecution, and maintenance, and we may not have the right to control the enforcement and defense of certain patents and patent applications retained by the collaborator and provided to us under a limited license. For example, under the Adimab Collaboration Agreements, patent rights relating to improvements to Adimab&#8217;s background platform technology that are invented in the course of the research under the Adimab Collaboration Agreements are assigned to Adimab. We also have an exclusive option under the Adimab Collaboration Agreements to obtain with respect to a specified number of antibodies directed against such target and discovered or optimized by Adimab, ownership of certain patent rights relating to such antibodies, including certain patent rights. Until we exercise such option, we and Adimab each grant each other a non-exclusive license to the relevant intellectual property. We cannot be certain that patents and patent applications that are controlled by our collaborators will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our collaborators fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the limited rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our product candidates that are subject of such licensed rights could be adversely affected, and we may have a reduced ability to prevent competitors from making, using, and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed to and from collaborators, we may still be adversely affected or prejudiced by actions or inactions of our collaborators that took place prior to the date upon which we assumed control over patent prosecution. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our or our collaborators&#8217; patents may be subject to a reservation of rights by one or more third parties. For example, we received an award from the National Institute of Health in support of our research into the production and characterization of novel therapeutic antibodies against SORT1. As a result, the U.S. government may have certain rights to resulting intellectual property. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve the practical application of the government funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in facilities in the United States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we option or license intellectual property rights from our collaborators or future licensors or otherwise experience disruptions to our business relationships with our collaborators or future licensors, we could lose intellectual property rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into agreements with our collaborators to option or license certain intellectual property and may need to obtain additional intellectual property rights from others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain additional intellectual property rights at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, each of our agreements with collaborators do, and we expect our future agreements will, impose various economic, development, diligence, commercialization, and other obligations on us. Certain of our collaboration agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products. In spite of our efforts, our collaborators might conclude that we have materially breached our obligations under such agreements and might therefore terminate or seek damages under the agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these agreements. If termination of these agreements causes us to lose the rights to certain patents or other intellectual property, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may have the freedom to seek regulatory approval of, and to market, products similar to or identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, disputes may arise regarding intellectual property subject to a collaboration agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope of the option or license rights granted under the agreement and other interpretation-related issues; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the extent to which our technology and processes infringe on intellectual property of the collaborator that is not subject to the option or license rights granted under the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the sublicensing of patent and other rights under our collaborative development relationships; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our collaborators and us and our other partners; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the priority of invention of patented technology. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we currently have rights to option or license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. Moreover, if disputes over intellectual property that we have optioned or licensed prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property and proprietary rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we, our collaborators or any of our future licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United&#160;States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our collaborators or licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We also are dependent on our collaborators or licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September&#160;2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March&#160;2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patents or patent applications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <font style="font-style:italic;">inter partes</font><font style="font-weight:bold;font-style:italic;"> </font>review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we initiated legal proceedings against a third party to enforce a patent covering our product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, <font style="font-style:italic;">inter partes</font><font style="font-weight:bold;font-style:italic;"> </font>review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. For example, on June&#160;18, 2019, we initiated a confidential arbitration proceeding against Dr.&#160;Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. Although an independent arbitrator issued a confidential decision in favor of the Company and which found Dr. Abeliovich liable for breach of his confidentiality agreement and for spoliation based on his destruction of documents relevant to the proceeding, asserting and maintaining such proceeding was difficult, expensive, and time-consuming. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in obtaining, through acquisitions or otherwise, necessary rights to our product candidates or other technologies. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the field of neurodegeneration therapy may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we co-own with third parties, we may wish to obtain licenses to such co-owners&#8217; interest to such patents. However, we may be unable to secure such licenses or otherwise acquire any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement, misappropriation, or other violation against us or our collaborators may prevent or delay the development and commercialization of our product candidates and other technologies. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The field of discovering treatments for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. Additionally, the technology used in our product candidates is still in its infancy and no products utilizing similar technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our and our collaborators&#8217; ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may become party to, or threatened with, such actions in the future, regardless of their merit. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including <font style="font-style:italic;">inter partes</font> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates and other technologies that we have developed, are developing, or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing product candidates, and other technologies might assert are infringed by our current or future product candidates or other technologies, including claims to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or other technologies may infringe. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our product candidates or other technologies infringes upon these patents. In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our product candidates or other technologies. In this case, the holders of such patents may be able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our product candidates or other technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing product candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates or other technologies, which could harm our business significantly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35&#160;U.S.C. &#167;271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may not develop additional proprietary technologies that are patentable; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patents of others may harm our business; and </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Dr.&#160;Arnon Rosenthal, and our scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct our operations at our facility in South San Francisco, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region and doing so may be costly and difficult. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided and will continue to provide restricted stock, stock option grants, and other equity awards that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had 171 full-time employees. As our development plans and strategies develop, and as we continue to implement the requirements applicable to operating as a public company, we must add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">identifying, recruiting, integrating, retaining, and motivating additional employees; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanding our operational, financial and management controls, reporting systems, and procedures; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">managing increasing operational and managerial complexity. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">services of these independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have engaged in strategic collaborations and may in the future engage in acquisitions, collaborations, or strategic partnerships, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have engaged in strategic collaborations in the past, such as our strategic collaboration with AbbVie, and we may engage in various acquisitions, collaborations, and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any acquisition, collaboration, or strategic partnership may entail numerous risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">increased operating expenses and cash requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">volatility with respect to the financial reporting related to such arrangements, such as our expected variability in the recognition of revenue each quarter from the AbbVie Agreement based on the percentage-of-completion basis under the applicable accounting rules; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">assumption of indebtedness or contingent liabilities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">issuance of our equity securities which would result in dilution to our stockholders; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">assimilation of operations, intellectual property, products, and product candidates of an acquired company, including difficulties associated with integrating new personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our inability to generate revenue from acquired intellectual property, technology, and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future amortization expense. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our internal computer systems and those of our future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to us. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business disruptions<font style="Background-color:#FFFFFF;">, including as a result of global pandemics,</font> could seriously harm our future revenue and financial condition and increase our costs and expenses. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to <font style="Background-color:#FFFFFF;">pandemic events and the spread of disease, </font>earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, political unrest, and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster, global pandemics, or other business interruption. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of our operations including our corporate headquarters are located in a facility in South San Francisco, California. Damage or extended periods of interruption to our corporate, development, or research facilities due to fire, natural disaster, global pandemics, power loss, communications failure, unauthorized entry, or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business is subject to economic, political, regulatory, and other risks associated with international operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to risks associated with conducting business internationally. Some of our CDMOs are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">differing and changing regulatory requirements in non-U.S. countries; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">difficulties in compliance with non-U.S. laws and regulations; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in non-U.S. regulations and customs, tariffs, and trade barriers; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in non-U.S. currency exchange rates and currency controls; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in a specific country&#8217;s or region&#8217;s political or economic environment; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">shipping of biologics/drugs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">trade protection measures, import or export licensing requirements, or other restrictive actions by U.S. or non-U.S. governments; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">negative consequences from changes in tax laws; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">difficulties associated with staffing and managing international operations, including differing labor relations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential liability under the FCPA, UK Bribery Act, or comparable foreign laws; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, and fires. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had federal and state net operating loss (NOL) carryforwards of approximately $195.3&#160;million and $191.4&#160;million, respectively, some of which have an indefinite life. Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period.  As a result of our initial public offering in February 2019 and follow-on public offering in January 2020, and other transactions that have occurred since our incorporation, we may have experienced such an ownership change. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation. In addition, the enacted legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (the Tax Act) imposes certain limitations on the deduction of NOLs. The Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act of 2020 (CARES Act), also provides that NOLs from tax years that began after December 31, 2017 may offset no more than 80% of current taxable income annually for taxable years beginning after December 31, 2020. Our NOLs may also be subject to limitations under state law. For example, California enacted legislation suspending the use of NOLs for taxable years 2020, 2021 and 2022 for many taxpayers.</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be sustained. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering in February 2019, there was no public trading market for our common stock. Although our common stock is listed on the NASDAQ Global Select Market, the market for our shares has demonstrated varying levels of trading activity. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our common stock may continue to be volatile, which could result in substantial losses for investors. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. Some of the factors that may cause the market price of our common stock to fluctuate include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of existing or new competitive products or technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">commencement or termination of collaborations for our product development and research programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure to achieve development, regulatory, or commercialization milestones under our collaborations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">failure or discontinuation of any of our product development and research programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory or legal developments in the United States and other countries; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the recruitment or departure of key personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results of our efforts to develop additional product candidates or products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">announcement or expectation of additional financing efforts; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sales of our common stock by us, our insiders, or other stockholders, such as if we use our at-the-market facility; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expiration of market standoff or lock-up agreements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in the structure of healthcare payment systems; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">market conditions in the pharmaceutical and biotechnology sectors; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">general economic, industry, and market conditions; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the other factors described in this &#8220;Risk Factors&#8221; section. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business cease to cover us or downgrade their evaluations of our stock or if we fail to meet their operating results estimates for us, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to decline significantly, even if our business is doing well. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amount of our common stock in the public market, the market price of our common stock could decline significantly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of shares of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-style:italic;font-size:10pt;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our<font style="font-weight:bold;"> </font>control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. On May 13, 2020, we filed a shelf registration statement on Form S-3 with the SEC that automatically became effective and permits us to use our at-the-market facility for sales of up to $150 million worth of shares of common stock from time to time. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors, executive officers, holders of more than 5% of our outstanding stock and their respective affiliates beneficially owned 42.1% of our outstanding common stock as of February 15, 2021. As a result, these stockholders, if they act together, may significantly influence all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other stockholders may believe is in their best interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred and will continue to incur significant additional costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we have incurred and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform, and Consumer Protection Act, the listing requirements of NASDAQ, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have hired, and expect that we will need to continue to hire, additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel have devoted and will continue to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to maintain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of Sarbanes-Oxley Act 404(a) of the Sarbanes-Oxley Act, which require annual management assessments of the effectiveness of our internal control over financial reporting. Section 404(b) of the Sarbanes-Oxley Act also requires our independent auditors to attest to, and report on, this management assessment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. If we are not able to comply with the requirements of Section 404 or if we or our independent registered public accounting firm are unable to attest to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, which would require additional financial and management resources. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish that our board of directors is divided into three classes, Class&#160;I, Class&#160;II, and Class&#160;III, with each class serving staggered three-year terms; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide that our directors may only be removed for cause; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">eliminate cumulative voting in the election of directors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">prohibit stockholders from calling a special meeting of stockholders; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">authorize our board of directors, by a majority vote, to amend the bylaws; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware (DGCL), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for the following (except for&#160;any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the exclusive jurisdiction of a court or forum other than such court, or for which such court does not have subject matter jurisdiction</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any derivative action or proceeding brought on our behalf; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any action asserting a claim of breach of fiduciary duty; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any action asserting a claim against us arising under the DGCL, our amended- and restated certificate of incorporation or our amended and restated bylaws; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.84%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are currently located in South San Francisco, California, where we lease approximately 105,000 square feet of office and laboratory space. The term of the lease agreement expires in May&#160;2029, with an option to extend the term of the lease for an additional 10&#160;years. The lease agreement also provides us a right of first offer to expand into available office space in the building. We sublease approximately 23,600 square feet of our corporate headquarters with a lease term that expires in November 2021. We lease approximately 18,700 square feet of additional office and laboratory space in Newark, California. We believe that these facilities will be adequate for our near-term needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We have been engaged in an arbitration against a third party as set forth below. Regardless of outcome, litigation, or other legal proceedings can have an adverse impact on us because of legal fees and settlement costs, diversion of management resources, and other factors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 2, 2020, we provided an update on our confidential arbitration proceedings against Dr. Asa Abeliovich, co-founder and CEO of Prevail Therapeutics. An independent arbitrator issued a confidential decision in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">favor, finding Dr. Abeliovich liable for breach of his confidentiality agreement and for spoliation based on his destruction of documents relevant to the proceeding. The arbitrator awarded damages for breach of the agreement and sanctions for the spoliation, as well as violation of orders during the proceeding</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and the amount of such </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damages will be determined in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a pending </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceeding.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity,<a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a> Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information for Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is publicly traded on the Nasdaq Global Select Market under the symbol "ALEC." </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 15, 2021, there were approximately 17 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments, and other factors that our board of directors deems relevant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This graph is not &#8220;soliciting material&#8221; or deemed &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Alector, Inc. under the Securities Act of 1933, as amended (the "Securities Act"), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on February 7, 2019 (the first day of trading of our common stock) and its relative performance is tracked through December 31, 2020. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gou0qrw2itv5000021.jpg" title="" alt="" style="width:590px;height:316px;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registration Statement on Form S-1 (File No. 333-229152) was declared effective by the SEC for our initial public offering of common stock on February 6, 2019. We started trading on the Nasdaq Global Select Market on February 7, 2019. In connection with our initial public offering, we sold an aggregate of 9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares. The aggregate offering price for shares sold in the offering was $185.1 million. The underwriters for our initial public offering were Morgan Stanley &amp; Co. LLC, Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, and Cowen and Company, LLC. The aggregate net proceeds received by the Company from the offering, net of underwriting discounts and commissions and estimated offering expenses, were $168.2 million. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We filed the Registration Statement on Form S-1 (File No. 333-236094) for issuing additional shares as part of a secondary public offering. The Registration Statement was declared effective by the SEC on January 29, 2020. We sold an aggregate of 9,602,500 shares of common stock at a public offering price of $25.00 per share, including 1,252,500 shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares. The aggregate offering price for shares sold in the offering was $240.1 million. The underwriters for our secondary public offering were Morgan Stanley &amp; Co. LLC, Goldman Sachs &amp; Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC. The aggregate net proceeds received by the Company from the offering, net of underwriting discounts and commissions and estimated offering expenses, were $224.5 million. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from our public offerings as described in our final prospectuses filed with the SEC on February 7, 2019 and January 30, 2020, respectively, pursuant to Rule 424(b)(4). We invested the funds received in interest-bearing, investment-grade securities and government securities, corporate bonds, and commercial paper.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7.<a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a> Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section titled &#8220;Special Note Regarding Forward Looking Statements.&#8221; Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled &#8220;Risk Factors&#8221; included elsewhere in this report. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines. As a result we have identified over 100 immune system targets, have advanced four product candidates, AL001, AL002, AL003, and AL101 into clinical development, and continue to develop our research pipeline.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have been financed primarily through the issuance and sale of convertible preferred stock, our collaboration with AbbVie, and issuance of common stock upon the completion of our IPO. We completed our IPO in February 2019, and received $168.2 million net proceeds, after deducting underwriting discounts and commissions and offering expenses. We completed a follow-on offering in January 2020 and received $224.5 million net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not had any products approved for sale and have not generated any revenue from product sales nor been profitable. Further, we do not expect to generate revenue from product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one of our product candidates. We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We have incurred net losses in each year since inception and expect to continue to incur net losses for the foreseeable future. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $190.2 million, $105.4&#160;million, and $52.2 million for the years ended December&#160;31, 2020, 2019, and 2018, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $410.0 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our expenses will increase substantially in connection with our ongoing activities, as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">advance product candidates through preclinical studies and clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">pursue regulatory approval of product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">hire additional personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">continue to operate as a public company; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">acquire, discover, validate, and develop additional product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">require the manufacture of supplies for our preclinical studies and clinical trials; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain, maintain, expand, and protect our intellectual property portfolio. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any revenue from product sales and do not expect to do so in the near future. Our revenue to date has been primarily related to the AbbVie Agreement to co-develop product candidates in two </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs in clinical development with AbbVie. We recognize revenue related to our research and development grant as the related research services are performed. We recognize revenue from the upfront payments under the AbbVie Agreement over time as the services are provided. Revenues are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. In addition to receiving the upfront payments, we may also be entitled to development and regulatory milestone payments, opt-in payments for continued development after proof-of-concept for AL002 and AL003, and other future payments from profit sharing or royalties after commercialization of product candidates from such programs. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our revenue for the next several years will be derived primarily from the AbbVie Agreement. The balance of deferred revenue was $132.3&#160;million as of December&#160;31, 2020. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of proof-of-concept for AL002 and AL003. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses account for a significant portion of our operating expenses. We record research and development expenses as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of our product candidates, which include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expenses incurred under agreements with third-party contract organizations, preclinical testing organizations, and consultants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs related to production of clinical materials, including fees paid to contract manufacturers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">laboratory and vendor expenses related to the execution of preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs related to the preparation of regulatory submissions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third-party license fees; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense, and other supplies. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators, and third-party service providers. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and as services are performed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specific program expenses include expenses associated with the development of our most advanced product candidates, AL001<font style="color:#000000;"> which </font>commenced dosing of the first patient in a pivotal Phase 3 clinical trial, INFRONT-3, and remains in an ongoing<font style="color:#000000;"> Phase 2 clinical trial, </font>AL002, which commenced dosing of the first patient in a Phase 2 clinical trial, and AL003 and AL101, which are in Phase 1 clinical trials. We also have expenses related to the discovery and development of future product candidates and separately tracked expenses related to programs that we expect to move out of preclinical studies and into Phase 1 clinical trials. We do not track personnel or other operating expenses incurred for our research and development programs on a program-specific basis. These expenses primarily relate to salaries and benefits, stock-based compensation, facility expenses, including depreciation, and lab consumables. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory approvals for any product candidates that successfully complete clinical trials, and incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, information technology, human resources, and other administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, consulting, and tax services, insurance costs, and facility costs not otherwise included in research and development expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our programs. We also anticipate that we will continue to incur expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and those of the NASDAQ Stock Market on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services. In connection with our arbitration proceeding against Dr.&#160;Asa Abeliovich, our former consulting co-founder, an independent arbitrator issued a confidential decision in favor of the Company and the amount of damages will be determined in a pending proceeding. We expect these arbitration related expenses to decrease.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net consists of interest earned on our cash equivalents and marketable securities and foreign currency transaction gains and losses incurred during the period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31, 2020 and 2019</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,098</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,219</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(121</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,869</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,403</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,308</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,272</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,649</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(195,174</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114,404</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,770</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,946</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,073</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,385</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,843</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue was $21.1&#160;million for the year ended December 31, 2020, compared to $21.2&#160;million for the year ended December 31, 2019. We recognize revenue from the upfront payments under the AbbVie Agreement over time as the services are provided. Revenues are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Changes in estimates for revenue recognized over time are recognized on a cumulative basis. Revenue decreased by $0.1 million, reflecting the level of our estimated cumulative research activities on the AL002 and AL003 programs under the AbbVie Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $156.9&#160;million for the year ended December&#160;31, 2020, compared to $100.5&#160;million for the year ended December&#160;31, 2019. The increase of $56.3&#160;million was driven by a $23.3 million increase in AL001 related to manufacturing runs and continued progression through clinical trials. We had a $15.6 million increase in personnel-related expenses, including stock-based compensation, due to an increase in headcount and issuance of option grants to employees. In addition, expenses increased by $9.9 million for AL044, a recent program to progress to preclinical trials, and increased by $6.6 million for other early stage programs as we continue to invest in developing our pipeline.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,398</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,067</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,292</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,860</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL003</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,386</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL044</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other early stage programs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,983</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,560</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Indirect research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel related (including stock-based</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; compensation)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,539</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,902</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,637</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and other unallocated research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,923</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,869</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,341</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $59.4&#160;million for the year ended December&#160;31, 2020, compared to $35.1&#160;million for the year ended December 31, 2019. The increase of $24.3 million was driven by a $12.2 million increase in personnel-related expenses, including stock-based compensation, due to an increase in headcount and issuance of option grants to employees. In addition, there was an $8.2 million increase in legal expense due mainly to our arbitration proceeding that we commenced in June 2019 with decision issued in November 2020. We also had a $3.4 million increase in consulting expense to support the growth of the business related to information technology, accounting, human resources, and other administrative functions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net was $4.9 million for the year ended December 31, 2020, compared to $9.0 million for the year ended December&#160;31, 2019. The decrease of $4.1 million was due to due lower investment yields on our marketable securities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31, 201</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> and 201</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,289</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,677</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,458</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,528</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,031</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,497</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,095</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,934</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,623</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,965</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,658</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114,404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,288</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,116</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,979</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,137</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="Background-color:#auto;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue was $21.2&#160;million for the year ended December 31, 2019, compared to $27.7&#160;million for the year ended December 31, 2018. We recognize revenue from the upfront payments under the AbbVie Agreement over time as the services are provided. Revenues are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Changes in estimates for revenue recognized over time are recognized on a cumulative basis. Revenue decreased by $6.5 million, primarily due to an<font style="color:#000000;"> increase in </font>total expected costs for the AL002 and AL003 programs through the completion of proof-of-concept.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $100.5&#160;million for the year ended December&#160;31, 2019, compared to $73.0&#160;million for the year ended December&#160;31, 2018. The increase of $27.5&#160;million was driven by an $11.8 million increase in personnel related expenses, including stock-based compensation, due to an increase in headcount and issuance of option grants to employees. There was a $6.3 million increase in facilities and other unallocated research and development related to the lease expense for the new headquarters and higher depreciation expense due to purchase of property and equipment. Expenses for AL101 increased by $5.0 million as we did not incur any expenses for AL101 until the second quarter of 2018 and this year we began clinical trials in the fourth quarter of 2019. In addition, expenses increased by $3.7 million for other early stage programs, including AL044, as we continue to invest in developing our pipeline.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,067</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,531</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,159</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,044</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL003</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,386</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AL044</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other early stage programs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,980</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Indirect research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel related (including stock-based</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; compensation)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,902</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,836</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and other unallocated research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,321</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $35.1&#160;million for the year ended December&#160;31, 2019, compared to $11.9&#160;million for the year ended December 31, 2018. The increase of $23.2&#160;million was primarily due to an $10.1&#160;million increase in personnel-related expenses, including stock-based compensation, as a result of an increase in headcount and issuance of option grants to employees. Facilities and general overhead expenses increased by $6.6 million due to additional lease expense related to the lease for the new headquarters, impairment loss on the right-of-use asset related to the sublease, higher depreciation expense due to purchase of property and equipment, directors and officers insurance necessary to operate a public company, and other allocated costs from the increased headcount. The increase is also due to a $4.5&#160;million increase in legal expense due to increased costs of operating as a public company, increased patent costs, and our arbitration proceeding that we commenced in June 2019.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net was $9.0&#160;million for the year ended December 31, 2019, compared to $5.0&#160;million for the year ended December&#160;31, 2018. The increase of $4.0&#160;million was due to interest income earned after we invested the proceeds from the issuance of common stock upon completion of the IPO into marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception through December 31, 2020, our operations have been financed primarily by net proceeds of $210.5&#160;million from sales of our convertible preferred stock and through the $205.0&#160;million in upfront payments from the AbbVie Agreement. In addition, on February 7, 2019, we completed our IPO through issuing and selling 9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares, resulting in aggregate net proceeds from the offering of $168.2 million, after deducting underwriting discounts and commissions and offering costs. On January 30, 2020, we completed a follow-on offering through issuing and selling 9,602,500 shares of common stock at a public offering price of $25.00 per share, including 1,252,500 shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $224.5 million, after deducting underwriting discounts and commissions and estimated offering costs. As of December 31, 2020, we had $413.3&#160;million of cash, cash equivalents, and marketable securities. As of December 31, 2020, we had an accumulated deficit of $410.0 million. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future Funding Requirements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenditures related to our programs, and to a lesser extent, general and administrative expenditures. We expect our expenses to continue to increase in connection with our ongoing activities, in particular as we continue to advance our product candidates and our discovery programs. In addition, we expect to incur additional costs associated with operating as a public company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will enable us to fund our operating expenses and capital expenditure requirements through at least mid-2022. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We may also choose to seek additional financing opportunistically. We expect to need to obtain substantial additional funding in the future for our research and development activities and continuing operations. If we were unable to raise capital when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing and progress of preclinical and clinical development activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number and scope of preclinical and clinical programs we decide to pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful enrollment in and completion of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if our product candidates are approved, commercial manufacturing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to maintain our current research and development programs and establish new research and development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">addition and retention of key research and development personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our efforts to enhance operational, financial, and information management systems, and hire additional personnel, including personnel to support development of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing and amount of milestone and other payments we may receive under our collaboration arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our eventual commercialization plans for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property claims, including related to the ongoing arbitration proceeding that we commenced in June 2019; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing of regulatory approvals. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods indicated (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in) operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(166,734</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99,308</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,464</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,051</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,874</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(224,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,146</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, cash used in operating activities was $166.7 million. This was mainly due to the net loss of $190.2 million and the decrease in deferred revenue of $21.1 million as revenue was recognized related to the AbbVie Agreement. This was partially offset by a non-cash charges of $30.5 million for stock-based compensation and $5.9 million for depreciation and amortization expense. We also had an increase of $12.2 million in accrued liabilities and accrued clinical supply costs, which offset the cash used in operating activities.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2019, cash used in operating activities was $99.3&#160;million. This was mainly due to the net loss of $105.4 million and the decrease in deferred revenue of $21.2 million as revenue was recognized related to the AbbVie Agreement. This was offset by a non-cash charges of $16.3 million for stock-based compensation and $3.8 million for depreciation and amortization expense. We also had an increase of $9.2 million in accrued liabilities and accrued clinical supply costs.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2018, cash provided by operating activities was $127.5&#160;million. The net cash inflow from operations primarily resulted from the receipt of $200.0 million upfront payment from AbbVie in January 2018, that was reflected as a net increase in deferred revenue of $172.5 million during the period. This was mainly offset by net loss of $52.2 million. In addition, the company had a non-cash charge of $6.9 million for stock-based compensation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, cash used in investing activities of $105.1 million was primarily related to the purchase of marketable securities of $506.8&#160;million offset by the proceeds from maturities of marketable securities of $406.8&#160;million. In addition, we used cash for the purchase of $5.0 million of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2019, cash used in investing activities of $48.9&#160;million was primarily related to the purchase of marketable securities of $529.6&#160;million offset by the proceeds from maturities of marketable securities of $496.0&#160;million. In addition, we used cash for the purchase of $15.3&#160;million of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2018, cash used in investing activities of $224.1&#160;million was primarily related to the purchase of short-term marketable securities of $472.2&#160;million offset by the proceeds from maturities of marketable securities of $250.0&#160;million. In addition, we used cash for the purchase of $1.9&#160;million of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, cash provided by financing activities of $232.1&#160;million was primarily from net proceeds of the issuance of 9,602,500 shares of our common stock upon the completion of a follow-on public offering. In addition, we received $6.3 million cash from the exercise of options to purchase common stock.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2019, cash provided by financing activities of $172.4&#160;million was primarily from net proceeds of the issuance of 9,739,541 shares of our common stock upon the completion of our IPO.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2018, cash provided by financing activities of $131.1&#160;million was from net proceeds of the issuance of 9,373,633 shares of our Series E convertible preferred stock in April&#160;2018, July, and October 2018, offset by payment of $1.9 million of deferred offering costs for our IPO. </font><font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Polices and Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue from the upfront payments under the AbbVie Agreement over time as the services are provided. We recognize collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in our forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of our clinical trials. We have had changes to the overall expected costs to satisfy the performance obligations from period to period. For the year ended December 31, 2020, we had a 7% increase in the forecast of the total expected costs. For the year ended December 31, 2020, the increase in the overall expected costs to satisfy the performance obligation resulted in an approximately $6.7 million reduction in revenue compared to if the expected costs had remained the same, as a result of the cumulative catch up for the change in estimate. The balance of deferred revenue was $132.3&#160;million as of December 31, 2020. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of Phase 2 clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, contract research organizations in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, we accrue expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. We monitor patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of preclinical studies and clinical trial accruals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation is measured at the date of grant, based on the estimated fair value of the award and recognized as an expense over the employee&#8217;s requisite service period (usually the vesting period) on a straight-line </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of stock-based awards. These assumptions include: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<font style="font-style:normal;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility<font style="font-style:normal;">&#8212;We have limited information on the volatility of our stock as shares of our common stock were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry. These companies are considered to be comparable to our business over a period equivalent to the expected term of the stock-based awards. In 2020, we began giving weight to our own historical volatility in the determination of expected volatility. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate<font style="font-style:normal;">&#8212;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend<font style="font-style:normal;">&#8212;The expected dividend rate is zero because we have not historically paid and do not expect for the foreseeable future to pay a dividend on our common stock. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, we adopted Accounting Standards Update (ASU) No. 2016-13, <font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</font>. This ASU implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any changes in estimated credit losses immediately in earnings.<font style="font-size:12pt;">&#160;</font>There was no material impact to our consolidated financial statements from the adoption of ASU No. 2016-13.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.19%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes.</font> This ASU modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, and the methodology for calculating income taxes in an interim period. We early adopted this ASU as of January 1, 2020. There was no material impact to our consolidated financial statements from the adoption of ASU No. 2019-12.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A<a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Rate Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, invested in compliance with our policy. <font style="font-size:1pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had cash, cash equivalents, and marketable securities of $413.3&#160;million as of December&#160;31, 2020, which consisted primarily of bank deposits, money market funds, and short-term government marketable securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. Due to the short-term maturities of our cash equivalents and marketable securities, and the low risk profile of our marketable securities, an immediate 100 basis point increase or decrease in interest rates would cause a change in fair value of approximately $2.3 million.<font style="font-size:8pt;"> </font> </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Risk </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services with payments denominated in foreign currencies, including the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a material effect on our financial results. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8<a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>. Financial Statements and Supplementary Data. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALECTOR, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.75pt;;margin-right:1.07%;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited Consolidated Financial Statements</p></td>
<td valign="top"  style="width:1.12%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:1.12%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:1.12%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:1.12%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"><font style="text-decoration:underline;">Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit</font></a><font style="text-decoration:underline;">)</font></p></td>
<td valign="top"  style="width:1.12%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:1.12%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIALS"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:1.12%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of Alector, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Alector, Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders' equity (deficit) and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 25, 2021, expressed an unqualified opinion thereon.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.01%;width:101.01%;">
<tr>
<td style="width:24.09%;"></td>
<td style="width:76.92%;"></td>
</tr>
<tr>
<td colspan="2" valign="middle" >
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:107.3pt;;text-indent:5.05pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Description of the Matter</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded collaboration revenue of $21.1 million for the year ended December 31, 2020. As described in Note 2, collaboration revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure. In order to recognize collaboration revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations. Revenues are recognized as the program costs are incurred.</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing collaboration revenue was challenging as it involves assessing highly judgmental estimates with respect to the Company&#8217;s determination of the total expected costs to satisfy the performance obligations.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-1.01%;width:101.01%;">
<tr>
<td style="width:24.09%;"></td>
<td style="width:76.92%;"></td>
</tr>
<tr style="height:99.45pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">How We Addressed the Matter in Our Audit</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls that address the identified risks related to the Company's process used to determine total expected costs to satisfy the performance obligations, including management&#8217;s controls over updates to the budget for the relevant research and development programs.</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To test collaboration revenue, our audit procedures included, among others, obtaining an understanding of the Company&#8217;s estimated costs to satisfy the performance obligations, as well as assessing management&#8217;s updates to the budget for the relevant research and development programs. We also tested a sample of expenses recorded to the development program, evaluated the historical accuracy of management&#8217;s budget estimates for the relevant research and development programs, and inquired of Company personnel directly involved with supervising the development programs.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst&#160;&amp; Young LLP </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2017. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Jose, California </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A</font><font style="font-size:7.5pt;">LECTOR</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">, I</font><font style="font-size:7.5pt;">NC</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,969</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,641</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">363,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,364</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,470</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,476</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,617</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488,251</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,913</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities&nbsp;&nbsp;and stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,004</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical supply costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,148</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,538</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,512</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,565</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,970</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, long-term portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,236</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, long-term portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,744</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,471</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,721</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 5)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value; 200,000,000 shares authorized; 79,316,261 and 69,052,873 shares issued and outstanding as of December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676,956</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414,414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(410,048</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(219,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,530</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,743</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488,251</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,913</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A</font><font style="font-size:7.5pt;">LECTOR</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">, I</font><font style="font-size:7.5pt;">NC</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a>Consolidated Statements of Operations and Comprehensive Loss </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,677</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,869</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,528</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,031</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,403</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,095</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,934</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,272</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,623</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,965</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(195,174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114,404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,288</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,946</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190,228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain (loss) on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(189,756</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.45</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.71</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in computing net loss per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,758,806</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,734,492</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,302,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALECTOR, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"></a><a name="CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"></a>Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(In thousands, except member unit and share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other Comprehensive Income (Loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance &#8212; December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,001,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,776,153</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,153</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,187</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,033</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series E convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock, net of issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; costs of $214</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,373,633</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,035</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancellation of restricted common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,324</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance &#8212; December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,374,836</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,520</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,764,829</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,078</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97,398</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock into common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,374,836</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210,520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,374,836</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,516</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; initial public offering, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs of $3,874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,739,541</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,222</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,223</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeiture of restricted common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,973</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance &#8212; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,052,873</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414,414</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(219,820</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,743</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; follow-on public offering, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs of $1,148</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,602,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,510</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655,772</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,870</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeiture of restricted common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,754</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190,228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190,228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance &#8212; December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,316,261</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676,956</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(410,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267,530</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-size:7.5pt;">LECTOR</font>, I<font style="font-size:7.5pt;">NC</font>. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(In thousands)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,385</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,870</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,775</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premiums and accretion of discounts on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,701</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,745</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,799</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment loss on right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from disposal of property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,839</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,596</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(809</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and accrued clinical supply costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,232</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,210</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,743</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,098</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,219</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,492</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,407</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">868</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(166,734</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99,308</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,464</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,032</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,265</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,884</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(506,809</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(529,609</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(472,235</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,790</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(224,119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon initial public offering, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon follow-on public offering, net of issuance cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,603</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,050</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the exercise of options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,331</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of stock from employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,113</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,353</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,672</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,491</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,113</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,451</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; payable and accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,471</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs in accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant improvements paid by landlord</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,286</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="NOTES_TO_CONSOLIDATED_FINANCIALS"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIALS"></a></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Company and Liquidity </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public and Follow-on Offerings</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 7, 2019, the Company completed an initial public offering (IPO) through issuing and selling 9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $168.2 million, after deducting underwriting discounts and commissions and offering costs. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 45,374,836 shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the Company completed a follow-on offering through issuing and selling 9,602,500 shares of common stock at a public offering price of $25.00 per share, including 1,252,500 shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $224.5 million, after deducting underwriting discounts and commissions and estimated offering costs.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Summary of Significant Accounting Policies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates<font style="font-style:italic;">.</font> </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash, Cash Equivalents, and Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. <font style="font-size:12pt;">&#160;</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash as of December 31, 2020 relates to a letter of credit established for a lease entered into in June 2018. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,969</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,641</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,470</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity (deficit) until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, commercial paper, and overnight repurchase agreements collateralized by U.S. treasury securities. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s believes the carrying value of financial instruments, including cash and cash equivalents, receivables, accounts payable, and accrued liabilities, approximate fair value due to their short-term nature. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;1<font style="font-style:normal;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;2<font style="font-style:normal;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;3<font style="font-style:normal;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Update No.&#160;2016-02, <font style="font-style:italic;">Leases </font>on January 1, 2019. There was no material effect on the statement of operations upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds is fair value. For the year ended December 31, 2020, the Company recognized a $0.2 million impairment loss on its right-of-use asset related to decision to no longer utilize certain property through the end of the lease term. For the year ended December 31, 2019, the Company recognized a $1.2 million impairment loss on its right of use assets related to the portion of its headquarters being subleased.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when control of promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies the performance obligation. <font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company signed an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $205.0 million in upfront payments, of which $5.0 million and $200.0 million was received by the Company in October 2017 and January 2018, respectively. The Company will perform research and development services for the antibodies to the two programs through the end of Phase 2 clinical trials which the Company expects to conduct through 2023. AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration agreement with the Company for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one or both of the programs for $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million each. If AbbVie exercises its option for the programs, AbbVie will take over the development of the product candidates for such program and costs will be split between the parties. The Company will also share in profits and losses upon commercialization of any products from such program. However, following AbbVie&#8217;s exercise of its option for a program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie A</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greement, the Company will be eligible to earn up to an additional $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242.8</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in milestone payments per program related to the initiation of certain clinical studies and regulatory approval for up to three indications per program.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that there are two research and development performance obligations as part of the agreement with AbbVie, one research and development performance obligation for each of the two research and development programs. The non-refundable upfront cash payments of $5.0&#160;million and $200.0&#160;million received in October 2017 and January 2018, respectively, were included in the transaction price. None of the remaining development and regulatory milestone and program opt-in payment amounts have been included in the transaction price, as all these amounts were fully constrained as of December&#160;31, 2020 and 2019. As part of the Company&#8217;s evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestone amounts is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to royalties on net product sales will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in the Company&#8217;s forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of clinical trials. The Company has had changes to the overall expected costs to satisfy the performance obligations from period to period. For the year ended December 31, 2020, the Company had a 7% increase in the forecast of total expected costs due to changes to the clinical trial plans. For the year ended December 31, 2020, the increase in the overall expected costs to satisfy the performance obligation resulted in an approximately $6.7 million reduction in revenue compared to if the expected costs had remained the same, as a result of the cumulative catch up for the change in estimate. Collaboration revenue under the Company&#8217;s collaboration agreement with AbbVie during 2020, 2019, and 2018 was $21.1 million, $21.2 million, and $27.5&#160;million, respectively. Collaboration revenue recognized during the year ended December 31, 2020, was included in deferred revenue at the beginning of the period. The balance of deferred revenue was $132.3&#160;million as of December&#160;31, 2020. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of Phase 2 clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&#8217;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent may pay the Company up to $11.5 million in development milestones, $112.5 million in sales milestones, and future royalties for any sales. The Company retains the rights to develop and commercialize AL008 outside of China. The Company has determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement have not been included in the transaction price, as all these amounts were fully constrained as of December 31, 2020. As of December 31, 2020, no revenue has been recognized or payments received under the Innovent Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the grant agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, contract research organizations in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation for employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of options to purchase common stock are measured using the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have<font style="font-size:12pt;">&#160;</font>been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee 401(k) Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a qualified contributory savings plan under Section&#160;401(k) of the Internal Revenue Code (the &#8220;Code&#8221;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section&#160;401(k) of the Code. Eligible employees may defer up to 100% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the year ended December&#160;31, 2020, the Company made matching contributions of $0.7 million. The Company did not make any matching contributions for the years ended December 31, 2019 or 2018. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, the Company adopted Accounting Standards Update (ASU) No. 2016-13, <font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</font>. This ASU implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any changes in estimated credit losses immediately in earnings. There was no material impact to the Company&#8217;s consolidated financial statements from the adoption of ASU No. 2016-13.<font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes.</font> This ASU modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, and the methodology for calculating income taxes in an interim period. The Company has early adopted this ASU as of January 1, 2020. There was no material impact to the Company&#8217;s consolidated financial statements. There was no material impact to the Company&#8217;s consolidated financial statements from the adoption of ASU No. 2019-12.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,951</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,951</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357,725</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">401,290</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,104</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,104</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,446</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,587</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,735</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,735</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,103</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. There were no transfers between levels of the fair value hierarchy during the year ended December 31, 2020. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2020, the remaining contractual maturities of $336.9 million investments were less than one year and $64.4 million investments were after one year through two years. The Company does not intend to sell the investments that are in an unrealized loss position before recovery of their amortized cost basis, which may be maturity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Balance Sheet Components </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,542</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,222</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,610</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,458</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,222</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,764</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,554</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,265</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,957</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,413</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,181</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,852</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Liabilities </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,730</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,040</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,471</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,538</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 18, 2019, the Company initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, the Company&#8217;s former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of Alector&#8217;s confidential information that he learned during the course of rendering services to the Company as consulting Chief Scientific Officer/Chief Innovation Officer. An independent arbitrator issued </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a confidential decision in favor of Alector, finding Dr. Abeliovich liable for breach of his confidentiality agreement and for spoliation based on his destruction of documents relevant to the proceeding. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The arbitrator awarded damages for breach of the agreement and sanctions for the spoliation, as well as violation of orders during the proceeding, and the amount of such </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onetary damages will be determined in a pending further proceeding.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Leases </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company signed a lease agreement to lease approximately 105,000 square feet in office and laboratory space in South San Francisco which serves as the Company&#8217;s headquarters (the &#8220;Headquarters&#8221;). The lease expires in 2029 with an option to renew for a period of ten years. The landlord paid for $15.7 million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $1.5&#160;million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements. The measurement of the lease liabilities for the leases excludes the options to extend the term of the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#8217;s leases consist of operating expenses for the spaces. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into an agreement to sublease approximately 25,000 square feet of the Headquarters (the &#8220;Sublease&#8221;), which was amended to approximately 23,600 square feet in December 2020. The Sublease expires in November 2021. The sublessor has the option to extend the Sublease for one additional year subject to the consent of the Company. The sublessee is required to pay its proportionate share of operating expenses for the space. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, in connection with the Sublease, the Company evaluated the related right-of-use asset for impairment. The lease costs plus amortization expense of the leasehold improvements in the subleased space exceeded the sublease income over the remaining sublease term. As such, the Company recorded an impairment charge of $1.2 million in general and administrative expenses to write-down the right-of-use asset such that no loss is expected to be recognized over the sublease period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,255</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income and reimbursement of variable lease cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,263</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,008</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense under legacy guidance for the year ended December&#160;31, 2018 was $1.1&#160;million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the weighted-average remaining lease term for operating leases was 8.2 years and the weighted-average discount rate was 8.5%. Cash paid for amounts included in the measurement of lease liabilities for the year ended&#160;December 31, 2020 and 2019&#160;was&#160;$6.9 million and $3.2 million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the lease payments owed under the Company&#8217;s operating leases as of December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,872</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,171</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,732</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,130</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,378</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Present value adjustment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,122</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,256</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Stock-based Compensation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,980</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,542</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,730</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Determination of Fair Value </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3-6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 &#8211; 6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1 &#8211; 6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74%-78%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76% &#8211; 82%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73% &#8211; 81%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3% - 1.8%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4% &#8211; 2.6%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5% &#8211; 3.1%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term&#8212;<font style="font-style:normal;">The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility&#8212;<font style="font-style:normal;">The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">equivalent to the expected term of the stock-based awards.</font><font style="font-style:normal;"> In 2020</font><font style="font-style:normal;">,</font><font style="font-style:normal;"> the Company began </font><font style="font-style:normal;">giving weight to</font><font style="font-style:normal;"> in </font><font style="font-style:normal;">its</font><font style="font-style:normal;"> own historical volatility</font><font style="font-style:normal;"> in the determination of expected volatility</font><font style="font-style:normal;">.</font><font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate&#8212;<font style="font-style:normal;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Rate&#8212;<font style="font-style:normal;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock underlying its stock options in the foreseeable future. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restricted common stock generally vests over a four-year period with straight-line vesting with a 25% one-year cliff. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity for the restricted common stock is shown below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,917,848</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(866,037</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(726,659</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,754</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $0.9&#160;million, which the Company expects to recognize over a remaining weighted-average period of 0.8 years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Equity Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#8217;s employees, directors, and consultants. The Company&#8217;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options or shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing 10% or more of the outstanding shares, the exercise price of each share shall be at least 110% of the fair market value and the term of the award shall not exceed five years. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed ten years. The shares generally vest over a four-year period with straight-line vesting with a 25% one-year cliff. As of December 31, 2020, the Company had reserved 15,628,217 shares of common stock for issuance under the 2019 Plan, of which 2,973,219 shares were available for issuance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity for the options to purchase common stock shown below:</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,063,688</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.94</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,738,071</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178,648</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.52</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,442,824</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.79</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,597,148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(655,772</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.65</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(729,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.96</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,588,568</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,393</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was $11.1 million and $1.8 million for the years ended December 31, 2020 and 2019. There were no options exercised in 2018. The weighted-average grant-date fair value per share of options granted was $10.14, $12.06, and $6.27, for the years ended December 31, 2020, 2019, and 2018, respectively. As of December&#160;31, 2020, total unrecognized stock-based compensation related to unvested stock options was $82.9&#160;million, which the Company expects to recognize over a remaining weighted-average period of 2.6 years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 6, 2019, the Company adopted the 2019 Employee Stock Option Plan (2019 ESPP). The 2019 ESPP will enable eligible employees of the Company to purchase shares of common stock at a discount. Each offering period will be approximately six months long beginning on the first trading day on or after December 1 and June 1 each year. ESPP participants purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. As of December 31, 2020, there was $0.4 million in unrecognized compensation expense related to the 2019 ESPP to be recognized over five months.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Income Taxes </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net operating losses for the years ended December&#160;31, 2020, 2019, and 2018. The Company has not reflected a benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefit at federal statutory rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,948</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,081</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,972</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,570</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,010</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,387</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,493</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,251</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nondeductible expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefit recognized on utilization of attributes previous reserved</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,582</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred adjustment from amended tax return</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,073</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,280</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,346</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(449</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets consist of (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,382</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,223</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,129</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,781</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,125</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,538</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,053</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,899</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,495</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,934</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,990</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,899</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,485</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized.&#160;The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December&#160;31, 2020, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $58.2 million during the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had federal and state net operating loss (NOL) carryforwards of approximately $195.3&#160;million and $191.4&#160;million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed 80% of taxable income. State NOL carryforwards will begin to expire as early as 2030, if not utilized, or have an indefinite life. As of December&#160;31, 2020, the Company also had </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal and California tax credit carryforward of approximately $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million, respectively. The federal tax credits will begin to expire in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> while the California tax credits have no expiration date.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section&#160;382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section&#160;383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &#8220;ownership change.&#8221; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; prior year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; current year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,608</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; prior year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; current year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the unrecognized tax benefits for uncertain tax positions as of December&#160;31, 2020, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company did not accrue any interest or penalties and does not have any tax positions for interest or penalties for the year ended December&#160;31, 2020. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the year ended December 31, 2020, the Company recorded a tax reserve of $2.0 million as a reduction of the tax credit carryover. The Company&#8217;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Related Party Transactions </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its AL001 and AL101 product candidates, and the Company is developing antibodies optimized by Adimab in its AL002 and AL003 product candidates (2014 Adimab Agreement). In August 2019, the Company signed a new collaboration agreement with Adimab for research and development of additional antibodies (2019 Adimab Agreement). The Chief Executive Officer of Adimab is a Co-founder and Chairperson of the board of directors of Alector. For the years ended December&#160;31, 2020, 2019, and 2018, Alector incurred expenses of zero, $2.8&#160;million, and $2.3&#160;million for services provided by Adimab, respectively. The Company had no accrued liabilities due to Adimab as of December 31, 2020 and 2019. Under the 2014 Adimab Agreement, the Company will owe up to $3.5&#160;million in milestone payments per program to Adimab for its product candidates. The Company will also owe low- to mid- single-digit royalty payments for commercial sales of such product candidates. Under the 2019 Adimab Agreement, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company will owe certain milestone payments per program for its product candidates and low single-digit royalty payments for commercial sales of such product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, in connection with the Company&#8217;s follow-on offering, a member of the Company&#8217;s board of directors purchased 20,000 shares of the Company&#8217;s common stock at the public offering price of $25.00 per share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Net Loss Per Share</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,374,836</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock subject to future vesting</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,917,848</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,442,824</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,063,688</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares committed under ESPP</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,677</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,464</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,928,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,482,126</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,356,372</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements With<a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a> Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A<a name="ITEM_9A_CONTROLS_PROCEDURES"></a>. Controls and Procedures. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Principal Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that, as of December 31, 2020, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in&#160;Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#8220;Internal Control&#8212;Integrated Framework&#8221; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2020. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effectiveness of our internal control over financial reporting as of December 31, 2020 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.</p>
<p style="text-align:center;margin-top:22pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of Alector, Inc. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited Alector, Inc.&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Alector, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 25, 2021 expressed an unqualified opinion thereon.</font></p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Jose, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a>Item 9<a name="ITEM_9B_OR_INFORMATION"></a>B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None </p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10<a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A in connection with the Proxy Statement to be filed within 120 days after December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11<a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in the Proxy Statement to be filed within 120 days of December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12<a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in the Proxy Statement to be filed within 120 days of December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13<a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in the Proxy Statement to be filed within 120 days of December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14<a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in the Proxy Statement to be filed within 120 days of December 31, 2020, and is incorporated herein by reference.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.47%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15<a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>. Exhibits, Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The following documents are filed as part of this report: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.15%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of Alector, Inc. are filed as part of this report on Form 10-K under Item 8. Financial Statements and Supplementary Data.&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.15%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other schedules have been omitted because they are not required, not inapplicable, or the required information is included in the consolidated financial statements or notes thereto. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.15%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.47%;text-indent:-0.32%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16<a name="ITEM_16_FORM_10K_SUMMARY"></a>. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Index</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:549.9pt;;">
<tr>
<td style="width:45pt;"></td>
<td style="width:261pt;"></td>
<td style="width:40.95pt;"></td>
<td style="width:55.5pt;"></td>
<td style="width:39.9pt;"></td>
<td style="width:62.55pt;"></td>
<td style="width:45pt;"></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:9.5pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:21.55pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Title</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:1.1pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000119312519033930/d702882dex31.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of the Registrant.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38792</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/11/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000156459020045922/alec-ex31_6.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of the Registrant.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38792</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/6/2020</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:37.65pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex41.htm"><font style="text-decoration:underline;">Amended and Restated Registration Rights Agreement among the Registrant and certain of its stockholders, dated April&#160;26, 2018.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex42.htm"><font style="text-decoration:underline;">Specimen common stock certificate of the Registrant.</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex43_9.htm"><font style="text-decoration:underline;">Description of securities of the Registrant.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex101.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex102.htm"><font style="text-decoration:underline;">2017 Stock Option and Grant Plan, as amended, and forms of agreement thereunder.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex103.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">2019 Equity Incentive Plan and forms of agreements thereunder. </font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex104.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">2019 Employee Stock Purchase Plan</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex105.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Arnon Rosenthal, Ph.D.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/29/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex106.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Robert Paul, M.D., Ph.D.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/29/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex107.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Robert King, Ph.D.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/29/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex108.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Sabah Oney, Ph.D.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/29/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:25.9pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex109.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Calvin Yu.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/29/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1010.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Executive Incentive Compensation Plan.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000156459020012520/alec-ex1011_792.htm"><font style="text-decoration:underline;">Outside Director Compensation Policy.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38792</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/24/2020</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:26.65pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1012.htm"><font style="text-decoration:underline;">Form of Change in Control and Severance Agreement between the Registrant and certain of its executive officers.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:26.65pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13 </p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1014.htm"><font style="text-decoration:underline;">Lease between the Registrant and HCP Oyster Point III, LLC, dated June&#160;27, 2018.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:38.15pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14#</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1015.htm"><font style="text-decoration:underline;">Third Amended and Restated Collaboration Agreement between the Registrant and Adimab, dated September&#160;19, 2016, as amended.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:38.15pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15#</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1016.htm"><font style="text-decoration:underline;">Co-Development&#160;and Option Agreement between the Registrant and AbbVie Biotechnology, Ltd., dated October&#160;16, 2017.</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-229152</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/7/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.8pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16#</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000156459019042920/alec-ex1017_159.htm"><font style="text-decoration:underline;">2019 Collaboration Agreement between the Registrant and Adimab, LLC, dated August 16, 2019.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38792</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:28.8pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17+</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1653087/000156459019045755/alec-ex991_6.htm"><font style="text-decoration:underline;">Offer Letter between the Registrant and Shehnaaz Suliman, M.D.</font></a></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38792</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/11/2019</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex211_881.htm"><font style="text-decoration:underline;">List of subsidiaries of Registrant.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:15.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex231_6.htm"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:28.8pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Power of Attorney (included on the signature page to this Annual Report on Form 10-K).</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:549.9pt;;">
<tr>
<td style="width:45pt;"></td>
<td style="width:261pt;"></td>
<td style="width:40.95pt;"></td>
<td style="width:55.5pt;"></td>
<td style="width:39.9pt;"></td>
<td style="width:62.55pt;"></td>
<td style="width:45pt;"></td>
</tr>
<tr style="height:35.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 31.1</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex311_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:35.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex312_12.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:35.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex321_11.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:35.85pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2*</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex322_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:4.4pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.1pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.81%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicated management contract or compensatory plan.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:-4.81%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNATURES</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALECTOR, INC.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Arnon Rosenthal</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arnon Rosenthal, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-founder and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Arnon Rosenthal, Ph.D., Shehnaaz Suliman, M.D., and Calvin Yu as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his capacity as a director and/or officer of Alector, Inc.) to sign any or all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:469.1pt;;">
<tr>
<td style="width:175.5pt;"></td>
<td style="width:198pt;"></td>
<td style="width:95.6pt;"></td>
</tr>
<tr>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Signature</font><font style="font-weight:normal;">&#160;</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font><font style="font-size:12pt;font-weight:normal;">&#160;</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Date</font><font style="font-weight:normal;">&#160;</font></p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Arnon Rosenthal</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arnon Rosenthal, Ph.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-founder, Chief Executive Officer, and Director<br /><font style="font-style:italic;">(Principal Executive Officer)</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Calvin Yu</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calvin Yu</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal&#160;Financial&#160;and&#160;Accounting&#160;Officer)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Tillman Gerngross</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tillman Gerngross, Ph.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairperson of the Board</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Paula Hammond</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paula Hammond, Ph.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Louis J. Lavigne, Jr.</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Louis J. Lavigne, Jr.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Terry McGuire</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Terry McGuire</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Scheller</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Scheller, Ph.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Wehner</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Wehner</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left";>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:469.1pt;;">
<tr>
<td style="width:175.5pt;"></td>
<td style="width:198pt;"></td>
<td style="width:95.6pt;"></td>
</tr>
<tr>
<td valign="bottom"  style="white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Signature</font><font style="font-weight:normal;">&#160;</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font><font style="font-size:12pt;font-weight:normal;">&#160;</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Date</font><font style="font-weight:normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kristine Yaffe</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kristine Yaffe, M.D.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>alec-ex43_9.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex43_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><a name="_Hlk35299016"></a>Exhibit 4.3</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">DESCRIPTION OF CAPITAL STOCK</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="C3"></a>The following description summarizes certain important terms of the capital stock of Alector, Inc. (the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;), as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to this Annual Report on Form 10-K, as well as by the applicable provisions of the Delaware General Corporation Law.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Authorized Capital Stock</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of convertible preferred stock, par value $0.0001 per share. All of our outstanding shares of common stock are fully paid and&#160;non-assessable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;ALEC.&#8221; The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#8217;s address is 6201 15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>&#160;Avenue, Brooklyn, New York 11219.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Voting Rights<font style="font-weight:normal;">&#160;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Dividends<font style="font-weight:normal;">&#160;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to preferences that may be applicable to any then-outstanding convertible preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidation<font style="font-weight:normal;">&#160;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation, dissolution, or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of convertible preferred stock.</p>
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rights and Preferences</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock have no preemptive, conversion, subscription, or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences, and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our convertible preferred stock that we may designate in the future.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring, or preventing change in our control or other corporate action. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration Rights of Certain Stockholders</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our registration rights agreement, as amended, certain holders of shares of common stock or their transferees have the right to require us to register the offer and sale of their shares, or to include their shares in any registration statement we file, in each case as described below. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Demand Registration Rights </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of shares of our common stock are entitled to certain demand registration rights. The holders of at least 25% of the shares (or a lesser percent for which the anticipated aggregate offering price would be at least $15 million) having registration rights then outstanding can request that we file a registration statement to register the offer and sale of their shares. We are only obligated to effect up to two such registrations. Each such request for registration must cover securities the anticipated aggregate public offering price of which, before deducting underwriting discounts and commissions, is at least $15 million. These demand registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under certain circumstances. If we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve month period, for a period of up to 60 days. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Form S-3 Registration Rights </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of shares of our common stock are entitled to certain Form S-3 registration rights. At any time when we are eligible to file a registration statement on Form S-3, the holders of the shares having these rights then outstanding can request that we register the offer and sale of their shares of our common stock on a registration statement on Form S-3 so long as the request covers securities the anticipated aggregate public offering price of which is at least $3 million. These stockholders may make an unlimited number of requests for registration on a registration statement on Form S-3. However, we will not be required to effect a registration </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">-2</a>-</p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on Form S-3 if we have effected two such registrations within the twelve month period preceding the date of the request. Additionally, if we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve month period, for a period of up to 60 days. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Piggyback Registration Rights </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of shares of our common stock are entitled to certain &#8220;piggyback&#8221; registration rights. If we propose to register the offer and sale of shares of our common stock under the Securities Act, all holders of these shares then outstanding can request that we include their shares in such registration, subject to certain marketing and other limitations, including the right of the underwriters to limit the number of shares included in any such registration statement under certain circumstances. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to (1) a registration related to any employee benefit plan or a corporate reorganization or other transaction covered by Rule 145 promulgated under the Securities Act, (2) a registration in which the only stock being registered is common stock issuable upon conversion of debt securities also being registered, or (3) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of our common stock, the holders of these shares are entitled to notice of the registration and have the right, subject to certain limitations, to include their shares in the registration. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expenses of Registration </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will pay all expenses relating to any demand registrations, Form S-3 registrations, and piggyback registrations, subject to specified exceptions. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Termination </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registration rights terminate upon the earliest of (1) the date that is five years after the closing of our initial public offering and (2) a deemed liquidation event (as defined in our amended and restated certificate of incorporation, in effect prior to the completion of our initial public offering).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated Bylaws </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain provisions of Delaware law and certain provisions that are included in our amended and restated certificate of incorporation and amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay, deter, or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting the series and the designation of the series, the voting rights (if any) of the shares of the series and the powers, preferences, or relative, participation, optional, and other special rights, if any, and any qualifications, limitations, or restrictions, of the shares of such series. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">-3</a>-</p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Classified Board </font><font style="font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o</font><font style="font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">f </font><font style="font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Directors</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated Class I, Class II, and Class III. Each class is an equal number of directors, as nearly as possible, consisting of one-third of the total number of directors constituting the entire board of directors. The term of initial Class I directors shall terminate on the date of the 2022 annual meeting, the term of the initial Class II directors shall terminate on the date of the 2020 annual meeting, and the term of the initial Class III directors shall terminate on the date of the 2021 annual meeting. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Removal of Directors </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of no less than a majority of the shares present in person or by proxy at the meeting and entitled to vote. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Director Vacancies </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation authorizes only our board of directors to fill vacant directorships. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">No Cumulative Voting </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Special Meetings of Stockholders </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provides that, except as otherwise required by law, special meetings of the stockholders may be called only by the Chairperson of our board of directors, the Chief Executive Officer, the President, or our board of directors acting pursuant to a resolution adopted by a majority of the board of directors. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advance Notice Procedures for Director Nominations </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders must provide timely notice thereof in writing. To be timely, a stockholder<font style="color:#000000;">&#8217;</font>s notice generally will have to be delivered to and received at our principal executive offices before notice of the meeting is issued by the secretary of the company, with such notice being served not less than 90 nor more than 120 days before the meeting. Although the amended and restated bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, the amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">-4</a>-</p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Action by Written Consent </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that any action to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amending our Certificate of Incorporation and Bylaws </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation may be amended or altered in any manner provided by the Delaware General Corporation Law (&#8220;DGCL&#8221;). Our amended and restated bylaws may be adopted, amended, altered, or repealed by stockholders only upon approval of at least majority of the voting power of all the then outstanding shares of the common stock, except for any amendment of certain provisions set forth in the bylaws, which would require the approval of a two-thirds majority of our then outstanding common stock. Additionally, our amended and restated certificate of incorporation provides that our bylaws may be amended, altered, or repealed by the board of directors. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Authorized but Unissued Shares </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized but unissued shares of common stock and preferred stock are available for future issuances without stockholder approval, except as required by the listing standards of Nasdaq, and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of the company by means of a proxy contest, tender offer, merger, or otherwise. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusive Jurisdiction </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware, or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware, is the exclusive forum for (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee to the us or our stockholders, (iii) any action arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (as either may be amended from time to time), or (iv) any action asserting a claim governed by the internal affairs doctrine, except, in each case, (A) any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than such court, or (C) for which such court does not have subject matter jurisdiction. Although our amended and restated bylaws contain the exclusive of forum provisions described above, it is possible that a court could find that such provision is inapplicable for a particular claim or action or that such provision is unenforceable, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business Combinations with Interested Stockholders </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are governed by Section 203 of the DGCL. Subject to certain exceptions, Section 203 of the DGCL prohibits a public Delaware corporation from engaging in a business combination (as defined in such section) with an <font style="color:#000000;">&#8220;</font>interested stockholder<font style="color:#000000;">&#8221;</font> (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any person affiliated with such person) for a period of three </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">-5</a>-</p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years following the time that such stockholder became an interested stockholder, unless (i) prior to such time the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (A) by persons who are directors and also officers of such corporation and (B) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer); or (iii) at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we must indemnify our directors and officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors<font style="color:#000000;">&#8217;</font> and officers<font style="color:#000000;">&#8217;</font> insurance providing coverage for our directors, officers and certain employees for some liabilities. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive directors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The limitation on liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">-6</a>-</p></td></tr></table></div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>alec-ex211_881.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex211_881.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES OF REGISTRANT</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alector LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>alec-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the following Registration Statements:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11pt;">Registration Statement (Form S-3 No. 333-238230) of Alector, Inc., and</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.77%;text-indent:-5.77%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11pt;">Registration Statement (Form S-8 No. 333-237369) pertaining to the 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan of Alector, Inc.,</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.77%;text-indent:-5.77%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our reports dated February 25, 2021, with respect to the consolidated financial statements of Alector, Inc. and the effectiveness of internal control over financial reporting of Alector, Inc. included in this Annual Report (Form 10-K) of Alector, Inc. for the year ended December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Jose, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#666666;font-size:5.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A member firm of Ernst &amp; Young Global Limited</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#666666;font-size:5.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A member firm of Ernst &amp; Young Global Limited</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>alec-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex311_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO SECTION 302 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Arnon Rosenthal, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Alector, Inc;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&nbsp;&nbsp;&nbsp;&nbsp; Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 25, 2021</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Arnon Rosenthal</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arnon Rosenthal, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>alec-ex312_12.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex312_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO SECTION 302 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Calvin Yu, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Alector, Inc;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&nbsp;&nbsp;&nbsp;&nbsp; Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 25, 2021</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Calvin Yu</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Calvin Yu</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>alec-ex321_11.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex321_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Alector, Inc. (the &#8220;Company&#8221;) for the period ended December 31,2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Arnon Rosenthal</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arnon Rosenthal, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>alec-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Alector, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) </font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Calvin Yu</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Calvin Yu</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)<font style="font-weight:normal;"> </font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gou0qrw2itv5000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,1!#D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U73M.2ZC#
M$9S5_P#L*/\ NBET+_4+6U3 Q/["C_NBC^PH_P"Z*VZ*0&)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=%;=% &)_84?]T4?V%'_=
M%;=% &)_84?]T4?V%'C[HK;I#T- '*FU6VU&$ 8^:NKKG;S_ )"<'^]714 8
MFA?ZE:VZQ="_U"UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4AZ&EI#T- '/7G_ "$X/]ZNBKG;S_D)P?[U=%0!BZ%_J%K:K%T+_4+6
MU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !14$EY!%]^0"JLNLVJCY)5)H%=&C5:[O([./?)G%9,O
MB!E^X@:LN_UEKU%BD78">M.PN9&DWBZQ5L;7I/\ A+[(?P/66V@HD'GJV[C-
M9\*_:+@V_E#CVIV1#E-,ZNV\2VERX1 P)]:V4<.@8=#7,V?AA0ZS&0J1VKI(
M8O)B"9SBI-%>VI)1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ ICRJG4T^L35W99.&(XI2=D:4X
M<\K&K]IC]1^='VB/U'YURR-*YX9OSJ?9ZS'/UJ.=G0\,EU.C^T1^H_.D^TQ^
MH_.N5>216P'/YTGFR?WS^=+VA7U1=SJ_M$?J/SH^TQ^H_.N4,DHZNWYTGFR?
MWS^='M ^J+N=9]HC]1^='VB/U'YUR@DE/1V_.D\V3^^?SH]H'U1=SK/M,?J/
MSH^TQ^H_.N3\V3^^?SH\V3^^?SH]H'U3S.L^T1^H_.C[1'ZC\ZY56E89#-Q[
MTAED!^^?SH]H'U1=SJ_M,?J/SH^TQ^H_.N4$DA. [?G2EY0<;F_.CV@?5%W.
MJ^TQ^H_.C[1'ZC\ZY3S9/[Y_.CS9/[Y_.CV@?5/,ZP3HQP"/SJ6N6L9'-T@+
M$\UU"_=JXRN<]:E[-V%HHHJC$**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0]#2TAZ&@#GKS_ )"<'^]715SMY_R$X/\ >KHJ ,70
MO]0M;58NA?ZA:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**0D*,F@!:3('4BLR\UF&$$1,'<=JQ)-;N9^'C*#UIV9,IJ.YUV]?[P_.EKB
MK>ZN&O8A$S."WS<]*[1>@H:L.,E)70M%%%(84444 %4-6DGCM<P'#5?I&4,,
M, 10!PC33S,1<AFY]*K>=:+.8A&P85W5U%#%;N_E+P/2N+A@74-9; QC!XJD
MS&=,GMM+O;OYH&"IZ$5K6WA\<&[ ;'-;MO$L4*JH P*H:W?&QM-PZMQ2NV6H
M1B4-7U."RM6M8?OD<8JAX9LY9+QYYN0P]*JZ7I[ZG<F:1B5W=Z[6VMDMH@B@
M<=Z 6KN3C@8HIDDJ1#+MBE1U=0RG(-(L=1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%K'^L_
M"MVL+6?]9^%1/8WP_P#$*UDHV2'VJF6.\FI+>;RR0>AJ4Q0DYWUENCO^&3N,
MBC$JL>X%200ILW.*2W;;*0O*YIUU(%FPOW:?F)MMV0ZY2(^6$7&:00Q*WEE?
MFI))$Q&0<D4[?&TGF%L'TH)5[$EO!&HD+C([5!Y4;RY ^6GI<KEE/0TU9$63
M;GY?6C0+238>3%(K%!C;UIJ6PDCRM/WQQ*P5L[J2*X$2X'-&@_>MH$2#8X';
MK0(%6/S9!E33EE148@\M2"5)81$QP!1H+4B 1I5\L8JW&D7FL'&3BJGR12J5
M;-3+.IN&)/!%""2;V&^3'(LA4<@U"\02$,1S4D)Q<<<J3S27L@,A0=!1T*5^
M:PEC_P ?2?6NJ7[M<K8_\?2?6NI7[M73V.7%_$AU%%%:'(%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %(>AI:0]#0!SUY_P A.#_>
MKHJYV\_Y"<'^]714 8NA?ZA:VJQ="_U"UM4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 51U4RBR;R3AZO4A 88(R* .%6+,K9C;S">3BJ][++
M$?);(;UQQ7?_ &>'.?+7/TK'U_3DFLV95 ;U JN8R=);DFBV=JMNLB*-Y&6.
M:V*Y#PU=-!+)"[$\X&:Z^I9I%W04444#"BBB@ HHHH KWR&2SD4=2*XW3#]C
MUM]_IBNY8;A@UPVMP26VIF8 A2PY_&FB9=SN$.44^HKFO%Q_T-/]ZMK3+I;F
MU4@YV@"L7Q</]#3_ 'J%N$OA*FA:Q;65JRN#DFM"3Q7:@$!'S6'HVC?;AN+$
M+GFN@3PQ IR7S1H2N9HP+O5KS4)PD!8(?4&NOTI)$L8Q(?FQS3K?38+<8"*?
M?%6P !@#%!:3ZBT444AA1110 4444 %%%% !1110 4444 %%%% !1110 444
MQID3[S8H ?15234[2+[\P%5G\1:6GWKI10!J45BMXJT@?\OB5$?%NF?PW*&G
M8+F_17._\);8]IE-)_PEEIVD6BP'1T5S?_"66O\ ST6E_P"$LM/^>JT6 Z.B
MN='BVP_BG44]?%NE=[I!18+F_16,OBG2&_Y?$J9/$&F2'Y;E32L!IUB:NC-)
MP">*TH]0M9?N2@U)^ZEYX-*2NC2G/DE<Y/R7_NG\J/*?^Z?RKK?(C_N+^5'D
MQ_W%_*L_9G3];\CEH@\>?E//M3&21CD@_E76>3'_ '%_*CR8_P"XOY4_9A];
M5[V.2\I_[I_*CRG_ +I_*NM\B/\ N+^5'DQ_W%_*E[,/K?D<EY+_ -T_E36!
M4\UU_D1_W%_*N>U50MVP Q2E"R-:6(]I*UBA1@GH*4 DX%:^G6&<.X_.I2N:
MSFH*[,KRG_NG\J/*?^Z?RKK!!&!C8OY4OD1_W%_*K]F<WUOR.2\I_P"Z?RH\
ME_[I_*NM\B/^X/RH\B/^XOY4>S%];\CEHPZ _*<_2F,DCMD@_E76>3'_ '%_
M*CR8_P"XOY4_9A];5[V.:L8V%TF0>OI74+]VFB% <A1^5/JHQL85JOM'<***
M*HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/0T
MM(>AH YZ\_Y"<'^]715SMY_R$X/]ZNBH Q="_P!0M;58NA?ZA:VJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IDLJ1)N8@?C3;B=((BS'&!Q7(ZAJ,
MM](4R5C_ +P--*Y,I**NS1NO$48G6./<.<&MJSF,\ <YKBK. WMTBIR(VY-=
MS#&(HPH]*&K"A)O5DE1S()(BIZ8J2H;F40PEC2+.&M6,>N,HZ>97?#H*X.RC
M,FLL_;S,UW@Z"FR(;"T444BPHHHH **** "L+Q):&XLAMZ@YK=JIJ"[K5N.Q
MH$SG_"]R45XF/.[%3>+,?8T_WJSM".R_9?5S5GQ//YA6'T8?SI]2/L%WPH,6
M3_6N@K(T"W,%G@]^:UZ1:V"BBB@84444 %%%% !1110 4444 %%%5+G4K2T&
M9I0OUH MT9 ZFN;N_%]D@(MIED?TK&G\3:U<';;V.Y3W%.PKG<M/$@^:1!]6
M%4;C6[2WSEU;'HU<4=,U;5O]?YL.?0U>LO FT[Y;V4GT+&BR"YHW/C:R@)'D
MRM_N@G^E9LWC1KDXMHIE^JFNBM?#UK;@;@KX_O"KZ:?:)TMX_P#OFC0-3AOM
MVOWA_P!'F* ^JFE72/%EP<F]3;]/_KUWJP0K]V-1]!3P .@Q1<+'##PMJ\H_
MTB9&]?\ .:D3P2K?Z]5:NVHHNPL<FG@72_X[<&K">"-&7K;?RKI**+L+&"O@
M_1E_Y=J?_P (GH__ #[5MT4KC,3_ (132/\ GVI/^$2T<_\ +M6Y11<# ;P=
MHS=;;]:@?P/HQZ6P_2NFHIW"QR+^!=._Y9P 56?P4Z']QM6NWHHNQ6.$;PSK
MD0_T>X1?\_6H#IOBRU.3>H1[#_Z]>A4A4'J :+A8\^&JZU9G_2)&?'HIJU#X
MX2'B>"=C[*?\*[,VT#?>B0_45"^FVC];>/\ [YHN@L8MMXRL[C_EE(O^\,5K
MP:M:SXQ(@SZL*H7GABVN00K>7_NBN>N_ CHQ>&]FSZ!C1H&IW:RQM]UU/T-/
MKSE8M:TKB&*28#U-7+;Q7JD6!=V?EJ.I-%@N=U7-ZL,WIQ4MKXLTZ48EN%5_
M2IE\B_O/,C<,IJ)IM&^'FHRNR+3K N=[CI6XJ!%P*$0(H %.II6)J5'-W844
M44S,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "D/0TM(>AH YZ\_Y"<'^]715SMY_P A.#_>KHJ ,70O
M]0M;58NA?ZA:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#CM;U*2:
MX\F,-A#@\=:K6]A<7I"PY5#U!%=4^E0O-YA R3GI5U(HXQA5 ^@IW,W"[NSS
M^"2XT6^(.<%N<"NH3Q):L!P<U=OM,AO4PP /J!6(WA=4;Y9&- [-;&M%KEO*
MP XSZFF:S=1C3F974_0UC3Z#*D9\LMG'K6%=6M[!'MG+A,]2:+"<G;5&YX:B
M^T7$SD?=.:["N=\,>2L+"-LMCFNBH9459!1112*"BBB@ HHHH *CG7="X/\
M=-252U.Z6UMBS'&>* .,CN5LM09R> QXI6,FL:F6CSM!!Y%9T]F]W?;U)W$\
M =Z[70]+%K$LKKAR.0:IZ&4=36MH_*@1?114M)2U)J%%%% !1110 4444 %%
M-+JIP33@<C- !69J^KQZ5$&>-WSTVC-:=136\<^/,4-CU% '!W.NZGJQ*Z<9
M(<]-RFGVOAK6;P[M1G61#V_R:[A+2WC^Y"@^BU* !T%.XK'.VO@W2X&#FW&[
MUK;@LH+9<1)@"K%%*XPHHHH **** "BBH9[J&W'[UPM $U%58=1M;AML4H8U
M:H **** "BD+!>M (/2@!:**JSZA;6S[99 K&@"U144-Q%.,QMN%2T %%%%
M!1110 4444 %%%% "$ ]:J7.F6MVI$T>X&KE% '+W7@O3FRT, 5^QK%N=#\0
M:>=UI<JL8Z #_P"O7H5(5##! /UIW%8X*U\4W6FD)J"2RMTRJFNBT_Q/9WY
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MM71ZO=I!9NN[#D<"N;T&T-U?F29>,9YIHF78U=#TCRHQ+. 7ZJ?2N@I%4*H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#T-+2'H: .>O/\
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MOV&.@"'^U4_N-2?VK'_<:I_L,='V&.@"'^U8_P"XU']JI_<;\JF^PQT?8HZ
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M HHHH **** "BBB@ I#T-+2'H: .>O/^0G!_O5T5<[>?\A.#_>KHJ ,70O\
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MS7 :UXFGO=%F\R),YQG JHJ[$QFM^*+;4K6W#1,64<U-9^*H;+1#%!$ROGC
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M"_G\V/D$]:ZVT&VTB'HM(":BBBF 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "D+!1DD 4M9FM?:C8N+9=S]J +,U_!".9%/MFJAUR
M?_KKF;70;Z=R]QO7/^T:TU\-\<L_YT]";R[$EYXFB$;1JAW$8!K)TFUEO]06
M68$H3W%;"^&(&*EV;BMJULX[2/8@'UQ0*S>Y+&@CC5!T%/HHI%A1110 54U"
MU%U;E/QJW2'H: .9LG(DDC8_<.!6@#6=?)]EO5V_QMS5P-Q5HYY:,G!I>O6J
MLMS'"/F;%5C<7LW-M&'7L:=P2;-+:OI2YXK,!U8];<4A.K#_ )=QBES%<K-(
MFF$U1%ZT?%R K5*ES'+]QLTR'=#;[+6S@=<5>T.;-FD1^\!S51N1@U#IUP+;
M4'WG"G@4I(JG+6QT]%(IW*".]+4&X4444 %%%% !1110 4444 %%%% !1110
M 5%<[A;2;/O8XJ0G%9L^N6,,GEO* <XQ0-)O8XN_U'4+>](\QASUQ70Q3PZM
MIVR615D"X!8]ZN7&F66LH95;@]P*X_7M&EL'4PO(!V^8UGK'7H;2FI)*UFB>
MRMSIFK9=PZ^HZ5W\#!X$8=Q7E4-\6A6!V_>@Y/K7?>';[[7;%<_<&*(-+0BI
M)R=V;=%%%:&96O+M;.'S'&17$:]K&FZA93-Y(\Y!A37;7UDE]!Y3D@>U<+KW
MAC3M/L9Y!/)YA&0"?_KU4;7U!G$0R-.BJYRO85HQ9C90S9B[KZUCPOY2@GI5
M^"03RJKG$9ZFO1:AR&&MST#3-<T_3;*'RX@&8[>#77PRB:)7'1AFN+TSPII]
M[:0R">0D'.,G_&NSMX%MXEC4DA1BO-=C<EHHHI 5K\R+:R&,D-M.,5YU=7FK
M_P!G7!DDD.&../K7II /45R/BS539J;2&*,LXSC:*J+$>9HY:8M)]\]<U;>4
M"+Y/O5:O- OC;K>K#S)R1VI+31KZ33WNA%DH<5W>VAR&7([F]:W>JBTM1$[A
M>^!7>:8TKVH,I.[WKG?"6J_;$-G+&FZ$<\"NN  '  KADS5"T445(QCQJ_WA
MFG*H0848%+10 444A( R: %HK/FU>UB;:9.138]:M&;;YG- [,TJ*:CK(H93
MD&G4""L75;R5&,<9*$?Q5M54O;".]CV.2/<4 8B7L\.&>7>/05IV6K1W)VL-
MA]ZI2:']F0M 6=NP)K-(+/MF)CF')"T@.Q!!&0<TM86G:J5(AN2%/1?>MQ6#
M#(Z4P%HHHH *Q]?B#P1^S5L5C:](ODQC/\5 &6"?[8M_85UB]*Y$,/[5MW_A
M YKK8V#(".E) .HHHI@%%%% !7.7MNUE<F95)WGG%='45PF^!QM!..,BLZE-
M5(\K&G9F/!=1RKU /H31<!'A;)'3BN/U66\L=0+A< =LUHZ=JL-ZOE3R;2>.
M*\B6"FI6BSJY9*/,:^G7OV.$ACE<]>U95AJM[=ZQ(JRL8P_3VI=;>*RTMK>!
MR<\Y/6KGA#3S$CS.OWQD$UZD$TE%]"5%*FYOKL=8/NCZ4M%%;G,(QPI^E8<+
MB1+L8Z5>U6Y:VM=R=<XJ"*V$>GRRC[TBY- $^C@"Q7%7ZS-&D_T14;[U:= !
M1110 4444 %%%% !1110 4444 %%%% !534;H6MHTF>1VJQ+((HV8GH*YB\O
M6NY=Q_U X8T 5C(PF$O7SCBNHT^U%K;[1WYK#TZU-W-\P_=(<J:Z8#"@>@H
M6JU[>):0EVYQVI]Q.MO&68XXXKG9)3J$WF,?W?3B@"">8W#F28Y7J@-6K"RE
MN\2,<1?W352\CMI3&/,(,9X [U9AU2Z@( C40CO2$;,6DVJ'/E#-7$147"C
MJM:7\-TORMEAUJW3&%%%% !2'H:6D/0T <]>?\A.#_>KHJYV\_Y"<'^]714
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M X&_N/L^KNWE&3YN@J&]MI]1U2.[6%T55QC%=6=&0WK3%<Y.:UEB15 "K^5
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MG83"2  '[HQ5>3E2/:LZSN6L+GRG. YS30T=)134<.NY>AIU,84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2'H:6D/0T <]>?\A.#_ 'JZ*N=O
M/^0G!_O5T5 &+H7^H6MJL30O]2M;= !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %5YK&VN&W2Q*Q]ZL44 5$TVSC.4@4&IU@B5]P0!O6F7=S':
M6[S2'"J,DU6TK5;?5K;S[=MR9QF@"T;6$DGRQSUH2UAC?>D8#>M344 %%%%
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ML259FO8'MV\UL*10!@Z5<2G5+A#(2@C) _ U0T+6YK6:\#1-*!(>?3FKNEP
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M&_AOX%DB;((S0T"9;HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:[K&NY
MB *=7,>,M0DLM,!B.&+XH U6U>(,0N& ZD5<MYUN(@Z]#6/I.D0/IR2MG=,N
M6J:YN8-#ME!)"9P* -BBL>]UJ*WCBPWS2#*UE:=KUU<:S);R$>6JY_G0!UM5
MKR\CLT5Y&"@G S61+KP)9HF^5.&K$\7:G'=:+;2*QSYH)_,4 =PDBO&'!&",
MYI-\4I*9#>U8.G:I%-91(K9 4 T@U&UM+EV#'=B@#;6RME;<L*AO6IP !@5S
MH\0YDW;OW8ZU)<>(X/*!B?YN] &_16/IFMQ79V,WSD\5K%AZT .HIN\>M&\>
MM #J1CA2?2DWCUJ.>0"!SGM0!F;3-K"3#H!BMFLO2#YL3.>H:M2@ HHHH *1
ME#*5(R#2T4 <W?1FSU#S%&(O3M5I&WH&'>K>JVOVFT*@<UEV4P?=%WCXI,1;
MHHHJ0&NX1<L<52MX)-1N@Q)5$/(]:+DM=3_9D^\.:WK.V6WA4 <XYJD!-'&D
M2!$4*H["GT44QA1110 4444 %%%% !1110 4444 %%%% !4<T231E'4$'L:D
MHH Y>ZT^6TF+@&5&/"^E-4.PRMN4_"NIP#U I"BGL*5@.9*28_U1SZU6<3[_
M /CX,8]*Z[RUQC JA=Z1!<Y)SGVHL(HV.K,A$<JD@<;CWK=CD25=R$$>U<I<
M126Q9)QA.B8K3T1W\L*O^K]Z8S;HHHH *0]#2TAZ&@#GKS_D)P?[U=%7.WG_
M "$X/]ZNBH Q=#_U"UM5BZ%_J%K:H YS5?\ C[;ZTZ%HP%Y IVJ1.]PQ K/\
MB7TK%W3/2@E*"5S0\]!*W(Y%4I(P,MO_  IGV>7TH\B7TI-MEQBH[,L,P:U0
M;N0:;)* RD'H*B\B7TI/LTGI2U&E'N6I)E\I6&-QZT^%T'.0*I?9Y/2E\B7T
MIW8G"-K7+9F42'GK3$94NU.[(JM]GDSTH\B7THNPY8]RZ95>5QD#WIH=8K=D
MW Y-5/L\OI1]GE]*+L.2/<GEE!6/!Z&H[MP[@CTIGV>3TH^SR>E+4I**>Y-I
MPS,/K74#[H^E<Y80.LN2.]=&.@K2GL<6*=Y"T'I116ARGG>O#;K]G[RUZ$G^
MK7Z"N \4+Y>NZ>?67_&N_3_5K]!38D.HHHI#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH H:EI5OJ$#(\:[C_$:X:6VU'PU>F5'DGA8\(.BBN^N
MK^&S0M*V *B2:UU2%E7E2*:8BII'B&WU&-0S*DG3:3S6R"",BN%U;PO/8S&[
MTI3Y@Z9JQI/BU8G6UU!L3#Y?QHMV"YV=%,BE25 RG(-/I#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K#\3:4=3T_RU.&#9K<HH YK3]5FMK40-;-^Z&T>]/U*-M9TH
M%HS&P^;FMQK:-FR0/RJMJ,5Q]E"6@&[//TH Y+0(9=4:83 _Z.VU<U8L[9XO
M$-P/)(79PWYUT>E6 LD8D8=^6^M7?)3>7QR: .,M_,M(KI'M2Y=CCBLK6])N
MKO2H6C1QE_N =.E>CM;QN02!Q[4[RD*[<# ]J .&T6WN-,A%O)"TAD'WB/NU
M)<V,[79/EL1FNU,:9S@<>U+L7T% '+3V!&FN%B^?%8*:5=0@2L'8-_#Z5Z/M
M&,8I&A1EP0/RH YS0[(AA(8]I!K6FL)I)"RSD ]JNI&L8PHI] &7_9L__/P:
M/[-G_P"?@UJ44 9?]FS_ //P:/[,F/6X)%:E% $%K;BVCV"IZ** "BBB@ HH
MHH 0C((KFDC^S7DI/\;5TU8&LXBN8,?Q&DP)ZCG?9 [#J!4@Z53O)=LB1?W^
M*0BSHT'F@73#YC6W533X?(M50C%6ZH84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 126\4O\ K(PWUIT<,<0PB!1[4^B@ HHHH *0
M]#2TAZ&@#GKS_D)P?[U=%7.WG_(3@_WJZ*@#%T+_ %"UM5BZ%_J%K:H 8T2,
M<E0:3R(O[@J2B@=V1^1%_<%'D1?W!4E% 79'Y$7]P4>1%_<%244!=D?D1?W!
M1Y$7]P5)10%V1^1%_<%'D1?W!4E(2!U- 78SR(O[@H\B+^X*DHH"[(_(B_N"
MCR(O[@J2B@+L8(HU/"@4^BB@5PHHHH X/QFNW6=*/K)_C7=1_P"K7Z"N/\9Q
M9OM.?^Z^?YUU%A-YUJK9[4WL)%JBBD)P":0Q:*Q/[>A^V_9]W.[%;0.1F@!:
M*:[!%+'H*BBNHIFPAR: )Z*** "BBB@ HHHH **** "BBJ]W=I:Q;G./2@"Q
M45PXC@=L]!659:VES<B'/)/%,\27K6MNFT_>X- KJUSG9YYK^]QN)&2-GK73
M:)I[V@,C,?F'W?2L?0+0W%TMT!\H/-=C39,%U8A 88(R*P-9\-07\9:%5BE'
M.X=:Z"BD6>;V]WJ?ANY\J59;F,<[CTKLM-UZTOD7,J+(>JYY%7KJSAO(C'*H
M(/M7&:EX2ELIOM.E@[\Y;-/<6QW0((R*6N%L?%<^GR"#53AAZ5U]GJ$%]$'B
M;((SUHL.Y;HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 51U34DTRU\YP",XYJ]7,>-X'GT=50<
M[Q0!<A\0*\#2R1^6 ,KGO4=MXEBFEVNH1?[QK+U73YI-*M&0?*D8W5GZ?;VM
MW#Y#!MP% '53ZZ$8""/S@>I7M4DFM1PV2SS 1D\8-<_I<D6BM(EWG#GY*9XH
MA.J:7'); [-^?Y4 ;,'B6*698V4)N/&>].F\1!+IH(XO,*\G%<U:V]I<RV^X
M-YD8Q1;7EO9>)+M9,\H0/UH Z*Y\0@:7/<)'EHQT%&BZ\U[IZ3S1&,$9!/>L
M&UM)9=)OBHX=B15JT!ET.&TC'[V/EOI0!KKX@)EP8"$!Y;M4D^O1Q*I10^3C
MBL)[ZWFL9+1,^<>!Q45E82A8ED!R"* .RLKEKJ+>T93V-6:9$ L2#V%/H **
M** "BBB@ HHHH *.E%5;V\BM;=GD8  >M $CW4$?WY5'UIB7]K(VU)T8^@->
M.>*_%5RUZPLF/E5TW@;3+Z<&[O<X;YDJK"N>C5S_ (@_X^K7Z_XUT X&*P/$
M'_'S:_6I&3CI69J'_(2M/]ZM)?NBLW4/^0E9_P"]4H1U0Z"EI!T%+5#"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MD/0TM(>AH YZ\_Y"<'^]715SMY_R$X/]ZNBH Q="_P!0M;58NA?ZA:VJ "BB
MB@ HHHH **** "BBB@ KE?$4US%>KY;,L>.2.E=552^LH[V!HW&0:!-71EZ-
MJZRJ(I6Q@<,>];P.1D5P-Y;-IMST(13\M=1HVIBZ@"NWS=!39,9=&:](2%&2
M<"EJEJOG&Q?R/O\ :D66PZM]TYIU<98:W/!=&*X;OBNN@G2>,.IR*+"33):*
M**!G->+(MT,<G]P9JSX5N/M&D!\YYJ7Q'#YFCW#=U0XK%^'TY;1 K'G<:?07
M4[&D/*D>U+12&<5JMLUE>>:%R2V16[HNI"YA5'.)/0U;U&Q6[A/&7 ^6N/S-
MIEXV.)@.:>Y'PNYT.O7WD((@<;QU]*I>';>87'FM*SH160UVVKSK')RP.*[+
M2K3['9+$1R* 6KN7J***184444 %%%% !114<LJPH68\ 4 .=PBEF. .]<?K
M.H-=SF!3M4'@^M6;_5Y+PM';M^[Z&L812><&E^XIR*I(RE-;&_H&F[%\Z088
M'C-4M7N$N[MH&(^4\5;?78UMO+@;]X!@5BPV\E_?[T&9-V6H02M;E1TFD^5I
MVGL78#G/-:L%S'<+F-@?I65J^GF32F1!\V!_*L70[Q[&X\F8\'@4B[VT.UHI
M%.5!]12TB@I" 1@TM% &7J.AVE_&08D#G^+%<?<Z'J6BS&>"XEE3.=BUZ)2%
M0PP13N*QQ^F>,&+"*]MS!ZL]=1;7UM=(##*K_2LS5O#-EJBGS%.X^E<Q)H^M
M:(^[3\"$=<^E&C ]#HKBK#QHD#B#42?-[X%=5::C;WB!XG&#ZFBP[ENBC.>E
M%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IDL,<R[9$##T-/HH 88HVCV% 5QC%1)8VL9RD"*?:K%% $$EE;2D&
M2%6QTS2_98/+\ORUVCM4U% %7[!;*"4A56]161;:#&NM2W4JAPPZ&NAHH B2
MVA1"BQJ%/4"D2U@0DK$HS4U% %8:?:!MP@0-ZXJ46\0.1&*DHH **** "BBB
M@ HHJM<WT%HA>1A@>] %FH+B\@M4W32JGUKD]0\;0.Q@L6;SCTXK/33M<UQ\
MWN# >F/2G85S5U/Q?Y>8[*'[0>Q2LB'2=3UV;S9II8$SG8:Z72?"MEIF&13O
MZ\UOJH48 %%PL<R/!UF;?RW1&;^\1706EK':6Z11J %&.*GHI7&%8'B#_CZM
M?K_C6_6%K6&N;?V- $O85F7X_P")C:'T:M.LZ_'^E0-Z&I0CJ%.5!I:@M&W0
M U/5#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D/0TM(>AH YZ\_Y"<'^]715SMY_P A.#_>KHJ ,70O]0M;58NA
M?ZA:VJ "BBB@ HHHH **** "BBB@ HHHH S]3T]+N$_*-P&:X_\ ?:;>;LL,
M?P^M>@5DZKI*7:F5%_? <4TR91OJB33M3BNHE!8!L<BM$@,,'D5P313:9*6
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MB@ HHHH **** "BBB@ HHHH **** ();2&4'?&I)[FLFY\.K.V5DV#T%;M%
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MKS7.*]!I,#T%.XK'!P^,]0A;9-ID@ [G_P#76W9^*[68?OV2(^A-:USIMO=
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M^Z*/LD/]VBZ XK_A-]4_Z \GZ?XTA\::L>FCR?I_C757RI;E"  #UJ6T,,R
M@"ES*]BW3ER\QQI\6:P__,*E'Y?XTTZYK,H_Y!\J_P"?K7?B)!T IVT#L*=R
M+'GF[6+D\I,E/71=4GZW4R9]Z] P/04M%PL<!_PANH2\G59A[9_^M5J#P1.
M/,U%W^O_ .JNUHHN%CFH?"-NG^L*R?45I0:!I\('^BQ$^N*TZ*+CL5TL;6+[
MD"+]!4X11T&*6BD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'
MH:YJWYO9_9JZ4_=/TKF;3_C]N?\ >I,"_5:Z[59JM==J0C5TS_CS6KE4]-_X
M\UJY5#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGYJ+$N71$^DV)GOEEZKW-=BBA$"CM533K)+. *HQGFKM)E15D%%%% PHHHH
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MZK6(Q;**LU0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ2)G24,0?RIIB=/S+4R_.#NZ&@RJTZX/:J\LCN> ?RJ$!P<X/Y47&H::EI&
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M>2*H:5I[74I,XRJ\BFB6V]$06MC<7H\J56VG^(UKV_AM(L'S3]*V8ECA3:I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDW$[ ,C 5U&FZ4EH@8\M[U/#=PDX52OUJX&4]"#]#1<TIX>,-3.O9,WL5O\
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M(Y%)@4*_8U@Q+-;7R1HK!@V&..M!.J.WHIJ9V+GTIU(L**** "BBB@ HHHH
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M]T_E0Q1LB[I/^L/UKHZY_2XV60Y!Z^E=!6T-CS\2_?"D/0TM(>AJSG.>O/\
MD)P?[U=%7.WG_(3@_P!ZNBH Q="_U"UM5BZ%_J%K:H **** "BBB@ HHHH *
M*** &/&D@PR@_44)&D8PB@?04^B@ HHHH **** "BBB@ H/ HK.U:\^S6K%3
M\WI0!D:O?M/+Y<1SL."!3])T[SY1<N,?[/:J-K%]KNE>,8R<O[UU\,2PQA4&
M!39*U=P$$0& B_E2^3%_SS7\J?12*,_43%%;M'M4%AQQ6%I*E[S[,P^4<U<U
MZ7,\.#P#S2Z5$#>^<.A%/H3U-]5VJ%':EHHI%!1110 4444 %<MJL96ZD=N
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MA?ZA:VJQ="_U"UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5S&M0W1O]\:%EQT[5T]13>6J[GQCWH$U<S])TX6T?FM]YQD@]JTV=5ZFN=OM
M=&3%!D,.,UG+=ZA(<LS'\*8KI'7->0)]Y\52N=8@C4['!-8.+F3A@QS[5+!H
M,\S^86 4]C1H%V59;Y)VD,K8;/RUNZ",VJMWJAJ&A*D2R!1\@R:;HE]LG$1R
M$]Z.@EH]3JZ*12&4$=Z6D6%%%% !1110 UV"*6)X%<=J=VPO'9.0:Z35I=EE
M(H.&(XKG=)M#>7!$O.!FFB9:Z%>QNI%O$EE&Q17:PS)/&'0Y!KG-7TQHR'C'
M[M1R!WJ'3=6-JX63/E] OI1N"TT.MJK=V:7,1! S]*E@G2=-RD?G4M(HY!M+
MNH;G$2-MSUKJ+166V0/]X#FIZ*!)6"BBB@84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNF"SC!?!D[FF2U=EV%/*A5/08J2BBD4%%%% !1110!%)!'*<LH/U%/10B[5
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M=')96\H = 0!BE@M(;?_ %2!: )^U%%% !1110 4444 %%%% !1110 4444
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MXP>$,=NSIFLO3+-IY]2NFFDW0,2HW'':NGL_#[Q:A]KF8,Y&,U<LM'CM3<Y
MQ,>: .8L[5=4MA=SSR))Z*QQ5:2\GGN%MBS!%.T$&NBF\/SB7_1I D7]VK(T
M&(-&VT;AU/K0!S$L+:7(L\<KL20,,QKN[1S):1.>I4&L^YT=+A0"!P<UIQ)Y
M42H/X1B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4AZ&EI#T- '/7G_(3@_WJZ*N=O/^0G!_O5T5 &+H7^H6MJL70O\
M4+6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'H:6D/
M0T <]>?\A.#_ 'JZ*N=O/^0G!_O5T5 &+H7^H6MJL70O]0M;5 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH <GWQ5ZB
%BD!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gou0qrw2itv5000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0(!:H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-]_S^W'_ '];_&CZH^X?7E_*?6=%5[$DZ?;$G),2_P A5BN0[PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1R,CC#*2"/>HI)7=F:5V[*Z&UZ/\$_\ D>9O^O&3_P!"2O.*]'^"?_(\S?\
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M<NG)19V.?^ D\UWGB+68_ ?A^T33]-:Y4$1)$I(Z#J2 :Y.S^,=Q<ZE!9R:
M(S(X0_Z0<C/MMJKM[$-);LZ[4-6U#3?AW)J%^?+U 6O)Q@AR../7->5^&-(\
M6^+;:XN[77KN)8WP0]RXR3GIS7>?&&^^S^$DM@<&YF"_ES7"^%?B$_A+PY]B
MCTDRR/(7$KN5!S^%$;VT"35[,FTWQ3XF\)^+4TG5+M[A!*J31R-ORIQR#UZ&
MO3O'VLRZ/X-N;JVD,<\@"1L.H)_^L#7GOA#PUJ/C'Q&/%&K%%M_-$@ .=Y7H
M,=AQBM;XT7NS3-.TY3S+*9,#_9&/_9J'9M FU%LY'P/XOU6S\56:7^H7,UK<
MN$=9Y"PY.,\],5Z]X[U1])\'7]S#(4F*!8V4X.21T_#->2>.?#QT?1?#]_"N
MW=;*KD?WOO9_6MGQ_P")!JOP^T4JW[RY8/(!_LJ01^9%#5VF";2:9U/PG>^N
M/#$MU?W4]PTLY*--(6(4 #O[YKO:Y_P38_V=X-TRWQ@^5O/_  (EOZUODA5+
M$X &2:A[FD=A:*P7\:>'$=D;5[<,IP1SP?RK6LKZVU&U6YM)EFA?[KKT-*P[
MH=>7*6=G-<R?<B0L?PKQ.'5/%'Q(UN:'3[Y[&UB!8!'*!5SQG')->T:E9+J.
MFW%FQPLT90GTS7@$+>(?AGKTC^3\A^4DC*2KGU[5<2)_@=[X:\*>+O#_ (D@
M:XU1KO3B#YQ,I8?DQKT2"_L[J1X[>ZAE=/O*C@E?K6'X7\5V?B_1Y)+<&.=5
MVRPD\J2/Y5YC\.Y&TWXG7.GNQPS31')_NY/]*+7W"Z5K'MEQ=VUHH:YGCA4G
M ,C!<_G1)=V\5O\ :))XTAQGS&8!?SKQKXG:A+KGC&RT.S8L(<*0I_C8\_D
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MJG/JVG6LPAN+ZVBE/1'E )_"N8\;>*)O#O@Z.=#B^N46-">S$<G\.:X/PO\
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MYC]/Z5T$?PABL[NSN;35IO,AE5Y-RXW '/'-+E2W'S-['IU% X&**DL****
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MJG_7$_RKI:J:GIMOJ^G36-T&,$RE7"G!Q36X/8\P^"]M!/IVJF:&.0B2/&]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!Z45MB,8ZTXSM9HQH854H.%[W/G!_#&N(Y5M*N@0<']V:3_A&M;_ .@7=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** )8/OGZ58JO!]\_2K% !1110!Y9\<_^
M18TW_K\_]D:O"*]W^.?_ "+&F_\ 7Y_[(U>$5Z.&_AGDXO\ BL****W.8***
M* "O1_@G_P CS-_UXR?^A)7G%>C_  3_ .1YF_Z\9/\ T)*SK? S6A_$B?0=
M>:?%[6-0T2RT^YTVZ>VF9RA=,9*XSCGZ"O2Z\F^.7_((T[_KL?Y5Y])7FCU:
M[:IMH\T_X6#XL_Z#=S_X[_A1_P +!\6?]!NY_P#'?\*YJBO2Y(]CQ_:3[LZ7
M_A8/BS_H-W/_ ([_ (4?\+!\6?\ 0;N?_'?\*YJBCDCV#VD^[.E_X6#XL_Z#
M=S_X[_A1_P +!\6?]!NY_P#'?\*YJBCDCV#VD^[.E_X6#XL_Z#=S_P"._P"%
M'_"P?%G_ $&[G_QW_"N:HHY(]@]I/NSI?^%@^+/^@W<_^._X4?\ "P?%G_0;
MN?\ QW_"N:HHY(]@]I/NSI?^%@^+/^@W<_\ CO\ A1_PL'Q9_P!!NY_\=_PK
MFJ*.2/8/:3[LZ7_A8/BS_H-W/_CO^%'_  L'Q9_T&[G_ ,=_PKFJ*.2/8/:3
M[L]U^$VOZKKMMJC:G>R7+1/&$+X^7(;/3Z"O1Z\G^"'_ !YZU_UTB_DU>L5Y
MU=)5&D>MAFW2384445D;A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$L'WS]*L57@^^?I5B@ HHHH \L^.?_(L:;_U^?\ LC5X17N_QS_Y%C3?^OS_
M -D:O"*]'#?PSR<7_%84445N<P4444 %>C_!/_D>9O\ KQD_]"2O.*]'^"?_
M "/,W_7C)_Z$E9UO@9K0_B1/H.O)OCE_R"-._P"NQ_E7K->3?'+_ )!&G?\
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MW-K#.HPLJ!P#Z$9I.-@C),EHHHI%!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHNVY4E?8X7XC^.]%UGPV=,TZ9IY))%8L%P% .:=H=_)X?^"]Q<@E9IW98O\
M@1'],US/BBWTG5M?M-"\)V:;%;:9$);>QZ\GL*[CX@Z*=.^&-M96^2EFR;R!
MU&".?Q(JM-$1JVV97P;T2.=KS6IT#R(_E1ENQP"3^M>LWA46-P7^X(V+?3%>
M:?"37]-AT";3Y[F&"X28L%=@-P('-:'Q!\>6&GZ--8:?<QSWMPI3]VV1&#U)
MQ^5)IN146E$X;X9*9/B1(\7"!93QTQFHOB/J,4_Q%)E)-O;/&CA1DX!&['Y5
MV'PF\-2Z;IMQK=VA26X7$0;J$'?\?Z5R7A*VB\4_$Z:YN(UFMVDEG=6&00<X
M_4BJOK<BSLD;GB/XG6>JZ&VC:'9W+R7""',JA2!TX )S6_\ "WPG=:!IT]Y?
MIY=S=8VQ]U7WKB_B;HD'AKQ!97^EI]F64;@(SC#J>2/3J*];TO6/M7@Z'5V8
M%OL?G.?<+DU+VT*7Q:GB.OZO:M\4)K^\WM:0W(W!!D[0.WXUZEIGQ3T#5M2@
ML;:&_P#.F8*NZ)0,^_S5Y[\--+M]>\8WMQ>0I<0(K,5<9&6/'\C7LUMX=T>R
MN%GMM-MHI5^ZZQ@$4Y6V"-]S3KQGXI>)Y-5U&/PWIA,BJX$NS^-^R_A7=^/?
M%*>&=!=D8?;)\I"O\S^']:X?X4>%WO;M_$E^I?#GR2_.YN[?GFE%6U8Y.[Y4
M=_X)\,Q^&?#\5O@&YD >=_5O3\*V;Z^L])LI;RZD2&% 69O\]Z9J^K6FB:;+
M?WLFR&,<^I/H/>O$-5U^^^(NN"U:[BL-,C.0)9 J@>ISU-))O4;:CHBK#;W?
MQ!\?/<0Q%8&EW,V.$0'O7T)#$L$$<*?=C4*OT Q7-^%+?PYHMG'INE7MK+*W
M+%9%9Y#ZUT]$G<(JP4445)04444 %%%% !1110 4444 %%%% !1110 4444
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M?9ILAA0*H]?<^]7*YCPOJ'BR\NIE\0Z79V<*IF-H&)+-GH<D]JZ>D4@HHHH
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MUU:"ZBF4P$9#G@?K4ZL&4,I!4C(([UB:Q;I:^#[B!!A4@  _*M#2?^0-9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP?+A46T9/M][^0H Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
ME@^^?I5BJ\'WS]*L4 %%%% 'EGQS_P"18TW_ *_/_9&KPBO=_CG_ ,BQIO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]D:O!Z]'#?PSR<7_ !6%%%%;G,%%%% !7H_P3_Y'F;_KQD_]"2O.*]'^"?\
MR/,W_7C)_P"A)6=;X&:T/XL3Z#KR;XY?\@C3O^NQ_E7K->3?'+_D$:=_UV/\
MJ\^C_$1ZF(_A2/#Z***]0\4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Z[X8_\E"TOZR?^BVKZ.KYQ^&/_)0M+^LG_HMJ^CJX,5\:/4P7
M\-^H4445S'8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-_UXR?\ H25YWBO1?@J/^*XF_P"O*3_T)*BM_#9KA_XL3Z!KR;XY?\@C3O\
MKL?Y5ZS7DWQR_P"01IW_ %V/\J\ZC_$1ZN(_A2/#Z***]0\4**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Z[X8_P#)0M+^LG_HMJ^CJ^<?
MAC_R4+2_K)_Z+:OHZN#%?&CU,%_#?J%%%%<QV'/^,O$7_",>'9M055>8$+&C
M="2<?_7KA_"/Q3OM8\16^GZA;V\<4^55DR"&[?UJM\6[]]2US3?#]N<MN4L!
M_?;@?H:QO'^A?\(KK&D7MHI2,Q+T_OKU_G6B2L9RD[Z'O5>::=\0]2N_B!_8
M+V\ MC,T>X9W8 KOM(U!-5TBTOHR")HE<X[$CD?G7B.A_P#)9U_Z^W_D:F*W
M')[6/>Z\X\8?$J72=7.CZ/:BYO%.UR03AO0 =37H]?/OBJ/4/"GQ&DU9H"ZF
M<S1,WW7![9]:(I-A-M(ZB'Q]XQTVZA;6-%86LC!2QA*XS[^M>LJ=R!O49KCO
M#GQ#T/Q+Y=NY^SW9_P"6,P&"?8]_TKLJ)#CZA1114E!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC-39=R[OL<A\1?#-EX5UNW.F3,BS+Y@CW<QG)Z'KCBO<O#T\]SX>L)KG_7O
MI?ZXKSW2/A),VHI>>(-0%UM()C3+!_8DXXKU)$6-%1  JC  [4Y/H**L[CJ*
M**@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9L8\N4J3]?E)% '.RZ?!8>+M&$>YG9)"\CL69CM/)_P'%=;7.ZG_ ,CEHO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSSR?:9#(PE?(3V7T%7Z* .=\-1FYNM2U9@1]IFVQYZ[%X'ZDUT5%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG9_\+.U[^Y9?]^C_ /%4?\+.U[^Y9?\ ?H__ !5<911]6H_RH/KF(_G9V?\
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MC_\ %5QE%'U:C_*@^N8C^=G9_P#"SM>_N67_ 'Z/_P 51_PL[7O[EE_WZ/\
M\57&44?5J/\ *@^N8C^=G9_\+.U[^Y9?]^C_ /%4?\+.U[^Y9?\ ?H__ !5<
M911]6H_RH/KF(_G9V?\ PL[7O[EE_P!^C_\ %4?\+.U[^Y9?]^C_ /%5QE%'
MU:C_ "H/KF(_G9V?_"SM>_N67_?H_P#Q5'_"SM>_N67_ 'Z/_P 57&44?5J/
M\J#ZYB/YV=G_ ,+.U[^Y9?\ ?H__ !5'_"SM>_N67_?H_P#Q5<911]6H_P J
M#ZYB/YV>_>&]1GU;P]9WUP$$TRDML&!]XC^E:M<_X(_Y$W3?]QO_ $(UT%>%
M524Y)=SZ>@W*E%OL@HHHJ#4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"6#[Y^E6*KP??/TJQ0 4444 ><_&'_D7K#_ *^O_9&KQK%>S?&#
M_D7[#_KZ_P#9&KQO%>O@_P"$CP,P_CLT- MQ<^(=.A.,-<1Y^FX5L?$.Y>?Q
MC>1%B4M\1(">@ _^O6%IEZVFZG;7BH&,,BOM/?!KNYOB1IMQ*TL_AFREE8Y9
MWB4DGW)K2:DIJ25]#.FX.FXRE;4\WQ7=>$7>[\%^)+!R2BQI)'G^$Y.:M?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBBBH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 2P??/TJQ5>#[Y^E6*
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M74.W(4GD_A3JP/$P^S&QU-5^>VG 8_[#=?Y"@#?HHHH **** "BBB@ HHHH
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M_$N?Y4^UM+^+5;NXGO\ S;20+Y-OL \K'7GOF@#.T#C7-=!X/G@X_ T>,O\
MD"H.YN$ 'K5F]T>8ZC_:.FW(MKIEVR!UW1R#W'!R/8BFQZ1=W-W%<ZM=QS^0
M<Q101E(P?4@DDG\: -JL/Q?C_A&;O/H,?7-7-4M+ZZ%O]AOOLGERAY?D#>8O
M=?:L[Q63<6]GIB',EW. 0/[HZG^5 &[!N^SQ[OO;1FI* ,# [44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#W/P1_R)NF_P"XW_H1KH*Y_P $?\B;IO\ N-_Z$:Z"OG*W\27J
MSZ_#_P &'HOR"BBBLS8**** "BBB@ HHHH #R,&HX+>&VB\N")(TR3M08&2<
MG]:DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(A:P"Y-R(4$Y7:9-OS$>F?QJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *B>V@>X2=X4::,$(Y7E0>N#4M% !1110 4444 %%%% !1110 4444
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M.:)_T";+_OPO^%:=%'M)]P]E#^5&9_PCFB?] FR_[\+_ (4?\(YHG_0)LO\
MOPO^%:=%'M)]P]E#^5&9_P (YHG_ $";+_OPO^%'_".:)_T";+_OPO\ A6G1
M1[2?</90_E1F?\(YHG_0)LO^_"_X4?\ ".:)_P! FR_[\+_A6G11[2?</90_
ME1F?\(YHG_0)LO\ OPO^%'_".:)_T";+_OPO^%:=%'M)]P]E#^5&9_PCFB?]
M FR_[\+_ (4?\(YHG_0)LO\ OPO^%:=%'M)]P]E#^5&9_P (YHG_ $";+_OP
MO^%'_".:)_T";+_OPO\ A6G11[2?</90_E1F?\(YHG_0)LO^_"_X4?\ ".:)
M_P! FR_[\+_A6G11[2?</90_E1F?\(YHG_0)LO\ OPO^%'_".:)_T";+_OPO
M^%:=%'M)]P]E#^5&9_PCFB?] FR_[\+_ (4?\(YHG_0)LO\ OPO^%:=%'M)]
MP]E#^5&9_P (YHG_ $";+_OPO^%'_".:)_T";+_OPO\ A6G11[2?</90_E1F
M?\(YHG_0)LO^_"_X4?\ ".:)_P! FR_[\+_A6G11[2?</90_E1F?\(YHG_0)
MLO\ OPO^%'_".:)_T";+_OPO^%:=%'M)]P]E#^5&9_PCFB?] FR_[\+_ (4?
M\(YHG_0)LO\ OPO^%:=%'M)]P]E#^5$<%O#:P+#;Q)%$G"HBX ^@J2BBH+2L
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14
M<\\5M"TLTBI&HR68U%8W]MJ-L+BUE$D9)&10!9HHJD=7L%U!; W*?:6&0@-
M%VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3]:LT4 5O)?T_6CR7]/UJS10!6\E_3]:/)?T_6K-% %;R7]/UH\E_3]:LT4
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MT_6K-% %;R7]/UH\E_3]:LT4 5O)?T_6CR7]/UJS10!6\E_3]:/)?T_6K-%
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M_D"V?_7Q_P"RFO+L5ZE\3?\ D"V?_7Q_[*:\OQ7O8#^ CY?-/]Y?R-'P\/\
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MQTR,9_E6G10!F3'5O['0Q+%]OP-P.,9[^U.O3JGV*'[(L9N,CS,XQ[XK1HH
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M6_LN7[0(_MO/E@8Q[4*=6_L5BPC_ +0QP,C&<_E6G10!F3G5O['3R1']OXW
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MU%<1@%XV##/3(KI?^$^U7_GG;_\ ?%=-251/W%?YG)2C2:_>2:^5SE_LD_\
MSQ?\J1K:9%+-$X ZDBO1-)U7Q-JGS^1;P6_4RRI@8IWB/Q190:9+8)(MU=2+
MM9T7"K7-]9J<_)RW]'_P#L^ITO9NHYM+S5K_ (GFN*ZWX=#_ (J63_KV;^:U
MRF*ZSX=C_BI)/^O9OYK6N+_@2]#GP/\ O,/4]3K,N_\ D-6__7"3^:UIUF7?
M_(:M_P#KA)_-:^:/LB:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[8HXPP]:5.%:"LE%+YCJU,/4;E*4F_D8F*ZSX>?\C')_U[M_-:Y7%=7\/O\
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MHUJ*R?\ A)M'_P"?U?\ OAO\*/\ A)M'_P"?U?\ OAO\*/J];^1_<P^MX?\
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M;1_^?U?^^&_PH_X2;1_^?U?^^&_PH^KUOY']S#ZWA_YU]Z-:BLG_ (2;1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** )8/OGZ58JO!]\_2K% !1110!QWQ%_P"01:?]=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** -?PQ_P C%:?5O_037I5>:^&/^1BM/JW_ *":]*KY_-?XR]/U9]5D?^[R
M]?T04445YA[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^^?I5BJ\'WS]*L4 %%%% ''_ !"_Y!-K_P!=_P#V4UYUBO1OB#SI-K_UW_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :_AC_ )&*T^K?
M^@FO2J\U\,?\C%:?5O\ T$UZ57S^:_QEZ?JSZK(_]WEZ_H@HHHKS#V@HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^AQ%%%%?5'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(IVNXMM=T6\#;<RM WN&Q_A18+G14445)04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 2P??/TJQ5>#[Y
M^E6* "BBB@#DO'__ ""K7_KO_P"RFO/J]!\?_P#(*M?^N_\ [*:\^KZ3+?\
M=U\SX_./]Z?H@HHHKO/+"BBB@ KI_ G_ "'W_P"N#?S6N8KI_ G_ "'W_P"N
M#?S6N;&?P)^AV9?_ +U#U/1ZXCX@=;+_ (%_2NWKB/B!ULO^!?TKY[!_QX^I
M]9F'^ZS]#B****^J/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#7\,?\C%:?5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC3_E7W%+^R--_P"?"V_[]"C^R--_Y\+;_OT*NT4>UGW8>QI_RK[BE_9&F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M??/TJQ5>#[Y^E6* "BBB@#DO'_\ R"K7_KO_ .RFO/J]!\?_ /(*M?\ KO\
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M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!DZ[HO]M6\<)G,2HV3@9S5O3;&/3;"*UC.0@P3ZGUJW16:IQ4^>VIJZ
MTW35-O1%'5M-CU:P>UD;;NY#8Z&J6F>'ET[3;FR-PTB3C&<8V\5MT4G2@Y<[
M6HXUZD8>S3TW.,_X0% >+]A_P#_Z]7+/P1I\$@DG>2<CG!. :Z>BLHX.A%W4
M3>688F2LYC418T5$4*JC  [4ZBBNHXPHHHH$%>C^%?\ D7;;ZM_Z$:\XKT?P
MK_R+MM]6_P#0C7F9K_!7K_F>SD?^\/T_5&U1117SY]62P??/TJQ5>#[Y^E6*
M "BBB@#DO'__ ""K7_KO_P"RFO/J]!\?_P#(*M?^N_\ [*:\^KZ3+?\ =U\S
MX_./]Z?H@K=LM:LA9QV>H:<DT:<+(IPP_P :PJWK'4](T^TC8:?]HO,?,TAR
MF?I7172<=F_30Y,+)QDWS)+SU_ NKX;L=6C:72;B5"!GRKA,?K7+2(8Y&1L9
M4X.*U[WQ/J5VAC646\/:.$;<?B.:QR23DG)/>E0C5C?VC]/^'*Q4Z$FO9+7K
MT3^6HE=/X$_Y#[_]<&_FM<Q73^!/^0^__7!OYK2QG\"?H/+_ />H>IZ/7$?$
M#K9?\"_I7;UQ'Q ZV7_ OZ5\]@_X\?4^LS#_ '6?H<11117U1\.%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%1S2&&!Y C.5&=J]3533]8L]1^6*3;,.
M&A?AU/?BI<XI\K>I:A)Q<DM$7ZC$\+-M$L9;T#"B:%9XFB?=M88.UB#^8K'U
MFQT^UTJ1DACAF Q$\:[7+]L$<DYJ:DI15T52A&;47NS;)"C+$ #N:C^TV_\
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MU?M58A>\ER7ON1A9/D;]IRM;?>O(KV?B/4+^Y6W@M+,R,"0"GH*YB;=Y[[P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&#_PB&D_\\Y?^_AH_P"$0TG_ )YR_P#?PUO44?6J_P#._O#ZCAO^?:^XP?\
MA$-)_P"><O\ W\-'_"(:3_SSE_[^&MZBCZU7_G?WA]1PW_/M?<8/_"(:3_SS
ME_[^&C_A$-)_YYR_]_#6]11]:K_SO[P^HX;_ )]K[C!_X1#2?^><O_?PT?\
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MVON,'_A$-)_YYR_]_#1_PB&D_P#/.7_OX:WJ*/K5?^=_>'U'#?\ /M?<8/\
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M/_/.7_OX:/\ A$-)_P"><O\ W\-;U%'UJO\ SO[P^HX;_GVON,'_ (1#2?\
MGG+_ -_#1_PB&D_\\Y?^_AK>HH^M5_YW]X?4<-_S[7W&#_PB&D_\\Y?^_AH_
MX1#2?^><O_?PUO44?6J_\[^\/J.&_P"?:^XP?^$0TG_GG+_W\-'_  B&D_\
M/.7_ +^&MZBCZU7_ )W]X?4<-_S[7W&#_P (AI/_ #SE_P"_AH_X1#2?^><O
M_?PUO44?6J_\[^\/J.&_Y]K[C!_X1#2?^><O_?PT?\(AI/\ SSE_[^&MZBCZ
MU7_G?WA]1PW_ #[7W&#_ ,(AI/\ SSE_[^&C_A$-)_YYR_\ ?PUO44?6J_\
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MC<E@^^?I5BJ\'WS]*L4 %%%% ')>/_\ D%6O_7?_ -E->?5Z#X__ .05:_\
M7?\ ]E->?5])EO\ NZ^9\?G'^]/T04445WGEA1110 5T_@3_ )#[_P#7!OYK
M7,5T_@3_ )#[_P#7!OYK7-C/X$_0[,O_ -ZAZGH]9EW_ ,AJW_ZX2?S6M.LR
M[_Y#5O\ ]<)/YK7RI]P34444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7UKJ-JEU9SI- _W70\&@!ODOZ?K1Y+^GZTZUOK6]\S[-,LOE.4?;_"PZBK%
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MDYZ'\*O4 0Q(RMDCM4U%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC&YU6VTV6_MKR%4(A(W1D8['MQ0!+INJ:Q9>+1H>IW4=XLL!FCF6,(5P<8(
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ML(]N7EEV@@^@ SG]* .C&2 3P:6L_3[V]NKR]BN=/:VAA<+#(SY\X>N.U:%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!EZQI$FJ"$Q:C=64D3;@T!Z^Q!X-0Z1X<ATR\EO9;J>\O)%VF:<\A?0 <#\
M*VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gou0qrw2itv5000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,E!J8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+U&2^Q<,"74CRSQ\@SV% &K1110 4444 %%%% !1110 4444 %%%% !1110
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M(*GD$=ZAIK<U4E+9BT444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M.L=CTJ&*4_=EHST6BBBN<ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_:H;6,^<VS[/T*]BW^U6C6/X?CMXXKW[/8W%H#<N6$V?G;CYAGL: -BBBB@
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MZF'H/A'1?#D073[-%DQS*WS.?Q_PK<HHKG;;=V=:2BK(****0PHHHH ****
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M/L<$$ @Y!Y%+6%X.U/\ MCPEIUX6R[Q /[$<5NUY+5G8]V+NKA1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!FZ_JL>B:%>:C*?E@C+ >I[5\H7MY+J%]/>3L6EFD,CGW)S7M_Q
MMU4VV@V>G(^#<REG ]%Q_C7A%=^&C:/-W/+QL[SY>P4445TG&%%%% !1110
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M1:#>:=XB\-W^IZC)>W\]^BN<XC0=<*.PKUVB44DK,(3<FTU:P4445!H%%%%
M!1110 4444 ?/OQHO3<>,8K<-\D%LHQZ,2V?TQ7G%=C\4I-_Q!U(?W"J_P#C
MH_QKCJ]2DK01XE=WJ,****T,CJ]+T#26\'3Z]J37KF.X$(BMG1>O?YE-.L?#
M^C^(K>Y319[R&_@C,HM[ME82*.N"H'-:6FV=U??"2\BM+::XD^W*=D49<_D*
MB\(:?<>&[J;7=71K**WA<1QSC;)*Y&  IY(YZXK%R>KOJ=*BKQ5M+'+:1HMY
MK6IK86J?O3G<6X" =2?85HSVWA:PE,$D^H7\BG#2VKI&F?8,I)^N:V= D\OP
M7XGU91MN)G$(8'E0V2?YUR.G6=I=R.MUJ4-BH&0TL;ON]OE!JKW;\C.RBE;=
MEK4['2DM4N]+OVD1FVM;S@"5/RX(]\5J6>AZ-'X.37-1-_([W!A$=O(B@8 Y
M^93ZU4U/PN+'0(]:MM4MKVTDG\@&)'4AL9Z,!70VEI;7?PKA2ZU"*R47[$/+
M&[ \+Q\H)I.6BL^I48ZNZZ&1_P (]IFK:-=W^AS72R6:;Y[:Z*L=N>H90!^E
M-\#>&['Q+JEQ;ZA<S6\,4!EWQ$9SD#G(/'-;,D,?@[PE<2V4PU!M6C\DW</^
MJC7NI!Y#<=Q5/X=_Z_6O^P=)_,4G)\K:&HKGBFC \1:'-X?UF:QD.]!\T4G9
MT/(/Y5=C\/6S^!9-=,LOVA+@1!,C9C\LY_&MI&_X33P88F^;6-&C^0Y^:6#K
MCWQSQ3(?^2/W'_7\O]:?,[)=;BY%=M;6.%HHHK4P"OIKX97AO/ 6G$MN:(&-
MC]#G^M?,M?0OP7<OX%<?W;R1?_'5KFQ2]P[,$_WECT2BBBN ]0**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#R[XO^$/[2TY=;LXR;JV7;*%'+)Z_AS7@]?8[HLB,CJ&5A@@]Z^>OB5X
M"D\.WSZE8QDZ9,V< ?ZHGM]/2NS#U?L,\[%T-?:1//:***[#@"BBB@ HHHH
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MBX89*[?*Z?)^%:E9^E+<JEQ]IM;:W)F8H+?HR]F;WH T**** "BBB@ HHHH
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M61M.N'6)@V=T1.0<_C6K_P *X\)?] >+_OM_\:YRYTRS\#>/M)NM/@^SZ=J
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M] YGD'0_[([5V-<57$7TB>A0PG+[TQ%4(H50 H& !VI:**Y3N"BBB@ HHHH
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M2H4D170]589!KE=7^&_AC5V9Y=.2&4_QP$IC\!Q^E=9134G'8F48RW1Y)=_
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M6?'%%>A?$GP#+X=OFU&QC+Z;,V?E'^J/H?;WKSVO3C)25T>+.#A+E844451
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M%'4#HW^?05Z&&J<LN5]3S\92YH\RZ'BM%%%=YY84444 %%%% !1110 4444
M%%%% !116GH&BW/B#6;?3K5"SR-\Q'\*]R:3=E=C2;=D>F?!3PZ7N;C7ID^5
M 8H"?7N?Z5[55#1=)MM#TBVTZT0+%"@7ZGN?Q/-7Z\RI/GE<]JC3]G!1"BJ%
ME?K=7EU"/^63#!]JOUA3J1J1YH[&\HN+LPHHHJR0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9G6U:\MA_P M8%+8'J1VKC65D8JP(8'!!KKC)25T>?*$HNTD)1115$A1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDC&UOSKEKOX)Z#*2;:ZNH/J=_P#A70L5![G)+!5%MJ>!45[8?@3:9XUZ8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM=%8>@>+]%\21!M/O8VDQS"QVN/P/-;E8--.S.I24E=!1112&%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOO\ M/4MQDK_ +- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!'/-';P23S.$CC4N['H .2:^:/B!XPE\5ZVQ1F6Q@)6!/7U8^Y
MKT;XR>*6L=/CT.UDQ+<C=,0>0GI^->%UVX:G9<[/-QE:[Y$%%%%=9PA1110
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MVE>7*+B[,]N$E**D@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  KWLORB4FJE=67;_,\_$8Q+W:?WB1QI%&J(H55& !3J**^E225D>6%%%%,
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MFGCB4$EV  %?6VBV TO1+&P'_+O D?Y#%<N*?NI'=@8^\V7Z***X3T@HHHH
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MD..XK3K,T:.6*.Z\W3HK+=.Q41D'S!Q\YQW- &G1110 4444 %%%% !1110
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M18HJO]NM/^?B+_OH4?;K3_GXB_[Z%%F%T6**K_;K3_GXB_[Z%'VZT_Y^(O\
MOH468718HJO]NM/^?B+_ +Z%'VZT_P"?B+_OH468718HJO\ ;K3_ )^(O^^A
M1]NM/^?B+_OH468718HJO]NM/^?B+_OH4?;K3_GXB_[Z%%F%T6**K_;K3_GX
MB_[Z%'VZT_Y^(O\ OH468718HJO]NM/^?B+_ +Z%'VZT_P"?B+_OH468718H
MJO\ ;K3_ )^(O^^A1]NM/^?B+_OH468718HJO]NM/^?B+_OH4?;K3_GXB_[Z
M%%F%T6**K_;K3_GXB_[Z%'VZT_Y^(O\ OH468718HJO]NM/^?B+_ +Z%'VZT
M_P"?B+_OH468718HJO\ ;K3_ )^(O^^A1]NM/^?B+_OH468718HJO]NM/^?B
M+_OH4?;K3_GXB_[Z%%F%T6**K_;K3_GXB_[Z%*MY;.P59XRQ.  W6BS"Z)Z*
M**0PHHHH **** "BBB@ HHHH **** "L?P_]D\J\^R&Z(^TOO^T]=W&=O^S6
MQ6;H\LLL=UYNH0WNV=@IB 'EC^X<=Q0!I4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 5[ZR@U&QFL[E \,R%'4^AKY?\ &7A>X\*Z
M[)9R@M Q+028X9?\:^J*P?%GA:R\5Z0]G<H!*O,,V/F1O\/:MJ-7D>NQSXBC
M[2.FY\J45JZ_X?O_  WJ<EC?PE'7E&QPZ]B*RJ]%--71Y#33LPHHHIB"BBB@
M HHHH **** "BBIK2TGOKJ.VMHFEFD;:B*,DF@"73=.NM6U"&QLXS)/,P50*
M^H/"'AJ#PMH$-A%AI,;II,?>;O6#\._ $?A:T^V7BJ^IRK\QZ^4/[HKO*\^O
M5YW9;'JX6AR+FEN%%%%<YUA1110 4444 %%%% !1110 4444 07C%+*9AV0F
MO/#UKT#4L_V;<X_YYG^5>?U\SGS_ 'D%Y'J9?\,A\4C12K(IPRG(KN]/DM[N
MW2ZCCC#L/F(49SWK@:UM#U+[%<^7(?W,AP?8^M<V4XWZO5Y9/W9&N,H>UC=;
MHK_$L7AL[41!S;;CYFWU[9KC/#OAZYUV_6-5*P*<R2$< ?XU[8Z1S1E7171A
MR&&0:2&WAMTV00QQ+UVHH4?I7Z+A\UE0P_LH1U[GQV(RF-?$^VG+3L16%A;Z
M;9QVMK&$C08'O[FK-%%>5*3D[O<]>,5%66P4444AA1110 4444 %%%% !111
M0!E:]H5MKM@T$PVR 9CD Y4UXSJ.F76EWSVMQ&0ZG@XX;Z5[W4,UI;7#*T]O
M%*R_=+H&(_.O3P&93PJ<6KQ/+S#+(8IJ2=I&'X*^V#PU +P-G)V;NNW/%:M]
M+;Z?;27(CC63'!"@$FKG"C P *X[7]2%Y<B&-LQ1GMW->'FN/]E&55:.6R_K
ML>M@<+I&F]5'J9,CF21G8Y+')K7\,MC5-OJIK&K6\.?\AA/]UOY5\?@6_K4'
MYH]RNOW4O0[2BBBON3P0HHHH **** "BBB@ HHHH **** "BBB@ KB/B3X-7
MQ/HOGVZ@:A:@M&?[X[K7;T549.+NB9P4X\K/CB2-XI&CD4JZ$JRGJ#3:]P^)
MGPW-^9-:T6#_ $G&9X$'^L_V@/6O$&4JQ5@01P0:].G44U='C5:4J<K,2BBB
MK,@HHHH **** "BBB@ HHHH *[SX:>"Y/$FL+>7*$:=:L&<D??;LHK)\&^#+
M[Q=J(CB5H[1&_?3XX4>@]Z^E='TBTT/3(;"RB$<,0P .Y]3[US5ZW*N5;G7A
MJ#F^:6Q=551 J@!5& !V%+117 >J%%%% !1110!Q5%%%=1RA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5'<?ZA_I4E1W'^H?Z5SXO\ W>IZ/\C6
MA_%CZHSJHI9/'K$EVC+Y<L85U/7(Z&IKNU:Z50MU/;X/6$@9^N0:P_LUY+K9
MLX=6OA#"FZ9F9"23T ^7BO@\/3YE*TDM-=]OZL?15IV:O&^NA))!?6\%QIT-
MF\L4Q/ES!E"H#U!R<_D*VK6#[-:0P9SY:!,^N!6-JEA>VMF;BVU:])C(9U=D
MY7OCY>#6U:NLMI#(K,ZL@(9NIX[U>(;E34DTTWK:^_G?]":*M-II[>6WE82Y
M29X2+>41R=B1D51-UJEN,S6*S@]/L[\_CNQ6I1D>M<T*BBK.*?\ 7D;2@V[I
MM&5_:MY_T!KO_OJ/_P"*IRMJ]P5)2&VC)SR=S@>A'3]:TZ*OVT?LP2^]_FR?
M9RZR?X%JQSALG)XYJW52S_C_  JW7V>3?[E#Y_FSPL?_ +Q+Y?D%%%%>H<84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 58L/^/^#_ 'Q5>K%A_P ?\'^^
M*3V&MSK:***YCI"BBB@ HHHH **** "BBB@ HHHH *S-%CDCCNO,TZ.QS<,0
M$8'S!Q\YQW-:=8_A\VABO/LC7;#[2^_[3U#<9V_[- &Q1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 8WB/PQIOB>P-KJ$0;'
MW)!]Y#Z@U\_^+OAWJ_A>9Y!&UU8Y^6XC&<#_ &AV_E7TS39(TE0I(BNC#!5A
MD&M:=:4/0PK8>-3U/CBBOHGQ)\)M$UK?-99L+IN=R#*'ZK_]>O,-8^$_B;3&
M8PVZWL0Z- ><>X[5VPKPD>=4PU2'2YPM%7+G2M0LY#'<6<\;#J&0U4*E3@@C
MZBMKF#30E% !)P!FIXK.ZG8"*WE<GIM0F@1!176:5\-_$^JLNS3V@C;_ ):3
MG:M>D^'?@O86;+/K5R;QQSY*#:@]CW/Z5E*M"/4VAAZD]D>2>'O"NK>)KM8=
M/M69,_/,W"(/<_X5[_X,^'VF^$X1+@7&H,,/.PZ>R^@KJ+*PM-.MUM[.WC@B
M48"H,58KCJUY3T6QZ-'#1IZO5A1116!TA1110 4444 %%%% !1110 4444 %
M%%% $%ZN^RF4#.4(KSP]:])(RI'K7G=Q&8;F2,_PL17SF?0UA+U/3R]_$B*B
MBBOGCT3I=!UG&VTN&]D8_P JZ6O-<X.171:/KY3;;W9RO17]/K7T.69HDE1K
M/T?^9YV*PE_?@=112*RNH92"#T(I:^C/,"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M #S'YT?9(/\ GF/SJQ11=A9%?[)!_P \Q^='V2#_ )YC\ZL4478617^R0?\
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M #S'YT?9(/\ GF/SJQ11=A9%?[)!_P \Q^='V2#_ )YC\ZL4478617^R0?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@/]:VZQ/#_6X_X#_6MNOH\H_P!SA\_S9Y^-_CR_KH%%%%>D<@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4^'_7)]:93X?\ 7)]:!FE1114%A1110 44
M44 %%%% !1110 4444 %9>BQO''=;]-2QS<,0%8'S!Q\_P"-:E8_A\VIBO?L
MLMU(/M3[_M'4-QD+_LT ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "$ @@C(-<;KFE&RG,L2GR7.?\
M=/I79TR:&.>)HY%#*PP0:XL=@XXJGRO=;,WH5G2E?H><45I:KI,NGRE@"T)/
MRMZ?6LVOC*M*=*;A-6:/;A.,US1"BBBLR@HHHH **** "BBHVGB4X:1 ?0FA
M)O8&TB2BHQ/"QPLJ$GL#4E#36X)I[!1110 444JJ78*H))Z 4 "JSL%4$D]
M*[31=,%A;[Y!^^<?-[>U5]$T7[,!<7 S*?NK_=_^O6[7U&59<Z7[ZJM>B['E
M8O$\WN0V"BBBO<. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RZ***L@*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFJ?\@V?Z?UJW535/\
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M:1A(8PH_4U/7TV!RJ%#WZFLOP1Y=?%RJ>['1!1117KG&%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P : -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK,A_W3YL\7,?X_R"BBBO:. **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** 'Q_>_"BB/[WX44F-'2T4M%8&PE%+10 E%+10 E%+10 E%+10 E%+10 E
M%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E
M%+10 E%+10 E%+10 E%+10 E%4]3U:PT>T:YO[A(8U&<L>3]*\B\3?%^ZN&>
MWT*(01=//D&7/T';]:N%.4]C.I6A3^(]=O\ 5;#2XC)?7<,"@9^=P"?H.IKB
M=4^+^@699;1)[QNQ1=J_^/8->'7FH7FH3-+=W,LSL<DNV:K5U1PT5\1Q3QDG
M\*L>IW?QKOWXM=,AC'9F<D_EBLYOC#XC+$A;8#T\NO/:*U5&"Z&+Q%1]3T)/
MC#XA5LO';,/39BM6T^-ERI N]*C8=VCDY_*O***3HP?0%B*JZGO5K\7/#]Y&
M!)'-!(?X95X_,9IMSJT&JD2P>45]8R#7@]6;6_NK*0/;SO&1Z'BLIX5/X6;P
MQLE\2/9Z*XG1_'.XK#J2 =A*G]1790SQ7$2RPR*Z-R"IKDG3E!ZG?3JPJ*\6
M25?TF]%C>K(V2O0BJ%%0:'>-K-BL7F&8=.F.:X[4KO[;>O-C@]/I4"PRR?=5
MB*:R,OWE(H%8;79>&YUDT_R\Y9#S7&U8M;R:SDWPOM- V>B45Q__  DUV2N0
MG'7 ZUHVWB:)\":/!]C3N38WZ*J0:G9W'W)@">QXJV"&&00?I3$%%+10 E%+
M10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+
M10 E%+10 E%+10 E.C_UB_6DIR?ZQ?K0,M4445)04444 %%%% !1110 4444
M %%%% !6?I37+)<?:;FVG(F8(;?HJ]@WO6A67HD8CCN\::;'-PQP6W>;T^?\
M: -2BBB@ HHHH **** "BBB@ HHHH **** *>J_\@R;Z#^8KEJZZ]C$MI(C9
MP0.GUK%_L^'U?\ZUA))&4TVS+HK4_L^'U?\ .C^SX?5_SJN=$<K,NBM3^SX?
M5_SH_L^'U?\ .CG0<K,NBM3^SX?5_P Z/[/A]7_.CG0<K,NBM3^SX?5_SH_L
M^'U?\Z.=!RLRZ*U/[/A]7_.C^SX?5_SHYT'*S+HK4_L^'U?\Z/[/A]7_ #HY
MT'*S+HK4_L^'U?\ .C^SX?5_SHYT'*S+HK4_L^'U?\Z/[/A]7_.CG0<K,NBM
M3^SX?5_SH_L^'U?\Z.=!RLRZ*U/[/A]7_.C^SX?5_P Z.=!RLRZ*U/[/A]7_
M #H_L^'U?\Z.=!RLRZ*U/[/A]7_.C^SX?5_SHYT'*S+HK4_L^'U?\Z/[/A]7
M_.CG0<K,NBM3^SX?5_SH_L^'U?\ .CG0<K,NBM3^SX?5_P Z/[/A]7_.CG0<
MK,NBM3^SX?5_SH_L^'U?\Z.=!RLRZ*U/[/A]7_.C^SX?5_SHYT'*S+HK4_L^
M'U?\Z/[/A]7_ #HYT'*S+HK4_L^'U?\ .C^SX?5_SHYT'*S+HK4_L^'U?\Z/
M[/A]7_.CG0<K,NLL]374?V?#ZO\ G7+M]X_6OFN(FFJ?S_0];*TTY?+]2.52
M\3J.I4@5BZ)>6UCIZV5U(EM/"2K"4[=W/W@3USUXK<)"J6/0#)KG[K5I)8/M
M::3#/;;PB22R@,W.,XVGC/O7B8:,JD73M=-KJEKK;<[JTE"2G?77HWI\A]Q/
M'J.N6(LV\P6[,\LJ<J!C&W/0]?TK>K#M]2N8=3AL)=+AMEF4N'2;(X]!M'-;
ME+%)QY8VLDM-4^K[>8Z#3YG?6^NC73S"LVXU4V=P5N+298>TRC</R'/Z5I5G
M76KV\,C0)')<3#K'&N36="/-*W+S?U_6Y=67*KWL6K:]MKM=UO.DG'(4\CZB
MIZY:71[[4YQ,(H=-& 0R$LYY_ #]:VK"*_MV:&ZE6>,#Y)<8;Z$?UK6O0IP5
MX3U[?\%:,SI59R=I1^?_  -S6M/]<?I5ZH=)A6>\*OG&PGC\*VO[/A]7_.OJ
M,BDEA/FSR<QBW6^1ET5J?V?#ZO\ G1_9\/J_YU['.CAY69=%:G]GP^K_ )T?
MV?#ZO^='.@Y69=%:G]GP^K_G1_9\/J_YT<Z#E9ET5J?V?#ZO^=']GP^K_G1S
MH.5F716I_9\/J_YT?V?#ZO\ G1SH.5F716I_9\/J_P"=']GP^K_G1SH.5F71
M6I_9\/J_YT?V?#ZO^='.@Y69=%:G]GP^K_G1_9\/J_YT<Z#E9ET5J?V?#ZO^
M=']GP^K_ )T<Z#E9ET5J?V?#ZO\ G1_9\/J_YT<Z#E9ET5J?V?#ZO^=']GP^
MK_G1SH.5F716I_9\/J_YT?V?#ZO^='.@Y69=%:G]GP^K_G1_9\/J_P"='.@Y
M69=%:G]GP^K_ )T?V?#ZO^='.@Y69=%:G]GP^K_G1_9\/J_YT<Z#E9ET5J?V
M?#ZO^=']GP^K_G1SH.5F716I_9\/J_YT?V?#ZO\ G1SH.5F716I_9\/J_P"=
M']GP^K_G1SH.5F716I_9\/J_YT?V?#ZO^='.@Y69=%:G]GP^K_G1_9\/J_YT
M<Z#E9G1_>_"BM-=/A!ZO^=%',A\K-.BEHK(U$HI:* $HI:* $HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
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MU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU%
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M!/1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUH'_ "$&_P"N9_F*Z:OJ\D_W7YL\C'_QOD)12T5ZYQ"44M% "44M% "44M%
M"44M% "44M% "44M1RSPP*6ED1 .['% #Z*P+OQOX;LB1-JMON'\*MDUEM\4
MO"RMC[5*?<1\?SJE"3Z$.K!;L[.BN-C^*/A:1L?:Y%]VCP/YUKV?C'P]?L%M
M]5MF<_P[L&APDMT"J0>S-NBFI)'(,QNK#U4YI]26)12T4 )12T4 )12T4 )1
M2T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 (.M%.'6BD!-1110,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(XK#^R::[*)M4>90<[))P0:W1C''2HQ#]U)MMZ[W_4JCNVDDO(U= _Y"+?\
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M]F]_>O6N&7L5(_.N-.=&1Z+5/$0N?&_0X-%>V^/_ (5)=>;JF@1JDHRTEJO
M;U*^_M7BLL4D,K12HR2(<,K#!!KNIU%-71YM6E*F[,97M?P0CVZ5JK_WI8_T
M#5XI7T!\'K/R/!IG(PT\S'\!T_G6>(?N&F$5ZIZ#12T5YYZHE%+10 E%+10
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M2K<O^K:JM-$L2BEHIB$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
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M "44M% "44M% "44M% "44M% "44M% "44M%  **444#)<48I:*0Q,48I:*
M$Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B
M@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BE
MHH XOXHZ8=1\$715<O;D3#'7CK7SA7U]=6Z75K+;R*&212I!]Z^4_$&D2Z'K
MMWITH(,,A"D]U['\17;A9:.)YV-AJI&;11174<(4444 %%%% !1110 4444
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MGV?H%[;O]JM&LK0XXXX[OR]-DL<W#$AV)\P\?.,]C0!JT444 %%%% !1110
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MQUQ5VJHTRQ!R+. ?]LQ5JN>HZ;=X7^9K#G2]XUO#W_(1;_KF?YBNHKE_#O\
MR$F_ZYG^8KJ:^KR3_=?FSR,?_&$HI:*]<XQ**6B@!**6B@!*"0 2> .M+6!X
MTU?^Q/"E]=J<2;-D?^\::5W84FHJ[/$?B1XC;7O%$R1OFUM3Y48SQD=3^>:X
MZE)+$DG)/))I*]2,5%61XDY.4G)A1113)"BBB@ HHHH **** "BBB@ HHHH
M*]'^$GB,Z=KK:5.^+>\'R9/"N.1^?3\:\XJ:TN9+.\AN8CB2%U=?J#FIG'FC
M8NG-PDI(^MZ*I:-?KJFC6EZAR)H@WX]ZO5Y;T/:6JN)12T4#$HI:* $HI:*
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M2;_KF?YBNHQ7+^'?^0DW_7,_S%=37U^2?[K\V>-COXPF*,4M%>N<0F*,4M%
M"8HQ2T4 )BO+_C7?F'1=/L0>)Y6=A_N@8_\ 0J]1KQ#XUSEM>L8,_*D&X#ZD
M_P"%:T%>:,,2[4F>7T445Z)Y 445WG@61K;PWXENXMJW$-MF.0J"5/MFIE+E
M5RH1YG8X.BNT\.>);K5-9@TS6@E]97;>4ZN@#)GH5(Z'-5;?PD+GQS<Z*)=M
MM;R,TLO7;&.<_7%+GMHRO9W2<3E:*ZB_\5M:W+P>'HDL;*,[495!DD _B8GN
M:IWGB-]3L'@U&TAGN/\ EG= ;'7ZXX(_*FF^PG&/<PZ*[GPE<2V7@KQ#=VY"
M7$9CV2;02O7IFI_"6H3^++R?2-;"75NT$DBRL@#1,JD@@@>U2YVOIL4J:=E?
M5GG]%=;X C1?'MJA59$1GP&&0< UH>/=.M+^)/$FE1*D4DC0W<2_\LI5.,_0
MC!IN=I<HE3;AS'!45W/@Z*-_!WBAF1698%VDC)'(KAJ:E=M=B91LD^X44451
M)]"?"6_-YX)CB8\VTK1 >W!'\S7=8KRCX(SEK+58,\(\; ?7=_A7K%>;65IL
M]C#N]-,3%&*6BLS83%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEH
MH !10** )J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@##\5>&++Q3
MI#V=TH$@&891U1O\*^:M?T"^\.ZG)8WT15E/RMCAQV(KZQK$\3^%M/\ %.G&
MUO4PR\QR@?,A]JWHUG!V>QS8C#JHKK<^5:*Z7Q7X*U3PI=E;B,RVK']W<(,J
M1[^AKFJ[TTU='E2BXNS"BBBF(**** "BBB@ HHHH ***[3P9\.]1\42K/,K6
MNG@_-,PP6_W1W^M3*2BKLJ$)3=HF;X1\(WWBO5%@@1EMD.9IL<(/\:^E-'TB
MTT/3(;"RC"0QCMU)[D^])HVBV.@Z='8V$(CB0=NK'U/O6A7!5JN;\CUJ%!4E
MYA1116)N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4HZTE*.M #Z***0PHHHH
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MBEHK(W$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*0$M%%% PHHHH
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MB@ HHHH **** "BBB@ HHHH *!UHH'6@!]%%%(84444 %%%% !1110 4444
M%%%% !6=I'VO9<_:_LN?/;9]FZ;>V[_:K1K)T****.\$6G2V6ZY8L)"3YAX^
M<9[&@#6HHHH **** "BBB@ HHHH **** "BBB@!&^Z:AJ9ONFH\4Q,;13L48
MH ;13L48H ;13L48H ;13L48H ;13L48H ;13L48H ;13L48H ;13L48H YS
MQQIG]J^#M1M@N7\O>GU%?+U?83H'1D895A@BOE_QOH3^'_%=[:%<1,YDB..-
MK<@#Z9Q^%=>%EO$\_&PVD<[11178< 4444 %%%% !1110 4444 %%%% !111
M0 5] ?!_3/L?A%KIEQ)=2EL^J@<?UKPG3;&74]2M[* $R3R!!CMD]:^KM*L(
M]+TJULH@ D,84 ?K7+B96CRG;@H7DY=BU13L48KB/2&T4[%&* &T4[%&* &U
MYZ_WV^M>B8KSQ_OM]:^=S_:G\_T/2R[[7R&T445\X>F%%%% !1110 4444 ;
M'AO_ )";?]<C_,5U=<IX:_Y";?\ 7(_S%=;BOKLE_P!U^;/&QW\4;13L48KU
MSC&T4[%&* &T4[%&* &UP7Q<TPWW@QIU7+VL@DSZ+W_I7?XJKJ-E'J&G7%G*
MH9)HRA!JH2Y9)D5(\T7$^1:*N:MITVD:K=6$X(>"0ISW /!_&J=>JG<\1JSL
M%%%% @HHHH **** "BBB@ HHHH **** "BBMWP?HDFO^*+*R5<H9 \G' 4<G
M^6*3=E=CBG)V1[_\/],.E^"]/A9=LCIYCCW/_P!;%=-21QK%$D:#"HH4#V%/
MQ7E2=W<]R,>5)#:*=BC%(H;13L48H ;13L48H ;13L48H ;13L48H ;13L48
MH ;13L48H ;13J* 'T4M%(8E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E
M%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%12W5M"VV6XB
MC;KAW -.BGAG&8IHY,?W&!H ?12U ]W:Q/LDN84;T9P#0!-12*RNH96#*>A!
MR*BDN[6%]DMS"C#LS@&@":BF1RQ3+NBD21?56!%$DT4./-E1-QP-S 9H ?12
MTP21F0QAU+@9*YY'X4 .HI:* $HJAJ^KVVBV:W5V)#&TBQC8N3D]*T* $HI:
M* $HI:* $HI:* $HI:* $HJGJNIV^CZ;+?76_P F+&[8,GD@#]35J*19H4E7
M.UU##/H: '44M% "44M,$D9E,8D4R 9*[N1^% #J*6B@!**6B@!**6B@!**6
MB@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6
MB@!**6B@!**6B@!*!UI:* %HHHH **** "BBB@ HHHH **** "BBB@ K)T*6
M*6.\\K49;W%RP8R CRSQ\@SV%:U9VD_:]ES]K%J#Y[;/LW3;VW?[5 &C1110
M 4444 %%%% !1110 4444 %%%% "-]TU'4AZ4RF(2BEHH 2BEHH 2BEHH 2B
MEHH 2BEHH 2BEHH 2BEHH 2BEHH 2O.OBSX5;6=$&IVR;KJR4E@!RR=2/PY-
M>C4C*&4JP!4C!![U4).,KHBI!3BXL^.Z*] ^)G@A] U-M0LHB=.N&SP.(F]/
MI7G]>G&2DKH\:<'"7*PHHHJB HHHH **** "BBB@ HHHH ***Z7P5X2N?%>L
MQP*K+:1D&>7'"CT^M)M)7948N3LCN?@YX4+S/XANH_E4%+8$=3T+?S%>S5!8
MV5OIUE%:6L8C@B4*BCL!5BO,J3<Y7/9I4U3ARB44M%0:"44M% "44M% "5YX
M_P!]OK7HE>?/#+O;]V_7^Z:^>SY-JG;S_0]++W\7R(J*?Y,O_/)_^^31Y,O_
M #R?_ODU\YRR['IW0RBG^3+_ ,\G_P"^31Y,O_/)_P#ODT<LNP70RBG^3+_S
MR?\ [Y-'DR_\\G_[Y-'++L%T,HI_DR_\\G_[Y-'DR_\ /)_^^31RR[!=&KX:
M_P"0HW_7(_S%=;7*^'(W74V+(P'E'DCW%=77UV2IK"Z]V>-COXHE%+17K'&)
M12T4 )12T4 )12T4 >._&/PJS;/$-JF< )<@#\ W\A7CE?7]W:07UI+:W,:R
M0RJ5=6Z$&OFGQQX0N/"NLO'M9K*4EH)<=1Z'WKMP]2ZY6>;BZ-GSHY:BBBNH
MX@HHHH **** "BBB@ HHHH **** "O>OA'X5;2M(;5[J/%S>*-@(Y6/K^O%<
M#\-O!+^(]46\O(B--MVRQ(_UA_NBOH=$6-%1%"JHP !P*Y,14^PCOPE'_EXQ
M:*6BN,] 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH ?12T
M4AB44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M
M% "44M% "44M% "44M% "44M% '!K96E_P#%.^2\M8;E%L8RJS1AP/F;IFI?
M$UG%X<N=.U728UM6^TI#+#"-J2HQ P5'&>>N*K.=17XI7W]G1VKR?88]PN)&
M48W-TV@UO_V)?ZGJ%K=ZS+ $M7\R*VMB63>.C$D G\J (?$>IW3WMAH>GR>5
M=7V6DE'6*(#YB/?H/QJ_!X8T>*!8Y+""Y<#F6Y02N?\ @39-8UZRVWQ/T]YO
MN7%F\<1QQN!!Q^0-='J&F+J(3-W>6^S/_'M,8\_7'6@"/3M'ATN64VTDPAD_
MY8LY95/^SGI]!Q7-V6G6-_\ $#6Q>6=O<[88MOG1*^.O3(JQX?:XM_&6L:<U
M[=7%M!%&T8N)2Y4D GD_6J<&F#4?B!K8-W>6^V&+FVF,>>O7'6@"6Y@BT7QO
MI<&E+Y,=VK_:+:,X3 QAMO0=3R*@^(>FIJ]WH=B[M'YMPP#J<%3M.#4^B6YT
M+QA/I]XWVF2ZB\VWO9>9& ZH3[?UJQXK_P"1A\-?]?9_E0!9\(:M->V,MA?'
M&HV#>5.">3Z-^-9]C_R5/4?^O*/^;4_Q1;R:+JUMXHLU)6/]S?(H^_$?XOP.
M/SJ'2IH[GXEWL\3!HY+")E([@EJ .VK/U/6;+21$+J4^9*<11(-SN?91R:T:
MY#3T6[^(VJ33C+VMO''"#_"&))/Z"@#-\9Z]9:CHJ6T?G0W*743&"XC,;XSU
MVGG%=U=W=O8VLES=2I%#&,L[G %<E\1[.WET:UN7C4S17<81\<C)YI/',\G]
MJ:%:BUENH7N?,:"(J#(5!('S$#J >M &M_PEVF!HS,MW!#(P5)YK=DC8GIAC
MQ6Q<W<%I:O=7$J1P(NYG8X 'K7,ZKJ&H:CI-Q9'PGJ6)8RJYD@P#V_Y:5EZ_
M%>VGPZTV/4?EFA>(3Q$ABP!^[QU.* -JX\=Z1:VZ7$L6H+;NP5)OLC[')Z8.
M,'-:PUFV_LB34Y([B&WC7<PEA9&QZ[3S7.^+-8TN_P#"LUE9RQW5Q<J(X8(?
MF?<2,$C^''7G'2K^M0R0> +F&7_6):!6^N!0!8B\5:;</&ML+FXWA26A@9Q'
MN (W$?=X(ZU:O=;M+*;R")IIP,F&WB,C@>I YJMX1LK>R\*:;';QA%:W1S[D
MC)/YFGW^O6]G??8H+::\OMNXPP*,@>Y) 'XF@!^G^(+#4;MK2-I8KI5W&"XC
M,<F/7:><5/J6K6>DPI)>2[-[;44#+.?0#N:XV_OKBZ\=^'I)=(NM/<^:A:9H
MSY@^7CY&/3W]:TW47?Q,59AE;6R#1 ],DG)H H^,?$-C?>%KZT G@N2(V6*Y
MB,3,/,7D!NM=4E[;V&CVTUS*L:>6@!/<XZ#WK#^(UE;W/A&XFEB5I('C:-L<
MJ=ZC^1-;,FHVFEZ';W-XX6,1H -I)8XX  ZF@"J_BS3H67[5%>VD;,%$US;-
M''D]/F(Q4WB+4A8Z'<R+'<R%X7"-;Q,Y4[3@G'0>]8'BK5[F]\+:E&WAS4!
MULY$SM$%7C[Q&_=Q],UIV;M)\.U=R68Z>Q)/?Y#0!6\&:X;O0M/@EM]1>8QG
M=/+;OL/)_C/!K0MH]&_X2Z]>&-AJWDKY[$M@I@8]O2F^"O\ D3=,_P"N7]35
M+3_^2DZO_P!>L?\ (4 ;&H:[8Z=<+;2&26Y8;A!!&9)"/7:.<4VP\0V%_>&S
M4RPW07=Y%Q&8W(]0IYQ61X- N;O6K^7YKA[QHR3_  JO0?K3?'2^1'I5_  +
MN*\18SW(/4?I0!N:AKNGZ7=PVUY/Y3S*SJ6'RX4$G)[=*JKXKTTW,4,@N8!,
MVV*6:!DC<_[+'@UD^([6"\\>>'8KB)9$ D;:PXR%)'ZU>\>1H?!UXVT9BV,G
ML0XH Z2BJ^G,7TRT9N6:%"?R%6: $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* "BBB@ HH
MHH **** "BBB@ HHHH **** "LC08HHH[SR=/FL@URQ82DGS#Q\XSV-:]96A
M21R1W?EZC)?8N&!+J1Y9X^09["@#5HHHH **** "BBB@ HHHH **** "BBB@
M!#TIM./2FXH **,48IB"BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&*
M "BC%&* "BC%&* *U]8VVI64MG=Q++!*NUE8=:^>?'7P]O/"]RUS;JTVF.?E
MD R8_9J^C\4R>"*YA>&9%DC<896&016E.JX/0QK48U5KN?'E%>S^+_@\',E[
MX>8*3\QM&.!_P$_TKR*^TZ]TRX:"]MI8)0<;77'_ .NO0A4C-:'E5*4Z;]XJ
MT4459F%%%% !1110 45)!!-<RK%!$\LC=$122?P%>F^$/A#>:CLN]<)M;?J(
M!]]Q[^E1.<8*[+A3E-VBCD/"?@_4?%>H"&VC9;=3^]G(^5!_C7T=X>\/6/AO
M2H["QC"JHR[]W;N35O3=+L](LH[.Q@2&%!@*HQ5O%<%6LYOR/5H8=4E?J%%&
M*,5D;A11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC%
M !11BC% !11BC% !11BC% !11BC% !11BC% !69KVA67B+2I;"^B#1N/E;NA
M[$5IXHQ0G9W0-)JS/EWQ=X-U#PG?F.=&>U<_NIP/E8>GUKFZ^O=0TZTU2SDM
M+V!)H7&&5AFO%_%WP?NK+S+O06-S!U-NQ^=1[>M=U+$)Z2/,K81QUAJCRJBI
M;BVGM)FAN(9(I%ZJZD$5%72<84444 %%%% !115BRL+O49Q!9VTL\I_AC4F@
M-RO79^!_ %[XJNEGE5H=-0_/*1C?[+78>#_@\?W=[XB('1A:*<_]]'I7K]O;
M0VD"001K'$@PJJ, "N6KB$M(G=0PC?O3(=.TZUTJPALK.)8H(EVJHJU1BC%<
M5ST4K!11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC%
M !11BB@!]%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '.6^B7<7CJ[UAO+^RRVJ1+AOFW L3Q^-
M='110!E:YH5OKEM&LC-%/"XD@G3[T;#O]/:JD,_BBU3R9;&RO2O G%P8=WU7
M:W\ZZ"B@# T31;RUU>_U>_FB:XO JF*)2%C"@ #)/)XZ\4NGZ1<VWBO5-2DV
M?9[F-%CPW.1G.16]10!@>)-'NM0ETZ\L&1;NSGWC><!E/WAG\!2ZYI%UJ.K:
M/<P;/+M)_,EW-@XQVK>HH CG@CN;>2"9 \<BE64]P:XOPIX/U#0/$M]=37"3
M631B.VY^95R3M(]LUW%% !7.:CHU[!KZ:YI/E/.T7DW%O*VU95SD$-V(^AZU
MT=% '$>(="\1>(X83*UO:I%,CK:I)N!P>2SX&?88%;_B#1#J\$#P3^1>6L@E
MMY2NX!AV([@CC\:V** ,);GQ*R^4VFV2-C'VC[26&?79M_3-9/C<32:=I5G\
MLFJ37*>0RC;&'&,D@YX]J[.L[5]&MM9@CCG+H\3AXI8V*LC#N#0!CC2_$%F'
MN$GT2255)PE@8R?^!;S_ "J1;N3Q;X+N#;Q"*>=&BV,W 8'GGTJ:3P_?7$30
M7/B"]DMV&&C$<:$CTW*H;]:UK&QM]-LX[2UC$<,8PJB@"/2+62QT:RM)L>9#
M D;;3D9  -8LNE:IIOB2ZU73(8+N.[0"6&64QE2.X;!X]L5T]% '(2Z)KFH>
M)=+U:\>W2*U9O]&1L^6"!_%_$3CT'2M#6-&NGU>UUK3#']L@4QO%*<+*A[9[
M'GKS6_10!Q7B+1O$?B;3)()/L]D@*E;=)=_F$,#\SX'&,\8ZXYK4UW0;C4M'
MLHX)$2[LV22/?RC,HQ@^U=#10!RFK6OB77=(N+!H+2P$L15W6<RF3(Z#Y1MS
MZ\UJV&ER1>%HM+G8"3[-Y+E3D#(Q6M10!S7ANTUO2+6#2[BVMGM8,JMTL_S,
MN<CY,=>?6K%II-S#XQO]4?9]GG@2-,-\V1C.16[10!S/]D:EHVL75]HZPW%O
M>-OFM9G\O#_WE;!_+%/_ ++U+6-3MKO5TAM[>U;?%:Q/YF7_ +S-@?EBNCHH
M P=1TBZNO%>DZE'L^SVJR"3+<\J0,#\:G\3Z;/J_AV[L;;9YTH4+O.!PP/\
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MKC;WX.>)K9CY'V:X3L5<@G\,5]#T5M'$31SRPM*72Q\O2?#GQ;&V/[$N']U
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M12T4 )12T4 )12T4 )12T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gou0qrw2itv5000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'H!WD# 2(  A$! Q$!_\0
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MV('!QGD59K%TS_C\'^Z:VJ *NH_\>3_45AUN:C_QY/\ 45AT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2$A1DD #N:6N)U+P1>Z]J]S<:GK5PMH7_ '%O =H5?>@#
MM001D'(]J6O)U@O_  #XXTVRAU":YTW4&VF.5LD<X/\ .O1?$.K)H>@WFHL
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M&JE6]._X_%^AH @N/^/B3_>-1U)<?\?$G^\:CH **** "BBB@ HHHH ****
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M:[CP4[2>#-*=V+,8!DDY)ZT6"^IO4444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<
MTS_C\'^Z:VJQ=,_X_!_NFMJ@"KJ/_'D_U%8=;FH_\>3_ %%8= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU   8' %#$MQ:***104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D=%D0HZAE88((R#2T4
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M!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\
MO@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08
ME_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_
M  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__
M !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X
M/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BM
MW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'
M_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5
M=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&
M)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W
M?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10
M!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\
MO@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08
ME_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_
M  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__
M !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X
M/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BM
MW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'
M_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5
M=/10!S'_  BMW_T&)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&
M)?\ O@__ !5'_"*W?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5'_"*W
M?_08E_[X/_Q5=/10!S'_  BMW_T&)?\ O@__ !5*OAB]1MRZU,I]0I'_ +-7
M344 <P?"UX3DZS*2>I*G_P"*H_X16[_Z#$O_ 'P?_BJZ>B@#F/\ A%;O_H,2
M_P#?!_\ BJ/^$5N_^@Q+_P!\'_XJNGHH YC_ (16[_Z#$O\ WP?_ (JC_A%;
MO_H,2_\ ?!_^*KIZ* .8_P"$5N_^@Q+_ -\'_P"*H_X16[_Z#$O_ 'P?_BJZ
M>B@#F/\ A%;O_H,2_P#?!_\ BJ/^$5N_^@Q+_P!\'_XJNGHH YC_ (16[_Z#
M$O\ WP?_ (JC_A%;O_H,2_\ ?!_^*KIZ* .8_P"$5N_^@Q+_ -\'_P"*H_X1
M6[_Z#$O_ 'P?_BJZ>B@#F/\ A%;O_H,2_P#?!_\ BJ/^$5N_^@Q+_P!\'_XJ
MNGHH YC_ (16[_Z#$O\ WP?_ (JC_A%;O_H,2_\ ?!_^*KIZ* .8_P"$5N_^
M@Q+_ -\'_P"*H_X16[_Z#$O_ 'P?_BJZ>B@#F/\ A%;O_H,2_P#?!_\ BJ/^
M$5N_^@Q+_P!\'_XJNGHH YC_ (16[_Z#$O\ WP?_ (JC_A%;O_H,2_\ ?!_^
M*KIZ* .8_P"$5N_^@Q+_ -\'_P"*H_X16[_Z#$O_ 'P?_BJZ>B@#F/\ A%;O
M_H,2_P#?!_\ BJ/^$5N_^@Q+_P!\'_XJNGHH YC_ (16[_Z#$O\ WP?_ (JC
M_A%;O_H,2_\ ?!_^*KIZ* .8_P"$5N_^@Q+_ -\'_P"*H_X16[_Z#$O_ 'P?
M_BJZ>B@#F/\ A%;O_H,2_P#?!_\ BJ/^$5N_^@Q+_P!\'_XJNGHH YC_ (16
M[_Z#$O\ WP?_ (JC_A%;O_H,2_\ ?!_^*KIZ* .8_P"$5N_^@Q+_ -\'_P"*
MH_X16[_Z#$O_ 'P?_BJZ>B@#F/\ A%;O_H,2_P#?!_\ BJ/^$5N_^@Q+_P!\
M'_XJNGHH YC_ (16[_Z#$O\ WP?_ (JC_A%;O_H,2_\ ?!_^*KIZ* .8_P"$
M5N_^@Q+_ -\'_P"*H_X16[_Z#$O_ 'P?_BJZ>B@#F/\ A%;O_H,2_P#?!_\
MBJ/^$5N_^@Q+_P!\'_XJNGHH YC_ (16[_Z#$O\ WP?_ (JC_A%;O_H,2_\
M?!_^*KIZ* .8_P"$5N_^@Q+_ -\'_P"*H_X16[_Z#$O_ 'P?_BJZ>B@#F/\
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MF/\ A%;O_H,2_P#?!_\ BJ/^$5N_^@Q+_P!\'_XJNGHH YC_ (16[_Z#$O\
MWP?_ (JC_A%;O_H,2_\ ?!_^*KIZ* .8_P"$5N_^@Q+_ -\'_P"*IS>&;Y@
MVMS$#H"IX_\ 'JZ6B@#F/^$5N_\ H,2_]\'_ .*H_P"$5N_^@Q+_ -\'_P"*
MKIZ* .8_X16[_P"@Q+_WP?\ XJC_ (16[_Z#$O\ WP?_ (JNGHH YC_A%;O_
M *#$O_?!_P#BJ/\ A%;O_H,2_P#?!_\ BJZ>B@#F/^$5N_\ H,2_]\'_ .*H
M_P"$5N_^@Q+_ -\'_P"*KIZ* .8_X16[_P"@Q+_WP?\ XJC_ (16[_Z#$O\
MWP?_ (JNGHH YC_A%;O_ *#$O_?!_P#BJ/\ A%;O_H,2_P#?!_\ BJZ>B@#F
M/^$5N_\ H,2_]\'_ .*H_P"$5N_^@Q+_ -\'_P"*KIZ* .8_X16[_P"@Q+_W
MP?\ XJC_ (16[_Z#$O\ WP?_ (JNGHH YC_A%;O_ *#$O_?!_P#BJ/\ A%;O
M_H,2_P#?!_\ BJZ>B@#F/^$5N_\ H,2_]\'_ .*H_P"$5N_^@Q+_ -\'_P"*
MKIZ* .8_X16[_P"@Q+_WP?\ XJC_ (16[_Z#$O\ WP?_ (JNGHH YC_A%;O_
M *#$O_?!_P#BJ/\ A%;O_H,2_P#?!_\ BJZ>B@#F/^$5N_\ H,2_]\'_ .*H
M_P"$5N_^@Q+_ -\'_P"*KIZ* .8_X16[_P"@Q+_WP?\ XJC_ (16[_Z#$O\
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M_P"$5N_^@Q+_ -\'_P"*KIZ* .8_X16[_P"@Q+_WP?\ XJC_ (16[_Z#$O\
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M_P"$5N_^@Q+_ -\'_P"*KIZ* .8_X16[_P"@Q+_WP?\ XJC_ (16[_Z#$O\
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M@NR;[7<_\_$O_?9H^UW/_/Q+_P!]FH:*+(+LF^UW/_/Q+_WV:/M=S_S\2_\
M?9J&BBR"[)OM=S_S\2_]]FC[7<_\_$O_ 'V:AHHL@NR;[7<_\_$O_?9H^UW/
M_/Q+_P!]FH:*+(+LF^UW/_/Q+_WV:/M=S_S\2_\ ?9J&BBR"[)OM=S_S\2_]
M]FC[7<_\_$O_ 'V:AHHL@NR;[7<_\_$O_?9H^UW/_/Q+_P!]FH:*+(+LF^UW
M/_/Q+_WV:/M=S_S\2_\ ?9J&BBR"[)OM=S_S\2_]]FC[7<_\_$O_ 'V:AHHL
M@NR;[7<_\_$O_?9H^UW/_/Q+_P!]FH:*+(+LF^UW/_/Q+_WV:/M=S_S\2_\
M?9J&BBR"[)OM=S_S\2_]]FC[7<_\_$O_ 'V:AHHL@NR;[7<_\_$O_?9H^UW/
M_/Q+_P!]FH:*+(+LF^UW/_/Q+_WV:/M=S_S\2_\ ?9J&BBR"[)OM=S_S\2_]
M]FC[7<_\_$O_ 'V:AHHL@NR;[7<_\_$O_?9H^UW/_/Q+_P!]FH:*+(+LF^UW
M/_/Q+_WV:/M=S_S\2_\ ?9J&BBR"[)OM=S_S\2_]]FC[7<_\_$O_ 'V:AHHL
M@NR;[7<_\_$O_?9H^UW/_/Q+_P!]FH:*+(+LF^UW/_/Q+_WV:/M=S_S\2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3
MU34K?2-,N+^Z;;#"A8^_H![FOG#Q'X@N_$FKR7UTV 3B.,'A%[ 5Z!\8==.^
MUT.%N //GP>_(4?S/XBO**^ARO#*$/:O=_D>%F.(<I^S6R_,FM;6:]NH[:WC
M,DTC!54=S7N7@WX=6>API=:@B7-^1GYAE8_8>]9GPI\+);6']N7<0,\W$&X?
M=3U_&O3:Y<QQLI2=*F]%N=.!P:454FM7L'08%%%%>0>H%%%% !1110 4444
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MU%I>R]3PR*)I;A(1PSL%Y[$FO0W^$-['M$NM6$;,,@-D$US_ (DT@Z)XY>U
M_=FX62/_ '2<UTWQC)&JZ60<$0M@CZBJJ5ISG3C3E923>UR:=*$(3=17<6CE
M/$G@S5?#.V2[19+9SA9XSE2??TKG:]<\.W,NM_"35XM0)F^S+((W?D\+N'/L
M:XRW\1:3%X%GT5]+#:@[[ENMJ\?,#UZ].*JC7J.\9*[3MI^8JM&"M*+LFKZ_
MD<M72:IX/NM*\,V.N27,3PW87;&H.Y=PSS7-U[==Z7IVK?#30X-3U1-.A6*)
MA*^,$[>G)%/%5W2<.S>HL/1552[I:'FGAWP?<^(]/OKR"YBA2T4E@X)+<9XQ
M7.D8)'I7N7A;1M)T?P]K*Z7K,>I+)$Q=DQ\AVGC@FN=^'/ABVN=*NM:FL5OK
MA'*V\#D!21ZYXK&..2YY/96MTW-7@V^2*W=[]3RZBO=-0\-_VYX?OO[4\/VF
MF742%H)+>16Y _V?ZUS'@193HC"P\*1:A="0[[BY95C(] 3WJXXZ,H.26WFO
MS)E@VIJ+>_D_R/,AUKN?&GA33="\.:+>V8E\Z[4&4N^0?D!X';DUT/Q'T*U7
MPM::LVFPV&H"54ECA(VX.>..#VYJSXUU!=*T/PE?/;1W*P@,89/NO^Z P:R>
M*=25.4.[T]$7]65-34^RU]6>:ZUX7U30+>UGOXD2.Z!,15PV> ?PZBN@_P"$
M4TW_ (5B-?\ WOVXMC._Y<;B.E=U\0/$<6E:'8;]*M[K[;$ZKYF/W/RCE>/?
M]*IZ)=V-E\(H;K4+7[3;QL6\GLS;SC/MFL_K5:=*$VK>]TZ[FGU:E&I*"?3K
MTV/&**]<NSI'C#X>7NIQZ5!8W-IG'E*!@CW &1BJ5Y96GB#X4Q7]K:0QWEB<
M2&- "<<'..M=2QG\T;:V?D<SPG:5]+KS/,**]-U.QM/#WPIMUEMH3?WQ!#L@
M+#//!Z]*YKX?W5K;^+K6.\ABE@N,Q$2H& )Z'GWK2.(YJ<II;7^=B)4.6<8-
M[V^5SEZ*]/'A",_%[[+Y"BQ!^V;-OR[?3'INXJY9Z+I7BCXD:M));1+IVF(J
M>5&H578<<X]PWY"LWCH)7MI:_P#P"U@YO2^M[?\ !/)*ZWX?>';'Q)KDUKJ
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M0TZOBVW\1:U:S"6'5KU''0^>W^->E>#?C=J5A<1VOB'_ $NT)P9P,2)[GUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJX1DEU/1_AUJVG6'A_7(;R]M[>25#Y:RR!2WRXXSUIW@3Q/IL>AWGA_4KU[
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MW4ZB71WLX>=[3SH6]L!"P/XD5D6]EJGAW5]1DL[!]0L;Z03A8I41X9,8.0Y
M(/'0_A7544#.0T32]<7QO?:QJD4*0SV:11B)P=A#YVGN3CG.,<UU]%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5']I8;^;\&']GXC^7\4>045Z_P#\*6M?^@W-_P" X_\ BJ/^%+6O_0;F_P#
M<?\ Q5']I8;^;\&']GXC^7\4>045Z_\ \*6M?^@W-_X#C_XJC_A2UK_T&YO_
M  ''_P 51_:6&_F_!A_9^(_E_%'D%%>O_P#"EK7_ *#<W_@./_BJ/^%+6O\
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M_:6&_F_!A_9^(_E_%'D%%>O_ /"EK7_H-S?^ X_^*H_X4M:_]!N;_P !Q_\
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MJ/\ A2UK_P!!N;_P''_Q5']I8;^;\&']GXC^7\4>045Z_P#\*6M?^@W-_P"
MX_\ BJ/^%+6O_0;F_P# <?\ Q5']I8;^;\&']GXC^7\4>045Z_\ \*6M?^@W
M-_X#C_XJC_A2UK_T&YO_  ''_P 51_:6&_F_!A_9^(_E_%'D%%>O_P#"EK7_
M *#<W_@./_BJ/^%+6O\ T&YO_ <?_%4?VEAOYOP8?V?B/Y?Q1Y!17K__  I:
MU_Z#<W_@./\ XJC_ (4M:_\ 0;F_\!Q_\51_:6&_F_!A_9^(_E_%'D%%>O\
M_"EK7_H-S?\ @./_ (JC_A2UK_T&YO\ P''_ ,51_:6&_F_!A_9^(_E_%'D]
ME97&H7D=I:1-+/*VU44<DU[YX(\$6_A>S$TP674I%_>2=D_V5_QJ;PGX&T_P
MH))(W-S=/P9W4 A?0#M74UY>.Q_MO<I_#^9Z.#P7LO?G\7Y!1117EGHA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 -9U169F"JO4D]*9]HAR!YJ<KO'S#[OK]*=)$DL;1NH
M97&&![U&+*V!!$*Y$?E#_<]/I0 X7,#%0)D.X97##D>M N8#MQ,AW_=^8<_2
MF+8VJ%"L*CRUVK[#TH6QM5\O;"H\O.S_ &<T /%S P4B9#N;:N&')]*/M,&,
M^='][;]X=?3ZTQ;&U0(%@4"-]Z^S>M)]@M<8\A,;_,_X%ZT 2&Y@ 8F:,!3M
M/S#@^E#7,"B0M-&!'C?EA\N>F:8UA:NKJT"$.V]AZGUI'L+603!X$(F(,F?X
ML=,T 2-<0H7#2H"@!?+#Y<^M!N(02#*@PNX_,.!ZTQ[*VD:5GA5C, )"?X@.
MF:4V5LQ8F%2638WNOI0 [[1"2 )4R5W#YAT]?I0+F [<3(=PW+\PY'K3!96P
M8$0KD)Y8/^SZ4+8VJ^7B%1Y:[$]AZ4 /%S VW$R'?]W##GZ4"Y@.W$T9W-M7
MYAR?2F+8VJ>7MA4>7G9[9H6PM5V;8$&Q]Z^S>M #_M,&,^='C=L^\/O>GUH-
MS  Q,T>%;:?F'!]/K3/L%KMV^0F/,\W'^WZ_6@V%J0X,"$._F-[MZT /:Y@7
M?NFC&PX;+#Y?K0UQ"N_=*@V %\L/ESTS3'L+63S=\"'S2#)G^(CI0]E;2&4O
M"I\T 29_B Z4 /\ M$()!E3*C<?F' ]:/M$.<>:F2N[[PZ>M,-E;$L3"N678
MWN/2C[%;;@?)7(38/]WTH >+B%MN)4.\;EPPY'J*%N8&V;9HSO\ NX8<_2FK
M96R&,K"H,:E4]@>HI$L;5/+VP(/*SL_V<]: 'BY@.W$T9W':OS#D^E'VF @'
MSH\%]@^8?>]/K3!8VJA (%'EMO7V;UH%A:A0H@3 E\X#_;]?K0 \W, W9FC&
MUMA^8<-Z?6@W,"[MTR#8<-EAQ]:C-A:L&!@0[Y/,;W;UI6L;5Q(&A4^807_V
MB* 'FY@7?F9!L&6RP^4>]!N(02#*@*KN/S#@>M,:QM7\W="I\T!7_P!H#I0U
ME;,S,T*DLFQCZKZ4 /\ M$.<>:GW=WWNWK0MQ"Q4+*A+C*X8<CVIOV*V!!\E
M<A-@_P!WTI$LK9&C985!C4JA] >HH >MS VS;,A\S.S##YL=<4"Y@8*5FC(<
M[5PPY/H*8EC:Q^3LA4>3GR\?PYZXH6QM4$86! (V+)[$]Z '_:8, ^='@ML'
MS#[WI]:#<P ,3-&-K;#\PX;T^M1_8+4 #R$P)/,''\7K2FQM6# P(0\GF-[M
MZT /-S -V9D&TX;YAP:#<P+NW3(-@RV6''UIC6-JWF;H5/F'<_N:&L;5_,W0
MJ?, #^X% #S<0@L#*@VKN/S#@>OTH^T0YQYJ9*[OO#IZ_2FFRMF+$PJ2Z>6W
MNOI2"RM@P(A7(3RP?]GTH >+B$E0)4)<97##D>HH6X@?R]LJ'S,[,,/FQUQZ
MTQ;*V4QE85!C4JGL#U%"6-M'Y.R%5\C/EX_ASUQ0 ];F!@I6:,ASA<,.3[4?
M:8, ^='@MM'S#KZ5&EA:H(PL" 1L63_9)ZFE^P6N /(3 ?>/][UH ?\ :8 "
M3-'@-M/S#@^GUH-S N[,T8V'#98<'WIAL+4JRF!,,_F$>K>M#6-J_F;H%/F,
M&?W(H >;B!=V9D&P9;+#CZT?:( 6!F3Y5WGYAP/7Z4QK&V?S-T*GS  _N!0;
M&V)<F%<NGEM[KZ4 /^T09QYJ9V;_ +P^[Z_2@7$+;<2H=R[EPW4>M,^Q6V0?
M)7(C\K_@'I]*5;*V4QE85!C0HGLI[4 .6Y@?9MF0[_N88?-]*!<P,%(FC(<D
M+AAR1Z4Q+&UC,12%1Y.?+Q_#GK0MA:H(PL" 1,63_9)ZF@!XN8" 1-'@MM'S
M#KZ4&Y@ ),T8 ;:?F'!]*8+"U"@"!,!]X_WO6D-A:L&!@0AGWGW;UH D:Y@7
M?NF0;" V6'RD^M!N8%WYF0;!ELL./K3'L;5Q*&A4^:P9\_Q$=*&L;5_,W0J?
M- #_ .UB@!YN8 6!F0;5W'YAP/7Z4?:(<X\U,[/,^\/N^OTIC6-LQ<M"I+IY
M;>Z^E+]BMLY\E<^5Y/\ P#^[]* '"Y@)4"9#N7<OS#D>M N8&VXF0[_NX8<_
M2F+8VRE"L*@HFQ?9?2A;&U3R]L*CRL[/]G- #Q<P-MVS(=YPN&')]!1]I@(!
M$T>"VT?,.OI3%L;5!&%@0>6Q9/\ 9)ZFD%A:@ "!,!]XX_B]: )#<P $F:,
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MZT?:8 "?.CP&VGYAP?3ZTS[!:A0/(3 D\P?[WK0;"U(8&!,,_F'W;UH >US
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MV-[KZ4 /^T0YQYJ9V[_O#[OK]*47$)*@2H=R[A\PY'K4?V*V)R85SY?E_P#
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M<#UH^T0Y(\U.$WGYA]WU^E,:QM7+EH5/F+M;W'I2FRMB23"N3'Y1_P!ST^E
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M8VJ>7M@0>424Q_"3UH >+F A2)HR&;:/F')]*/M,&,^='C=M^\.OI3!86JA
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M8.&@0AV#M[D=Z5[&UD\W?"I\X@R9_B(Z4 /-S N_,R#8,MEA\H]Z#<0@D&5
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MO_ O_P"PKR2BC^S<-_+^+_S#Z_B/YOP1ZW_PNN/_ * +?^!?_P!A1_PNN/\
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M11_9N&_E_%_YA]?Q'\WX(];_ .%UQ_\ 0!;_ ,"__L*/^%UQ_P#0!;_P+_\
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M?\+KC_Z +?\ @7_]A7DE%']FX;^7\7_F'U_$?S?@CUO_ (77'_T 6_\  O\
M^PH_X77'_P! %O\ P+_^PKR2BC^S<-_+^+_S#Z_B/YOP1ZW_ ,+KC_Z +?\
M@7_]A1_PNN/_ * +?^!?_P!A7DE%']FX;^7\7_F'U_$?S?@CUO\ X77'_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\^^(WC?^Q;8Z7I\O^GRCYW4_
MZI?\:ZSQ'K,>@Z%=:A)C,:?(I_B;L*^:;V\GU"]FN[AR\TK%F)KU,MPBJR]I
M/9?F>=C\2Z<>2.[(G=I'9W8LS')).236WX=\):KXFG*V4.(5.'F?A5_Q-6O!
M7A&;Q3JH5@R6,)!GD]O[H]S7T%86%KIEG':6<*PPQC"JHKT,;CU0]R'Q?D<.
M#P3K>_/;\SB]&^%&B6*(U]OO9QR=QPF?I_C750>'M'M<>1IEJF.F(Q6G17@U
M,15J.\I,]J%"G!6C$@^QVO\ S[0_]^Q1]CM?^?:'_OV*GHK*[-+(@^QVO_/M
M#_W[%'V.U_Y]H?\ OV*GHHNPLBI-I>GSC$ME X]XQ6)J7@#PWJ:8DTZ.)_[\
M/R']*Z:BKC5J0=XMHF5.$M)*YXCXF^%=]IBR76E.;NV7DQG_ %BC^M>>,K(Q
M5@0P."#VKZQKS7XB^ X[ZVDU?2X0MU&-TT:#_6#UQZU[&#S)MJ%;[_\ ,\K%
MY>DN>E]QXO1000<'J**]H\@**** "BBB@ HHHH **** "BBB@ HHHH ****
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MR\4::MQ;L$G48EA)Y0_X5\WCL"Z#YH_#^1[^#QBK+EE\7YF]1117G'>%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K1T76KW0=2CO;*0JZGYE[./0UG44I14E9[#4G%W1]*>%O%-EXHTU9X
M&"SJ,2PD\H?\*WJ^7M%UJ]T'4H[VRD*NI^9>SCT-?0?A;Q39>*--6X@8+.HQ
M+"3RA_PKYO'8%T'S1^'\CW\'C%67++XOS-ZBBBO..\**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /G7XAH4\<ZEG^)P1^0I_PWD6/QUIY89R64?4J
M16I\7+ V_BJ.ZQA+F$$?4<&N0T/4&TK7;*^7_EC,KD>HS7U5/][A$EU7Z'S=
M3]WBFWT9]15D>*O^1/UO_KPG_P#1;5JQR++$DB'<CJ&4CN#5;5+$:GI%[8&3
MRQ=0/#OQG;N4C.._6OE3Z0^=OAOX9\2:_IM\=%U[^S;=90DR;F!8D=>!Z5Z/
MIOPYL_!GA+7+IKAKS49K*57G88 &T\*/ZUN?#[P,W@?3[NV?4!>-<2^9N$6S
M;QC'4YKIM4LAJ6DW=B9/+^T0O%OQG;N&,X[U39*6AY/\ K.V;1M5NV@0W N!
M&)"N3MV@X^E4/AW&L'QEUR&)0D8\P!0,#K7H7P^\$-X'TNZM&OQ>&XF\W<(M
MFWC&.ISTJMX?^'C:'XXU#Q$=2$RW6[$'D[2N??=_2BX6V.YKPSQG_P E_P!!
M_P"NEK_Z&:]>\1Z1/KFA7&GVVH2Z?+* !<1 EE_(C^=>82? N]FNTNY?&ES)
M<IC;,UJ2ZXZ8;S<BD@=RW\?/^13TW_K^'_HMZUX(-)'P+VJMN+8Z-O?;C'G>
M7R?][?\ K5/4/A1>ZAX0AT.Y\3374L5\;H7,\)8[=FW9@N3[]?PK,O?@?.Q:
MTT_Q/<6^E2,&>UD1F4-ZX# 'GUY'O3T#6Y-\ S+_ ,(QJ0.?*%Y\OUV+G^E>
MMUD>&?#EEX5T.'2K#<8X\EG?[SL>I-:])[C2LC@OBY(J^#U0CYFN$Q^&:\*K
MUCXR:H"]AI:'H#,_\A7D]?399!QPZOU/GLPDI5W;H>I:&Q3X+ZDRG!$KD?I7
M2V.FV_C/3O#>M2L-]F<S9_BVCD?F!7DMMXLU"U\,3^'XX[?[),Q9G*G?SZ'.
M.WI5G0_'6K^'])FTVS%NT,I)S(I+(2,';@BLJN$JOFE#1W;7HU8UIXJFN52V
MLOO1Z7X4U<:UX]\17"-NACB6&/\ W5./YYK#^%2&;3O$L*<R.@ 'U#@5P_AK
MQ7?^%I[B:QCMY&G38_GJ6'7/&"*BT#Q+J/AO46O=/= SC;)&XRCCKR,TY8*7
M+.,>JC;Y"CBXWA*72]_F=O\ "*PNX]=U"XDMY$A2(QEV7 W9Z?7BKWP\_P!;
MXJ^K?^S5SC?%GQ(UZMQBS"JI7R!&VPY[GYLY_&L?1O&>I:&VH-:Q6S?;L^;Y
MB,<=>F"/7WI5,-6J<[DDF[=>P0KT:?(DW97_ !.V^&0+:-XC4#).[ '^Z:R/
MA0CQ^,W#J5/DOP1BN:\/>+-3\,WDUQ8&(^=_K(Y5)5OR(/ZUH#XA:S_PDG]N
M>59FY\KRMGEML"_3=G]:NIAZK=1):21,*]-*FWO%FD^H^%K+Q%K2Z_I-Q>RM
M=$QM$V-H[_Q"MCP+=Z#>?$!I-%L7L[?[&0D<K9)?/)')[>]>97][+J-_/>3!
M1),Y=@@P,GTI=.U&ZTF_BO;*4Q7$1RK#_/(K2>$YJ;5W=JV^GW&<,3RS3LK)
MWVU._P!(363\8969;D$7+F8\X\KG&?\ 9QC'X5T<7D_\+PN/,V[OL8\O/][:
MO3\,UQES\6/$EPD2C['#L=6)BB(+X.<'+'@]\8K U/Q1J6I^(1KA=+>]7;M:
MW! 7 P.I-8?5:LW>22]VQM]8I07NMOWKF[?Q:VWQ3;:+@W0O<H1GB/=_Z#MK
MJ?%^KSZ/\1;*\L;0W<\5IBXBC4D[<\GCVQ7.?\+=\2_9O*V6._;CS?);=]?O
M8S^%<Y8>*M6L-?;6DG$MZ^=[2C(8'MCT^E4L/5FTYQ6BM:^XG7IQ5H-ZN_H>
MA2Z5H7C/3M1U;16O=.OT1FG1B0KG&2#V.?8_A6AHSZ9;_"FW>]L9[VU'^OBM
MB=V<\DX(X_&N&U?XG>(=7L7LW-M;1R#:YMXR&8>F23^E9OAWQIK/AA6CL98W
M@8Y,,R[DSZC!!'X&H>$K2IV?1II7_4M8JE&=UU5F[?H=C>>*]#;P7J.G:/H&
MIPVSH07==T<;'H22QQ7GPBUG^Q6D5;[^RMWS$;O)W9[]LYQ6YKWQ%USQ#I[6
M-R+6*W?&]88R-WXL3^E45\7ZDGA5O#H6W^QL<[MA\SKG&<X_2NBC2G3C\.K>
MNM_GZF%6K"I+?9=K&'#$\\\<,2EI)&"JH[D\"O;_ !%H&D#PUIGARZ\0VVEK
M;*KD2%<RG!&<%AQG=7C&EZA)I6IV]_%%%));N)$64$KD=,X(JSX@U^]\2:HV
MH7WEB4J$"Q@A5 [#)/\ .JQ%&I5J1L[):_,FA5A3A*ZNW^1ZKXZTZ'6/ $%U
M9WL6H/I^,W$1!#C&&Z$^QZUES?\ )#HO]_\ ]F-<7HOC+4M#T>[TJWBMI;6Z
MW;Q,C$C(P<8(IK>+]1;PLOAXQ6WV-6R&V'?USUSC]*YXX2K%*&Z4K_(WEB:<
MFY=7&WS.Q\)V</@[PI-XGOXLWMPNRTC(YP>GYU0^&MU/>_$%KJY8M-+'(S$^
MIJ.V^+>OVMM%;I:Z:4C4*"T3YP/^!UE+X\U5?%#>(!#:?:S'Y938VS'TW9_6
MG["M)5.9:RZW^Y"]M2BX<KTCTM][-^WO;I_C/\UQ(?\ 2O+Y8_=]/I72:>L/
M_"ZM0+[0_P!FRGN=HS^F:\KC\17D7B7^W@D)N_-\W:5.S/TSG'XTZ^\4:E>^
M(O[=#I;7V00T ( P,="3^M.>$G+1:>[;YBABHQ5WK[U_D>EW/B'POI'BZ:3_
M (1S5O[725AYBY)<GC(!?D'MQ1X,OTU/XG:Y=I:S6N^ 9AF7:ZD%0<CL<BN9
M'Q>\2"#R_*T\MC'F&%MWU^]C]*P](\::KH^MW>KQ"WFNKL$2F9#@Y.<@*162
MP=1PDFM;6WO_ ,,:/%4U.+3TO?:QWWPY8IJ7BEE.&#D@_BU4?A5=W$WB/5S+
M/(Y9-S;F)R<GFN0T;QIJ6ARZA):Q6K-?<R^8C''7I@CU[YJOX>\4W_AJ]GNK
M*.W=YUVN)E)'X8(K2>$G)5/[R5OD1#$P3I^5[_,[3X=7ES<?$+46FG=S(K[M
MS9S@\5N>!5@77O%.4+2"4_(I^8KSTKR_0_%%]H&L2ZG:1V[SRA@RRJ2O/7H0
M?UIMIXGU2PUV75[280W,K%G"CY&SV(/:BMA)S<K:72_ *6*C!1OK9O\ $]&T
MGQ5X8TS4YUTOPQK"7K@K*JJ78^N07-.^']T6T7Q5=VZM#F5I$4]4X8C\JYJX
M^+?B.>W:(1V$188WQQ-N'YL1^E8FC>,=2T/3[ZSMH[9X[W/FM*A+#@CC! [U
M#PE24)*VKMUOLRUBH*:=]%?I;<P))))79Y'9V8EB6.22>IKJ_ GB&X\.W=Y<
M#3Y;NQ= MSY2DE!S@YZ>O6N2K<\-^*]2\+7$TNG^2WG "1)4+*<=.A![GO7?
M7ASTW%*_X'#1GR5%)NQV.O>'=&O_  A<^(/#TUW;0 AIK60L$8YQT/<$^]<;
MX/\ *_X2[2_.QY?GC.>GM5[Q#X_USQ):?9+IX8;<G+1VZ%0WUR2?UKF$=XI%
MD1BKJ<JP/(-94*514G"H]_G;YFM:K3=12@MOE^!Z5\1$U9_B!9_9UN",)]G\
MO/XXQ6K\1M_]L>&?,SOW#=GUR,URH^*WB4:>+7=:[@NW[08CYGUZXS^%96L>
M,]4UN:PENUM_,LN8V52"Q]6R>?PQ7-3PU:\.9*T4T;SQ%*T[-^]9G>^.M0O-
M+^(>E7EC:M=310$^2JDEE[]/:G)I^A>/A?7VEF^TS6$0^<22 Q(QSV(.,<$?
M2N&O/'VL7GB"UUHK;175LA1!&AVD'KD$FKVI?%/Q'J-D]KFUME<;6>WC(8CZ
MECC\*E86LHQ459I6O?S[=2OK-)RDY:IO:WZ]#L_")L(/A/(US:37D"R/]I@M
MB=[?/[$=L$\]*S!XM\/Q^%M4L-%\/:I';R1-O)7=&A(P"27..U<-X<\7ZOX7
M>3^SYD,4AR\,J[D)]<<$'Z&M36OB5KVN:=)8SK:0P2C#B&(@L/JQ/Z53P<_:
M-M73=]VOP$L5#V:6S2MM?\3I;'1-!T;P/I^IZ[#>ZF+C:8X(W;;&6YPHR /S
MJ]\0W"^$M$EL[66';,AA@E!+KP, \DY_&N)T/XCZ[H&FK86_V::!.(_/C)*#
MT!!'ZU!K/CW6==M+:"\^SYMY1*DB1D-N'3/./TI+"UW64I:I-]?T!XBC[)QC
MHVNWZG=P7VC>.;N#3]7L+[3M<B3"2)D8(]/3\0*F\ ::NDZUXDLYY6N;B$@%
ML_.ZXS]<]*Y,_%SQ(;7R0EBK8QYHB;=]?O8_2N9L/$FK:;K#ZK;W;B[D),C-
MR'SV([BCZG6E"4-D]E>_7\$/ZU24XRW?5VM_3/2=)\5>&-,U2<:7X8UA+Y\K
M(JJ78^N07->5:C,EQJEU/'&8TDF=U0CE023BNRN/BYXDGMVB$=A$6&-Z0MN'
MYL1^E<*S%W+L<LQR373A:,H-RDK-^=SGQ-:,THQ=[>5CU[QVE\_PTT3[*)C"
M(XC/Y><;?+XW8[9_I3)A/'\#PNH[A(P B$G7'F?+^GZ5>\1^);_PUX,\-WFG
M/'N>*-621=RNOECKW_(UYMXD\:ZQXI6..^>)((SE88%*KGU.223^-<6'I5*D
M8JRLI7OUW.NO5A3E)W=W&UCT"YT7P[X:L=)35K/4=7O)P!$4=CM(QPHW# ]J
MK_%/;_:7A\A"O(P&ZCD<&N:L/BEXBT_34LD-K*$78DLL9+@=NA /XBLCQ%XN
MU+Q/]F-^L"M;C"M$I4GW/)_3%:4L+7552GTOU[^70SJ8FBZ3C#K;I^O4['XO
MQR-/I#JC%1 <D#BK7B3;_P *KT'=]WS(\_3)KEI_B5KUSH3:3,+1HGC\LRF,
M^9C\\?I6=?\ B[4=1\.VNB31VXM;?&QD4ASCU.<?I54\-5481:^%_@3/$4W*
M<E]I'K'C&Z\/6>G:8VL:1=W]MY8\EH"=B<#&<,!DCI7'^,?$MEK.C:/;6>E7
M]K#%.##+<I\I4#&%;)SU%9&B_$OQ!HEBEG&UO<PH,(+E"Q4>@((/YUG^(/&.
MJ^)9X)+\PA8&W1QQ)A0?Q)/;UI4,'.$ES*]KZW?Y%5L5"<7RO?I;]3MOC)<S
MI<:3"DSK$4=R@; + C!^M,^)3M+X-\.2R$M(R9+'J247-<3XF\6:AXJFMY;^
M.W0P*500*0#GUR32ZUXMU#7=+L=/NHK98;-=L9C5@QX YR3Z5=+"SA&DG]F]
M_F15Q,).I;[5K'<_$V-Y/"GA\HC, #D@9Q\HJGH?B+3Y_#MGH'B?2KH6K8%M
M<(K $=CZ_EFL2S^)6O6>B#2E%K)"(S$LDD9+A<8Z@@?F*?I'Q-U[1M.CL84L
MY8HAA#-&Q('X,*A8:JJ7LW&]GIK;]"GB*;J<Z=KK72Y'\0/#@\/:C;+%>37%
MM-'NA$S99!Z5R%:6MZ]J'B&^^UZC-YDF,* ,*H] *S:[Z$9QII3=V<5:493;
M@M HHHK4S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KUGX7^#[Z"===NI);>,KB*('!D'JWM57X>_#TWACU
MC6(B+<?-! P_UG^T?:O8@ H    & !VKQ<PQRLZ-/YGKX'!NZJS^0M%%%>&>
MP%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 N2>])110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>G_#WX>F\,>L:Q$1;CYH+=A]__ &F]O:CX>_#TWACUC6(B+<?-! P^_P#[
M3>WM7L0 4    < "O&Q^/M>E2?JSUL%@K_O*GR0 !0   !P *6BBO"/9"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^!ZLWQHM=IV:--N[9F&/Y5C:E\8-5N$V6%K#:_[9^=OUXK@O[-O_ /GRN?\
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M'*^Q5HJU_9M__P ^5S_WZ;_"C^S;_P#Y\KG_ +]-_A1S1[AROL5:*M?V;?\
M_/E<_P#?IO\ "C^S;_\ Y\KG_OTW^%'-'N'*^Q5HJU_9M_\ \^5S_P!^F_PH
M_LV__P"?*Y_[]-_A1S1[AROL5:*M?V;?_P#/E<_]^F_PH_LV_P#^?*Y_[]-_
MA1S1[AROL5:*M?V;?_\ /E<_]^F_PH_LV_\ ^?*Y_P"_3?X4<T>X<K[%6BK7
M]FW_ /SY7/\ WZ;_  H_LV__ .?*Y_[]-_A1S1[AROL5:*M?V;?_ //E<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,C+\K]W'8^] %NBJD=]YA@'V>9?.S]Y?NX]?2D2_WK"?L\X\UBN"OW<=S[4
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MV>8;XO,^[T]C[T 6Z*J)?;_*_P!'F'F*3ROW<>M(E_O\G_1YAYC%>5^[CN:
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M^E)'?^8MN?L\Z^>6&&7[F/7TH N4532_WK&WV><;W*8*]/<^U']H?+G[-/\
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M3_H\P\TD<K]W'K0!<HJFM_N6,_9IQOD*8*],=S[4?;_ES]GG_P!9LQM_7Z4
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MOFJ6Y7[N.Q]Z +=%4X[_ ,SR/]'G7S21ROW<>M"W^X1'[/./,D,?*_=]S[4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5A_*?3M%?,7_  D^O_\ 0<U/_P "Y/\ &C_A)]?_ .@YJ?\ X%R?XT?V//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6CZQ*!<#Y8)V/W_]EO?WKT^OEJ]"=&?),^CHUHUH\T0HHHK$U"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "KFF:9=ZQJ$5C8PM+/(< #M[GT%&
MF:9>:QJ$5C8PF6>0X ';W/H*^@?!_@^S\*:?L3$M[*/W]QCK_LCT45QXS&1P
M\>\GLCKPN%E7EY!X/\'VGA73PJXEO9!^^GQU]AZ"NEHHKYBI4E4DY2=VSZ*$
M(PBHQV"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@".XMXKJWDMYXUDAD4JZ,,A@>HKY]\<>
M#IO"^IEHE9].F.89.NW_ &3[C]:^AJKWUC;:E9R6EY"DT$@PR,,@UUX3%RP\
M[]'N<N*PT:\;=3Y;M;J>RN8[FVE>*:,[E=#@@UZ[X7^+%M<)':ZZODS 8^TJ
M,JWU':N=\6_#*^TJ22[TE6NK+KL'+Q_AW%>?LK(Q5U*L#@@C!%>]*&'QL+[_
M )H\6,Z^$G;_ (9GU3:7]G?Q>99W4,Z>L;AOY58KY3M[NYM7WV\\D3#NC$5I
MIXM\11KM36KY5]!.U>?+)Y7]V1W1S6-O>B?3-%?-'_"8^)/^@Y?_ /?]J/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD74<S>6\(RH\K(Z'OFKM% %-EU#=)M>''E#9D?Q]\^U 74-XR\.WRN>/X_\
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M(KJ&Z3#PX\G"<?\ +3U/M2[=0W)\\.WR,-Q_RU]?I5RB@"FBZAF'>\. A\S
MZMVQ[4D2ZCFW\QX2 3YV!U],5=HH HHNH[8=[P[A(?,P.J]L>]*%U':,O#N\
MST_@_P :NT4 4774MLFQX=WF#9D=%[Y]Z65=1Q<>4\(RR^3D=!WS5VB@"DZZ
MAF?8\."H\G(Z'OFE9=0WR;7AV^5A,C_EIZ_2KE% %,+?[ER\./(P>/\ EKZ_
M2D1=0S%O>'&P^9@=6[8]JNT4 5(1? P^<\1'/F;1U],5;HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUZ4 =-4$MW'%=P6S!C),&*X' "XSG\Q7+ZKI$-OX<:\/SZPRJT=UN^<S$C:
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M^P["S$8;!P=B  ^] '6T5SVE:-+;ZDMW]C@T]%0H\<,A<S$XY8X'3Z=ZZ&@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:4NL?^Z#TXJ=]+A;4QJ DG2;:$8)(0K@9QN'?[QJ[10!6OK*'4+5K>;>$)#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gou0qrw2itv5000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +C U\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK-OO$.C:9<?9[
M[5+2VFVAMDLH4X/?!JK_ ,)EX:_Z#NG_ /@0O^- &Y16'_PF7AK_ *#NG_\
M@0O^-'_"9>&O^@[I_P#X$+_C0!N45A_\)EX:_P"@[I__ ($+_C1_PF7AK_H.
MZ?\ ^!"_XT ;E%8?_"9>&O\ H.Z?_P"!"_XT?\)EX:_Z#NG_ /@0O^- &Y16
M'_PF7AK_ *#NG_\ @0O^-'_"9>&O^@[I_P#X$+_C0!N45A_\)EX:_P"@[I__
M ($+_C1_PF7AK_H.Z?\ ^!"_XT ;E%8?_"9>&O\ H.Z?_P"!"_XT?\)EX:_Z
M#NG_ /@0O^- &Y16'_PF7AK_ *#NG_\ @0O^-'_"9>&O^@[I_P#X$+_C0!N4
M5A_\)EX:_P"@[I__ ($+_C1_PF7AK_H.Z?\ ^!"_XT ;E%8?_"9>&O\ H.Z?
M_P"!"_XT?\)EX:_Z#NG_ /@0O^- &Y16'_PF7AK_ *#NG_\ @0O^-'_"9>&O
M^@[I_P#X$+_C0!N45A_\)EX:_P"@[I__ ($+_C1_PF7AK_H.Z?\ ^!"_XT ;
ME%8?_"9>&O\ H.Z?_P"!"_XT?\)EX:_Z#NG_ /@0O^- &Y16'_PF7AK_ *#N
MG_\ @0O^-'_"9>&O^@[I_P#X$+_C0!N45A_\)EX:_P"@[I__ ($+_C1_PF7A
MK_H.Z?\ ^!"_XT ;E%8?_"9>&O\ H.Z?_P"!"_XT?\)EX:_Z#NG_ /@0O^-
M&Y16'_PF7AK_ *#NG_\ @0O^-'_"9>&O^@[I_P#X$+_C0!N45A_\)EX:_P"@
M[I__ ($+_C1_PF7AK_H.Z?\ ^!"_XT ;E%8?_"9>&O\ H.Z?_P"!"_XT?\)E
MX:_Z#NG_ /@0O^- &Y16'_PF7AK_ *#NG_\ @0O^-'_"9>&O^@[I_P#X$+_C
M0!N45A_\)EX:_P"@[I__ ($+_C1_PF7AK_H.Z?\ ^!"_XT ;E%8?_"9>&O\
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M-'_"9>&O^@[I_P#X$+_C0!N45A_\)EX:_P"@[I__ ($+_C1_PF7AK_H.Z?\
M^!"_XT ;E%8?_"9>&O\ H.Z?_P"!"_XT?\)EX:_Z#NG_ /@0O^- &Y16'_PF
M7AK_ *#NG_\ @0O^-'_"9>&O^@[I_P#X$+_C0!N45A_\)EX:_P"@[I__ ($+
M_C1_PF7AK_H.Z?\ ^!"_XT ;E%8?_"9>&O\ H.Z?_P"!"_XT?\)EX:_Z#NG_
M /@0O^- &Y16'_PF7AK_ *#NG_\ @0O^-'_"9>&O^@[I_P#X$+_C0!N45A_\
M)EX:_P"@[I__ ($+_C1_PF7AK_H.Z?\ ^!"_XT ;E%8?_"9>&O\ H.Z?_P"!
M"_XT?\)EX:_Z#NG_ /@0O^- &Y16'_PF7AK_ *#NG_\ @0O^-'_"9>&O^@[I
M_P#X$+_C0!N45A_\)EX:_P"@[I__ ($+_C1_PF7AK_H.Z?\ ^!"_XT ;E%8?
M_"9>&O\ H.Z?_P"!"_XT?\)EX:_Z#NG_ /@0O^- &Y16'_PF7AK_ *#NG_\
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M5A_\)EX:_P"@[I__ ($+_C3D\7^'))%C37+!G8@*HG7))_&@#:HHHH ****
M/GSXS?\ (]#_ *](_P";5YY7H?QF_P"1Z'_7I'_-J\\H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [SX0?\
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MYM7GE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_/A\S\N#7HO_  EWPW_YZ:9_X!'_ .(KYWHJF[DI6/HC_A+OAO\ \]-,_P#
M(_\ Q%=!IMMX:U:Q6]LM/L);=NC_ &15!_-17S[X&\,/XG\0Q6S*WV5/GF8=
MAZ5ZO\2/$\'A;P_'HNFXCN)4V*$X\M*4O=C?J]AQ]Z5CS#XD7.FW'B^<:6D*
MP1H$/DH%7<,YZ5R-*2223R324HJRL.3N[A1113$%%%% !1110 4444 %%%%
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M0Z\' VR^O'8UX/6OX7NVLO$^FW"$@I.IX^M:4TKJ+(G)I<R/:?C$H3P2JJ,
M3( /Q%>9?#;PM'XE\0XN1FUM@))!_>]!^E>F?&%MW@=&]94/\JJ?!*VC7P_>
M7('[QIRA/L /\:FDO>D^W^2"I\,5W_X)=\<_$&'P@D>EZ7#&]T$Z=%B';\:\
M_MOC%XGBN5>XD@FB!YC\I5R/J!7<ZY\(8-<UFYU*;6YD>=MQ40 XXQUS6?\
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M.?\ "NO^%7BVYU_3I[#4)#+<6V,2,>74YZ_E2>$=,AT7XD:]:0KMCD1)47'
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MHH **** "KNC_P#(;L/^OF/_ -"%4JNZ/_R&[#_KYC_]"% 'US1110 4444
M?/GQF_Y'H?\ 7I'_ #:O/*]#^,W_ "/0_P"O2/\ FU>>4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =?\,R1
MXVM2#CY'_E7TLOW1]*^:/AI_R.UK_N-_*OI=?NCZ4 +6?KW_ "+VI_\ 7I+_
M .@&M"L_7O\ D7M3_P"O27_T T ?)-%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]TK5]/G*/:$IW.* *4=['*Q50<BG^>^['DM]<T-&(V)6/#8]*KK<7N3B$8H
MNOE$W;<^U-A<RYRNW'J:B@:XD;]ZN*:;5A<>9YC8STS0!*EPKS-& <BGEL/M
MQ3))HXF'R@,W>G$%U!Z4 .8[:4=,U& >]/W8%  #D]*4@CM44<JR$[3TJ49[
MT )VZ4!LTI-11S([LJ]10!*>*3-!ZTUU.TXZT .W>U&ZJ\4Q2/,_R\XJ:1=R
MY0\4 =Y\,+%I/$,%^' 1 5VXYYKZ,7[J_2O OA7Q*H/]ZO?%Z+]* '5G:^0/
M#FJ$]!:2_P#H!K1K,\2 GPOJX'4V4V/^^#0!\E"1&&0PYJ-KJ%7V%OF^E9<%
MO<C823CZUJM%'P2!GUH 1KN%'V,^&/M4NX8SFJ<EBDDHDW<U/M(P* )20!DT
M;A3<%EP:-HH 7>OK2[A3=@H.%H 7S%]:4,#TIORGM2$@=* 'Y HW TW&5S0!
M0 [(I::143SA'$9ZF@";(HW"H@#GFI%P: '4F12-FD - #LBDWKZTM-V<T /
MS2;@#B@4;><F@!:;O%12W:0MM;K4B$.-WK0 X,"<"@L!6=/>O%/L5,U:B9V0
M,XP: )\BC(J&=G 7RQGGFI<9% "[AZT9%)LQ2,<#- #L@T9&:H17,KW)4)\H
M/)J^!F@!<BDR*J0)*ES(7)VGI5D4 /I,BBFF@!2P%-:9$7+' ^E&_GI00KC!
M% #@X90PZ&EW"HY)%B3..!3(KE)1\M #A=0F3R]WS>F*FJL]LC2K*."*L#)&
M: %IDDJ1+N<X'THYS2;0QPPR* '*ZL,@]:225(EW.<#Z4O Z4;5?AAD4 ,CN
M(Y1E"2/I4FX4FQ$X4 "@@&@ WKZUK>'+&XU'6[5+5 [),C-D@8 (/>LC8,UU
M_P -A_Q4?XB@#Z8C_P!4G^Z*=3$_U2?04^@ HHHH ^<OC9:F;X@J^\J/L<?
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M@A,:;2Q/O3VP*&;%-Y- "]:;@T[I2]10 F:3 -&.:",=* %P,4G7M0.33NE
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M]W(OYT:=IGV6/#J&_"O'+;Q_J<2A!)T]ZT[?XG:A;\.P*T >JRB-),& 8/\
MLU#/X<T_45+-" Q]JXVR^*%M.!]I4Y^E;,?C^RF3%N#NH P]>^&D5VY$("CO
M7#ZM\*KFVC9H 2W;%>Q:%XB75+N1+CY0.F:Z0QQOG #)0!\H'2M1TDLMU&Q1
M?:E2X0IO^X#V-?1NK^&K'4RRO$ ?I7F>O_#1FE;R%(4=,4 >?B19>A!IW;%6
M+_0+G0E8M&S#V%48+A)U.?D8=FH E;D8%(JGO02%Y'-.1Q)G!Z4 )CFD-*QQ
MP*820.* %Y%./2FJQ/6F^<IF\H Y]: )"<<9I&CR,YI'4THR5YH  NWBEQ3>
M<\T,3VH 4K76_#8K_P )'C/.17(*S$\UUWPWA0>)_,YW$B@#Z9C_ -4GT%.I
ML?\ JE^@IU !1110!\]?&=]OCP?]><?\VKSU/F;->@_&@9\=C_KSC_FU>?(,
M4 *X .:9PW-/<9J!)@93'@Y% $^,#BE/*TH((J)LYH 4#'2G@TQ 6:I)8\+D
M4 .=_)B,O7%5G3[24GSCOBI(\E2K4(K32B* 9;I@4 (Z-<[8%!);CBO2O /@
M)I72[N5PL?(S5OP/X#,R+=WR84<\UM>+/&5KH-O_ &=IQ 8C:<4 =9?^(M-T
M"Q*ETW(.BUXGXO\ B+?:W,]G:N50GK[5S=_=:GJ%ZTLLI,;=LU"8HP<C[U %
MG3M)FOCY<.6=CDD^M=#=>#KZPL/.G90N,USFE^(+O2=46.%1L(SDBM;7_$^L
M:G;>7D!2,<4 84DC@,MN06!Q4=O)>[F\]A@CM4^GV1"$CEVY-:/]E.R%CUH
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M:K_UYS?^@&M*LWQ#_P BUJO_ %YS?^@&@#Y%C3=&N*E4;#S386VQ+3BVXYH
M'9<TH^84T@$4B'MF@ ZG!Z4X!5JK,MQYWR8VU/Y;;>: )=P/2FDTQ5Q3^.]
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MP=* )"2#2@EN/6G*H/6E!1,L>B\T *!Y5-:0FHUO(;ISM!&*5Q*PVP@%CTH
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MV79>?+TSS6<TK [<UN:%9;@\CCKTH V]L<OS5&,K-\IXIIC=6P.E/D1D3=0
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M;$!LH M4AZ&EP1C/7O2&@#TSX5Y\U?\ >KWM?NCZ5X+\*P?,7_>KWI?NK]*
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M6,JV0-QJ7S=_ IJ!U?/:@#D-1LG34B1]W-$4[1S;4!XZUHZG)_IFWU-6;#2
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MJRK@@UV"Z<J09..E8=S#^^( H R/+R,&I8(5SCK5FXB"0,>X%9MG<$7 !]:
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MKNKWE.@^E #JS?$/_(M:K_UYS?\ H!K2K-\0_P#(M:K_ -><W_H!H ^1X?\
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M7'B,O/YFX\=J )F^]2$T#G-*%S0 HY%==\-_^1C_ !%<CT.*Z_X<?\C)^(H
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MLK:BOCWH WQ<B2' ]*RID <DT\2^4O%4KNYR* *=VVYMH[UGM;^7)NJP7+2
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MN3\U #G [4U6(I3C?C-!X/%  V6Z"KNG7;VEU$Z'&#S557VD'%2!@LH;U/-
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M"_"PGS5Q_>KWI?NCZ4 +6;XA_P"1:U7_ *\YO_0#6E6=X@_Y%K5?^O.7_P!
M- 'R/" 81SVJ>TAW7*KZFJT.=@K9T&R>ZU&, 9^:@#UWP=IS6U@LVWH,UQGQ
M*UIKN_\ (1NAZ"O5+8II?AH^8 #LKYXU[4FO/$\JGE030 R7]Y$$;CO4,2#S
M,GI3Y7R^*:P^7:GWJ +$J+MRIK+N(9YIX_+Z \U9M[>\+'S5P.U;5A:$O\RT
M 1Z;I+RLK.*["U1;>$(/2HX(ECB& !3FFCA^9VH NQWHM<,3C-=!8ZD+L(JF
MO,M2U<27(2,\9KLO";9968T :'C.8Q:2ZYZBO'YFR2:]8\>R VF!TQ7D<OWJ
M %0U:CDPO)JB#@4X.2.* +@D ;K2B;YJIC(Y-/!P,T 7DEWOBE;BJ:28.10T
MQSUH ED((YJJQ(/'2GF456N97V?NQDYH [/P;K3V%\N7.WTKU>TU7[3*LI/R
MU\_V-PT,B/T->HZ;J!_L8R \@4 3^//$:O;_ &>-]I'7!KR>:4R'.><]:T]9
MNGN;V0LQ-8[.%4GL* $..H !]:O6[?N^:S8)EEY7I5U7VC% $F?GJ&3[^::T
MF.:9OW-0 LC\8IJ_+BD93NI7' H Z?PG-Y.JPG.,L*](UQ]T<;YR*\ET>4QW
MUN0?XJ]4U%O,TJ)^^* .:U:'[1:GC/%>>7*F"<CT->CR'-L0?2N&U6#%PQ(H
M T-"NHSQ(:Z%6A)RAK@4=HA\AQ6_HEP7/[UJ -UH5)++4$]G',GS#)IYD2-7
M;?Q]:IKJ\"E@S4 +#I4;-R@*CU%<]K$*6UR1&H7GM6O-XBBB#*G?O6)=2K>O
MO)ZT 4V9GCXY--ADF$1$H'6I6C\M<BD0F3C% #U821$, 0*]"^$&J Z@80QV
MYQBO.EW%C'ZBNF^'4\>E:VJD_>.: /6?B'IL-Q8LP'S$5X%-!]FN'0#'-?36
MJZ?_ &KIXD'397SMXOM);'4W6,<YH QWW$BNQ^&W'B+'N*Y"$N\0+C#5UOPX
M!_X27\10!],1_P"K7Z"G4V/_ %2?[HIU !1110!\Y_'.9H/&JLHR?LD?\VKS
MNX$LMF#'][K7I7QI59/':H1G_1(_YM7G9G5)UMQU- '1^"+>>YNHQ(O0U[CK
M=VFD^$RIPI,9%<'\/-'+&.4KWS6A\4]66*SCLT;!Z$"@#R:XG-W?2N.Y-02(
M\8##G-/A78">YJ\D8\L,XR!0!'9-B5"X[UV(PUJ"OI7'S21ED*=C6[:ZFD<(
M5B* -NS48P_%9MYJ<,%RT8P2#1>ZFOV8"(_,1QBL^PTYIY#-/U//- #9-8E>
M?:D?&?2M.VU S;4*[2*=!:Q)<<1J>?2IKJV"2*ZJ%SZ4 2%2Q!SQ5B:-'BP0
M.E1;"L(:I)&'V-F]J .=MH5DUH8' KIE&9 !V%<[H:F:^D?N":Z2U8(6+=J
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MO,(/8T 13!]F8QDTL0?RLL/F[U(3A*6,[AB@ ^;:.*>5.RI, (,T9!7 H A
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MU=7\.B__  DO'3(KEFX%=;\-V'_"0X]Q0!])1_ZM?H*=3$_U:_04^@ HHHH
M^>/C2&_X3Q<=/LD?\VI/A[&[7J$>M2_&?_D>E'_3I'_-JU_A?8&1ED([T >D
MZ]+Y'AV3<?X*^<KJ9&OKE_4FO??'DC1:!.JG&$KYPW'+D]6)H D0X5WQUI+*
M.,3&3'S-WIQ=5ML8YQ4VF1>=C Z4 ='I]LABWM5MHT<8%-MX\6VWOBD0-'0
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M6#>M=Q!^\@9:Y"^4Q7K ^M &=Y9_M:*<'Y5(XKZ3\'2+?^&0G7"XKYU.WS%
M]:]X^&+,VE,I/% 'F'CJT%IK<AQU-/\ AS_R,?XBM_XI:=MN?. ZFN?^&_\
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MQ]F,C:!4Y'D'+4 1ZFZW4YD8#(Z4N@1%]:A/HU03RA^@K<\%69N-:B)&1NH
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M"L]X\-YB]0: ,[Q/H[1L;J ;5/)Q7).^5Y^\*]*,POK%K>0<XK@=6TU[:Y(
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M56:[$4V8SCZ4DUYYK[BN30!J6][E!O-:D$BLN5-<E+(2H.=M7K'46@ !&X4
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MHBC1<BO!IAD*!UR*]X^&D3)HA9CQ0!ROQ4=\@9.,UQWPX)'B7'O77_%62,X
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MK^\+$'F@"4%)N,5'+:",[LBD)DB^X*0>;/\ ?H &);"BM.RM0@#$5!;665W
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MA( R@D9KK?AJ<^(A]10!]+Q_ZM?]T4^FQ_ZM?H*=0 4444 ?//QH(7QZ&/\
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M4\]ZLK+\H- '?P0?8-"52<$K6%"RB<LP!YK:UR7]W'!&>BUR.J7JV,.,_.:
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MV/\ U:_04Z@ HHHH ^>OC.3_ ,)XH_Z=(_YM7G\@+1\5W_QH./'@_P"O./\
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M']ZO>5^Z/I7@/PK=6G7:<_-7OR_='TH 6LWQ#_R+6J_]><W_ * :TJS?$/\
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M_P!6OT%.H **** /GCXT#/CP?]><?\VKSX"O0_C/_P CV/\ KTC_ )M7GXH
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M%$@!&.:>H$1J::':<K4>T.!GK0!#*F#Y@K.N+IY T9/!K5N0?(*K7,SF1+D
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MQR*<R9Q0 I8+%FAB7BS1.F(@!2J,6^#0!4+'/!I0F\<'YJ4H2:?'$R-N'Y4
M/@+(VV2C4Y%@M]Y...*L@)Y9>3Y<5QWB#6&O+A+2V^;:<-B@"A>?:=3FVHS!
M >U7EBCTVT^0 .>IK1M#;6=D-X DQ7,7]\\VI"W3D/TH =(]QJ5VEI"I+2?Q
M#M7L_P .OAQ%ID2WEX@:0_,"PK.^&'@/@W]\N3G*;A7KUXRVUIM4[544 -O+
MF"RLV;>%"CBO"?%OB!KR]F17RH)QS71>+_$4BJ\*2G'3K7E=S<%Y&8G))H @
M=@V2W4U 4^1N>HH.Z1N*=M.,$T 5[)&2%@1CFK!I01LJ-FYH ]/^%JD2J<_Q
M5[TOW1]*\%^%I/FK_O5[TOW1]* %K.\0?\BUJO\ UYR_^@&M&LWQ#_R+6J_]
M><W_ * : /D>+_5+3Q4<7^K7-2=Z %V#;N'WJZWP;JKVE]'EL#-<@<BKEA.8
M)T8''- 'T5K&GP^(_#A; +!<YKY_OK?^S]1DB/0&O=?!6JQ7ND?9F<;F7'6N
M!^(/A%K!WNXE)!.: .#E594)7K4VD3_9+D!C]XU0B9P&4\$>M2CA=_\ $O2@
M#OL+)"LBU3:U,TF2.*S]"U4S+Y4QZ=*UGN!#N)(VT ,QM.SH*K7U_#8J 6&3
M5._UR%4*QGYJQXK*769P]QG8#D8H Z"TNC>'(Z5U>A9#=#7/6EJEE$%A'/O7
M2Z/*(URQ'O0!TJJ7'%2I+Y?!/-9YU6UB4Y;YJSI=8A9BP;Z4 ;L]I;W +2GD
MUA7VF1QY:/I3X]4$HP6IT\X:+&>* .9N,JQ%<UJ,<PEW,2%KJKS8'R.N:Q?$
M3?Z'\N,T 5+4$QY0YJ:.3YMK"H]%&+4D]:GX&3CO0 .L8<$"FS 2$ BGXR01
M392JD;J *-[9A8@PJUIQV6_(J*\F1H@ :FM.;7(H <C#S3FE)R_ J)&0YSG-
M2QR)GWH IW4KO)LJ6&,*1GK4S0AI-]/P,Y[T .5L58C;'2H-KD<4J@T 6PP!
MR>]0SR,!QTJ,2!6XY-$TC;><4 ,1\]:<Y; *TR,XY:GB3GB@!X8/%ANM)L"(
M<5$6RU.#-G H 6-' )S2\)\[=JGBB)X'>J.JRI;Q%3U- %/5=3$J>4IK(PJH
M">M-&9'W'I3)&#9YZ4 (\ZXP.M>I?"O2$FG%U(G3OBN!\,^'I]=U1(D7,?>O
M?]+L+3POI@AC&&"Y)H S/'VMK8:>T2MCBOGN^N6GNVED/!/>NT^(7B%[^\:+
M=D#TK@W03Q;9.E "X#'(IW04@PB83M2*2W6@ (W5U_PV&/$6/<5R)R.E=?\
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MF1AM[XI4E&SAN1VH W;+5)88Q')TJY=7L,]OA3\U8-O.DR$-P14>R3>3$2:
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MJO\ UYS?^@&M*LWQ#_R+.J_]><W_ * : /D>$GREYI[#/!Z&J\);RUJ?F@"
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M(^X&@#5DUAM@5%.?6J#O)+(79^O:GJHAY;I5*YF_>EE/RT 3S,L:9')JCO\
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MQC"73_G0!Z='X!TR$ M*K$>U:UKX<T!4VR>7D>PKQL>*-5R6:[?GMFH1XCU
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M_P#]#-;?^ K?_%5]$44 ?.__  S7J'_0S6__ ("M_P#%4?\ #-6H?]#-;_\
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MM_\ %5]"T4 ?//\ PS=J7_0SV_\ X"M_\52_\,WZE_T,]O\ ^ K?_%5]"T4
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M_ 5O_BJ^A:* /GK_ (9PU/\ Z&BW_P# 5O\ XJC_ (9PU/\ Z&BW_P# 5O\
MXJOH6B@#Y\_X9TU79L_X2BWV_P#7JW_Q5,_X9NU+_H9[?_P%;_XJOH:B@#YX
M/[-NHG_F9[?_ ,!6_P#BJ7_AFW4?^AGM_P#P%;_XJOH:B@#Y[/[.&HXP/$]O
M_P" K?\ Q5'_  SAJ.,?\)/;_P#@*W_Q5?0E% 'SU_PS=J/_ $,]O_X"M_\
M%4']F[4?^AGM_P#P%;_XJOH6B@#YY_X9MU'_ *&>W_\  5O_ (JC_AFW4?\
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M#X:_Z".J_P#?U/\ XF@#P*]N&BARI'-9MI=2K-USD]Z^C3^S]X888.H:J?\
MMJG_ ,335_9Z\+*<B_U7_OXG_P 30!XED,HY%-<@J0",_6O=/^%!^&O^@CJO
M_?U/_B:3_A0/AK.?[1U7_OZG_P 30!\\/;W$3F7<,#GK4L6HI@^> ?2OH,_
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MJ?\ Q- '@TK.J_NR,T]&R.2,U[J?@#X9/_,1U7_OZG_Q-)_PH#PR/^8CJO\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gou0qrw2itv5000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )L!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<7T-(2YHJ2ZA1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-U&>N'4XXX(]:XLO=ZKOV=SLQNE)6[H]G$,2SO.(T$SJJ-(%&YE!) )] 6;
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MF?9D*6=2C#H^XXY('(.5QSS]O\2/%/AVYCMO%&D/+%N9#*83#*Y#C<RG_5N
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MGRI.+6WF;)2I5XPYFU)/?R+/BGQYJ]]XD3P[X0R+N*5TDD*H&ED0-N1?,^4
M;6R3U(XX^]C^(];^)/A>1?[0U'_1W;;'<PP0M&YP#C[F0>O# 9P<9 S5!/$D
M/@_XIZM>Q$7EM+<S13_(48!G#.$!/WE88YX;:>F01=\7^+9OB ;31M TFZE1
M'$[;T'F%N4'0E50;^6)[CICGLIT5"4%R+DM=MG+.JY*3YWS7T2.KTJ[UZ_\
MA3K5YK[L\UQ9SRV[LL8W0- "IPG Y+=>:SOAN-1/PUUC^R'1-0^TRFW+(&&_
MRX\#!(&3T!/ )!((&#U^JV/]E_#:]T_S/-^RZ1)!YFW;NVPE<XYQG'3-<_\
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M;.)UOD%U+;6MM)"N$/FX7 0!G.T%0-W5L\XP>H^#G_(H7?\ U_O_ .BXZQ?
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M"KD XRQ SCC.:\NAU_XE^(S+J>B0/'I\DA6&-5MPJ@<8!DPS>YZ9SC&,#?\
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MM:WEO'',1)!:JL&YHVP05W*0% ;^)MWRGJ<9[[PMJ&HZKX<M;W5;0VE[)O\
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M^/C7_P#=MOYRUZ[7-BZ<:=:4(['1A:CJ48REN%%%%<QN%%%% !1110 4444
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MP4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MR:58())G#E8U+$(A=B ,\*H))]@,FO)OASX?U.X\9WVOZSIDEHZ^9,HDBDB_
M?2L<E >J@%P<DXW+]1ZY16U.LZ<)12^(RJ4E.49/H%>._$'P_J]KX\M]=TG3
M+J]W>5<Y6(RHLT9 VD)R!A4//7)P>./8J*="NZ,^9*_05:BJL>5Z'EWQ8TK4
M=;@T*\TS3[JYB19MX2%MZ;Q&5W)C<.%;.1P1@X)%9>G^*_B'IFFVMA!X9W0V
ML*0H7TVX+%5  SAAS@>E>RT5K#%15-4Y032,YX9NHZD96;."T>?6O'/AW6=)
M\3:2=/9E00S?9Y8E).2I"L<DHR GYL'(! [\3I/B#6_A;=W6EZEIHFM9I"\8
M+>6KN H+QR;3N!7;D8XX^Z<@^YT4H8I1YHN'NOI_P0EAV[24O>74\5F37OBK
MK-A='3FM=#A8*) X 5"?WC*Y'SL2A' (!"@@<D]OX]\&?\)#H%O%IL<45UI^
M?LT0^52F #&.0JYVK@D<;0. 2:[.BB6+ES1<%91V0XX:/+)3=W+=GBFC_%._
M\+Z;%HNJZ1YD]FJQKYLGV=TCVC8K(4/(&,'C(QWR3J^#_#.MZSXQD\5>);'R
M0/WL22($+2#Y5_=D$@(%R"<'(0@MR:]6HJI8N-G[."BWN_ZV)CAG=<\KI;?U
MU/+OBN=>U">UTC3=.U":Q$8GG:WB9TE?<0JMA?X=N[&?X@<< US7AO4/&OA:
MRDMM.\*9,K;I9I=-G:23K@$AAP <   =3U))]VHHABXQI*DX)KYA/"N51U%-
MIGG?A;Q;XRU#Q#;V>M>'C!93!P9TLYHO*8*6!)8D8.-N..6'/8U]>\<^)O!^
MN7@U;2X+K2I93]CEC+1J ?N+YF"-V%8E2,Y)(.W%>F45G[:GSWY%;MJ:>RGR
MVYW?OH>)7ESJWQ<U.QCM=.%C8VN]9+DL940G:6RV%!;&S"#GG)..1[;114UJ
M_M$HI62V0Z5'V;<F[M[G+_$2UN+WP+J-O:6\MQ.YBVQQ(79L2H3@#GH":7X>
MVMQ9>!=-M[N"6"=/-W1RH59<RN1D'GH173T4O;/V/LK=;_A8?LE[7VGE8X[X
MB>$9?%.C1-9[/[0LV9X0Q($BD?,G7 )PI!/=<< DUP^E_$W5?"6DVNCZQH;M
M+!&!"9W-J_DCA05*'.,$;N.G/()/M-%:4\0E#V=2/,NG2Q$Z#<^>$K,\^\->
M,?%/B#Q';H_A\6FB31F4S/%)D)LX(D)"MEBN,+T/L36;\1_!^I'68?%&A1/+
M<(T;2QQ(9)%D0C9(JG(8<*" .-N<')(]3HI1Q/)4YX126U@EA^>GR3E=[W/'
M/^%LZ]K-E]CT31E;4!'NEEMPUP0,8+)&!\OS$$9+ ="#FNG\0V6OW7PEFM=3
M1[S6G$;2);QAF/[]6 P@P2%P#@8X/)ZUWE%-XB"E%TX)6=^XE0DTU.;=U8YC
MX>VMQ9>!=-M[N"6"=/-W1RH59<RN1D'GH12>/_#DWB;PN]K:\W<$BW$"%PH=
M@""I)'=6;'3G&2!FNHHK/VTO:^U6][FGLH^R]D]K6/%?#_Q"US0].3PR=#FN
M]4A5E@60R>:H*[E#18+, .< K\H XQFLNU\.^*6\7Z)JFJ6%]/+=7EM=S3&%
MF,:^:/\ 68&$(5<[?X5P,#&![]173]=2;<()7W.?ZHVDI3;ML<)\6+"]U'PO
M:0V-I<74JWRL4@B+D#RY!G '3D?G74>&XI(/"VD0S1M'+'90JZ.N&4A ""#T
M-:=%<SK-TE3ML[G0J251U.YX'I&J:O\ "O6;J+4[ R17">7MW[(YF4@ATD*G
M< &/ Q]_G!&*]G\.:A>ZKH<-[J-DUE<RO)FW=&4QJ)&"@AN<[0O/&>H !Q6K
M15XC$*MJXVEU?<BA0=+12NNP5YA\']*U'3%UC[?875IY@@V?:(6CW8\S.,CG
M&1^=>GT5$*SA3E3M\5OP+G24IQGVO^)PGQ8L+W4?"]I#8VEQ=2K?*Q2"(N0/
M+D&< =.1^==/X:BD@\*Z/#-&\<L=C"KHZD,I" $$'H:U**'5;I*G;9W!4DJC
MJ=SS Z5J/_"]!J'V"Z^PY_X^?);R_P#CVV_>QCKQ]:/&>E:C=?%/P_>6]A=3
M6L0MO,FCA9D3$[$Y8# P.:]/HK58N2DI6VCRF3PJ<7&^[N8'C+PVOBGP[+8!
MTCN%82V\CYVK(,]<=B"P[XSG!(KRW1/'6K?#ZU?0=7T@N(F+P1ROY+("S;L'
M:0ZELD-]>2,8]QHJ:6(48>SG'FCN54H.4^>$K,X3P/J'C/5]5O+W7XOLFGK'
MY<=JUMY/[WY>5##>5P&R2Q&6XZ<9?P?TK4=,76/M]A=6GF"#9]HA:/=CS,XR
M.<9'YUZ?10\3[LXJ*2E;\ 6']Z,FVW&_XF=KVCPZ_H5YI<YVI<1X#\G8P.5;
M (SA@#C/.,5Y!I&MZ_\ "][VRU'26GL'F^5SF.-I2!ADEVD,"J_=Z\?PD,#[
MA111Q')%PDKQ?0=6ASR4XNS1X=J.K^)_BFR6FG:9''IT,P8$'*(^ I+RG@D;
MR=J@'#=&QFNZ\9:=IFC?"^XTI;E+2".)(X"R@M+(K!P,+C+.5.2!W+'@&NWK
ME/B#X;N_$WAK[+8NOVF"87"1MQYI"L-N>Q.[@GC(P<9R-8XA3J0C\,4_Z9E*
M@XPG+XI-'G/@NY^(,>EV[Z%;_:=)A>14AF6)8W))+<DJY 9CR&QD$=B*WHOB
M9K6C>)%T[Q;IEO:0[ 7,"-N0-T<'<P=>"#MYZ]UVF'0?%?C+0+(:5?>$[V_2
MT @A>.!T("Y&"RJRN,8 (QP,Y;.:K2:#XE^)'B".ZUFSGTC2X T85@R,JYSA
M4?JY# %]H7Y?]G;77)1E.3JQBHZZIZ_G^ARQ<HQBJ4I.6FC6GY?J:?Q>TK4=
M3;1OL%A=7?EB??Y$+2;<^7C.!QG!_*NG^(EK<7O@74;>TMY;B=S%MCB0NS8E
M0G '/0$UU%%><L0TH*WP._XW.]T$W-W^+_*QQ7A?2+V3X3_V3)"UM>36MS"$
MN59-K.T@7<,9 Y!Z=*\]\/\ C/4?AS%=:-J6B9=Y?/"32F%A_ 2#A@RG8,$<
M<'DYX]WHK2.*5Y*<;J3O8AX;X7&5G%6/GSQ?I_C#Q+?/K%WX?OE6>-H[>**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***J7VJZ=IGE_;[^UM/,SL^T3+'NQC.,G
MG&1^=-)MV0FTM66Z***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJA8ZYI&IS>
M38:K8W<H3?L@N$D;;P,X!Z<CGW%7Z;36XDT]@HJM>ZA9:;"LU]>6]K$S;%>>
M4("V"<9)ZX!_*IHI8YX4FAD22*10R.C95@>001U%%G:X75[#Z***0PHHHH *
M*** "BBB@ HJI;ZKIUW>2V=M?VLUU%GS(8YE9TP<'*@Y&#P?>K=-IK<2:>P4
M444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !117(_$X _#S5 0",P]?^NR5=.'/-0[LBI+D
M@Y=CKJ*\%\*^"]<\8Z0D4VHR6>BVV1:B2,NC/N8DK&"H."[Y<G/.T9P0L%S!
MKOPV\536.EW+22W,*JA6$'[0&!"D1Y;YE?<%SSD="&(/;]1BY.G&:YET_P""
M<GUQJ*FX/E?7_@'T#17B=_\ "O7)M#FUB]U(W.JB'S9+-T::1MH^YYFXEGVC
M  !&> <?-73_  E\0W^KZ=J%E?SS7+VDB.D\TF]BLF[Y3D9."I.23]['  K*
M>&BJ;J0GS6W-(8B3J*$XVOL>BT5YIJOPVU?Q+XBN;S6M<7[$MP6M88P9"L1/
M*@'"QG:JC(#9/)SCGD=>T6^^%_B.RO\ 2]065;@2>5O3!**PW1R <,N&3D8R
M<D!2 :JGA:=1\L9^]VM^HIXF<%S2A[OK^A[S17/:S?1:K\.=0OX4=8;O29)D
M60#<%:$D XR,X->+>#_#.H^,/,TF&\%MIEK)]IERH8)(Z[5.P$%F(3')P &Z
M9PTT<*JD'.4K)%5<0X34(QNV>N_$W_DGFJ?6'_T<E'PS_P"2>Z7_ -M?_1KU
MSFM>%?\ A$?A+K5A]L%UYEQ'.9!%Y>,R1+C&3_=ZY[U!I/C:U\)_##2T39/J
M<RS&"W)X4>:XWOCHN?Q8C Z$C=4G/#<E/7W_ -#!U.7$<]33W?U/5Z*\Z\"^
M#;T:D?%GB-Y'U>;+11OPT89=NY_0[3@+T4=L\+@7%WJOQ4\276G65ZUGH5NC
M'<J.R.H8;6=?EW,Q (5L;0#CD'."PJ<VE+2.[_R[FSQ#44W'5[+^MCV2BO&_
M%'P__P"$,ME\2:%JDT;63(=LP!<%FVY5@ "#N4%2,$;LD]*Z^/Q!_P )/\*=
M3U&185G:PN8YXHGW!'",/J,C#8/0,.O4J>&7*IPE=-V[68XUWS.$U9I7^1VM
M%?.O@_PSJ/C#S-)AO!;:9:R?:9<J&"2.NU3L!!9B$QR< !NF<-[1X,\*_P#"
M(Z/-8?;!=>9<&<R"+R\955QC)_N]<]ZK$8:%"\7.\NUA4,1*M9J-EW.BHHKQ
M'4=5U?XG>*VT;3;D0:2NXX#$(8589E=3@N2=N%QP2!Q\S5E0H.JVV[);LTK5
ME3LK7;V1[=17BFK_  OU3PQILNM:9K7G3VBF1O*B-LZ1[3O96WGD#MQD9ZG
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M*_?0[JBO%/#7@&X\;V=UXAUC4IDFNVD$3!%8NPP!(3G[H(9=F%X48(&*YU?
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MV=^YZW17EGQ'\8:D-9B\+Z%*\5PS1K+)$YCD:1R-D:L<!1RI)!YW8R,$'/\
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MBO.OC*H;PC9Y /\ Q,$ZC_IG)7,:+X#U_P 9Z'97.K:H;2UM85@T]);8.?*
MZA05P#A0&.2P )X"DZT\-%TE5G*R,IXAJHZ<8W9[97DOQL^]H7TN/_:=8=C/
MJ7PO\:Q65]>,=+9M\JQN?+EA?Y?-V8)##:#@#=\A4$@Y.Y\;/O:%]+C_ -IU
MU8:A[+%0L[IWL_DSGQ%;VN&G=6:W7S/6J*K:@EU)IMTEC*L5XT+B"1QPLF#M
M)X/ ..QKS&W^#]S>^==:[KK2WTL;#=&IDPXX1F=SEP% RN%/8'CG@I4Z<DW.
M5OE<[:DYQ=H1O^!ZO17B/A>_O? /C]_#4UP+BRGND@E6->"\@7RY "1M;YDW
M=>,CYL*:Z/XL^*Y]*M[72=/NYK:ZE_TB:6%RC+&"0HSC^)@>A!^3!X:MG@Y>
MUC3B[\VJ?D9+%1]FYR5K:->9Z717CEI\&[];.WO$UE;6^6-95@^SX,4N,A?,
M5SC#<;@#TR*R_!U]JL_Q>MWU.=C?R2S07A7:N[9$XVG9A2 47VRH/O5?5(2C
M*5.=^5=B?K,XRC&<+7?<]WHKR3QVJGXP>&B5!(%KSC_IX>O6ZYZM'V<8RO\
M$KF].KSRE&VP45X=\&KNYF\7W9EN)7^T6#S3;G)\Q_,C^9O5OF;D\_,?6ND\
M>>)]5N_$5OX1\/RO#<2-&)YXBZNK-\P7(&54+AF89X..,,#M+!R5;V2?2]_(
MR6*BZ7M&O*QZ;17E-S\%+;^R0EOJK-J R2TL($+CG"[1DK_#DY;H>.<#4^%W
MB^ZUZRGTW494DNK-%:*5I/WDT9R"2.I*_*"W?<,\\F9X>/(YTY<R6^EAQKRY
MU"I&S>VMST*BO#/#=A-\4-;NI]>UB1?LX$BVL6/NL"#Y0)(15*IDX.<C)R<U
MW?A'P1?>$O$%R\.IFXT66%]D#,RLLI=<$H/E)"+C?P3Z 4ZV&A2O&4_>72WZ
MA2KRJ:QC[O>_Z'<4445R'2%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !16=KVL0Z!H5YJDXW);QY"<C>Q.%7(!QEB!G'&<UX
M[I6@Z]\4KN[U+4-36"UAD*(Q4R*DA"DI''N&T!=N3GGC[QR1TT</SQ<YNT5U
M,*M?DDH15Y,]SHKPS5= U[X775KJ>GZFL]K,X60A3&KN Q"21[CN!7=@YXY^
MZ<$^H#QA9GP+_P )1L_=>1O\K+?ZW.SR\[<_?^7=C'?I3JX9Q494WS)Z?/L*
MGB+MQFN5K\CHZ*\,T+PGJGQ+2ZUO4=<59HI!:AWMQ(3M4,1M!4*/F!XZDL<#
MOUOA;P-KOA+Q-:_9M7%QHSQR/=I@QJ7Q@#R\L-V=A# YPK D<!JJ8:G3O%S]
MY=+?J33Q$YV:A[KZW_0]&HKQWQ9JMYXT\<CPA97P@T[S?)D#+\KR1AG=B,!C
MC! 7.TE <C.0Z7X0:II<,E[I.O>9?PJ3 L4)MV)Q@@2"0[202/3L2!S3^JPB
ME[2?*WK:WY]A?69-OV<+I>?Y'L%%>-_%R*Y33?"\>HR1SWB02K/(H&UY,1;B
M.!P3GL/I7LE8U*/)3C._Q7_ UA5YZDH6VM^(45X=X<N[EOCE,6N)29+^]A<E
MS\R*LNU3ZJ-BX'0;1Z"M7XWHK_V&& /%P.1_USK98-NK&E?XE?\  R>*2I2J
M6V=CURBO'X?AOX@\7PQZSXAUDVU]*H BEM0[K&/NY 90AZG:!QG)Y) J>"M5
MU+P;XV_X1K5YW^S2,+;R1*7BCD8[HW08. Q;'\/W\M]W@^J1<9<D[M;K_)]0
M^LR4ESQLGL_^ =1XW\ ZIXG\4V>IV-Y;6D<,$<1F+,)8V5V;<H ZC<"/F'/I
MUKT.O)/':J?C!X:)4$XM.<?]/#UU?Q#\72>%M'B6SV_VA>,R0E@2(U ^9^F"
M1E0 >[9Y (ISI5*BI03O=:"A4A!U)/2SU.PHKR;3/A3)K&FG4M>U6[.I7<*N
MH926B;;P)"_S.0-N1\N,$9/!IG@[5+WP;XT?P7>74$]@TNV*1FV")V7>NW/]
M_(!3^\W!Z[I>%@U+V<[M;Z?D4L1)-<\;)^9ZY17D7Q1\17MYKEOX7TF:8,<1
MW$<<FSSI)0 L;$XR-K#OM._GE:7_ (5+JNBM_:>C:ZLFHVW[RW06WE%CW&XN
M1R,C!&#G!X)HCA8J"E4GRN6VGY]@>(DY.,(W2W_KJ8GP6_Y&^3_L%O\ ^C(J
M]WKPKX-!1XRF"G*C39,?3S(J]UJLQ_WA^B_(G ?P%\_S/._C)_R*-G_U_I_Z
M+DKKO"W_ "*&B_\ 7A!_Z+6N1^,G_(HV?_7^G_HN2N8T?P)K_C;1K.[U;53:
M6UO$(=/26W#DQ>H4%< X4!CDL "> I.D:<9X2//*R39G*<HXF7+&[LCVNBO"
M+&?4OA?XUBLKZ\8Z6S;Y5C<^7+"_R^;LP2&&W. -WR%02#DW/&B/X1^*5KKJ
M&X:&9DN6;9O.W[DL:LY()VYXR-H=0,  UG]1;GRQE>ZNO/R-/KEH\SC:SL_+
MS/:Z*H:WJD>BZ)>ZE+L*VT+2!7D"!V ^5<]BQP![FO,?@WIDD^H:KK\YE=\?
M9EE9PWFLQ#R;L_,6&(SD]=QZ]L(4>:E*HW9+\3:=7EJ1II;GKM%%>$^+#JD7
MQBNI="5_[4\R(0>7&K$DP*I^\",;2<D\ 9/&,T\/0=>3BG:RN*O65%)M7N['
MNU%>,W_P<U0V,UXNK17FHLOFO T1'FR'EAYK-R3S@E1DXSC)(V_A/XKN-4AN
MM'U&ZFN;J'-Q#),Y=FC) 8$X_A8CJ2?GP.%JYX:/LW4IRYK;Z6(AB)<ZA4C:
M^Q0\"?\ )7/$OUNO_2A:]:KR7P)_R5SQ+];K_P!*%KK_ !OX?UOQ'!9V6F:D
MEG9EF%Z"S R(<#&%'S#!?Y20#D9]1KBXJ5:*;LK+\C/"R<:3:5]7^9U=%>,Z
M_P#"*/2_#4U]!J@FGLX9)KA98=J2JO/RX)*D*#UW9./NBNJ^%WBFZ\0:1<V=
M^[S7=@4'G,/OQL#MR<Y+ HV3@<;>IR:QGAXJFZE.5TM]+&L*\O:>SG&S>VMS
MO**\,NYKWXH>.I;"WOI8]*7=)$#\T<4:#:)/+)7)9F'^T/,QT%2Z]X)UKP)H
M5Y>Z?K*W%G=)]FOU$ CS&QVK\K%@W+%<C##=QP21K]2BFH2G:3Z6_4CZVVG*
M,+Q77_@'MU%>=_!J61_"%W&\C,D5^Z1J3D(OEQM@>@RQ/U)]:R/@BJJNN84#
MBWZ#_KI64L*XJH[_  6^=W8N.(NX*WQ?Y'K=%>=_&661/"%I&DC*DM^B2*#@
M.OER-@^HRH/U ]*T?A[J"V_PPLKZ^G?RK:.=GD;+%8TD?ZG 50 !V  J/8/V
M*JWW=B_;+VKI]E<[.BO&-.L]7^+&JW-UJ%Y)9:/;2)MMT!9,\_*N<*7VELN<
MD;E^7! #/$/ABY^&=[:^(=#U$M$TWD>5.GS$%=Q5B,!U.UL\+CY<<C(W^IQY
MO9N?O]K?A<Q^M/E]HH^[W_6Q[517GGC3Q?=CX<V&K:5-'!)J3I%(T;[VAW(Q
M=588PP9=N<9'/0\C#TGX667B#PY'JDFN2RWU\!/YP0.BEL%U<9R[ [P3N'/4
M<',0PRY.>I+E5[;7+EB'S\E.-W:^]CU^BL?PM8:EIGARUL]7NA=7\>_S9A*T
MF[+L1\S $X! Y':MBN622;2=SHBVU=A1112&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5R7Q-_P"2>:I]8?\ T<E=;6'XPT:Y\0>%;S2[1XDG
MG\O:TI(4;9%8YP">@/:M:$E&K%O9-&=9.5.279F=\,_^2>Z7_P!M?_1KUR/C
MO_DKWAO_ +=/_2AJ[_PAHUQX?\+6>EW;Q//!OW-$25.YV88R >A':L+Q+X,U
M'6?'>D:Y;S6JVMGY'F)([!SLE+G "D=#ZUUTZL%B9S;T?-^)RSIS>'A%+56.
MYKR7X)_>UWZ6_P#[4KUJN'^'G@W4?"1U(W\UK)]J\K9Y#L<;=^<Y4?WA65&<
M5AZD6]7;\S6K"3KTY):*_P"1Q^E7_BSXD:[.T&K3:386X+$6TI A##"KA2ID
M)V]6.!\Q&,A3E?$/P_J.@2Z6-0UZYU?SUFV&<-^ZV[,XR[==P]/NBMI_!'C3
MPCJ<S^%+EKBVGRH97B#!1@CS%DPI;D@%<]#]W=BG7_PS\6>(%75-5U:U?4Y
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MQ//!OW-$25.YV88R >A':O.'\$>-/".IS/X4N6N+:?*AE>(,%&"/,63"EN2
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MN9Y)"FP%C%MP%R<#"CN><GV%3X.?\BA=_P#7^_\ Z+CK?M="U)/ $VB7E_\
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MYAM/9LL1SP<CD8YT=>F\6Y7T:M?Y$*C46&4;:IWM\ST.O)? G_)7/$OUNO\
MTH6NB\&VOC=]3:]\4W 6W2%XH[8M'NW%D(<B,;2,*P!)R.>,'D\->#=1T;QU
MJ^N7$UJUM>^?Y:1NQ<;Y0XR"H'0>IKGI\M*-2#DG==#>IS5)4Y*+5F<O<W<%
MI\?Q+.^Q#*D6<$_,]N$4<>K,!7L%<3X^\!#Q8D5W9RI#J42B,&9CY<D>2<'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2-<MYK5;6S\GS$D=@YV2LYP I'0^M;WBCPW:^*=%?3[EWB(;S(95_P"6<@!
M./XA@D$'L>QP0X8F$)49=EJ*5"<XU8]WH<=:>!]>O[*"\MOB'J3P3QK+&WER
MC<K#(.#+D<'O3K'X4S1>(K75]1\1S7TD$Z3MN@(>1DP5R[.W&57MT&..HQ;;
MP_\ $WPQ;+IVD3)+:\R_N)(61&)Y4>< P]>!CG/4FNB\->'/&J^([?6-?UPM
M;^67DLTG8@L4VA2B@1C&<DKD97OG<'4G.,6U55O+=_@*$(-I.F[_ (?F8%S=
MP6GQ_P#-G?8AE2+."?F>W5%''JS ?C7KLTT5O!)//(D4,:EWD=@JJH&223T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '*>/_#5[XJT*WL;"2WCECNEF8SLRKM"..P/.6%;NBV<FG:%I]C,4:6VM
MHX7*$E2RJ <9[<5>HK1U9."I]$0J<5-SZL****S+"BBB@ HHHH *\TTCX>ZO
M8?$<^(9;BQ-F;RYN-B2.9-L@D"\;<9^<9Y]>M>ET5I3JRIIJ/56,YTXS:;Z:
MA11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW^-2T4 1?9T_O2?]_6_QH^SI_>D_[^M_C4M% $7V=/[TG_?UO\:/LZ?WI/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&M<U2'3;&>[:YF)"![&9!P,\L5 '3O0!UM%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6U*PN-.7[?%IT" 6\Z2<DLP')#,1@]"..E>ZTF!NW8&XC!-+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7&2?\EI@_[%]_\ TH6NSKC)/^2TP?\ 8OO_ .E"T =G1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 V3_ %3_ .Z:X_X4_P#),=#_ .N3_P#HQJ["
M3_5/_NFN/^%/_),=#_ZY/_Z,:@#LJ*** "BBB@ HHHH **** "BBB@ HHHH
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M_:%E_P _EO\ ]_5_QH_M"R_Y_+?_ +^K_C7._P#"L_!/_0L:9_WX%<IX_P#
M?A33M'TZ6S\/V$+R:M9Q.R1 $HTJAE^A'% 'IO\ :%E_S^6__?U?\:/[0LO^
M?RW_ ._J_P"-<[_PK/P3_P!"QIG_ 'X%'_"L_!/_ $+&F?\ ?@4 =4&#*&4@
M@C(([TM0VMK!8VD-I:PI#;PH$CC0855'  'I4U !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M9)_R6F#_ +%]_P#TH6NSKC)/^2TP?]B^_P#Z4+0!V=%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM$FGBPDW,S#&TY&/KR: -7PKX\\.WTNGZ%H^FZI;0^7LM_,L72)45<CYCQC
MZ]Z[BN?\#:;>Z/X&T73]1)^V6]JB2@G.TX^[GVZ?A704 %%%% &'XT_Y$77_
M /L'7'_HMJE\*_\ (GZ)_P!>$'_HM:B\:?\ (BZ__P!@ZX_]%M4OA7_D3]$_
MZ\(/_1:T :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y=XIUW
M5K3Q+>06^H3Q1(5VHK<#Y17J->/>,?\ D;+_ /WE_P#017GYC)QIJSMJ>SDD
M(SKR4E?3]45_^$FUS_H*W/\ WU1_PDVN?]!6Y_[ZK*HKQ_:U/YG]Y]1]7H_R
M+[D:O_"3:Y_T%;G_ +ZJK?ZIJ&J0QPWM[//''*DR*S='0Y5OP(JI11[6I_,_
MO#ZM1_D7W(U?^$FUS_H*W/\ WU1_PDVN?]!6Y_[ZK*HH]K4_F?WA]7H_R+[D
M:O\ PDVN?]!6Y_[ZH_X2;7/^@K<_]]5E44>UJ?S/[P^KT?Y%]R/5O M]=ZAH
MLTMY<23R"=E#.<D# XKJ*X_X<_\ (OS_ /7RW\EKL*^@PK;HQ;/BLPBHXJ:2
MMJ%%%%=!QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7&2?\ ):8/^Q??_P!*%KLZXR3_ )+3!_V+[_\ I0M
M'9T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"BBB@ HHHH **** &R?ZI_\ =-<?\*?^28Z'_P!<G_\ 1C5V$G^J?_=-<?\
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M/A<R_P![GZA11170<04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M])A/X$3X7,O][GZA11170<04444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIW/^_'_Z$*\EKP\R_C+T_P SZ[(O]V?J_P D%%%%>>>R%%%% !1110 4444
M=O\ #7_D(W__ %R7^9KT>O./AK_R$;__ *Y+_,UZ/7T& _@+YGQF<_[Y+Y?D
M%%%%=AY84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MQ3?%SP&K%6\1VP(.#^[D_P#B:3_A;O@+_H9+;_OW)_\ $U4^*UC$GA*"<6 D
ML8=0MY=2CAB!9[4-EQQR1TS[53UWQK\,I_"EU!]JTNZAD@*16D$(,C$C"A5
MRISTZ8H ]"TS4[/6=-@U#3YUGM)UW12J" PZ=ZMUSG@"VOK3P!H=OJ2LEY':
M()%<?,O' /N!C-='0!YMXVL/%U]XSTVYLO#\&K:+IRB>*"2]2 -<\X=@<YVC
MH,=3FL;P%?\ B6X^)/BV.YT&*V6ZF@&H/'?*39D0G9MX^?/MTKV*J-GHVGV&
MH7U_:VRQ75^RM=2 G,A487//8>E '">*? @M/"&LW'_"4^)YO*L9G\N;4=R/
MA"<,-O(/<5V7A7_D3]$_Z\(/_1:U%XT_Y$77_P#L'7'_ *+:I?"O_(GZ)_UX
M0?\ HM: ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\>\8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY%.Y_P!^/_T(5Y+7AYE_&7I_F?79%_NS]7^2"BBBO//9"BBB@ HHHH ****
M.W^&O_(1O_\ KDO\S7H]><?#7_D(W_\ UR7^9KT>OH,!_ 7S/C,Y_P!\E\OR
M"BBBNP\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUH UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ[QC_P C9?\
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MHHKL/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .0
M^(NJZEINA64&E70M+O4M1@L%NM@;R1(3E@#QG _6N&&B^*IO$?B71X?'^KH^
ME6D$\$D@3$A=6)##T&T#(]:]7UO0]/\ $6F-I^IP>=;LZO@,5(92""".0<CM
M6)XE^'>B^*-16_NI;^UN?)^SRO97)B\^+.=C_P!X=: )_A]?S:IX!T6^N)YY
MYI[8/)+.079LG.<?YQBNEJO86-MIFGV]C9PK#;6\8CBC7HJ@8 JQ0 4444 8
M?C3_ )$77_\ L'7'_HMJE\*_\B?HG_7A!_Z+6HO&G_(BZ_\ ]@ZX_P#1;5+X
M5_Y$_1/^O"#_ -%K0!KT444 %%%% !11534]-M-8TZ:POHVDMIAAT61D)&<]
M5((Z=C0!;HKCO^%6^#O^@9-_X'W'_P <IDOPN\(+"Y73)LA21_I]Q_\ '* .
MTHKRGX?> /#>M> ](U'4;*>>[N(2TLAO9P6.XCH' [5TO_"K?!W_ $#)O_ ^
MX_\ CE '8T5E:'X<TKPW!+!I5N\$<K[W#3/)DXQU=CBM6@ HHHH **** "O'
MO&/_ "-E_P#[R_\ H(KV&O'O&/\ R-E__O+_ .@BO.S+^$O4]O(?]XEZ?JC"
MHHHKQ#ZP**** "BBB@ HHHH ].^'/_(OS_\ 7RW\EKL*X_X<_P#(OS_]?+?R
M6NPKZ3"?P(GPN9?[W/U"BBBN@X@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L+Q3XJL?">GPW-W#<W$EQ,(+>VM8]\LTAR0JC\#6[7)>,M
M(U&]U7PQJ6G6XN6TW41)-"7"?NW4HS G^[G.* .<F^-5G;QW<DWA+Q+&EFXC
MN6:U3$+$9 ?YOE.".OK7I%C=?;M/MKOR9(?/B67RI1ATW '!]QGFO*O$%KXB
MTG4O&6F67ANZU2#Q(H-K=0E?+B9HO+82Y/R@=?>O3M#L7TOP_INGROODM;6*
M!F'\150I/Z4 7Z*** "BBB@ KC)/^2TP?]B^_P#Z4+79UQDG_):8/^Q??_TH
M6@#LZ*** "BBB@#Y%U?_ )#FH?\ 7U+_ .AFJ=7-7_Y#FH?]?4O_ *&:IUZR
MV/#ENPHHHIB"BBB@ HHHH *^GOAQ_P D\T3_ *]_ZFOF&OI[X<?\D\T3_KW_
M *FN;%?"CLP7QLZBBBBN$]$*I:MJ*:3IDU])&TB1 $JO4Y(']:NU@^,_^12O
M_P#=7_T(5G5DXTY271&V'@IUH0ELVOS,?_A9-C_SX7/_ 'TM'_"R;'_GPN?^
M^EKS>BO$^OU^_P"!];_8V$_E_%GI'_"R;'_GPN?^^EH_X638_P#/A<_]]+7F
M]%'U^OW_  #^QL)_+^+.HT'Q7#I6N^(K^6UE>/4[M)XE5AE0L2H0??*FN@_X
M638_\^%S_P!]+7F]%'U^OW_ /[&PG\OXL](_X638_P#/A<_]]+1_PLFQ_P"?
M"Y_[Z6O-Z*/K]?O^ ?V-A/Y?Q9Z;:?$&SN[R"V6QN%::14!)7 R<5V->'Z-_
MR'=/_P"OF/\ ]"%>X5Z.!KSJQ;F]CP\VPE+#3BJ2M=!1117<>0%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!P_Q4O-&MO"]M#KUE]HL+R^C
MMGE#E7M<JQ\Y,*Q+*%/ '.2.02#1N?A'X8UF*"Z@U'4DBDL8+8R6ERA2YBC5
M0C-\I!R$C/&%^4'&>:W/B"/"X\,-/XLC\VP@E$D<2R,KR2[6"JFU@2Q!;C..
MI. "1YO#'\))?#46OOX=OX;%]0&GDO-(61RF_>0LI^4#TR?0&FB6>UV5G!IU
MA;V5K'Y=O;Q+#$FXG:BC &3R>!WJ>JNF164&DV<.G%#8QP(ML8WWJ8PH"X;)
MR,8YR<U:I%!1110 45Q.M_$,V.OW&B:-H&H:Y>VB![L6N D&1D L?XB.U;7A
M3Q38^+M&_M"R2:(I(T,]O.NV2&1>JL/6@#<HKG_%OB^Q\(6$$]U%<7-Q<RB&
MUM+9-TL\A[*/ZUCZ3\1C<:_:Z+KOA_4-"N[T'[(;K:T<Q'50PZ-[?_6H [:3
M_5/_ +IKC_A3_P DQT/_ *Y/_P"C&KL)/]4_^Z:X_P"%/_),=#_ZY/\ ^C&H
M [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\=?\BG<_
M[\?_ *$*\EKUKQU_R*=S_OQ_^A"O):\/,OXR]/\ ,^NR+_=GZO\ )!1117GG
MLA1110 4444 %%%% ';_  U_Y"-__P!<E_F:]'KSCX:_\A&__P"N2_S->CU]
M!@/X"^9\9G/^^2^7Y!11178>6%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <SXY\0WOAW0X'TN"&;4KZ\BL;59R1&))#@%L<X !KAS
MKGQ1;5]<TN"[\.RW6D6\4[@6\@$HD5B I)Z_*>N*Z_Q0_AOQ-X;5Y_$-M9V\
M%\C0W\=PBB&XC;( +<;NHQ[US/B./1-2UZ?5M#^)6F:-->VRVM\JS0RB9%S@
MC+#:P!(S0!W'@S5Y]>\&Z5JMU+%)/=0"1VA0HN3V /(QT_"MVLGPS9:;IWAG
M3K+2+A+C3X(%CAF1PXD _BR.#DYZ5K4 %%<MXM\:1>&9[&PMM.N-4U>_+"VL
M;<@,P7JS,>%4>O\ @:J^'_'DVH>(O^$>UW0+K0]5DB,UO'+*LJ3H.NUUX)'I
M0!K^-/\ D1=?_P"P=<?^BVJ7PK_R)^B?]>$'_HM:B\:?\B+K_P#V#KC_ -%M
M4OA7_D3]$_Z\(/\ T6M &O1110 5Y5\;+^]L;/139WEQ;%Y90QAE9-W"]<'F
MO5:\A^.W_'EH?_767_T%:UH?Q$8XC^$SRC_A(-;_ .@SJ7_@7)_C1_PD&M_]
M!G4O_ N3_&LZBO1LCR>9]S1_X2#6_P#H,ZE_X%R?XT?V_K1&#K.HD?\ 7W)_
MC6=119!S/N7+?5]4L[=+>VU.]@A082.*X=54>P!P*E_X2#6_^@SJ7_@7)_C6
M=119!S/N:/\ PD&M_P#09U+_ ,"Y/\:/^$@UO_H,ZE_X%R?XUG4460<S[GI7
MPEU;4KSQVD-UJ-Y/%]ED.R6=G7/'.":]\KYW^#G_ "4"/_KTE_I7T17!B?C/
M3PC;IA1116!TA7CWC'_D;+__ 'E_]!%>PUX]XQ_Y&R__ -Y?_017G9E_"7J>
MWD/^\2]/U1A4445XA]8%%%% !1110 4444 >G?#G_D7Y_P#KY;^2UV%<?\.?
M^1?G_P"OEOY+785])A/X$3X7,O\ >Y^H4445T'$%%%% !1110 4444 %%%%
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M6A_]=9?_ $%:]>KR'X[?\>6A_P#767_T%:UH?Q$88G^$SQ>BBBO2/)"BBB@
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M_P#H0KW"O8RSX9'S&?\ \2'HPHHHKU#Y\**** "BBB@ HHHH **** "BBB@
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MRHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_'7_(IW/\
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MW&K*?0@G(K4) !)Z"OGWPY?Z1/:ZOK.J_#Z_UUKG4KBYFO38)((8]W"KNY;
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M** +VC?\AW3_ /KYC_\ 0A7N%>'Z-_R'=/\ ^OF/_P!"%>X5[&6?#(^8S_\
MB0]&%%%%>H?/A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8$$=R\@D:9=HPY8<,2.<]\YJW2*"BBB@ HHHH **** &R?ZI_P#=-<?\*?\
MDF.A_P#7)_\ T8U=A)_JG_W37'_"G_DF.A_]<G_]&-0!V5%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 <WXZ_Y%.Y_WX_\ T(5Y+7K7CK_D
M4[G_ 'X__0A7DM>'F7\9>G^9]=D7^[/U?Y(****\\]D**** "BBB@ HHHH [
M?X:_\A&__P"N2_S->CUYQ\-?^0C?_P#7)?YFO1Z^@P'\!?,^,SG_ 'R7R_(*
M***[#RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ,ED6&%Y6SM12QP,G K/T/Q#I/B2P
M6]TB^ANX#U*'E#Z,.JGV-:$LJ00R32L%CC4LS'L!R37B6MW46H*WC'2O"VMZ
M'#L\X:]82Q*SQ?\ /22WS^\3')SSB@#I/^$J\9ZCH^H^)M-.@PZ19R3A;2Z$
MAF=(696WN#A&.TX&.,C->@:3?KJNC6.HI&T:W=O'.J-U4.H;!]^:\=FT_2-,
MO_MOC[PI!/!<L)/[=TTR&TF)Y#30@_(3P22""37M-M)!-:PRVS(UNZ*T3)]T
MJ1P1[8H EHHHH :^_P MMA ?!VEAQFO-[7XF:EIMK+8>(?"VJ_V_$[(L6GVC
M/!<\_*R/DX!XSGW^E>E44 <7\._"DFB^"+*RUFU@:\9Y+B2)E#B$R,6V#Z#&
M<=Z8EM!;?&:%8((XE/A]R1&@4$_:%]*[>N,D_P"2TP?]B^__ *4+0!V=%%%
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MO):\/,OXR]/\SZ[(O]V?J_R04445YY[(4444 %%%% !1110!V_PU_P"0C?\
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M;C&,>F*='&D4:QQHJ(@"JJC  '0 4ZB@ HHHH **** "N,D_Y+3!_P!B^_\
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MBBO4/GPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QDG_):8/\
ML7W_ /2A:[.N,D_Y+3!_V+[_ /I0M '9T444 %%%% 'R+J__ "'-0_Z^I?\
MT,U3JYJ__(<U#_KZE_\ 0S5.O66QX<MV%%%%,04444 %%%% !7T]\./^2>:)
M_P!>_P#4U\PU]/?#C_DGFB?]>_\ 4US8KX4=F"^-G44445PGHA6#XS_Y%*__
M -U?_0A6]6#XS_Y%*_\ ]U?_ $(5EB/X4O1G3@_]XI^J_,\?HHHKY@^^"BBB
M@ HHHH **** +VC?\AW3_P#KYC_]"%>X5X?HW_(=T_\ Z^8__0A7N%>QEGPR
M/F,__B0]&%%%%>H?/A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%137$%N 9YHX@3@%V"Y_.I001D'(- !12$@ DG
M'4FHX;B"Y4M!-'*H."48-C\J 'R?ZI_]TUQ_PI_Y)CH?_7)__1C5V$G^J?\
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ME\OR"BBBNP\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY+/'+O7YE!4'Y@1BM#P%>);VWBSQSJD<MAI^I7?VB+SXR'%O&NU7*CGGG\J
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MZDOYCY<\R/\ YZ)_WT*WO!$\,?CK0W>:-56[0DEP *^A?^%>^#?^A6T?_P
MT_PH_P"%>^#?^A6T?_P#3_"D\5=6L..#2:=S9_M;3?\ H(6G_?Y?\:/[6TW_
M *"%I_W^7_&L;_A7G@S_ *%;1_\ P#3_  H_X5YX,_Z%;1__  #3_"N4[39_
MM;3?^@A:?]_E_P :/[6TW_H(6G_?Y?\ &L;_ (5YX,_Z%;1__ -/\*/^%>>#
M/^A6T?\ \ T_PH K^-]2L)/"MRJ7ULS;DX$R_P!X>]>4_:K;_GYA_P"_@_QK
MU[_A7O@S_H5M'_\  -/\*/\ A7O@W_H5M'_\ T_PKBQ&"5>?-S6/6P.:/"4_
M9J-];[GD/VJV_P"?F'_OX/\ &C[5;?\ /S#_ -_!_C7KW_"O?!O_ $*VC_\
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MTO\ Y[R?^ \G_P 37TE11_9M+N_Z^0?V]B/Y5^/^9\V_\)%I?_/>3_P'D_\
MB:/^$BTO_GO)_P" \G_Q-?25%']FTN[_ *^0?V]B/Y5^/^9Y3X*^(7A?2M'E
M@O=2:&1IRP4VLQXP/1:Z3_A:O@O_ *#)_P# 2;_XBNRHKNITU3@H+H>37K2K
M5'4ENSC?^%J^"_\ H,G_ ,!)O_B*/^%J^"_^@R?_  $F_P#B*[*BK,CCE^*?
M@QF"C6"23@?Z)-_\178T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% #)95AADE?[J*6;Z"O(]#TSQ7X[\.S>+5\7:GIMS=
M-*^G65L0((T5B$5UQ\^<=?YUZS=PFXLIX <&2-D!^HQ7F/PW\7Z+H?POCMM4
MU"WM;S1O.@N[>60+(K*[8 4\G/&,4 =?X \12^*O!&FZM<!1=2H4G"C \Q&*
MMQVR1G\:HO\ \EH@_P"Q??\ ]*%KGOA]X(M=7^&>A_VP+V*3]]<(L%U)!A99
M"PSL(SQM//K6Y_PJ?PO]H%Q_Q-/.";/,_M.?=MSG&=^<9[4 =Q17%_\ "KO#
MO_/76/\ P:W'_P 71_PJ[P[_ ,]=8_\ !K<?_%T =I17%_\ "KO#O_/76/\
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M]X0_Y][_ /\ !A-_\51_PI[PA_S[W_\ X,)O_BJ/[,E_-^ ?ZP0_Y]_C_P
MXS15/]NZ?P?^/F/M_M"O;ZX1?A!X15@RPZ@&!R"-1F!'_CU3_P#"KO#O_/76
M/_!K<?\ Q==F%PSH)IN]SRLQQRQ<HR4;6.THKB_^%7>'?^>NL?\ @UN/_BZ/
M^%7>'?\ GKK'_@UN/_BZZSSCM**XO_A5WAW_ )ZZQ_X-;C_XNMK0/"VG>&S<
M&P:\;S]N_P"TW<DW3.,;R<=3TH VJ*** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7UFQ;3+HMNTZ21\I>Q^JGH&SGY?ZT ;?B#Q#IOAC2)=3U6?RK:+&<#<QR0.
M.3UKS2TUM?AOXBOKV16NO!.OS?;H-0ME,BVLS_>#8_A/^'O5RQT_2/$/Q6\2
MV/BNVBO+Z%8_[,MKL;HQ:E>6C4\9W=3U_6LJZOT^%/C.32;>.2\\(7< NKFU
M(,ATT,^PL,Y_=EL<'U/IR ;>J?$3P\L=U;>!XXM5\1ZI]U;*'^/&T22M@ !1
MZ_IUKK/!'AI?"/A"PT?>))84+3R#H\C'<Q^F3Q[ 5J:=8Z9:PB73;2UACF ?
M=;Q*H<'D'@<U=H **** "BBB@ HHHH **** "BBJFIWHTW2;R_:-I!;0/,47
MJVU2<#\J +=>2>'-#F^(FGWVO7_B+5[/5EO9H(XK.Z,:6&QB%38."<8)SUS5
MC3+/QYK_ (=M?%6G^+8UOKN(7,6F-;*;0*>1$3][..K=<_G6'I&H:P^NW_B+
MPUIY@UN)A'XB\,ROM\XCI-$3W/KW]\\@'8>$_$^KZ?X@/@[Q@4.J!"]AJ"+M
M2_C'7CLX'4?Y/%Z)_P ))JNL>*?"6D1RZ?YVN7,^IZN1_JH6(VI'ZNP'X Y]
MQT%[J=Q\0M=\.1Z?X?U;3VTO4$O;N\O[;R1 J@[HE)^\6.!QQQFO4515+%5
M+'+$#J>F3^0H I:+H]GH&C6NE6",EK;)LC#,6/U)/<GFK]%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5)M5TO28[:\F!RV2?+!Y(0$D(#W"XH Z*-B\:LR%&8 E3C*^W%.HHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZOK.G:#ITFH:K>1
M6EI']Z64X&>P'J?8<U>KSSXCYT[7O#/B._MGN]!TR:4WL:IO\AG4!)RO<*<_
M3- &;XHO])UWQCX4FUEO-\(WML[6WG*R0R79/R>:"!_#T#=Z35O#FG^%/%VE
MZ=80H^@^)9'M+W1FYC#!=PFC'\.,<X]O;&[XO\1^']2TO3](CALM?;6;B.&.
MSCF!S&3EI<KDJ%'.>/J*TO#W@'0_#=^;ZU2ZN+L)Y4<UY<-,T2?W4W?='TH
MN>%?#S^&-(.F?VE<7UO'(QMOM&-T,7\,>?X@/4UMT44 %%%% !1110 4444
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M?N@GJ<9K*\(^&T\+:']B-RUU<RS/<W5RR[3-,YRS8[#V]JW: "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %-=$DC:.15=&!5E89!!Z@TZB
M@#&TGPGX?T*ZEN=*T:RLYY1AY(80K$>F>P]A6S110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!Q>J^ 9)-;GUCPYKMSH%[=C%YY$2RQ7![,4;@/_ +7_ ->MOPUX
M;M/#.FM:V\DL\TTAGNKJ=MTMQ*W5V/K_ "%;-% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gou0qrw2itv5000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *' U,# 2(  A$! Q$!_\0
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M%<_W31_85S_=-=910!R?]A7/]TT?V%<_W37644 <G_85S_=-']A7/]TUUE%
M')_V%<_W31_85S_=-=910!R?]A7/]TT?V%<_W37644 <G_85S_=-']A7/]TU
MUE% ')_V%<_W31_85S_=-=910!R?]A7/]TT?V%<_W37644 <G_85S_=-']A7
M/]TUUE% ')_V%<_W31_85S_=-=910!R?]A7/]TT?V%<_W37644 <G_85S_=-
M']A7/]TUUE% ')_V%<_W31_85S_=-=910!R?]A7/]TT?V%<_W37644 <G_85
MS_=-']A7/]TUUE% ')_V%<_W31_85S_=-=910!R?]A7/]TT?V%<_W37644 <
MG_85S_=-']A7/]TUUE% ')_V%<_W31_85S_=-=910!R?]A7/]TT?V%<_W376
M44 <G_85S_=-']A7/]TUUE% ')_V%<_W31_85S_=-=910!R?]A7/]TT?V%<_
MW37644 <G_85S_=-']A7/]TUUE% ')_V%<_W31_85S_=-=910!R?]A7/]TT?
MV%<_W37644 <G_85S_=-']A7/]TUUE% ')_V%<_W31_85S_=-=910!R?]A7/
M]TT?V%<_W37644 <G_85S_=-']A7/]TUUE% ')_V%<_W31_85S_=-=910!R?
M]A7/]TT?V%<_W37644 <G_85S_=-']A7/]TUUE% ')_V%<_W31_85S_=-=91
M0!R?]A7/]TT?V%<_W37644 <G_85S_=-']A7/]TUUE% ')_V%<_W31_85S_=
M-=910!R?]A7/]TT?V%<_W37644 <G_85S_=-']A7/]TUUE% ')_V%<_W31_8
M5S_=-=910!R?]A7/]TT?V%<_W37644 <G_85S_=-']A7/]TUUE% ')_V%<_W
M31_85S_=-=910!R?]A7/]TT?V%<_W37644 <G_85S_=-5+NRDM&Q("*[>N;\
M1?ZX?04P+VF_\@Z#_=HI--_Y!T'^[12 R=#_ ./U?K76UR6A_P#'ZOUKK: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH IZCJMEI-OY]]<)#%G&YJ?8W]KJ5LMS9S++"QP&7I7"_%[/
M_")28_OK7&_"WQ<]A=C3+QB(7XCSZFM52O#F1A*MRU.5GL,OB'28;X64E[&M
MR>D9/-:8((!'0C(KQ35V#?$VW(.06;I^%>E:[XKL/#=A$]TS%V4!549.<>E*
M5.UK=2HU;WOT.BHKS_2OBCIU[>I;3I+$9#A2T94?K6UXE\86GAVWBGFR4D(P
M0,]:3A).UBE4BU>YTU%>>0?%*RN;V.**"X9'.-WDFKNM_$2QT2]A@G5\RQ[P
M AS1[.5[6%[6%KW.VHKSB'XM:7]J"3QSQQL< M$11+\6=.2ZVB*?R,XWF(XI
M^RGV%[:'<]'HK*77[231&U2,L\ 7/RC)KBG^+%HLQ)MK@0Y^\86J5"3V*E4C
M'=GHT\\=M"\TSA(T&68]A533-:T[6$9]/NDG5>I7M6-<ZW::]X,OKNT8E#"P
MY&#G%<G\&/\ CPO/PJE#W6WT)=3WTEU/4V8(A9CA0,DUEV_B32+N]-G!?1O<
M X* \U>O?^/&?_KFW\J^;7U:31O'+7BEML<F6 [TZ=/GN*K5]G8^F&8(K,QP
MJC)-9=IXDTB^NFMK:^CDF7J@/(KFO%/BZ*T\&+>1.#),@& ?[PKSGX62/+XF
MF=R26(//UHC2O%R8I5K345U/:_\ A(])_M$:?]MC^U'/[O//%:H.1D5YY]OT
M?_A.DM_+/VLAN=GT[UM^)/&NG>' L<Q9IFZ(BY-2X.Z2+516;9U%%<3X=^(5
MIK=^MF8)TE;[N8B!^=3^(_'VGZ%<_9<22W& =J)NX_"CDE>UA^TC:]SKZ*Y#
MPYX^T_7;C[+B2*XSC:Z;>?QKKZEQ:=F.,E)704444B@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Q=0\4:7IFH1V5U=1QS28VJ3R<UKRR+#&TCG"CJ:
M^;_$=U=ZSXDDU",%DMI<9^A_^M6M*'.]3&M4Y%H?20(8 CH:YO4/'.AZ;<FW
MN;V))!U!-3>#=5&K^'+:Y+9<CFO)+W38=5^)+6L_W&W$_G1"";:?0*E1J*<>
MIZK9>._#]],L,6HPF1C@+GK72*RNH93D'H:\<\<^!K/1M+CU#3Y'25/F...U
M=Q\/M3EU'PW"926:-0N3U-$H1Y>:(0G+FY9&]JFK6ND6WGW<JQQYZM2:5K-E
MK-OYUE,LJ=RM<G\5?^197_>/\JX+X3>(VL-2.G3L0EPV5+=!BB-.\.84JW+4
MY6>T:MK-EHMJ+B^F6*,G +>M0P>(;"XTEM2BG1K<+N+@\8KQSXL^(SJ&I"PM
MV+0( QQZUU?@R>*V^&WFS('C6($@C.:?LK138E6O-Q70[O1]=LM;A>6SE615
M;:2I[UIUQ?@?5["ZTFZN+>)(8XI&W87'2L?4OBM#%>/%8V\DR(?F(B)_E4^S
M;=D6JL5%.3/3**YS1O%=OJ>BR:A(KQ+'PV]"O./>N4N/BN@N6-M:RO;*<%_*
M-)4Y-C=6*5VSTZBL?P]XAM/$-C]HMF/&-P(Q@UL5+36C+335T%%%%(84444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1130Z,2%921U - #J*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\1?ZT?05TE<WXB_UH
M^@H O:;_ ,@Z#_=HHTW_ )!T'^[10!D:'_Q^K]:ZVN2T/_C]7ZUUM !1110
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MZX_U:J,#]* .XR/6EKRBZM->\,^*M#AF\175[#=W&QT< #&"?2O5Z "BBB@
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M HHHH *YOQ%_K1]!725S?B+_ %H^@H O:;_R#H/]VBC3?^0=!_NT4 9&A_\
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M-0!LT444 %%%% !1110 4444 >?>.?\ D;_"O_7V?_037H->?>.?^1O\*_\
M7V?_ $$UZ#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R4H(F+C*XYKF
M-"N?#\NLWJ:?&HNEDQ(=N.<5T\RHT++)]PCFN7T+2_#5MK5Y-ILR/>-)F50Q
M)!Q0!U=%%% !1110 4444 %%%% &3JN@6FKNC3YR@P,"L[_A!],]6_*NGHH
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M'RN=>FJB>Y[1YB?WU_.N<UGPRNK71F_M*2'/\*XKSK^W;_\ Y['\Z/[=O_\
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MWI/^$@T[_GO7C7FR?WV_.CS9/[[?G2_M"78/[%I_S'LW_"0:=_SWH_M_3O\
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M TF8S6#PP2$8W(O:OGG<W]X_G1N;U/YT?5XA];GV/IK_ (61X7_Z"*_E2_\
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MG_D;_"O_ %]G_P!!->@T %%%% !1110!Y=\:/^1?B_ZZK7A->[?&C_D7XO\
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MOQ?]=5KPFO=OC1_R+\7_ %U6O":[Z'P'F8G^(%%%%:G.%%%% !1110 4444
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MT >Q>%O^0%#]36S6-X6_Y 4/U-;-?14OX:/A\3_&EZA1116AB%%%% !1110
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M%%9&X4444 <!\0?O)^%<%7>_$'[R?A7!5X6,_C,^ORS_ ':(4445S'>%%%%
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MY5Q<RCD^0A?'Y54\)WAL/A787"]5M_\ &L_X6:7%<V=YJEPH>X>YD7<?3)H
MZKP[XQT_Q'N6 212KU29=K?D:Z*O*/$ENOA_XC:1=6XV+=S$R =\5ZE'.CQ*
M^X#<,T <'XY_Y&_PK_U]G_T$UZ#7GGC=U;Q?X6P<_P"EG_T$UZ'0 4444 %%
M%% 'EWQH_P"1?B_ZZK7A->[?&C_D7XO^NJUX37?0^ \S$_Q HHHK4YPHHHH
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M#]36S6-X6_Y 4/U-;-?14OX:/A\3_&EZA1116AB%%%% !1110 4444 %%%%
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MJ",&NWH \?U?PPOA_P 8^&V74+JZ\RZQB9LXX/2O8*\^\<_\C=X5_P"OP_\
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MAW9P,5V,[M' [J,L!D"N.\-^(-5U#7[ZUN[-XX(Y=L;F/&1@=ZZ#C.UHHHH
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MF]W?7DT<Y.<+,5Q0!TZZM8[1B=<?6K$%W#<Y\IPV.N*\_P#^%=^&?^@O>?\
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M_P#>:N[KSJGQL]>E\""BBBH- HHHH \E\9?\AG\*YVNB\9?\AG\*YVOGJ_\
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MJ_\ $9]MA/X$?0****R.@**** "BBB@ HHHH *5/OK]:2E3[Z_6@#V+PM_R
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MZ#7GWCG_ )&_PK_U]G_T$UZ#0 4444 %%%% 'EWQH_Y%^+_KJM>$U[M\:/\
MD7XO^NJUX37?0^ \S$_Q HHHK4YPHHHH **** "BBB@ HHHH ]B^"'_'QJ'_
M %R'\Z]EKQKX(?\ 'QJ'_7(?SKV6N"M\;/4P_P##04445D;A1110!P'Q!^\G
MX5P5=[\0?O)^%<%7A8S^,SZ_+/\ =HA1117,=X4444 %%%% !1110 4444 >
ME> O^/%OI795QO@+_CQ;Z5V5>]A?X2/C<P_WB0R5E6)F<94#FN7T'5=$N]9O
M8;&$+<I)B0[1R<5U$P0PL)/N8^;-<KH$'A9-:O&TOR?MOF?O=O4-BN@XSK:*
M** /!/C3_P C1#_UQ%>9UZ9\:?\ D:(?^N(KS.O1I? CR:_\1A1115F04444
M %%%% !1110 4444 ?1GPF_Y$FW_ -YJ[NN$^$W_ ")-O_O-7=UYU3XV>O2^
M!!1114&@4444 >2^,O\ D,_A7.UT7C+_ )#/X5SM?/5_XC/ML)_ CZ!11161
MT!1110 4444 %%%% !2I]]?K24J??7ZT >Q>%O\ D!0_4ULUC>%O^0%#]36S
M7T5+^&CX?$_QI>H4445H8A1110 4444 %%%% !1110 5S?B+_6CZ"NDKF_$7
M^M'T% %[3?\ D'0?[M%&F_\ (.@_W:* ,C0_^/U?K76UR6A_\?J_6NMH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^\<_\ (W^%?^OL
M_P#H)KT&O/O'/_(W^%?^OL_^@FO0: "BBB@ HHHH \N^-'_(OQ?]=5KPFO=O
MC1_R+\7_ %U6O":[Z'P'F8G^(%%%%:G.%%%% !1110 4444 %%%% 'L7P0_X
M^-0_ZY#^=>RUXU\$/^/C4/\ KD/YU[+7!6^-GJ8?^&@HHHK(W"BBB@#@/B#]
MY/PK@J[WX@_>3\*X*O"QG\9GU^6?[M$****YCO"BBB@ HHHH **** "BBB@#
MTKP%_P >+?2NRKC? 7_'BWTKLJ]["_PD?&YA_O$ADJJ\3*QPI&":YC0O#FC:
M;K-Y=V5WYEQ-)ND3S <''I73S1^;"T9XW#%<EX>\(1:1KM]?I="1II=Y0?P\
M5T'&=A1110!X)\:?^1HA_P"N(KS.O3/C3_R-$/\ UQ%>9UZ-+X$>37_B,***
M*LR"BBB@ HHHH **** "BBB@#Z,^$W_(DV_^\U=W7"?";_D2;?\ WFKNZ\ZI
M\;/7I? @HHHJ#0**** /)?&7_(9_"N=KHO&7_(9_"N=KYZO_ !&?;83^!'T"
MBBBLCH"BBB@ HHHH **** "E3[Z_6DI4^^OUH ]B\+?\@*'ZFMFL;PM_R H?
MJ:V:^BI?PT?#XG^-+U"BBBM#$**** "BBB@ HHHH **** "N;\1?ZT?05TE<
MWXB_UH^@H O:;_R#H/\ =HHTW_D'0?[M% &1H?\ Q^K]:ZVN2T/_ (_5^M=;
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y]XY_Y&_PK
M_P!?9_\ 037H->?>.?\ D;_"O_7V?_037H- !1110 4444 >7?&C_D7XO^NJ
MUX37NWQH_P"1?B_ZZK7A-=]#X#S,3_$"BBBM3G"BBB@ HHHH **** "BBB@#
MV+X(?\?&H?\ 7(?SKV6O&O@A_P ?&H?]<A_.O9:X*WQL]3#_ ,-!11161N%%
M%% ' ?$'[R?A7!5WOQ!^\GX5P5>%C/XS/K\L_P!VB%%%%<QWA1110 4444 %
M%%% !1110!Z5X"_X\6^E=E7&^ O^/%OI795[V%_A(^-S#_>)$<Z&2!T!(+#&
M1VKD/#GAN^TW7KZ[N+YY8I)=R(9,X&/2NOF#M"XC;:Y'!]*Y#PYIFO6VOWTU
M]=;[9I<HNW&1BN@XSLZ*** /!/C3_P C1#_UQ%>9UZ9\:?\ D:(?^N(KS.O1
MI? CR:_\1A1115F04444 %%%% !1110 4444 ?1GPF_Y$FW_ -YJ[NN$^$W_
M ")-O_O-7=UYU3XV>O2^!!1114&@4444 >2^,O\ D,_A7.UT7C+_ )#/X5SM
M?/5_XC/ML)_ CZ!11161T!1110 4444 %%%% !2I]]?K24J??7ZT >Q>%O\
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MHHK(W"BBB@#@/B#]Y/PK@J[WX@_>3\*X*O"QG\9GU^6?[M$****YCO"BBB@
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M#]36S6-X6_Y 4/U-;-?14OX:/A\3_&EZA1116AB%%%% !1110 4444 %%%%
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M\9_^_M'_  J'PM_SQG_[^T?6?(/J?F<C\%KF&"XO_-D5<QC&3CO7L']I6?\
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M/5?[2L_^?B/_ +Z%']I6?_/Q'_WT*Y7_ (5AH7_/6_\ _ EJ/^%8:%_SUO\
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M^TK/_GXC_P"^A1_:5G_S\1_]]"N5_P"%8:%_SUO_ /P):C_A6&A?\];_ /\
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M*--_Y!T'^[10!D:'_P ?J_6NMKDM#_X_5^M=;0 4444 %%%% !1110 4444
M%%%% !1110 4444 (1D8/>N!U;X>3/J+WNC:I+ISR?>6%1SZGFN_HH X_P ,
M>"%T:Z>^O;MKZ\<@^;(.0:["BB@ HHHH **** "BBB@ HHHH **** "BBB@#
MF-2T":Z\:Z7JRY\NVC96_$UT]%% $-Q=0VL1DF<*HZU%9ZG:7V?L\H?%<((&
M\7^+M0M;F:1(-.EV!8W*[@?YUHWEOI/@QC?1O<23E=BQ!RWZ4 =K17.^&/%,
M.OP%61H;A!\\;C!'X5T5 !1110 4444 %%%% !1110 4444 %%%% ',0Z!,G
MBC^T3G9N)KIZ*:753@L ?3- #J*J:GJ$.EZ?+>3_ .KC&37/Z-J^J75T]]?2
M00Z9@A PVL3VH ZNBJEIJ=E?%A;7,<I7J$8'%6Z "BBB@!DS(D+-)]P#FN5T
M'5O#MUK5Y#IT4:W:R8D*@Y)Q752[?*;?C;CG-<QH4.@IK-ZU@RFY,G[SD=<4
M =51110 4444 %%%% !1110!R^A:!-IWB#5;UR=EU-O7\A74444 (2 ,DX%4
M#K>GBX\CSQYG3%<_XXU">..WTR!]C7F5WYQC\:CB\%:5;:?'<7%S<;E D9C*
M>2.: .T!R,BBN'L/'EI_:ZZ>89A S;8IF'RG\:[=&5T#*05/((H 6BBB@ HH
MHH **** "BBB@ HHHH *9,A>%T'<8I]% '-^&M#FTG4-3FDSBYD#+GZ5TE%-
M5U8X5@?I0 ZBN>\2:_)IAAM+1=UY<Y$61D ^]/L-4DLK0?VW=VR7#G( ('%
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M?IMMIL BMXP,#!..35N@ HHHH 9,B20LC_=(P:Y/P_H.B6.N7MS9-&UPTF7
M'*G%=7-&)870D@,,$BN4\/\ A:UTS6[R\COGE>23<4\W../2@#KZ*** "BBB
M@ HHHH **** "BJL&H6MQ<201RH9(SAEW#.:Q?&.NRZ)8P>0!YEQ*(ER. 30
M SQ5I"Z]:.EI+MOK<?(PZJ:S="UV'4XCH>LH([J,;=CGEU'>LBZT+Q!H=P=>
MBG\V3.^:+>6!^@K42QT?QU:+.DKV]VG#F([7R.OOB@!OC.QTRPT".RMHT2?!
M%LHZAO:NNT)9%T*R67/F"(;L^M8.E> [2PNUN9KJXN74Y F?<!76@!0 !@#H
M!0 M%%% !1110 4444 %%%% !1110 44'I7*:QXSAL;YK*WAEFF0;F*(6&/P
MH =XMU:ZMY+?3+*0Q7%T#LD7JN*P;ZUU_P -&VOFU66[CD=5>(C&,]36G9W^
ME^+[B,R^;!=VW 5QM)/M6MXGM@^@L!R(EW9/L* ,O7=(NM9EL-7TV9DD@)8*
MH^]63?Z%906DMWXGN5NKAE(B$HY4D<#\\5L:+XAMM/\ !-I>W#;OW>0B\LWT
M%7H]%L=9GBU20S'*@B.3I^5 $'@*VGMO#<*S*4'.U#VKJ::B+&@1%"J.@ IU
M !1110 4444 %%%% !1110 4444 %%%% !7-^(O]:/H*Z2N;\1?ZT?04 7M-
M_P"0=!_NT4:;_P @Z#_=HH R-#_X_5^M=;7):'_Q^K]:ZV@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J6J:9!JUC):SKE7&*YK4_$>H:%KB+?0C^SY/XT!)![5UMO<17,*RQ.&1A
MD$'- 'GEG?7O@K4?L&H%GTN0XCE/"Q+Z58U6RO-,U5?$&C*T\4J@/%'Z=<UV
M.JZ5;:M9M;W"!@1P2.E<IH%IJVA:K)IDX\[3R-R.QR>>WTH S-8NYO&WDZ>-
M-=$<8DDSGR_K6EX,GO--U)M"NI3-L0NK^@["NDU.SN(K.3^R;>$7##OQ57PY
MX>.E[KBY<R74A)9B<XSV'M0!T-%%% !1110 4444 %%%% !1110 444AZ4 4
M[W5K'3L?:[A(L]-U<;XO<O+8:O;C[1:1S;G*]$ [U6T.UC\1:WJO]HSN'@G,
M<49/5<=<&F7]C=^$KPL=UUI,_P K*_S%1WXH ZFYM=,\8:(&38ZNN58=JQ-"
MU:^T'4O[&U8LT?\ RRG;@'/1:SX3<:!.NJZ0QGTN?YY(R<F/T 45/)/-XTU2
MV:WMWB@MW60O(A1B1U'- #=1\*:I=>*+LPNT=E>29F.."*[O3-,M]*LUM[=
MH Y([FKM% !1110 4444 ,F0R0NBMM+# /I7)>'O"E]I.N7M]-?^;'/)O"8Z
M<5UDZLT#JGWB.*X[PWHWB&R\07]QJ$X>UDEW1+YF<+@=J .UHHHH **** "B
MBB@ H/(Q6/XDGU*WTMY=-C1Y5()#'MWJ'PYXDM];M <[)UX=&&#D>U &!XB\
M/W6E7[:YHH;S,[IH5ZR&I)9[3QUH:K&ZK>6S;@G4AU_^O7<,H92K#(-<-KOA
MJZT[45U;0_E?(\R+.%QW/UH KVOBO5-,M6L=2TV6:XC&T.2!YIKGDTZ_\)[=
M=0M$;NZ53#WPY_\ KUZC8+'J-C#=7-LGG,,G*]*P)?#NHZQJ8?52J6L3[HTC
M;(X/'% '71/YD2MZC-/I%4*H4= ,4M !1110 4444 %%%% !1110 4A.!DTM
M<_XPNIK;0IO*)7<I!9>JT 77US37G>T%W'YY!&SO7&Z7>+X?\4S6^H+MCF'[
MN=NC$GI4]CX3M=5\-P317<GVET#&16^;-9J2&Y9]"UU/+NX^89P/R^;UH W_
M !+X::9QJVDGR[V/Y@5'+4_2]:;Q%X?N[62,QWBQO&4)Y) QFL>RU_4/"X;3
M]3BDGA7Y89(U+EA[XK4\'Z=<M<RZI<1B+S"P5!Z'H?K0!D^$/!=['#;_ -LL
M7CMO]3$PQMKT9$6- BC"@8 IU% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5S?B+_6CZ"NDKF_$7^M'T% %[3?^0=!_NT4:;_R#H/]VB@#(T/_ (_5
M^M=;7):'_P ?J_6NMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "H;FYALX'GN)%CB099FZ"BYNH;2$RS.%
M0=S7%^+]0%_IEE=6Y<V#.?/XZKCTH OW7B'P[K*M83W4)#_=)/7TK#M;N\\%
M:@+><M-I,I^1QT3/))-;#>'-%U3P\CVT44;B/<LJ ;ABH/"1_M72WT[4T6X\
MIFPS\\9Q0!T>F:]I^L;_ +#<QS!#@E36E@9S@9JEI^D6&EJ5L[:.+=R=HQFK
MU !1110 4444 %%%% !1110 4444 %%%)O7=MW#/IF@")[J!)Q TJB4C(4]:
MFKF/%F@W&I0BZLIWBNHL$;3C('.*A\*^*3?9T_40(;^(?.O8^F">M %?Q+X<
MG@NAK.D'R[J/[R@9W>M6=-\3:7K6EO!J3)!, 5EBD/('K7432QPPM)*P" <D
MFN1BTK0O$EP]S:!XVSAR(\;L4 4_ *XU'6HHOGL5G @SR-N!7>*B)]U%7Z"J
MVGZ=;:;;B*WC5!W('6K= !1110 4444 %%%% $<^_P A_+^_CBN-\-2^)G\0
M7ZZF6^QB7]SE<97 KLIV=(':, N!P#7'^&]<UR^U^^MKVS2.WCEVJP)Z8^E
M':4444 %%%% !11T%9%YJ\#_ &BSMY"URJ\8Z?G0!#?^*](LIC!+=Q%QPRYZ
M5S6J:='+)_PD'AN=7D'^M6/G>!V%'A.TTO4+C4H[Z%)+H38/FCD<=J8;=O"_
MBA4MG+6=R0@ASPI/4XH V](\;Z=>6Z1W,RPWN,/ Y^8'TKJ%(= W4,,UF?\
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MKLK+3K>P4K;KM4]AT%5-#T*WT2V,<0!=CN9@.I/4UK4 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ-0_O+_WU110 ?V)J']Y?^^J/[$U#^\O_?5%% !_8FH?WE_[ZH_L34/[R_\
M?5%% !_8FH?WE_[ZH_L34/[R_P#?5%% !_8FH?WE_P"^J/[$U#^\O_?5%% !
M_8FH?WE_[ZH_L34/[R_]]444 ']B:A_>7_OJC^Q-0_O+_P!]444 ']B:A_>7
M_OJC^Q-0_O+_ -]444 ']B:A_>7_ +ZH_L34/[R_]]444 ']B:A_>7_OJC^Q
M-0_O+_WU110 ?V)J']Y?^^J/[$U#^\O_ 'U110 ?V)J']Y?^^J/[$U#^\O\
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MQ-0_O+_WU110 ?V)J']Y?^^J/[$U#^\O_?5%% !_8FH?WE_[ZH_L34/[R_\
M?5%% !_8FH?WE_[ZH_L34/[R_P#?5%% !_8FH?WE_P"^J/[$U#^\O_?5%% !
M_8FH?WE_[ZH_L34/[R_]]444 ']B:A_>7_OJC^Q-0_O+_P!]444 ']B:A_>7
M_OJC^Q-0_O+_ -]444 ']B:A_>7_ +ZH_L34/[R_]]444 ']B:A_>7_OJC^Q
M-0_O+_WU110 ?V)J']Y?^^J0Z%?'KL/_  *BB@#<L[22"SBC?&Y1@X-%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gou0qrw2itv5000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +K!H\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)@M0TF$.,EFSDC!P3D#)4+P2*Z#Q+X@L[GPVR6%S%+]K<P,,@,%Q\^489Z$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,CQ/??8/#]TZOMEE7R8\
M2[&W-QE3UR!EN/[O;K7"^'-$77+Z6&5IH[>*+<TD+*"&) 488'@C=V_A_/TB
M]L+74;<P7D"31G. PY4D$9!ZJ<$\C!YIMEIEEIR;;.UBARBHS*OS,%SC<W5L
M9/))ZGUKCK87VU:,Y?"NAW4,6J-&4(?$^ISW_" :=_S_ &H?]]1__$5Q$<L^
MF7ZR A[BSG^80RE0[(V&4-C.TD%3QT)X[5['6;?:!I>HW<5U=6BO-&VX,K,N
MX\?>"D!QP.&R,<=S6=? 1E9TK1:-,/F$HW5:\DT<QX[ECG&DS0R+)%(DK(Z'
M*L#L(((ZBJVD^+_[+TR&R^P^;Y>[Y_.VYRQ/3:?6NX?3+"2.&.2QMG2!=D2M
M$I$:\<*,<#@<#T%,_L?2_P#H&V?_ 'X7_"E4PM;VSJTY6N%/%T?8*C4A>WF<
M_'J:^,=,U#3C9>5((@\6Z1BA<'*EF"\88*<<YYX(!KDM,U&?0]6,Z('DA+PS
M0[P V."I;!QA@#Q_=KU.WL[6TW?9K:&'?C=Y<87..F<?4U6U'1--U;:;VU61
MEQAU8HV!G W*0<<GC.*=7"59J,^;WX]0I8RE!RAR^Y+H>=ZSK<_B&XM2]FD+
M1 I''&YD9BQ&><#.<+@8_/-=/8>"[:71[5-0C>&\1I)':&7.-^!@YR/NI'G
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M4&Y/=_D;8O&NO&,5LM_4****[3@"BBB@ HHHH **** "BBB@#S?QI_R,+_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<-XH\3M([6
M&GRE44XEE0_>/H#Z5AB,1"A#FD;X?#SKSY8G<T5P7@F]O&U-[<R.]N8RS!B2
M%/8BN]HPU=5Z?.E8>)P[P]3D;N>;^-/^1A?_ *YK6OX!_P!1??[R?R-9'C3_
M )&%_P#KFM:_@'_47W^\G\C7DT?]_?JSV*__ "+EZ+]#L:***]T^?/*_$O\
MR,5[_O\ ]!78>"/^0"W_ %W;^0KC_$O_ ",5[_O_ -!78>"/^0"W_7=OY"O"
MP?\ ODOG^9[^-_W*/R_(Z2BBO)KG5-1.HO<27$R7"N> Q&PYZ8]/:O2Q6+6'
M2NKW/,PF#EB6[.UCUFBL3P[K\>L6VR3"W<8^=?[P_O"MNNBG4C4BIQV9SU:<
MJ4W":U044459F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***QO$&NQ:-:_+A[J
M0?NT]/<^U14J1IQ<I;(NG3E4DH16K(/$OB%=)@\B AKR0<#^X/4_TKSH"6YN
M,#=+-(WU+$_UHFFENKAY97:261LL3U)KM/#EEIND1B\U"]M5NV'RJTJ_NQ^?
M6O"_>X^M9?"OP_X)] O99?1N]9/\?^ 'A:WATG4);.^A,6HN,QLQ!#)Z*?\
M/Z5V-<YJ]]X?U.V$<NI0+(IW12H^6C;UXJ'2/%EL(WMM2N8_-AX$Z9*RCUX[
MUZU./U9>SDO=Z/\ 1^?YGD59?67[2/Q=5^J\OR.BO+N&QM9+FX<)&@R3_0>]
M>7ZUK,^LWAE?*Q+Q%'GA1_C4_B#7I-9NL+E+6,_NT]?<^_\ *F:!I<.I7O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*EAY^QK;?E_P#U,9A8XF'MZ._P"?_!/2**165T5T8,K#((/!%+7NG@!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y7K6H7/B;7UM[;+1[_+MT[8[L?KU^E=_P")+QK'P]>3IP^S8I]"QVY_6N-\
M#Q0P37FJW+!(K:/:&/8M_P#6&/QK>DU"#J/H9S3E)074ZBQT[3?">EM/(09
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4444 (0""" 0>H->4:E;GPYXI.Q<Q(XD13T:,]5^F,K7K%<9\0;
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MM7:5UX.=25).JM3CQL*4*S5)W04445U'(%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]2<$_D /SKOZVQ#O,BDO="BBBL#0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (Z[D9?48KP3X5
M_P#(]6__ %QD_P#0:]\KP#X='['\1[2!N.9HCG_<;^HKKP_\.?I_F85?BB>_
MT445R&X4444 86J>#O#VL%FO-*@,AY,D8\MR?<K@G\:Y2^^#FD39-EJ%U;$]
M X$BC^1_6O2**UC6J1V9#IQ>Z/$;[X/ZY "UG=6ETHZ+N,;'\",?K646\<>#
M3N8ZA:Q+ZGS(?ZK7T'39"@C8R8V '=GICO6RQ<MII,S=!;Q=CYVF\:7-Q=2Z
MA<6J/=C$BK"=@=P.!SG&<=??I7<_\+G73P/^$B\'>(-*&,F3R/,C'ON.W(]P
M*\_\:6;RFZU+2((8F:8L8R,(%+<<#IU _&MWP1\1_&5GH2VDG@V?6+:S_=F>
MRGS(J]0-F&)QT'3@>U5BHII.*%1;NTSTCPY\3/"?BJ62'2]3WW$41FDBDA=&
M5!C)Y&#C(Z$UDZCX^O))V73XHXH0>&<;F;W]!4-KXBT_Q-H.N7EMX9O=(U&W
MC2.=KRS6)V5VR0&'+#Y<D'':K7P\@@DGOI71&F0)L)'*@[LX_(5C3C%0<VKF
MDVW)11GQ>.=:C.6>"3V>/_#%:-O\1)AQ<V$;>IB<K^AS7=2P0SC$T4<@]'4&
MLZY\-:-=9\S3X03WC&P_^.XI^TIO>(N6:V9F6_CS2)<"5;B ]RR9'Z$_RK2A
M\3:+/]S481G^^2G\\5E7'@#3),F":XA/8;@P'YC/ZUF3?#N4?ZC44;V>(K_(
MFBU%];!>HNAV:ZII[XVW]JV>F)E.?UIDNLZ9 ,R:A:K[>:,_E7#-\/M4S\MS
M9D>[,/\ V6G1?#W42W[V[M47U0LQ_D*/9T_Y@YI]CH;KQQHUOD1O+<-_TS3
M_,XK$NOB'.V1:6,:>C2L6_08J]:_#VR3!NKR:8^B (/ZUMVOAG1K/!CL(F8?
MQ2#>?US1>C'S"U1^1P#:WXCUEBD,MRX/\-LA4#\5_J:L6G@C6+Q]]R4MP>29
M7W,?P&?UKTQ55%"HH51T & *6AUVOA5@]EW9RMCX#TRV(:Z>2Z<=B=J_D.?U
MKI;>V@M(A%;PI%&.BHH J6BL93E+=FBBEL%%%%2,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUII6M?V>T=RP0O;A@T3'[N<G')Q^=4_%7C+4#XONM,BUB33;"W(C62*$-N?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#3,,''11Z4NA?\@I?^NTW_HQJTJBK5;;B5""6ISFLZ=-',US I:-N6 ZJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *S="_Y!K?\ 7S<?^CGK2K-T
M+_D&M_U\W'_HYZM? _E^I/VC2K-U[_D%-_UVA_\ 1JUI5FZ]_P @IO\ KM#_
M .C5HI_&@E\+-*BBBH*,W6?]79?]?D7_ *%6E6;K/^KLO^OR+_T*M*K?PHE;
ML*S;7_D8-1_ZXP?^U*TJS;7_ )&#4?\ KC!_[4HCL_ZZH'NC2HHHJ"C-T[_D
M):Q_U\I_Z)CK2K-T[_D):Q_U\I_Z)CK2JY[_ '?D3'8HZS_R ]0_Z]I/_035
MFW_X]HO]P?RJMK/_ " ]0_Z]I/\ T$U9M_\ CVB_W!_*C[ ?:):***@HS8/^
M1FOO^O.V_P#0YJTJS8/^1FOO^O.V_P#0YJTJN>_W?D3'8*S?#W_(N:;_ ->T
M?_H(K2K-\/?\BYIO_7M'_P"@BA? _E^H?:-*JVH_\@R[_P"N+_\ H)JS5;4?
M^09=_P#7%_\ T$U,=T-[!IW_ "#+3_KBG_H(K)\9Z-_;OA2^LU7,P3S8?7>O
M(_/D?C6MIW_(,M/^N*?^@BK-5S.,[H5KQL?-4$GFP*_<CGZU)6IXJTK^P_%]
M_9JNV"9OM,'IM;J!]#D?A677TM*:G!21Y$X\LF@J&=FA:.Y3[T+!OJ.]34C*
M&4J>A&#5-75A)V9T".LD:NIRK $'VK1\(6_VWXA60QE;.WDG/U/RC^8KG-#F
M+V;6['YX&V_AVKN?A?;^;JNN:@1PK1VR'Z9+?^RUP8F7+29U4E>:,?XA:68Y
MAKD8X%[):SGV/*G_ -"_2N1KVF^TA==\.:[IQ WRW$OED]G&"I_,"O$;=F:(
M!P0ZG:P/4$56"J\T7!]"<1"S4NY+1117><P_39?L^JM$?N7"Y'^\*U[R7R;*
M:3NJ$CZ]JYZYW*BS)]^)@X_"M>])O[.V@@/S7LL<2?\  C7/-69K'5'I_A&Q
M_L_2_#,!&&-E-*P]W*-_[-795E2QK#K>EQ(,(EO,JCT \NM6OGZCYK/^MV>G
M!6T"LUO^1F3_ *\V_P#0UK2K-;_D9D_Z\V_]#6E#J.1I4445!1FZ#_R"E_Z[
M3?\ HUJTJS=!_P"04O\ UVF_]&M6E5U/C9,?A05F^'_^0%:?[G]36E6;X?\
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M3I:V+0>;,7)(B8':R= 6(<%1@?,<8!R*X?X^S1#P=IT!E03/J*NL98;F58Y
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M<_-DAL@$$@*2.G4$#5\3^-M,L/ ,VNV6IH%NX'33KA(RX:<HY08P<'*G(8
M@@XZ5YIK?@#P[IOP5BU^&SD;5GM+6<W+SN3NE>/<-H.W&'(''3'4\U+X.ABU
MSX ^(+?4HTN(]-:Z>S#* 866$2J01SG>['/<,1TXHL@NR7X>_%[']I'QKKO&
M(OLG^B?[^_\ U2?[G7\.]7O^$9T+_A=WG_\ "87O]K_:OM/V#[.^_P#U>_R_
M/^[LV\;<?<^3KS7,_!;PKHGB2YU>;6+!+MK)K=X [L%!)D)RH.&!VKPP(X]S
M6S_S='_G_GRHZBZ(JZEJ5GH_[2,^H:A<);VD"[Y)7Z ?8OS))P !R20!S7H&
MA_%GPKK^LMI<%S/!.TOE6[7,6Q+D\XV')QG P&VD[@ ,\5YQKNB6?B/]HN72
M]0#M:3-&TBHVTL$M5?&>H!*X..<$X(/-9GQCTJQ\.>-[.;15AL'DM4G,5H&C
M,<BNP$@P JYVC&TYRI) SDFX7:/=O$_B[1O"%@MUJ]SY?F;A#"B[I)F SA1^
M0R< $C)&17,:1\:/"&J3F&:>ZTUBRHAO8@%<L<?>0L% XR6( S]<>;_$#_B<
M_':WTW4/WUF+JRM!']W]T^QF7*X/)D<YSGGKP*U?C?X6T/2;+2]2TV"SL+AY
M&@>UMXUC\Y,;M^T$#Y3P2!SYBY/ %%D.[/7?$WB?2_"6DG4=5E=(2WEQK'&7
M:1]K,%&. 2%/)('J17C'Q,^(V@^-/!MM;:=]JANXM060V]S%M;8(W&[*DKC+
M 8SGKQCFN?\ BA>W5R/"AN+F:;/AZUF/F2%LR-NW/S_$VT9/4X&>E==\9O!>
M@Z'X<TS4=*L4LYHYTLRL7"R)L=@6[LX*_>SDY.<\8$A-MEG3=,L=4_9VT]-3
MUB;2K.*9Y)+B.-I%/^DNH5T7EE)8<=B%/:NU^&]EI>A> 8Y+377U#32\L_VR
MX4PQHH)#!5;E$!4DY/4LW>N$7_DUO\3_ .EM9>K7D]M^S?H4,,FV.ZOFBF&T
M'<@EF<#GI\R*>/3ZT#O8[J7XX^$(]2%JG]H2PEE7[6EN!$ <9;!8/@9Y^7/!
MP#QGM/\ A)=&_P"$<_X2'^T8?[)\KS?M.3C&<8QUW9^7;C.>,9XKYWTZ22_^
M':Z3!\.KJ\F=7$>N6MN3(6$I8$,(3D C81NY (R.VY8>#/%&M?!QM*6PNDO+
M76O/BM;W,+&+R@#L#X &YV;L/O=^"6079Z%I/QA\*ZOKJZ3"U[$\LHA@GE@_
M=S.6"J%P2PSG(W <=<=*[^OFWPKXNTWP_?VFD^+O"5E"]I+"1?+9>1=VY4[U
M>0 !G_@Z8)4'.\G!^DJ30T[G#^*?BMX<\*:JVF72WMS>1_ZZ.VA!\K*JRY+E
M0<AA]TGH<XKQ[5=8L->^.MCJ>F3^?9S:I8^7)L9-VWRE/# 'J#VJ3X.Z;9^(
MO'MTVM6Z:B5LY;D_:OW@:0N@+,#]XX=NN>3GJ :KZAHEGX=^.5EI6GAUM(=6
MLVC5VW%0[1OC/4@%L#/. ,DGFG:Q-VSZ!\3^+M&\(6"W6KW7E^9N$,*+NDF8
M#.%'Y#)P 2,D9%<_X<^+OA?Q)J2:?&]U8W,KJD"WL:J)F.>%968 \ 88C)(
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M?*K:!?4J_![0M"L+_5;O1?%,VKXBCCEA6T>VC3))#,&SN;Y2 1T!;^]6Q?\
MQH\(6.K+8K/=72;MLEW;1!H8SN(/)(+ 8SE0P((QFO/OA%;?;?"7CRT\Z&#S
M[%(_-G?;''NCG&YCV49R3Z5R/A_Q#X>TOPCKEC?Z!'>:O=H4M+QPK"(%=O\
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M<*W0-E  #@?-R1CGT6BBX[:6/!;GX?\ Q0\6Z3;6VNZE;QPVC8BM[RX!8X4
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MBZ&VDUZ^MD:S7R(8[VYW,%P/F_=JP)/0L3N.WGH*^@:*+ARH\Y'@'51\&?\
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M\A+6/^OE/_1,=:57/?[OR)CL4=9_Y >H?]>TG_H)JS;_ /'M%_N#^55M9_Y
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M!ED()"YZ*, DD] #U. 3J">AOT5X9)\9O&%C)%J6H>%8X]%G;,):&:(NK E
M)FRI.,'(7D X [=;XG^*G]A:/H^M66C?VAI>IQ;DF%UL,4@ZQOA&4-U&-V<J
MXQ\N26871Z-17F6M_&73=*\.:+J=O8_;+C4XC*UL+C9Y 4[7W$KD_.&4';AM
MK'/',GC7XL1>%+.WM%L4DU^6!9)[,S!DLF9,@.R_>()'RC&1SE<KDLPNCTFB
MO+_!GQ,UK4?$UOX<\3Z ]A?7:O)!(L3PC:%)&8Y,G'R/\P/7 QU-96I_&'7M
M3U&>'P3X=?4+2V;:]P]M+,9 ?NML3!C!(;&XDD8X4@BBS"Z/9:*X3X<?$>+Q
MQ!<6]Q;)::E:HC.BR K,I&"Z _, &ZCG&Y?F.:Y74_C#KVIZC/#X)\.OJ%I;
M-M>X>VEF,@/W6V)@Q@D-C<22,<*0119A='LM%<)\./B/%XX@N+>XMDM-2M41
MG19 5F4C!= ?F #=1SC<OS'-<KXC^,FIMXF;2/!VFVNI+&Q59@DDYN"%!.Q4
MV\*0_.6! R,#J6871VEW\2M#L?&Z^%+F.]2]:6.$3>6IB+R*K(,AMW.Y1]WJ
M>>.:[&OEA/$/_"5_&'2];^R_9?M.J67[GS/,V[6C3[V!G.W/3O7T=XJUN7PW
MX9OM8AL'OFM5#F!&*DKN 8Y . H)8G'0'ZT- G<V:Y;QEX^TOP/]B_M*WO9O
MMGF>7]F1&QLVYSN8?WA^M?.?@'QBO@77)=3^PB]\RU:W\OSO*QED;.=I_N=,
M=Z[SXXW<M_I'@^\N+5[2:X@FEDMY,[H69824.0#D$XZ#ITIVU%S:'O-%>$W7
M[0-W_;6ZST2!M+3(,4LI$\G7#;AE4_ARNUNAYYR/3->\>:=H7@FV\320S/'>
M11M:VY&'D>1-ZJQ&0O&23SC!QDX!5F.Z.JHKPR3XS>,+&2+4M0\*QQZ+.V82
MT,T1=6!* 3-E2<8.0O(!P!V]ET;5K77=&M-5LGW6]U$)$R02N>JG!(# Y!&>
M""*+ G<O4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&V2VD7A"%&"75B<!!^O6G=7N*SM8YGXZPQ6WP_TV"")(H8M0B2..-0JHHBE
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MU#_KVM__ $*6M*LVW_Y&/4/^O:W_ /0I:TJN>_W?D3'8*S=!_P"0/%_OR?\
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MNE_\?FK_ /7Y_P"THZTJS=+_ ./S5_\ K\_]I1UI5<]_N_(F.P5FZ/\ \O\
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MVE_Q*_L/V+RO^7CS=^_?_LKC&SWZUV] ;C((8K:"."")(H8E"1QQJ%5% P
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M5!1FV_\ R,>H?]>UO_Z%+6E6;;_\C'J'_7M;_P#H4M:57/?[OR)CL%9N@_\
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M=:59NE_\?FK_ /7Y_P"THZTJN>_W?D3'8*S='_Y?_P#K\D_I6E6;H_\ R_\
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MICFAV!-GM->*77Q;\6'QGJ/AW3-'T^\G6\EM;-0CALK)C<_SX(V*V?N@?>R
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M=?\ VK2_L]?\S'_V[?\ M6F^HET&? &>*V@\3SSRI%#$MN\DDC!510)222>
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6_^/.W_ .ORV_\
M1J5I5FZW_P >=O\ ]?EM_P"C4K2JW\"^?Z$KXF%9J?\ (S3_ /7G'_Z&]:59
MJ?\ (S3_ /7G'_Z&]$=F#Z&E1114%&;;_P#(QZA_U[6__H4M:59MO_R,>H?]
M>UO_ .A2UI5<]_N_(F.P5FZ#_P @>+_?D_\ 0VK2K-T'_D#Q?[\G_H;4+X'\
MOU#[1I4445!1F^'_ /D7[#_KBM:59OA__D7[#_KBM:574^-DQ^%&;K/^KLO^
MOR+_ -"K2K-UG_5V7_7Y%_Z%6E0_A0+=A1114%&;HW^KO?\ K\E_]"K2K,T<
M@1WN3_R^2_\ H5:(D0G =3^-7/XF3'8HZ[_R+VI_]>DO_H!J]'_JD_W15'7?
M^1>U/_KTE_\ 0#5Z/_5)_NBA_ OZ[!]H=6;X@_Y%^_\ ^N+5I5F^(/\ D7[_
M /ZXM13^-!+X6:5>0^-;G[9\0ID!RME:I%CT9OF_DU>O5X4US_:&N:QJ&<K/
M>.$/^PIPOZ5U8&-YM]C'$/W;"M_Q\1_[K?TJ2HV_X^(_]UOZ5)7JG$,E<11/
M(>BJ6/X5V?PWLS:Z;IKL,27-K<3O^,J ?H!7 ZQ(8]+FV_><! /7)Q7L&FV8
MTZ^TNR _X]],,7Y&,5QXR5HJ/J=%!:W/./B9I7]G>+(M01<0ZC'\Q[>8O!_3
M;^M<G7L?Q&TM=6\(W!C*FXLR+F+GGY?O#_OG/Z5XU&XDC5QW&:Z,!5YZ5GT,
ML3#EG?N.HHHKN.8GT67RKBXM#TSYB?3O_2MG3[;[=XHMXB,I;6L]P_\ WP0/
MUQ7-/)]FNH+H=$;#_P"Z:[OP/;_:+SQ-J&,K#9_9T/KD$G_T$?G7%B'R19T4
MES-'J$=O'=Z.EM,NZ*6W".I[@K@BOGN>RETO4;S3)L^9:2M'D]QG@_B.:^A[
M1E6PM]Q _=+U/L*\I^*6FK:Z]9ZO%@QWB>3,1_?7H3]1@?\  :X,#4Y:KB^I
MTXF%X7['&4445[AYQ'<1^; R=\<?6O9?#6L_V[8>';QFW3!)8YO7>J@'\^OX
MUX]75_#.]:#Q1_9C-^ZDWSQ#_:VX;] /RKAQU/FAS=K_ )'3AYVE;N>S4445
MX)Z1FZ7_ ,?FK_\ 7Y_[2CK2K-TO_C\U?_K\_P#:4=:57/?[OR)CL%9NC_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J]W>0V4/F3-@=@.I^E6*YG5P\]^^[
M.U/E4>E73BI.S)D[(AOM:>\ 3R@D:NKKSSE2"#^8%0'5KLG)GD_!B*3[-[4?
M9O:NQ*"5K&#<F.36+Q#D3/\ B<_SJS9ZSMU-KJZ7.^)8B5'0 DYQ_P "-5/L
MWM1]F]J3C!@G([*.1)8UDC8,C#(([U6O=2MK$?O6RYZ(O)K-TF5[:UN01E47
M>H]ZQY8WFE:20EG8Y)-81I+F=]C5S=M"T=99=0GNHD"F:-(R&YP%+$?^A&G?
M\)!=9SN7Z;:H_9O:C[-[5OR0,N:1J1>)) ?WL2L/;@U<\/W$+:>MN)!YJ,Y*
M]\%B?ZUS_P!F]J='$\4BR1DJZG((J94XM612D[W9V;NL:%W8*JC))[5@W?B/
M#%+5 0/XV[_05+JLSW%A; <"0;F ]1VK&^S>U9TJ<;7D5.3V0V+4)X+>."*1
MTCC7:JJV,"GC5;L'(GD_%C2?9O:C[-[5O[IEJ22:O/.(5GPZQS)+TP3M.<5U
M%G>PWT/F0MG'WE/4?6N3^S>U7=)5X-0C*YPWRL/45G4A%QT+A)IZG3,RHI9B
M H&23VKF[[7Y7<I:#8@_C(Y/^%:^K!C8,J]R ?I7._9O:LZ,8[LJ;>R*AGE)
M))/)+'W)ZFD\Z2KGV;VH^S>U=/,C*S*K7,[6\L!=_*E0HZYX((P:Z/2M86ZV
MP3*$E ^4CHW_ ->L;[-[4Z.!DD5DX8$$?6HFHR5BHMIG4W%Q%:PF69PJC]:Y
MK4=;-[#);K"!!(-K;NI']*M:YOFNUC/W$7@>YK+^S>U12A%+F94Y.]D5]3U^
M[MM-NKDSR QQ,PPV.0.*\UTS=#I\*@GD;C^/-=?XW)MO#4B#AKB1(5_$Y_D#
M7,K&$15'0# KT<-%)-HY*S=[#Q-^\5F[ CCW_P#U59!##(.153;4L.02/;-=
M+1DB*7_2-8TNU49S<K(P]0O)KT26\N)Y/,E<LV,9]O2N'\,VQO/&.[&5M;8M
M_P "8X_D:] ^S>U<.(DN>QT4D^4I&1V!!&0>"#7EEQ:G3M4N[ ](I,I_NGD?
MH17L'V;VKR'7Y6D\2WUX#^Z6X-N?^ C']*O"R]_059>Z,HHHKTSC&R()(F0]
MQBNP^']S)#X>NH$?E[AO-'<_*!@^W_UZY&MGP9=_9?$;V;G$=ZGR_P"^O/\
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MV4)!LCG#^>T8ZY8-M5CS_"0,_P 6,FU%XY:/]GPHZ/+=%VT3<\:[ "I(/!'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %4+VR\U_-0<_P 0J_13
M3:=T)JYA_9CZ4?9O:MID5NJBF^0GI6GM">4Q_LWM2BU+' 7)K7\E/2GA0O0
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M='N;8.94RL@D\PA]K'Y6VK@[>#EAE@#7D/C76XOB/XUM_P#A'=$=+B95A4D
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MYR:TJ+A8Q/!G_(B^'_\ L&VW_HI:VZ**104444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 445S7CCQ/-X4T6&^@MXYVDN%A*N2  58YX_W:NG"522A
M'=DSFH1<I;(Z6BO&_P#A<^H_] FU_P"_C4?\+GU'_H$VO_?QJ[/[,Q/;\4<G
M]H8?O^![)15;3KIKW2[2[90K3PI(5'0%E!Q^M6:X6K.S.Q.ZN%%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSSXQ_
M\BA:?]?Z?^BY*]#KSSXQ_P#(H6G_ %_I_P"BY*ZL%_O$/4YL9_ EZ'B%%%%?
M6'S)]0Z!_P BYI?_ %Z1?^@"M&L[0/\ D7-+_P"O2+_T 5HU\94^-GUL/A04
M445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%(3A2?09H 6BO(_^$T\2Q@L]T2/5K=!C_P =I/\ A.?$+?*MTN3TQ"N?Y5T?
M5IF7MHGKM5;W4;/3HO-O+F.%>V]N3]!U/X5Y9_:OB_4.$DU%]W>&(K_Z"!4U
MKX'U[49?-N\0!C\SSR;F/X#)_/%/V"7Q2%[1OX4:VM_$3(:'1XR.WVB5?_05
M_P ?RK%TKPOJ_B2?[9=.\<+G+7$^26_W1U/\J[71_ ^EZ6RRS WDXZ-*/E'T
M7_'-=-0ZL8*U-?,%!RUF9FCZ#8:'!Y=I%\Y'SRMR[_4_TK3HHKG;;=V:I);!
M1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7GGQC_P"10M/^O]/_ $7)
M7H=>>?&/_D4+3_K_ $_]%R5U8+_>(>IS8S^!+T/$****^L/F3ZAT#_D7-+_Z
M](O_ $ 5HUG:!_R+FE_]>D7_ * *T:^,J?&SZV'PH****@H**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSSXQ_\BA:?]?Z
M?^BY*]#KSSXQ_P#(H6G_ %_I_P"BY*ZL%_O$/4YL9_ EZ'B%%%%?6'S)]0Z!
M_P BYI?_ %Z1?^@"M&L[0/\ D7-+_P"O2+_T 5HU\94^-GUL/A04445!0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GGQ
MC_Y%"T_Z_P!/_1<E>AUYY\8_^10M/^O]/_1<E=6"_P!XAZG-C/X$O0\0HHHK
MZP^9/J'0/^1<TO\ Z](O_0!6C6=H'_(N:7_UZ1?^@"M&OC*GQL^MA\*"BBBH
M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %9^N?\ (%NO]S^HK0K/US_D"W7^Y_45S8S_ ':I_A?Y
M&M#^+'U1P%%%%?F!]4%*OWU^M)2K]]?K36X'IU%%%?JY\@%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5YY\8_^10M/^O\ 3_T7)7H=>>?&/_D4+3_K_3_T7)75@O\ >(>I
MS8S^!+T/$****^L/F3ZAT#_D7-+_ .O2+_T 5HUG:!_R+FE_]>D7_H K1KXR
MI\;/K8?"@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "L_7/\ D"W7^Y_45H5GZY_R!;K_ '/Z
MBN;&?[M4_P +_(UH?Q8^J. HHHK\P/J@I5^^OUI*5?OK]::W ].HHHK]7/D
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O//C'_P BA:?]?Z?^BY*]#KSSXQ_\BA:?]?Z?
M^BY*ZL%_O$/4YL9_ EZ'B%%%%?6'S)]0Z!_R+FE_]>D7_H K1K.T#_D7-+_Z
M](O_ $ 5HU\94^-GUL/A04445!04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J][90W]LT$ZY4]#
MW4^HJQ14SA&<7&2NF.,G%W1YYJ.G3:;<F*494\HXZ,*IUZ/>V4-_;-!.N5/0
M]U/J*X34=.FTVY,4HRIY1QT85\'FV4RPDO:4]8/\/)GT&#QBK+EE\7YE.M;1
MM&?4I/,DRMLIY;^]["C1M&?4I/,DRMLIY;^]["NVCC2&-8XU"HHP%':NC)\G
M>(:K5E[G1=_^!^9GC<;[/W(;_D$<:0QK'&H5%& H[4^BBOM4DE9'A-W"BBBF
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %-DC26-HY$5XW!5E89!!Z@BG44 >'>/?A[+HLYU#28
MGET^5L&)06:%B>![J3T/X?7K?A]\/ET9(]6U:,-J+#,41Y$ _P#BOY5Z)17=
M/,*TZ7LG]_<XX8&E&K[1?<%%%%<)V!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!=V<
M%] 8;A-RYR/4'VJ>BIG",XN,E=,:;B[H9'&D,:QQJ%11@*.U/HHII)*R$W<*
M***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !17/7?BVRT_Q='H-[B$SP+)#,3\I8LPVGTZ#%=#5RA*-KK<F
M,XRO;H%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M80)&0,* .K'\ZS;#PSXE\/?#_P 8-XEUU]3FN-/E$*?:))EB58GR0SXY8MR
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MR:G::U9M9Q8\Z2201^5EBJ[P^"F2#C<!GMFC0/&/A[Q1O&C:I#<R)DM%ADD
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M9WMIJ-JEU8W4-U;R9V302!T;!P<$<'D$?A0!/17(_$CQ)%X<\%:C(MRD=]/
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M%%% !1110 4444 %%%% #)I5A@DE8$JBECCK@"O/_P#A<?A[_GSU3_OU'_\
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M#E<CD9ZU/7CW@/PSH5A\3M0EL?&%[J&H6OVCS[1[=T9OGVMYLIXEPQ!. ,L
MW;%=AXK^)OASPA=?8[V6>YOAM+VUH@=XU()!8DA1T'&<_,#C!S18+G8T5R7A
MCXD^&O%D\5I8W;Q7\BLXM+F,H^%///*DX^; 8G&3V.)]3^(7A71]7GTK4-62
MWO8%W21O%)@#9O\ O;<$E>@!R20!SQ2'='345P&A?&/PEK=T;=[B?3'_ (#J
M"K&C\$GYPQ48Q_$1G( R:+;XR^#;K63IXO)XHSM"7LT)2!R<<9/S+UY+*H&T
M\],NS%='?T5A^)_%VC>$+!;K5[GR_,W"&%%W23,!G"C\ADX )&2,U@>'/BYX
M7\2:BFGQO=65S*P2%+R-5$K'/"LK, >,8)&20!DTK!='=T5A^(O%^A>%!;G6
M[[[+]IW>5^Y=]VW&[[JG&-PZ^M9WASXC:#XK\07&D:1]JF:&#S_M+1;(G4%0
M0,G=G+@<J.A]L@[F_IVM:5J_F?V9J=G>^5CS/LTZR;,YQG:3C.#^1J]7AWP!
MFBMH/$\\\J10Q+;O))(P544"4DDG@ #O7J7A_P :Z!XIGFAT6]>Z:%0\A%M*
MBH"<#+,H&3S@9R<'T--H2=S?HKSG5OC9X2TN^:UB-[J&S(::SB4QA@2" 69=
MW3.1D$$8)KK;#Q5HFI^'Y]=LK])M-MU=II51LQA!ELKC<"!SC&2"".HI6"Z-
MFBO/=0^-7@NS@$EO=W5^Y8*8K:V96 P3G]YM&.W!SR.*T?%?Q-\.>$+K['>R
MSW-Z-I>VM$#O&""06)(4=!QG/S XP<T[,+H[&BL?PUXGTOQ;I(U'2I7>$-Y<
MBR1E&C?:&*G/!(##D$CT)K8I#"N"O/BUH-E>SVLEIJ1D@D:-BL:8)4X./GZ<
M5WM?+VO_ /(QZI_U]R_^AFO1R_#4Z\I*?0X,=B)T8IPZGKW_  N/P]_SYZI_
MWZC_ /BZ/^%Q^'O^?/5/^_4?_P 77B%%>I_9>'\_O/._M&OY'M__  N/P]_S
MYZI_WZC_ /BZ/^%Q^'O^?/5/^_4?_P 77B%%']EX?S^\/[1K^1[?_P +C\/?
M\^>J?]^H_P#XNC_A<?A[_GSU3_OU'_\ %UXA11_9>'\_O#^T:_D>W_\ "X_#
MW_/GJG_?J/\ ^+H_X7'X>_Y\]4_[]1__ !=>(44?V7A_/[P_M&OY'M__  N/
MP]_SYZI_WZC_ /BZ/^%Q^'O^?/5/^_4?_P 77B%%']EX?S^\/[1K^1[?_P +
MC\/?\^>J?]^H_P#XNC_A<?A[_GSU3_OU'_\ %UXA11_9>'\_O#^T:_D>W_\
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MXL!F0J&^8 DJ,Y W'DY 9T$DTL_[+X>:5Y&"J@9V)(5;P*HY[   #L !3/\
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M! QC P3G/%>B_$/P/X@U/P-X32RL?.N-(L?*N[='!D4^5'G:.CX,9&%)))&
M>W/ZE8_$WQSX;L-,E\.+;V%@P54\E+1G94"@E)&' !.-@5>2,<  0,]O\)32
MW/@S0IYY7EFET^W>221BS.QC4DDGDDGO6S65X8LY].\)Z-974?EW%O8P0RID
M':ZH 1D<'D=JU:DL**** "BBB@ HHHH KW__ "#;K_KB_P#(U\JU]8D!E*L
M01@@]ZS_ .P-&_Z!-A_X#)_A7H8+&K#*2:O<XL9A'B&K.UCY>HKZA_L#1O\
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ML+!(K^_\.%[B<NSLQ:#<<;B=H).2%P#@>@Q)XZ^&4^M^"=&L;"Z\S4=#M1#
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M'5B>=I&T8R3@9VJ?#7XD^,X[:\\0:G8":-&1(+B7:8AGGB)"F3@'())&,],
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M9EVE$7^)1SE3VKC?%'AWXJ+-JUKIE\NH:1JD]P3;B:-FBA<X"$S %1M. $)
MP>G4E]0MH=7\+_$F@^(-*OCHVDII,R3B2[LHO]6K,NU64@!<%8^@ Y!R.<MW
M=<)\,O $O@;3KPWEVD]]>LOFB'/E(J;MH4D D_,22<=ACC)[NDREL%?+VO\
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M[Z&&WU2UP[)$V$EC).&522PQP&ZCE3GYL L%SOJ***0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(_P"%>G_A:7_":_VI
M_P!N?V?_ *8>5]_=^/W?;WKMZ** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X#QS\,_\ A.-=LKVX
MUN:VL[:(1FT2+=GYB696+85F&!G:?NC.<8KNX((K:WCM[>)(H8E"1QQJ%5%
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M)LA[L[^BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gou0qrw2itv5000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *\ F4# 2(  A$! Q$!_\0
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M+J%Y:3SS168F\QMV37?A(M1<T>5F$XN4:;VZG1^!KLVM_<V4IQLX45>^(_\
MR!X/^NH_F*XNVO[F#Q(MQ+%Y(FD&178?$"99M!MI%.091_2KG"U>,NYE3J*6
M%G#L:G@G_D"_C6QJTYMM.EE7JHKG_!M];Q:-M>0 YK4UFYANM)FCB<,Q' %<
MM2+]J[]SOI27L%9ZV.*\,:<FN:M?R7+,0IR.?I4,_P#Q(_%DRPLWEY  )]ZT
M/ ,J0:CJ"2'!SC^59VO@W7B^9(^<,/YUVW;JRB]K'FV2H1FOBN2:@6UCQ7'
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M*:<8\NXG.LU.:ELS1UO5PWAYKI0K$H"01Q63)J=])X;+6T2;6C^? QBH+_\
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M>?[X_K6GX$MXFL[@LBG\*3A3A&3:O9E*I5J3C%2M=#M#\77=Y--;W:HLR#@
M=ZY;Q#>:@WB'+C#;A@ ^]7K10GC6Z51@;QQ2^* H\4#C^)?YUI",8U-%NC&I
M.<Z/O/9EOQ)/=S^&=UVH5P% QZ8J2/6[S1]&BDMT5EV DFK'C;'_  CZ[1_
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MHQ25HW/*CB)2;YJEM3J].U4S6+7-QP%&37,ZCXWD^U-#8_,5.#Q5SQ'J"_\
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M.B^E% &/X=_X^&_W:Z2N;\._\?#?[M=)0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (1D8/>L>\\,:=
M>R;Y4.[V-;-%5&3CJF3*$9JTE<RK'P]8:>VZ%#GWK5HHI2DY.[",(Q5HH***
M*104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6!XBZQ_2M^L#Q%
MUC^E &GI?_(.B^E%&E_\@Z+Z44 8_AW_ (^&_P!VNDKF_#O_ !\-_NUTE !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:XLC;28S@_\ ZZZ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \1=8_I6_6!XBZQ_2
M@#3TO_D'1?2BC2_^0=%]** ,?P[_ ,?#?[M=)7-^'?\ CX;_ ':Z2@ HHHH
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MZ8JJNEVJ3>:(QNSGI0!E>$-.:RT>%Y!B1T^;-=!)_JV^E*  , 8%))_JV^E
M'%V7_(\?\ KMJXFR_P"1X_X!7;4 %%%% !1110 4444 %%%% !1110 4444
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MBB@ HHHH **** "FR?ZMOI3J;)_JV^E '%V7_(\?\ KMJXFR_P"1X_X!7;4
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M #_)2I\2/#SN%6^3)HY)=@]I#N=A15>RO(;^U2X@;=&_0U8J"PHHHH ****
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M#5^^I:#;7;YW2+DYK7H **** "BBB@ HHHH *;)_JV^E.ILG^K;Z4 <79?\
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MVF[M@4 =+8W,=Y9I/#@HPXQ5FH+0P&V0VVWROX=O2IZ "BBB@ HHHH ****
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M2!U$9Q_*@""R_P"1X_X!7;5YUX=U./5O%HN(HW1=N,.,&O1: "BBB@ HHHH
MRO$?_( N_P#<KY;UC_D)S?6OJ3Q'_P @"[_W*^6]8_Y"<WUKKPW4X<7NBC11
M172<04444 %%%% !1110 4444 %3V?\ Q]Q_6H*GL_\ C[C^M UN?4'@K_D5
M;3_=KH*Y_P %?\BK:?[M=!7FR^)GL0^%!1114E!1110 4444 %%%% !1110
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M% !1110 4444 %%%% !1110 4444 %%%% !6!XBZQ_2M^L#Q%UC^E &GI?\
MR#HOI11I?_(.B^E% &/X=_X^&_W:Z2N;\._\?#?[M=)0 4444 %5=0NA9V<D
MI[*<5:JEJ=H+RRDB[X.* /-;+3M<\87$UU'J<EI#'(4\L]^:?=:)KOA:5+U]
M6DN($^9U[8_*H],\2W/@Z:>SO;.XN \A96C0X S4M_XNG\6$:=:6-S!'+\KF
M1#B@#T+0]1&JZ3#> 8$@SBM&LOP]IQTK1;>S;&8QCBM2@ HHHH **** "BBB
M@ ILG^K;Z4ZFR?ZMOI0!Q=E_R/'_  "NVKB;+_D>/^ 5VU !1110 4444 97
MB/\ Y %W_N5\MZQ_R$YOK7U)XC_Y %W_ +E?+>L?\A.;ZUUX;J<.+W11HHHK
MI.(**** "BBB@ HHHH **** "I[/_C[C^M05/9_\?<?UH&MSZ@\%?\BK:?[M
M=!7/^"O^15M/]VN@KS9?$SV(?"@HHHJ2@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P
M/$76/Z5OU@>(NL?TH T]+_Y!T7THHTO_ )!T7THH Q_#O_'PW^[725S?AW_C
MX;_=KI* "BBB@ HHKC_$7C-=+O38VNU[L#)0^E '4S6=O.,21(?<J*2&RMX/
MN1(#Z[17GLWQ)EBM6A*1_P!HM_JXO45'9^./$<-S$=6L(H+60Y#CT_*@#TZB
MJ]E>17UHEQ"VY'&0:L4 %%%% !1110 4444 %-D_U;?2G4V3_5M]* .+LO\
MD>/^ 5VU<39?\CQ_P"NVH **** "BBB@#*\1_P#( N_]ROEO6/\ D)S?6OJ3
MQ'_R +O_ '*^6]8_Y"<WUKKPW4X<7NBC11172<04444 %%%% !1110 4444
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K \1=8_I6_6!XBZQ_2@#3TO_ )!T7THHTO\ Y!T7THH
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M<WUKKPW4X<7NBC11172<04444 %%%% !1110 4444 %3V?\ Q]Q_6H*GL_\
MC[C^M UN?4'@K_D5;3_=KH*Y_P %?\BK:?[M=!7FR^)GL0^%!1114E!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5@>(NL?TK?K \1=8_I0!IZ7_ ,@Z+Z44:7_R#HOI
M10!C^'?^/AO]VNDKF_#O_'PW^[724 %%%% #9$$D;(>C#!KS+7-+U;P]X@;5
MM+B#Q$8.X\5Z;(Q6-F R0.!7 ZYXLU:WNVMTT=9XAW- %9/B='$FRYPLPZ@+
M6?/?ZUXRO88HH5^PYQ(PX.*C;7[MVW-X6@)]<5>L/%NJPRJD6@)$I/.V@#T'
M2-/32]-BM(_NQC J]573KB2ZL8YI8]CL.5]*M4 %%%% !1110 4444 %-D_U
M;?2G4V3_ %;?2@#B[+_D>/\ @%=M7$V7_(\?\ KMJ "BBB@ HHHH RO$?_(
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M?99_[E%F'U:M_*R.BI#;3@9V5&BN\AC498=119C^K5OY6%%2?99_[E'V6?\
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M/[ TK_GQB_*K\4T<R!XV#*1U%/H S?[ TK_GQB_*C^P-*_Y\8ORK2HH S?[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444A( R: .,\=ZS<6D%O;6C;7EDV/GT-5(?A_I
M(LA=7_F&3&\D/^-0_$*&1EM;JU&\I,&D![ $5T&G7]CXJT9$2=@!@$KQR* .
M2'C>+2[U4MDE&GP_+)N4]J]%TS4H-4LX[B!P5=<XSR*XWQG8:?8^%KJRA"F>
M094[1FM#P'X?&DZ3'-YLK-.@)#L2!]* .OHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K \1=8_I6_6!XBZQ_2@#3TO_D'1?2BC2_^0=%]** ,?P[_ ,?#
M?[M=)7-^'?\ CX;_ ':Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(Z$C- '(:KX9MI(EO-/B,=P3G)J#1O#VI7.J+>ZG(CQ@8  P:[G:,8P,?2@
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M4 %%%% !1110 4444 %%%% !1110 4444 %8'B+K']*WZP/$76/Z4 :>E_\
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M&!0!5\,Z=J&HW3ZE?R$QN=\2,.5KNJ9'&L2!$  '2GT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>(NL?TK?K \1=8_
MI0!IZ7_R#HOI11I?_(.B^E% &/X=_P"/AO\ =KI*YOP[_P ?#?[M=)0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&<4 %<3X
MFUJ\DNTL-/4,Q;;)S@@4_5?&D\-VT&F6@NRAQ)@_=K"UA-3/V75HK1@[OND0
M?PB@ U&TUO046>*+SHV.&\QB0 >M1+97&]=:T(&1DX>/.%W=^*VKGQ?!>Z7Y
M)B1KAAM,?I[UH>!]*ET_2)H[E3^\E+@-Z$D_UH WK)6N;*&2[A3SBH+ C.#5
MP *, 8'H*  !@=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$90RE3R#UKRO7-+31?&3:K*@,,[*B@C(SG_Z]>JU6N["VO0HGB5]IW#<.AH
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MBX3E6SWJMIG@Q4G674 )&0Y3!Z&@#6MO#>E!EN!9J)" <ULJ JA0. ,"@#
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GT]!76_98/^>2?E1]E@_YY)^5 $.E_P#(.B^E%6U4*,*, =J* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gou0qrw2itv5000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %^!ZL# 2(  A$! Q$!_\0
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MF,]S9'Y9CR3SC!/?ZT["N>@45ROCOQ/+X;T=#9JKWUT_E0 \X/\ >QWQ6 /
M?B66Q^US>++\:F5WA!*VQ6_N]?P_I18+GI-%<7\/?$UWK=E<V>IG-_9/L=L8
M+CU/O5_Q-K.LVL\.G:'IIN+RX4GSY/\ 5Q#U/O\ YYHL%]#I:*\Q^']]K+^-
M-:L=6U*:[> 88&0E P;!*KT'X"O2Y)%BB>1ONHI8_04F"=Q]%>7:8VN_$._O
M+I=8N=,TF"0QQQVK%6?ZD>WKGK2I>:UX#\5V.GW^IS:CI-^0B/.2S(>G4],'
M'MS3L%SU"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "KVE_ZV3_ ':HU>TO_6R?
M[M %)OO'ZTE*WWC]:2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y3Q-I?B75]2B
MMM,U0:;IHBS++'GS&?)X&.<8QWH ZNBO)->T[Q)X"BAU:V\075]:B0+-%<,6
M'/L21S7J6GWBW^FVUXHP)HEDQZ9%.PDRS17F,E[K7CWQ)?66FZE+IND6#&-Y
M8&(:5LXZC'7!_2J^H?V[\.]4L[AM7N-2TJXDV2)<,6*_GT_"BP7/5J*IWLMS
M+H\TNF;&N7A+6^_[I8CY<UPW_""^)[Z+[1?^+[Q+PC(2!F$:'T&"/T H!L]%
MHKS_ .'^OZK-J6H^']:F\^ZL3\LIY)&<$$]_K6MX[\3S>&]'3[&JO?73^5 #
MSM/]['>BP7TN=517FP\!^)9;'[7+XLOQJ97>$$K;%;^[U_#^E:WP]\37>N6-
MQ9ZD<W]D^R1L8+CU/O18+G9T444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5?OO\
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MLG^[5&KVE_ZV3_=H I-]X_6DI6^\?K24 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M17&>.?&B^'XDT^R*/JMR,(&.!$#QN)Z4 W8ROB)?'7;VS\)Z?^\GEE#S[>B
M>M=W% NFZ,L$?(MX-H]\"N0\'VFA:! ]W=ZU8W&JW/S3S-<*<$]AS7;1S07E
MMYD$J2Q." Z,"#^(IL2//O@RH/AF^E/+M>L"?7Y$_P 35SXMH&\%,_=+A,?C
M6-\-K^'PYJFK^&M1F6"5+@O$9#M$G;C/J I_&K/Q*U.#5UL/#EA,MQ=7$ZEU
MB.[:!ZXI]1?9.ZT!S)X>TYFZFVC_ /014FK:I;:-IDU]=R!(HESR>I[ >YI
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M_K0MQ/8]$ P !VKS/PO^X^,'B&)!\IC.?_'#7:6OBC1[C1DU+^T(!!LW,6D
M*\="/7VKD/AU$^J>(]=\2E6$-P_E1$C[PR#G]!^= ,](KS?XAWIUZ_L_">G_
M +R>24/<%>B >M:OCGQHN@1IIUB4?5;D80,<"('C<2>*K^#[30?#]N]U=ZU8
MW&JW/S3S-<*<$]ASTH7<;UT.TLK5;*PM[5/NPQJ@_ 8J'6/^0'J'_7M)_P"@
MFK,%Q#=0K-;RI+&WW71@0?Q%9NN:A91:5J$,EW LOV>0;&D .2IQQ2&<K\(O
M^15F_P"OAJ] KS?X47UI;^&98YKJ&-S<-A7< FO2.HR*;W$M@HHHI#"BBB@
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M44 %%%% !1110 4444 %%%% !1110 5?OO\ CUM_I5"K]]_QZV_TH H4444
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M?B+_ )]8?^^U_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\
MGUA_[[7_ !KL** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B
M+_GUA_[[7_&C['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y
M]8?^^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_
M )]8?^^U_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_
M[[7_ !KL** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GU
MA_[[7_&C['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^
M^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8
M?^^U_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_
M !KL** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[
M7_&C['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^^U_Q
MKL** ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8?^^U
M_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_ !KL
M** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C
M['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^^U_QKL**
M ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8?^^U_P :
M/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_ !KL** .
M/^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C['XB
M_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^^U_QKL** ./^
MQ^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8?^^U_P :/L?B
M+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_ !KL** ./^Q^
M(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C['XB_P"?
M6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &I8(O$MNQ9+2#)&#EE_^*KJZ* ./
M-GXB)S]EA_[[7_&C['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['
MXB_Y]8?^^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L
M?B+_ )]8?^^U_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\
MGUA_[[7_ !KL** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B
M+_GUA_[[7_&C['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y
M]8?^^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_
M )]8?^^U_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_
M[[7_ !KL** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GU
MA_[[7_&C['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^
M^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8
M?^^U_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_
M !KL** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[
M7_&C['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^^U_Q
MKL** ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8?^^U
M_P :/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_ !KL
M** ./^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C
M['XB_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^^U_QKL**
M ./^Q^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8?^^U_P :
M/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_ !KL** .
M/^Q^(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C['XB
M_P"?6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^^U_QKL** ./^
MQ^(O^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8?^^U_P :/L?B
M+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O\ GUA_[[7_ !KL** ./^Q^
M(O\ GUA_[[7_ !H^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C['XB_P"?
M6'_OM?\ &NPHH X_['XB_P"?6'_OM?\ &C['XB_Y]8?^^U_QKL** ./^Q^(O
M^?6'_OM?\:/L?B+_ )]8?^^U_P :["B@#C_L?B+_ )]8?^^U_P :/L?B+_GU
MA_[[7_&NPHH X_['XB_Y]8?^^U_QJ66+Q+*B(UI!A.F&7_XJNKHH X_['XB_
MY]8?^^U_QH^Q^(O^?6'_ +[7_&NPHH X_P"Q^(O^?6'_ +[7_&C['XB_Y]8?
M^^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_GUA_P"^U_QKL** ./\ L?B+_GUA
M_P"^U_QH^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C['XB_Y]8?\ OM?\
M:["B@#C_ +'XB_Y]8?\ OM?\:/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_
MQH^Q^(O^?6'_ +[7_&NPHH X_P"Q^(O^?6'_ +[7_&C['XB_Y]8?^^U_QKL*
M* ./^Q^(O^?6'_OM?\:/L?B+_GUA_P"^U_QKL** ./\ L?B+_GUA_P"^U_QH
M^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[[7_&C['XB_Y]8?\ OM?\:["B@#C_
M +'XB_Y]8?\ OM?\:/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O^
M?6'_ +[7_&NPHH X_P"Q^(O^?6'_ +[7_&C['XB_Y]8?^^U_QKL** ./^Q^(
MO^?6'_OM?\:/L?B+_GUA_P"^U_QKL** ./\ L?B+_GUA_P"^U_QH^Q^(O^?6
M'_OM?\:["B@#C_L?B+_GUA_[[7_&C['XB_Y]8?\ OM?\:["B@#C_ +'XB_Y]
M8?\ OM?\:/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O^?6'_ +[7
M_&NPHH X_P"Q^(O^?6'_ +[7_&C['XB_Y]8?^^U_QKL** ./^Q^(O^?6'_OM
M?\:/L?B+_GUA_P"^U_QKL** ./\ L?B+_GUA_P"^U_QH^Q^(O^?6'_OM?\:[
M"B@#C_L?B+_GUA_[[7_&C['XB_Y]8?\ OM?\:["B@#C_ +'XB_Y]8?\ OM?\
M:/L?B+_GUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O^?6'_ +[7_&NPHH X
M_P"Q^(O^?6'_ +[7_&C['XB_Y]8?^^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+
M_GUA_P"^U_QKL** ./\ L?B+_GUA_P"^U_QH^Q^(O^?6'_OM?\:["B@#C_L?
MB+_GUA_[[7_&C['XB_Y]8?\ OM?\:["B@#C_ +'XB_Y]8?\ OM?\:/L?B+_G
MUA_[[7_&NPHH X_['XB_Y]8?^^U_QH^Q^(O^?6'_ +[7_&NPHH X_P"Q^(O^
M?6'_ +[7_&C['XB_Y]8?^^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_GUA_P"^
MU_QKL** ./\ L?B+_GUA_P"^U_QH^Q^(O^?6'_OM?\:["B@#C_L?B+_GUA_[
M[7_&C['XB_Y]8?\ OM?\:["B@#C_ +'XB_Y]8?\ OM?\:/L?B+_GUA_[[7_&
MNPHH X_['XB_Y]8?^^U_QH^Q^(O^?6'_ +[7_&NPHH X_P"Q^(O^?6'_ +[7
M_&C['XB_Y]8?^^U_QKL** ./^Q^(O^?6'_OM?\:/L?B+_GUA_P"^U_QKL**
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MU+_H%6G_ 'VU'_"Y]2_Z!5I_WVU>944?4,-_*'UW$?S'IO\ PN?4O^@5:?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B3JS:5X0N!&V);@
MB%?7GK77UY1\9[D^7IEKVRTG]*ZL%34Z\4SFQ<W"C)H\DKLOAMX>77/$JRS#
M-M9@2N/4_P (_,9_"N-KV[X/V*0^&KB\Q^\N)R"?]E0 !^>:^@Q]5TJ#:W>A
MX>"I*I62>VYZ)T&!45Q<P6D7FW$T<,><;I&"C]:EKR7X^D_\(MIHR<&]&1_P
M!J^61](W9'IT.K:=<2".&_MI'/14E4G^=5M>\1:7X:L!?:M<&"W+! P1GY/L
MH)KQ>;X4Z6WPUM_$5K>7,5_]B2Z8,P*$E02.F1[<U@W/B"_UKX1207\KSFSO
MDCCE<Y)4C.">^*=A<Q](Z;J-KJVG07]E)YEM.NZ-]I&1]#S5JO&O#_Q:\/\
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M^$]%@N;>Y6T9KF"3S$GDF=Y"V,99B26X]2: L;5%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF801VH8JN< Y8CGO5E[/0_$7A+4-3L]+&EW-C@X20ND@].>]0Z\%._+MI?\
MK4I49.._G;^M#AO+D$8D*-L)P&QQGZTVNV\,)_;7@_7-&?#26Z?;+<'JI7[V
M/KP*XFM85.:4HOH9SARI2[A1116AF%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5Z9\+/#>IOJ*ZSYLEM9)QC_GM[?2J'@'P%+KTRZA?HT>G(<@
M'@RGT'M[U[E##%;PI#"BQQH-JJHP *\C,<:HIT8:OJ>I@<&Y-59[=!]%%%>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]W?IBN(KII:UIOT7]?><]32E!>K_ *^X****Z# **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8Q)Y@BP,;O6JE%%))+8;;>X4444Q!1110 4444 %%%% !1110 4444 %%%%
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M'_"$^&?^@)9?]^Q6D;JY\QE^R-M$>X'/5O2A;JY+PJ;1@'0LQS]T^E'MJO\
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M7_?L5HO=72F<+9LWEH&3G[Y]*4W5SYA7[(VWR=^<_P 7]VCVU7^9_>'L:?\
M*ON,W_A"?#/_ $!++_OV*/\ A"?#/_0$LO\ OV*T4NKEC#NLV7>A9^?N'TI(
M[NZ;R-UDR[V(?G[@]:/;5?YG]X>QI_RK[C/_ .$)\,_] 2R_[]BC_A"?#/\
MT!++_OV*T/MEWY:M]B;<9MA&[HO]ZAKNZ"S$63$I)M09^^O]ZCVU7^9_>'L:
M?\J^XS_^$)\,_P#0$LO^_8H_X0GPS_T!++_OV*T9+NZ4S[;-FV %.?OGTI3=
M7(=P+1B!#Y@.>K?W:/;5?YG]X>QI_P J^XS?^$)\,_\ 0$LO^_8H_P"$)\,_
M] 2R_P"_8K12ZN6:(&S8!XM['/W6_NT)=W3>1NLV7S"=_/W*/;5?YG]X>QI_
MRK[C._X0GPS_ - 2R_[]BC_A"?#/_0$LO^_8K06[NBD9-DP+3>6PW?=7^]0U
MY=A9"+)B5EV*-WWE_O4>VJ_S/[P]C3_E7W&?_P (3X9_Z EE_P!^Q1_PA/AG
M_H"67_?L5HR7=TOG[;-FV8V<_?H-U<AI0+-B%AWJ<_>;^[1[:K_,_O#V-/\
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M++?8FW>?Y>-W\']^@"]15%[NZ43[;)FV.%3G[X]:5[JY4S;;-FV(&3G[Y]*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^?FW_[\+1_9-?NOZ^0?VG1\SWVBO O^%J^*O^?FW_[\+1_PM7Q5_P _-O\
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M%7_/S;_]^%H_LFOW7]?(/[3H^9[[17@7_"U?%7_/S;_]^%H_X6KXJ_Y^;?\
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M^%H_X6KXJ_Y^;?\ [\+1_9-?NOZ^0?VG1\SWVBO O^%J^*O^?FW_ ._"T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 *"000<$="*]<^'OQ"$OE:-K$N'^[!<,>OHK>_
MO7D5%88C#PKPY9&U"O*C+FB?65%>5?#SXA^:(M&UF7YQ\MO<N?O>BL?7T->J
MU\M7H3H3Y9GT=&M&M'FB%%%%8FP4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[TEN4]A?A!_R3>T_WW_G7DG@CQ:_A7Q%K;V^G37]Y=.8X((^Y#,23CFO6OA
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBNG\'>#KOQ3?X ,5E&?WTV.GL/4U%2I&G
M%RD[)%0A*<N6.X>#O!UWXIO\ -'91G]]-C]![U] :9IEII%A'9V<2QPQC  [
M^YHTW3;32+"*RLH1%!&, #O[GU-6Z^8QF,EB)=HGT6%PL:$?,****XSK"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_D_'_@!_93_G_#_@GRI17U7]BM?^?:'_ +]BC[%:_P#/M#_W[%']L+^3\?\
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M0_\ ?L4?VPOY/Q_X ?V4_P"?\/\ @GRI17U7]BM?^?:'_OV*/L5K_P ^T/\
MW[%']L+^3\?^ ']E/^?\/^"?*E%?5?V*U_Y]H?\ OV*/L5K_ ,^T/_?L4?VP
MOY/Q_P" ']E/^?\ #_@GRI17U7]BM?\ GVA_[]BC[%:_\^T/_?L4?VPOY/Q_
MX ?V4_Y_P_X)\J45]5_8K7_GVA_[]BC[%:_\^T/_ '[%']L+^3\?^ ']E/\
MG_#_ ()\J45]5_8K7_GVA_[]BC[%:_\ /M#_ -^Q1_;"_D_'_@!_93_G_#_@
MGRI17U7]BM?^?:'_ +]BC[%:_P#/M#_W[%']L+^3\?\ @!_93_G_  _X)\J4
M5]5_8K7_ )]H?^_8H^Q6O_/M#_W[%']L+^3\?^ ']E/^?\/^"?*E%?5?V*U_
MY]H?^_8H^Q6O_/M#_P!^Q1_;"_D_'_@!_93_ )_P_P""?*E%?5?V*U_Y]H?^
M_8H^Q6O_ #[0_P#?L4?VPOY/Q_X ?V4_Y_P_X)\J45]5_8K7_GVA_P"_8H^Q
M6O\ S[0_]^Q1_;"_D_'_ ( ?V4_Y_P /^"?*E%?5?V*U_P"?:'_OV*/L5K_S
M[0_]^Q1_;"_D_'_@!_93_G_#_@GRI17U7]BM?^?:'_OV*/L5K_S[0_\ ?L4?
MVPOY/Q_X ?V4_P"?\/\ @GRI17U7]BM?^?:'_OV*/L5K_P ^T/\ W[%']L+^
M3\?^ ']E/^?\/^"?*E%?5?V*U_Y]H?\ OV*/L5K_ ,^T/_?L4?VPOY/Q_P"
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M/^?\/^"?*E%?5?V*U_Y]H?\ OV*/L5K_ ,^T/_?L4?VPOY/Q_P" ']E/^?\
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M7V^OM5NB@"HM^&:(>1,/,C\S)3I['WI$OPWD_P"CSCS21RGW?KZ5<HH IKJ
M9(V^SSC?-Y6"G3W/M[TC:B%60_9YSLE\O 3K[CVJ[10!4>_">=_H\Y\K'1/O
M?3UH-^ T@\B;Y(O-SLZ^P]ZMT4 5!? M&OD3?/#YN=O3V/O[4)?A_)_<3#S0
M3RGW?K5NB@"DNHAA&?L\X\R3R^4Z>Y]J#J ".WV><[9O)P$Z_P"U]/>KM% %
M-M0"^=_H\Y\H@<)][Z4KWX1I1Y$Q\N/?PG7V'O5NB@"I]N&]5\B;F'SL[>G^
MS]?:D2_#F$?9YQYJEN4^[]:N44 4UU ,(3]GG'F/LY3[ON?:D_M$;-WV>?\
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gou0qrw2itv5000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'T!X\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#VO5OO1?0U
MFUI:M]Z+Z&LV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *M:>H:[ 8 @@Y!^E5:MZ;_P ?B_0_RH \(\0@#Q+J@ P!=RX
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M =_KL:#X6Z,X10Q?DXY-<!7H6O?\DJT7_?KSVHCL7/<****L@**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"1PTG_ *^4_G6)6WX/_P"1PTG_ *^4_G2>PX[H]LO_ /C]D_#^55JLW_\
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M?[7BDWV?DF;<!SM R>/7CI6-\0O^1-NO^ND7_HQ:Q')\._V[X>?(L[JSFN[
MGH,J=\8^AY'L:+!<[:#5+6YT==4C9C:M#YP)7G;C/3Z5CVOCC2[PQ>1!J#+*
M0%?[*VTY]ZBT?_DF-O\ ]@S_ -DJIX.O]<_L72X#HJ_8_+4?:/M*?=]=N<T!
M<Z+6=>LM"B@DO/-(GD\N-8HRY+?05#I/B?3=9NI+6W:6.XC&XQ3QE&(]0#U%
M9'CJ=[:XT":."2X9-04B*/&YN#P,U7TJY?Q#X[%]+:R:>VFV[)]GGP)9-_<@
M?PBBP7U.XHHHI#"BBB@ HHHH **** "BBB@ K1TG_62_05G5HZ3_ *R7Z"@!
M=6^]%]#6;6EJWWHOH:S: ,KQ'IDVL:%<V,#HDDH 4R$@#GV!JZ(IHM.$4>PS
M+$%7<2%W 8ZXZ58HH YS1?".GV>EQ1:C8V-W>DL\\[P*^YV))Y(SCFIM T.;
M0[G4XT,(T^XG\ZVC3(,>1\PQC &>F*W:* L<UIGAEH/",VBWS12&7S,E"2/F
M)(ZBK-IH<L_A5=&UEXYF\ORF>)CR.QY YK<HH"QR$>E^,+*S_L^VOM*NK95V
M1S7*R+*%Z<A>#@?2MOP]I!T+0+73#,)C"I!D"[<Y)/3\:U**!6.*T72?&&AZ
M9'I]O_8DD4;,59Y9<G))[)[UV6':#:^W>5P<=,T^B@9D>&M*GT;1UL[AXWD$
MCMF,DC!.>X%:]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5;TW_C\7Z'^55*MZ;_
M ,?B_0_RH \(\1?\C-JO_7Y+_P"AFLVM+Q%_R,VJ_P#7Y+_Z&:S:ZUL<#W"B
MBBF(**** "BBB@#8\,ZM!HNMQWMPDCQJCJ1& 3RI ZD>M2^']:M].CU&TODE
MDLKZ HRQ@$JXY5L$@<&L*BE8:;1T/AW5M,L;#5++4TNS#>JBAK95+#:2?XB*
MIZI_8.R/^R?[0+[OW@NE0#'MM)K*HHMK<+Z6.IM=0\)02PWAL=36YBPWD+(A
MB+#_ &C\V*SX]=\WQ='K=VAQ]I69TCY. 1P,^PK&HI6'S,Z?5+KPG?37EW'_
M &RMS.SR*&2+8&.2,_-G&:K6>O#3/#<ME8O<0WT\X>69#M 0#A00<U@T46#F
M9TFE^*)4MK^TU>XO+NWN82BAI"Y1NQ&XU4M-6@M_"^H:8R2&:YEC=& &T!>N
M><UC44[(7,S<FUJWN_"4.F7"2F[M9BUO( "NP]5)SGWZ5:L]>TN[T2#2M?MK
MIUM"WV:XM2N]0>JD-P17,T4K(?,S2U631R8TTF"[55Y>2Z=2S?@O _.IO$NK
M0:SJBW5NDB((4CQ( #D#!Z$UCT4["N;.O:O!JL>GK"DBFVMQ$^\#DCTP>E8U
M%%"5@;N%%%%,04444 %%%% !7H6G?\D?O_\ KO\ UKSVO0M._P"2/W__ %W_
M *U$BX=3SVBBBK("BBB@ IR':ZL>QS3:* -?Q/JL.M>(;K4+=)$BEV[5D ##
M"@<X)]*9X=U*'2->M;^=7:*%B6$8!8\$<9(]:RZ*5M+#N[W-_1->@T_4;TW4
M<DEC>(Z2QJ 6YZ'!('%+X<U;3=-;4HKY+IK:[@,(,"KO SUY.*Y^BE9#4F:V
MJ?\ "/\ V=?[).I>=N^;[4J!=OMM)YZ5DT44Q-G0Z+KUG!I<VD:O;2W&GR/Y
MBF%@)(G]1G@_2JVIR>'A;;-*@U S$Y,MTR  >@5?\:QZ*+!S:6.L.K>&[_1=
M,M-275%FLXRA-NL>TY.>[51T+5=/T3Q5'?HMR]E'O"@JOF$%2!D9QU/K6#12
ML/F>YK>'=4ATCQ#;:A.DC11%BRQ@%N5([D>M6?#GB%=$UQ[J2)I;28D31#&6
M7.1^(K HIV0E)HV-7U:#4/%$VIQ1R+ \XD"L!N &/>FZYJR:AXCN-3M!)&KR
M!TW@!A@#T/M63118+LZZ\UGPUKDJWNK6FHPW[ "8V90I(0,9^;H:I:5K.FZ5
MJEY>VUO<1_N&CLUW!BC$8W,>/KP.]<]12Y1\SW-[2O%>J66JP7-QJ%Y/"CYD
MB:9F#+W&"<5/I.MZ;IOBNXU Q7/V&02*J*J^8 P],X_6N:HHL@YF;&I_\(X;
M;.EG4_M&[_EY6,)CO]TYK'HHIH3=PHHHIB"BBB@">R_X_K?_ *ZK_.NT^*O_
M ",EM_UZK_,UQ=E_Q_6__75?YUVGQ5_Y&2V_Z]5_F:A_$BU\#.$HHHJR HHH
MH **** "BBB@ K9UO5H-3M=+BA216M+58'W@<L.XP>E8U%(=R6VD$-U#*P)5
M'#''7@UH:_J<.J^(+G4($=8I7#*K@!AP/0UE44!?2QT>HZWIVI>*;34)8KC[
M'$L0D3:N]M@&0!G'./6H-2\5:M>:I<74.HWD,<DA9(UG8!%SP, XZ5AT4K(?
M,SH]6US3=5UNUU">SFE4Q*MU&6"[F QE2"?UJS#K>@:-#<R:+;Z@UY/&8@UV
M4V1@]<;>IKDZ*.5!S/<WO#&K6&EOJ":BERT%W:M ?LX4L,D<\D5!J?\ PCWV
M9?[*.I_:-XS]J5 NWG^Z2<]*R**=M;BOI8*Z?POJF@:/*EY>KJ+WBAE*PHA3
M!X[D'-<Q10U<$[.Y?U=],DO"^E_:_);EOM(4-G_@)/%4***!!1113 **** "
MBBB@ HHHH ] ^%'_ "%]3_Z\S_Z$*X&3_6-]37??"C_D+ZG_ ->9_P#0A7 R
M?ZQOJ:A?$RW\*&T4459 4444 %%%% !1110!>T:\CT[6K*]E5FC@F61@@Y(!
MSQ3-4NDO=6O+J,,$FF>10W4 DGFJE%*P[Z6-CP[JT&D7-W+.DC":TD@7RP#A
MFQ@G)'%)X<U2'1]92\N$D>-592(P">1CN161118+LW='UN#2?[2N$$PO)XV2
MW=0,1Y/))SD'Z5+H?BV_T_5X+B^O;RZM02LL+3%]RD8/!.,USM%*R'S-&S8S
M^'Q/=QW]K>-;N^Z"6!E$D:\X!4\'/'?M5C5]:L'T:'1](@N$LTD,SR7)&]W^
M@X %<]13L+FT.IM-6T";PS:Z7JJ:B)()7D#6RH0=W^\:PM2_LW[5_P 2O[5]
MGVC_ (^0H;/?[I(Q5.BA(&[DD'E?:(_/#F'<-^S[VW/./>NSU77/">J16]N5
MUFWM+9-L-O$D05?4\MR3ZUQ%%#5P4K#Y?+\U_)W>7GY=_7'O3***8@HHHH *
M*** "BBB@ HHHH ]"U[_ ))5HO\ OUY[7H6O?\DJT7_?KSVHAL7/<****L@*
M*** "BBB@ HHHH V;?5H(?"MYI3)(9IYTE5@!M  [\YS^%8U%%(;=S9U/5H+
MW0='L8TD$MDL@D+ 8.YLC'-$^KP2^$K/25203PW#RLQ VD-TQSG/X5C446"[
M.BU'Q-+]DL+/2+F\M+>VA"-M?RR[]2QVFFW?B%=1\,QV%^UQ/>PS[XIG;<"I
MZ@DG-<_12LA\S.HM;[PE$\%V]CJ:7,6&,,<B&)F'^T?F -4#KIN?%T>MW49'
M^E).Z1\D*I' ]\"L:BBP<S.IU6\\):A<WEX@UE;B=GD *1;0QR?[V<9KEJ**
M:5A-W-729M$6.6+5[:[;<04FM7&Y?;#<$5>U?7+!]$AT71X+B.S27SI)+DC?
M(V,=!P!7.446"^E@HHHIB"BBB@ HHHH **** "MOP?\ \CAI/_7RG\ZQ*V_!
M_P#R.&D_]?*?SI/8<=T>V7__ !^R?A_*JU6;_P#X_9/P_E5:N0[PHHHH ***
M* "BBB@ HHHH *QM8TB?4-6TB[B>-4LIFDD#$Y((QQQ6S10 5SMMX9BFUG4=
M1UBWL[MIV58%=!((XU'^T."2>U=%10!SL?AL6'BN#5-+BM;:U:W:"ZA1=F[G
M*L !@G.<YQ5BQTB>V\3ZKJ<CQF&\2)44$[AM7!SQBMJB@+&%X?T6XT2XU"+?
M$UA-,9;=%)W)GJ",8QGWJ272)W\6V^K!X_(CMFB*DG=DGZ8Q^-;-% 6,;Q3I
M,^N:!-86SQI*[HP:0D+\K GH#Z5!XM\.R>(='$-M,L%]"VZ"9N@)&"#[$$UT
M%% 6,:RTB>U\(1Z.TD;3I9^07!.W=MQGIG'X5E:18^,-+L+6QQHCP0*$+>;+
MN(_[YZUUU% K&+KFD7&IW>DS0O&HL[H3R!R>0 >!@=:9?:+</XIT_6K)XD,:
M-#=*Y(\R(\C& >0>>U;M% [!1110 4444 %%%% !1110 4444 %:.D_ZR7Z"
MLZM'2?\ 62_04 1ZS87]YY'V254V [\GJ:RO[#US_GYC_.NNHH Y'^P]<_Y^
M8_SH_L/7/^?F/\ZZZB@#D?[#US_GYC_.C^P]<_Y^8_SKKJ* .1_L/7/^?F/\
MZ/[#US_GYC_.NNHH Y'^P]<_Y^8_SH_L/7/^?F/\ZZZB@#D?[#US_GYC_.C^
MP]<_Y^8_SKKJ* .1_L/7/^?F/\Z/[#US_GYC_.NNHH Y'^P]<_Y^8_SH_L/7
M/^?F/\ZZZB@#D?[#US_GYC_.C^P]<_Y^8_SKKJ* .1_L/7/^?F/\Z/[#US_G
MYC_.NNHH Y'^P]<_Y^8_SH_L/7/^?F/\ZZZB@#D?[#US_GYC_.C^P]<_Y^8_
MSKKJ* .1_L/7/^?F/\Z/[#US_GYC_.NNHH Y'^P]<_Y^8_SH_L/7/^?F/\ZZ
MZB@#D?[#US_GYC_.C^P]<_Y^8_SKKJ* .1_L/7/^?F/\Z/[#US_GYC_.NNHH
M Y'^P]<_Y^8_SH_L/7/^?F/\ZZZB@#D?[#US_GYC_.C^P]<_Y^8_SKKJ* .1
M_L/7/^?F/\Z/[#US_GYC_.NNHH Y'^P]<_Y^8_SH_L/7/^?F/\ZZZB@#D?[#
MUS_GYC_.C^P]<_Y^8_SKKJ* .1_L/7/^?F/\Z/[#US_GYC_.NNHH Y'^P]<_
MY^8_SH_L/7/^?F/\ZZZB@#D?[#US_GYC_.G)I&O0MO2ZC!'?-=92-]T_2@#S
M>X^'S7-Q+<31PM+*Y=VW=23DFH_^%<+_ ,\8/^^C74>--6NM#\(W^I6107$"
MJ4+KD<NHZ?0UXU_PM[Q7_P ];3_OP/\ &K7,]F9RY4]4=[_PKA?^>,'_ 'T:
M/^%<+_SQ@_[Z-<%_PM[Q7_SUM/\ OP/\:/\ A;WBO_GK:?\ ?@?XT[2[BO#L
M=[_PKA?^>,'_ 'T:/^%<+_SQ@_[Z-<%_PM[Q7_SUM/\ OP/\:/\ A;WBO_GK
M:?\ ?@?XT6EW"\.QWO\ PKA?^>,'_?1H_P"%<+_SQ@_[Z-<%_P +>\5_\];3
M_OP/\:/^%O>*_P#GK:?]^!_C1:7<+P['>_\ "N%_YXP?]]&C_A7"_P#/&#_O
MHUP7_"WO%?\ SUM/^_ _QH_X6]XK_P">MI_WX'^-%I=PO#L=[_PKA?\ GC!_
MWT:/^%<+_P \8/\ OHUP7_"WO%?_ #UM/^_ _P :/^%O>*_^>MI_WX'^-%I=
MPO#L=[_PKA?^>,'_ 'T:/^%<+_SQ@_[Z-<%_PM[Q7_SUM/\ OP/\:/\ A;WB
MO_GK:?\ ?@?XT6EW"\.QWO\ PKA?^>,'_?1H_P"%<+_SQ@_[Z-<%_P +>\5_
M\];3_OP/\:/^%O>*_P#GK:?]^!_C1:7<+P['>_\ "N%_YXP?]]&C_A7"_P#/
M&#_OHUP7_"WO%?\ SUM/^_ _QH_X6]XK_P">MI_WX'^-%I=PO#L=[_PKA?\
MGC!_WT:/^%<+_P \8/\ OHUP7_"WO%?_ #UM/^_ _P :/^%O>*_^>MI_WX'^
M-%I=PO#L=[_PKA?^>,'_ 'T:/^%<+_SQ@_[Z-<%_PM[Q7_SUM/\ OP/\:/\
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M_C1_PM[Q7_SUM/\ OP/\:+2[A>'8[W_A7"_\\8/^^C1_PKA?^>,'_?1K@O\
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M_A;WBO\ YZVG_?@?XUJZ+\9=3CNXUU>WAF@8X9XEVLOOBBT@O#L=1_PKA?\
MGC!_WT:/^%<+_P \8/\ OHUZ!:W,5Y:Q7,#AXI5#HP[@U-4<S+Y8]CSG_A7"
M_P#/&#_OHT?\*X7_ )XP?]]&O1J*.9]PY(]CSG_A7"_\\8/^^C1_PKA?^>,'
M_?1KT:BCF?<.2/8\Y_X5PO\ SQ@_[Z-'_"N%_P">,'_?1KT:BCF?<.2/8\Y_
MX5PO_/&#_OHT?\*X7_GC!_WT:]&HHYGW#DCV/.?^%<+_ ,\8/^^C1_PKA?\
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ML/7/^?F/\Z/[#US_ )^8_P ZZZB@#D?[#US_ )^8_P Z/[#US_GYC_.NNHH
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MFKE_AU_R3_1_^N1_]":NHK![G0M@HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %(WW3]*6D;[I^E '&_$S_ ))YJW^Y'_Z,6OFROI/XF?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z?PMX:BU".75M6D-MHEH
M<RR=#*W9$]2:YBM74/$.HZGI]I83R(MI:KB*&) BCW('4^])C5BSXG\2RZ_=
MHL<8MM/MALM;5.%C7_'WK!HI0"S!0,DG  I@?2WPZ_Y)_H__ %R/_H35U%8'
M@FRET[P9I=K.I61(<L#VR2?ZUOU@]SH6P4444AA1110 4444 %%%% !1110
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M?\))9= /^/Q.WXTO_"3^%\Y_X2.QZD_\?B=_QIWD*T3$_P"%0>%?[EY_W_\
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M+S_O_P#_ %JVO^$E\+[=O_"267W57/VQ.QSZ]:7_ (2?PONS_P )'8_>+?\
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MA?;M_P"$DLON[?\ C\3USZ]:?_PE'AC?N_X2.Q^_OQ]L3'3&.O2B\@M$P_\
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M^Y>?]_\ _P"M1_PJ#PK_ '+S_O\ _P#UJVO^$E\+[<?\))9?=V_\?B?XTO\
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M /\ ]:C_ (5!X5_N7G_?_P#^M6U_PDWA?&/^$DLNC#_C\3O^-+_PD_A?.?\
MA(['JI_X_$[?C1>06B8G_"H/"O\ <O/^_P#_ /6H_P"%0>%?[EY_W_\ _K5M
M?\)-X7VX_P"$DLNC#_C\3N?K2_\ "3^%\Y_X2.QZ@_\ 'XG;\:+R"T3$_P"%
M0>%?[EY_W_\ _K4?\*@\*_W+S_O_ /\ UJVO^$F\+_\ 0R670C_C\3O^-+_P
MD_A?/_(QV/53_P ?B=OQHO(+1,3_ (5!X5_N7G_?_P#^M1_PJ#PK_<O/^_\
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M'^+_ )?$_B_'\J3_ (2;PO\ ]#'9=O\ E\3M^-%Y!:)B_P#"H/"O]R\_[_\
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MT+G[8GKGUZT7D%HF-_PJ#PK_ '+S_O\ _P#UJ/\ A4'A7^Y>?]__ /ZU;?\
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M)'8_>W?\?B?XTW_A)?"^W;_PDEE]TKG[8GKG/7K1>06B8W_"H/"O]R\_[_\
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MI2?9%VX\R7[I'W_6CF8<J.*_X5!X5_N7G_?_ /\ K4?\*@\*_P!R\_[_ /\
M]:NV^RKNSYDOWE;[WH,4GV-=N/-E^Z5^_P"IS1S,.5'%?\*@\*_W+S_O_P#_
M %J/^%0>%?[EY_W_ /\ ZU=M]E7=GS).H/WO2D^R+C'FR]"/O^M',PY4<5_P
MJ#PK_<O/^_\ _P#6H_X5!X5_N7G_ '__ /K5VWV5<Y\R7JI^]Z4GV1<8\R7H
MP^_ZT<S#E1Q7_"H/"O\ <O/^_P#_ /6H_P"%0>%?[EY_W_\ _K5VWV5=V?,E
MZ@_>]!2?8UQCS)>A'W_6CF8<J.*_X5!X5_N7G_?_ /\ K4?\*@\*_P!R\_[_
M /\ ]:NV^RKG_62]0?O>E)]D7&/,EZ,/O>O^>*.9ARHXK_A4'A7^Y>?]_P#_
M .M1_P *@\*_W+S_ +__ /UJ[;[*N<^9+U4_>]/\\TGV1<8\R7H1][UHYF'*
MCBO^%0>%?[EY_P!__P#ZU'_"H/"O]R\_[_\ _P!:NV^RK_STEZC^+TI/LB_\
M])>_\7K1S,.5'%?\*@\*_P!R\_[_ /\ ]:C_ (5!X5_N7G_?_P#^M7:_95_Y
MZ2_P_P 7]W_/-'V1<8\R7^+^+U_SQ1S,.5'%?\*@\*_W+S_O_P#_ %JOZ5\-
M/#.D7:W,-H\LB'*^>^\ _2NF^R+_ ,])>W\7I1]D7_GI+W_B]:+L?*BQ15?[
M(O\ STE_A_B]*/LB_P#/27^+^+^]_GBD,L457^R+_P ])?X?XO3_ #S2_95_
MYZ2]_P"+UH GHJO]D7_GI+T'\7I1]D7.?,EZD_>]: +%%5_LBXQYDO11][^[
M_CWI?LJ_\])>K'[WK0!/15?[(O\ STEZ ?>]*7[*N<^9+U)^]ZT 3T57^R+M
MQYDO11]_T-+]E7.?,EZL?O>M $]%5_LBXQYDO11]_P!*7[*N<^9)U)^]ZT 3
MT57^QKC'FR] /O\ I2_95W9\R3[Q/WO48H O456^QKMV^;-]U5^_Z?U]:7[(
MN[/F2_>)^]ZT 6**K?8DVX\V;H!]_P!*=]E7=N\R7[Q;[WJ* )Z*K?8DV[?-
MF^Z%^_Z'/YT[[*N[=YDOWBV-WJ/Y4 3T56^QKMQYLWW0OW_2G?9%W9\R7[Q;
M[WK0!/15;[$FW;YLWW0OW_?/YT[[*N_=YDOWR^-WJ,8^E $]%5OL2;-OFS?=
M"YW\\'.?K2_9%W9\R7[Q;[U %BBJWV)-N/-F^[M^_P"_\Z=]E7?N\R7[V[&[
MCIC'TH GHJM]B39M\V;[@3._GKG/UIWV5=^[S)?O%L;N.F/RH GHJM]B7;M\
MV;[NW[_^>:=]D7=N\R7[V[&[V_E0!/15;[$A3;YLW*;<[^>N<_6G?95W[O,D
M^_OQNXZ8Q]* )Z*K?8DV[?-F^[MSO]\Y^M.^R+NSYDOWMWWJ )Z*K?8DV[?-
MF^[MSO\ ?/YT[[*N_=YDOWP^-W'3&/I0!/15;[$FS;YLWW-F=_/7.?K3OLJ[
MMWF2_>W?>]L?E0!/15;[&NW;YLWW=N=_^>:=]D7=N\R7[P;[U $]%5OL2;-O
MFS?<*9W\\G.?K3OLJ[]WF2??#XW<=,8^E $]%5OL2[=OFS?=V_?]Z7[(N[/F
M2_>#?>]* +%%5OL:[=OFS?=*_?\ 7^M.^RKOW>9+]X-C=QP,8^E $]%5OL2;
M-OFS?=*YW^IS^=2QQ"-F(9SN_O'.* )**** .&\>^ )?&=WIT\>H):_9&R0T
M6_=SGU%=M#'Y4$<><[%"Y]<"GT4!8Y3X@>#Y/&N@1:;'>+:-'<+-O:/>#A6&
M,9']ZMW1]/.EZ'8Z<SB4VMND!?& VU0,X_"KU% 'E5_\)=0L];N-2\*>(9-+
M%P<O#M.!GL"#T] 16SX,^'$7A>_GUC4+^34]6E!S.RX"YZXR22??-=Y13N*R
M/G+3+>V\0_$#7IT\1GPL!(P4+,4:0AL'DLOIG&:W_ FNZU:?$]O#L7B"7Q!I
M.Q]]RY+@ )N# DG&&PO4@Y^F/2=6^'_A?6KMKN^TB%[ACEI%RA8^^.M:&B^&
MM&\.QLFE:?#;;_O,B_,WU/4T[BLSG- \ 2Z+X_U7Q*VH)*E]YF(!%@IO8-US
MSC'I4'CCX=3^)-8M-;TK4_[/U*W  <ID''0^QKOZ*5QV1Y3-\)M6U#5+'5=5
M\4/>7T$H9R\/R;1_"H!X^M;VO> )=9^(&E^)EU!(DLO+S 8LE]K%NN>,Y]*[
MBBBX61Q'Q%\!R^.;>PBBOTM/LKNQ+1%]VX#W'I5SQQX)@\9Z#'827!M[B!M\
M,P7< <8((]#75T4KA8\=_P"%+:E?::T&K^*9[EXDVVB89HXO?!/\L5UM_P"!
M);WX:P^$Q?HDD2(OVCRL@[6S]W/]:[6BG=A9'%3^!)9OA@OA#[>@D5 OVGRN
M.)-_W<_AUH3P)*OPN_X0_P"WIYFPK]I\KC_6[_NY_#K7:T47"QS/AGPJ^@>"
M%\/O=K,XCE3S@FT?.3VSVSZU4^'W@B7P38WUO+?+=FYF$H98]FWC&.IKL:*5
MPL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "D;[I^E+2-]T_2@#C?B9_R3S5O]R/_ -&+7S97TG\3/^2>:M_N1_\
MHQ:^;*UAL8U-PHHKMY_ ^DV%O:/J7BJ"TEN85F6)K1F(!]P:JY"5SB**[#3O
M"6A:C<QVT?BZ!9Y9O*C3[&_S$G"]^],U_P ):3H:W<7_  D\,]];MM-J+5E)
M;.",YQ1=!9G)45W5WX#TG3I88+[Q;;VUS+&KB-[5^-PR.0:Y[Q#X:O?#ES''
M<F.6&9=\,\1RDB^H-%T#31C445T^E>#7NM*75=5U&#2=/<[8I9E+-*?]E1R1
M[T[@E<YBBNFN?"'F7ME;Z)JEMJPNV*H8@49".I93T'O5X>!+6X^TV]AXCM+K
M4;>,N]JL3 ';]X!^AQ]*5T%F<712D$$@C!%)3$%%%=-H/A_3[C1+K6]:N;B&
MPAE$"K;*"\CD9[\8 H&E<YFBNHMM#\-7HDE_X2<64?F$1Q7%JSOM[$E3BI?$
M'@VUT;1+34[?7([Q+M]L*"W,>X=SR>E*Z"S.2HKM],\!6.IS)90^*;$ZFZDK
M:K$S G&<;^E<==6TMG>36LPQ+#(T;CT(.#1<&FB&BBBF(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-V/[H]:X>ZN9+R[FNICF6:1I'/J2<FNVU_Q)X3UV::ZFLM9:Z*$1!IDV1^@
M'05PE"!]@HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!J?_ ("/_A1_PB'B7_H :G_X"/\ X5]*?V[IG_/VGY'_  H_MW3/^?M/R/\
MA1SL/9H^:_\ A$/$O_0 U/\ \!'_ ,*/^$0\2_\ 0 U/_P !'_PKZ4_MW3/^
M?M/R/^%']NZ9_P _:?D?\*.=A[-'S7_PB'B7_H :G_X"/_A1_P (AXE_Z &I
M_P#@(_\ A7TI_;NF?\_:?D?\*/[=TS_G[3\C_A1SL/9H^:_^$0\2_P#0 U/_
M ,!'_P */^$0\2_] #4__ 1_\*^E/[=TS_G[3\C_ (4?V[IG_/VGY'_"CG8>
MS1\U_P#"(>)?^@!J?_@(_P#A1_PB'B7_ * &I_\ @(_^%?2G]NZ9_P _:?D?
M\*/[=TS_ )^T_(_X4<[#V:/FO_A$/$O_ $ -3_\  1_\*/\ A$/$O_0 U/\
M\!'_ ,*^E/[=TS_G[3\C_A1_;NF?\_:?D?\ "CG8>S1\U_\ "(>)?^@!J?\
MX"/_ (4?\(AXE_Z &I_^ C_X5]*?V[IG_/VGY'_"C^W=,_Y^T_(_X4<[#V:/
MFO\ X1#Q+_T -3_\!'_PH_X1#Q+_ - #4_\ P$?_  KZ4_MW3/\ G[3\C_A1
M_;NF?\_:?D?\*.=A[-'S7_PB'B7_ * &I_\ @(_^%'_"(>)?^@!J?_@(_P#A
M7TI_;NF?\_:?D?\ "C^W=,_Y^T_(_P"%'.P]FCYK_P"$0\2_] #4_P#P$?\
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MNF?\_:?D?\*/[=TS_G[3\C_A1SL/9H^:_P#A$/$O_0 U/_P$?_"C_A$/$O\
MT -3_P# 1_\ "OI3^W=,_P"?M/R/^%']NZ9_S]I^1_PHYV'LT?-?_"(>)?\
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M4?V[IG_/VGY'_"CG8>S1\U_\(AXE_P"@!J?_ ("/_A1_PB'B7_H :G_X"/\
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M?\^=Y_WY'_Q5>)44<B#VC/;?^%B^!/\ GSO/^_(_^*H_X6+X$_Y\[S_OR/\
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M]@Z9_P ^J4?V#IG_ #ZI6E10!F_V#IG_ #ZI1_8.F?\ /JE:5% &;_8.F?\
M/JE']@Z9_P ^J5I44 9O]@Z9_P ^J4?V#IG_ #ZI6E10!F_V#IG_ #ZI1_8.
MF?\ /JE:5% &;_8.F?\ /JE']@Z9_P ^J5I44 9O]@Z9_P ^J4?V#IG_ #ZI
M6E10!F_V#IG_ #ZI1_8.F?\ /JE:5% &;_8.F?\ /JE']@Z9_P ^J5I44 9O
M]@Z9_P ^J4?V#IG_ #ZI6E10!F_V#IG_ #ZI1_8.F?\ /JE:5% &;_8.F?\
M/JE']@Z9_P ^J5I44 9O]@Z9_P ^J4?V#IG_ #ZI6E10!F_V#IG_ #ZI1_8.
MF?\ /JE:5% &;_8.F?\ /JE']@Z9_P ^J5I44 9O]@Z9_P ^J4?V#IG_ #ZI
M6E10!F_V#IG_ #ZI1_8.F?\ /JE:5% &;_8.F?\ /JE']@Z9_P ^J5I44 9O
M]@Z9_P ^J4?V#IG_ #ZI6E10!F_V#IG_ #ZI1_8.F?\ /JE:5% &;_8.F?\
M/JE']@Z9_P ^J5I44 9O]@Z9_P ^J4?V#IG_ #ZI6E10!F_V#IG_ #ZI1_8.
MF?\ /JE:5% &;_8.F?\ /JE']@Z9_P ^J5I44 9O]@Z9_P ^J4?V#IG_ #ZI
M6E10!F_V#IG_ #ZI1_8.F?\ /JE:5% &;_8.F?\ /JE']@Z9_P ^J5I44 9O
M]@Z9_P ^J4?V#IG_ #ZI6E10!F_V#IG_ #ZI1_8.F?\ /JE:5% &;_8.F?\
M/JE']@Z9_P ^J5I44 9O]@Z9_P ^J4?V#IG_ #ZI6E10!3_X1[2_^?1*/^$>
MTO\ Y]$K3HH S/\ A'M+_P"?1*/^$>TO_GT2M.B@#,_X1[2_^?1*/^$>TO\
MY]$K3HH S/\ A'M+_P"?1*/^$>TO_GT2M.B@#,_X1[2_^?1*/^$>TO\ Y]$K
M3HH S/\ A'M+_P"?1*/^$>TO_GT2M.B@#,_X1[2_^?1*/^$>TO\ Y]$K3HH
MS/\ A'M+_P"?1*/^$>TO_GT2M.B@#,_X1[2_^?1*/^$>TO\ Y]$K3HH S/\
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M&#VR,FE8$V>L4444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )Z*** "BBB@ HHHH
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MP4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(WW3]*6D;[I^E '&_$S_DGFK?[D?\ Z,6OFROJ#QKI5UK?A#4-.LU5
MKB94"!C@<.I_D*\8_P"%2^*O^>%O_P!_?_K5I!I(RJ)MG#5>U+5[[5F@:]F\
MTP1"*/Y N%'0<"NK_P"%2^*O^>%O_P!_?_K4?\*E\5?\\+?_ +^__6J[HCE9
MS5QXBU6ZT*#19[LR:? _F11%5^4\_P 6,]SQFKNF^./$>DV"V-IJ)%LARB21
M)($_W=P./PK8_P"%2^*O^>%O_P!_?_K4?\*E\5?\\+?_ +^__6I7B%I',_\
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M G/2LO3-?M])^'&H:=%>[K[4)P#  1Y2#&3G&,G'K4__  J7Q5_SPM_^_O\
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M_GA;_P#?W_ZU'_"I?%7_ #PM_P#O[_\ 6HYD'*SAJ*[G_A4OBK_GA;_]_?\
MZU'_  J7Q5_SPM_^_O\ ]:CF0<K.&HKN?^%2^*O^>%O_ -_?_K4?\*E\5?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU_\ P%?_  HY6',NYL_\)3#_ ,^D_P"5'_"4P_\ /I/^58W_  M3P;_S^O\
M^ K_ .%'_"U/!O\ S^O_ . K_P"%'*PYEW-G_A*8?^?2?\J/^$IA_P"?2?\
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M_"U/!O\ S^O_ . K_P"%'_"U/!O_ #^O_P" K_X4<K#F7<V?^$IA_P"?2?\
M*C_A*8?^?2?\JQO^%J>#?^?U_P#P%?\ PH_X6IX-_P"?U_\ P%?_  HY6',N
MYL_\)3#_ ,^D_P"5'_"4P_\ /I/^58W_  M3P;_S^O\ ^ K_ .%'_"U/!O\
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M_P" K_X4<K#F7<V?^$IA_P"?2?\ *C_A*8?^?2?\JQO^%J>#?^?U_P#P%?\
MPH_X6IX-_P"?U_\ P%?_  HY6',NYL_\)3#_ ,^D_P"5'_"4P_\ /I/^58W_
M  M3P;_S^O\ ^ K_ .%'_"U/!O\ S^O_ . K_P"%'*PYEW-G_A*8?^?2?\J/
M^$IA_P"?2?\ *L;_ (6IX-_Y_7_\!7_PH_X6IX-_Y_7_ / 5_P#"CE8<R[FS
M_P )3#_SZ3_E1_PE,/\ SZ3_ )5C?\+4\&_\_K_^ K_X4?\ "U/!O_/Z_P#X
M"O\ X4<K#F7<V?\ A*8?^?2?\J/^$IA_Y])_RK&_X6IX-_Y_7_\  5_\*/\
MA:G@W_G]?_P%?_"CE8<R[FS_ ,)3#_SZ3_E1_P )3#_SZ3_E6-_PM3P;_P _
MK_\ @*_^%'_"U/!O_/Z__@*_^%'*PYEW-G_A*8?^?2?\J/\ A*8?^?2?\JQO
M^%J>#?\ G]?_ ,!7_P */^%J>#?^?U__  %?_"CE8<R[FS_PE,/_ #Z3_E1_
MPE,/_/I/^58W_"U/!O\ S^O_ . K_P"%'_"U/!O_ #^O_P" K_X4<K#F7<V?
M^$IA_P"?2?\ *C_A*8?^?2?\JQO^%J>#?^?U_P#P%?\ PH_X6IX-_P"?U_\
MP%?_  HY6',NYL_\)3#_ ,^D_P"5'_"4P_\ /I/^58W_  M3P;_S^O\ ^ K_
M .%'_"U/!O\ S^O_ . K_P"%'*PYEW-G_A*8?^?2?\J/^$IA_P"?2?\ *L;_
M (6IX-_Y_7_\!7_PH_X6IX-_Y_7_ / 5_P#"CE8<R[FS_P )3#_SZ3_E1_PE
M,/\ SZ3_ )5C?\+4\&_\_K_^ K_X4?\ "U/!O_/Z_P#X"O\ X4<K#F7<V?\
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M]Q?RHV)_<7\J ,/_ (2F'_GTG_*C_A*8?^?2?\JW-B?W%_*C8G]Q?RH P_\
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M?W%_*@# _P"$L@_Y\[C\J/\ A+(/^?.X_*M_8G]Q?RHV)_<7\J ,#_A+(/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!/1110 4444 %%%% !1110 445A>(?%5AX=$,<RRW%Y<'$%K;KND?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#94 =-17,_VAXG_P"@;!^7_P!E1_:'B?\ Z!L'Y?\ V5 '345S/]H>)_\
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M &5']H>)_P#H&P?E_P#94 =-17,_VAXG_P"@;!^7_P!E1_:'B?\ Z!L'Y?\
MV5 '345S/]H>)_\ H&P?E_\ 94?VAXG_ .@;!^7_ -E0!TU%<S_:'B?_ *!L
M'Y?_ &5']H>)_P#H&P?E_P#94 =-17,_VAXG_P"@;!^7_P!E1_:'B?\ Z!L'
MY?\ V5 '345S/]H>)_\ H&P?E_\ 94?VAXG_ .@;!^7_ -E0!TU%<S_:'B?_
M *!L'Y?_ &5']H>)_P#H&P?E_P#94 =-17,_VAXG_P"@;!^7_P!E1_:'B?\
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MA_T#H_\ P)C_ ,:]H^W^)/\ H'P_E_\ 94?;_$G_ $#X?R_^RI\[)]FCQ?\
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M1_PJGQA_T#H__ F/_&O:/M_B3_H'P_E_]E1]O\2?] ^'\O\ [*CG8>S1XO\
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M?R_^RHYV'LT>+_\ "J?&'_0.C_\  F/_ !H_X53XP_Z!T?\ X$Q_XU[1]O\
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M\:]H^W^)/^@?#^7_ -E1]O\ $G_0/A_+_P"RHYV'LT>+_P#"J?&'_0.C_P#
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MCQ?_ (53XP_Z!T?_ ($Q_P"-'_"J?&'_ $#H_P#P)C_QKVC[?XD_Z!\/Y?\
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MXU[1]O\ $G_0/A_+_P"RH^W^)/\ H'P_E_\ 94<[#V:/%_\ A5/C#_H'1_\
M@3'_ (T?\*I\8?\ 0.C_ / F/_&O:/M_B3_H'P_E_P#94?;_ !)_T#X?R_\
MLJ.=A[-'B_\ PJGQA_T#H_\ P)C_ ,:/^%4^,/\ H'1_^!,?^->T?;_$G_0/
MA_+_ .RH^W^)/^@?#^7_ -E1SL/9H\7_ .%4^,/^@='_ .!,?^-'_"J?&'_0
M.C_\"8_\:]H^W^)/^@?#^7_V5'V_Q)_T#X?R_P#LJ.=A[-'B_P#PJGQA_P!
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M +*C[?XD_P"@?#^7_P!E1SL/9H\7_P"%4^,/^@='_P"!,?\ C1_PJGQA_P!
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M-*L]2D"-:W>[RW1LX*G!!]#6?19!=FW_ ,)CXE_Z#^I_^!3_ .-'_"8^)?\
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MB446079M_P#"8^)?^@_J?_@4_P#C1_PF/B7_ *#^I_\ @4_^-8E%%D%V;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?TL^%YM<U&UO+Y5F\KR+5MIC']YC6XFL:;_PL#Q-=_;[86\]G*L4IE&UR0,
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MK0-26^M!&SA61HY02CJ1@A@",BOHS_A!/"W_ $!+/_OV*/\ A!/"W_0$L_\
MOV*7.@]FSYDD?S)&?:%W$G Z"FU]._\ "">%O^@)9_\ ?L4?\()X6_Z EG_W
M[%/G0>S9\Q45]._\()X6_P"@)9_]^Q1_P@GA;_H"6?\ W[%'.@]FSYUN]<NK
MO1;+22D4=K:%BBQ@@NS')9LDY/Y5F5]._P#"">%O^@)9_P#?L4?\()X6_P"@
M)9_]^Q2YT'LV?,5%?3O_  @GA;_H"6?_ '[%'_"">%O^@)9_]^Q3YT'LV?,5
M%?3O_"">%O\ H"6?_?L4?\()X6_Z EG_ -^Q1SH/9L^8J*^G?^$$\+?] 2S_
M ._8H_X03PM_T!+/_OV*.=![-GS%17T[_P ()X6_Z EG_P!^Q1_P@GA;_H"6
M?_?L4<Z#V;/F*BOIW_A!/"W_ $!+/_OV*/\ A!/"W_0$L_\ OV*.=![-GS%1
M7T[_ ,()X6_Z EG_ -^Q1_P@GA;_ * EG_W[%'.@]FSYBHKZ=_X03PM_T!+/
M_OV*/^$$\+?] 2S_ ._8HYT'LV?,5%?3O_"">%O^@)9_]^Q1_P ()X6_Z EG
M_P!^Q1SH/9L^8J*^G?\ A!/"W_0$L_\ OV*/^$$\+?\ 0$L_^_8HYT'LV?,5
M%?3O_"">%O\ H"6?_?L4?\()X6_Z EG_ -^Q1SH/9L^8J*^G?^$$\+?] 2S_
M ._8H_X03PM_T!+/_OV*.=![-GS%17T[_P ()X6_Z EG_P!^Q1_P@GA;_H"6
M?_?L4<Z#V;/F*BOIW_A!/"W_ $!+/_OV*/\ A!/"W_0$L_\ OV*.=![-GS%1
M7T[_ ,()X6_Z EG_ -^Q1_P@GA;_ * EG_W[%'.@]FSYBHKZ=_X03PM_T!+/
M_OV*/^$$\+?] 2S_ ._8HYT'LV?,5%?3O_"">%O^@)9_]^Q1_P ()X6_Z EG
M_P!^Q1SH/9L^8J*^G?\ A!/"W_0$L_\ OV*/^$$\+?\ 0$L_^_8HYT'LV?,5
M%?3O_"">%O\ H"6?_?L4?\()X6_Z EG_ -^Q1SH/9L^8J*^G?^$$\+?] 2S_
M ._8H_X03PM_T!+/_OV*.=![-GS%17T[_P ()X6_Z EG_P!^Q1_P@GA;_H"6
M?_?L4<Z#V;/F*BOIW_A!/"W_ $!+/_OV*/\ A!/"W_0$L_\ OV*.=![-GS7<
M:C?7<$4%S>7$T,0Q'')*S*@]@3Q5:OIW_A!/"W_0$L_^_8H_X03PM_T!+/\
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MZ*** "BBB@ HHHH **** "LW6= TOQ#:"VU2SCN(U.5W9#*?8CD5I44TVG=
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M0!S/]@ZQ_P!!<_K1_8.L?]!<_K7344 <S_8.L?\ 07/ZT?V#K'_07/ZUTU%
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M7</K+['?_P!G7G_0>C_[[_\ KT?V=>?]!Z/_ +[_ /KUP%%'U==P^LOL=_\
MV=>?]!Z/_OO_ .O1_9UY_P!!Z/\ [[_^O7 44?5UW#ZR^QW_ /9UY_T'H_\
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M_P"/B+_?'\Z]DKQN#_CXB_WQ_.O9*QQ'0WPW4****YSI"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH GHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*,QVL$<*$Y*QJ ":=<6T%W"8KB%)8R<E77(HN'*87@2\^W>!M'N#]YK90WU
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!CRQQXWN
MJYZ9--^U6_\ SVC_ .^A534-&M=2\H7&_P#=C"[6Q5+_ (1+3/\ IM_WW_\
M6H V/M5O_P ]H_\ OH4?:K?_ )[1_P#?0K'_ .$2TS_IM_WW_P#6H_X1+3/^
MFW_??_UJ -C[5;_\]H_^^A1]JM_^>T?_ 'T*Q_\ A$M,_P"FW_??_P!:C_A$
MM,_Z;?\ ??\ ]:@#8^U6_P#SVC_[Z%'VJW_Y[1_]]"L?_A$M,_Z;?]]__6H_
MX1+3/^FW_??_ -:@#8^U6_\ SVC_ .^A1]JM_P#GM'_WT*Q_^$2TS_IM_P!]
M_P#UJ/\ A$M,_P"FW_??_P!:@#8^U6__ #VC_P"^A1]JM_\ GM'_ -]"L?\
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MH V/M5O_ ,]H_P#OH4?:K?\ Y[1_]]"L?_A$M,_Z;?\ ??\ ]:C_ (1+3/\
MIM_WW_\ 6H V/M5O_P ]H_\ OH4?:K?_ )[1_P#?0K'_ .$2TS_IM_WW_P#6
MH_X1+3/^FW_??_UJ -C[5;_\]H_^^A1]JM_^>T?_ 'T*Q_\ A$M,_P"FW_??
M_P!:C_A$M,_Z;?\ ??\ ]:@#8^U6_P#SVC_[Z%'VJW_Y[1_]]"L?_A$M,_Z;
M?]]__6H_X1+3/^FW_??_ -:@#8^U6_\ SVC_ .^A1]JM_P#GM'_WT*Q_^$2T
MS_IM_P!]_P#UJ/\ A$M,_P"FW_??_P!:@#8^U6__ #VC_P"^A1]JM_\ GM'_
M -]"L?\ X1+3/^FW_??_ -:C_A$M,_Z;?]]__6H V/M5O_SVC_[Z%'VJW_Y[
M1_\ ?0K'_P"$2TS_ *;?]]__ %J/^$2TS_IM_P!]_P#UJ -C[5;_ //:/_OH
M4?:K?_GM'_WT*Q_^$2TS_IM_WW_]:C_A$M,_Z;?]]_\ UJ -C[5;_P#/:/\
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M_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\
MA%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^J
MR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9
M/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,
M'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^
MJ/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D
M_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP
M?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#
M6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\
M]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\
M??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z
M:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%
MM-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:
MC_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??
M_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"F
MO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-
M_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\
MA%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^J
MR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9
M/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,
M'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D_P"^
MJ/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP?\]D
M_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#6^TP
M?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\ ]:@#
M6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\ ??\
M]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z:_\
M??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%M-_Z
M:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%M-_P"FO_??_P!:C_A%
MM-_Z:_\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:
MC_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??
M_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"F
MW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-
M_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\
MA%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^J
MR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9
M/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,
M'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^
MJ/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D
M_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP
M?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#
M6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\
M]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\
M??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z
M;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%
M=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:
MC_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??
M_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"F
MW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-
M_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\
MA%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^J
MR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9
M/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,
M'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^
MJ/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D
M_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP
M?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#
M6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\
M]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\
M??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z
M;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%
M=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:
MC_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??
M_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"F
MW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-
M_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\
MA%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9/^^J
MR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,'_/9
M/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^J/M,
M'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D_P"^
MJ/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP?\]D
M_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#6^TP
M?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\ ]:@#
M6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\ ??\
M]:@#6^TP?\]D_P"^J/M,'_/9/^^JR?\ A%=-_P"FW_??_P!:C_A%=-_Z;?\
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M/^$2TS_IM_WW_P#6H V/M5O_ ,]H_P#OH4?:K?\ Y[1_]]"L?_A$M,_Z;?\
M??\ ]:C_ (1+3/\ IM_WW_\ 6H V/M5O_P ]H_\ OH4?:K?_ )[1_P#?0K'_
M .$2TS_IM_WW_P#6H_X1+3/^FW_??_UJ -C[5;_\]H_^^A1]JM_^>T?_ 'T*
MQ_\ A$M,_P"FW_??_P!:C_A$M,_Z;?\ ??\ ]:@#8^U6_P#SVC_[Z%'VJW_Y
M[1_]]"L?_A$M,_Z;?]]__6H_X1+3/^FW_??_ -:@#8^U6_\ SVC_ .^A1]JM
M_P#GM'_WT*Q_^$2TS_IM_P!]_P#UJ/\ A$M,_P"FW_??_P!:@#8^U6__ #VC
M_P"^A1]JM_\ GM'_ -]"L?\ X1+3/^FW_??_ -:C_A$M,_Z;?]]__6H V/M5
MO_SVC_[Z%'VJW_Y[1_\ ?0K'_P"$2TS_ *;?]]__ %J/^$2TS_IM_P!]_P#U
MJ -C[5;_ //:/_OH4?:K?_GM'_WT*Q_^$2TS_IM_WW_]:C_A$M,_Z;?]]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116MI.MM8*UO<1+<6
M4G#Q,.GN*3O;0:LWJ9-&36]J&A1R6YO](<SVAY9/XX_8U@T)IC<6MS<T#7KJ
MPOHHWF9[=V"LC'('N/2O3*\;@_X^(O\ ?'\Z]DKFKI)IG5AVVF@HHHK Z HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBN+V2=ID*%F4 */859LK86=E#;!BPC4+N(QFA1U$Y:$]%%%60%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3I?_ #U?_OB@#:HK%_X2G2_^>K_]\4?\)3I?_/5_^^* -JBL7_A*=+_YZO\
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MST?_ +YH_P"$FTS_ )Z/_P!\T ;%%8__  DVF?\ /1_^^:/^$FTS_GH__?-
M&Q16/_PDVF?\]'_[YH_X2;3/^>C_ /?- &Q16/\ \)-IG_/1_P#OFC_A)M,_
MYZ/_ -\T ;%%8_\ PDVF?\]'_P"^:/\ A)M,_P">C_\ ?- &Q16/_P )-IG_
M #T?_OFC_A)M,_YZ/_WS0!L45C_\)-IG_/1_^^:/^$FTS_GH_P#WS0!L45C_
M /"3:9_ST?\ [YH_X2;3/^>C_P#?- &Q16/_ ,)-IG_/1_\ OFC_ (2;3/\
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M /?% &U16+_PE.E_\]7_ .^*/^$ITO\ YZO_ -\4 ;5%8O\ PE.E_P#/5_\
MOBC_ (2G2_\ GJ__ 'Q0!M45B_\ "4Z7_P ]7_[XH_X2G2_^>K_]\4 ;5%8O
M_"4Z7_SU?_OBC_A*=+_YZO\ ]\4 ;5%8O_"4Z7_SU?\ [XH_X2G2_P#GJ_\
MWQ0!M45B_P#"4Z7_ ,]7_P"^*/\ A*=+_P">K_\ ?% &U16+_P )3I?_ #U?
M_OBC_A*=+_YZO_WQ0!M45B_\)3I?_/5_^^*/^$ITO_GJ_P#WQ0!M45B_\)3I
M?_/5_P#OBKEAJUIJ3.MLS,4&3D8H GFM+>XV^="DFT<;AG%1?V58?\^D/_?
MJY10!3_LJP_Y](?^^!1_95A_SZ0_]\"KE% %/^RK#_GTA_[X%']E6'_/I#_W
MP*N44 4_[*L/^?2'_O@4?V58?\^D/_? JY10!3_LJP_Y](?^^!1_95A_SZ0_
M]\"I8KRVGFDAAN(Y)(_OHK E?K4] %/^RK#_ )](?^^!1_95A_SZ0_\ ? JT
M\B1@%W5<\#<<4Z@"G_95A_SZ0_\ ? H_LJP_Y](?^^!5RB@"G_95A_SZ0_\
M? H_LJP_Y](?^^!5IW2-=SLJKZL<"E!!&0<@]Q0!4_LJP_Y](?\ O@4?V58?
M\^D/_? JY4-Q=6]I&'N)HXD)P"[ #- $/]E6'_/I#_WP*/[*L/\ GTA_[X%6
MU8,H92"I&01WI: *?]E6'_/I#_WP*/[*L/\ GTA_[X%7** *?]E6'_/I#_WP
M*/[*L/\ GTA_[X%7** *?]E6'_/I#_WP*/[*L/\ GTA_[X%7** *?]E6'_/I
M#_WP*/[*L/\ GTA_[X%7** *?]E6'_/I#_WP*/[*L/\ GTA_[X%7** *?]E6
M'_/I#_WP*/[*L/\ GTA_[X%7** *?]E6'_/I#_WP*/[*L/\ GTA_[X%7** *
M?]E6'_/I#_WP*/[*L/\ GTA_[X%7** *?]E6'_/I#_WP*/[*L/\ GTA_[X%7
M** *?]E6'_/I#_WP*/[*L/\ GTA_[X%7** *?]E6'_/I#_WP*/[*L/\ GTA_
M[X%7** *?]E6'_/I#_WP*/[*L/\ GTA_[X%7** *?]E6'_/I#_WP*/[*L/\
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M .M1_:'AG_GK:_\ ?/\ ]:O-JM1Z=>36K7,=O(\*_>=1D"CV$>X_K$NQW_\
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MYJW10!4_LRQ_Y](O^^:/[,L?^?2+_OFK=% %3^S+'_GTB_[YH_LRQ_Y](O\
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M_OFK=% %3^S+'_GTB_[YH_LRQ_Y](O\ OFK=% %3^S+'_GTB_P"^:/[,L?\
MGTB_[YJW10!4_LRQ_P"?2+_OFC^S+'_GTB_[YJW10!%_95A_SZ0_]\"C^RK#
M_GTA_P"^!5RB@"G_ &58?\^D/_? H_LJP_Y](?\ O@5<HH I_P!E6'_/I#_W
MP*/[*L/^?2'_ +X%7** *?\ 95A_SZ0_]\"C^RK#_GTA_P"^!5RB@"G_ &58
M?\^D/_? H_LJP_Y](?\ O@5<HH I_P!E6'_/I#_WP*/[*L/^?2'_ +X%7**
M*?\ 95A_SZ0_]\"C^RK#_GTA_P"^!5RB@"G_ &58?\^D/_? H_LJP_Y](?\
MO@5<HH I_P!E6'_/I#_WP*/[*L/^?2'_ +X%7** *?\ 95A_SZ0_]\"C^RK#
M_GTA_P"^!5RB@"G_ &58?\^D/_? H_LJP_Y](?\ O@5<HH I_P!E6'_/I#_W
MP*/[*L/^?2'_ +X%7** *?\ 95A_SZ0_]\"C^RK#_GTA_P"^!5RB@"G_ &58
M?\^D/_? H_LJP_Y](?\ O@5<HH I_P!E6'_/I#_WP*/[*L/^?2'_ +X%7**
M*?\ 95A_SZ0_]\"C^RK#_GTA_P"^!5RB@"G_ &58?\^D/_? H_LJP_Y](?\
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M*;C&)"W7.X<_ATI6"[.[!R,BBD4!5"@8 &!2TB@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %7=-U2ZTNX\VW? /#(>58>A%4J*35]QIM:HZ>6P
MLO$,37.EA8+P#,EJ3U]UKFY(WAD:.1"CJ<%2,$5MZ-H\FU=3NYVLK.,[A+G#
M/[+4/B'6(]7O \4"HB#:'(^=_<U$79V6QI)75WHS+@_X^(O]\?SKV2O&X/\
MCXB_WQ_.O9*RQ'0VPW4****YSI"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH GHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \]^(W@?4_%FHZ1<6$ENB6CYD\UB#C.>, U/\ $SP-
M<>,M%M8K%X4O;:3<C2D@%2,$9 /^17=T4[BLCC/"7@R3P[\/YM#9XC>7$<IF
M=3E=[C _ #%5/ASX'O?#/AC4M*U=X7-Y,Y/D,2-C(%ZD#G@UWU%%PL>*:?\
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M*** "BBB@ HHHH **** "BBB@ HHHH *1ONGZ4M(WW3]* ,'Q3_R+5Y]%_\
M0A7E]>J^(;>6ZT&Z@@C,DCA=JCJ?F%>??\(YK'_/A+^E=-%I1U.2O%N6AETA
M /4 UJ_\(YK'_/A+^E'_  CFL?\ /A+^E;<T>YAR2[&7CC%)@#H!6K_PCFL?
M\^$OZ4?\(YK'_/A+^E'-'N')+L9=%:G_  CFL?\ /A+^E'_".:Q_SX2_I1S1
M[AR2[&5@9S@9I2 >HS6I_P (YK'_ #X2_I1_PCFL?\^$OZ4<T>X<DNQEX&,8
MHK4_X1S6/^?"7]*/^$<UC_GPE_2CFCW#DEV,NBM3_A'-8_Y\)?TH_P"$<UC_
M )\)?THYH]PY)=C+HK4_X1S6/^?"7]*/^$<UC_GPE_2CFCW#DEV,NBM3_A'-
M8_Y\)?TH_P"$<UC_ )\)?THYH]PY)=C+HK4_X1S6/^?"7]*/^$<UC_GPE_2C
MFCW#DEV,NBM3_A'-8_Y\)?TH_P"$<UC_ )\)?THYH]PY)=C+HK4_X1S6/^?"
M7]*/^$<UC_GPE_2CFCW#DEV,NBM3_A'-8_Y\)?TH_P"$<UC_ )\)?THYH]PY
M)=C+HK4_X1S6/^?"7]*/^$<UC_GPE_2CFCW#DEV,NBM3_A'-8_Y\)?TH_P"$
M<UC_ )\)?THYH]PY)=C+HK4_X1S6/^?"7]*/^$<UC_GPE_2CFCW#DEV,NBM3
M_A'-8_Y\)?TH_P"$<UC_ )\)?THYH]PY)=C+HK4_X1S6/^?"7]*/^$<UC_GP
ME_2CFCW#DEV,NBM3_A'-8_Y\)?TH_P"$<UC_ )\)?THYH]PY)=C+HK4_X1S6
M/^?"7]*/^$<UC_GPE_2CFCW#DEV,NBM3_A'-8_Y\)?TH_P"$<UC_ )\)?THY
MH]PY)=C+HK4_X1S6/^?"7]*/^$<UC_GPE_2CFCW#DEV,NBM3_A'-8_Y\)?TH
M_P"$<UC_ )\)?THYH]PY)=C+HK4_X1S6/^?"7]*/^$<UC_GPE_2CFCW#DEV,
MNBM3_A'-8_Y\)?TH_P"$<UC_ )\)?THYH]PY)=C+HK4_X1S6/^?"7]*/^$<U
MC_GPE_2CFCW#DEV,NBM3_A'-8_Y\)?TH_P"$<UC_ )\)?THYH]PY)=C+HK4_
MX1S6/^?"7]*/^$<UC_GPE_2CFCW#DEV,NM329=*M2UQ?)+/*O^KA"C83[G-'
M_".:Q_SX2_I1_P (YK'_ #X2_I0W%K<:C).]B+5-7NM6GWSMA%X2->%4>PJA
M6I_PCFL?\^$OZ4?\(YK'_/A+^E"<5HF#C)N[1GV__'S%_OC^=>R5P6A>%+LW
ML<]]'Y449W;3U8UWM<]:2;5CIH1:3N%%%%8'0%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gou0qrw2itv5000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *X!X(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHKS""Y\0>,M7UZ:RUR;3+339/(MXH4!WN
M<EL^_P#.@+GI]%<CX%\32ZQX/?4-4D19;262&XEZ*=G5JS_"=WJ7BSQ'<>(W
MEE@T>'=#96^<"7L7(IV%<[ZBBJ&M:M;:'H]SJ5VV(8$+'U/L*0R_17DVF+X[
M\?0-JJ:J-"TN4_Z/$@W.RCN?Q^E=#X;L?&VC:XMIJU[#JNE2(Q^T])(V&, C
MCKSTS3L*YVHEC:0QK(AD49*AAD?A3Z\Q\-RN?C?XD1I&\M;+(!;@?.E>CP7M
MK<LRP7,,K+]X1R!B/KB@$R>BD9@JEF( '4D]*K0ZE87,IB@O;:60=4256/Y
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M@O;];V:-/GN0>']\T :U%0->VJ6_GM<PK#_ST,@"_GTJ2*:*>,20R)(AZ,C
M@_B* 'T4V22.)"\CJB#JS' %16]Y:W:EK:YAF ZF-PW\J )Z**YKQMIFH:KH
M\<.G:RFE2K*&,SM@,/3- '2T5"K"VM$-Q,OR* TC' /O237MI;JK374,2O\
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MO=0+,XRD9D 9OH.IH GHIDLL<*%Y9$C0=6=@!4=O>6MVI:VN89U'4Q.&'Z4
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MC;YR@^63ZDT;BV.W\5_\BCK'_7G+_P"@FN-^#6C:?%X(AOQ;(;JY=_,D89)
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M3>Z+:ZM?:M,IU35B3*$.1&.<8_%C^E/H);Z"-XYT2TO[C3?#^@W>JR1.?/\
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Q?%NMKX=\+:AJ;$!H83Y>>[GA?U(K:KS#XG2MK
MNO\ A_P? 2?M5P)[D#M&O)S^&3^%-">Q3^&OBOQ!+XCDT?Q-=/++=6RW-MO
M! (SC@#M7K=>4_%"V;P]J?A_Q5:(1]AE6&8+QE/?^5=OXG\0+I'@Z\UFV*R;
M8/,A.>&)'%#!:&O-?6ELX2>Z@B=NBR2!2?SJ+5=1CTW2KF\9XP8X7D0.P 8A
M20*\U\)?#NR\0^'8=9\13W5WJ%^#,7\TC8#TQ^&*V]3\"6,/@6ZTZ\NKJ[CL
MUFN+=W?#)\G"D]P,4:!=FEX(\7IXG\/0W]T;>WN9'*^2)!GCIUYIUUI>JR>/
M+2_CUI(]/2(A[#/S.<'G%<-\*?!.C:AX;L=:G2<WD<Y92LI"Y4@CBM347?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT4-@E8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$@#)(
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M_P!><G\J .BTO_D%6G_7%?Y5;JII?_(*M/\ KBO\JMT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<IXG\/ZG-JEKK_A^>*+5+9#$T<P)CGB/.TXY'(!
M!KJZY+Q+XFU.VUFWT#P_81W6IS1&9WF?;'!'G&YNYR>U"$SE]/D\>V.MZK>Q
M^&K;SK_9\SW'[M"H//J1S77^$?#MWI"WE_JMRMSJM^_F3N@PB^BK["L<P_%4
MGBZ\+@>FV;_"M_PVGBM/._X2672Y.GE?80XQZYW4V"-^BBBD,**** "BBB@
MKAOBC_R ])_["]O_ .S5W-<-\4?^0'I/_87M_P#V:@#N:*** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6:>*,GH'<#-2!@RAE((/0B@!:Y+XG?\ )-=?_P"O.3^5=;7)?$[_ ))KK_\
MUYR?RH Z+2_^05:?]<5_E5NJFE_\@JT_ZXK_ "JW0 4444 %%%5-2U*VTG3Y
M;V[9E@B&6*J6/Y"@"W17&_\ "T?"W_/U<?\ @,_^%-?XJ^$XRH>]F7<<+NMW
M&3Z#B@#M**XW_A:/A;_GZN/_  &?_"M'1?&FBZ_>FTT^:5Y@A<AH648'N10!
MT-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<)J-Q;Z3\6+6]U)ECMKK3C;VTT
MGW5E#@D9[$C^5=W69J]GI&K(NEZFMO,9062&1AN..I4=>,]10)G->'+NVC\:
M^*IGN(5BS"=[. N,-WI/"=RFK^-_$.KV9+6+".W20#Y9&7J1ZU0U7P+X#T!3
M=ZI/);12'&V2Y.']L=37:Z ^COI,7]A-;M8@83R"-H_^O3!&G1112&%%%% !
M1110 5PWQ1_Y >D_]A>W_P#9J[FN&^*/_(#TG_L+V_\ [-0!W-%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N UC4K/P_\4(M2UB46]G/II@MYY/N+('!89[$C'Y5
MW]9.OW^B6-D&UV6U2W9OE%QC!/L#0A,Y/0XK;QQXLNO$$\/GZ5:+]GL!(ORN
MW\3@'\OQJQX3C@M?'GB6TTY0E@GEED3[JS8^8>U3Q_$OP;;H(8=1C5$X"HG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY!>B?]AFT_\ 1@KNZX3XH_\ (+T3_L,VG_HP4 =TOW1]*6D7[H^E+0 4444
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M;UQ'Q1_Y &F?]A:U_P#0J .V7[H^E+2+]T?2EH **** "BBB@ HHHH ****
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MOFLT_P!X?HCZ#+OX""BBBO..\^=_B1_R/^J_[T?_ *+6N5KJOB1_R/\ JO\
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MSINK;_L%[#<;/O>6V<5F?\(-X7_Z EI_WS6CIFA:7HV_^SK&&V\S[WEC&:-
MU-"BBBD,**** "BBB@ KAOBC_P @/2?^PO;_ /LU=S7#?%'_ ) >D_\ 87M_
M_9J .YHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KB/BC_ ,@#3/\ L+6O_H5=O7$?%'_D
M :9_V%K7_P!"H [9?NCZ4M(OW1]*6@ HHHH **** "BBB@ HHHH *X3XH_\
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M;="?>@#K:***0PHHHH **** "N&^*/\ R ])_P"PO;_^S5W-<-\4?^0'I/\
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MBW0;^PAN8=2ME1U!"LX!7VQ5V'6M,N)EBAO[>21CA560$FF!?HHHI#"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_OI?\:/^%?^*O\ H#3_ /?2_P"-?1M%']KUOY5^/^8?V72[L^<O^%?^*O\
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M2#QE'%"SDI']@!V+G@9W\XKE/&FB^);"TTF;5?$J:A;?VI /(%IY?/.#G<:
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M'XBVL"00>"[>.)!A46=0 *ZK5-&N/&/@1K#5H%M+VYB!9 <B*0'(Y_ 5U%%
M'DEK-\4])TX:+%I5O<%%\N*]\U>!V/7^==?X \)R^%-$>.[E6;4+J0S7,@Z%
MCVKK** "N&^*/_(#TG_L+V__ +-7<UPWQ1_Y >D_]A>W_P#9J .YHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBJFIQWLNG31Z;/'!>,O[J21=
MRJ<]Q]* +=%<1_97Q$_Z&/2__ /_ .M6+XBO/B#X>ALY)-<TR7[5=); "TQM
M+'&>E 'J-%<1_97Q$_Z&/2__  #_ /K5=TG3_&D.I12:IK>GW%F/]9%%;;6/
MT.* .JHHHH **** "BBB@ JIJ4%S=:=/#9W7V6X=<)-MW;#ZXJW10!P__"+^
M,O\ H=3_ . 8_P :Q/%%KXS\.Z=!=CQ=YWFW,<&TVH&-QQGK7J=<7\3?^1=L
MO^PE;_S- $?_  B_C+_H=3_X!C_&K>E^'_%%IJ4,][XJ-W;(<O!]F"[QCUSQ
M76T4 %%%% !1110 4444 %! (P1110 W8G]U?RKB/B>JC1]'PH'_ !.+?M_O
M5W-</\4/^0/H_P#V&+?_ -FH [;8G]U?RI0J@Y"@?A2T4 %%%% !1110 444
M4 %%%% !7$?%'_D :9_V%K7_ -"KMZXCXH_\@#3/^PM:_P#H5 ';+]T?2EI%
M^Z/I2T %%%% !1110 5Q7Q4_Y$2Y_P"NL?\ Z%7:UQ7Q4_Y$2Y_ZZQ_^A5T8
M3^/#U1AB?X,O1G@5%%%?7'RX4444 %%%% !5W1O^0YI__7S'_P"A"J57=&_Y
M#FG_ /7S'_Z$*F?PLJ/Q(^I:***^+/K0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH YOQMK-WH>CV]U:N(]UY%'-(RA@D9/S'G_/--\1>+(=)M-.FM);:
MX^U7D-NQ,G17;!;@]A70W-M!>6TEO<PI-#(,/'(N0P^E<!KOPB\.7HMFT[38
M;:1;F-YSYDF'B!^90-V!D>E-6$[G>?;[/_G[@_[^"E2\M9'"I<PLQZ!7!)KD
M?^%2^!_^@$O_ ($S?_%U;TWX;^$M(U"&_L-(6&YA;=&_GR'!^A8BC0-3JJ**
M*0PHHHH **** "BBB@ KDOB=_P DUU__ *\Y/Y5UM<E\3O\ DFNO_P#7G)_*
M@#HM+_Y!5I_UQ7^56ZJ:7_R"K3_KBO\ *K= !1110 4444 %%%% !1110 44
M44 %%%% !1110 445E:OXET?07C35+^*U:090/GG\A0!JUPWA_\ Y*KXK_Z]
MK3_VI6E_PL7PC_T'+;\F_P *Y#1/&?AV#XC>)+Z7584MKB"V6*0AL.5\S...
MV1^= 'JU%<Q_PL7PC_T'+;\F_P *VM+U>PUJT^UZ=<I<0;BN],XR/K0!=HHH
MH **** "OE";_7R?[Q_G7U?7RA-_KY/]X_SKV\GWG\OU/(S7['S_ $&4445[
M9XX4444 %%%% !7N/P>_Y$^X_P"OU_\ T!*\.KW'X/?\B?<?]?K_ /H"5YV:
M?[O\T=^6_P ?Y'H-%%%?-'T!YE\9_P#D"Z;_ -?#?^@UXU7LOQG_ .0+IO\
MU\-_Z#7C5?3Y9_NR^9\[F'^\/Y!1117><04444 %%%% %W1_^0W8?]?,?_H0
MKZEKY:T?_D-V'_7S'_Z$*^I:\+./BA\SV<J^&7R"BBBO&/6/%OC+_P C%I__
M %Z?^SM7FU>D_&7_ )&+3_\ KT_]G:O-J^KP/^[P/FL;_'D%%%%=9RA1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K@]9O(O#GQ*MM8U'*:?>6)M%G(^6*0.&P?0$?RKO*Y77O%6@VFK3:)
MKJPK;_91.SW&&1LMM"XQUIH3,?0->TFW\7^*+N;4+=+=C"RR%Q@C#58\&S_V
MWXKUWQ# C"QF"6\#D8$@3JPIFB^'/AQKLCSZ58V%RZ'+!2W'_ 2?Z58O_'>G
MZ+?3:=8Z1=7-O8X6X>TC&R#VQWH$=K1573M0M=5T^"^LY1+;SH'1QW!JU2*"
MBBB@ HHHH *X;XH_\@/2?^PO;_\ LU=S7#?%'_D!Z3_V%[?_ -FH [FBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&^)?_'GHG_85M_\
MT,5W-<-\2_\ CST3_L*V_P#Z&* .YHHHH **** "BBB@ HHHH **** "N+^)
MO_(NV7_82M_YFNTKB_B;_P B[9?]A*W_ )F@#M**** "BBB@ HHHH **** "
MBBB@ KA_BA_R!]'_ .PQ;_\ LU=Q7#_%#_D#Z/\ ]ABW_P#9J .XHHHH ***
M* "BBB@ HHHH **** "N(^*/_( TS_L+6O\ Z%7;UQ'Q1_Y &F?]A:U_]"H
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MD?\ (_ZK_O1_^BUKE:ZKXD?\C_JO^]'_ .BUKE:^PPW\&'HOR/E<1_%EZO\
M,****V,@HHHH **** /2?@U_R,6H?]>G_LZU[37BWP:_Y&+4/^O3_P!G6O::
M^9S/_>'\CZ'+OX"^84445YYW!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-0!W-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-\2_\
MCST3_L*V_P#Z&*[FN&^)?_'GHG_85M__ $,4 =S1110 4444 %%%% !1110
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M +"MO_Z&*[FN&^)?_'GHG_85M_\ T,4 =S1110 4444 %%%% !1110 4444
M%<7\3?\ D7;+_L)6_P#,UVE<7\3?^1=LO^PE;_S- ':4444 %%%% !1110 4
M444 %%%% !7#_%#_ ) ^C_\ 88M__9J[BN'^*'_('T?_ +#%O_[-0!W%%%%
M!1110 4444 %>/?&C_D):3_UQD_F*]AKQ[XT?\A+2?\ KC)_,5WY;_O,?G^1
MQ9A_N[^7YGEU%%%?3GSH4444 %%%% !6YX-_Y'#2_P#KN*PZW/!O_(X:7_UW
M%95_X4O1_D:T/XL?5?F?2U%%%?''U05Q7Q4_Y$2Y_P"NL?\ Z%7:UQ7Q4_Y$
M2Y_ZZQ_^A5T83^/#U1AB?X,O1G@5%%%?7'RX4444 %%%% !5W1O^0YI__7S'
M_P"A"J57=&_Y#FG_ /7S'_Z$*F?PLJ/Q(^I:***^+/K0HHHH **** "BBB@
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M@#D=34G]D:G_ - Z[_[\-_A1SQ[ARR[%*BKO]D:G_P! Z[_[\-_A1_9&I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\3?^1=LO^PE;_P S0!VE%%% !1110 4444 %%%% !1110 5P_P 4/^0/H_\
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M51V$Q JWI_@'0=+OXKRU@E6:)MR$RDC/TIZ"U.GHHHI#"BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT3_L*V__ *&* .YHHHH **** "BBB@ HHHH **** "N+^)O_ "+ME_V$K?\
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MD_&7_D8M/_Z]/_9VKS:OJ\#_ +O ^:QO\>04445UG*%%%% !1110!Z+\&_\
MD:[S_KR;_P!#2O;:\2^#?_(UWG_7DW_H:5[;7S6:?[P_1'T&7?P$%%%%><=Y
M\[_$C_D?]5_WH_\ T6M<K75?$C_D?]5_WH__ $6M<K7V&&_@P]%^1\KB/XLO
M5_F%%%%;&04444 %%%% 'I/P:_Y&+4/^O3_V=:]IKQ;X-?\ (Q:A_P!>G_LZ
MU[37S.9_[P_D?0Y=_ 7S"BBBO/.X**** "BBB@ HHHH **** "BBB@ HHHH
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M_HU:[FN&^)__ ""M'_["]I_Z-6@#N%^Z/I2TB_='TI: "BBB@ HHHH ****
M"BBB@ KAOB7_ ,>>B?\ 85M__0Q7<UPWQ+_X\]$_["MO_P"AB@#N:*** "BB
MB@ HHHH **** "BBB@ KB_B;_P B[9?]A*W_ )FNTKB_B;_R+ME_V$K?^9H
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MX>9CB&0S2@8&=FX!NHW'., \9%0Z3\/(]+T>^LA)YKN/]&<S2J%/7Y@'&1N
MZ8XX-=W10!R/@_P4GA9YOWIE!_U3;WR,\L",[>O0XS77444 %%%% !1110 4
M444 %,:&)R2\:,2,$E0>/2GT4 ,:*-L;HT.!@94<#TH\F+Y?W:?*,+\HX^E/
MHH 155%"HH50,  8 I:** "BBB@ HHHH \<^+]G=7'B"P:"VFE46N"40L!\[
M>E>=_P!EZA_SXW7_ 'Y;_"OJ>BO4H9FZ5-0Y;V\SS:V7*K-SYMSY8_LO4/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>\L;7
M4;9K:]MXKB%OO)(H8'\ZL44 <H/AKX.6?SAH5OO]V?'Y9Q736]M!9P+!;0QP
MPH,*D:A0/P%<]J'CW0-/O7M&GFGGC;;(MM TFP^Y Q6MI&MZ=KMJ;G3KE9HP
M<-P05/H0>13U%H:%%%%(84444 %%%% !7#?%'_D!Z3_V%[?_ -FKN:X;XH_\
M@/2?^PO;_P#LU '<T444 %%%% !1110 5PWQ/_Y!6C_]A>T_]&K7<UPWQ/\
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MH:%IL-H;5Q+)'>EF5<<D#;S7K=<E\3O^2:Z__P!><G\J!'1:7_R"K3_KBO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %84/BS3
MI]8_LM#)]J$C(RE?N@#.X^QZ ^M;C*'1E895A@BN(M_AQ8P>(AJN82OF$F'R
M_EV#E .>"&P<T ;<_BO3K?6/[+<R?:C(J*H7J&_B'L.YHN_%>G6>K?V;(9#<
MED"*%SOW=Q[#OZ5B7OPWL;OQ!_:G[E5#C]SY?RLA^^#SU/KVHU#X;V%[KPU-
M?)0*X*Q>7D%3]\-SR3Z]J .XZC(HIL<:Q1)&@VHBA5'H!3J "BBB@ HHHH *
M*** .5U?P!H^M:E)?74M^LTF,B*[D1?R!Q5+_A5?A_\ Y[:I_P"!\O\ C72Z
M[JR:+I,UXVPNJGRT<D!V[+GMFL+1?'VGZQ87EXK1Q1PC<@=CEATR>.!GB@"G
M#\)/#-NFR ZC$F2=J7L@&3U/6I/^%5^'_P#GMJG_ ('R_P"-+H?Q%LM62X:4
M1VWD1_,&8D^8!\PZ= >,U/X9\>6WB*_:T$:0R(NUAN))E!.Y1QT QS[T =19
MVL=E9PVL18QQ($4NQ8X'J3UJ>BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ,3Q)H+:Y:VYM[IK6]M)?.MIP,[6QCD=P:Y^Y\.^,M8@;3]5URR6P?"S_9
MX-KRKW /:N[HHN*Q';P);6T<$8PD:A%'L!BJ5KH6FV6K7&J6ULL5U<)LE9.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<_<A_P"^#_C2?\)MJ/\ <A_[X/\ C0!Z#7#?$_\ Y!6C_P#87M/_ $:M5_\
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M<V,_@2/$J***^L/F0HHHH **** "I;7_ (^X?^NB_P ZBJ6U_P"/N'_KHO\
M.D]AK<^K:***^*/K@KQ[XT?\A+2?^N,G\Q7L->/?&C_D):3_ -<9/YBN_+?]
MYC\_R.+,/]W?R_,\NHHHKZ<^="BBB@ HHHH *W/!O_(X:7_UW%8=;G@W_D<-
M+_Z[BLJ_\*7H_P C6A_%CZK\SZ6HHHKXX^J"N*^*G_(B7/\ UUC_ /0J[6N*
M^*G_ "(ES_UUC_\ 0JZ,)_'AZHPQ/\&7HSP*BBBOKCY<**** "BBB@ J[HW_
M "'-/_Z^8_\ T(52J[HW_(<T_P#Z^8__ $(5,_A94?B1]2T445\6?6A1110
M4444 %%%% !1110 4444 %%%% !1110 C*KHR, 588(/<5Q\_P -/#\L[R(;
MV!'.3#!<E(_?BNQHH J:9IEGI%C'96,*PP)T4?SJTRJWWE!P<\BEHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_GDG_?(H\B'_GDG_?(KO_M7$>7W''_9V'[/[SY&_M!/^?>Y_P"_+4U]4AC
M+Q7"Y.!F(C)KZ[\B'_GDG_?(KB/B5%&MGHF(T&=5M^BC^^*/[5Q'E]P?V=A^
MS^\^??[03_GWN?\ ORU']H)_S[W/_?EJ^N?(A_YY)_WR*/(A_P">2?\ ?(H_
MM7$>7W!_9V'[/[SY&_M!/^?>Y_[\M3HKQ))%3RITS_$\1 'XU];^1#_SR3_O
MD4>1#_SR3_OD4?VKB/+[@_LW#^?WG%P_%/PHD$:&]ERJ@']RWI3_ /A:WA/_
M )_9?^_+5V/D0_\ /*/_ +Y%'D0_\\H_^^17FG<<=_PM;PG_ ,_LO_?EJPO&
M7Q&\.:IX1U&RM+F:2XE0!$$+<_,#_2O3O(A_YY1_]\BCR(?^>4?_ 'R*J$G"
M2DNA,HJ47%]3Y&_M!/\ GWN?^_+4?V@G_/O<_P#?EJ^N?(A_YY)_WR*/(A_Y
MY)_WR*]#^U<1Y?<<?]G8?L_O/D;^T$_Y][G_ +\M37U2&/&^*X7)P,Q$9-?7
M?D0_\\D_[Y%<9\18HUL]%Q&@SJD/\(]31_:N(\ON#^SL/V?WGSS_ &@G_/O<
M_P#?EJ/[03_GWN?^_+5]<^1#_P \D_[Y%'D0_P#/)/\ OD4?VKB/+[@_L[#]
MG]Y\C?V@G_/O<_\ ?EJ?#>H\R*8ITR1\SQ$ ?6OK;R(?^>2?]\BCR(?^>2?]
M\BC^U<1Y?<']G8?S^\XT?%7PF !]ME_[\M2_\+6\)_\ /[+_ -^6KL?(A_YY
M1_\ ?(H\B'_GE'_WR*\T[CCO^%K>$_\ G]E_[\M7&_$KQOH?B#P]!;Z=<22R
MQ7(E9?*8$KM8<?F*]C\B'_GE'_WR*/(A_P">4?\ WR*TI5)4YJ<=T14@JD7&
M6S/D;^T$_P"?>Y_[\M1_:"?\^]S_ -^6KZY\B'_GDG_?(H\B'_GDG_?(KN_M
M7$>7W')_9V'[/[SY&_M!/^?>Y_[\M37U2&, O%<*"<#,1&37UWY$/_/)/^^1
M7$?$Z*-=(T?$:#_B;V_11_M4?VKB/+[@_L[#]G]Y\^_V@G_/O<_]^6H_M!/^
M?>Y_[\M7USY$/_/)/^^11Y$/_/)/^^11_:N(\ON#^SL/V?WGR-_:"?\ /O<_
M]^6J:TOXS>0[HIT4."6:(@#FOK/R(?\ GDG_ 'R*/(A_YY)_WR*/[5Q'E]P?
MV=A_/[SCO^%K>$_^?V7_ +\M1_PM;PG_ ,_LO_?EJ['R(?\ GE'_ -\BCR(?
M^>4?_?(KS3N.._X6MX3_ .?V7_ORU>=?$SQ3I/B*XLKC3;AI%MXG#J8V#$DC
M&!CFO=O(A_YY1_\ ?(H\B'_GE'_WR*UHUI49J<=S.K2C5AR2V/D;^T$_Y][G
M_ORU']H)_P ^]S_WY:OKGR(?^>2?]\BCR(?^>2?]\BNW^U<1Y?<<O]G8?L_O
M/D;^T$_Y][G_ +\M37U2&, O%<+DX&8B,GTKZ[\B'_GDG_?(KA_B;%&MAX?Q
M&@SKEOT4>CT?VKB/+[@_L[#]G]Y\_?V@G_/O<_\ ?EJ/[03_ )][G_ORU?7/
MD0_\\D_[Y%'D0_\ /)/^^11_:N(\ON#^SL/V?WGR-_:"?\^]S_WY:M;PQK=K
M8^)=/NKF.YCABE#.QA;@5]1^1#_SR3_OD4>1#_SR3_OD5,LSKRBXNVOD5' 4
M(R4DGIYG'?\ "UO"?_/[+_WY:C_A:WA/_G]E_P"_+5V/D0_\\H_^^11Y$/\
MSRC_ .^17GG8<=_PM;PG_P _LO\ WY:N8\?^/_#^M^$KBRL;B62<NC!?)89
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M+L.M=?O.._X6MX3_ .?V7_ORU'_"UO"?_/[+_P!^6KL?(A_YY1_]\BCR(?\
MGE'_ -\BO..XX[_A:WA/_G]E_P"_+4^'XH^%IYDBCO)2[L%4>2W4UUWD0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4V2-)HVCD171AAE89!%.HH Y;_A7'A'[;]K_L2W\W.>K8S],X
MKIXXTBC6.-%1%&%51@ 4ZB@ HHHH **** "BBB@ HHHH *YWQ5X?GUY]&:"9
M(_L.HPW;[P?F5&!('O7144 %%%% !1110 4444 %%%% !1110 5SWBSP_/X@
M@T^."9(S;7D=PV\=0K D5T-% !1110 4444 %%%% !1110 4444 %8'BG09M
M>@T^."5(S;7D=PV\=0O:M^B@ HHHH **** "BBB@ HHHH **** "N>\7^'Y_
M$5C8P6\T<36]]%<L7!Y5<Y'UYKH:* "BBB@ HHHH **** "BBB@ HHHH *YW
MQ=X?G\0VVEQ6\T<1M-1BNW+@_,J!L@>_-=%10 4444 %%%% !1110 4444 %
M%%% !7.>,/#T_B*TT^&WFCB-M?P73%P>51PQ ]^*Z.B@!!P *6BD9U099@H]
MSB@!:*:DB2KNC<,,XR#FG4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%<OJ7C6"UO9K+3M-OM5N8#
MB9;2,L(SZ$],T =116!H_BNVU2[^Q3VEUI]]MW"WNHRC,/4>M;] !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM#X9LX86C62)2DZ C(E!._(]2V3^-=!7G/B:3P.^I3^;)>#4 VV<Z69 V?\
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MHH **** -O0&XF3Z&MNN>T%L74B^J5T- !1110 4444 %%%% !1110 4444
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M#T'%5** %9V;[S$_4TE%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 7]&;;J*#U!'Z5T]<EI[;+^$^K@?G76T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !VKF/"
M$=I':3V[Q1+J<4K?:P1\Y8GKGJ0:AG^''A^XGDFD2ZWR,6;%PP&37-ZOH?PX
M\/WGDZA>R0W3#YD6=F?'N!R/QIB.H\0I9G6](CMHT_M47*.#& &$0/SEO;&>
MM=37'6G@7POINIV5[&)5NBP,!><DL1SCGK]*[&D""BBB@84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 44QY8XAF215_WCBJDFKV<?_+3<?]D4 7J*Q9-?'_+*$G_>-4Y=9NY.
MC!!["@#I20!DG%027MM%]^9!]#FN6DN)I3EY6;ZFHJ .BEURV3A%=S],"J<F
MO3-_JXE7ZG-9-% %N34KN7[TQ ]!Q55G9OO,3]3244 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 6+!ME]"WHU==7&1';,A]&%=D#D ^M
M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<WW@674M-NM*O;B*24R6\EM'O#=AGTZ"M'PII]]H.DZOKUY:/]KNV,J6RC+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYIE '02:]"O$<;M]>!5.37+EON*J#\ZRZ* +$E]<R_?F;Z9J DDY))^M)10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=#
MH39M'7^ZU<]6WH#?ZY?QH VZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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MU7HH 4DDY))^M)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M235FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/1O^^J/[%M/1O^^JT:* ,\:+9CJC'_@1I?[&LO\ GFW_ 'T:OT4 4/[&LO\
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M;3_GVB_[X%*+*U!R+>(?\!%3T4 0_9+?_GA'_P!\BC[);_\ /"/_ +Y%344
M0_9+?_GA'_WR*/LEO_SPC_[Y%344 0_9+?\ YX1_]\BE%M .D*#_ (#4M% $
M?D0_\\T_*CR(?^>:?E4E% $?D0_\\T_*CR(?^>:?E4E% $?D0_\ /-/RI1%&
M!PBC\*?10 SRT_N+^5'EI_<7\J?10 SRT_N+^5*$53D*!^%.HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gou0qrw2itv5000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /<!S0# 2(  A$! Q$!_\0
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M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '.W/_'U-_OM_.BBY_X^IO\ ?;^=% &QIW_'C'^/\S5J
MJNG?\>,?X_S-6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(U'QY)=ZA_97A.S75;W
M:S/*3B*/:>>>-PZ\Y Y7!.<55^*?B*33M*BTBV91)?*WG,),.D8(XP.S<C)X
MP&&#VU?AWH<>C^%;>7"FXOE%Q(X]",HN< X"XXYP2V.M !'HWC*93+<>*X+:
M1F),,&GI(B#)P%9L$C&.O/UZU4U'4O&/AB+[1<0V>MZ="K--/&AAGQZL 2
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M9W#6]UJMC!,F-T<MPBL,C(R"<]#0!?HID4L<\22Q.LD;J&1T.0P/((/<4^@
MHJNE]9R7LEDEU UW&NYX!("ZCCDKU Y'YBHKO6-,T^417NHV=M(5W!)IU0D=
M,X)Z<'\J +M%%% !1110 45%<W5O9V[7%U/%!"F-TDKA5&3@9)XZFJ]IK&F:
MA*8K+4;.YD"[BD,ZN0.F< ].1^= %VF2RQP1/+*ZQQHI9W<X"@<DD]A3ZYOQ
M_<S6O@;5)(7VNR+&3@'Y7=58<^H)% &/HNH:EX\EU&X6^O-+T6-A# EJ4661
MA\Q9GP2IQC(''S 9.#G U+4/$W@7Q5#;I?7FK65TP:&*X+2&49(\L$@X<9_A
MZY4D<[:W?A%_R*EU_P!?S_\ H$==]0 4452U?48](T>\U"7:5MXFD"L^T.0.
M%SZDX ]S0!F^)O%^F>&+<_:9/,O&0O#:I]Y^<<GHHSW/H<9(Q65:?\)QKN+B
M6XMO#]M\S1QK )IF!P5WAN!@9_NG.<KTQR?P^M)/%'C*]U_4"LC6S"783D>8
M^0F V?E4 XYR"%QTKV"@#DY=/\::?$\]KKEGJL@4_P"C75FL(/?*LA^]Q@ D
M#DY-96E^.-7U#QAI^@WFFKI\R-(+P;MQD(B8C;Q\JY^;@G(QSCKZ#7)^+]!:
M^U/0-4MK=I+BTU"$2E ,^27!)/<A2!] S'U( .LHHHH **** "BJ]Q?6=I+#
M%<W4$,D[;84DD"F0\#"@]3R.GJ*+N^L]/B$M[=06T9;:'FD" GKC)[\'\J +
M%%16UU;WENMQ:SQ3POG;)$X93@X."..HJ*\U.PT[9]NOK:U\S.SSY53=CKC)
MYZC\Z +5%,BECGB26)UDC=0R.AR&!Y!![BGT %%%% %>^-X+*7[ L#7>W]T)
MV*IGU; )P.N!UZ9'6O)[[Q!XF'Q%L-,U'4%C$5Y KPV+,D1#E"1V+ @_Q9ZG
M'%>P5XOX@_Y+3#_U_6G\HZ /:***KW=]9Z?$);VZ@MHRVT/-($!/7&3WX/Y4
M 6**I6FL:9J$IBLM1L[F0+N*0SJY Z9P#TY'YU=H 9)+'"H:5U12P4%C@9)
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M.>AJU;75O>6ZW%K/%/"^=LD3AE.#@X(XZB@"EK!UORHAHBZ?YFX^8UZSX ]
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M(FM9+9EW('9Q*&8+@[B<$9SD>_'0C?\ AUJ<^L>"DBD=HY+5FM%F3;G 4%2
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MQ-Q;&22>22>I-<7\(O\ D5+K_K^?_P! CKOJ "N&^*]S-!X/2.-]J3W21R#
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M1<XD8#@,!T JQ\5]4U&QT>UMK0M':W;.ES(JG. !A-W8-ELCJ0OIG.Q\./\
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M?QIKFI'R8)YVCA=8HI6V=&7!)&%48+'OC&:Y_P"%]G=WZ:M;P7LME"WE>?+
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M>,URW_"HM _Y_-2_[^Q__$5T.B^#]#T!EEL;%?M 4#[1*2[Y ()!/W2<G.W
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M7._"&^MCHEY8><OVM;DS&(]=A5!N'J,@CVXSU%>C5Q=S\+_#MSJ;7FVYB1I
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M0/4@=1QZ7:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MITKS3QM_R5?P[_V[?^CVKTG4(KV>T:.PNXK29N/-D@\W:,'H-P&<X/.1QT-
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M<CCI7"> =5\1>))=5,NKLA#0%YBH8H/FRL:8V*6 Y;!QC[I)R #U"BO+WO\
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M"XZY(.><<8ZYXR_!4EWJ?@*Q>:_N1<R>9FYW!Y.)6[N&!X&.0>*XCP782_\
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MO^/&/\?YFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M["N? ?Q T;[)<--:7THB#.,95G"LC 'YB R-G &<<<5T7Q=_Y%2U_P"OY/\
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MQ&:1Q\C;OF.P9Y)Z8X_.M_Q/IFKZ_P"&9--CAL89KC'FLURY6/:ZL-O[O+9
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MLDXYP%XSWQ@[7AKP];>&='2PMG:0[O,EE;K(Y !..PX  ]!W.2>8_LGXE_\
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MDU>WT+2H8KO6+C.$>3;' -I.YSUZ#.T<D#MD9Y7XFV-W!X7MYK[4I;R9KX
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MFO66IW.CSZ5I%MI\<$UL8 \TK((P1M("*A& O3D<]N.0#GOA%_R*EU_U_/\
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M^6=-M[:UWB/=-(7?<1R?DP.%7@9QSR:Z&^M];U#PS<V4MOIZWMQ$T#E+E_+
M9""X_=YSD_=]/XJ .>^$7_(J77_7\_\ Z!'65_S7O_/_ #ZUT7@?P]K?A>VE
ML;O^SYK264R^9%,^]#M /!3##Y5[C'/7I6?)X4\1GQV/$\0TI6W#-NUQ(PQY
M8C(W>6.2,X..#V- &;\9/^8+_P!M_P#VG7J=>4_%\R&+03*JI(5FWJC;@#^[
MR <#(]\#Z5T]S=^-H[=M-@TRVFGXC75_M"*A!/\ K##U! ZCD9!P"." <7I-
MM<7'BOQUY,$LN;6^C&Q"<NS_ "KQW.#@=\&N@^$-S$WAZ^M5?,T=UYCK@\*R
M*%.>G)1ORKH?!WA>/PMH_P!G+K+=S-YEQ*JX!..%!Z[1VSW)/&<5STGA;7O"
M_B675?#*Q75C<R9FT\NL7!R2!G"@#^$CD9Q@C.0"7XN_\BI:_P#7\G_H$E3W
MOA*V\2>$="L+N9K/4;>SC,6X?,H"H) 4)&1]T'H0<?0OGT;6/%FIV$^N646F
MZ;92&0V0G$[7#\8+8&S;V]?O#^+(T/$6GZ[<:UI-[HC6RO:I.)3=.PC8/L 4
MA>3T)],J/:@#@_[1\8_#MH8K_;>Z66")N<NG 7Y4;[R$ $ $8ZD XKL?'MS%
M>?#>]NK=]\,R021M@C*F1"#@\]#5?5H?$_BO39-'N-$@TFWF9#+<RWBS':K
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M9'&PGU#2=4MM:TJWU&S+&"=<KO7!!!P01Z@@CTXXS3=2M&U'19;6XLK:X>9
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MLCZT^B@"K9V?V;?++)YUU+CSIBN,XZ*H_A49.%]R2222;5%% !1110 4444
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MR/K3Z* *MG9_9M\LLGG74N/.F*XSCHJC^%1DX7W)))))M444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 R6*.>)XI8UDC=2KHXR&!X(([BN6M_ \>C7KW?AW4I]-:1E\V"1?/A=1V
MVDALD]]V1E@,9KK** *6G/J;18U."SCD"K\UM,SAS_$<,HVCT&3UZ\<W:**
M"BBB@ HHHH **** "BBB@ HHHH \V^(6BZ_XFN[2.PT:7R;3S!YLEQ$/,+$=
M!NR!A0>>>>@Q7?Z?<W-U:+)=V$ME-T:*21'YP,X*D@C.1S@\=!5JB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#G;G_CZF_WV_G11<_\?4W^^W\Z* -C3O\ CQC_ !_F:M55T[_CQC_'^9JU
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!SMS_Q]3?[[?SHHN?\ CZF_WV_G10!L:=_QXQ_C_,U:JKIW_'C'
M^/\ ,U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH YVY_P"/J;_?;^=%%S_Q]3?[[?SHH V-._X\8_Q_F:M5
M5T[_ (\8_P ?YFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%'VF#_GO'_WV* ):*B^TP?\ />/_ +[%'VF#_GO'_P!]B@"6BHOM,'_/>/\
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M:*B^TP?\]X_^^Q1]I@_Y[Q_]]B@"6BHOM,'_ #WC_P"^Q1]I@_Y[Q_\ ?8H
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MV* ):*B^TP?\]X_^^Q1]I@_Y[Q_]]B@"6BHOM,'_ #WC_P"^Q1]I@_Y[Q_\
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M^^Q1]I@_Y[Q_]]B@"6BHOM,'_/>/_OL4?:8/^>\?_?8H EHJ+[3!_P ]X_\
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MX\?\:/[.M?\ GE_X\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&K5%
M%7^SK7_GE_X\?\:/[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^>7_C
MQ_QJU10!5_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ_P :
M/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK7_GE
M_P"/'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44
M5?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\
MCQ_QJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.
MM?\ GE_X\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&K5% %7^SK7_G
ME_X\?\:/[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^>7_CQ_QJU10!
M5_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ_P :/[.M?^>7
M_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK7_GE_P"/'_&C
M^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44 5?[.M?\
MGE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QJU10
M!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\ GE_X
M\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/
M[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^>7_CQ_QJU10!5_LZU_YY
M?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ_P :/[.M?^>7_CQ_QJU1
M0!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK7_GE_P"/'_&C^SK7_GE_
MX\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44 5?[.M?\ GE_X\?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%]I@_P">\?\ WV*/M,'_ #WC_P"^Q0!+147VF#_GO'_WV*/M,'_/>/\ [[%
M$M%1?:8/^>\?_?8H^TP?\]X_^^Q0!+147VF#_GO'_P!]BC[3!_SWC_[[% $M
M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL4 2T5%]I@_Y[Q_]]BC[3!_SWC_ .^Q
M0!+147VF#_GO'_WV*/M,'_/>/_OL4 2T5%]I@_Y[Q_\ ?8H^TP?\]X_^^Q0!
M+147VF#_ )[Q_P#?8H^TP?\ />/_ +[% $M%1?:8/^>\?_?8H^TP?\]X_P#O
ML4 2T5%]I@_Y[Q_]]BC[3!_SWC_[[% $M%1?:8/^>\?_ 'V*/M,'_/>/_OL4
M 2T5%]I@_P">\?\ WV*/M,'_ #WC_P"^Q0!+147VF#_GO'_WV*/M,'_/>/\
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M]]BC[3!_SWC_ .^Q0!+147VF#_GO'_WV*/M,'_/>/_OL4 2T5%]I@_Y[Q_\
M?8H^TP?\]X_^^Q0!+147VF#_ )[Q_P#?8H^TP?\ />/_ +[% $M%1?:8/^>\
M?_?8H^TP?\]X_P#OL4 2T5%]I@_Y[Q_]]BC[3!_SWC_[[% $M%1?:8/^>\?_
M 'V*/M,'_/>/_OL4 2T5%]I@_P">\?\ WV*/M,'_ #WC_P"^Q0!Y;J^KZE'K
M5]''J-VB+<2*JK.P  8X YJG_;6J_P#03O?^_P"W^-&LD'7-0(((-S(01_O&
MJ->_"$>5:'A3G+F>I>_MK5?^@G>_]_V_QKI?!&H7MWK4T=S>7$R"W9@LDK,
M=R\\FN,KJ/ ;I'KDY=E4?9F&2<?Q+6>(C%4I:&F'E)U5J>DT5%]I@_Y[Q_\
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M7VF#_GO'_P!]BC[3!_SWC_[[% $M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL4
M2T5%]I@_Y[Q_]]BC[3!_SWC_ .^Q0!+147VF#_GO'_WV*/M,'_/>/_OL4 2T
M5%]I@_Y[Q_\ ?8H^TP?\]X_^^Q0!+147VF#_ )[Q_P#?8K-UC7K?3;?]VR2W
M#CY$!R![G';^?Z@ UZ*\VN==U.YF,C7DL?HL3%% ^@_KS3(M9U.&0.M]<$CL
M[EA^1XH ],HK#T+Q"FJ9@G"QW0R0%^ZX]O<>GX_3<H **** .=N?^/J;_?;^
M=%%S_P ?4W^^W\Z* -C3O^/&/\?YFK55=._X\8_Q_F:M4 %%%% '+>,/!_\
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M* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\
MSR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+
M_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J*
M *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6
MO_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_
M ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB
M@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O
M_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_
M\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6
MJ* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_
M #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/
M+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J
M* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\
MSR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+
M_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J*
M *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6
MO_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_
M ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB
M@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O
M_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_
M\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6
MJ* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_
M #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/
M+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J
M* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\
MSR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+
M_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J*
M *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6
MO_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_
M ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB
M@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O
M_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_ #R_\>/^-6J* *O]G6O_ #R_
M\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/+_QX_P"-']G6O_/+_P >/^-6
MJ* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J* *O]G6O_/+_ ,>/^-']G6O_
M #R_\>/^-6J* *O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JB@"K_ &=:_P#/
M+_QX_P"-']G6O_/+_P >/^-6J* *O]G6O_/+_P >/^-']G6O_/+_ ,>/^-6J
M* *O]G6O_/+_ ,>/^-8'BF_M=&LA';HAO9ON L247^_C]!G]<$5T%_?0Z;8R
MWEP6$40R=HR3S@ ?4D5Y!?WTVI7TMY<%3+*<G:, <8 'T %=>$H>TES2V1R8
MJO[./*MV5V9G8LS%F8Y))R2:2NBL/!NI:A8Q7<<EO&DHW*LI8-C/!QM[]1[&
MK'_" :K_ ,_%E_WVW_Q->D\123M<\]4*K5['*U)#-);S++$Y213D,*Z;_A -
M5_Y^++_OMO\ XFJNH^#M4TVR>Z<PS1IRXA8DJ/7! X%"KTI:7!T*L=;'6^'=
M1T[7+;!B6.\C'[R+<>?]I>>G\OR)VO[.M?\ GE_X\?\ &O(;"^FTV^BO+<J)
M8CD;AD'C!!^H)KUW3M1MM5LDNK5]T;<$'JI[@CL:\W%8?V;O'9GHX:O[16EN
MA?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M45R'45?[.M?^>7_CQ_QH_LZU_P">
M7_CQ_P :M44 5?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_
MQH_LZU_YY?\ CQ_QJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7
M_GE_X\?\:/[.M?\ GE_X\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&
MK5% %7^SK7_GE_X\?\:/[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^
M>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ
M_P :/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK
M7_GE_P"/'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :
MM44 5?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_Y
MY?\ CQ_QJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\
M:/[.M?\ GE_X\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&K5% %7^S
MK7_GE_X\?\:/[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^>7_CQ_QJ
MU10!5_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ_P :/[.M
M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK7_GE_P"/
M'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44 5?[.
MM?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\ CQ_Q
MJK<^(=+MLAKM9&V[@(OGS[9'&?J:QKKQI]Y;2T]-KRM^>5'X]Z .C_LZU_YY
M?^/'_&O/=8D+ZO=# "I(T:@$X !QWJ>[\1ZG=DYN#"N<A8?EQQZ]?UK*H **
M** )K6YDL[J*XB.'C8,/?V/L:]31UD171@RL,A@<@BO)T5I'5$4LS' 4#))K
MU:*)((4BC&U$4*HST X% #Z*** .=N?^/J;_ 'V_G11<_P#'U-_OM_.B@#8T
M[_CQC_'^9JU573O^/&/\?YFK5 !1110!FZEH&EZO+#->V:O/"P:.9&,<B$9(
MPZD-@$DXSC/-5-/\*:;92)-*C7<\4LLD3W$CR"+?)O\ E#L0&'R_,.21GN:W
M:* "L6\\*:1J%VEU=Q7,LT<ADC9KV;]VQ.<H-^%Y Z8Z#TK:HH BMK=+6W6&
M-I61<X,LK2-R<\LQ)/XFJM]HNGZC<17%Q;_Z3%_J[B)VBE48(P'0AL?,>,XY
MJ_10!FVN@:;:7OVU(&DNPH59[B9YG0<\*SDE1\QZ8SFK\L4<\3Q2QK)&ZE71
MQD,#P01W%/HH S8M TV*5)! SB-@T4<LSR1Q$="B,2J$=MH&!P,"M*BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;';!P#@^U.MM;TV\?9#=QEL@!6RI)/3&<9_"@"_1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XAUW^RXQ! ,W4BY!
M(X0=,^Y]!^?OP]S=3WDQEN)7D<]V/3O@>@]J??W/VS4+BXRY$DA9=_4#/ _
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MW*< [=Q?T.>HU=-U"WU;3+>_M6W0SH'7D$C/4'!(R#P1V(- %JBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH
MH?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?
MV3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3
M!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_
M?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D
M_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,
M?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X
M4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?
MV3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3
M!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_?D_,?X5?HH H?V3!_?D_,?X4?V3!_
M?D_,?X5?HH \7_M&^_Y_+C_OZW^-']HWW_/Y<?\ ?UO\:K45]#R1['@<\NY9
M_M&^_P"?RX_[^M_C6CI?B![+S?M237>_&W,^-N,YZ@]<_I6+6KHN@7>N^?\
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M>W]T\#\,D_W:YO1+U+'5899B1 QV2D=E/?H>G!_#%>M7EI%?V4UK.,QRJ5/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445A^*-<_L;3?W38NY\K#E<@8QDGMP#^9'&,U4(.<E%$SDH1<F>544Y$>2
M18XU9W8A551DDGH!74?\(!JO_/Q9?]]M_P#$U[TZL(?$['APISG\*N<K7<?#
MO_F)?]LO_9ZH_P#" :K_ ,_%E_WVW_Q-=)X4T"[T+[7]JDA?SMFWRF)QC=G.
M0/6N7$UZ<J347J=6&HU(U4VCHZ***\D]0*RK_P -Z3J.YIK-%D;<?,B^1LGJ
M3CJ?KFM6BJC*47>+L3**DK-'$7WP^3:6T^]8$ 82X&<G//S#IQ[&N%KW&O#J
M]3!59U$U)WL>;C*4(-<JW"BBBNXXCM_AVZ"348RRAV$;!<\D#=D_J/S%=U7B
M".\<BR1LR.I#*RG!!'0BNUT/QP_F>1K#+LQ\MPJ<@_[0'Y<#_$>;BL-.4G4C
MJ>AA<3&,5"6AW5%-1TDC62-E=& 964Y!!Z$4ZO-/1"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KCO'NJ^5:Q:9&?FFQ)+_N \#IW(['^'WKJKR[BL+*
M:ZG.(XE+'D9/L,]ST%>0:G?R:GJ4]Y(,-*V0O]T= /P&!7;@J7//F>R./&5>
M6'*MV2Z+ICZOJT-HNX(QW2,/X4'4YP<>@SW(KU]$2.-8XU5$4!551@ #H!7+
M^!])^R::U_*F)KG[F1RL8Z=L\GGT(VUU53C*O/.RV16$I<D+O=A1117(=044
M44 %%%% !1110 5P?C_3E26VU&-,>9^ZE88 )'*^Y.,\_P"R*[RJFIV,>IZ;
M/9R'"RK@-_=/4'\#@XK:A4]G44C*M3]I!Q/-?"FK?V5K*>8^VWG_ '<N3P/1
MNH'![GH":]5KQ*:&2WGD@E7;)&Q1USG!!P:]1\*:M_:NC)YC[KB#]W+D\GT;
MJ3R.YZD&NS'4MJB.3!5-Z;-RBBBO-/0"BBB@ HHHH ***9+*D$+RR':B*68X
MZ <F@#&UWQ"FEX@@"R71P2&^Z@]_<^GX_7C+K5+Z\W"XNI75\;DW84X_V1QV
MJO+*\\SRR'<[L68XZD\FF4 7[36M0LG0Q74C*H"B-V++@=L'IT[5OGQHOV)=
MMJ3=XPV3A ?4=SVX_6N1I\43SS)%&-SNP51GJ3P* )[[4+G49S+<R%N257/R
MI[ =N@JUI>A7>J-N1?*@[RN#@\X^7U/7\NHKH=+\)0V[>;?LL[CI&,[%.?\
MQ[MUXZ]:Z1%6-%1%"JHP% P * ,[3-#L],12D8><#F9AR3ST].O;]:TJ** "
MBBB@ HHHH **** "BBB@ JE=Z387Q+7%K&[$Y+@;6/&.2.:NT4 >3.K1NR.I
M5E."I&"#25TOB;1)(;IKVUB=X9,M+CG8W))]AW_/IQ7-4 %%%=+H7AG[;";F
M]WI"ZGRT!PS9_B^GIZ_3J 4H/$^JP%,W E51C;(@.>.Y'/ZUJVOC3[JW=IZ[
MGB;\L*?P[T^Y\%QG)M;MUPO"RKG)^HQ@?@:RIO"FJQ.%2*.88SN20 #V^;%
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M#@D9!X([$&@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY3^%7(G4C#XG8Z6BN5_X3_2O^?>]_P"^%_\ BJ@O/'UFUE,MG!<K<%2(V=5
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M ,+PQHTES=1W\J[;>)LIG^-ATQ[ ]_;'KCN*1%6-%1%"JHP% P *6@ HHHH
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MBGU]"G?5'S;5M&%%%% '.W/_ !]3?[[?SHHN?^/J;_?;^=% &QIW_'C'^/\
M,U:JKIW_ !XQ_C_,U:H **** ..\9^%]1U*]LM:T*=8-5LE(&6(,B\D 'IG)
M88(P0YR<"J7@GQK:3AM(U0?8M4-U+B-U(5W>1G*C/W2"2NUO;!).!V*:C&VM
MS:8=JR1VT=PN7Y<,SJ<+Z#:.?]H?CQ/B#0=,U'P7J.H7*Q17EI/>F&Y8X/%S
M(=G4 [C\HSG!;CD\@'H$44<$2111K'&BA41!@*!P !V%<)X^_P"1K\&?]?Q_
M]#BK?\$W-[=^#M-GU!Y7N70Y>489EW$*3ZY7:<]^O.:P/'W_ "-?@S_K^/\
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M7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\
M2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^
MPS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3
M]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]
MAG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-
M7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\
M2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^
MPS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3
M]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]
MAG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-
M7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\
M2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^
MPS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3
M]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]
MAG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-
M7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\
M2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^
MPS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3
M]?\ &C[#/_S_ $GZ_P"-7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]
MAG_Y_I/U_P :/L,__/\ 2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-
M7Z* *'V&?_G^D_7_ !H^PS_\_P!)^O\ C5^B@"A]AG_Y_I/U_P :/L,__/\
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M[=WFKC.<XQACZ5YE7<?#O_F)?]LO_9ZQQ&%IPIN4=S:AB:DZBBSJOL,__/\
M2?K_ (T?89_^?Z3]?\:OT5YIZ)0^PS_\_P!)^O\ C1]AG_Y_I/U_QJ_10!0^
MPS_\_P!)^O\ C7E.KJ5UJ^4L6(N) 2>_S&O4[O7])L<B>_A#*VQE1M[ ^X7)
M'2O*=0N$N]2NKF,,$FF>10W4 DD9KT<!&2;;1Y^.E%I),K4445Z9YQT7@NU%
MUKC?.4>*%G5AV.0O\F->@?89_P#G^D_7_&N'\ ?\AZ?_ *]F_P#0EKT>O&QO
M\4];!_PBA]AG_P"?Z3]?\:/L,_\ S_2?K_C5^BN0ZRA]AG_Y_I/U_P :/L,_
M_/\ 2?K_ (U?HH H?89_^?Z3]?\ &C[#/_S_ $GZ_P"--U36;72H_P!ZVZ8K
ME(AU;_ >Y]#UKEI_&&H2!UB2&$$_*P4EE&??@_E0!U?V&?\ Y_I/U_QH^PS_
M //])^O^-<W;>,[@3#[5;1-$>OE9##WY)S]./K766EY;WT FMI1)'G&1Q@^X
M/2@"O]AG_P"?Z3]?\:/L,_\ S_2?K_C5YW6-&=V"JHR6)P *S+GQ#I=MD-=K
M(VW<!%\^?;(XS]30!+]AG_Y_I/U_QH^PS_\ /])^O^-8ESXTC&1:VCME>&E;
M&#]!G(_$5C77B75+G</M'E(V/EB&W'T/7]: .MO8I;.RFN6O7Q&A;!)&3V&<
M]SQ7GCNTCL[L69CDL3DDTZ662>0R2R/(YZL[9)_&F4 %%%% !6I;>'M4N<%;
M1XUW;29?DQ[X/./H*;H%LUUK=JJY 1Q(Q"YP%YY^IP/QKTB@#D8/!3;5-Q>
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M7_&C[#/_ ,_TGZ_XU?HH H?89_\ G^D_7_&C[#/_ ,_TGZ_XU?HH H?89_\
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M'4X]3[DUCBL''#Q5Y7;-\)C98F;2C9(H4445P'H'=^!]3\VUDTV0_-#F2/\
MW2>1T[$]S_%[5UU>0:=>OIVHP7<8RT39(_O#H1^(R*]<AF2X@CFB;='(H=3C
M&01D5]%EM?VE+D>\?R/F\TP_LZO.MI?F/HHHKT3S#G;G_CZF_P!]OYT47/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3FK'GT,%BU"]2#N='16,GBK1'=4%\ 6.!NC<#\21@5<_MC2_^@E9_P#?]?\
M&H5:G+:2^\J5"K'>+^XNT4U'61%=&#(PRK*<@CU%.K4R"J]]>PZ=92W<Y(CC
M&3M&2>P _&K%<)XXU/S;J/38S\L.))/]XC@=.P/8_P 7M7/BJ_L:3GUZ>ITX
M2@Z]50Z=?0[E'61%=&#(PRK*<@CU%.KF/!>J_:M.:QE?,UM]W)Y*'IW['CT
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MI#[#J5K;3W9N(F#PR[4E<?(Q9A@8)P1PH &3S0!VE%5=,O/[1TFSOO+\O[3
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M_BJVM'UBWUJT>YMDE1%D,9$@ .0 >Q/K4RHU(*\D5&M"3M%FA11161H%%%%
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M#!=3Q1K]U$D( _#-/?4K^1&1[VY96&"IE8@C\Z[&+PAID<@9FN) .J.XP?R
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MNEV_9KV&3.=WF*4QZ8QG-8MQX=UBVV^9I\QW9QY8\S\]N<?C7H>TQU#XKO\
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MY^(_R_\ K5?HH H>5J7_ #\1_E_]:CRM2_Y^(_R_^M5^B@"AY6I?\_$?Y?\
MUJ/*U+_GXC_+_P"M5^B@"AY6I?\ /Q'^7_UJ/*U+_GXC_+_ZU7Z* *'E:E_S
M\1_E_P#6H\K4O^?B/\O_ *U7Z* *'E:E_P _$?Y?_6H\K4O^?B/\O_K5?HH
MH>5J7_/Q'^7_ -:CRM2_Y^(_R_\ K5?HH H>5J7_ #\1_E_]:CRM2_Y^(_R_
M^M5^B@"AY6I?\_$?Y?\ UJ/*U+_GXC_+_P"M5^B@"AY6I?\ /Q'^7_UJ/*U+
M_GXC_+_ZU7Z* *'E:E_S\1_E_P#6H\K4O^?B/\O_ *U6+N[@L;5[FY?9$F-S
M;2>IP.!SU-<KJ?B^5G:+3U"(#@3,,ENG(!Z=^N?PHMU"YT7E:E_S\1_E_P#6
MH\K4O^?B/\O_ *U<%_;.I^=YOVZXW;MV-YVY^G3'MTK;TSQ?*KK%J"AT)P9E
M&"O7D@=>W3'XT =%Y6I?\_$?Y?\ UJ/*U+_GXC_+_P"M5BTNX+ZU2YMGWQ/G
M:VTCH<'@\]14]#5M&"=RAY6I?\_$?Y?_ %J/*U+_ )^(_P O_K5?HH H>5J7
M_/Q'^7_UJ/*U+_GXC_+_ .M5^B@"AY6I?\_$?Y?_ %J/*U+_ )^(_P O_K5?
MHH H>5J7_/Q'^7_UJ/*U+_GXC_+_ .M5^B@"AY6I?\_$?Y?_ %J/*U+_ )^(
M_P O_K5?HH H>5J7_/Q'^7_UJ/*U+_GXC_+_ .M5^B@"AY6I?\_$?Y?_ %J/
M*U+_ )^(_P O_K5?JAJ6LV>E@"X<F1AE8T&6(S^GX^AH /*U+_GXC_+_ .M1
MY6I?\_$?Y?\ UJPG\;*'8)8$KG@F7!(^F*V-.U^QU.3RHF=)><1R#!('IV_K
MP: )?*U+_GXC_+_ZU'E:E_S\1_E_]:K]% %#RM2_Y^(_R_\ K4>5J7_/Q'^7
M_P!:K]<YJOC/3;#*6Y^V3>D3?(.G5NG0]L].<5<*<INT5<B<XP5Y.QJ>5J7_
M #\1_E_]:LK6;QHM.OK>;4[,2^0X,)D4.<J>,8SDUQ.I>)M5U-B);EHHB"OE
M0DHN",$'N<^Y/4UE*I=PHZDUW4\"X^]-G%/&W]V"&@$G &2:?Y,N,^6WY5H1
M0K$N ,GN:DISQ^ONH4,#I[S,D@J<$$'T-=[X(2[;19C!*B+]H;(([[5]JY62
M-9%PPS[^E=)X/UBRTV&33KN7RG>5I5D? 0C &,YX/!Z_G4U*_MZ3BEJ53H>Q
MJIMZ'5>5J7_/Q'^7_P!:CRM2_P"?B/\ +_ZU7Z*\\[RAY6I?\_$?Y?\ UJ/*
MU+_GXC_+_P"M5^B@"AY6I?\ /Q'^7_UJ/*U+_GXC_+_ZU7ZCFN(;9 \\T<2D
MX#.P49_&@"IY6I?\_$?Y?_6H\K4O^?B/\O\ ZU5_^$FT?_G\_P#(3_X5?L[^
MUOX]]K.L@'4#J/J.HZ4 0>5J7_/Q'^7_ -:CRM2_Y^(_R_\ K5?HH H>5J7_
M #\1_E_]:CRM2_Y^(_R_^M5^B@"AY6I?\_$?Y?\ UJ/*U+_GXC_+_P"M5^B@
M"AY6I?\ /Q'^7_UJ/*U+_GXC_+_ZU2:AJ5KID(DN9-N[.U0,LQ'H/\CFL.3Q
MI;B91':2M$<;F9@&'K@<Y_,4 ;'E:E_S\1_E_P#6H\K4O^?B/\O_ *U0V'B+
M3]0?RTD,4A. DH"ENG3MWZ9S6K0!0\K4O^?B/\O_ *U'E:E_S\1_E_\ 6J_1
M0!0\K4O^?B/\O_K4>5J7_/Q'^7_UJOT4 4/*U+_GXC_+_P"M63JNN3:7+Y+3
MK+-C)1 /E^IQQ6QJUZVG:7/=(@=D P">,D@?UKS-W:1V=V+,QR6)R2: -S_A
M+=4]8?\ OBK%KXLN6<+<L%!/WU48'U'^?I7-44 >E(M_(BNEU"RL,AA@@C\J
M7RM2_P"?B/\ +_ZU<7IWB*]TRU^SQ+$Z;BP\P$XSV'/3_$TZ7Q3JTDA99UC!
M_@2-<#\P3^M '9>5J7_/Q'^7_P!:H)KB>V<)/J-I$Q&0KNJG'XBN"FO;NY0)
M/<S2J#D*\A89_&H* .RE\21QQEEOUD(_@2(Y/YJ!^M9>H>)9KNUDMT+A9%P6
M.%/7D<=OQ[UD0V5W<H7@MII5!P62,L,_A6A%X9U:50WV78"NX;W4=LXQG(/;
M^= &11110 445U7@RS?SKB])P@7R@/4\$_E@?G0!S<%K<7.[[/;RR[?O>6A;
M'Y5<A\/ZK.A9+*0 ''SD(?R8BO2** .%3P=J3(K&2V4D9*ESD>W JR/!<VX;
MKN,C/("D5V-% '*#P<@/,I/'=_\ ZU<S?6,^GW36]PFUUY!'1AZCVKU&JFH:
M;:ZG"([F/=MSM8'#*3Z'_(XH \PHIVH26T.H3Q69>2!&VJ[,"6QU.1QC.<>V
M*Z?PGI^FW]M]J=3)<1DI)%(05&>AQ]/7N#Z5ST\51J3Y(RU.FIA*U.'/.-D/
M\-:5>10M?*1$THVIOZE>N?Q_I[UO^5J7_/Q'^7_UJOUB>++X6/AVY.5WS#R4
M# G.[KT_V=Q_"NJ$7*2BNIR3DHQ<GT/-]7O3J&K7-R75][X5E& RC@''T KL
M?!FG74.D&[ADC7[2V>I)PI(&>/7=^=<)##)<3QP1+NDD8(BYQDDX%>T6MNEI
M:0VT98I#&L:ENI &!FO2QLE"FJ:_JQY^#BYU'4?]7*OE:E_S\1_E_P#6H\K4
MO^?B/\O_ *U7Z*\L](YK5/#<^I2>>985GQ@MCAO3.!^M8<OA;5HY"JP+(!_&
MDBX/YD']*]!HH X>U\'WT@5KAXH0>J;LMU]N/U-=+!9WMK D$$D*1H,*H'3]
M*TZ* *'E:E_S\1_E_P#6J"YTVXO$VW)MY1@@;D!(SUP<<?A6M10!RDW@\./W
M4BQ'''S$C]1_6LN[\*ZE; M&J7"C)_=MR /8]_89KOZ* /*)8I()#'+&\;CJ
MKK@C\*97HWB&V^TZ'<J NY%\P%NVWDX]\9'XUYS0 4444 ;7AFYN8]2^S0.%
M^T#!R!U4$@]/K^==CY6I?\_$?Y?_ %J\_P!-OWTV^CND17*\%6'4'K@]C[UW
M>EZ[::HNU&\J?O$Y&3QGY?4=?RZ"@"7RM2_Y^(_R_P#K4>5J7_/Q'^7_ -:K
M]% %#RM2_P"?B/\ +_ZU'E:E_P _$?Y?_6J_10!0\K4O^?B/\O\ ZU'E:E_S
M\1_E_P#6J_10!0\K4O\ GXC_ "_^M1Y6I?\ /Q'^7_UJOT4 4/*U+_GXC_+_
M .M1Y6I?\_$?Y?\ UJOT4 4/*U+_ )^(_P O_K4V7[;!&9);R"-!U9R !^.*
M=JFKVVE0,TK!I<?)"#\S>GT''6N%U36;K59/WK;80V4B'1?\3[GU/2@"]J7B
M6YGCDMH) 8G4HSE!\P/''MC\>>U8%7M.TF[U23;;QX09S*^0@QVSZ\CBK>MV
MNCZ;:K##>/-?*WSA<$>A![+@@\9)YY]1$ZD*:O-V+ITYU':"NS&HI@D0_P 0
M_&D:9%Z')]JB6(I1CS.2L7'#UI2Y5%W]!_VA[5TFB;;*C!D. <$'/>H;N_N[
MY]]U<23$$D;VR%SUP.@_"MG3/"M_JRI<2E;:W895V&2PYY"_XXZY&:ZO3_"6
MEV2H9(OM,PY+R\CI@_+TQ]<_6O+K4J^,G>.D//\ .QZU&KA\%#EEK/R_*YY[
M9:=>:E*8[2W>5AU(Z+UZD\#H>M=#:^!;UPK7,\,8."44DGW!., _G7>(BQHJ
M(H5%&%51@ >@IU;TLKI1UF[G/6S6K+2"LOO9S-IX3AM.5C@E;&"9AOS^!&/T
MK0FBU2VLF%KY3LB8CB0*!Z <@# ^M:U%=\:4(*T%;T//E5G.7--W]3S)_"NO
M2.SO:%G8Y9FF0DGU/S4W_A$M<_Y\?_(J?XUZ?17!_95'N_P_R/0_M>OV7X_Y
MGF'_  B6N?\ /C_Y%3_&KNEZ'XATS4([F*T(QPX$J<J>HQNY_P 0*]"HJHY9
M2C)23=UZ?Y"GFM:<7&459^O^90\K4O\ GXC_ "_^M1Y6I?\ /Q'^7_UJOT5Z
M)YA0\K4O^?B/\O\ ZU'E:E_S\1_E_P#6J_10!FS6E[<1-%,\$D;=4= 0?P(J
MK_82_P#/KI__ (#I_P#$UN45+A&6Z*4Y1T3,/^PE_P"?73__  '3_P")H_L)
M?^?73_\ P'3_ .)K<HI>SAV0_:S[LYN^\-&ZLI88XK*)V7Y72)5(/4<A<X]?
M:O-'1XY&CD5D=2596&"".H->WUYUXWT8VM]_:42J(+@@/@@8DP>WN!GOSGVK
MT,OE&$G"UKG!CXRG%3;O8Z30=0OM8TJ.Y6X3>I\N0%?XA_P''(P>/6M+RM2_
MY^(_R_\ K5YWX4UDZ3JRI(RBUN"$ER!QUVMD],$\^Q/M7J=98FC[.>FS-,-5
M]I#7=%#RM2_Y^(_R_P#K4V5-42%VCDCD=5)5!@;CZ9(K1HKG9T(\TF\,:_<3
MR32V>Z21B['S8QDDY/>H_P#A$M<_Y\?_ "*G^->GT5YCRJB^K_#_ "/46;5E
MHDOQ_P SS#_A$M<_Y\?_ "*G^-7=+T/Q#IFH1W,5H1CAP)4Y4]1C=S_B!7H5
M%5'+*49*2;NO3_(4\UK3BXRBK/U_S*'E:E_S\1_E_P#6H\K4O^?B/\O_ *U7
MZ*]$\PH>5J7_ #\1_E_]:CRM2_Y^(_R_^M5^B@#.DAU1HV5+J-&((5MH.#ZX
MQ7+_ /" S_\ /_'_ -^S_C7<T5A6PU*M;VBO;U-Z.)JT;^S=K^APW_" S_\
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M7"QYN6A=SC9*A&.<<D9 _.N6MAZBFVHZ'32KTW%)RU-ZBHK>ZM[N,R6T\4R
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M]8FIZA)J-JEE+=K/')#$#N:-P>?3KUZ<>]>>:EJ=QJ=R99G.T$^6G9 3T_\
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M_P"?'_R*_P#C5M-$TI$5!IUJ0HP-T2D_B2,FM/[+K-WE)?B9_P!K48JT8O\
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M/^$2US_GQ_\ (J?XUY-2GB:KYY1;OY'KTZF&I+DA)*WF8M%;7_"):Y_SX_\
MD5/\:/\ A$M<_P"?'_R*G^-1]6K?R/[F:?6J'\Z^]'4>"]5^U:<UC*^9K;[N
M3R4/3OV/'H!MKIZ\_P!&T37M*U2&Z%D=@.)%$J?,AZC[PSZCW KT"OH,#.;I
M<M1--=SYW'PIJMS4VFGV"BBBNPX0HHHH **** "BBB@ HHHH **** "BBB@
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MN%FB"MV9'7<KCKAAW'']>M=-IUMI>NQ".VF-GJ)!)MV):-L#^$GGGKU)'/!
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M;RQ]KV,^/E=&&TGL3C ^N<41Q="6TD*6#Q$=X,VJ*KP7]G=.4M[N"9P,E8Y
MQ ]>*L5NFFKHYVFG9G)ZSX4+N]QIP&6()M^ /<J>WT^OL*YV32K^&\CM)+9Q
M-(<(O9NYP>AQW].]>G5YAJFNRW'B/^T;=OE@8+!U *CUZ'!YR/?%<V*Q4</%
M-]?Z9U83"RQ$FET7_#&WI?A*X>=9-1 CA4\QALL_XCH/QSQ^-=FBK&BHBA54
M8"@8 %0V=U%?6<5U"<QRJ&'(R/8X[CH:GKI335T<K33LRIJ.G6VJV3VMTFZ-
MN01U4]B#V->2:CIUSI5Z]K=)MD7D$=&'8@]Q7LU9NM:+;:W9>1.-LB\Q2@<H
M?ZCU'?\ (UUX;$>R=GLSDQ.']JKK<Y#PCXH2R5--OBJVY)\J7IL).<-[$GKV
M^G3T!U61&1U#*PP5(R"*\6O+26PO9K6<8DB8J>#@^XSV/45V_A'Q0DL<.E7I
M5)% 2"3H& X"GW]/7Z]>C%X=->TA\_\ ,QPN(L_9S-C6M$MIM*F%K9PI.HWH
M8X\$XZC@<Y&>/6N KUJN?UGPQ%?N]Q:L(KEB"P/W&]3TX/\ A[YKS3T#A:*O
M7.D7=I?Q64JQB:4D1CS5^;WZ\9[9QFN@L/!H5]]_.& /$<1.#TZD_CP/SI*2
M>B&XM)-K<J:%X;34;1KF[:1(V.(O+89.,@DY![_R-:O_  ANG?\ /:Z_[Z7_
M .)KH458T5$4*JC 4#  I:8CG?\ A#=._P">UU_WTO\ \31_PANG?\]KK_OI
M?_B:Z*B@# B\(:9'(&9KB0#JCN,'\@#^M/NO"VFR6LJV\'ES%3L?S&X/;.2>
M/PK<HH \HEB>"9XI!M=&*L,]".#3*]&U30K35%W.OE3]I4 R>,?-ZCI^745A
M2>"I@\8BO8V4GYRR%2![#G/?TH Y:NW\)::UM:->2@;K@#8"O*J,]_?@_@*?
M8>$K.U?S+ES=,#D C:HZ=N_YXYZ5T% !1110 4444 %0W-K!>0F*XB61#V8=
M.V1Z'WJ:F33);P232MMCC4NQQG  R:&[ E?1'%ZSI^CV&L6=L3-$DYS)AQB-
M>@.6'=N22> #QR*ZBQT6PTXAH(!Y@ 'F.=S=,9YZ9SVQ7E^HWKZCJ,]W(,-*
MV0/[HZ ?@,"NIM?'"V^EV\<EM)/=H-KDMM4@=#GDD],\=<UY5#,8.<N=V70]
M>OEDXTX>S5WU_K\#MJRM0\1Z9IH(DN!)("1Y4)#-D'!![#\2.AK@M0\2ZIJ*
MO')<>7"W6.(;1TP1GJ0?0FLN&&6XE6*&-Y)&Z(BDD_@*SJYK?2DOO_R-*.4V
M]ZM+[O\ ,WM3\8:C?92 _9(?2-OG/3JWU';'7O6 [M([.[%G8Y9F.23ZFNET
MKP7>76V6^;[+"<'9UD(X[?P\9Z\@CI73Q6.A>'%69_)ADV\23/EVP.2N>_/(
M4=ZQA@\5BGS5']_Z+_AC:>-PN$CRTU]WZO\ X<X_3_"6J7K(9(OLT)Y+R\'K
M@_+US]<?6M/4_#NF:%H4TUP7NKI_W<3$E &.<$ >@YY)SM[9JY?>/;"!BMG!
M+=$$?,?W:D8[$\^W05SE]XSU6^M'MF%O$D@*N8T.64@@CDGU[<U[-'([1T6O
M=_Y'C5L];EJ].RZ_,Q:*KT5/^K'_ $]_\E_X)?\ K1_TZ_\ )O\ @%BNJ\"W
ML<&HSVCC#7*@HWNN3C\B3^'O7&UKZ%X@N-"DE,,,4B3%?,#YS@9Z$=.I[&M*
M7#\Z$O:0J7:Z6M?\3.MQ!"O!TYTK)];[?@>M45SFE>,]-O\ "7!^QS>DK?(>
MO1NG0=\=>,UT=;SIR@[25CEA.,U>+N%%%%064-9-[_9<R:?$7N9!L7#!=N>K
M9)'0=/?%>?\ _"):Y_SX_P#D5/\ &O3Z*Y,1@X5Y)S;T_KL=F&QL\/%Q@EK_
M %W/,/\ A$M<_P"?'_R*G^-'_"):Y_SX_P#D5/\ &O3ZJ:G?QZ9IL]Y(,K$N
M0O\ >/0#\3@5@LIHMV3?X?Y'0\XK)7:7X_YGE-]!>:8TMC.YB9PIDB64$'N-
MVTD>_-2^'=*_M?68;=AF%?WDW^X.W4'DX''KFJ-Y=RW][-=3G,DK%CR<#V&>
MPZ"O1_!FE?8-&%PX_?7>)#[)_".N.A)_X%CM7T-*A'+\-[.#;OW[GSU;$2S#
M$^TFDK=C6N](TZ^WFYLX79\;GVX<XZ?,.>WK6+=^!].FWM;2S6['&T9WHOKP
M>3^==/17E5,/2J?%%'J4\36I_!)H\ZNO!.J09,!AN%W8 5MK8]2&P/U-8]SI
M6H6@=KBRGC2,X9S&=HYQ][I7KM%<,\JI/X6T=U/-ZJ^))_@>+45J>(-3_M75
MY9U.85_=Q?[H[]!U.3SZXK+KPYI1DU%W1]!"3E%.2LR6"YGM7+V\\D+D8+1N
M5)'IQ5C^V-4_Z"5Y_P!_V_QJE73^&]!TW6K.1I9;E+B)L.J,,$'H>5^HZGI[
MUI0C4J2Y(/\ $RKSITX^TJ+3T,7^V-4_Z"5Y_P!_V_QH_MC5/^@E>?\ ?]O\
M:[B'P1I,<JN[7,JCJCN,'\@#^M6O^$2T/_GQ_P#(K_XUW++\4_M6^;//>8X1
M;1O\D>9S32W$K2S2/)(W5W8DG\33*]/_ .$2T/\ Y\?_ "*_^-7?['TO_H&V
M?_?A?\*%E55_%) \WHK2,7^!Y'17KG]CZ7_T#;/_ +\+_A7F6LW4%WJDTEK#
M'%;@[8EC0*"H[\ =>O//..U<^)P;P\4Y2O<Z<+C5B9-1C:Q0J6"YGM7+V\\D
M+D8+1N5)'IQ45%<:;3NCM:35F;UKXOUBVP&F2=0NT+,F?QR,$GZFMVQ\=V\F
MU+ZV>)OE!>,[E]R1U _.N;T;0_[:BG6&Z2.ZBP1%(O#*>^0<\?3T]:=>^%]7
MLB<VIG3( >#Y\\9Z=?S%>A2K8R$5.-VOO/.JT<%.3A*RE]QZ#9:UINH$+:WD
M;N20$)VL<#/"G!-5]2\.V.H[GV>3.>?,C&,GGJ.AY/U]Z\MK2M-?U6R39!>R
M!, !7PX4#H!NSC\*Z:6;?\_(_=_7ZG+5R?\ Y]R^_P#K]#8OO"^H68+QJ+F/
M)YBR6QGC*_X9K$KHK7Q[*,"\LD;+<M"Q7"_0YR>O<5;N?$>@ZI;7 EC\J<Q%
M(Y+B#)R0<8*[B,'^==T,=AY[2^_0X)X#$0WC?TU.2HI <C(Z&EKK3OJCC:MH
MPI45I'5$4LS' 4#))I*9+*T2_(Q5F!7(..#P?TX_&LZU14H.;Z&M&DZM1074
MOO!:V)D&H3'SE) M[=E9B<'JW(7D8[GVJC>ZC)=+Y*((+17+QP(<@$]R>K'W
M/X8'%5889;B58H8WDD;HB*23^ KKM'\$NS>;JIV*.1#&W)Y_B([8]#WZC%>'
M*KB<:^6*LOP^;/>C1PV!7-)W?X_)'-:?IEWJEP(;6(MR SX^5/=CVZ&N^T3P
MM::6%FG N+O RS#*H<Y^4?ESUX[9Q6U;6T-I;I;V\8CBC&%4=JEKT,-E\*/O
M2U9YN*S&I6]V.D0HHHKT#S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEQ;VHDBD&582IS^M=5#%8I)0IZV\KG)7PF%;<ZFC?6]CH_\ A.HO^>#_ /?
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M]3[DU0K@I8^I0]R/O16UST*N7TZ_OR]V3WL6FG0#CDUOZ9X6DO88+V5A-'(
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M #[Q_G_]>K]% %#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->K]% %#S=2_P"?>/\
M/_Z]'FZE_P ^\?Y__7J_10!0\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7J_10!0\W
M4O\ GWC_ #_^O1YNI?\ /O'^?_UZOT4 4/-U+_GWC_/_ .O1YNI?\^\?Y_\
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M^?\ ]>CS=2_Y]X_S_P#KU?HH H>;J7_/O'^?_P!>CS=2_P"?>/\ /_Z]7Z*
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MC_/_ .O5^B@"AYNI?\^\?Y__ %Z/-U+_ )]X_P __KU?HH H>;J7_/O'^?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK*O/$FDV%T]K=7?ES)C<
MOEN<9&1R!CH:J,92=HJY,I1BKR=C5HK#_P"$PT'_ )__ /R"_P#\31_PF&@_
M\_\ _P"07_\ B:KV-3^5_<3[:G_,OO-RBL:'Q5HMQ/'!%>[I)&"(OE.,DG [
M5LU,H2C\2L5&<9?"[A1114E'.W/_ !]3?[[?SHHN?^/J;_?;^=% &QIW_'C'
M^/\ ,U:JKIW_ !XQ_C_,U:H **** "BBB@ HJO?7UMIME+>7DRPV\*[G=N@'
M]3V ')-8'_"6R_:9WBT;4+JR6VAGB:WC1G=9&<!]N_.TA1@8W##;@.* .GHJ
MAI&MZ?KUHUUIMQY\*2&-FV,N& !QA@#T(JHWB6UDU.?3]/M[G4;FWS]H%J%V
MPGCAF=E7)YX!)^5O2@#:HK*TSQ!9:I=W%DGFP7]M_KK2X7;(@S@'C(8'@Y4D
M88>HJWJ&I6FEVZS7DOEH\BQH I9G=C@*J@$L3Z 4 6J*REUV*.X@AO[2YT][
MB01P&YV%9'P3M#(S 'C@,1GMGFM6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5_S\7O\ WVO_ ,37545PO$U6[\QV+#TDK6.5_P"$ TK_ )^+W_OM?_B:/^$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU139RJ"QP,E2 /J20![FJ7@"VFM? VEQS)M=D:0#(/RN[,IX]00: .DHHHH
M*K7%S+#(%2V>0$9R,_X59HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I
M_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH
MH?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5
M?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,G
MZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\
M\^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[
M=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7
M_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#G
MQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I
M_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH
MH?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5
M?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,G
MZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\
M\^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[
M=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7
M_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#G
MQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I
M_P#GQD_7_"C[=/\ \^,GZ_X5?HH H?;I_P#GQD_7_"C[=/\ \^,GZ_X5?HH
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M7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\
MGQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;
MI_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH
M H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X
M5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,
MGZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_
M ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C
M[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_
M7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\
MGQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;
MI_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH
M H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X
M5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,
MGZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_
M ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C
M[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_
M7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\
MGQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;
MI_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH
M H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X
M5?HH H?;I_\ GQD_7_"C[=/_ ,^,GZ_X5?HH XNZ\+6EW=S7,D%^'FD:1@KC
M ).3CY*B_P"$/L?^>.H_]]K_ /$5W-%;+$55]HQ>'I/H<-_PA]C_ ,\=1_[[
M7_XBLG5/"EW;LTME;SRP<?(5+2#\@,C_ !]LUZ?15PQ=6+NW<F6%I25K6/$$
M=XY%DC9D=2&5E."".A%=1I7CB^LPL5Z@NXAP&)Q(.G?OWZ\DGK79:KX=TW5\
MM<0[9C_RVB^5^W7L>!CD'VKB-2\$ZG9L6M@MY" 3E/E88']TGZXQGI7:J]&N
MK3T?]=3C=&M1=X:_UV.LL/%EKJ3!+>(^:>D3-AN_08YX&>*T?MT__/C)^O\
MA7C[H\<C1R*R.I*LK#!!'4&M?3O%&K::J1Q7'F0ITBF&X8Q@#/4 >@(K*I@.
MM-FE/'=)H])^W3_\^,GZ_P"%'VZ?_GQD_7_"L#3O'ME,J)?Q/;R=&=!N3IU]
M1D]L'MS1J7CJ*RU"6W@M$NHTQB9+@8;(![ ^N.O:N7ZM5YN6QT_6:5N:YO\
MVZ?_ )\9/U_PH^W3_P#/C)^O^%<K_P +$_ZA7_DQ_P#8T?\ "Q/^H5_Y,?\
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MU_PH^W3_ //C)^O^%7Z* *'VZ?\ Y\9/U_PH^W3_ //C)^O^%7Z* *'VZ?\
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M>&])O[I[JZM/,F?&YO,<9P,#@''05"QZYM5H6\"[:/4\CHKU7_A#]!_Y\/\
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MBA41!@*!P !V%/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH J7VFV6IQ".\MTF4=">"O3H1R.@Z5RNH^ (W9Y-.NO
M+SR(9AD Y_O#D#'L>G6NUHK6G6J4_A9E4HPJ?$CR#4=!U+2V?[3:OY:_\MD&
MY,9P#D=,^AP>16;7N->3^*H8K?Q+=Q01)%&NS"(H4#Y%["O2PV*=5\K6IYV(
MPRI+F3,:BBBNTY#<\'_\C59?\#_] :O5:\>T34$TK6;>]DC9TC)W*IYP00<?
MG7J.F:U8:O'NM)U9P,M$W#KTSD?B!D<>]>7CH2YU*VECT\%./*XWUN:%%%%>
M>=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4453U+5+/
M2K8S7<RIP2J9^9\=E'?J/ZTTFW9";25V>;>,/^1JO?\ @'_H"UAU<U74'U74
MY[UXUC,I'RJ<X   _0"J=>_3BXP2?8\*HU*;:[A5FPL9M2OHK.W"F64X&XX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP_\ '_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\
M_K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\
MZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9
MG]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\
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M\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\
M'_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5I
MT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']
MK_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9G]K_
M /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\ 3#_Q
M_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9G]K_ /3#_P ?
M_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\ 3#_Q_P#^M6G1
M0!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO
M_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\
M],/_ !__ .M1_:__ $P_\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_
M /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__
M .M1_:__ $P_\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=%
M&9_:_P#TP_\ '_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__
M $P_\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#T
MP_\ '_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\
M_K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\
MZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9
MG]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\
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M\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\
M'_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5I
MT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']
MK_\ 3#_Q_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9G]K_
M /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\ 3#_Q
M_P#^M6G10!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9G]K_ /3#_P ?
M_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\ 3#_Q_P#^M6G1
M0!F?VO\ ],/_ !__ .M1_:__ $P_\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO
M_P!,/_'_ /ZU:=% &9_:_P#TP_\ '_\ ZU']K_\ 3#_Q_P#^M6G10!F?VO\
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M !5'_"?ZK_S[V7_?#?\ Q5;_ %*J8_7*1VG]K_\ 3#_Q_P#^M1_:_P#TP_\
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M\?\ _K5IT4 9G]K_ /3#_P ?_P#K4?VO_P!,/_'_ /ZU:=% &9_:_P#TP_\
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MH& ,GGH*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_P :/[6@_N2?D/\
M&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K
M]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_ !H_M:#^Y)^0_P :
MOT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT
M4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\ &C^UH/[DGY#_ !J_
M10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10
M!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_P :/[6@_N2?D/\ &K]%
M %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %
M#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_ !H_M:#^Y)^0_P :OT4
M4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/
M[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\ &C^UH/[DGY#_ !J_10!0
M_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M
M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_P :/[6@_N2?D/\ &K]% %#^
MUH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH
M/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_ !H_M:#^Y)^0_P :OT4 4/[6
M@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_
MN2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\ &C^UH/[DGY#_ !J_10!0_M:#
M^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y
M)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_P :/[6@_N2?D/\ &K]% %#^UH/[
MDGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DG
MY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_ !H_M:#^Y)^0_P :OT4 4/[6@_N2
M?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D
M/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\ &C^UH/[DGY#_ !J_10!0_M:#^Y)^
M0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_
MQH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_P :/[6@_N2?D/\ &K]% %#^UH/[DGY#
M_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&
MC^UH/[DGY#_&K]% %#^UH/[DGY#_ !H_M:#^Y)^0_P :OT4 4/[6@_N2?D/\
M:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/
M[6@_N2?D/\:OT4 4/[6@_N2?D/\ &C^UH/[DGY#_ !J_10!0_M:#^Y)^0_QH
M_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M
M:#^Y)^0_QJ_10!0_M:#^Y)^0_P :/[6@_N2?D/\ &K]% %#^UH/[DGY#_&C^
MUH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH
M/[DGY#_&K]% %#^UH/[DGY#_ !H_M:#^Y)^0_P :OT4 4/[6@_N2?D/\:/[6
M@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_
MN2?D/\:OT4 4/[6@_N2?D/\ &C^UH/[DGY#_ !J_10!0_M:#^Y)^0_QH_M:#
M^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y
M)^0_QJ_10!0_M:#^Y)^0_P :/[6@_N2?D/\ &K]% %#^UH/[DGY#_&C^UH/[
MDGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&K]%% !11
M10 4444 <[<_\?4W^^W\Z*+G_CZF_P!]OYT4 ;&G?\>,?X_S-6JJZ=_QXQ_C
M_,U:H **** "BBB@# \5ZG<:-:V&HQ6US<0P76ZZCMP<^5Y<@9CVP"0W/&0.
M1UJE!XIT/^WKJ[74H)(YK.T2)8R7=V,DWRA!EBWS+D8R,\UUE1+;1+=R72IB
M:1%C=LGE5+%1CIP7;\Z .(\*>#UDTW5Y=8L5@M]8E64:<"5,"*S,JDKC!Y'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.#@X(XZBI: "BJMGJ=AJ._[#?6UUY>-_D2J^W/3.#QT/Y5:H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#C_ )$+3/\ MK_Z->@#J:*** "H9;J&!PLC[6(SC!-34QX8I#EXT8],E0:
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M^T;7_GK_ ..G_"C^T;7_ )Z_^.G_  J7[-!_SPC_ .^!1]F@_P">$?\ WP*
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M^T;7_GK_ ..G_"C^T;7_ )Z_^.G_  J7[-!_SPC_ .^!1]F@_P">$?\ WP*
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M;^=%%S_Q]3?[[?SHH V-._X\8_Q_F:M55T[_ (\8_P ?YFK5 !1110 4444
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M5##'5LX /-=)8VD>GZ?;6419H[>)8D+GDA0 ,^_%6** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .=N?^/J;_?;^=%%S_P ?4W^^W\Z* -C3O^/&/\?Y
MFK55=._X\8_Q_F:M4 %%%% !1110 4444 %%%% !1437,2W<=JSXFD1I$7!Y
M52H8YZ<%U_.I: "BBB@ HHHH ***C$T;3-"&_>*,D8_SZT 24444 %%%% !1
M110 4444 %%1B:-IFA#?O%&2,?Y]:DH **** "BBB@ HHHH ***C$T;3-"&_
M>*,D8_SZT 24444 %%%% !1110 4444 %%1B:-IFA#?O%&2,?Y]:DH ****
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M0,IRK#(-+0 4444 %%%% !1110 44V21(HR[G"CJ<4JL'0,IRK#(- "T444
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MY[[PSXFLO$^F"ZM3LE3 G@8Y:)OZ@]CW]B"  ;5%97_"3:!_T'--_P# N/\
MQK2BECGB26)UDC=0R.AR&!Y!![B@!]%%% !6<KI'J\Q=E4; ,DX]*T:S?)CG
MU:99%W*%!QG'84 7?M,'_/>/_OL4?:8/^>\?_?8J+^SK7_GE_P"/'_&C^SK7
M_GE_X\?\: )?M,'_ #WC_P"^Q1]I@_Y[Q_\ ?8J+^SK7_GE_X\?\:/[.M?\
MGE_X\?\ &@"7[3!_SWC_ .^Q1]I@_P">\?\ WV*B_LZU_P">7_CQ_P :/[.M
M?^>7_CQ_QH E^TP?\]X_^^Q1]I@_Y[Q_]]BHO[.M?^>7_CQ_QH_LZU_YY?\
MCQ_QH KQS1#5IG,B!2F VX8/2KOVF#_GO'_WV*SX[6%M2EA*?NU7(&3[?XU;
M_LZU_P">7_CQ_P : )?M,'_/>/\ [[%'VF#_ )[Q_P#?8J+^SK7_ )Y?^/'_
M !H_LZU_YY?^/'_&@"7[3!_SWC_[[%'VF#_GO'_WV*B_LZU_YY?^/'_&C^SK
M7_GE_P"/'_&@"7[3!_SWC_[[%'VF#_GO'_WV*B_LZU_YY?\ CQ_QH_LZU_YY
M?^/'_&@"7[3!_P ]X_\ OL52CFB&K3.9$"E,!MPP>E6/[.M?^>7_ (\?\:J1
MVL+:E+"4_=JN0,GV_P : -#[3!_SWC_[[%'VF#_GO'_WV*B_LZU_YY?^/'_&
MC^SK7_GE_P"/'_&@"7[3!_SWC_[[%'VF#_GO'_WV*B_LZU_YY?\ CQ_QH_LZ
MU_YY?^/'_&@"7[3!_P ]X_\ OL4?:8/^>\?_ 'V*B_LZU_YY?^/'_&C^SK7_
M )Y?^/'_ !H E^TP?\]X_P#OL4?:8/\ GO'_ -]BHO[.M?\ GE_X\?\ &C^S
MK7_GE_X\?\: *\<T0U:9S(@4I@-N&#TJ[]I@_P">\?\ WV*SX[6%M2EA*?NU
M7(&3[?XU;_LZU_YY?^/'_&@"7[3!_P ]X_\ OL4?:8/^>\?_ 'V*B_LZU_YY
M?^/'_&C^SK7_ )Y?^/'_ !H E^TP?\]X_P#OL4?:8/\ GO'_ -]BHO[.M?\
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MC_[[%'VF#_GO'_WV*B_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@"7[3!_P ]X_\
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MC_[[%'VF#_GO'_WV*B_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@"7[3!_P ]X_\
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M: )?M,'_ #WC_P"^Q1]I@_Y[Q_\ ?8J+^SK7_GE_X\?\:/[.M?\ GE_X\?\
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MVF#_ )[Q_P#?8JG9V=O+:([QY8YR=Q]:G_LZU_YY?^/'_&@"7[3!_P ]X_\
MOL4?:8/^>\?_ 'V*B_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !H E^TP?\]X_P#O
ML4?:8/\ GO'_ -]BHO[.M?\ GE_X\?\ &C^SK7_GE_X\?\: )?M,'_/>/_OL
M4?:8/^>\?_?8J+^SK7_GE_X\?\:/[.M?^>7_ (\?\: %N+B$VTH$T9)0@ ,/
M2DT[_CQC_'^9ID]A;);R,L>&520=Q]*?IW_'C'^/\S0!:HHHH **** .=N?^
M/J;_ 'V_G11<_P#'U-_OM_.B@#8T[_CQC_'^9JU573O^/&/\?YFK5 !1110
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M  YXJ6B@ HHHH **** "BBB@ HHHH BN+=+F,(Y8 '/%2T44 %%%% !1110
M4444 %17%NES&$<L #GBI:* "BBB@ HHHH **** "BBB@".:)9XFC8D*W7%.
M1!'&J#.%  S3J* "BBB@ HHHH **** "HYHEGB:-B0K=<5)10 U$$<:H,X4
M#-.HHH **** "BBB@ HHHH CFB6>)HV)"MUQ3D01QJ@SA0 ,TZB@ HHHH **
M** "BBB@ J.:)9XFC8D*W7%244 -1!'&J#.%  S3J** "BBB@ HHHH ****
M(YHEGB:-B0K=<40Q+!$L:DE5Z9J2B@ HHHH **** "BBB@ IKH)(V0YPP(.*
M=10!'#$L$2QJ257IFI*** "BBB@ HHHH **** &N@DC9#G# @XIL,2P1+&I)
M5>F:DHH **** "BBB@#G;G_CZF_WV_G11<_\?4W^^W\Z* -C3O\ CQC_ !_F
M:M55T[_CQC_'^9JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!P: .WHKCOACJ,E_X-BCEW%K25K<,S[BP&&'T #!0/1?PKL: "BBB@ HHHH
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M4 <W-_;>NO++IFJ?V1;03R0+NM4G:<H=K/RWRC<& &,\9/4 <[=^(O$_@K4
M?$!75M+N&VQW$*+&8R#Z  ;BO.T\'LW!I\?B2X\%>(;^PUV"4Z;>W4EU9W4>
M7"!WRPQZ#.2!R#G@[@:U-;UK1?$=A;:):7,5])JDB*(X9!NCC!#N[<C:54$@
M'DD ;3R* .JM;F*\M(;JW??#,BR1M@C*D9!P>>AJ6N!^&$UQ;6^L:%<'>^FW
M14.')7DD%5!' RA/ONZ"N^H **** "BBB@ KFYO[;UUY9=,U3^R+:">2!=UJ
MD[3E#M9^6^4;@P QGC)Z@#I*\\C\27'@KQ#?V&NP2G3;VZDNK.ZCRX0.^6&/
M09R0.0<\'<#0 R[\1>)_!6H ^("NK:7<-MCN(46,QD'T  W%>=IX/9N#7H-K
M<Q7EI#=6[[X9D62-L$94C(.#ST-<KK>M:+XCL+;1+2YBOI-4D11'#(-T<8(=
MW;D;2J@D \D@#:>15#X837%M;ZQH5P=[Z;=%0X<E>2054$<#*$^^[H* .^HH
MHH **** "BBB@#FYO[;UUY9=,U3^R+:">2!=UJD[3E#M9^6^4;@P QGC)Z@#
MG;OQ%XG\%:@#X@*ZMI=PVV.XA18S&0?0 #<5YVG@]FX-/C\27'@KQ#?V&NP2
MG3;VZDNK.ZCRX0.^6&/09R0.0<\'<#6IK>M:+XCL+;1+2YBOI-4D11'#(-T<
M8(=W;D;2J@D \D@#:>10!U5K<Q7EI#=6[[X9D62-L$94C(.#ST-2UP/PPFN+
M:WUC0K@[WTVZ*APY*\D@JH(X&4)]]W05WU !1110 4444 %<W-_;>NO++IFJ
M?V1;03R0+NM4G:<H=K/RWRC<& &,\9/4 =)7GD?B2X\%>(;^PUV"4Z;>W4EU
M9W4>7"!WRPQZ#.2!R#G@[@: &7?B+Q/X*U 'Q 5U;2[AML=Q"BQF,@^@ &XK
MSM/![-P:]!M;F*\M(;JW??#,BR1M@C*D9!P>>AKE=;UK1?$=A;:):7,5])JD
MB*(X9!NCC!#N[<C:54$@'DD ;3R*H?#":XMK?6-"N#O?3;HJ'#DKR2"J@C@9
M0GWW=!0!WU%%% !1110 4444 <P^H^)=56.]T"+2DTZ1<Q'4!,)9!DC?@ 84
M\$=21@\9P,K3O'US8ZK_ &3XNL5TZ[=E,4T?^JVD<%CN/&1C<"1R<XVDTWPA
MXOM]/M$\/>(9/L&I6/[D&XPJ.@!*_,/E&% ')YX()S5KQ_I]OKT-KH\*^9JI
MWW$(0#<B*C9+$CA68*G)7D@\[2* .THKEOA[K,VM>$H9+F666YMY&@EDDQER
M.0<]_E91D\D@_4]30 4444 %%%% !6!?/JVKWEU9:5??V6EE(BR7+6Z3&9V0
M,552?E #(22.2>,8.=^N!U?6[WP7XNO;^]MI9]#U/85>$Y,4J1A>A( )V\^H
M (/RD4 1:KJ?C#P;<"_O[F+6])^XVV)860D#!;:OR\\ _,#WP2*[;2=4MM:T
MJWU&S+&"=<KO7!!!P01Z@@CTXXS6!JOB[0[[P_+%8W4%]/?*;6WM Q#R.^4
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MC=U8=B/_ *XR"#5^O,7T]OAUXPMKFT;=H>J2""1978+;DD<ENG&203SC>/\
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M16\D$\?V75;;Y;FU8$$$'!90><9X(Z@\'L3M:?J5EJUHMU8745Q"W\4;9P<
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M;S=!+P)K64?, >0&'3H1D<CG!!Y$\44<$2111K'&BA41!@*!P !V% #Z***
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M13)98X(GEE=8XT4L[N<!0.22>PH ?6%XJTFYU_2O[(@=8(;A@9[ADW;%4A@
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MP4X9>2!N4\C.#C(YKG_%GA.6_N(]<T.3[+KMM\RNI $X QM;MG' )X(X/'0
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M8PQ/^SDD=*ZF@#-\/Z6NB^'['3@%#01 2;&)!<\N03S@L2?Q[5I444 %%%%
M'.W/_'U-_OM_.BBY_P"/J;_?;^=% &QIW_'C'^/\S5JJNG?\>,?X_P S5J@
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M_9EY4XY4X/3@C-8OP^M9K+PR8&NXKJV2ZG6UEC P8@Y7/'JP9NIX8<T ,O\
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M\1.>&7L>#[''&16%X)TS^R;SQ!:VMS%+ID=]M@1.3&^P%U)Y)P&1>2>4/ H
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MOB)SPR]CP?8XXR*PO!.F?V3>>(+6UN8I=,COML")R8WV NI/). R+R3RAX%
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MQU-<;/K?B?Q3K%U#X5F@L].LF,37<P5EG?/8[6X[C';DGD"I?"OBC7%\0?\
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M\]G<Q&SG@BFN(!RR3NS$<\GH';J/]8.,8KKZ *]C8VVFV45G9PK#;PKM1%Z
M?U/<D\DU8HHH ***X;4O&&M7FNW&E^%-+BO3996ZEN 54/G&T991P0>IYP<#
M R0#5\?VTUUX&U2.%-SJBR$9 ^5'5F//H 36EH.M6VOZ/!J%LRD.H$B!LF)\
M?,AX'(^G(P>A%<[X3\;W&L:G)H^L6'V#4T3> <H'[XV-\P.T@XYR 3Q7,:CI
MVK_#GQ!/JVDV[2:#(RB2,R;A@_PMW!!SM;!QD DY((!=\3>&;WPGJ9\4>%QL
MB3)NK51E57^+Y>\9[C^'J, ?+WF@ZU;:_H\&H6S*0Z@2(&R8GQ\R'@<CZ<C!
MZ$4:+KVG:_9+<Z?<+("H+QDC?$3GAE['@^QQQD5A>"=,_LF\\06MK<Q2Z9'?
M;8$3DQOL!=2>2<!D7DGE#P* (O$?A-M9\6Z?>6,DMA)&C->WD!9'9> BJ>A8
MC>,]AC/\(/66-C;:;916=G"L-O"NU$7H!_4]R3R35BB@ HHHH *H:[;37GA[
M4K6W3?--:RQQKD#+%" ,GCJ:Y76=>U[5_$4FA>%6BA-GS=WT@5D5L<)T8#GC
MIG(/0*2:NE>)?$NC>);71O%21217DC)!=J@&6Z+@H,$$XX(!&\$X'% &YX"U
MJVU?PK9QQ,HGLXDMYH@V2A48!/ X8#/IU&>#6+XQ\'7,=[_PDOAHM#J4+>9+
M#$.93W91W;KE>C#/?(:AXJT+5_#/B.3Q3X=C8P,K2W:[]P!+9?<O4H>#QG!!
M/RX&.S\->*].\3622VTBQW6W,MJSC?&1C)QW7D8;ISV.0 !OA#Q-%XGT5+G,
M27D?RW,*$_(W.#SS@@9'7N,D@U%XN\,KXH33[1QY<<4YEEN %W*@!!1<\Y8E
M>V/ER>@!J:+IG]G_ !"UY[.YB-G/!%-<0#EDG=F(YY/0.W4?ZP<8Q77T 5[&
MQMM-LHK.SA6&WA7:B+T _J>Y)Y)JQ110 445PVLZ]KVK^(I-"\*M%";/F[OI
M K(K8X3HP'/'3.0>@4D@'5:[;37GA[4K6W3?--:RQQKD#+%" ,GCJ:Q_ 6M6
MVK^%;..)E$]G$EO-$&R4*C )X'# 9].HSP:P]*\2^)=&\2VNC>*DBDBO)&2"
M[5 ,MT7!08()QP0"-X)P.*I>*M"U?PSXCD\4^'8V,#*TMVN_< 2V7W+U*'@\
M9P03\N!@ O\ C'P=<QWO_"2^&BT.I0MYDL,0YE/=E'=NN5Z,,]\ANB\(>)HO
M$^BI<YB2\C^6YA0GY&YP>><$#(Z]QDD&G>&O%>G>)K));:18[K;F6U9QOC(Q
MDX[KR,-TY['(&;HNF?V?\0M>>SN8C9SP137$ Y9)W9B.>3T#MU'^L'&,4 8N
ML_VUK?BC6/#&E_Z/:RSQS7UYS\L9@B79^.T\9RW3@!J[K1M&LM!TR.PL(MD2
M<DGEG;NS'N3_ /6&  *OT4 %%%% !17#:SKVO:OXBDT+PJT4)L^;N^D"LBMC
MA.C <\=,Y!Z!235TKQ+XET;Q+:Z-XJ2*2*\D9(+M4 RW1<%!@@G'! (W@G X
MH N?#;48QHTF@3[8M1TR62.6$ODD;R2P[8#$KP3T'J*?XU\%?VUC5=*/V?68
M,,K*VWSMO0$]F&.&_ \8(H>.?"VIC5X/$OAQ9?M\?-P(W^8[5PK*IZ\ J5'7
MC@Y-;7A#QM9>);1(Y7BM]37Y7MRV-YP3N3/)& 3CJ._8D 9X'\52:]92VFH[
M8M7M&*3Q$;68# W[<<'/! Z$=L@5A:S_ &UK?BC6/#&E_P"CVLL\<U]><_+&
M8(EV?CM/&<MTX :MJ73/(^*5K?65S$CW-C(U] >69%VJK=\9)3T_U9Y/(KKZ
M *&C:-9:#ID=A81;(DY)/+.W=F/<G_ZPP !5^BB@ HHKCO%'B'5&UB'PYX;1
M3J4BB6>X;#+;)GN.<'H3D=", EA@ [&N(^&VHQC1I- GVQ:CIDLD<L)?)(WD
MEAVP&)7@GH/45EMXB\7^$M5@7Q,8+O2YY5C:Z1!A!CDJ4 .1G.&7)VG'K5CQ
MSX6U,:O!XE\.++]OCYN!&_S':N%95/7@%2HZ\<')H O^-?!7]M8U72C]GUF#
M#*RMM\[;T!/9ACAOP/&"+'@?Q5)KUE+::CMBU>T8I/$1M9@,#?MQP<\$#H1V
MR!3_  AXVLO$MHD<KQ6^IK\KVY;&\X)W)GDC )QU'?L3#+IGD?%*UOK*YB1[
MFQD:^@/+,B[55N^,DIZ?ZL\GD4 8NL_VUK?BC6/#&E_Z/:RSQS7UYS\L9@B7
M9^.T\9RW3@!J[K1M&LM!TR.PL(MD2<DGEG;NS'N3_P#6&  *OT4 %%%% !17
M'>*/$.J-K$/ASPVBG4I%$L]PV&6V3/<<X/0G(Z$8!+#&*WB+Q?X2U6!?$Q@N
M]+GE6-KI$&$&.2I0 Y&<X9<G:<>M &I\-M1C&C2:!/MBU'3)9(Y82^21O)+#
MM@,2O!/0>HI_C7P5_;6-5TH_9]9@PRLK;?.V] 3V88X;\#Q@BAXY\+:F-7@\
M2^'%E^WQ\W C?YCM7"LJGKP"I4=>.#DUM>$/&UEXEM$CE>*WU-?E>W+8WG!.
MY,\D8!..H[]B0!G@?Q5)KUE+::CMBU>T8I/$1M9@,#?MQP<\$#H1VR!6%K/]
MM:WXHUCPQI?^CVLL\<U]><_+&8(EV?CM/&<MTX :MJ73/(^*5K?65S$CW-C(
MU] >69%VJK=\9)3T_P!6>3R*Z^@"AHVC66@Z9'86$6R).23RSMW9CW)_^L,
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M\=1ZHO\ 9FM,MIJ\+>61+^[$QSMX!Z/G@KZ].X%CQ+IF_P 8^&M1M+F*&_\
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MJ*>ZM[;R_M$\47FR"./S'"[W/11GJ3Z5+0!@'S;J_P!7\/ZC+*\-W TMM*
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M0U*TTNW6:\E\M'D6- %+,[L<!54 EB?0"@"U6!J/FR:O-I5Y+*VFZO:O#"5
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M:&AVTUEH5C9SIMEMH$@;D$$H-N1['&1WP1D \4S7=,;5=*>&)ECNXV6:UE8
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M"[VR22<DD^I))].>,4 %AI-EIC3O:Q,))V#2RR2M([D# RS$D@#H,X%7:**
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MDE:1W(&!EF)) '09P*J^&O#UMX9T=+"V=I#N\R65NLCD $X[#@ #T'<Y)UZ
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M7VL.MC3%<7*EMP+1$G<=VX*0"V[.3SGU(Q6_8:39:8T[VL3"2=@TLLDK2.Y
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MOMS2VTWFLL11BRE4.<,552<<9^H.UI_C;PYJEVMK::I$TS?=61&CW$D  %@
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M!X4+V5CV X'/W?=2".N!TSQ-9QR1/Y\,%TLD<RI@>9$X.48C!&05W+P06 -
M$VMZ1;Z]I$^FW3RI#-MW-$0&&&##&01U'I4]C8VVFV45G9PK#;PKM1%Z ?U/
M<D\DU8HH ***9++'!$\LKK'&BEG=S@*!R23V% #ZR/$.BMX@LETV6=H;*1MU
MP8R-[@<JHR" -V"3U^7&/F)'*R_%2VCNGE71[R32%E,(OT_B;;G 4@#)]"P.
M.<=J[RUN8KRTANK=]\,R+)&V",J1D'!YZ&@#@=&UF]\%:G'X<\1R[]/?BPU
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M!AP1P1D<$"O,]$UO4?A[K#Z+K4<[Z.TK+!.T9PHS]].N5.064$D$^N00!_\
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M\ >150L@1N-KG& 3S\AYZ\4 :M9'A[PUIWAFR:VL$8EVW232$%Y#VR0!P.P
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MK-\/>&M.\,V36U@C$NVZ2:0@O(>V2 .!V &/Q))NZ=I]OI=F+2U7;"LCNJX
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M?8\%Y%?&3P!G;@9WX QUP<@;5GI]O827CVZ[?M4YN)%  &\JJDC [[<GW)-
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MZ?IYTF62&W@BA>;S@&^50&(7&.H./FYXZ=NIU+0M%^(FBVNI1M+#(R'R;A5
M=>H*.#]X!L\9['!Y)/3QV-G#9&RBM8$M"I4P+& F#G(V],')S]:P/#-BVG:]
MXCMK:%8=+6YB:"-,861HE:3 Z@<IQT';O0 VS\.>(+:P>QE\5RSPR8!E:U_?
MHN<MLD+D@D'&2&QQC&*Z2UMHK.TAM;=-D,*+'&N2<*!@#)YZ"I:* "BBB@ K
M(N[J:[O;_0_FM));,R6MW&6)(.58]  R,5. V<,IX[:]8OB2TF>TAU*SB\R_
MTV3[1"H W2+C$D8.UC\R$C@==OI0!8\/6+:;X<TVS>%89(;9%D1<8#[1NZ<$
M[LDGN:\Y@\3>(=&:YTCP[H'VBPL+J>!7\B6;GS6;&5(Q@,HP<GOGFO4[6YBO
M+2&ZMWWPS(LD;8(RI&0<'GH:=%%'!$D44:QQHH5$08"@<  =A0!A^$_%-OXJ
MTR2YCA^SS12;)8#(&*]P<\'!'<@<@CM5KQ#I']O:0^F,_EPSR)YS@_,J*P;Y
M>""25 YZ9SSC!H6T&[XC7]Q;RQ")-.B2ZC1N6E9V*%@.I"+U/(##'!KI* *]
MC8VVFV45G9PK#;PKM1%Z ?U/<D\DU8HHH **** ,B[NIKN]O]#^:TDELS):W
M<98D@Y5CT #(Q4X#9PRGCM+X>L6TWPYIMF\*PR0VR+(BXP'VC=TX)W9)/<U7
M\26DSVD.I6<7F7^FR?:(5 &Z1<8DC!VL?F0D<#KM]*U;6YBO+2&ZMWWPS(LD
M;8(RI&0<'GH: /+(/$WB'1FN=(\.Z!]HL+"ZG@5_(EFY\UFQE2,8#*,')[YY
MKN?"?BFW\5:9)<QP_9YHI-DL!D#%>X.>#@CN0.01VK<BBC@B2**-8XT4*B(,
M!0.  .PKGK:#=\1K^XMY8A$FG1)=1HW+2L[%"P'4A%ZGD!AC@T :^KVDFH:/
M>6,156N8FA+,>%##:6]R 20.,D8R,Y#=&T:RT'3(["PBV1)R2>6=N[,>Y/\
M]88  J_10 4444 %8M_=W5U<:EHD2_9KF6Q:2RN0[88D%2<A?E*,4Z$G# UM
M5B^)+29[2'4K.+S+_39/M$*@#=(N,21@[6/S(2.!UV^E #/!]C;6'A73XK:%
M8F,2M.!U\[ $F[ON# @@],8XQBLN?3%T?XDZ?J%E JPZM%-!=8C. ZCS-V<X
M#-M'&/X6/))(ZRUN8KRTANK=]\,R+)&V",J1D'!YZ&L_5O\ D):%_P!?S?\
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M(U?3EANH5"7%L[<..A(!PRD,/JIV\YJ73O %CH][)<Z7JFJV1=B3'%,A3'.
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MOF49.WJ #CC-=+I>ER64MU=75VUW>W3#S)=NQ%5<[$1,G:HR>Y)))).:TJ*
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M=Q;>7<I@9=U8>6W3.0I<'GIMXXK2H 9%%'!$D44:QQHH5$08"@<  =A3Z**
M"BBB@#@?&6BW?B/QAI6E3WWV;2G@:8+N ,DBGYPH[MM9<9X W$9Y!U5\6^#]
M MX-.@U*VCAC0>6EL&E4#)ZL@(SG).3GG)ZU/XO\-2>)-/@AM[E;6XBER)BN
M3Y; K(H(YP5/3H< 'U%6R^&_ABSB56L6N7"LIEGE8E@V1T!"Y /! !& >O-
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M%>9U.!MW9X&-W&"#GD'%:MC8VVFV45G9PK#;PKM1%Z ?U/<D\DU8HH ****
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M;/KAF!SG("],<@'FVJ>&;_X>RIKNBW\\VG1RI]JMG<*67@88]&!+$9VY7<"
M>2/4XI8YXDEB=9(W4,CH<A@>00>XJ*^M(]0T^YLI2RQW$31.4/(# @X]^:H>
M'I8X/!VE2RNL<::?"SNYP% C!))["@"OHJ_V1JUYH>S;;'-Y8X7"B-F_>1C"
M@#:YSC).)%]*M>(-,O=7TS[)8ZK+ILAD#--$F6*C/RCD$<XY![8[UBZ/??\
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M?+5\$J5*X;:?X@H)/0]]XB\(:5XBM)EFMXH;R3!6\CC'F!@,#)ZL,<8)Z>A
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M-';S>1,Z,L<NP-Y;$<-@\'!YQ6+X;\+1:#YUQ-=2ZAJ<_$U[/DNRCHHR20,
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MQG&<5@>'_#M[;7']I^(+[^T-5Y$; _NK=2 #Y:X !8 9( ]/4GI** "BBB@
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M6Z_*<-P>* .._P"$5NX/'%W'X>O)=-TN:!3?M"PPKDG]W&,?*V,,/[@?(P"
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M>%=J(O0#^I[DGDFK%%% !1110 4444 %%%% '(>-?#+:_<:6;(?9]0CG!-Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .=N?\ CZF_WV_G11<_\?4W^^W\Z* -C3O^/&/\?YFK55=._P"/&/\
M'^9JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU/%!"F-TDKA5&3@9)XZF@"6BJZ7UG)>R6274#7<:[G@$@+J..2O4#D?F*L4
M%,EEC@B>65UCC12SNYP% Y))["GT4 97_"3:!_T'--_\"X_\:T+:ZM[RW6XM
M9XIX7SMDB<,IP<'!''45P.KVUNWQIT7=!$=]J9'R@^9U$NUCZD;5P>VT>E=]
M<W5O9V[7%U/%!"F-TDKA5&3@9)XZF@"6BJMYJ=AIVS[=?6UKYF=GGRJF['7&
M3SU'YU:H **I7>L:9I\HBO=1L[:0KN"33JA(Z9P3TX/Y5=H **** "BBB@ H
MHJO=W]I8IONKB.$$$C>V"V.N!U/X4FTE=C2<G9%BBL7_ (2W0_\ G^_\A/\
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MMC+$7),)4\.!R<A?3.0I!YVFO78I8YXDEB=9(W4,CH<A@>00>XH S?\ A)M
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M:Z\O&_R)5?;GIG!XZ'\J +5%5?[3L/M_V#[=;?;/^??S5\SIG[N<].?I5J@
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M6]-LWV37<8;)!5<L01USC./QJO\ \)-H_P#S^?\ D)_\* ->BLC_ (2;1_\
MG\_\A/\ X4?\)-H__/Y_Y"?_  H UZP-1\5VEG)Y5NOVIQC)1P$'X\Y/3_&J
MNM^)X#9>5IMP3+(<,X0C8OL3CG_Z_3BN.H Z-/&=^'4O;VQ7/( 8$CZYK?TC
MQ%;:J_D[3#<8SL8Y#?0]^/\ /%>>TJ.T;JZ,593D,#@@T >LT5S^G>*+)K"$
MWUR%N<$.!&WKP>!CD8JS_P )-H__ #^?^0G_ ,* ->BLC_A)M'_Y_/\ R$_^
M%'_"3:/_ ,_G_D)_\* ->BJ5IJUA?$+;W4;L3@(3M8\9X!YJ[0!FR^(M$@E>
M*76-/CD1BKH]T@*D<$$9X-:5<=\3;&VN/!EU<RPJT]JR-#(>J%G53@^A!Z=.
MGH*9X/U^]2_N?#&OS1'5+/ BDWY-PF,]>Y P?4@\C(8T =/=ZQIFGRB*]U&S
MMI"NX)-.J$CIG!/3@_E1::QIFH2F*RU&SN9 NXI#.KD#IG /3D?G57Q5%'-X
M1UA98U=19RL PR,A20?J" 1[BCPK%'#X1T=8HU139Q,0HP,E02?J223[F@#7
MJ*VNK>\MUN+6>*>%\[9(G#*<'!P1QU%97BG59=)T5FM!NO[F1;6S7@9F?A>2
M"..3SP<8[USOP_EDTB]U7PG=NS3V4IF@8G(>)L=!R%'*MC/60^AH [RJMYJ=
MAIVS[=?6UKYF=GGRJF['7&3SU'YU:KS;X:ZQ9:G?ZK=7IB&N74^[<[\O$1D)
M&"2<+M.0.VWK@8 ._@U.PNK?[1;WUM-")!&9(Y59=Y( 7(.,DD<>X]:BN==T
MBSN&M[K5;&"9,;HY;A%89&1D$YZ&N?\ %'A6*\UG2M<M(,7EO?6_V@H#^\BW
M@9( Y*\<\?*#GH,/^)44<G@2_9XU9HVB9"1DJ?,49'H<$CZ$T :__"3:!_T'
M--_\"X_\:NVE]9ZA$9;*Z@N8PVTO#(' /7&1WY'YU2\,_P#(J:/_ ->,/_H
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M!@>N=WH- !117GDUS+XY\9WFB.]S#H6G?\?,2@ 7$J.1AF'*@G.!DY"9X/(
M.N_X2;0/^@YIO_@7'_C6D)8S*T0=3(JAF0'D Y )'H<'\C3?LUO]D^R>1%]F
MV>7Y.P;-F,;=O3&.,5SNDZ"N@>+KLZ?;K'INH6WFN%!Q%,C ;1V52)"0.>0<
M8 Q0!T]%17-U;V=NUQ=3Q00IC=)*X51DX&2>.IJ*SU.PU'?]AOK:Z\O&_P B
M57VYZ9P>.A_*@"U145S=6]G;M<74\4$*8W22N%49.!DGCJ:BO-3L-.V?;KZV
MM?,SL\^54W8ZXR>>H_.@"U15>[OK/3XA+>W4%M&6VAYI @)ZXR>_!_*GVUU;
MWENMQ:SQ3POG;)$X93@X."..HH EHJ+[5;_:_LGGQ?:=GF>3O&_9G&[;UQGC
M-16>IV&H[_L-];77EXW^1*K[<],X/'0_E0!:HIDLL<$3RRNL<:*6=W. H'))
M/855M-8TS4)3%9:C9W,@7<4AG5R!TS@'IR/SH NT4R66.")Y976.-%+.[G 4
M#DDGL*JV^L:9>*[6VHV<ZHRJQBG5@I8X4'!ZD\#U- #;_6]/TN[LK6\N/*FO
M9/+MUV,V]L@8R 0.6'7'6K]4KZ+3#+:2ZA'9F190ML]P%R)#R A/\1P.G/%<
MWX\\76VB:/<6=M=*=5F7RT2-LM""!EFP05.TY'?)'!&: .QHJK9ZG8:CO^PW
MUM=>7C?Y$JOMSTS@\=#^5,DUC3(;T64NHV:798*(&G4/DXP-N<Y.1CZT 7:*
M** *5WK&F:?*(KW4;.VD*[@DTZH2.F<$].#^5-MM=TB\N%M[75;&>9\[8XKA
M&8X&3@ YZ"J_BJ*.;PCK"RQJZBSE8!AD9"D@_4$ CW%97PUBCC\"6#)&JM(T
MK.0,%CYC#)]3@ ?0"@#K**BCNK>6XFMXYXGFAQYL:N"T>1D;AU&1TS45GJ=A
MJ._[#?6UUY>-_D2J^W/3.#QT/Y4 6JH:KK>F:';B;4KR*W1ONACEFY .U1R<
M9&<#BKDLL<$3RRNL<:*6=W. H'))/85YI\4+K2-1\/07=C/8W5S'=1QO- Z.
MZH4D(4L.0,@G'M0!Z=115*/6-,FO391:C9O=ABI@6=2^1G(VYSD8.?I0!=HJ
ME=ZQIFGRB*]U&SMI"NX)-.J$CIG!/3@_E3_[3L/L'V_[=;?8_P#GX\U?+ZX^
M]G'7CZT 6J*JV>IV&H[_ +#?6UUY>-_D2J^W/3.#QT/Y5:H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=N?^/J;_?;^=%%S_Q]
M3?[[?SHH V-._P"/&/\ '^9JU573O^/&/\?YFK5 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7F/C:&Y3Q#)+,K^3(J^2Q.00 ,@>G.>
M/?/>O3J*VH5O92YK7,:U+VL>6]CPZBO<:*[/[0_N_C_P#E^H?WOP_P"">'45
M[C6'XP_Y%6]_X!_Z&M5#'<TE'EW\R9X+EBY<VWD>54445Z!P!116YX/_ .1J
MLO\ @?\ Z U1.7+%R[%0CS24>YAT5[C17!_:']W\?^ =_P!0_O?A_P $\.IR
M(\DBQQJSNQ"JJC))/0"O;Z*/[0_N_C_P ^H?WOP,KPU#<V_AZSBNU=9E4Y5S
MR!D[1[<8X[=*U:*YWQ=XGL_#VCW.;M4U!XB+:)<,^X@A6VG^$$9)/'&.3P?/
ME+FDY=SNC'EBEV,JVUC3+GQUJ=[J&HV<,>G*+.R6:=4PQYF;:QR&SA=PP"..
M:R'U'3=)^*MM>Z9-;7-KJZ""<V\J/LE9@,@*>,D(23G.6QD].Q\'K81>%=/@
MT^X@GCBB59'A<L/,(#/UY!RQ." 1GH.E9'Q/BLI_"3I<WL5O/'()[='?!E9?
ME( P2>'/3H2"2!FI*.TKS;X;7G]G?#[5K[R_,^S3S3;,XW;8D.,]NE=!X5\8
MV&K>'8;B]O[:&\A3%TLLJH000N\YP &)4\< MCJ*YWX8K9ZAX.U/1Y;A5DN)
M90\2./,$;1HI8#TYQG&,T 7_  :=3OO#9OVT[3[R34FD:ZGN;ME>?#,N&7RF
M 4 8"@XQV&33=!T/5_!?]MZA*]L=*$$MQ'80SN^UU^91N9!_""I/?C(.!C"T
M3Q'J/P[9]%U[3IY+/S6:&>-B1C'/E[L!E)*G&006.>3BNTL3/XLBN[R=;RST
MFZLS;6T#LJO('^_*5P<'[H7)/ )Q\U $7P]1I_#?]KW$C37VHRO+<3.!DE6*
M*HP/N@+P.@R<8'%/\&>&KWPQ_:5K+<12V$L_F6BJ<NHY!+G:.2 G3(X-<AH/
MB*]^'GGZ+XAL;E[42,UM-"-P)XR$W$ KR#Q@@DY&3QW.A7EWKEVVLM'<VNFM
M ([2WE8 R9.6E91TZ*%Y/ 8_Q4 8'@'_ )&OQG_U_#_T.6I=,:+Q1\0M2N[A
M=\&A[;>VA=3@2ECNDZXSE#CCIM/!6L_PUJ$6A^./%%E>+*;R\N@]M;Q(7:4$
MR.,$?*/E93EB ,\D8.'^3-X)\>WVJ7*SG0=15GEN%W.L+DAOG"KUW$JOL_4\
MT 6/B3I[V5I;>)=,7[/J%G.#)/$%4E&&W+<9;!"KCGACQBLWXE>1J?@[1]=,
M+)<3M%M4RLP17C9R .F<@<XR<"MSQ5>Q>*+!-!T2XBNWN9XA=2P*94MX<EBY
M<':#E/NDY/8<BLKXIFRL_"FGZ5;R1(\,\?EV_F9<1!'4'!.<<8S0!U]IX4T>
MSO[;4$M=U_ FP7+,0\A((+/C 9CDY8C)S6U45M=6]Y;K<6L\4\+YVR1.&4X.
M#@CCJ*P-#\<Z+X@U.6PLY)5F3)C\Y0HF SDISGH,X.#CMP< '2444R66.")Y
M976.-%+.[G 4#DDGL* .$U;_ )+3H7_7BW\IJK_%ZR@.B6=\58W"W(A5B[8"
ME7)PN<9) YQG@55U3Q!I#?%S2;U=0@:T@MO)DG5LHK,),?,.,?.N3T&><8-3
M_%34["\\+V:6M];3N]TLBK%*K$H%D4L,'ID8SZ\4 =!XF\.:4WA?59I[.*XN
MTM9)3=RH#,SJI8,7 !Z@<#  X  XK*TW7KO3O@[%J@;?<PP&&)L ;?WAB0],
M':,=1SCGKFM_Q)J=@_@S4KA;ZV:&>UFCAD$JE9'*,-JG."<@\#TKF_#-E;^(
M_A/_ &+%=1?:=C[E609C?S69-XY(!(';D9Q0!O\ AW2+>7P)#:.\I_M*U,ES
M,2/,=YER[%L<GYL G/ '6G>"]%U'P_X?&G:C/!*T<K&'R22%0X.,D YW%C^-
M<=H/CF;PE8#1/$NG7R36W$#JH8LF2.=S $ C *D@@8[<]YH9O[IKK4KY9[=;
MIE^SV<K#,,2C@L .'8EB1DX&T9XH UZ*R/#GB.S\3Z?)>V4<\<:2F(B90#D
M'L3Q\PK7H **** "O.O&EK=)K3W,@=K>15$;X)5>/NYZ Y!./?->BT5SXK#J
MO#D;L=.%Q+P]3G2N>+45[317G?V1_?\ P_X)Z?\ ;/\ <_'_ (!XM17M--=U
MC1G=@J*,LS'  ]32_LC^_P#A_P $/[9_N?C_ , \8HJ_K.I-JNJ371SL)Q&I
M_A0=!U./4^Y-4*\B22DTG='LP;<4Y*S"BBN[\#ZGYMK)ILA^:',D?^Z3R.G8
MGN?XO:M<-15:IR-VN8XFLZ--U$KV.$HKVFBO3_LC^_\ A_P3S/[9_N?C_P
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MOP'-=Z/XHUCPI,97M;;=-;>8X8HFX8Z#^(.K=L$'C)-2^ ?^1K\9_P#7\/\
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M5O\ \(]:VGGQ?:?M22>3O&_9LD&[;UQGC- &E\3;*"X\&75S*K&2V9&BP[
MEU4DJ#@G!(Y!QDXZU8T+PYI5_P"%--.H6<5Y)+8Q RSH&=5*#"J<94 =-N/7
M[Q)-3XA:G83^ KOR;ZVD^T[/(V2J?-VRINVX/S8[XZ5J^&]3L$\&:;<-?6RP
MP6L,<TAE4+&X11M8YP#DC@^M '._#;5&MOA_>7-T6>#3Y9BJHHR$""0@=,G+
M-U/>M#X?VJW>FS>)+G;)J.J2R.\F#F- Q41KDGY1MS],#G:*Q?ABMGJ'@[4]
M'EN%62XEE#Q(X\P1M&BE@/3G&<8S5CP9?MX12X\/^(Y/L;"=FM)YF;R95QE@
MC$;0!@'DCE\8!H AU"-_"'Q*TV33H?)TW5]D,L$95(R^=G"@<;=R-TY)89Y-
M6]6_Y+3H7_7BW\IJM2PIXM\9Z;>0CS='TI&E6X",%EN-^-JMD!@"BME<CC!Z
MUE:QJ=@GQATFX:^MEA@M7CFD,JA8W F&UCG .2.#ZT :&HM%XF^(\.B7*[K'
M2H#=2PNI*SRG;C/." '4\C^\.0:M?$+1EO?#LVHVT6W4K#;/%/'M60*AR1NZ
MX +-@'J!6;K]A>:!X^MO%4$<\VG3*([_ ,LD^4 NTLRJ,[ H5N_*GIQ6EX@\
M16FK>';BQT&>+4+^^@V100@N0CE58OC_ %> _5\8/T(H P/$?B:]O/A-8WN=
MDU_(+:X<'!(&\,1C &XQ\C&,,172^(]&TJ;X>W5K:Q1"SM[4W%J8<$ JI=6!
MYSGN>I#'GG-5-?AM/"GP[CT\VGVNV7RX)282Z_,V7D8;P1SDC###%0"*Y!?%
M7A9M,@TNZG\2W>FPXQ:S&$*P&< LI#D#J!NP,#T% '7^#]$M=0^'<-O>6443
MWT#),ZP*CNH9A&QXY(&"&.?7O5+X;7,FG2ZGX6O8UCO+*5I5*ICS%. 3]T9'
MW2">2'&.!73^&?$&E:_I@?2OW<<&(VMV4*T('W1M' &!QCCMV(',>.=*O['Q
M!I7B;0X5:]$JVTB%1ARWRH6XZ')0L2.J 8ZT =5IL4=WK&H:J44L&^Q028Y,
M<9.[W!\TR ] 0BG'<Z]5[&TCL+**UB+,L:X+N<LYZEF/=B<DGN235B@ K@?'
MW_(U^#/^OX_^AQ5WU>7^.O$&D3>)O#$L&H03QV=SYT[PMY@1=\9ZKG)^5N!S
M^8H W_B;907'@RZN958R6S(T6'8 $NJDE0<$X)'(.,G'6K&A>'-*O_"FFG4+
M.*\DEL8@99T#.JE!A5.,J .FW'K]XDFCX_UC3+OP)?+;:C9S-*R+&(YU8N5D
M0L!@\D @GT!K8\-ZG8)X,TVX:^MEA@M88YI#*H6-PBC:QS@')'!]: .=^&VJ
M-;?#^\N;HL\&GRS%511D($$A Z9.6;J>]:O@**.]T;^WYXU?4=1EEDEE(R5&
M_:(U)Y" (N%)-8'PQ6SU#P=J>CRW"K)<2RAXD<>8(VC12P'ISC.,9H\+^(E\
M%+-X;\3EK8V[&2VG5"Z.C'H-HR1G)!/J0<$8H E\.6-MIWQ?UNVLX5A@6SW+
M&G12WE,<#L,D\=!VJQI.H:AK7CC7+B.RMK@Z9(+6V6YNFC$ RRL4Q&P)<IDD
M\@<9(JEHE]/+\6-2O!I.H*EQ;11,K1KF#<D; R?-A1A"<9SVQGBJ^J?VKX \
M87^MV]G+>:3?[GE&\A59B#\Q PI#GY20>&P#G. #7;PIK8\:P:_9#3]-1F7[
M9%#<._G#=\YP8P,D8X]1G.>:E\:Z+<VMU#XMT58$U#3U9[@.O^NC"X.><9"Y
M'J0>#D 58TWQ(_C*XMQI,%]:V%O.)+NYDVIOVC*Q+C=G)P6Z848_BJ[+J^G:
MQX@?0UO8&2!3]I@W@&=^T8_O* &+@?[(.1O6@!NB7EOXQM+35Y8XO(@DW0VN
MX.8YP,%G/J,G:/0ACR0$Z2O+Y;JS^'OCI_*O8&TK4F)NK:-09+4]5^5>BC?D
M?[)(P2 3Z7;75O>6ZW%K/%/"^=LD3AE.#@X(XZB@"6BBB@ J&ZCDELYXX7V2
MO&RHV<8)'!R*FHH \HEBD@D,<L;QN.JNN"/PIE>M44 >2T5ZU10!Y+17HNOZ
M6=4TXK&H-Q&=T><#/J,^X_4"O.W5HW9'4JRG!4C!!H 2BBI(();J=(($+R.<
M*H[T 1T5Z;I5@NFZ=%;#&X#,C#^)CU_P'L!5V@#R6BO6J* /,M*MKBZU.!+;
M(D5P^\+G8 ?O'/I_]:O3:** .6^(_P#R(6I_]LO_ $:E.\8^%8]?LOM5MNBU
M>T7?:SQ':Q(Y"$Y'!/0Y^4\^H.?\2M7TY/"=_IQO8/MKM$HMPX+@[U?E1R!M
M&<GCIZBNJT[5].U>+S=/O8+E0JLPC<$H&Z;AU4]>#@\&@#D+3Q5'K_@?6;6Y
MW1:O::?,EU!*-K$A""X&!P3U&/E/'H3T_AG_ )%31_\ KQA_] %<M\0/#=VR
M7/B#2)_)N%M7AO8A@":#!W'W('KV48P5&=>SU[3M \#Z3<ZA<+&!I\12,$;Y
M2$7A5[GD>PSS@4 4M3U.PN?']O;:A?6T-GI,'G[9Y5C#7+_=R&/S;4^8%1\I
M/7G%8?BW5M)TWQ?H_B;3;JSNV5C%>+;S1N2N,!MH();:S#)./E4?7I/A[/;3
M^&_-2[@N+ZXE>YO?+;D2.Q^\O&TX '  X)&1R;OC2*RN/"5_;WU[%:1RI\DD
MC[077YU'0D\KT )(SB@#?KAO%/P[BU2[;5='G^PZH9%DSN*QLP/+<#*MT.1W
M'3))H^&_BBWU+0H-,N;F);^U_<I&S -+&!E2HP,X (.,GY<GK1X'\2^7X:MK
M?6TEL/(14@NKM/*AGC_@VN0%R%P,=2!GGG !D:)XUUKP]JL.A>+(&)=D5+F1
MU!C4C );HZYQELY'S9)/ Z?XC_\ (A:G_P!LO_1J5F>+;>S\<-8Z3I,\%Q-%
M*)I[R+$B6\1!!!8'[S'&$!YVY. ,U+\2M7TY/"=_IQO8/MKM$HMPX+@[U?E1
MR!M&<GCIZB@#HO#/_(J:/_UXP_\ H K2EEC@B>65UCC12SNYP% Y))["N;\/
M>(M$@\,Z5%+K&GQR)9PJZ/=("I" $$9X-9_B+5]1\16K:1X7M6GAN5:.XU%T
M*P*F[8P1B,.>N2N>,XR>0 8WP<BD$6L2F-A&S0JKD<$C>2 ?49'YBMS4]3L+
MGQ_;VVH7UM#9Z3!Y^V>58PUR_P!W(8_-M3Y@5'RD]><5;M$T7X=>&A#/=_WI
M6W$>9<2< [$S_NC X QD]33/A[/;3^&_-2[@N+ZXE>YO?+;D2.Q^\O&TX '
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M 2^.;*"'QQX4O$5O/N+Q5D8NQ&%>/: "<*/F/3'))JQ\7?\ D5+7_K^3_P!
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M.N16_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '.W/\ Q]3?[[?SHHN?^/J;_?;^=% &C9WEO%:(CR88
M9R-I]:G_ +1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@ _M&U_P">
MO_CI_P */[1M?^>O_CI_PH_LZU_YY?\ CQ_QH_LZU_YY?^/'_&@#&G8/<2,I
8RK,2#^-%;/\ 9UK_ ,\O_'C_ (T4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gou0qrw2itv5000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .P!-D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^), 7Y+%R?=L4 =W17'Z-XY&KZM!8BR\OS2?FWYQ@$^GM784 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5/56V:3=-Z1FKE9VOMLT"^;TA:@#Q"BBB@ HHHH ****
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MT_I7-UU>M6=Q>6\:6T+RLKY(09P,5D+X<U=E!%A-@^U?H?#O^X1]7^9X./\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_-<0J?3K7IU% 'FJ_#>](^:]B4^R9_K4J?#2<_>U*-?I$3_6O1:* //D^&C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOF>*/]VA_B_1GHY;_$?H4J***^&/9"BBB@ HHHH **** -OPS_Q^3?\ 7/\
MK73US'AG_C\F_P"N?]:Z>OT/AW_<(^K_ #/!Q_\ '84445[AQA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UK_D$7'T
M'\Q7&5V>M?\ ((N/H/YBN,KX7BC_ 'N/^']6>UEO\)^O^04445\T>@%%%% !
M1110 4444 =MI7_(+MO]P5<JGI7_ ""[;_<%7*_5L'_N]/\ PK\CYFK_ !)>
MK"BBBNDS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*U;_D*7'^_
M7:UQ6K?\A2X_WZ^9XH_W:'^+]&>CEO\ $?H4J***^&/9"BBB@ HHHH ****
M-OPS_P ?DW_7/^M=/7,>&?\ C\F_ZY_UKIZ_0^'?]PCZO\SP<?\ QV%%%%>X
M<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 4-:_Y!%Q]!_,5QE=GK7_((N/H/YBN,KX7BC_>X_X?U9[66_PGZ_Y!1117
MS1Z 4444 %%%% !1110!VVE?\@NV_P!P5<JGI7_(+MO]P5<K]6P?^[T_\*_(
M^9J_Q)>K"BBBNDS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*U;
M_D*7'^_7:UQ6K?\ (4N/]^OF>*/]VA_B_1GHY;_$?H4J***^&/9"BBB@ HHH
MH **** -OPS_ ,?DW_7/^M=/7,>&?^/R;_KG_6NGK]#X=_W"/J_S/!Q_\=A1
M117N'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %#6O^01<?0?S%<979ZU_R"+CZ#^8KC*^%XH_WN/\ A_5GM9;_  GZ
M_P"04445\T>@%%%% !1110 4444 =MI7_(+MO]P5<JGI7_(+MO\ <%7*_5L'
M_N]/_"OR/F:O\27JPHHHKI,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KBM6_P"0I<?[]=K7%:M_R%+C_?KYGBC_ ':'^+]&>CEO\1^A2HHHKX8]
MD**** "BBB@ HHHH V_#/_'Y-_US_K73US'AG_C\F_ZY_P!:Z>OT/AW_ '"/
MJ_S/!Q_\=A1117N'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %#6O\ D$7'T'\Q7&5V>M?\@BX^@_F*XROA>*/][C_A
M_5GM9;_"?K_D%%%%?-'H!1110 4444 %%%% ';:5_P @NV_W!5RJ>E?\@NV_
MW!5ROU;!_P"[T_\ "OR/F:O\27JPHHHKI,PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% ",P12S$ #DDUS.J:VTQ:&V)6/H6[FFZUJIN'-O W[I3R1_%6-7
MQ6=9W*;>'P[TZOOZ>1Z^$P:2YZFX4445\J>F%%%% !1110 4444 %%%% !3D
M=HV#(2&'0BFT4)M.Z Z?2M:$^(+D@2= _K6W7GO2NGT35?.46T[?O!]TGO7V
MF29VZC6'Q#UZ/OY,\C&8-17M*9MT445]6>8%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2)_K+=?M$?\ OI\Z_J!7I>F7 N]+M;@'/F1*Q/OBN#GC$MO+&1D.A7\Q71^
MIC/X'TF0G),)Y_X$17V7"M1N%2GVL_O_ .&/)S*.L9'1T445]:>6%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!69XC0R>&-60=6LIA_XX:TZCN(5N+:6!_NR(4;Z$8H \TT<[M&LS_P!,E'Y"
MKM9?AYF_LE8GXDAD>-AZ88X_3%:E?D^)@X5IP?1O\SZ>F[P3"BBBL"PHHHH
M**** "BBB@ HJK/J=A;7,=M/>V\4\GW(WD 9OH#UJU3<6M6A7045%<7,%G T
M]S-'#"OWGD8*H_$TEK=VU] L]I<13PMTDB<,I_$4<KMS6T"ZO8FHHHI#"BBB
M@!KL$1F/11FM[X>H8_ 6D*>HB/\ Z$:Y36YS;:'?3#[RP.5'JVTX'YUW_A^T
M%CX>L+8#&R%?UY_K7V'"L':K/T_4\G,G\*-*BBBOKSRPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N;\0V&UQ=QC@\/]?6NDIDL231-&XRK#!%<.8X*.,P[I/?IZFU"LZ4U)'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MERTEIWZ(QK5X4E>3*&EZ1)>N)) 5A'4]S]*ZN.-(HU1%"J!@ 4Y5"J%4  =
M*6OT#+<LI8&G:.LGN_ZZ'AXC$2K2N]@HHHKTCG"BBB@ HHHH **** "BBB@
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M*[D6=L.D"<?[-2+%&OW44?04X<*RO[U3\ >9+I$XV'2;V<C; P'JW%:MMX;
M(-S+G_92N@HKT\-P[@Z3O.\GY[?<CFJ8^K+1:$%O:06J[88POJ>YJ>BBO=A"
M,(\L%9'&VV[L****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=JBG,<5X(XS_ +)5E'_H5;T:+J1E+LCGKUU3E&/=GO5%%%8'0%%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 <A=_#S2VD,NG7%WILI[P2%D'T1LJ/RK/D\)>)K8_Z-J=E=(/\ GYB*N?\
MOG KOZ*XZ^7X6OK4IILUA7J0^&1YN^F>+83SHUO<8[Q7*IG_ +Z-,^R^*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,"*?0=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'P_]]&O-Z*AX'#O[)HL?B5]L](/Q>U#'&GP _P"\:KO\6];*G9;68;L2A/\
M6O/Z*%@<.OLB>/Q+^V=I+\4?$<N<-;1Y_N1G_&LZY\=^)+H$-J<BJ?X4 %<Y
M16D<-1CM%&<L57EO-_>6Y]3O[EBTUY.Y/7+FJA))R>:**V22V,6V]PHHHH$%
M%%% !7JGP:TTBUU/5G7B:00Q'V7.[]<5Y1*SB,B)"\K<(@&2S'H*^D?"NCKH
M/AFQTY<%HH@';'WF[FO(S:K:*IKKJ>SE%*\I5'TT-FBBBO"/?"BBB@ HHHH
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MV\\C>2WE.FX9/H<C KBM2\ >(--RQM//C'\4)W5[[11<ZZN6T9ZK1GR_+!+
MQ66-T8=F&*M:?K.HZ6P:RO)8<'.%/'Y5]$WVD:?J2E;RSAFSW= 3^=<AJ7PK
MT:ZW-9R2VKGH VX?K1<X)Y95@[TW?\#E=+^*NK6N%OH8KJ,=Q\K?GS_*NQT[
MXF:!?@)<E[5CU$HROY__ %JXC4_A=K=GEK4QW:#^X<'\C7)7NF7VG/LO+2:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% ''_$?PZVO^&)&MTW7MIF:#CD
MD=5_&O!HW$D:NO0C-?5)Y&#7@GQ$\-?\([XA-Q FW3[]B\>!PDG4K_,@>U>K
MEF(Y)^SEL_S/)S7#<\/:QW7Y')T445[Y\Z%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 444Z.*:YGBMK="\\SB.-0,DDTI244Y/9%1BY245NSK?
MAIH7]L^*UNY4W6FG8D)(X,O\(^HX->\5A^$O#L/AG0(+", RXWSR=WD/)/\
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M,5:/++XE^)\SC\$Z,N>/PO\  AHHHKT#S0HHHH **** "BBB@ HHHH ****
M"BBB@ HHI"0HR3@4 #,%4EC@"O6OA?X.-M%_PD&HQ$7$JXMHV',:=S]3Q^59
M'P^\!MJ<T6LZO"19H=]O PQYA[,WMW KV0 *    . !7@9AC54_=0VZ^9]#E
MV"=/][4WZ>0M%%%>4>N%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'D?Q=U$O?V.GJW$:&1Q]<8_D:\X)
M+<DD\=ZZ+Q_=&Z\9WW.1&PC'T'_ZZYRO4Q2Y,/3I_,^3Q<^>O.7F>P_"6S\K
M1;N[(_UTH4'_ '<UP?CZ\^V>,;T@Y6,A%_ #^N:]7\%P#3/ ]J[#&8C.WXC-
M>&ZE.;K4[J<G/F2LV?QKS#NQ?N86G3^?]?>>E_"&SQ%J%Z1U(C!]1U_I7I]<
M?\-+/[+X0A<C#3,SGZ9XKL*1ZF"AR4(H****#J"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!DL@BA>1C@(I)KQWPAXA:X^),UP[GR[UW4?3G:/Y5W/Q#
MUD:3X7F5&Q-<_ND]?<UXCI%R;36;*X!QY<Z-GZ$5[& P_/1G)]=#QLPQ/)7A
M%=-3Z:HIL;;XD;^\H-.KQSV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\PE5]R&B_,^@P>6QI>_4UE^0@  P!@"EHHKS3U HHHH **** "BBB@ HHHH
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M58-+V$6EN@HHHKF.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\N=9 9@I^4J>IQ]<5Y+7MY51WJ_(^1Q5&5&?)(?33UHR:2ML'@ITJKG,YV]
MKL_"OQ!OM!"VMR#<V6?NL?F3Z&N,HKOJTH58\LU=%4JLZ4N:#LSZ2T7Q%INO
MVXEL;A7./FC/#+]16K7R_:7MS87"W%I/)#*O1T;!KNM&^*VI6FV/4HENXQU<
M<.!_6O%KY5.+O2=T>YA\VA)6JJS_  /9J*YC2_'WA_5%4+>K!(>J3#;C\>GZ
MUT<4\-PNZ&5)%]48$?I7F3IS@[25CU(585%>#N24445!H%%%% !114%Q>VMH
MI:YN880/^>CA?YTTF]A-I;D]%<9JWQ,T+3MR0.]W*.T2\?F>*X+7?B9J^J(T
M-IBRA/!\L_,?Q[5V4<!7J=++S.*MF%"EUN_(]-\0^--*\/1L)9A-<@?+ AY/
MU]*\6\1>*-1\1W9DNI"L(/R0J<*O^-8K,SL68DL3DD]Z2O;PV!IT-=WW/#Q6
M/J8C39=@HHHKL.$*Z#P3IYU'Q=I\6,A)!*?HO/\ 2N?KT[X1Z47N;O5'7Y4'
ME(?<]:Y\74]G1E(Z<'3]I7C$]9HHHKY,^O"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U:6]];M;W
M,*2Q-U1QD&IJ*:;6J$TFK,\9\?\ @BRT&V&HV$C+&[[3"W.,^AKSZO:_BO\
M\BQ'_P!=A7BE?39?4E4H)S=V?+9C3A3KM05D%%%%=IPA1110 4444 %%%% $
MMM;37=PD%O$TDKG"HHR37HN@?"FZG*SZS*((^ODH<L?J:YKP#_R.FG_[S?\
MH)KZ"KR<QQ=2E)0AI='L9;@Z=:+J3ULREIFDV.CVJVUC;I#&.NT<GW)[U=HH
MKPFW)W9[ZBHJR"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;=247TL$X)4XS76_X#:***V,#W#X5?\ (F#_ *^9/Z5V]?(U[+(EQA9'48'
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M*T444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_785XI7M?Q7_ .18C_Z["O%*^DRO_=_FSYG-?]X^2"BBBO0/-"BBB@ HHHH
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MTW_G_MO^_HH NT52_M?3?^?^V_[^BC^U]-_Y_P"V_P"_HH NT52_M?3?^?\
MMO\ OZ*/[7TW_G_MO^_HH Y#XK_\BQ'_ -=A7BE>Q?%&_L[GPW&D%U#*WF@X
M1P37CM?297_N_P V?,YK_O'R04445Z!YH4444 %%%% !1110!TO@'_D=-/\
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MTW_G_MO^_HH NT52_M?3?^?^V_[^BC^U]-_Y_P"V_P"_HH NT52_M?3?^?\
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MN^_Z#EO_ -^&_P : /):*]:_X47??]!RW_[\-_C1_P *+OO^@Y;_ /?AO\:
M//[;_CVC_P!T5+5K4=,;1M1N-->02M:R&(N!@-COBJM?8T?X<?1'Q=;^++U8
M4445H9'7:'XYDT72H[$:7;W C)/F.>3DY]*TA\3I6.!H5H?H?_K532.#2?AL
M+H0QO=:E*R"1D!**#@XSTZ5:\#7,6G>&==U)K.WN)+<QE1,@8<G%>=4A1:E4
MY+ZVWWU/3ISK)QI\]M+[;*U_R'GXGW4:L4T6WB8@C<#C'Z5Y^S%F+'J3FO4=
M%\16_C%KO2+C2;&W,D#%'BCP00*\N9=K%?0XK;"J,7**CRO3K<QQ<I249.?,
MM>EA****ZSB,K4/^/G_@(JK7H^@_#&Y\6:;_ &G%J<5NN\Q['B+'COG/O6G_
M ,*+OO\ H.6__?AO\:^3QG\>?J?88/\ W>'H>2T5ZU_PHN^_Z#EO_P!^&_QH
M_P"%%WW_ $'+?_OPW^-<QTGDM%>M?\*+OO\ H.6__?AO\:/^%%WW_0<M_P#O
MPW^- 'DM%>M?\*+OO^@Y;_\ ?AO\:/\ A1=]_P!!RW_[\-_C0!Y+17K7_"B[
M[_H.6_\ WX;_ !H_X47??]!RW_[\-_C0!Y+17K7_  HN^_Z#EO\ ]^&_QH_X
M47??]!RW_P"_#?XT >2T5ZU_PHN^_P"@Y;_]^&_QH_X47??]!RW_ ._#?XT
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MH_\ WT:6X_X^9?\ ?/\ .HZ10_S9?^>C_P#?1H\V7_GH_P#WT:910 _S9?\
MGH__ 'T:/-E_YZ/_ -]&F44 /\V7_GH__?1H\V7_ )Z/_P!]&F44 /\ -E_Y
MZ/\ ]]&CS9?^>C_]]&F44 /\V7_GH_\ WT:/-E_YZ/\ ]]&F44 /\V7_ )Z/
M_P!]&CS9?^>C_P#?1IE% #_-E_YZ/_WT:/-E_P">C_\ ?1IE% #_ #9?^>C_
M /?1H\V7_GH__?1IE% #_-E_YZ/_ -]&CS9?^>C_ /?1IE% #_-E_P">C_\
M?1H\V7_GH_\ WT:910!=L'=IR&=B,=S6E67I_P#KS]*U*^DRO_=_FSY?-O\
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M /?1H\V7_GH__?1IE% #_-E_YZ/_ -]&CS9?^>C_ /?1IE% #_-E_P">C_\
M?1H\V7_GH_\ WT:910 _S9?^>C_]]&CS9?\ GH__ 'T:910 _P V7_GH_P#W
MT:/-E_YZ/_WT:910 _S9?^>C_P#?1H\V7_GH_P#WT:910 _S9?\ GH__ 'T:
M/-E_YZ/_ -]&F44 /\V7_GH__?1H\V7_ )Z/_P!]&F44 3V\LGVJ+]X_WQ_$
M?6OK33/^039_]<$_]!%?)-O_ ,?4/^^/YU];:7_R";+_ *X)_P"@BF)ENBBB
M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]WAZ!1117,=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=?6VE_\ ()LO^N"?^@BF)ENBBB@04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\Y^,/^1QU?\ Z^G_ )UB5M^,
M/^1QU?\ Z^G_ )UB5]A1_AQ]$?%UOXDO5A1116AF=)IGB+Q+I>C?Z#+*EA$V
M-_EY4$GIG\:O:=XO\8:M>I:65T\LS]%"#]3VJQ-;W%S\+;%;&-I MPYN @R?
MO''%7]$A?P9X+NM8N$$>H7>([=6^\ ?\Y_"O.G*FTWRIRO9?\$]*$:B:7.U&
MUW_P/R$UJY^(.CV1N+R4^01AFCVMM^N.GUKS@DDDGJ:[[P%JU_J>K7EC>3O/
M;7$#M()#D XZUP3C;(RCL<5OAERRE!I75MC'$OGC&:;:=]]1M%%%=1QGN'PJ
M_P"1,'_7S)_2NWKB/A5_R)@_Z^9/Z5V]?*8O^//U/K\'_N\/0****YCI"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '!_%?_D6(_\ KL*\4KVOXK_\BQ'_ -=A7BE?297_
M +O\V?,YK_O'R04445Z!YIO>&O#MUKSW30W(MH;=-\DIS[X'Z5=\,^%KOQ,]
MT(-3\J. XWMD[OUK8^' 6[TO7-.C8+<S0@ISUZUAZ7K$_AJQU72KFRE6XND,
M8R,%3TKBJ5*CG.$-U:WZL[Z5.FJ=.<]FW?Y;(U-<^'>HZ5H\]_\ VFMU'$,L
MB@]/SKA*]/T&VN]-^&VLW&H>9&MP (DDX/Y'US^E>856%G.3G&3O9[_(G%P@
MHPG%6NGI\PHHHKK.(Z7P#_R.FG_[S?\ H)KZ"KY]\ _\CII_^\W_ *":^@J^
M?S;^,O0^BRC^"_4****\L]8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***ANKNWLH#/=3)#$.KN< 4 345D?\ "4Z#_P!!>T_[^BC_ (2G0?\
MH+VG_?T4 :]%9'_"4Z#_ -!>T_[^BM*VN8+N!9[>598FY5T.0: ):*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YCQ_\ \BG<?[PKIZYCQ_\
M\BG<?[PH \6HHHI$A7N'@K_D4['_ '*\/KW#P5_R*=C_ +E T=!1113&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P?Q7_ .18C_Z[
M"O%*]K^*_P#R+$?_ %V%>*5])E?^[_-GS.:_[Q\D%%%%>@>:%%%% !1110 4
M444 =+X!_P"1TT__ 'F_]!-?05?/O@'_ )'33_\ >;_T$U]!5\_FW\9>A]%E
M'\%^H4445Y9ZP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,>/_P#D4[C_ 'A73US'C_\ Y%.X_P!X4 >+4444
MB0KW#P5_R*=C_N5X?7N'@K_D4['_ '*!HZ"BBBF,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "N8\?_\ (IW'^\*Z>N8\?_\ (IW'^\*
M/%J***1(5[AX*_Y%.Q_W*\/KW#P5_P BG8_[E T=!1113&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C'Q _P"1LF_W
M%KEJZGX@?\C9-_N+7+4A!70>"?\ D;++_>KGZZ#P3_R-EE_O4"/<****9044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#QCX@?\C9-_N+7+5U/Q _Y&R;_ '%KEJ0@KH/!/_(V67^]
M7/UT'@G_ )&RR_WJ!'N%%%%,H**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@/&O@L7*OJ6F
MQ@3#F6)1][W'O7F(BD:41!&,A. N.<U]&UCIX8TN/66U1;<>>1T_A!]<>M K
M'/\ @SP8NFQIJ&H(&NF&40_\LQ_C7<444#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *R/$'A^U\06)AG4+*HS')CE3_A6O10!\_:MI-UHU^]K=
M1E64_*W9AZBJ%>\^(/#]KK]@T,RA90,QR <J?\*\5U;2+O1KY[6[3:RGANS#
MU%(10JWIVG7.J7J6MI&7D<X]A[FC3M.N=4O8[6UC+R.?R]Z]H\->&;;P]9!5
M >Y<?O)2.I]![4 'AGPU;>'K/:H#W+C]Y+CK[#VK=HHIC"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKD=7^)/AW1-;_LB\FF%UD [8\JI/3)S0!UU%(K!T5E.589!I: "BBL+QCK[
M^&/"M[K$< G>W"XC+;0<L%Z_C0!NT5POPX\>S^-X;YI[)+8VQ7&R3=NSGV'I
M7=4 G<**RO$FNP^&]!NM5N$:2.!<[%ZDUSO@+XC6_C>6[A2R>UFMU#$%MP(/
MO185SMZ*\HNOBY=V_C^3PZ-+B,*7GV;S?-.3SC.,5ZO18$[A117F>J?&*QTW
MQ:^B'3Y72.41/,&&<GT'ISZT W8],HIDDT44?F22*B?WF.!1%-%.NZ&5)%Z9
M1@1^E Q]%<?X\\>V_@BWM6DM'N9;AB%0-M  ZY-:GA+Q+!XL\/PZK!$T2N2K
M(W.".#185S<HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45Q7CSXB6W@AK2-[-[F:XW$*&V@ 8SS^- ':T5D>&/$$'B?P_:ZM;QM&DX/R
M-U!!(/ZBM>@ HHHH **** "BBB@ HHHH ***\HU3XMW=AX\E\/+I<;Q1W(@\
MTRD$^^,>]%A-V/5Z*Y#QWX\M_!%I;226KW,EPQ"H&V@8ZY-:/A#Q/!XNT"/5
M8(6A#,49&.<$=>:+!<WJ***!A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>;Q0+KPJ42U #?ND**''< @4[(3;1]7453TJ0S:19R-]YH4)_(5<J2PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OF+XF_\E4G_P"NL?\ .OIVN'USX7:)KVOMK%T\
MXG8JQ"MQD4T["DKE+XN?\DIF_P!Z#_T(5B_ +_D":M_UV3^35Z/XA\.67B30
M7T>\WBW?;]TX(VG(_E57PEX.T[P=:3V^GM(RSL&<N<],X_G1?05M;GD'Q\_Y
M&C3?^O,?^AM77>)?^3>H_P#KQMO_ $-*Z7Q;\/=)\8WL%WJ#3+)#'Y:[&QQD
MG^M:-[X5L+[PB/#<F\60B2(8;YL*01S^ IW"VYYE^S__ ,>^L_6/_P!FK/\
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M1^*'_)-=;_ZXK_Z&M>>_L_\ ^MUC_=2O8-;TBWU[1KK2[O=Y%PNU]IP>H/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <UXE\!Z!XK82:E:GSP,":)MKX^M<Q%\#?"L<Q=I+]T!R$,H_
M7CFO3**=V*R,S1/#^E^'K/[+I=HEO'_%MZL?4FM.BBD,**** "BBB@ HHHH
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MB:K_ &'H5NMQJ (#N1N"D_P@>M%@NK7/4Z*\(OO'7Q+\.1QW^L6(^QNPXD@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $2VMNDOF+"@?^\%YI98(IP!+&K@= PS4E% #418T"(H51P
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M,UI900,W4QH%S5RBB@"D=(TXW'GFQMS-G._RQG/UJS+!%.H66-7 Z!AFI**
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M/@M-2F"K=(K)+M'&X=_QKRWX<>)];O\ XEO:W6I3S0.9,QNV5X/'%=3\%?\
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M0Y=+&#H^G2/X)M=/N$,<C6@C96'(.*^?+31O&?@'Q'))8V4IE3*AQ'N21?\
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M?^)5U77HY(+?<"\DJXRH_A45]%T55Q<IXY\<K?38/#NEVXG\JXMSMMX ,[D
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M:7X#MK:^MY()Q*Y*.,$ FNVHHJ2D%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gou0qrw2itv5000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +B!LD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BL?4/%6A:5+Y5]JEM#)_==Q
MFK>GZMI^JQ>;87<5P@ZF-LT 7:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **JZCJ5II-C)>WTZPV\8RSL< 52T/Q/
MI'B1)7TJ\2X$1 ?:>F: ->BBB@ HHIDDB0QM)(P5%&2Q/ % #Z*S/^$BT?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !WHH[T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7$_%+Q!=>'O!DT]D^RXE81*_\ =SW_ $KMJYOQSX9'
MBSPQ<:<'V3'YHF/9A0!X5X"^'4OCVWNM1NM3:((^T\;F8G//7VKOO"'POU7P
M?XSBO8K]9]-\MA)SM/48X[]Z\KBF\6_#74GVK+:_-AMRDQR8_G7L7@+XLVOB
MBXCTO4(1;Z@X^4C[DA]O2@9VT7BG0Y]2_LZ+4[9[S=L\D2#=GTQ6LS!5+,<
M<DFOF;XBV$W@_P")7]H6;%!+(+F,^^>17KOC?Q.(OA;+JEM(%>[@"QL#W84
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MR-W'UKSOXB6[WWQ1O;82%3)*$!STKZFKYA\9_P#)89?^OE?YT CH+CX#:M!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP[X?M-*64RBW3;O/?G-<1I_PD2Q\;'Q!_:3,OFF41;?7WH L_&G_ ))[<_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ [T4=Z* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<\4Z-J>MQ
M1VUKJ)L[,@_:-@^=QZ ]JP/A+;)::1JEM&24BOI$!)R<!B*] D_U3_[IKA/A
MC_QY:UC_ *"$O_H34^@NIS.I7FF^&?'NIW&MZ>=6^U*#"442^6/[I4]/RJ[X
M'E2*Q\2:W91?9K.4EHK;<,H>>2.U0Z+K>D>%O%.O1^)U$$\]P7AN)HRX9,G
M!P?:I_#:0^(?$OB*\TF%HM(N+?RU^7:LDG]X#\Z9)?\  GA?2]2\$K=ZC9Q7
M-UJ"F6:650S9//![=>U7?AHSVMGJFCEBT6GW;1Q%CD[>P_2L'PIX[TOPOX;;
M1-:>2WU"PS$L10DRXX&VNB^&UM,VE7FK7$+0R:E<M.$;J%/3^=)C1V$]Q';J
M&D) /HI/\J@_M2T_OO\ ]^F_PJY12*.=T*XC;5-6<$[6GR,C'85O>?'_ 'JY
MS3?^0SJ^?^>_]!6M0!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!
M=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!
M=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!
M=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!
M=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!
M=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!
M=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!
M=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\
MO4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\
M>JE10!=\^/\ O4>?'_>JE10!=\^/^]1Y\?\ >JE10!=\^/\ O5E'Q3I(D,9G
MD# X/[A_\*L4THAZJI_"@"U:ZA:WN?L\RN0,D=#^56:PK:../Q"NQ%7,/.T8
MSR:W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC"1(.W?W-,2+E%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!6A_P"1@3_KC_4UM5BP_P#(P)_UQ_J:VJ "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLG6
MO$ND^'H/.U.\C@4\ $\FM"TNH;ZTANH&W0RH'1O4$9% $U%8VM^*=&\/(K:E
M>QPECA5)Y)K4@GCN+9+B-LQNH93[&@"6BN6OOB'X;T^[DMI;X-)$<.4&0I]S
M6_IVHVFJV4=Y8SK-!(,JZG@T 6JP?$VEZCJ]O#96=R+:VE8BZ<'Y]GHOZUO4
M4 <9X9TVVTBYU*RM(PD,4V /7@5T59.F_P#(9U?_ *[_ -!6M0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK?B;2(^+6UN_W2]E!)X'Y4GAR^\2>%_#ZZ'<^'[F[FM1Y<,\.=CCH,\<5M>
MO#MYH]I>7VJ!1J.H3&:95/"^@_4T".KN)C#'N$3R<XP@R:K?V@__ #Y7/_?%
M7J* .4T>0RZKJSF-DS/]UA@]!6U63IO_ "&=7_Z[_P!!6M0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5H?^1@3_KC_
M %-;58L/_(P)_P!<?ZFMJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YC3?^0SJ
M_P#UW_H*UJR=-_Y#.K_]=_Z"M:@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>;'G&]?SIV01D'CUH 6BFJZ,<*P/T-.H **** "BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110!P7Q'T;3X?"&KWZ6L?VJ15W2D9;[PZ9Z5N:$[1>
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MK44 <EH<TD^IZL\D#P,9_N,02.!Z5N5DZ;_R&=7_ .N_]!6M0 4444 %%%%
M!1110 4444 %%%% !112$@=2!0 M%)N7^\/SHW+_ 'A^= "T4@(/0@TM !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445B:GHU]
M?77FV^LSVB8QY:(I'ZTTDQ-M&W17'WFA:G:Q+(_B>\ +JO$"GJ<>E6?^$9U;
M/_(RW?\ WZ3_  JN5=R>9]CIZ*I:79SV-F(;B\>[DR3YCJ ?TJ[4,M!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4-2MM,A$MR7"$X&
MR-F/Y 5<I" >H!^HH0&%_P )AI &=]Q_X#2?_$TU/&>BRH'CEG93T(MI"/\
MT&MUHT*L-B]/2JVG6\,-A#''%M4+P&4 U?N]B?>(=/UVQU.8Q6S2E@,G?"R_
MS K2I JCHH'T%+4NW0:OU"BBBD,K0_\ (P)_UQ_J:VJQ8?\ D8$_ZX_U-;5
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M$WQ@OGU"2WTNW@%M$^ TJ!]Y!ZX(XYKL/A]\1O\ A*I'L;Z-(;U%W J>)/\
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MBN9_XK.3MI</_ V/_LM-:S\9O_S%;"/_ '8@?YBCD\PYO(ZBBN3.B>*Y/O\
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M>\0V/B72TO[%R4)PRL,,A]"* -6BBB@#F--_Y#.K_P#7?^@K6K)TW_D,ZO\
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M]"CSHAUE3_OH5SW_  @VB_\ 3Y_X$&D/@30V&&2Z8>C3DT6CW"\NQT/GP_\
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M4****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K0_\C G_ %Q_
MJ:VJQ8?^1@3_ *X_U-;5 !1110 F1G&1GTH) ZD"O/?&TT^@^,-"UR.1A;22
M?9KE,\-D''\A3_$<\NN>/]'T2VE(@MA]JNMI[=A_X]3L*YWY8+U('U- 8,,@
M@_2O-8[1_'?C+6+:^N9AI>F.(1;QO@,YSR?R-)90R^#/B'8Z-:W,SZ3J$3&.
M&1L['!'3\Z+!<W?"FLWNH^)_$UI<R[X;.Z$<*_W1S_A77 @]"#7 >"?^1O\
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M7-S (SF%/EZC\#7>6VNV'BCXI:;-I#^?%:VS&:51P,]!^E ST^BBB@04444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZCF5VO'?A .N#@9KU&BBX6&HI5%4G.!C-.HHI#"BBB@ HHHH **** "BBB@
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MBAO;I(3MDFM[=W0'Z@8-=-HVLV.O:;'?Z?,)8)!P>X]B.QH OT444 <QIO\
MR&=7_P"N_P#05K5DZ;_R&=7_ .N_]!6M0 4444 %%%% !1110 4444 %%%!(
M R>E '(^*G&J:SI?A]>5DD^T7 _V%(('XX-=:JA$5%&%48 KD?"F=6UG5-?D
M7Y7?[/;Y[(O.1^)-=?5STM$B.NH4445!84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6A_
MY&!/^N/]36U6+#_R,"?]<?ZFMJ@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !;X:_X2?3[>V\_R?*N%FSC.<=J -R#_ (]X_P#=%24V-=D:KZ#%.H ****
M"BBB@ HHHH **** "BBB@ HHHH YC3?^0SJ__7?^@K6K)TW_ )#.K_\ 7?\
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M0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T
M4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0
MT?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4
MZ*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T
M?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z
M*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?
M9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*
MN?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9
MX_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N
M?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X
M_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?
M9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_
M0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9
MX_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0
MT 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X
M_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T
M 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_
M0T?9X_0T 4Z*N?9X_0T?9X_0T 4Z*N?9X_0US;/XL,[*ND:6L.?E?[<Q./IL
MH OP_P#(P)_UQ_J:VJR-.T^[2Z^V7LJ>;LVB.,<+^/>M>@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O!_&%CJ7C[XHR>'TNS#:VBC/<*,9SCUYKWBO"_%/A?
MQQ!X_P!0UCP]#(BS[0LJ,>1M H!&#>6OBGP!KDOA?2;UYO[10"%AD$=,D>AZ
MUU?ACX,W9O8-5\1:B[W2.)/+0YY]V_\ K5RMUX6^)UYJ\&JW$4SWL Q%*6.5
M%;^EP?%L:M:F[EN#;"0>:&8XV]Z!GN(& !Z4M(,[1GK2T"/&OB/H/B:3Q4=2
MMWOFT@Q@,+1SN3'4XK,T32="UR86\'C;4X;D\>3/\K9^FZO=SC'/2N#\<6W@
M18&.OFW@G;E7C($OX4#*,'PJD65)1XJU%PI!QN.#^M>DQIY<2IDG:,9/>O _
M#FI^)TUQ8_!TE]?Z,& )O4.T#ZU[W$7,2&08? W >M A]%%% !1110 4444
M<IX_\1?V#X=D$+?Z=='R;=!U+'_ZV:Q)?#S^'?A%>VNW_3)(#)<-W9S@G/XY
MKH-5\(QZQXIL=8NKDM%9 ^5;;>-WJ370W%O'=6TEO,H:.12K*>XH YGX=,A^
M'VD%"-HMESCZ"L+X<@GQ7XNDC_X]S>?*>V<MFKEKX!U+2;::QTCQ%+:Z=(25
MA:/<8P>RG(Q^5=)X:\.6GAG2ELK4L^6+R2.<L['J30!IW"S-'B"14;/4KFJO
MDZE_S]Q?]^O_ *]7Z* .>\/"5=3U<3.'?[1U"X["NAK"T3_D+ZQ_UW_H*W:
M"BBB@ HHHH **** "N*\0R?VSXQTO0@NZ" _:KGTXQM!^N3^5=E-(L,+R,<*
MBDFN1\#AM2DU+Q#*O-]-B$G_ )Y+G;_.KAI>1$M;([ # P.U+114%A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ [T4=Z* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *X/XE^&?#VM:='-J][%I\\9Q%<,P4_3GK7>5X1XHTFY\?
M_%>?0YKMX;.T0' [#&>/?)H S-,^'^K:LS6^C>,+>YMUZB.7) ^F[->D^!?A
M=9^$KAK^YG^V7[#B0CA/I7G6N>#I_AAX@T?4-,U&5X9[A8F#=>>H.*^@XG\R
M%'_O*#0,?1110(\BO_$VE^&/C#J%SJLYBB>T15(4GFL[4/B%X<G^)FG:O'>,
M;.&W9'?RSP3CM^%>F7TGAJ[\1IIEW;P3:F\>\*T6X[1ZGMUJIXC3PEX7TM[_
M %'3[5(QPJB/)8^@% SA?'WQ \/>)-*L['3+MI9_MD;;3&1P#7L5K_QZ0_[@
M_E7F/AKQGX,UK5H;)M#%A<2$>09X<!S['%>I#   Z=J!"T444 %%%% !111T
M&: "BN(_X2?6-?UV\TWP]%;);6;;)KNX!(W^@ (]ZVK6YU72M/N[G79[22.%
M=ZO K+Q[Y- &[17 :5K?BWQ-IC:QIR6-K:-DV\4RL7D7L20>*V/!?BE_$NGS
M_:H!;W]K*8KB(= P]* .GHHHH PM$_Y"^L?]=_Z"MVL+1/\ D+ZQ_P!=_P"@
MK=H **** "BBB@ JCK%_'IFD75Y(P58HR<^_:KU<9XT?^U-1TOPY&Q!N9/-G
MQVC7KG\2*J"NR9.R+G@33YK3P\MU=9^U7S&YESU!;G'X9KIZ:B+&BHHPJC
MIU*3N[C2LK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSL7O]/$S- 3E649]LUV&G?&NYOM2M[4^'I$$T@0MN/&?PH&>OC.T9ZTM(#D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [T4=Z
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *S/$,$5SX>OX9Y1%&\#!G/1>.M:
M=5-3%J=+NOMH!M?*;S0?[N.: /"/A[XX\,^$[*ZT[4H5>1925N84#>:,\>E=
MW9?%CP7=WT-M"LHEE<*A,('/YU1L_"_PVO\ P_/KD6FJMC%NW.Z@9P<<?C6'
MX6O/ACJOB&&UM=)-M<[\P/*H 8B@9[@#D9%+0.!@44"*]\CR6$Z1G#LA"GWQ
M7F'PRL/#\&EW-OJ-O;#5XIF6Y,P!8^ASZ=:]4EC6:)HVSM88.*\XNOA7X*2X
M9KFYN%E;KNN<'^5 '8+:>'0X*PV.[/& *V1C:,=.U>9P_#/P-',CI>3%E;(_
MTGO^5>E1*J1*B?=48% #Z*** "BBB@ H[44C+N0J<\C'% ''?\($D%W?7FGZ
MS?6<EXYD?RI"%W?3-<C%K.L:AX;\7:)?W)O9+ ;([@#EAGO[\5VLW@^[,D@@
M\1:G% Y),?FDXSV'I6AHGA32]!L9[6UB+"X),[R'+2$]R?QH SOAS-%)\/=)
M9&!5;=0?8@<UA_#@&7Q/XLNX^;>2\PC#H2"V:TX_AY%9++;Z9J]]96,K$M;1
M2849ZX]*Z/0]"L?#NFI8:?&4A4YY.23ZD^M %NZAEGBVQ3M"V<[@,U3_ +.O
M?^@G)_WS_P#7K3HH YWPY&\6HZLDDIE87'WB,=A715A:)_R%]8_Z[_T%;M !
M1110!E^(M272=!N[LMAE3:GNQX'ZD53\&:2=(\.0))S//FXE/^TYW'^=9?BH
M?VWXETK0$;,:-]JN0/[JYP/^^L5V8 50!T P*MZ1MW(6LKBT445!84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 '>BCO10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !69XBLY+_P .ZA:P\R20,JCU.*TZ@O+J.QLIKJ8XCA0N
MWT S0!\UOJNL7OANS\"0Z9/%.EP5F8 _,-Q/3]:Z7Q=X8T_1+_PGI>EVH74P
MZ-*Z#DX'S$_C3[[XV3_:I;C3O#ZFV1MHF<9S^.*FTWXNZQJ.NV5G+X?423N
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [T4=Z*
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MF-=U7$0E3LNIR4J$HSNSH****X#L"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^<>AXK1_X3NR_P"?"_\ ^_#?X5U5%.X%33K]-2LDNHXY$5\X61<$?A5NBBD
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !WHH[T4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'-!#<1F.:))$/57
M7(K&N/!OARY;=+HUD3ZB%1_2MVB@#)M?#&AV1!M])LXV'0B%<_RK5 "@!0 !
MT I:* "BBB@ HHHH ***0]#B@!:*XRZE\<S/=S6ZZ?:PQLWE(Y+%P.A/R\9I
M/"/C:36/#M]?:I"L$]@[)/L.5)&>GY4 =I17G>FZ[XR\2:=)J^EQV=M9-DVT
M<W+2+V)XXK=\$^*)/$NFS?:X1!J%K(8KB('@,/2@#IZ*,XZTFX>H_.@##T3_
M )"^L?\ 7?\ H*W:PM$_Y"^K_P#7?^@K=H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** #O11WHH **** "BBB@ HHHH
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M8]#U4[A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2Y_M=CRXYI3=;D^SW/:Z*9%+'/$LL3!D<95AW%/KS#U0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "JEMJ=E=W,UO!<))-"<2*#R*X3QYX\6P5],TR0-<$;99!_
M![#WKR_2M;O=(U-;ZVF82@Y;)^_[&O2H9=.K3<WIV/,Q&9PI5%!:]SZ6HK!\
M+^*+3Q)IZRQ,%N% \V+/*FMZO/G"4).,EJ>C"<9Q4HNZ84445)04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPQX4;PT72*_>6!^L;+P#ZCFNEHHKY2I4E4ES2W/KJ=.-./+'8****@L****
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MT70:4E>W<^7HX:LJ\9.+M?L>LT445\R?4!1110 4444 %%%% !1110 4444
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M0^&'BC/_ !ZP_P#?]:^CP6(I1H1C*23/FL=AJT\1*48MKT/6_"/_ "*FG?\
M7%:VZS/#UE-I^@V=I<*%FBC"L <\UIUX%5IS;7<^AI)JG%/L%%%%9F@=Z*.]
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXUI44 9O_$Y_Z<_^^6_QH_XG/_3G_P!\M_C6E10!F_\ $Y_Z<_\ OEO\:/\
MB<_].?\ WRW^-:5% &;_ ,3G_IS_ .^6_P :/^)S_P!.?_?+?XUI44 9O_$Y
M_P"G/_OEO\:/^)S_ -.?_?+?XUI44 9O_$Y_Z<_^^6_QH_XG/_3G_P!\M_C6
ME10!F_\ $Y_Z<_\ OEO\:/\ B<_].?\ WRW^-:5% &;_ ,3G_IS_ .^6_P :
M/^)S_P!.?_?+?XUI44 9O_$Y_P"G/_OEO\:/^)S_ -.?_?+?XUI44 9O_$Y_
MZ<_^^6_QH_XG/_3G_P!\M_C6E10!D7,^L6]N\S"S(49QM;_&G12:S)$D@^QC
M<H/W6_QJ[>PM<6<D28W,.,_6I($,=O&AZJH!_*@"C_Q.?^G/_OEO\:/^)S_T
MY_\ ?+?XUI44 9O_ !.?^G/_ +Y;_&C_ (G/_3G_ -\M_C6E10!F_P#$Y_Z<
M_P#OEO\ &C_B<_\ 3G_WRW^-:5% &;_Q.?\ IS_[Y;_&C_B<_P#3G_WRW^-:
M5% &;_Q.?^G/_OEO\:/^)S_TY_\ ?+?XUI44 9O_ !.?^G/_ +Y;_&C_ (G/
M_3G_ -\M_C6E10!F_P#$Y_Z<_P#OEO\ &C_B<_\ 3G_WRW^-:5% &;_Q.?\
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M^-'_ !.?^G/_ +Y;_&M*B@#-_P")S_TY_P#?+?XT?\3G_IS_ .^6_P :TJ*
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MBL+PSXKL/%%K)):[XYHCMF@D&'C/H:W: "BBB@ HHHH **** "BBB@ HHHH
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M/Z5Z'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8GBC4[+1/#=[<7.P)Y3*J8^^Q&  /<FMB1Q%$\A!(52Q ]J\2E\56OB#Q8]
MWXC@NTT^QDQ:6BQ$AR/XF_&@#I/"F@7\/PIO80ICN;V.66.+H5W9('Y5!X+\
M7Z)I/@V/2-222VO(%:.6W:%B7.3G&!@YKM-'\56&LZ=<W-A#/LME.4:/:3@9
MP!7+7WQ TRXAD%AH=U-JK JB-;@$-TY- R+X.77GV.MI&K);)?N8488V@DG&
M*]-KE/ 'A^?0= )O0!?7<K7%P!V9B3C\,XKJZ!!1110 4444 %%%% !1110
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MF\U(I3Q+P1@#UYKT"O-/B5;W47B#0-6:REO=,M)"9XD&<'!PV.] &'<>(?\
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MJD"JOW0!]*JC4[,V9NQ.OD#J_:A]2M(UA9IE F_U9_O4 6MB[MVT9]: H7H
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MZCZU-0 F!Z4N!G.*** $P/2C ]*6B@!,#T%+@>E%% !@9SBDP/2EHH 3 QC
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ML@YP3GOC]:]+\$ZU;:WX;AEMK86PAS"\(Z(R\'%)#9T=%%%4(**** "BBB@
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M ZT 3TM)2U!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 UP2.*C\MJFHIW A\MJ/+:IJ*+BL0
M^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U
M%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U
M'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%P
ML0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM
M4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^
M6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%
M%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'
MEM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL
M0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4
MU%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6
MU'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%
MPL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'E
MM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0
M^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U
M%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U
M'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%P
ML0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM
M4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^
M6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U'EM4U%
M%PL0^6U'EM4U%%PL0^6U'EM4U%%PL0^6U*(VS4M%%PL%%'>BD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HJ.:>.WA>:9PD:#+,3T%9^C^(-.UQ)&L9PY
MC8JR]ZI1DUS):$N<4^5O4U****DH**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU.^GC=#<W+^2D@P4C#' ^G2NXH8T%%%%(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!QOC;P;<>*9K9X;I(?*7!W+G/7WKFK'X47MK?07
M#:C$PBD5R!'UP?K7J]%==/&UJ<.2+T.2I@:-2?M)+411M0#T&*6BBN0ZPHHH
MH **** "BBB@ I,#.<"EHH **** "BBB@ Z4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gou0qrw2itv5000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0C M4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **@NK
MNWLH&FN9DBC7JS' J.QU2QU-"]E=1SJ.I0]*5U>Q:IS<>=)V[]"W115"^UK3
M--D6.\O8H7;HK'DT-I:L4(2F^6"NR_13(I8YXEDB=71AD,IR#3Z9+36C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOZW\T?I.#A'^P'I]B7ZGT/7S%XGO9K_Q)J$T[EF$[H,G/ .!_*OIVOEK6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \8^,_\ R'--_P"O8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K@OB%XW70K0Z?8N#?2K@D'_5CU^M:?C;Q
M?!X8TU@A#WTHQ%'Z>YKY]O+N>_NY+JYD,DTC;F8FN#%XGD7)'<^KX=R3ZS)8
MFNO<6R[O_(C9GFE+,2\CMDD\DDU[-\-/!)TV-=9OTQ=2+^Y0_P  /?ZUB?#3
MP0M\R:UJ" P(?W$9YW$=S7IGB3Q#:>&M*>ZN&&X#$48ZL>U986@HKVM0]#/\
MVE6G_9^$U;T=OR7ZGF'QG(.NZ< >EL<_]]&L#X:_\C[IW_ __0&K$UO6;O7=
M3EOKMRSN>!GA1V KL_A9X:N;O6H]8<%+:VSM)_C)&,#\ZP4O:XGFCW/6J4E@
M,F=&M+51:^;OI^)[?7RUK7_(=U#_ *^9/_0C7U+7SUX_\,7.A:[-/M+VMRYD
M23'<\D'\<UUYA%N":Z'SO"%:$,14IR=G)*WR.X^##+_8FHKD;OM(..^-HK/^
M)G@AEDDUS3HR5;FXC4=/]H5P?AGQ'=^&M52[MV)0G$L>>&6OHC2M4LO$&DI<
MV[+)#*N&4]O4&IH<E>C[)[HWS7ZSE68_7H:PGO\ Y/\ 0^8[:YFL[F.X@<I+
M&VY6!Z&O?_ WC&'Q-IPCE8)?1#$B9^][BO+/B)X<M-!UO-E*IBF^<Q#K&?\
M"N:TG5;K1M1BO;20I+&<]>H]*YJ<YX6IRRV/9QF%P^>8-5:3][H^S[,^IJ*P
MO"OB:U\3:4ES"P$RC$L?=6K=KV8R4E='YK6HSHU'3J*S044451D%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUE5/,Z"Q.&UE;3S78^BZ*@L[R#4+2.ZMI!)%(NY6%3U[*=S\WE%Q=GN%%%%
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MF:;<ZM?Q6=I&7ED; QV]S7T/X3\+VOAC2U@B :X<9FDQRQ]/I6=X#\&1>&[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=:D;!2']X.X<<$?G555=W1%%\JL_4Y/XA:C?7EW+;Z=>S6\.FHLL[0N5W,6
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M$<0_WF[FK5?7Y=@%A87E\3W_ ,CQ<3B'5E9;!1117I',%%%% !1110 4444
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M7'^^/Y5T%<_X4_X]+C_?'\JZ"OM<L_W2']=3P\5_&D%%%%=YSA1110 4444
M%%%% !1110 4444 %%%% !7/^*_^/2W_ -\_RKH*Y_Q7_P >EO\ [Y_E7!F?
M^Z3_ *ZG1A?XT3E:***^*/<"N@\*?\?5Q_N#^=<_70>%/^/JX_W!_.N[+/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNA<^T/\ 9=W.,XS4'VCWK3\M/+V;1MQTK$TV,WZ3L2%\N4H*TK*<91@G=O\
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M;8K^)2_Q?HSPJ7PS]/U1M5B^'?\ 57G_ %\-6U6+X=_U5Y_U\-16_P!YI?\
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MQ[2_[A_E3I5%*,I)6LW^&@3BTTFR*X,3:?<-%L*M&W*8YX->,UZII'_(KO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS_KJ/Y5V-?99;_NL/ZZGB8K^-(****[CG"BBB@ HHHH **** "BBB@ HHHH
M**** /%[_P#Y"5U_UV?^9JO5B_\ ^0E=?]=G_F:KU\#/XF?0QV04445)05V'
MP^_Y"%Y_UR'\ZX^NP^'W_(0O/^N0_G7=EO\ O4/ZZ'/BOX,CT"BBBOLCQ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***S]7UBVT:T,]PW)X5!U8U,I**YI;#2;
M=D7G=8U+.P51U). *Q+[Q?I%BQ4W D?TC&X?F*\_U+7=3\07+*K,D.?EC4X
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MDAS@,1\R5ZN&S:%1VJ:')5P;CK$]*HJ.">.YA2:%P\;C(8&I*]A.YQ!1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?O.+'6Y#K:***^I/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %(S!5+,0 !DD]J6O/O'/BAE
M9M+LI/\ KLZG]*WP]"5>?)$YL7BH8:FZDR#Q9XT:8O8:9(5C!Q)*/XO85PA)
M)))))ZDTE%?54*$*$.6!\1B<54Q,^>H_^ %%%%;',%%%% !1110 4444 %%%
M% !1110 5-:W<]E.LUO(T<BG((-0T4FDU9C3:=T>N^%O%D.M1"WG(CO$'([/
M[BNGKP"WN);6=)H7*2(<@BO8/"WB%-=L/FP+F(8D7U]Z^>S# ^R_>4_A_(^M
MRK,_;KV57XOS_P"";]%%%>4>V%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?<^HR"JW3G3[:DM%%%>,?0A1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6=KMI]NT.\M_P"]&2/PY_I6C2$ @@]#51DXR4ET)G!3BXOJ?/K JQ4C!!P1
M25N>+-*.E:],@'[N4^8A^O)K#K[*G-5(*:ZGYY5IRI5'"6Z"BBBK,PHHHH *
M*** "G(5#J6&5!Y'J*;10!I:SJ@U.XC,<9BABC"1QDYQ@5FT45,8J"Y47.<I
MR<I;L****H@**** "BBB@ HHHH U_#%B;_Q#:1 <!]Y_#G^E>VUY]\.-+(6?
M4I%Z_)'G^=>@U\UFE7GK<JZ'V.2T'3P_,]Y:A1117FGL!1110 4444 %%%%
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MW=GW48J*45L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ IDT,=Q"T4JAD<8(/>GT4; U?1GD_BKPA+I4C75HK2
M6;') &2G_P!:N3KZ"=%D0HZAE(P01UK@_$?@(2LUUI0"L>6A/0_2O>P69)KD
MK?>?,9CD[3=3#K3M_D><T5+<6\UK,T,\;1R*<%6&#45>RFFKH^>::=F%%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,E_U3_[I
MKY[U'_D)W?\ UV?^9KZ$E_U3_P"Z:^>]1_Y"=W_UV?\ F:!,K4444A%BP_Y"
M-K_UV3^8KZ%B_P!2G^Z*^>K#_D(VO_79/YBOH6+_ %*?[HIC0^BBB@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 R7_5/_NFOGO4?^0G=_P#7
M9_YFOH27_5/_ +IKY[U'_D)W?_79_P"9H$RM1112$6+#_D(VO_79/YBOH6+_
M %*?[HKYZL/^0C:_]=D_F*^A8O\ 4I_NBF-#Z***!A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #)?]4_^Z:^>]1_Y"=W_ -=G_F:^A)?]4_\
MNFOGO4?^0G=_]=G_ )F@3*U%%%(18L/^0C:_]=D_F*^A8O\ 4I_NBOGJP_Y"
M-K_UV3^8KZ%B_P!2G^Z*8T/HHHH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ,E_U3_[IKY[U'_D)W?\ UV?^9KZ$E_U3_P"Z:^>]1_Y"=W_U
MV?\ F:!,K4444A%BP_Y"-K_UV3^8KZ%B_P!2G^Z*^>K#_D(VO_79/YBOH6+_
M %*?[HIC0^BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R
M7_5/_NFOGO4?^0G=_P#79_YFOH27_5/_ +IKY[U'_D)W?_79_P"9H$RM1112
M$6+#_D(VO_79/YBOH6+_ %*?[HKYZL/^0C:_]=D_F*^A8O\ 4I_NBF-#Z***
M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<MJ_C6WT2]-M=V4P;
MJK \,/4<4 =-+_JG_P!TU\]ZC_R$[O\ Z[/_ #->FO\ $W3&1E^S3<C'7_ZU
M>774HGNYI5& \C,/Q.:0F14444"+%A_R$;7_ *[)_,5]"Q?ZE/\ =%?.]M((
M;N&5N0CJQ_ UZBGQ-TQ8U4VTW  Z_P#UJ8T=U17+:1XVM]:O5MK2RF9CRS=E
M'J>*ZF@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65KV@VFO6+07"
MC>!F.0=5-:M% '@&LZ-=Z)?-:W28/56[,/45G5[WKV@VFO6+07"C>!F.0=5-
M>*ZSHUWHE\UK=)@]5;LP]12$9U%%% @K0T?1[K6[Y;6U0DG[S=E'J:-'T>ZU
MJ^6UM4))^\W91ZFO:M!T"UT&Q6"!<R$9DD/5C0,-!T"UT&Q6"!<R$9DD/5C6
MM113&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %96O:#:Z]8M
M!<*-X&8Y!U4UJT4 > :SHUWHE\UM=(1W5NS#U%)H^CW6M7RVMJA)/WFQPH]3
M7M>NZ#::]9&WN%PPY20=5-&A:!::#9""W7+GEY".6- K":#H%KH-BL$"YD(S
M)(>K&M:BB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<]-T_P 4:#XKT*_FMYC)91QNMQN&-J[>?TKCO -O\/4\2L_AZ6=]0PVSSB"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%/&&H^.FN]-@N9[8E/)D3.V,[1G/I3MJ3?2Y[M5&^UC3M,&;Z]AM^_[QL5%
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M-[!YGS+'< [2/85[=\/O&*^,M %TZ".ZA.R= >,^OXUF_&&R@N? -U-*J^9
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M'=?"O5KB%MT4MO&Z,.X+J17EWQWLX8/%-E<1@"2> E\>Q %=5=3R7'[/$[R
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M,38],NIJ[IOPX\*Z7,LT&DPM*IRKR ,0?45T%_IUIJFGR6-[ DUK( 'C89!
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M,/"45VMPNE1[E;<%(&W/TK;U?PYI.O6L-MJ5E%<10G,:NN=O&.*=U>X6=K'
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"EJVEVNM:5<:;>J6MKA=L@!P2,Y_I6+X7\
M!:'X0FFFTN.822KM9I9-W'Y5T]% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56'3;*WN&N(
M;6))G^\ZKR:M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;BVDAGM8IXI9)'<@G# MQCZU[_11=BY4(HPH'H*6BBD4%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gou0qrw2itv5000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /[!R$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0>A(J6CI4%Y>06%I)=7,@2&-=S,:\G=Z'I[+4DEFC@B:25U1%&2S'I7$ZO\
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M4W/6****\@]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q;XM:\UUJD>E1,?*MQN<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDU;48B+9#F%&'WSZ_2O?JU88>G=[(\2E3G7J66[.G^&?A+^R=/\ [3NTQ=W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X_XD7T]MX6E@MHI9);D
M^7B-22!Z\5Y-X.\.7>I>)[2*>UFCC1_,9GC('R\]_I7T.R(_WE5OJ,TBQQH<
MJBJ?4"NZAC71I.G%:OJ<5;!JK54Y/1=!RJ%4*HP , 4M%%<)VA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.6;Z"N&/QT\/"<*(+@QY^_M/\L5Q.M^9X\^,(TJ9R;6*0HJ@\;%&X_UKV9/
MOAI+06PTF Q@8Y!S^=/1$W;V-+1=:LM?TN+4+"0O;RC*DC!_$5H5S]QHB:1X
M2O-/T&'R6\E_*13DY(/3->:_"/3/%5GXFNWU=+I;7R6#>>^X;\C&.?K18=SV
MJBBBD,**** "BBB@ HHHH *X76/B1#IWC*#PY:Z>UW.Y"R.LF/+/?C'8<UU>
MLZG%HVC7>HS?ZNWC+GWQ7C_PATZ37O%&I>*+W+LKD1L?[Q_^L::$WT/;Z***
M0PHHHH **** "BBB@ HHHH **** "N7'CS2#XH70 9?M;,$!V<9^M=17@\?_
M "7"'_KZ%8U9N%K=6>CE^%IXCVG/]F+:/>*XCQ7\1(_"?B&STZ[TYV@N1D7(
MDP!^&.:[>O//B_X?&K>$)+V-?](L3YJD=2/3]:W1YKV/04=9$5U.589!%.KA
MOA1X@.N>"[=96S<6I\E\GDXQS^M=S2&@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKBOB+XYC\'Z0/* DOY
M^(4]/]HT =3?ZMI^EQ^9?WD-LG]Z5PHK)7QYX5>4QC7K#([^<,&O'?#7P_U[
MQ^3J^O:A<16TO*L3\SCV'3]*ZV7X#:$T 6+4;U9!T?Y>?KQ3LB;L]1MKNWO8
M1+;3)-&>C(<BIJ^;-1M?$WPHU^.:*YDFL6;Y6)RD@_NGT_2O>_#'B"V\3:%;
MZE;'B1?G7^ZW<4-#3N3W>O:383F"[U&V@E R4DD .*\!\(ZC91_&&6^N+F)(
M/-<B5FPOW2.M>H^*/A3IGBG6GU.XU&]MY'4*4A*[>/J*\5\.^$+75_'\F@2W
M5Q'"KLOFIC?P,_2FK$N]SZ23Q1H4CA$U:S9F. !*.:U000"#D&O+(/@7HT,Z
M2_VQJ3;#G!*\_I7J4:".)(P20JA1GVI,I7ZCJ***0PK@_BUKYT3P7,D3[9[L
M^2@SU!X;]#7>5X%\3[V3Q1\0['P];DO#"ZHX'9B<,?RQ36XI/0O>'O HN?@[
M>EXO],N<SQY'(*\#]*N? K7S+97>ARMS WFQ@]\]1^&*]9L[*.TTN&R4#9'$
M(^/88KY^!;P%\9B "EM+-@>GEN<9I[D['T7134=9$5U.589!]13JDL\?^/W_
M " ]*_Z^3_Z":[CX=_\ (B:3_P!<%_D*X?X_?\@/2O\ KY/_ *":[CX=_P#(
MB:3_ -<%_D*?0G[1U%4=5TBQUJR>TO[=)H7&"&&<?2KU%(H^9M<TV_\ A;XZ
MBN;.1OLK-NC;^\A/(/OUKZ,TC4H=7TFVOX&!CFC#\'H2.E>=?'*P2X\)PW>P
M;[>7.[ZX%6/@EJ#W?@G[.Y)-M*PR?0DFJ>JN2M'8]*HHHJ2@JE+J^G07BV<M
M[ ERWW8F<!C^%7:^>_B+J2Z7\78KR5F\J':Q /\ LBFE<3=CWF_U.QTN#S[^
M[AMHO[\K!15#3_%WA_59Q!9:M:33$X$:R@L?PKQRRT37/BYK$VI7EQ)9Z0K8
MB7V]!_\ 7KJ--^"UKHNN66H6.JW#"!]SK+CYN.V!19"NSU.21(HVDD8*BC+,
M3P!56RU73]1+BRO(;@I]X1N#BJOB<X\+:H1_S[/_ "KR?X$.S7^L;F)X[GW%
M%M!WUL>W5'//%;0M+/(L<:C)9C@"I*^?=2O]7^*'CJ32+6Z>VTV!B"%/  [G
MWSQ0D#=CV*3QSX7BE$3Z[8AO>8<5L6=_::A#YUG<1SQ_WHVR*\T7X%:#Y&V2
M^O&DQR_RYS^5.\*_#;5/"7B^"ZMM4:?2MK"2-S\W0XSVZXHT"[/4:^>-9_Y+
MK_V]"OH>OGC6?^2Z_P#;T*$*1]#TR::.WB:69U2-1EF8X I)YXK:!YII%CC0
M99F. !7@_C/QEJ?CW65\.^&U<V@?#2)QOYZGT%"5QMV/;K'6M,U.1TL;ZWN6
MC^^(G#%?K5ZN1\!^"+?P?I>S>9;R89FE)_2NNI#04444 (S!5+,< #))K"NO
M&OAJR;9/K5DKYP5\T9%>3?$+Q9JGB;Q6GA;0I9(XE;RY"G\;=<_0?TK;T_X%
M:8+53J6I74MRP^<IC:#[9&:=NY-WT/08_&'AR9=T>MV++ZB85+'XGT.:18X]
M6M'=CA5$HR37@?C_ .%\_A"U%_87<MQ8[L-N^\GN<<5O^ ?AQH/B/2[768M5
MU$31L/-BRN P_#I3L@N[V/<\Y&11344)&JCHHQS7BOQ$\=ZEJVN?\(MX:9BQ
M;RY)(^K-W7V%)*XV['J=]XM\/Z:[1WFKVD,@ZH\H!_*G6'BG0=4E$5CJUI/(
M>B1R@G\J\QTCX&130)/KFJ7#W##+)&00/S%5]>^";Z=:/>>'M2N&N(_F\N0@
M9]A@#]:+(5V>VT5Y1\*/'MYJ\LF@ZPV;R!<QR-PSXZ@_3%>KTF-.Y2N=6T^S
MN$M[F]@BF?&U'< FK4DT4,)EDD5(P,EB> *\%^,-W]B^(6G7#%MD21NP![ T
M^%?$WQ8OAY<TFGZ)#A0>@;''XG]*=A<QZTWCGPNLWDG7; /TQYPK;M[F"[@6
M:WE26)N5=#D&O+)O@/HK6NV/4KP3XXD.WD^_%<7HNJZW\,O&JZ1?3M)8R2!2
M&.593T84670+M;GT9134=9(U=&#*PR".XJGK&JV^BZ3<:A=,%BA0L<]SV'YT
MBBU/<0VT+2SR+'&O5F. *PG\=^%HY1$VNV(;O^^''UKQ>-O$WQ<U^0QS/:Z7
M$V.#A4';W)-=A%\!M$%N5FU*]:4]7&WCZ<4[+J3=O8].L-4L-4B\VPNX;F/^
M]$X85;KYY\0>%=>^%M[%J^D7TLU@&"DD]/9A^':O9_!WB6+Q5X=M]20*LC#$
MJ#^%NXH:&F;]5;W4;+38A+>W45O&> TC!14&O:JFB:%>:E(,K;QER/6O"O#7
MA_5OBMJMWJ6JZA-#8H^ $/\ XZ![4) V>S1^./"\LWE)KMB7S@#SAS]*W8I8
MYXEDB=71AD,IR#7EMQ\"M#>$B"_O(Y1]UOEZ_E6S\._".L>$IM0M[^_^U6C[
M?L_)..N>OX4:!J=Y1112&%%%><_$>Q\6ZS>6FF:"S0V<@)GE5@/3KW]>E ,Z
M^^\4Z#IDACO=6M()!_#)* :@LO&GAO4'6.VUFS>1C@()1N/X5Y[I_P "K5T6
M36-8N9I^I$9&W]1FJ^N_ V"WLY+G0]1N!<H-PCD( /L,#K3LB;L]H!R,BBO&
M/@]XROIM1F\.ZK,\KH#Y!?J,=1^E>ST-6&G<I76K:?8S)#=7L$,K_=1W )^E
M2W5]:V-L;FZN(X81R9'; _.O#OC1<?9O&NE2LS!(UC=L'L&)J!8]<^+FLA(I
M7M-&M5"9[' Q^)-%A<Q[':>,_#=]<_9[;6;.24G:JK*,L?:MWJ,BO(H_@79V
M5W:W-EJ]SYD4BNPEQ@@'/&!7J%]>P:-H\EW<N%AMX\LQ]J'Y#5^I:FFBMXFE
MFD5(UZLQP!6#+XZ\+0RB)]=L0V<']\./K7C#WGB3XM^(I(;25[73(ST!PJ#W
M]377P? ?1A;D7&I7CS,.6&W@^W%%EU%=O8],T_5M.U6/S-/O8+E!_%$X85=K
MY[\1^#-<^&4\>M:)J$TUFC -D\CV8=,'VKV#P/XIB\6^'8;X;5G'RS(/X6__
M %8H:&F=)1112&%5KW4+/3HA)>W,5NA. TC8!JS7E'QW9E\,V.UB/WYZ'V%"
M$W9'J<4\4\"S12*\3#(=3D$5C7'C/PU:7'D7&MV4<H."K3 8^M>+6.N^(?&F
MGV'A?0!);VT486YN/P&<GT^G-=9%\"=*>RQ=:G>/=,,M(-N,_B.E.PKM['J-
ME?VFHP">RN8KB(]'C;(JP2 "2< =37S9+_;/PD\8PHUR\UF_.,_+(G^-=)K/
MBS6OB3JXT3PSOM]/'^MN.FX=R3Z?K18.8]2N/&OAJUN/L\^MV22@X*F8<'WK
M6L[^TU& 3V=Q'/$>CQMD5Y;'\"-):SQ<ZG=O=,/FD&W&?Q%</_Q./A1XWA@>
MZDDL'89)/RO'G^>*+(+M;GTE39)$AC:21@J*,LQ/ %,MKA+JUBN(SE)4#C\1
M6;XJ)'A352./]&?^5(HMV6JV&I%Q97D-P4^]Y;@XJY7B7P'=FO-8W,3]3[BO
M;:;5A)W05BW_ (M\/Z9(T=YJ]I#(O5'E ;\J\R^*'CZ^;5!X8T!V$Y(2:2/[
MV3_"/TINB? Y;NVBNM>U*X^T,-S1QD''L211;N*_8]2L/%&A:I((['5;2XD/
M\$<H)K7KQ75_@<]G"UQX?U:?ST^8)*0,^PP*ZWX67FOS:3>V7B!)1/9RB.-Y
M!RPY_/&*+#3?4[BYNH+.!I[F5(HEZNYP!3+2^M+^#S[2XCFB_OQMD5R?Q5)7
MX?WY!(.4Z?6O&-#\5ZH_A2W\*Z()#>W4A\R1>H&3Q0D#=F>^W7C3PW9W/V>X
MUJRCE!P5,HROUK7M+RVOK=9[2=)H6^ZZ-D&O'[+X#0360DU+5[C[:PR?+P5S
M^(S7HO@SPRWA30ETY[G[1M8D/[9H=@5SHJR;_P 3Z'I<GEWVJVEN_P#=DE -
M>8_$WXA7PU+_ (1GP\6^TE@DLL?7)XVBJVA?!*34;5+OQ#J=RL\@W&*,@D?7
M(/Z46[BOV/3[3QIX:OG5+?6K)Y&Z()1G\JW58.H92"IY!%>/ZG\";$0O+I.I
MW,=P!\JR8VY_ 9KF?"'C/6O WB7^P]=,KVI?RRLASLST8&BW8+M;GT/138Y$
MEC62-@R,,J1W%<%\4_&DGA;1%@LV(O[H[8R/X!Z_SI%-V.MU#Q!I&E/LU#4K
M:V;&<2R!35&W\<>&+G_5ZY8D^AF&:\H\)_"BZ\46:ZQXBU&Y7S_G2-3\Q![G
M([^U:&O_  ,M8K&2XT6_G%PBEO+EQAL=A@=:=D3=GI__  E?A_\ Z#%E_P!_
MA6E:W=O>P+/:S)-$W1T.0:^8_ ?A73?$NLW&D:M?7MI>1DA!$1@X."#D'G-?
M1/ACP[;^%]&33+:>6:-"3OE(W'\J&K#3;/*?CS_Q^Z/_ +I_G7J_A3_D5-,_
MZ]UKRCX\_P#'[H_^Z?YUZOX4_P"14TS_ *]UH>PEN:DTT5O"TTTBQQH,LS'
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MSKWFD]RD[H\?^/W_ " ]*_Z^3_Z":[CX=_\ (B:3_P!<%_D*X?X_?\@/2O\
MKY/_ *":[CX=_P#(B:3_ -<%_D*.@OM'44444BCA/C!M_P"%<:AN^]NCV_\
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M9TV,TQ' SGC %&E@UN=A1114E!7D_P >/^18L?\ KN?Y"O6*\G^/'_(L6/\
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M%C^%>+_ ;_C\UC_/<5ZYXC5G\.:@JG#&!@/RH>XH['A/PKLQKWQ(N]0NLR/
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M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUN>^$@=3BHXIXIMWE2*^PX;!Z&O#GTGXJ^)%$=Q.UM;,/F_>*!^6<UZ/\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N7^(EK-=^!M4C@R7$); [@ UU%(RJZE6 *D8(- 'B?P0\1
MZ;8V5YI-W,D%T\V]-YQO& /SKVH2QGI(I_&O,O$OP7TS5;E[O2[@V$[G+#&4
MS]!6#'\(_%ULOE0>)5$8Z8!']:K1DJZ/8-0UC3]*M7N;V[BAB49+,U>!"=OB
M%\88KNR1OLL;KN<#^!.,UT5I\$]2NKE7UO73-"&R40')_'->G^'O"ND>&+7R
M-,M5CS]]S]YOJ:-$&K-E%VHJ^@Q2T45)04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5\XVU]%X6^-<]SJ@*Q"=@78=,K@']:^CJY/Q=\/]'\7H'ND
M,5THPL\?!_'VIIB:.CM;^TO8%GMKB.6-QE65NM2M/$BEFE0 #)):O%/^%+:_
M82DZ;XB5$/0!""/UI6^#_BF[<+=^)5,?<E2>/SHLA7?89\8_%]CK%O;^'],D
M6YD$P>1DY (R,?K7I?@#1YM#\&:?9W (F$8:13V)[5F>%?A;H?AMH[EXS=WJ
M\^;+R%/J!VKN:&^@TNK"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* / /C!_R473_P#<C_G7O%C_ ,@^V_ZY+_(5YYXX^'%]XH\46NJV]Y%%'$%!
M1ER>/QKT:WC,-M%$3DH@4GZ"F]A+<DHHHI#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.U[2H]<T*\TV7A;
MB(IGTSWKQSX0:A+H/BS4?#-Y\A=CL4_WAR?T%>Z5PFL?#B*_\96_B*SO/LLR
M,&E4+]\]_P!.*:$UU.[HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "O//
MC!X@&E>$)+*-O](OCY0 Z[?7]*]#KA_%?P]7Q7XBLM0N[TBUMACR,=?QIH3V
M(?A)X<.A>$(IITQ<W9\ULCD XP/YUWU-1%C144851@"G4AK0**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWN$,?0E**J/2,=';K:S7H_P9>US2K;4=/E-UODC2%CY)/R$X."15'P& OA6
M#@"1P/SK1U;2[O48Q';ZI-9H5*N(XU;<#]1530/#D^A 1#5[BXMAG$+QH!DG
M.<@9K1)JI>VAQ*I!X-TI3UNFEKTOY6-^BBBMCS3C?B9_R+EC_P!A:R_]'+79
M5QOQ,_Y%RQ_["UE_Z.6NRH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N5^)'_)/]6_W$_]&+755E^(M%3Q#H%WI,D[P+<J%,J %EP0<C/'
M:@#3'W1]*7 ]*Y#_ (13Q'_T/6H_^ D'_P 31_PBGB/_ *'K4?\ P$@_^)H
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MKM PHQT%=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!8/]^K@Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!'/"ES;RP29V2H4;![$8-8_AN:6.&XTJYQY]@P0
M!>@B.?+Y[G:!FMRN?UU/[.U"UUU20D(,5SG[HB;DN>Y(P,?6HGI[QU8?WTZ+
MZ[>J_P ]ON.@HI%8,H8<@C(I:LY0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D/0TM-?\ U;?0T >?!+(^/4E7
M4QYF?N!>_IG->A]J\AB*GXA(0#_KOZUZZ/NCZ5ZF9PY?9ZW]T\W+I\W/IU%H
MHHKRST@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BHY)X8O]9*B8_O,!4?V^S_ .?N#_OX* +%%11W,$S;8IXY#Z*X-2T
M%%%% !1110 4444 4K_K!_OU<'2J=_U@_P!^K@Z4 +1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'<01W5O)
M!,BO&XPRL,@U)10--IW1A^'9Y(DFTBZ=FN+)MJM(?FEC[28]"<C\*W*XWQ)=
M)H/B>PUE9R5E MKJ#S57Y"<(V#SPS?I70:3KVG:V;G^S[@3?9W\N0A2 #_7I
M64)I/D>Z.[%8><HK$Q7NR5WY/9^FNWJ:5%%%:G %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!<?^- &I167_ ,)+H/\ T&]-_P# N/\ QH_X270?^@WIO_@7'_C0!J45E_\
M"2Z#_P!!O3?_  +C_P :T89HKF%)H)4EB<95T8,K#U!'6@!]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT'_H-Z;_ .!<?^-'_"2Z#_T&]-_\"X_\: -2BLO_ (270?\ H-Z;_P"!<?\
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M5_PS-5A*LFTK:*[]Z-NV][%#_A6.A?\ /UK?_@VG_P#BJ/\ A6.A?\_6M_\
M@VG_ /BJUM*\31ZC#>F2UE@FLWV2Q ^8<X!X('/6F:?XE>\US^S)=.DMR8_-
M1VD!W+VR,9!]C0JD7:SW&\'77,G'X=7JOZ?R,S_A6.A?\_6M_P#@VG_^*H_X
M5CH7_/UK?_@VG_\ BJWKW6TL]<L-,,#,UWG#AN%P">GX5JU2:>QA.G*"3DM]
M5^1QG_"L="_Y^M;_ /!M/_\ %4?\*QT+_GZUO_P;3_\ Q5=G13(/+/&'@^P\
M.:3:ZEIU[JZW":A:H#)J4SJ0TR@@@M@\&O4ZXWXF_P#(JP?]A.S_ /1Z5V5
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M[_\ LQK>U*/4)+;&FSP0S9^]-&77'T!%)NRN5&/-))NQ6_X1CP__ - +3/\
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M#_\ T M,_P# 2/\ PK5HJS P[SPSH L;@C0]-!$;$$6D?I]*H_#7_DF^@?\
M7FM='>_\>%Q_UR;^1KG/AM_R3?0/^O1: .JHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2A\!,9[8YZ54I*.K.:E1G6;4%>R;^2U9FZM_R57PY_UX7G\XZ[#J,5Q^K?\
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MS'*F2-RGJ,BN;_X6#9?] 3Q#_P""R2C_ (6#9?\ 0$\0_P#@LDH 0?#3PRH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%(+>)=L<<:X51Z 4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4->N9X3<Z3;0VSC+2)=[R!CTV\U/.N;E.B.&J2I^UT2\VEMVON4/^%;^%_\
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M:QZMI4-O!<2"-9(KGS,$^V!74 Y&?6JC)2V,JV'G1LY;/:S3_(Y3_A6_A?\
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M-Y:V:*]U<PP*QP#*X4$_C4]<-X\L[;4/$/@VUO+>.XMY-1D#Q2J&5OW#]0:
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M\"$_QJA_PA'A7_H7=+_\!4_PH_X0CPK_ -"[I?\ X"I_A0!?_MW2/^@K8_\
M@0G^-']NZ1_T%;'_ ,"$_P :H?\ "$>%?^A=TO\ \!4_PH_X0CPK_P!"[I?_
M ("I_A0!?_MW2/\ H*V/_@0G^-']NZ1_T%;'_P "$_QJA_PA'A7_ *%W2_\
MP%3_  H_X0CPK_T+NE_^ J?X4 7_ .W=(_Z"MC_X$)_C1_;ND?\ 05L?_ A/
M\:H?\(1X5_Z%W2__  %3_"C_ (0CPK_T+NE_^ J?X4 7_P"W=(_Z"MC_ .!"
M?XU+;ZE8WDACMKVVG<#)6*56./H#67_PA'A7_H7=+_\  5/\*P8-'TW1_BQ8
MIIMA;6:2:1,76",(&/FIUQ0!WE8'C21$\*7@9U4ML"@G&3O' K?KB?B-83:G
M;:-9V^WS9;]=NXX'"L?Z5E6;5-V.[+81GBZ:D[)._P!VOZ';4445J<(4444
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M !H_X2?Q+_T(U[_X&P?XUUU% '(_\)/XE_Z$:]_\#8/\:/\ A)_$O_0C7O\
MX&P?XUUU% &3H.NQZW!/^X>VNK63R;JV<@F%\ [<C@\$'CUK6KCO!7_(>\9?
M]A?_ -HQUV- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&<C'K0(\B^Q>./3Q9_X'V?\ \31]B\<>GBS_ ,#[/_XFO7/,3^^OYT%U!P6
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M>Y*1-W0;5X'YUVUO:6UHI6VMXH5/41H%!_*N6M_#%]%HFM69>'S+V<R1'<<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_"6>'/\ H/:7_P"!<?\ C4O_  CFA_\ 0&T[_P !4_PH_P"$<T/_ * VG?\
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M'O&7_87_ /:,==C7'>"O^0]XR_["_P#[1CKL: "BBB@ HHHH **** "BBB@
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MX[&M7_A9FB_\^.N_^"F?_P")JS_PLCPC_P!!J+_OV_\ \31_PLCPC_T&HO\
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M*45;W5?Y-K] HHHK0X@KG/$7_(>\-?\ 7X__ **:NCKG/$7_ "'O#7_7X_\
MZ*:LZOP_=^9UX+^-\I?^DLZ.D/2EI#T-:'(>8R7%Q_PL>-5E8C>!C=VKTX=!
M7FF;G_A8R'R1C=_='2O3!TKU,R_Y=_X4>=E__+S_ !,****\L]$**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'Q;XJLO".C/?W?
MSMG;'$#\TC>@K>KRGXBQIJ/Q#\,Z;<X^REC*=W0L,_X4TKL#/@U?XI^*LW>F
M6MOI]BYS&)?E<#MU(S4DEW\6?#V+J[AM=0M4.75#N<CO@ U["B+&@1%"JHP
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M1G&=U'_"9H/"YU-K9A<"7[.8,_\ +3ICZ9-);ZUK":7#9Q^&K]9EA6,/(4V
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MU_3=2$RJMF23&5SNR".OXULU%)<P1-MDGC0^C.!2:3W-:52=.5X;V:^_1D@
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M#WC+_L+_ /M&.NQKCO!7_(>\9?\ 87_]HQUV- !1110 4444 %%%% !1110
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M>V\-RL,EL(Q,@?8#%DXSTR:Z'^P='_Z!-C_X#)_A6IP%+_A-/"__ $,.E_\
M@4G^-'_":>%_^AATO_P*3_&KO]@Z/_T";'_P&3_"C^P='_Z!-C_X#)_A0!2_
MX33PO_T,.E_^!2?XT?\ ":>%_P#H8=+_ / I/\:N_P!@Z/\ ] FQ_P# 9/\
M"C^P='_Z!-C_ . R?X4 4O\ A-/"_P#T,.E_^!2?XT?\)IX7_P"AATO_ ,"D
M_P :N_V#H_\ T";'_P !D_PH_L'1_P#H$V/_ (#)_A0!2_X33PO_ -##I?\
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MSR7H=M=0>&I26_O)_)W_ %"BBBM#B"N<\1?\A[PU_P!?C_\ HIJZ.N<\1?\
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M$CYB>X% &]7'?#S3#9:?J%WYN[[9>2/MQC;M8K^/2NQKGO!?_(N+_P!?$_\
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MKQ\D^;*J@_3@ 4Z47%RNK)_Y(PQ52$\/3C[3FE&_?KZKH7****W/-..\%?\
M(>\9?]A?_P!HQUV-<=X*_P"0]XR_["__ +1CKL: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;/XBC^S6]SI%K'"BA'D6[W$ #KC;7044XT^5W3%4Q\ZL6JD4[N_7=JS>C\C
MTO2+JT\3:I?RA/(N0@CPV3QG.1^-27_A>SU#4OM[W-[%<;-FZ"X*?+UQQ6W1
M3]G&R3Z&3Q=;G]HG9V2T[)6..T/PN^B:OJ.HW5Y<" LK1EKDD,!G._U[5J>&
M==N=?M[BZDL#:VZRE;=RV?.4?Q=..<_E6X0&!! (/4&A45%"HH51T & *<(*
M"LMB<3B:F)GSU'K_ )*PM%%%48!7*Z]_R/OA'ZWG_HH5U5<KKW_(^^$?K>?^
MBA0!U58.I_\ (W:#_NW/_H*UO5Y_,['XVVR%CM&GDA<\#AJRJRLEYM'?E]+V
MDIN_PPD_PM^IZ!1116IP!1110 4444 %%%% !1110 45Q?Q(T#7?$&BPV^A7
MOV:97)?G&X<<58^'^C:SH?AX6FMW?VFY#9#9S@>E:^SC[/GYM>PKZG64445D
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ]'_ +*T[_GPM?\ ORO^%']E:=_SX6O_ 'Y7_"@#SC_AH#P/_P ]-0_\!O\
MZ]'_  T!X'_YZ:A_X#?_ %Z]'_LK3O\ GPM?^_*_X4?V5IW_ #X6O_?E?\*
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M1M\?_P#/7PW_ -^Y_P#&@"Q_P@'A#_H6]+_\!E_PH_X0#PA_T+>E_P#@,O\
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ME6-9-\MNZ/2RZ:A[9R_DDOOLCKZ***V/-"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./U
M*>^M/B9I9B0BSN[4P2.5R"5W-@'UZ5V%<YXAD2+Q!X<>1U1?M,@RQP/]6:Z.
MLZ:LY+S_ $.W%RYJ=&5K>[;UM)H****T.(**** ,SQ%_R+6J?]>LG_H)J?2/
M^0+8_P#7O'_Z"*H>+[^WT_PKJ,MR^Q'A:)3C/S," /SJ_I'_ "!;'_KWC_\
M016=_P!Y\CK<6L(G;3F?Y(N4445H<@4444 %%%% !1110 4UT62-HW4,C JR
MD9!![4ZB@#R_X1HL>J^,410JKJ*A5 X P:]0KAO ^F1:3XK\8VT+.R&[ADR_
M7+1[C_.NYJ*:<8I,Z,7456O.I'9MLXK6/%VMP^+O[ T71[2[E6W\]GN+HQ#&
M0.RGUJ2^\3>(-$\,7^K:QH]E%);KNCB@NS('Z]3M&*Y+Q5!HZ_%$W'B'3[F>
MP-EM1HX)7&_</[@],U:UN30[SX;ZS9>&+*[150DQ-;RJ22#TWC)_"J5_9WZ_
M\$QLO:6Z:?D7[KQOXKTW2(=8U'PYIZ::P1G>*_9W56Q@[=@]1WK>UWQ<NDKH
MTD%N)X]2N$A#,VW:&(Y_6LG1O 8N]*TXZQK.IZA;K$C_ &*Z*B,' XP%!X^M
M0_$O25U >'K/[(\UM]OB61$4D!,C.<=!5M6=O-?<9Q=XW\G]]CK/$FMG0?#]
MSJ:Q+,T(!$9;&<D#K^-.CUR!?#,>MWF((?LXGDYR%&,FN*\9_#_P]:^$KR;3
M]'Q=*JE-CR,<[AVS5?7$U;5M#\/>%=.A\MY[=)+F6>-O+5% RK8]<].O%1JT
MTM[K]2ENF]M?T-WPKXYN=;U9M/U+3!I\LD7GVO[PMYL>2,\@8/!XK2\4^(-1
MT6UD?3=):\>)#*[RL8X@HZ_-@_-[8]:X?Q1H7C&SDT[7VDTN5]*90([&"0.\
M9X(Y)SP2:Z3Q9XMT]?"\D$D5Z+B^M-T<:6DC]0#@D+P>>]*H_<;CNK_\ <%[
MZ3V?],Z+PUJ[:]X>L]3>$0M<)N,8;<%Y]:U:X;X9ZY:77AFRTM8[J.[MH?WJ
MS6SQ@<GNP -=S6M1)2=MC.#;BK[F3XI_Y%#6O^O"?_T6U/\ #?\ R*VD?]>4
M/_H IGBG_D4-:_Z\)_\ T6U/\-_\BMI'_7E#_P"@"H+-.BBB@#E? _W/$/\
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MUG)VG'YG;1CS86KKLXO\U^J.SHHHK0X@KS[XJ_\ 'MH7_807^5>@UY]\5?\
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MZEWOJ,****0!1110 4444 4K_K!_OUS.JD+\5O#K,<*-.NQD].L==-?]8/\
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M_H!6_P#WTW^-3&5VUV-ZM'DA":=U)?BGJOU^9T_G1?\ /5/^^A1YT7_/5/\
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MR4EN6AS'#QUS_$?H>*F4E'<UI49U7ILMWT7J,'Q+\%G./$=B<=</_P#6I?\
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M)?\ Y5(O\*/[>\6?]"7_ .52+_"@#JJ*Y7^WO%G_ $)?_E4B_P */[>\6?\
M0E_^52+_  H ZJBN5_M[Q9_T)?\ Y5(O\*/[>\6?]"7_ .52+_"@#JJ*Y7^W
MO%G_ $)?_E4B_P */[>\6?\ 0E_^52+_  H ZJBN5_M[Q9_T)?\ Y5(O\*/[
M>\6?]"7_ .52+_"@#JJ*Y7^WO%G_ $)?_E4B_P */[>\6?\ 0E_^52+_  H
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M3Q5XA2WB6)6,#L%&,L58D_B:SG?GBSMP[B\/6B][)KY-+]3HZ***T.(****
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M4^2S^\D6>N<]6^O3M6\      . !2T548I(QJU74=WHNBZ+T"BBBJ,@HHHH
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MU&VGEQG9'(&.*?>ZQINFLJWM];V[-T$L@7/YT<Z23OH4Z%3FY.5W?EJ7 "%
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M?]@1/_1S5UE</H5^^M?$2ZU*+3M1M;5=+2#?>6S19?S2<#/7@UW%,S"BBB@
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MU'%;W.;*82+QMY<'/;D 5E4T:E_6IW8->TC.AW5UZQU_*Z.KHHHK4X0HHHH
M**** "BBB@ KFO"UE;1W^O7JQ 7$NH2QN^3RJXP/U-=+6%X9_P"8Q_V$YO\
MV6LY+WD==&35"I9[V_,W:***T.0**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *I:Q<FST:]N%D$;QP.R,2.&VG'7WJ[7)?$(VTOAZ*QN)
MIN[N&-4W8+CS%W8_"HJ2Y8-G3@Z2JXB$'LVC3\*6 T_PW:)YSRM,OVAW<#)9
M_F/3W-;516\"6MK%;Q9\N) BY/. ,"I:<5RQ2,Z]1U:LIOJVPHHHJC(****
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MWIMYSG_@5=?65&_+KW?YG?F7)[=*GLHQ7_DJN%%%%:G %%%% !1110 4444
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M%<I_PG47_0N^)/\ P6M_C1_PG47_ $+OB3_P6M_C0!U=%<I_PG47_0N^)/\
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M[ZQE=D26(@LO48Y_I6G4-W_QY3_]<V_E2DDTTS2E.4*D91W31C^"O^1*T?\
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MOHLEVC[V%Y!&5 ;Y\EOJ!Q75U-.3<==S?&4HTZSY/A>J]'J@HHHJSE"BBB@
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M9N?"MQ'H9?[7N!(C<J[(/O!2.<^E)NPTKNQTU%>8>&9/#T&M6D%UJ'B&QU8
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ME0?J*DHH&G9W.2^'MC+I>@W.GS2B5[:]EB+#.#C'3/:NMK"\,]-8_P"PG/\
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M6/;N^;L>:Z*>"=6E*OI[AG+,)4)+#)NT]^VAZ+1117.:!1110 4444 %%%%
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M(]:36?&7B#0K73H+S2M.&JW\YBCC%VWD@#')?;G//I3 TO\ A6_A'_H#1_\
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M<(*+=PS#$0Q.)E5IQY4WHO\ /S"BBBM#C"BBB@ HHHH **** "BBB@ HHHH
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M1?\ ?^/_ .(KK:*LYSDO^$*O/^AQ\1?]_P"/_P"(H_X0J\_Z''Q%_P!_X_\
MXBJTS^(-7\:ZQI]EK[:=:V,5NR(MI'+N+J2<EN>U6_\ A'O%/_0[2_\ @MAH
M ;_PA5Y_T./B+_O_ !__ !%'_"%7G_0X^(O^_P#'_P#$4[_A'O%/_0[2_P#@
MMAH_X1[Q3_T.TO\ X+8: &_\(5>?]#CXB_[_ ,?_ ,11_P (5>?]#CXB_P"_
M\?\ \13O^$>\4_\ 0[2_^"V&C_A'O%/_ $.TO_@MAH K7?P^:_MGM;WQ5KUQ
M;R8WQ23)M8 YP?D]J[,#"@>@Q7*_\(]XI_Z':7_P6PT?\(]XI_Z':7_P6PT
M=717*?\ "/>*?^AVE_\ !;#1_P (]XI_Z':7_P %L- '5T5RG_"/>*?^AVE_
M\%L-'_"/>*?^AVE_\%L- '5T5RG_  CWBG_H=I?_  6PT?\ "/>*?^AVE_\
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MK[);?\^\/_? H^R6W_/O#_WP*Y7[9\0O^@1H'_@;+_\ $4?;/B%_T"- _P#
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M?O;T^5L_B#6O51?,KHQJTW2FX2W3L%%%%,S"N6O%33_B!8W NFC6_@>.6-F
M5B@&S'O\QKJ:YOQM!)_88U""*%Y]/E6Z'F<?*G) /49Q6=7X;]M3LP#_ 'WL
MWM)./W[?C9G245#:3_:;.&?C]X@; .0,BIJT.1IIV85@^-0#X+U8D XMF-;U
M,FCCF@>.5%>-E(96&01[BIDN:+1IAZGLJL:G9I_<5-&O8-1T:TN[9BT,D0*D
MC&>W]*O5@^"]O_"(Z>%Q\J,,#M\QK>H@[Q3*Q4%3KS@MDVOQ"BBBJ, HHHH
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MY_U^H.S:\OZ_0;I.JVNM:=%?V3.UO*,HSH5)_ U=J.""*V@2&&-8XT&%51@
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MDD<[I9G^\[>IKH:EL84444@"BBB@ HHHH I7_6#_ 'ZN#I5._P"L'^_5P=*
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M3[2)T+!5VW9;>:_S(_\ A"9?^AL\2?\ @8O_ ,31_P (3+_T-GB3_P #%_\
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M<=@Y[8%=32IRYHIFN,I*E7G!;7T].@44459S')^'C'I/B;5M#\RX*.PNK=9
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M[O3[1K>2XN;V41I&AY ]?I725Y=X^EBTOXC>&M7O1BQ3=$S'[H8AL?S%-*[
M]0W83<W'&3[5Y7J/Q4U*[UBXLO#.B2W\5LV))P"0WTXK7^(OC:RTSPM-#I]X
MDNH7B^7;K$V6&?XJTOAYX<7PYX3M870"ZF'FW#8Y+&FM%=@,\$^.H?%B3P2V
MLEEJ-L<36\G4>XKKZ\K@,<?Q_N5M !FQ'G!>G1*]4I- %%%%( HHHH ****
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M1117(=(4444 %%%% !1110 4444 96N^(M,\-VBW.J7(@B8X4GN:DT77=/\
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M%%%%:G$%%%5KZ_MM-LY+N[E6*&,99FH;MJQQBY-1BKMD[NL<;2.P5%!+,3@
M#O6&JOXBEWR*R:2IXC88-P1W/^Q[=^#6;I0U+Q5<-J%^'MM&)'V>S/#2X.0[
M'KCVSVY%=>H"J%4 *!@ #I6:?/KT.RI#ZJ^6]Y_E_P '\O790 !@=****T.(
M**** "BBB@#D]%_Y*-XJ_P"N-G_Z ]=97)Z+_P E&\5?]<;/_P! >NLH SM0
MT'2M6D234+""Y=!A6D3) J33](T[249;"SAME8Y81KC-8[^+7?4+JTL]$O[P
MVS!9'B*8!/3JP]*U(]6"Z6]]?6TMBJ#+),1N'Y$UE&5/XE]YVU*>*A34)-V=
MM+]]M+_H17GAC0]0N6N;O2[::9OO.Z9)JRFD:?'I_P!@2SA%IC'DA?E_*L>/
MQ5>3H)(/#6IRPMRDBF,!AV(RU78M?1M3LM/EM)X+BZC:0*^/DP,X.#UX[4)T
M^BW\BITL8DHR;LM;<U[6\KZ6-:.-(HUCC4*B *JCH .@JIJ.D:=JR(FH6<-R
MJ'*B1<XJ/5]9AT>.!YHW<32B(;,<$_\ ZJAU[7X]"@@D>VFN&GD$:1Q8R2<
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MB9%?"GIR!CKQ4-EX7BL!"D&JZKY4. D1N<I@=L8Z53_X6/X3_P"@M_Y+R_\
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M9[21K5]A)SL.T$YYYQFM^G&7,DT9UZ3HU)4WT844451D%%%% !1110 4444
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M6U^S^9WU8O+?W=OWKW?\J?1>?=].@    # '2EHHK<\D**** "BBB@ HHHH
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M4D_YH_FC8T.\EU#0;"\GV^;/ DC[1@9(R:O/_JV^AK*\*_\ (IZ3_P!>L?\
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M$?C.:S?<M_-*25F8D)S]W/MTKZB?_5M]#7S%HD<B_&N4&*0'[0YQM/3=6M+
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M% !1110 4444 5[[_CQGS_<->3>"@O\ PFD8). 'Q7KEQ&9;:2->K*0*\_\
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M]2Q Q^-/TZPLK*RC@LHXQ !\NWD5M=^RMS/?;H9>Y[2_+^.OY%7_ (2/3?\
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MQ<*BVLK;5X0GI[5\V> IE_X71<':A5I)<9'3YATK'!*?LZEGT/1DZ=UH_O\
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M44 %%%% !1110 4444 %%%% !1110 4444 4K_K!_OU<'2JE_P!8/]^K8Z4
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M] S &N_.(<M6-ET^\XLIGS4Y7?46ZQ]DFST\MOY5\R^ ]C?&>7YEV^9)@_\
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MM;LZEX)%7J5(%15YW-^TW-%:VAG6_B71;K4VTV#487O%ZP@\UIM(BD!G4$]
M37SYX4\+ZU;_ !I:ZEM9%ABE:1I"#C!4C^M9/Q?U_7M.^(4L$>J3QI&B/$L;
M$!,_UKL6!C.JJ<)=+D\VEV?3=>>>+]2\=VWB6UBT*R\S3F(\QPH/YYKL-)N6
M/ARUN92TC_9P['NQQFN'TOXQ:??:]+IUSI\MG%&Q4W$K848/?CBN>A"=VXQY
MK%,]'@,C6\9E $A4;@/6I*HVNLZ;>V7VRWO8)+?O(K@J/QJ>&]M;B SPW$4D
M0ZNC C\ZP<6N@QFHW3V5C)/'"TS(,A%ZFLOPYKMUK*RFYL&M=AP,]ZO7FII'
MI\UQ:;;IHQ]Q&!S7'K\0[B' N-(E4EN,<?TKMP^&G6I24(7?>^J^1Q5Z\*51
M.<[+M;]3T"J.K:E'I.FS7DBEEC&<#O4MC=B]LX[CRVCWC.UNHK'\:@/X6O,,
M/NUST*:E6C"?>QO6J-4I3CV.3\2>($\1>$!<+&8F2<*R_B*WOAXZ?\(\B[AN
MW'C//4UP$1 \&2_,,M<#C//44_PE/+%XDM5CD8*QPP!X-?25L'%X6=*&BBV_
MN/GZ6+DL3"I/5M)&_P#$@'^T;8^PKO-#&-%M1_L5P/Q(+?VG;@XQ@8KJ;3Q!
M8:3I&GI>S;'E4!0!FO.Q%.4\%1C%7>IWT)QABZKD[+0W-0%R=/G%H0+C8?+S
MZ]JYGPBGB-+RZ_MG=Y7\&0.M=6L\30"<.OE$;MV>,56L=7L=1DD2TN$E:,X8
M*>E>=3J2C2E!1NGUML=\X1E5C-RMY7W+M%%%<QT!1110 4444 %%%-\Q-^S>
MN[^[GF@!U%<-X_\ 'T_@U[5(-'GOO/&3(GW5YQCH>:ZC0M3;6-%M=0>W>W:=
M YB?JN>QK25*<8*;V8KFC11168PHHHH **** "BN/U&+7CXC1K?588[7(S"7
M&<9],UUZYVC<><<UM5H^S47S)W_ RIU>=M6M86BLCQ+:ZI>:%<0:-<_9KYA^
M[DSTK)\#:7XGTRQDC\2:E]LE)RI+;B/QS4J"<.:_R-.IUC,%4EB !U)ID4\4
MP)BD1P.#M.:YCXC2RP^!]2>&4QL(6Y'T->;?L^WMQ.^IQ2SNZXW;6/&>.:UA
MA^:C*K?8+ZV/5=7\:^']"U*/3]2U&*"YD (1LYP>E>7_ ![3[7ING7,,D;1D
M9'/)Z\BNY\9>'O!LM_!K7B,0I,F%5I& WXZ#GKBO-OC?<:3>Z-I-QIY66,)M
MBDB8%0O/'%=."C'VL)1OY]B9;,[[X.VLMOX&MS)MP_(Q7H->=_!EE/@6W"[L
MCKDUZ)7)BOXTO4J.P4A(4$G@ 9-+4<XW02+GJI'Z5BMQL\Z\<>(;#4+9K&W<
MM*C<GM6/X'OH+#7U:YE$:,I4$]S6+J2"+5+E <XD//XU':PI<W<<+L5#'&Y1
MG%?:4\)3CA723T:/D9XJI+$JJUJF>^?)-%V9&'X$53L-&L-,=WM+=8F<Y8CO
M6%X=UZPAFCT,7$LTZ#&]QU/I769%?)585*#<'=)_BCZ>E.%9*:M=?@%<YX[@
M^T>#M0B\Y8<QGYV. .*R/%WQ2T?PCJ::?<Q2RSMC(0=,_A1X[U*+4_A??7MO
MN$<L.X9Z]**=*<90DU9-FS:.#^!.F?9]0O[C^T(I,@KY2,<]1S7NU?-_P!E9
M?$EVHQAH^?S%>H_%CQ9J7A7PR+K2BBSF55+,,[0?:NK&TI3Q7(MV3%VB<A^T
M*1_9^G#=SN/'YU2^&?C+3_!OPZ>[O5ED#3D!4 S6/\2M:NO$/@'P_J=\@6YF
M!+;>!U8?TKFTD5?A; ,,<W39&>O-=U*BI8:-*?<EO6Z/0M2\3VOBR_BU.R26
M.,D#;(,$'->T:02=)M23D^6O\J^>](=3IULR1[, 86O=/"EY=7FB1-<V_DE0
M%7W'K59O1Y,/!1V1Y&75>;$U+]3=KQ/7G:/Q5.Z#<RRY ]:]KR*\9\0,/^$O
MD,"@.)> >YK#)/XD_0US?^''U"SOKF\\66LTZLDF\#9GI7LR_='TKQ2#[4?%
M4'VG G\P9P:]J3B-<^@HSE).G;L+*6VIW[CJ***\0]@**** &2_ZIOI7BV@
M_P#":6H[_:'_ )&O:92!$V3@8KQ+2+F&U\6PW,S;88YW+'TZU[F4)NE62[?H
MSQ\T:52DWW_R/2-5U37K?78+>TL/,LR1ND_G72$DP$D8.WD5R]MX^TJXU 6F
M)%W-M5R.":ZEF#0LP/!4D5YV(A."C&<.7]3NH3A/FE"?-^AX;KN?[;NL_P!\
MUZ+\.#_Q3K_]=C_(5Y_J$8N/$\D4A&UY<'!]Z]@T;2K72+!;>T7:A^8Y/4U[
M6:U8QPL*;W=CR<LI2>(E4Z*YH445P'Q;U+5]+\)&XTBX:"0-\[HVT@<=*^>I
M4W4FH+J>^W8[74ED?3;A84620H=JGH37DWPTTCQ#8^+KN;4-#@M;=]W[T8R#
MSTQ6[X/OM9D^&$U[J%V\UT8BT<A;+5Y=\)?$&O7?C[R9+VXECDW&5'8D'K7?
M1HR5.K%-:$MZH^EZQ-<\.1:W+!))<2Q>4<X0]:UKFYBM+9[B=PD<8RS'M6/9
M>+]%OY&2*[56!Q\_RYKDH*M']Y23TZF=9TG^[J-:FS!"(($B!)"C&34E(K*R
MAE((/0BEK!W;U-EMH%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M#I;9(4,.1CTK@QY9N\/GRC)\V.N*]'!4HM37-S)[>1Y^,JS3@[6:W\STK6]
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M6-:EC;5FELKF5HL#:Y<UZ+HGA^.[TF":74II9&7+,DAQ]*\PF\I\RQX7<?\
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MA<R71/$4#;0/U%>QZ!I]GX@T6VU.&XNXTG7<$9SD?K7R9/?^?9Q6_D1KY?\
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M#UI**8"@LIRK%3[&I)KF6X5!(00@P,#%144K*]QW=K!1113$'Z4444 %%%%
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M!Y_X\_Y"</\ US_J:Y*NM\>?\A2+_KG_ %-<E7-+<^HP7^[Q"BBBD=04444
M%%%% !1110 4444 %=3X$_Y#9_W#_(URU=3X$_Y#9_W#_(T+<YL9_N\_0]$H
MHHKJ/E@HHHH **** "BBB@ HHHH *.]%% 'F'BXYUV3Z5@UM>*6#:[-CM6+7
M*]SZS#:48^@4444C8****8!1110 4444 %2V_P#Q\Q?[X_G452V__'U%_OC^
M=(3V/9+?_CVB_P!T5)4=O_Q[1?[HJ2NI;'Q[W"BBBF(**** "BBB@ HHHH #
MT/TKR37O^0U<?[U>MGH?I7DFO_\ (:N/]ZL:O0]7*OXDO0S:***S/="BBB@
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M-\*XV3?W&M#+<1"I&36B?<^4J*^D/^&>M"_Z"5S_ -\?_7H_X9ZT+_H)7/\
MWS_]>L?[4P_?\#W^1GS?17TA_P ,]:%_T$KG_OG_ .O1_P ,]:%_T$KG_OG_
M .O1_:F'[_@'(SYOHKZ0_P"&>M"_Z"5S_P!\_P#UZ/\ AGK0O^@E<_\ ?/\
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M/_UZ/^&>M"_Z"5S_ -\__7I?VIA^_P"!OR,^;Z*^D/\ AGK0O^@E<_\ ?/\
M]>C_ (9ZT+_H)7/_ 'S_ /7H_M3#]_P#D9\WT5](?\,]Z#_T$KG_ +Y_^O6%
M%\(_"+:^='?7)?M;?<C4<_SH_M3#]_P#D9X917TA_P ,]:%_T$KG_OG_ .O1
M_P ,]:%_T$KG_OG_ .O1_:F'[_@'(SYOHKZ0_P"&>M"_Z"5S_P!\_P#UZ/\
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M *]'_"L]._Y^YOR_^O6W]L83N_N/*_LK$]E]YYD>WUKV1[Q+'P8)I Q7R,8
M]>*R/^%9Z=_S]S?E_P#7KH1H8^PBT:Y=H0FS!7M7FYCCZ%?DY-;/7H>C@,%6
MH\_-I=:'B(.26_O'-+77GP_X:^VM%_:4OE>=Y*R@?)YG.5SGJ"#^5;H^&FFD
M B[F(/M_]>O2_MC"=W]QYW]E8KLOO/,Z*],_X5GIW_/W-^7_ ->C_A6>G?\
M/W-^7_UZ/[8PG=_<']E8GLOO/,)?]1)_NFO%W^^WUKZV;X8Z<R,OVN;D8Z?_
M %ZY?_AGO0B<G4[G_OC_ .O653-<,WHW]QZ67X.K1YN=;V/F^BOI#_AGK0O^
M@E<_]\__ %Z/^&>M"_Z"5S_WS_\ 7J/[4P_?\#TN1GS?17TA_P ,]:%_T$KG
M_OG_ .O67=?!OP=9:I;Z;/KDZW<_^KCV\G]?>C^U</W_  #D9X'17N3_  G\
M'6\DT5QK-R&@<)*P3Y4)Q@'GW%;D?[/WA^6-9(]4N61AD$+U'YT?VIA^_P"
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M-<9I&E:Y-K4-WK-K&L<61#'"XV1@^W.37;T4 <[8:)<6OBN_U(A!!. % Z\
M?X5T5%% &/XC34WL/^)3;0S76?E,I&%]^M<[#H^N6>BO]FM(VU6:3,UQ(X)^
MH^G:NZHH Y_PKHXTBR=&M##,[;I'+AC(?7BN@HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*HPH& !2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gou0qrw2itv5000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )2!W # 2(  A$! Q$!_\0
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M -C^U8/[LGY#_&C^U8/[LGY#_&L>B@#8_M6#^[)^0_QH_M6#^[)^0_QK'HH
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M0 4444 %%%% $MO_ ,?,?^]4NH?\?C_A45O_ ,?,?^]4NH?\?C_A0!5HHHH
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M (\G^H_G6)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8\D_G7%_#XEO'/BYG^_YXS_WV]=AX>\3Z;XF@FFTYI"L3;6\Q-ISUKAKV9_
M?Q#N]5N()&TG4QEY4&=KGD_KG\Z 9U/Q&"GP%JF>R*1]=XJQX&W?\(3I&[_G
MV7'TQ7'^+/%,'C*UA\/^'5EN9+B13-+L(5%'K_GM7H^FV2:=IEM91_<@C5!^
M HZ#6Y:HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "K]M_P @ZXJA5^V_Y!UQ0!0HHHH
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MI5U#*>H(R*@AT^SMV+0VL,;$Y)5 #5FB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** );?_ (^8_P#>J74/^/Q_PJ*W_P"/F/\ WJEU#_C\?\* *M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !4;P0R-N>*-F]64&I** (?LEM_S[Q?]\"I54*H50 !T %+
M10!!<65K=X^T6\4N.F] :DCBCA0)$BHHZ!1@4^B@!KQQRC$B*X'9AFH_LEM_
MS[Q?]\"IJ* &)%'$"(T5 >NT8HEACF39+&KJ>S#(I]% $%O9VUH,6]O%$/\
M84"IZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ J_;?\ (.N*H5?MO^0=<4 4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "D(# A@"#U!I:* (?LEM_S[Q?\ ? IR6\,;;DAC
M5O4*!4E% "$ C! (/8U7CTZRBE,L=I"LAZL$&:LT4 %1&VMV)+01DGJ2@J6B
M@"'[+;C_ )=XO^^!4N 1@CCTI:* (?LEM_S[Q?\ ? IR00QG*1(I]54"I**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH Z&U_X](O]P5+45K_QZ1?[@J6@"I?V
M*W]I);M(Z!R#N7J,?_JK'_X1"#_G]N/S%='10!SG_"(0?\_MQ^8H_P"$0@_Y
M_;C\Q71T4 <Y_P (A!_S^W'YBC_A$(/^?VX_,5T=% '.?\(A!_S^W'YBC_A$
M(/\ G]N/S%='10!SG_"(0?\ /[<?F*/^$0@_Y_;C\Q71T4 <Y_PB$'_/[<?F
M*/\ A$(/^?VX_,5T=% '.?\ "(0?\_MQ^8H_X1"#_G]N/S%='10!SG_"(0?\
M_MQ^8H_X1"#_ )_;C\Q71T4 <Y_PB$'_ #^W'YBC_A$(/^?VX_,5T=% '.?\
M(A!_S^W'YBC_ (1"#_G]N/S%='10!SG_  B$'_/[<?F*/^$0@_Y_;C\Q71T4
M <Y_PB$'_/[<?F*/^$0@_P"?VX_,5T=% '.?\(A!_P _MQ^8H_X1"#_G]N/S
M%='10!SG_"(0?\_MQ^8H_P"$0@_Y_;C\Q71T4 <Y_P (A!_S^W'YBC_A$(/^
M?VX_,5T=% '.?\(A!_S^W'YBC_A$(/\ G]N/S%='10!SG_"(0?\ /[<?F*/^
M$0@_Y_;C\Q71T4 <Y_PB$'_/[<?F*/\ A$(/^?VX_,5T=% '.?\ "(0?\_MQ
M^8H_X1"#_G]N/S%='10!SG_"(0?\_MQ^8H_X1"#_ )_;C\Q71T4 <Y_PB$'_
M #^W'YBC_A$(/^?VX_,5T=% '.?\(A!_S^W'YBC_ (1"#_G]N/S%='10!SG_
M  B$'_/[<?F*/^$0@_Y_;C\Q71T4 <Y_PB$'_/[<?F*/^$0@_P"?VX_,5T=%
M '.?\(A!_P _MQ^8H_X1"#_G]N/S%='10!SG_"(0?\_MQ^8H_P"$0@_Y_;C\
MQ71T4 <Y_P (A!_S^W'YBC_A$(/^?VX_,5T=% '.?\(A!_S^W'YBC_A$(/\
MG]N/S%='10!SG_"(0?\ /[<?F*/^$0@_Y_;C\Q71T4 <Y_PB$'_/[<?F*/\
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MQ71T4 <Y_P (A!_S^W'YBC_A$(/^?VX_,5T=% '.?\(A!_S^W'YBC_A$(/\
MG]N/S%='10!SG_"(0?\ /[<?F*/^$0@_Y_;C\Q71T4 <Y_PB$'_/[<?F*/\
MA$(/^?VX_,5T=% '.?\ "(0?\_MQ^8H_X1"#_G]N/S%='10!SG_"(0?\_MQ^
M8H_X1"#_ )_;C\Q71T4 <Y_PB$'_ #^W'YBC_A$(/^?VX_,5T=% '.?\(A!_
MS^W'YBC_ (1"#_G]N/S%='10!SG_  B$'_/[<?F*/^$0@_Y_;C\Q71T4 <Y_
MPB$'_/[<?F*/^$0@_P"?VX_,5T=% '.?\(A!_P _MQ^8H_X1"#_G]N/S%='1
M0!SG_"(0?\_MQ^8H_P"$0@_Y_;C\Q71T4 <Y_P (A!_S^W'YBC_A$(/^?VX_
M,5T=% '.?\(A!_S^W'YBC_A$(/\ G]N/S%='10!SG_"(0?\ /[<?F*/^$0@_
MY_;C\Q71T4 <Y_PB$'_/[<?F*/\ A$(/^?VX_,5T=% '.?\ "(0?\_MQ^8H_
MX1"#_G]N/S%='10!SG_"(0?\_MQ^8H_X1"#_ )_;C\Q71T4 <Y_PB$'_ #^W
M'YBC_A$(/^?VX_,5T=% '.?\(A!_S^W'YBC_ (1"#_G]N/S%='10!SG_  B$
M'_/[<?F*/^$0@_Y_;C\Q71T4 <Y_PB$'_/[<?F*/^$0@_P"?VX_,5T=% '.?
M\(A!_P _MQ^8H_X1"#_G]N/S%='10!SG_"(0?\_MQ^8H_P"$0@_Y_;C\Q71T
M4 <Y_P (A!_S^W'YBC_A$(/^?VX_,5T=% '.?\(A!_S^W'YBC_A$(/\ G]N/
MS%='10!SG_"(0?\ /[<?F*/^$0@_Y_;C\Q71T4 0VEN+2UCMU9F$:A0S=34U
M%% !116#XJ\567A;3O/N/GGDR(80>7/^%5"$IR48J[9,YQA'FEL:>HZG9:5:
MM<WUPD$2]V/7Z>M>9Z[\8%5FBT6TW=A/-_,"O._$'B/4/$=^US?2DC^"('Y4
M'H!617OX;*X15ZNK_ \2OF,Y.U/1'27WCWQ+?L3)J<L:G^&+Y164=<U4G)U"
MY_[^&K6E>%-;UK:;*PE>,_\ +0C"_F:ZF#X0:[(!YUQ:Q?\  BU=4JF%HZ.R
M.:,,15U5V<9)K6J31JDFH7+*IR!YIXJ'^TK[_G]N/^_K?XUZ+_PIC4/^@M:_
M]^VH_P"%,:A_T%[7_OVU1]=PB^TON+^J8GLSSK^TK[_G]N/^_K?XT?VE??\
M/[<?]_6_QKT7_A3&H?\ 07M?^_;4?\*8U#_H+VO_ '[:G]=PO\R^X/J>)_E/
M.O[2OO\ G]N/^_K?XT?VE??\_MQ_W];_ !KT";X-ZL@_=:A:R?@16%J?PY\2
M:8I<V?GH.K0-NQ5PQ6&F[*2(EA\1%7<6<Y_:5]_S^W'_ '];_&C^TK[_ )_;
MC_OZW^-0R1R0R-'*C(ZG!5A@BF5T\L>QS\S+/]I7W_/[<?\ ?UO\:/[2OO\
MG]N/^_K?XU6HHY5V#F?<L_VE??\ /[<?]_6_QH_M*^_Y_;C_ +^M_C5:BCE7
M8.9]RS_:5]_S^W'_ '];_&C^TK[_ )_;C_OZW^-5J*.5=@YGW+/]I7W_ #^W
M'_?UO\:/[2OO^?VX_P"_K?XU6HHY5V#F?<L_VE??\_MQ_P!_6_QH_M*^_P"?
MVX_[^M_C5:BCE78.9]RS_:5]_P _MQ_W];_&C^TK[_G]N/\ OZW^-5J*.5=@
MYGW+/]I7W_/[<?\ ?UO\:/[2OO\ G]N/^_K?XU6HHY5V#F?<L_VE??\ /[<?
M]_6_QH_M*^_Y_;C_ +^M_C5:BCE78.9]RS_:5]_S^W'_ '];_&C^TK[_ )_;
MC_OZW^-5J*.5=@YGW+/]I7W_ #^W'_?UO\:/[2OO^?VX_P"_K?XU6HHY5V#F
M?<L_VE??\_MQ_P!_6_QH_M*^_P"?VX_[^M_C5:BCE78.9]RS_:5]_P _MQ_W
M];_&C^TK[_G]N/\ OZW^-5J*.5=@YGW/6/A[\0R#'H^LS9!^6"X<_HQ_K7K0
M((R#D&ODWH<BO5_A[\0MOEZ/K$O'W8+ACT_V6KQ<?@-ZM)>J/6P6-_Y=U/DS
MUNB@$$9'(-%>(>P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY!HKQ#V HIKND4;22,%11EF)P *\7\:?')+2XDL?#423,AVM=R#*Y_V1W^M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY ''7ZT6079Z7X<U^W\2Z%;ZM;12113 D)*!D8J2'Q!H]SJC:9!J5M)?*"3
ML@+@#KQ52Y\,1-X630;"ZEL(%14$D/W]HZC/OZUY5X3TFUT/XZW&GV880Q0.
M!O;)/ Y)]:+#NSVVYN8+.!I[F9(HE&6=VP!6;IWBC0M6N#!I^K6=S,.J12@F
MO-/C9<2?;]!L[J22/29)-TY4\$Y[_A7+^.H_!VC2Z/?^#;R!;R.4&06TQ?CU
M/)P:$A-GT515>PG-SIUM.WWI8E<_4@&K%(H**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[.YBG5-/BC<QL&"L,Y!]ZY&BG##Q@TT]K_B*==R35M[?@6M.OI=-U*VOH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M49)X[5!_:,>X#RIN8//^YV]/K[5<HH IIJ43M&!%,/,B\T93H/0^](FI12&
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MH@'"=<^E7:* *3ZE%'Y^8ICY*AFPG7/IZTKZE$C2*8ICY<8D.$Z@]A[U<HH
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MO[41ZE%(8 (IAYR%URG3'KZ&KE% %*+4HIOLVV*8?:-VW<F-NWU]*2/5(I!
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M'KZ4+J<3+&PBF_>2&,93H1W/M5VB@"D-3B*@^5-S)Y?W._K]*1M4B4.3%/\
M)((SA.I/?Z5>HH I2:E%&)R8ICY+A#A.I/IZBA]2B3SLQ3'R<9PG7/I5VB@"
MD^I11F4&*8^4@<X3J#Z>]*=1C4N/*F^6$3'Y.WI]?:KE% %,:E&6"^5-S%YO
MW.WI]:%U&-VB BF'FH7&4Z =C[U<HH IQ:E'*;8"*8>>&*Y3&W;Z^E)%J<4H
MMR(IAYY(7*=,>OI5VB@"DNIQ,(B(IOWDIB&4Z'U/M0-3B*JWE3<W'V?[G?U^
MGO5VB@"BVIQ*')BG^2;R3A.I]1[>]+)J<4:S$Q3'R7"'"=2?3VJ[10!2EU.*
M(7),4Q^S[=V$^]GT]:674HHFG4Q3'R5#-A.N?3UJY10!3;48U+@Q3?)&)#A.
MH]/K0-2B+8\J;F'SON=O3Z^U7** *2ZE$QC BF_>1&493H/0^]*FI12>3B*8
M>:I893ICUJY10!2CU**0P8BF'G,5&4Z8]?2A-3B=8B(IAYLAC&4Z$=S[5=HH
M I#4XBH;RIN9/+^YW]?I2-J<2ACY4_RR",X3OZ_2KU% %*34HHQ,3%,?*<(<
M)U)[CVH?4HD\[,4Q\K&<)USZ5=HH I/J449E!BF/E('.$Z@^GO2MJ,:EP8IO
MDB$IPG4'M]?:KE% %,:E$6"^5-S%YOW.WI]:%U*-FC BF'F1F093H!V/O5RB
M@"G%J,<IMP(IAYZLRY3ICU]*2/4XI1 1%,/.)"Y3ICU]*NT4 4EU.)A$1%,/
M,D,8RG0CN?:@:G$54^5-\T_D?<[^OT]ZNT4 43J<2ASY4_RS>2?DZGU^GO2R
M:G%&LQ,4Q\EPAPG4GN/45=HH I2ZG%$+DF*8_9]N["9W9]/6EEU**)KA3%,?
M(56;"9SGT]:N44 4VU&-3(#%-\D8D.$ZCT'O0-2C+;?*F_U/G?<[>GU]JN44
M 4EU*)C&/*F_>1>:/DZ#T/O2IJ4<GDXBF'FJ6&4Z8]:N44 4H]2BE, $4P\X
MD+E.F/7TH34XG6$B*8>:Y093H1Z^U7:* *0U.)E5O*F^:3R_N=_7Z4AU2(!C
MY4_RR"/[G?U^E7J* *3ZE%&)B8ICY4@C.$ZD]Q[4/J42>=F*8^40#A.N?2KM
M% %)]2BC,P,4Q\I0QPG7/I2MJ,:F0&*8[(A*<)U![#WJY10!3_M*/=M\J;_5
M>;]SMZ?6A=2C9HP(IOGC,@RG0#L?>KE% %./4HY3;@13#SU9ERG3'KZ4D>IQ
M2B#$4P\XD+E.F/7TJ[10!274XG$1$4P\V0QC*=".Y]J%U.)E4^5-\T_D#*=_
M7Z>]7:* *)U2(!CY4_RS>2?D[^OT]Z634XHUF8Q3'RG"'"=2>X]JNT4 4I=3
MBB%T3%,?LY4-A/O9]/6EEU**%KA6BF/D*K-M3.<^GK5RB@"F^HQH9 8ICY<8
MD.$Z@]A[T?VE'N(\J;B'SON=O3Z^U7** *8U*(F,>5-\\/G#Y.@]#[^U":C'
M(8<13#S4+#*=,>M7** *46I12F "*8><2%RG3'KZ4)J<3K"1%,/-<H,IT(]?
M05=HH I+J<3*K"*;YI/+&4[^OTI#JD0!/E3\2^5]SOZ_2KU% %)]2B02DQ3'
MRI!&<)U)[CVH?4HD\[,4Q\H@'"=<^E7:* *4FI11^=F*8^4H8X3KGTI6U&-#
M(#%,?+B$IPG4'L/>KE% %/\ M*+=M\J;_5>;]SMZ?6@:E&60>5-\\9D'R= .
MWUJY10!3CU&.0P 13#SD9URG3'KZ4D>IQ2^1B*8>=G;E.F/7TJ[10!274XG$
M1$4P\UR@RG0CU]J%U.)E0B*;YYO)&4Z'U^GO5VB@"B=3B 8^5/Q-Y/W._K]/
M>EDU.*-96,4Q\J01G"=2>X]JNT4 4I=3BB6Y)BF/V<J&PF=V?3UI9=2CA:Y5
MHIC]G"EMJ9W9]/6KE% %-]1C0R@Q3'RXQ(<)U![#WH_M*/<5\J;B#S_N=O3Z
M^U7** *8U*,E!Y4WSP^</DZ#T^OM0FHQR&$"*8>:A<93H!Z^]7** *46I12F
MW BF'GYVY3ICU]*(]3BD6 B*8><Y5<ITQZ^E7:* *2ZG$RH1%-\\AC&4Z'U^
ME)_:D0!/E3\2^5]SOZ_2KU% %)]2B02DQ3'RY1$<)U)[CVH?4HD\[,4Q\I@I
MPG7/I5VB@"E)J<4?G9BF/E $X3KGTI7U&-#*#%,?+C$APG4'L/>KE% %/^TH
M]Q'E3<1^9]SMZ?6@:E&60>5-\T9D'R=O3ZU<HH IQZC'(80(IAYR%QE.@'KZ
M&DCU.*3R,13#SLXRG3'KZ5=HH I)J<3B$B*8>:Y093H1Z^U"ZG$RH1%-\\WD
MC*=#ZGV]ZNT4 4?[4BVD^5/Q-Y/W._K]/>E?4XHUE8Q3'RY!&<)U)[CVJ[10
M!2EU.*);DF*8_9RH;"?>SZ>M$NI10M<AHICY 4MM3.[/IZU=HH IOJ,:&8&*
M8^5&)#A.H/8>]']I1[F'E3?+!Y_W.WI]?:KE% %,:E$60>5-\\'GCY.@]/K[
M4)J,<AA BF'FH7&4Z =C[U<HH C@F6X@25590XR PP14E%% !1110 4444 %
M%%% !37=(D9Y&5$49+,< 5S?BWQKI_A:VPY$]ZX_=VZGGZMZ"O$-?\7:QXCF
M9KVZ80YRL$9VHOX=_J:[L+@*E?WMD<>(QM.C[N[/:=3^)'AG3&9#?&YD7JEL
MN_\ 7[OZUSEQ\9[!2?LVD7$H[>9*$_D#7CE68=.OKG'D6=Q+GIY<3-_(5ZT<
MLP\%[VOS/,EF->3]W0]1_P"%UC_H '_P,_\ L*/^%UC_ * !_P# S_["O.?^
M$;U[_H":E_X"O_A1_P (UKW_ $!-2_\  5_\*KZE@^WXO_,GZWB^_P""_P C
MT;_A=8_Z !_\#/\ ["C_ (76/^@ ?_ S_P"PKSG_ (1K7O\ H":E_P" K_X4
M?\(UKW_0$U+_ ,!7_P */J6#[?B_\P^MXOO^"_R/1O\ A=8_Z !_\#/_ +"C
M_A=8_P"@ ?\ P,_^PKSG_A&M>_Z FI?^ K_X4?\ "-:]_P! 34O_  %?_"CZ
ME@^WXO\ S#ZWB^_X+_(]&_X76/\ H '_ ,#/_L*/^%UC_H '_P #/_L*\W?P
M]K<:[GT?4%'JULX_I5&6": XFBDC/HZD?SIK 81[+\7_ )B>-Q2W?X+_ "/5
MO^%UC_H '_P,_P#L*/\ A=8_Z !_\#/_ +"O):*K^S<-_+^+_P Q?7\1_-^"
M_P CUK_A=8_Z !_\#/\ ["C_ (76/^@ ?_ S_P"PKR6BC^S<-_+^+_S#Z_B/
MYOP7^1ZU_P +K'_0 /\ X&?_ &%'_"ZQ_P!  _\ @9_]A7DM%']FX;^7\7_F
M'U_$?S?@O\CUK_A=8_Z !_\  S_["C_A=8_Z !_\#/\ ["O):*/[-PW\OXO_
M ##Z_B/YOP7^1ZU_PNL?]  _^!G_ -A1_P +K'_0 /\ X&?_ &%>2T4?V;AO
MY?Q?^8?7\1_-^"_R/6O^%UC_ * !_P# S_["C_A=8_Z !_\  S_["O):*/[-
MPW\OXO\ S#Z_B/YOP7^1ZU_PNL?]  _^!G_V%'_"ZQ_T #_X&?\ V%>2T4?V
M;AOY?Q?^8?7\1_-^"_R/6O\ A=8_Z !_\#/_ +"C_A=8_P"@ ?\ P,_^PKR6
MBC^S<-_+^+_S#Z_B/YOP7^1ZU_PNL?\ 0 /_ (&?_84?\+K'_0 /_@9_]A7D
MM%']FX;^7\7_ )A]?Q'\WX+_ "/6O^%UC_H '_P,_P#L*/\ A=8_Z !_\#/_
M +"O):*/[-PW\OXO_,/K^(_F_!?Y'K7_  NL?]  _P#@9_\ 84?\+K'_ $ #
M_P"!G_V%>2T4?V;AOY?Q?^8?7\1_-^"_R/6O^%UC_H '_P #/_L*/^%UC_H
M'_P,_P#L*\EHH_LW#?R_B_\ ,/K^(_F_!?Y'K7_"ZQ_T #_X&?\ V%'_  NL
M?]  _P#@9_\ 85Y+11_9N&_E_%_YA]?Q'\WX+_(]:_X76/\ H '_ ,#/_L*/
M^%UC_H '_P #/_L*\EHH_LW#?R_B_P#,/K^(_F_!?Y'K7_"ZQ_T #_X&?_84
M?\+K'_0 /_@9_P#85Y+11_9N&_E_%_YA]?Q'\WX+_(]:_P"%UC_H '_P,_\
ML*/^%UC_ * !_P# S_["O):*/[-PW\OXO_,/K^(_F_!?Y'K7_"ZQ_P!  _\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;QOXO
MA\+Z6=A5[^8$01^G^T?85TES<16EK+<S,%BB0N['L ,U\T>)-<G\0ZY<7\QX
M=L1KGA5'05WY?A?;U+RV1Q8[$^QA:.[,^[N[B^NI+FZE:6:0[F=CDDUU'A+P
M#J/B<B=C]EL0>9F7EO\ ='?ZU)\/_!Q\2ZD;BY&-/MF'F?\ 31O[O^->^Q11
MP1+%$BI&@PJJ, "O2QV/]C^[I;_D>?@\%[7]Y4V_,YW1O GA_18T\JQCFF7_
M );3@.Q/KST_"ND"*O10/H*6BO!G4G-WD[GMPA&"M%6"BBBH*"BBB@ HHHH
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MZ3XELOM6E7D=Q'_$!PR>Q'45JT %%%<QXMN)IKC2]$@E>+^T)BLSH<'RE&6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQUW5U]QG5@HRTV>H4445J9A1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ#I*:YH-WISX'G)A2>S#
MD'\Z^9;FWDM+F6WF4I)&Q5E(Y!%?5M>4_%#P6TK/K^GQY8#_ $F-1_X\/ZUZ
MN5XE4Y.G+9_F>;F.'<X^TCNOR*'PM\7QV,IT.^DVQ2MFW=CPK'^'\:]EKY.!
M*L""00<@CM7J7@WXH_9HTL->9F1>$N0,D#_:_P :WS# 2D_:TOFC# XU17LZ
MGR9Z_15>SOK74+=9[2>.:)AD,C9JQ7B--.S/833U04444AA1110 4444 %%%
M% !574-0MM+L)KV[D$<$2[F8UGZ[XJTGP] 7OKI1)CY8D.7;\*\0\7^-K[Q3
M<;"3#8H<QP ]?=O4UVX7!3KRN](]SDQ.+A15MV4/%.OR^)->GOWRL9^6)"?N
MH.@_K^-8M%%?3PBH148[(^=E)RDY/=A1115$G>^$87U+P#XBTNR(-^[1RB,'
MYG0$9 _(_G3OAUIU[I>M7&JW\$MK86UNXF>92H.>@YZUP]I>7-C<+<6L[PS+
MT=#@BKFH>(M9U6$17^I7%Q&.=KOQ7).A-\T4U:7WG5"O!<LFM8G9>'[&YU7X
M;Z[!81EY6O RH#@L  2!4?A&QNM'\->([[489+>VDMO)191M+N<@8!^M9VD:
MU!8_#[4K5+SR=0:\22)%)#$ #D?E6#J.OZMJT:QZAJ$]PB\A9&R!6:I5)N<=
MDW\^A;JPBHRZI?YGH O$D^'6C36VB6^K+;EHYD=23$WK@>M<_K>MW\_AA;'_
M (1V+3+ SAPR(RY?'O7-:=K&HZ2[/87DUN6Z^6V,TNH:SJ6K%3?WLUQM^[YC
M9Q5PPSC.^ZO?K^6Q$L0I1ML[6Z?\.=3\2R?[5TX9.!8QX%'CHEM#\,D\DV(Y
MKD;W4;S49$DO+B2=T4(I<YPHZ"ENM1O+V*"*YN))8X%V1*QX1?054*#BH+^4
MF=92<WW%TO\ Y"UG_P!=T_\ 0A7>:SI%MKGQ8:QNW*PNJD[3@MA>@KSI':*1
M9$8JZD%2.Q%6+C4KVZOOML]U*]UD'S2WS<=.:NI2E*7-%VT:^\FG4C&/*U?5
M,]3\*[5\5FUMO"D=I!!N7[6ZMO Z=3P<UD>"87GUOQ-#$0)'AD5<G')8UR;^
M+O$,C1L^KW1,9ROS]*H0:I?6KSO!=21M<#$I4X+C.>:Y_JLVI7>Z7=[>IO\
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M\T/%TTEMX?\ ",\3E)([9F5AU!!%=CI36^NV-UXH@VK/+IDEM>(/^>@P0?Q
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M\/2NRHHH *\@^,?B&*/4=,T"\>6'396$]V\:Y9E!^Z!7K]036=K<L&GMH96
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D95=2K %6&"#W%+10
M!Y#XX^&;0F34M#C+1_>DMAU7W7_"O+71HW*.I5E."",$5]85S7B#P+HOB'<\
M]OY-P?\ EM%P?Q]:]?"YFX+DJZKN>7B<N4GS4M/(^?K'5;_39 ]E=S0,.1L<
MBND@^)WBB  ?;4DQ_P ](PU:^I_!_58&9M/NH;E.RN=K5SL_P_\ %$#[?[)F
MD]X\$5Z7M<)6U;3]3S_9XFEHDUZ&E_PM?Q3_ ,][;_OP*/\ A:_BG_GO;?\
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M/_""^*/^@)=?]\BC_A!?%'_0$NO^^11[>E_,OO#V-3^5_<<]170_\(+XH_Z
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M7)9R+M@#&% V]&]: +=%5/L]QG_CZ;_5[?N_Q>M"6URK1EKMF"H58;?O'UH
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MH'VML^?YF=O\']R@"Y15-K:Z(?%XPW2[U^7HO]VEDMKEA,%NV4NP*?+]T>E
M%NBJDEM<L+C;=LOF >7\OW,=?SHDMKEFF*W;*'4!!M^X>YH MT54-O<$L1=,
M,Q[1\O1O6@6]R&!-TQ BV8V_Q?WJ +=%5%MKD&/-VQVQE6^7[S?WJ$MKE?*W
M7;-M!#?+]Z@"W151+:Y7R=UVS;&)?Y?OCTI%MKD+&#=L2LA9CM^\/2@"Y15,
M6USM -VV?,W9V_P^E#6UT0X%XP)D##Y>@]* +E%5'MKEA-MNV7>X*?+]P=Q0
M]M<MYVV[9=^-GR_<H MT54>VN6,NV[9=R!5^7[I]:#;W)+8NB,Q!!\O1O[U
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M0J@W;$B;>3MZI_=H N453-M=$,!>,"9MX.WHO]VB2VN668+=LI=PR';]P>E
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M<DR8NF&Z,*OR_=;^]0!;HJI]FN=V?M;8\O;C;_%_>H%M<AD)NV("%2-O4^M
M%NBJD=O<J8=UTS;%(?Y?OD]#^%)';7*^3NNV;9G?\OW_ $H N4546VN0(LW;
M':Y9OE^\/2D6VN0J W;$B;>3MZK_ ': +E%4S;76&'VQN9=X^7HO]VA[:Y99
M0MVREG#*=OW1Z4 7**IR6URZW 2[9#(5,9V_ZO'7\Z66WN7:X*7902 ",;?]
M61U_.@"W151[>X)D*W1&Z,*OR_=;UH^S7.XG[6V##L V]&_O4 6Z*J"VN<H3
M=L0(MA^7JW]ZA+>Y4Q;KHMM0AOE^\?6@"W152.VN5,&^[9MF=_R_?STI$MKE
M1"&NV8HQ+G;]\'H/PH N4536VN0J W;$A]Q.WJ/2C[-=8(^V-_K-WW?X?[M
M%RBJCVUR1)MNV&Z0,OR_=7^[0UM<GS<7;#>05^7[H]* +=%5'MKEO.VW;+O
M"?+]TT-;W),F+HC=&%7Y?NMZT 6Z*J?9KG<3]K;'E[<;?XO6@6]R&4_:V($9
M4C;U/K0!;HJHEO<J8=UTS;$(?Y?OD]#^%)';7*^3NNV;9G?\OW_2@"Y151;:
MY BS=L=KDM\OWAZ4+;7(" W;$B7>3MZK_=H MT53^S76"/MC9\W?G;_#_=H>
MVN660+=LI9PRG;]T>E %RBJ<EM<L+@+=LID*F,[?]7CK^=++;7+M<%+MD$@'
MEC;]S'7\Z +=%5'M[EC+MNBNZ,*OR_=;UH^SW.YC]K;!AV ;>C_WJ +=%5!;
M7.4/VML"'81MZM_>H2WN5,6ZZ+;4*M\OWCZT 6Z*CA1XX4220R.!@L1UJ2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK#USQ;H
MWA]#]NO$$N.(D^9S^ KS[4_C)*69-,TY57M).W/Y#_&NFC@ZU76,=#GJXJE2
MTDSUVJ_VZT_Y^H/^_@KP:Y^)_B>X/%U'$/2.,#^>:XZN^GE$W\<K?B<53-(K
MX(W/JK[=:?\ /U!_W\%'VZT_Y^H/^_@KY5HK3^QU_/\ A_P3/^U7_+^/_ /J
MK[=:?\_4'_?P4?;K3_GZ@_[^"OE6BC^QU_/^'_!#^U7_ "_C_P  ^JOMUI_S
M]0?]_!1]NM/^?J#_ +^"OE6BC^QU_/\ A_P0_M5_R_C_ , ^JOMUI_S]0?\
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M]0?]_!1]NM/^?J#_ +^"OE6BC^QU_/\ A_P0_M5_R_C_ , ^JOMUI_S]0?\
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M]0?]_!1]NM/^?J#_ +^"OE6BC^QU_/\ A_P0_M5_R_C_ , ^JOMUI_S]0?\
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M+?3[6.",==HY/U/4UT8K,847R05V<^'P$ZJYI:(\/L_A;XENHP[V\5N#VED
M/Y5I+\&]9*@G4+%3Z$M_A7M=%>;+-,0]K(]%9;06]V>+?\*:UC_H)6/_ (__
M (4?\*:UC_H)6/\ X_\ X5[314_VGB._X#_LZAV_$\6_X4UK'_02L?\ Q_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_L\2&0_9%6$Q3^9S(=W )]\+]=U1SNQEBDD^2\3SOLT FP)L=,_A@^V:G4
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MK^K_ (6\R4G?^OZM^-QQ>7_6;!]L\LX@\S@C=U_^O4!;9/*+4^<'DQ=;IO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9VD-M$,1Q($4>P%35F>']0N]4T.UO;ZPDL+F5,R6TF=R'T.0#^E:=24%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'IGPF\WS+X0%!*2-F_.W.UNN*]2V+]JF-B;<2&5
M?MV\MDKM[>AQ7EGPD!:[NT#LA)'S+C(^5O6O7V\R1\?OHA&P((*8E&.G<X_(
MU\]F+M7?H>[@5>BO4S(X[3^S]J_9_P"PO*^4 MNW;N>?2M%@#.AN/+WB4_9L
M9_N<Y]_O?A0&FV_:3'<;BN/LI,?!SUSGK_P+%3?,K8^=P[=>,(,?RX]^OI7!
M*;;^_K_7S?4[8Q27]?UZ=C-D23S2T!M?[;^SJ&+;MFS=SQZ9SBDB2$/+]A,
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MK;WZV6E6>UY)[;(D.1P@/K5V2675OC0K&UE9=*L21'E<EFZ8.<?K6;;:_:^
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MP!,$MT/J3U_F*N6L92762M^!,=)1B^D7?\3B****]$X HHHH **** "BBB@
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M^?:A+=[D6W]GR/"-/"Q-N#$<9&./;IBK>Z4;4E^S_P!H&.4PD*VW&1^/=,U
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M%J54DCY3U]#@-^%0S*TJF():/J8B1F\R,E,9/XX^]BIXU:&5C&TD_FS9D#2
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M/]T_U]:4;6_K^OE\QRO?^OZ^?R"WDM);0M:+;_V6!()E\L@Y'7C'3KGBI_\
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M?^TC%(8B%;9C(_''*9J)#<13>=&DLTMP\8G@:X4K:C;R5_P[U((BMJ;83S-
M\<FZ[,PWH<] ?Q.#VVU4K:?U_7Z]!1O_ %_7_##BY:=UL?($BSJ+K>IR1M!X
MQU;&WVK/%Q8-IPE1;1M":,A8_*(9I-_93QC(].O/2K>H3*B-+=22VL5O,KQM
M'(,S_+G:1Z9)&/;-06=I/J%PNH:@FW'^HM\Y">Y]_P#/T<$E'FEM_7X_D3)M
MRY5_7]?B/M+::^G6^OEV@<P0'H@]3[UK445A.;DS>$5%!1114%!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <!\1/ JZY;MJ>G1@:C$OS(!
M_KE';Z^E>'.CQ2-'(K*ZG#*PP0:^L*XWQA\/K'Q*C7-OMM=1 XE ^63V8?UK
MUL#F'LU[.KMW['F8S ^T?/3W/!K.\N+"ZCNK29X9XSE70X(KU#P_\8&2-8->
MMFD(X%Q;@9/U7I^7Y5Y]K7AK5O#\YCU"T>-<X64#*-]&K)KUZE"CB8WEKYGE
MTZU7#RLM/(^C[/QWX9O8PT>KP)G^&8F,C\ZO_P#"3:#_ -!O3?\ P+C_ ,:^
M8:*X7E%.^DF=BS2IUBCZ>_X2;0?^@WIO_@7'_C1_PDV@_P#0;TW_ ,"X_P#&
MOF&BE_8\/YF/^U9_RGT]_P )-H/_ $&]-_\  N/_ !H_X2;0?^@WIO\ X%Q_
MXU\PT4?V/#^9A_:L_P"4^GO^$FT'_H-Z;_X%Q_XT?\)-H/\ T&]-_P# N/\
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M2Q0XX)ZX[\\8J(HWFC/DG4/+.V?[,VT+GIG/Z;O>GO(\<A-O&9W:15E3S?\
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M!+:_:?\ 5 ]\=/TYHBG_ %;^OG\AR:_K^OP+ 4B1?.\M[K#>7(L!PH],Y/\
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M5F%8F88601'@_>/:@"W155M2LT\S=,!Y;A'X/#'M0^HVD8E+S >5C?P>,]*
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M6>TGSA@2^2>#]_TH MT54;4K-/,W3 >6XC?@\-Z4KZC:1B4O,!Y1 ?@\9Z4
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M.SD$12<$3,53@\D=:GZU7_G?WLKZM1_D7W'-?\*P\)?] U__  (D_P#BJ/\
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MCZU7_G?WL/JU'^1?<<S_ ,*P\)?] U__  (D_P#BJ/\ A6'A+_H&O_X$2?\
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MR>4O!Y;TH_M*SV[O.&/-\GH?O^E'UJO_ #O[V'U:C_(ON.:_X5AX2_Z!K_\
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M+SCP>$]:/K5?^=_>P^K4?Y%]QS'_  K#PE_T#7_\")/_ (JC_A6'A+_H&O\
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M&O\ ^!$G_P 51_PK#PE_T#7_ / B3_XJNE&I697(F&-_E]#][TH;4[-0Q,X
M1Q&W!X8]J/K5?^=_>P^K4?Y%]QS7_"L/"7_0-?\ \")/_BJ/^%8>$O\ H&O_
M .!$G_Q5=,^HVD8E+S >4P1^#\I/04-J-HGF[I@/*QOX/&>E'UJO_._O8?5J
M/\B^XYG_ (5AX2_Z!K_^!$G_ ,51_P *P\)?] U__ B3_P"*KIGU&T0R!I@/
M+0._!X![TIU"T4L#,,K%YQX/">M'UJO_ #O[V'U:C_(ON.8_X5AX2_Z!K_\
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MJ/\ (ON.9_X5AX2_Z!K_ /@1)_\ %4?\*P\)?] U_P#P(D_^*KISJ%JI8&8
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M!?RQP?O>E(=3LU#$SC"OY9X/#>E'UJO_ #O[V'U:C_(ON.:_X5AX2_Z!K_\
M@1)_\51_PK#PE_T#7_\  B3_ .*KIGU&TC$I:8#RG"/P>&/04-J-HGF[I@/*
MQOX/&>E'UJO_ #O[V'U:C_(ON.9_X5AX2_Z!K_\ @1)_\51_PK#PE_T#7_\
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M3R]LP/FJ63@\@=:/;3[C]E#L4UT-$$H6YF F),F#]\GKGUI1HBK;K MU,(5
M 0'Y1CIQ5M-1M)#"$F!\XD1\'YB.M(NI6;B,K,")7*)P>2.HH]O4[B]C#L5V
MT@LZNU[<%DSM);D9]*:NBA9VG6[G$K@*S@\D#H":M#4K-E!$PPS^6.#][TH.
MIV8#$SC"R>6>#][TH]M/N/V4.Q4CT-88FBBNIDC8DLJG .>M..C;D1&O)RJ$
M%06X&.F*M/J-H@D+3 >4XC?@\,>@H;4;1/-W3 >40'X/&>E'MJF]P]C#L5&T
M4-.D[7<YE0$*Y/(!Z@&B/11%)))'=SH\AR[*<%C[^M6WU&TC,FZ8#RE#/P>
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MM"4 F&7B\Y>#RGK0FHVCF/;,#YJETX/('4T>VGW'[*'8IKH2(LRK<S!9B3(
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M^B@!@BC&,(O!R..AH\J/^XO!ST[^M/HH 9Y4?]Q>N>G>@Q1G.47DY/'6GT4
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MVW_?U?\ &CDEV#GCW)_*C&/D7@Y''0T>5'_<7[V[IW]:@_M*P_Y_;;_OZO\
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M/HI#&>5'Q\B\#:..WI0(T&,(O P..E/HH 0*% "@ #H!2T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDTR-9+Y8H3 C="W.*UKCP/XW\<ZM:S>*I;>ULH#D1QD9QWP!W]ZL@3XSWO\
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MJJLC8MYOE?V]#7J8(8 @Y!Z&OF,QH.G7;Z/4^AP%95**75:"T445P':%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M :].GG$E\<?N/.GE2^Q(\5HKUR3PSHTIR]A'^!(_D:9_PB>A_P#0/3_OMO\
M&NA9Q1_E?X?YF/\ 9=7NCR:BO6?^$3T/_H'I_P!]M_C1_P (GH?_ $#T_P"^
MV_QH_MBCV?X?YA_9=7NOQ_R/)J*]9_X1/0_^@>G_ 'VW^-'_  B>A_\ 0/3_
M +[;_&C^V*/9_A_F']EU>Z_'_(\FHKUG_A$]#_Z!Z?\ ?;?XT?\ ")Z'_P!
M]/\ OMO\:/[8H]G^'^8?V75[K\?\CR:BO6?^$3T/_H'I_P!]M_C1_P (GH?_
M $#T_P"^V_QH_MBCV?X?YA_9=7NOQ_R/)J*]9_X1/0_^@>G_ 'VW^-'_  B>
MA_\ 0/3_ +[;_&C^V*/9_A_F']EU>Z_'_(\FHKUG_A$]#_Z!Z?\ ?;?XT?\
M")Z'_P! ]/\ OMO\:/[8H]G^'^8?V75[K\?\CR:BO6?^$3T/_H'I_P!]M_C1
M_P (GH?_ $#T_P"^V_QH_MBCV?X?YA_9=7NOQ_R/)J*]9_X1/0_^@>G_ 'VW
M^-'_  B>A_\ 0/3_ +[;_&C^V*/9_A_F']EU>Z_'_(\FHKUG_A$]#_Z!Z?\
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M_&C^V*/9_A_F']EU>Z_'_(\FHKUG_A$]#_Z!Z?\ ?;?XT?\ ")Z'_P! ]/\
MOMO\:/[8H]G^'^8?V75[K\?\CR:BO6?^$3T/_H'I_P!]M_C1_P (GH?_ $#T
M_P"^V_QH_MBCV?X?YA_9=7NOQ_R/)J*]9_X1/0_^@>G_ 'VW^-'_  B>A_\
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M +[;_&C^V*/9_A_F']EU>Z_'_(\FHKUG_A$]#_Z!Z?\ ?;?XT?\ ")Z'_P!
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MQH(U':V'ML^:-O!_U??\:N44 4W&H_O=C6WWQY>0?N]\^]*XU#$OEM;]O+W
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MML[QY>0?N]\^]7** *D@U#]_Y;6XR5\G<#P.^ZAQJ&9MC6^,#RL@\'OFK=%
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M:AF'S&M^I\W:#R.V*11J.V/<UMG>?,P#]WMCWJY10!3 U':,O;9\SG /W/\
M&@C4<-M>VSY@VY!^Y[^]7** *CC4,3;&M\[QY6X'A>^?>AQJ'[[8UOV\K(/'
MKFK=% %1QJ&9=C6_W!Y>0?O=\^U#"_R^UK?'E#;D'_6=\^U6Z* *@%_N&6M\
M>7SP?O\ ^%"B_P!T>YK?&P[\ _>[8]JMT4 5(Q?Y@\QK<X5O.V@\GMM_KFDC
M&HXA\Q[;@GS=H/([;:N44 4U&H8BW-;9\P^9@'[G;'O0!J.U<M;9\[+8!_U7
MI_O?I5RB@"F1J.&P]MGSOER#_J_?_:HD&H;9O+:WSO'E;@>%[Y]ZN44 4Y!J
M&+CRFMP3M\C<#QZ[O_K4L@O]T_E-;A2H\G<#P>^[VJW10!487^7VM;X\L;,@
M_?[Y]J +_=RUOCRO0_ZS_P")JW10!4 U#,>YK?'E?/@'[_M[4(+_ /=;VM_N
MGS, \GMCVJW10!4C&H9A\QK?&3YNT'D=L4BC4=L6]K;.\^9@'E>V/>KE% %,
M#4=J[GMMWF<X!^Y_C01J.&P]MGS.,@_<_P :N44 5'&H8EV-;YWCR\@\+WS[
MT.-0_?;&M^H\K(/'KFK=% %1QJ&9=C6_W1Y>0>&[Y]J&%_E]K6^/*&S(/W^^
M?:K=% %3%_NY:WQY?H?O_P"%"B_W1[FM\;#OP#][MCVJW10!4C%_F#S&M^%;
MSMH/)[;?:DC&H_N?,>VX)\W:#SZ8JY10!34:AB+<UOG>?,P#]WMCWH U':NY
M[;/G9; /^K]O]K]*N44 4R-1PV'ML^;\O!_U?_Q5#C4=LOEO;;MX\O<#PO?/
MO5RB@"G(-1Q<^4]L"2OD;@>/7=_3%+*+_=/Y36X4@>3N!X/?=_\ 6JW10!48
M7^9-K6^/+&S(/W^^?:C%_N/S6^/)XX/^L_\ B:MT4 5 -0RF6M\>5\^ ?]9[
M>U""_P#W6]K?[I\S /WNV/:K=% %2,:AF#S&M\ GS=H//IMI$&H[8=[VV=Y\
MW /*]L>]7** *:C4=J[FML^9\V ?N?XT$:C@X>VSYG'!^Y_C5RB@"HXU#$NQ
MK?/F#R\@_<[Y]Z&&H?O=C6_4>7D'@=\U;HH J.-0_>^6UO\ ='EY!Z]\^U#"
M_P R;6M\>6-F0?O]\^U6Z* *F+_=]ZWQY?H?O_X4 7^Y,M;XV'?@'[W;'M5N
MB@"H@O\ ,/F-;X"GS=H/+=L>U)&-1_<^8UL<9\W:#SZ8JY10!34:AB+<UOG>
M?,P#]WMCWH4:AM3<]OGSOFP#_J_;_:JY10!3(U'!P]MGS>.#_J__ (JAQJ.V
M78UMNWCR\@_=[Y]ZN44 4Y!J.VX\I[8$E?(W \#ON_\ K4LHU#=<>4UN%('D
M;@>#WW?_ %JMT4 5'%_F38UOCRQY>0?O]\^U&+_<?FM\>3@<'_6?_$_K5NB@
M"H!J&4RUOCROGX/^L]O]FA!?YBWM;_</F8!^]VQ[5;HH J1C4,P>:UN0,^=M
M!Y]-M(@U';#O:VR&/FX!Y7MCWJY10!34:CM3<UMG?\V ?N>WO1C4<'#VV?,X
MX/W/\:N44 5'&H8DV-;Y\P>7D'[G?/O0PU#][L:WZCR\@].^:MT4 5'&H?OO
M+:WZ#RMP/![YH<7^9-C6^/+'EY!^_P!\^U6Z* *F+_<?FM\>7QP?O_X4 7^Y
M<M;X\L[N#]_V]JMT4 5$%_F'>UOC8?-P#RW;'M21C4?W/F/;=_-V@\^F*N44
M 5%&H8BW-;_?/F8!^[VQ[TBC4,)N:VSYOSX!_P!7[?[57** *>-1P?GML^;Q
MP?\ 5_XT.-1VR;&MMV\>7D'[O?/O5RB@"G(-1VW'EM; DKY.X'@=]W_UJ64:
MANN/*:W ('D[@>#WW?\ UJMT4 5'%_F78UOCRQY>0?O]\^U&-0W-\UOCR<#@
M_P"M]?\ =_6K=% %0#4,IEK?'DX;@_ZSV_V?UH07^8M[6_W#YF >6[8]JMT4
M 1P^:(4\\H9<?,4Z9]JDHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**0D*I9B  ,DGM6=%XAT6>=8(=7L))F.U8TN4+$^F,T :5%5X+VWN9[B&&3=
M);MLD&TC:<9QGO\ A5B@ HHHH **** "BBB@ HI'=40N[!5 R23@"A65U#*0
M5(R"#P10 M%,66-W9%=2R?>4'E<^M/H **** "BBB@ HJ)[B*.XB@9L2RABB
MX/(&,_S%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNFWR++;F1E;&,J0PQQZ@T 9=Q/?7OA^]M9;V59H[O[*D\:(#*#C&X%2/XL'
M'3M71V5I)9VWE/>3W..CS*@('I\BJ/TJE-HI&F06MG<>7)#*LPEF3S-[ Y)8
M C.?8BM2(2"%5F=6DQ\S(I4$^P)./S- '-Z<DEFFHZQ-JMY+ LTC&)EBVNJ#
M;SA >H/0BDOI=9MM$?6GU!TF5!-]A6)#%C@["2N\G'&0PY[=JT+?1IAIMUIU
MU=1RVLP<)Y<11U#$DY.X@GGT%-32+Z;R(]1U"*>V@*LL<5N8S(5Z;R6;/K@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gou0qrw2itv5000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -_!:0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA:!J]R((;AXI&.%$ZA<GT'-8^G64&L?$;5'OD$OV08A5N@Y_^O5SX@:18_V
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MTB(PP*<&(GE#[U6+PT*<.:$7ZW31.&KRG+EDUZ6:9O4445YQW!1110 4444
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MQ'XULY[B.Q:U$3 8:3=G]*=A76QUM%%%(84444 %%%% !1110 4444 %%%%
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M%% !1110 4UW6-&=V"JHR2>U.KC_ !I<3WMSI_AZTE,;WTA\YAU6,#)_/!%
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MO+9-QS*H(^HSQ2D.!XA\=+&.'Q-;W2*%:6(!L=SS73? ;_D#7_\ OC^M>?\
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF]2DK(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX8T__5Z<DA]9OG_G754478614M]*T^T_X][*WBQ_<C JW112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 A4,,, 1Z&J%SH6DW@(N-.M9<]VB4_P!*T** ..O?ACX8O6W_ &-H'[-
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M?.ZVMA]KN%[-@E<'\P:[6N*\&_\ $QUW7=:(.V2<10G_ & HS^H-"!G:
M=!7&: 5N?B#KUU ,0K%'$Q'0NI;-;OB75TT70[BZ8_.1LC'<LW _4U6\':3+
MI6@Q_:1_IEPQGN">N]N2* .@HHHI#"BBB@ HHHH R?$.AP:]I;VTHQ(OS0R#
MJC=B#VK/\'ZQ<7EK-INI$?VG8-Y<^/X\?Q#V-=-7$^(%_P"$?\7V.NID07>+
M:Z Z?[!_[Z:F(U/&NG3ZCX<D%LFZX@=;B-1U)3G K,3X@6G]FPQVUK<W.I;
MIMA&0=^.<^@SWKM>HJ%+2VCE\Q+>%9#_ !! #^= '.^&M N8;N;6]8<2ZG<C
M[O585_NK^6:G\8ZS)H^ALT'_ !\SL(8OJQ S^&<UT-4-7T>SUNR-I>QEXR<C
M!((/J"* ,_0-,M/"^C+'<3QB=_WEQ,[<NYZG-0WGCK1+9_*@F>]F[):+YAS^
M%01?#W15;=,;J?'0/<.1^6:WK/1].T] MM9PQXZ$(,_G0&IS0U[Q7J8)T[0X
MX(^SW,NUO^^2*:^H^-=,4W-W86MW;KRZQ. P'L .:[6@\C!HN%C.T76;77=.
M2]M&)1CAE8896[@CL:T:XG1T&F?$C5;"WXMI[=+@H.BN2V3^.!7;4AH****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH YO5/ 7AG6;QKR^TF&6Y<C=(2<G'XU<TGPKH6A$G3--AMR>I4$G]:V**+A
M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !37C208=%8>A&:=6;K>N66@6!O+YF6(''RH6)/T
M% %+5/!?A_5\FZTV$R=G7((_*N7D^&M]ICM-X>\17-FV<B.4@H/T)I9/B'JN
MK.T/AWP_<R-_#-/\JG\#BF+X=\=:ZP?5=<33X3]Z"U!!/XY(JM2=# \4^)=>
MTK2)M+\16MKJ%K,NSSX&^;/K@G^E=-\(]>FU;PN+6XC=9+0[%9A]Y>W\ZNZ=
M\+O#MG)Y]S U].3DO<D-S^5==:V=O90B*VA2*,=%48%)M D[D]%%%(H****
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M!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]XD\5VWA\(A
MC,T[C(0'''UJEH?CRTU2X%O<1_9I&X7+9!_&N<^(FG7*:FM[M+0.,;NRGTKB
M58JP9201T(KZ7"Y9AZV&4OM/J?+XO-,30Q3C]E=#Z'HKS[P?XS#*FGZE)AAQ
M'*3U]C7H(.1D5X6)PU3#SY)GOX7%4\33YX?\,%%%%<YTA1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*7?@E(KIKW1+V;3K@G)1?FC8_P"YG _*F(ZVBN,%YXZL?EDT^QOE'1Q-L)_
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MVGT_K]#Q2M[3=2M[N&/3M6+&W!_=RC[T?_UJV/%_@YK!FOK!"UN3ED ^Y_\
M6KB:]:G4I8NDI1?^:9Y%2G5P=5QFO\FCOU\!:;+AHM7)5N5Z51U_P7#H^D2W
ML=[YIC&=IQS7(>8X_C;\Z#([#!=B/0FL?JV*3_C?@C;ZUA6OX/XLU?"NB?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%9NMZW::#8&ZNB3D[411EG;T% &E17&CQ3XAE430^%;HP'D9E3)'YT
M^'Q];QR^7JNG7>G-ZR+O'_CN:=A7.OHJK9:C9ZC");2X25#_ '3S^56J0SB;
M0_\ ".>/KBVD.VTU?][$>PE  V_D":[21%EB:-QE7!4CV-87B_13K&C-Y)V7
MEL?-MY!U5A_];-3>%]:&NZ%!=D;)@-LT?=&':F(Q?"$ATG6]4\.2<+$_VBWS
M_<<G 'T KLZXOQ@K:/J^E^(H4_U<@M[C'=7(4$_3)-=E&ZRQK(ARK $$=P:
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MXU&_PZUA3A#$P]=P']:]9HJEG6*\ON)>283S^\\C;X>:X%R$B)]-X_QJ+_A
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MBX6S"2W5ZPRMO;IO;\0.E &]17-Z5XQM+Z]6QNK>>QO'^Y'<(4W_ $SUKI*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML07!R-[%A^1XK?HH 0 *H50 !P .U+110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5Y-\14QXDW_P!Z)1^E>LUY?\24QJL#_P!Y,5ZN3.V*7HSR,[5\
M(_5'%1PFXD6$'!<XR:T-6\,W'AWRA/*LGG+O!48Q6?"_ES(_H<UWOQ$7-GIL
MG^P!^E?08AN.*I>=SY[#Q4L)5\K'!VYQ<Q'T<?SKWO3VWZ=;MZQ@UX"IPZGT
M.:]XT-M^A6+>L*G]*\_/E[L'ZGH\/OWYKT+]%%%?-'TX4444 %%%% !1110
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M0N?4/A1_.NRKE_'UH]SX8>2)<O;31W'X(P8_H*W-*NUO]*M;I&!$L2OQ[C-
M=3G?B,?^*5D3N[A174VW_'K#_N+_ "KD_'#+=W>BZ2IR]Q=JS#_8 .3^==>B
M[45?08H#J<O\0+AX?#)BC)#7$\4/X,X!_0UT.G6JV6FVUJGW88U0?@,5C>-M
M,GU/P[(MLNZ>&1)T7UV,&Q^E9D?Q#LCI\0CMYYM1*@-:(GS!^XR>.OO0'4V?
M$_B!="L%\J/S[Z<^7;6XZR.>GX53\-^&/LC-J>JM]JU6X^9V<9$?LH[5#H.A
MWMYJI\0:Z!]J(Q;VW:!?\>!737U[;Z=9RW5S(L<4:Y)- ')>/@DLFCV\2YO9
M+H>45^\ ,%OTS7:UQ7AFUN-?UF3Q3?1LD3+LL87ZJG][ZG)%=K0P05Q.BY\/
M^-]0TI\+;7X^TV_L1A2!^IKMJY+QW92BPM]:M!_I6F2"88ZLO0K^N:$#.MKB
MM'_XE7Q$U2P8D1WD:SQ>A;YBW]*ZS3[V+4-/@NX6W1RH&!KF?&UO<6K6.OV4
M9::QD_>JO5HFP&_(9H!G7UQNA@M\0M?9?NKL!^NU:T[SQAI-KHJZD+A9 Z9C
MB3EG)'W<>M5?!>FW=O:W>I:@I6[U&3S60_P <*/RQ0!U-<;X;#77C?Q!?=44
MK; ^Z,?\:Z?5+M+'2[FY=MJQQDY]\<5@^ +>1/"\=W.,37SFZ?/7+ ?X4 =3
M1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!A>,II(/"6HM%G)A8$CL"
M#DU8\.Q06WAS3UAVA/LZ,2/4J"36C/!%<P203('BD4JRGN#7(#X=6@<H-2O1
M9EB?LH8;![9Z_K3$2:KXLDO+AM*\-(+N^SMDE'^K@]R?6M'PYX:BT2)YI9#<
M7\WS37#]6/MZ"M'3M*L=)MQ#96Z0H/3J?QJ[0 4444AA1110 4A (P1D'L:6
MB@#B]9T*[T.];7?#R$OUN;(?=F'J!V/TKH]$UJTUW3DO+1\@\.O=&[@UH]:X
M;6K.?PEJY\0:9$6L9CB_MU[?[8]^@I[BV.YHJ&UNH+VUCN;:19(9%W*R]"*F
MI#"BBB@ K)\37?V+PWJ$P.&$#A3[D'%:U<UX\#'PE=8[%2?IGF@"UX1L%T_P
MQ8QKUDC$S?[SC<?U-;=4M(P=%L".GV>/'_?(J[0 4444 %%%% !1110!QGB8
M_P!G^,=#U)!C>6@D/KNP!79UQWCLCS=%'\1OHL?3<*[&F(****0PJM?SFUL)
MYQ_RS0M5FJFIPFYTNYA7J\944 87P_A6/PG;R8^>5Y'8^OSFNHKF? ,HD\(6
M@!^9&D5AZ?.U=-0P04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5Q/Q(3.CQ/_ '7KMJY+XB)GPPS_ -V5?YUV
M9>[8J'J<68J^%GZ'DE>BW_[_ .&5H_\ =4G]37G5>BP_OOA=*.OE1_\ LU?3
MYAHZ4O[R/ELNU56/]UGG5>O_  _??X6C]I6'\J\@KU;X<29T!D_NRL:RSI7P
MU_-&N1NV*MY,[*BBBOD3[$**** "BBB@ HHHH **** "BBB@ HHHH J:I81:
MGIEQ93KNCF0J17/^!;Z9],FTF[;-WILA@<GJP'.?UKJZXJ\_XD?Q$M;E1MM]
M5C\E_3>,MG]!3$=E-$D\$D,B[HY%*L#W!X-<':SZGX&EFLGLI;_2W<O;R1'F
M/)SM(_' ^E=_12&<?X?TZ_U/7)/$6KPF%@GEVENQR8T."2??(_6NPHHH *8(
M8U<L$4,>IQ3ZHZOJUKHNG27MV^V-!P.['L .YH FO;VWT^TDN;J58H4&69C7
M%06]WX[U!;N\C>#0H&S# W!N#ZL/3V]JDL]*O_&%RFHZXIATQ3NM['^_Z,_K
M]".]=O'&D4:QHH5%& !VI["W%151 J@!0, "EHHI#"H[B)9[>2)P"KJ00:DH
MH Y#P#(]O97NC2MEM.N#"H_V< _UKKF570HP!5A@@]ZX_2E^R?$C5H>BW%LL
MV/<MC^E=C38D8=KX/T"RO_ML&FP)<;MP8+T/K6Y12.P1&=CA5&2:0SCO'5Q)
M=FP\/VY_>ZA,!)C^%!\V?_'<5UT$,=O D,2A8T&% ["N-\+!M>\1ZAXBE&8%
M_P!'L\C^ <[A^.17;4V)!1112&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !3)HDGA>*10R."K ]Q3Z* .&T.1_"?B-_
M#\Y_XEMR2]@YZ(>Z?@!^M=S7/>,='.K:(S1';=6I\^%QU!7G'XXQ5KPSJ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9 ?U% '9T5R>BZ]J<.MC0=>CC^V/&9(9XAA)%&,\=CR.]=92&%%%% !1110
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M\>8@@TJ^ ^>WOXVS[<T SKJ*9&V^)&]5!I](84444 %%%% '&W"^5\4[1_\
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M9P/]XM_A79T,$<=J_P#R4G1\?\^K?^A5V-<A>?Z1\3K%1SY-BY/_ 'V*Z^@
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M%I5VM*6()./0;:[BD1%C4*BA5'0 8%+2&%%%% !1110 4444 %%%% !1110
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M&XRK @@]P: *FDZE%JVE6]]"?DF0-CTR.E7:X?0';PSXHN/#\QQ9W1:>S8\
M$\LOX<5W% ')7?[OXFV9'\>GD'_ONNMKC]5<1?$G26?@26AC4^^\FNPIL2.,
M&;;XJL1PMU: ?7:"?ZUV=<A?X_X67I&/O>1-N_[YKJ;NX2TM);B3[D:EC^%
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M$_A5*22Z\>ZC);02/#X>@8I,PX:X8<$#_9ZBNUL;&VTVTCM;2%8H4&%51@4
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MF.^>T/\ JYOPXP?>@-CLJ*PO#_B>UUQ&B*-;7L7$MM+PRGV]1[BMVD,****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'S-2O!Y>%Y\I3P6/I@&MO0]*BT71[>QB_@7+GU8_>/XG-,74T:***0PHHHH
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MEQ;07<?EW$22I_=<9%2T4 5K73[.Q!%K;10@]0BXJ4P1-*)3&ID'1L<U)10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "LSQ#"UQX?OXT +&!\ C/8UITC*'1E895A@B@#G_!$L$GA#3A ,!(E1QZ,
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M ,+6IF),T(\B0GNR\&NAKC_ [^5/K5EVBOI' ]BW_P!:NPH8D%%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ..U"7[!\2K"5AA+VV^S@_[0
M);^0KL:YGQKI4M_I*7=IG[;8OY\./U_3-:>@:S#KVC6^H0<"1?F3NC=P?>F(
MTZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "D9@J,QZ 9I:HZS<K::+>3L<!86P??'%
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MTJT.>XB7/\JQ9_ _V-O/T#4;BRF'(1G+QG_@.0*- U.QHKE=&\37*ZB-&UZ
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MZC%<9X?SI?C?6=-;"QW.+R(?4A<#\J8CLZ***0PHHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q[&]M%INL1</8W()/L^%/\
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MY4B0#O\ ,,_IF@"3P!;M#X0M)'^]<#SS]6 KIZK6%HEAI]O:)]R% @^@JS0
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M'AGXY]CT/X4Q7.CHHSD9%%(84444 %%%% "%5/50?J* JCHH'T%+10 4444
M%%%% !12$A022 !U)KF-7\8P6]Q]@TN%M0U!N%2+[J_5NGZT ;FI:I9Z3:/<
MWDZQ1J,\]3]*XZ.VU'QU<)<7BR6>AHVZ. \-<>A;V_*KNG^%+G4+M-3\33"Z
MN%.Z*W'^KA^@]:[   8 Q3%N1P6\5K D,$:QQH,*JC@"I***0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "J6KEQH]V8P"XB. 1UJ[39$$D;(W1A@T <WX CCC\'VAC_B+D_7>:Z:N
M2^'DN?#K6YZP3R+^;$UUM#$M@HHHH&<=H#"V\=^(+8<+*R2 ?1 *[&N-5?LW
MQ2YX%S9,WU(91794V)!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %9^I:U8Z0T(O9A$)6VJS?=S[GM6A5>\L;74(&ANX(YHR.CJ#
M0!+%+'/$LD3JZ,,AE.0:?7 W-M>> [I;NS>2XT.1P)H7)8P9XRI/;IZ5W5O/
M%=6\<\#AXI%#*PZ$4 8'CS?_ ,(5JFW_ )X-N^F#FM71?+_L2R\K&SR$QCZ"
MI-1LH]2TVXLI?N3QE&^AKG? E^SZ;-I-SD7FGR&*13UP22OZ8I]!=3K****0
MPHHHH ***P/$?B6/1ECM;>,W.I7'$%NO4^Y]J +VN:K#HNC7-_,ZJ(HRRY/4
MXX%<+X2\4:/HVD,T\LMQ>7<C3R?9XS)]XD@<>@.*U[7P?<:PZWWBBY>>8\BT
MC8B*/VX^]^(KJ+;2=/M$"V]E;Q@# VQ*#_*F+4YS_A86G9_Y!^J[?7[$_P#A
M5B#Q]H,SA'FFMR?^?B(Q_P ZZ7RTQC8N/I5:?3+"Y!$UE;R9_O1*?Z4:!J/M
M;^TODWVMS%.OK&X;^56*Y.\\!:>\GGZ=/<:?< Y#0R';_P!\YQ5;^UO$GAM\
M:M;?VAIZ_P#+U O[Q1[J!C]: )M5T+4-+U9];\/;3)+_ ,?5HQPLON/0\"G6
MWC_3N(M2@N;"<<,)8B%_!CP:W]*UBQUJT%S87"31]#M/W3Z'WJ>>RM;K_CXM
MH9?^ND8;^= >AQOC'Q%HFH>%[B.'4K9W)5E42#)(.1QFNJT1B^@Z>QZM;H3_
M -\BN4\>Z3I5IX=+0V%LD\L\4:%8E!^9P/3WKL--@-MIEK >L<2H?P&*.@=2
MU1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %<]XE\.-JPBO;&7[-JEL=T,P[^JGV.,5T-
M% '&6_C=[ ?9M?TZZM[E."\432(_N"!BJ]_K]_XK0Z9H%M<00R<37D\938O^
MR#U/XUW$D,4HQ)&CCT90:5(TC7:B*J^BC%,14TG3+?1]+@L+9<10KM'O5VBB
MD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K*UCP[INN1XO( 9!]V5>'7Z'M6K10!Q0LO%'ALYLYEU6Q7GR96Q(H_W
MCG-7;#QUI=Q((+T2Z?<="ERA09]B<9KJ*IWVE6&HQE+NTAER,99 2/H:8BQ#
M/%<1B2&1)$/1E.14E<?)X!@@E\W2=3O+%^H'F-(O_?).*88O'.GM^ZELM1C'
M3S2(B?R!H [.BN-3Q/XD@;;>^&93CJ;8M)_05./'$<?_ !\:)J\9_P"O;_Z]
M%@N=717)_P#"?Z?_ - [5?\ P&_^O0?'"R?\>VAZO(>W^C?_ %Z5@N=917&-
MXE\37#;;/PRRYZ&Z9H_Z&E6V\;Z@V+BZM-.C;J(0)3^H%.P7.MN+F"UC,EQ-
M'$@ZL[ "N9OO'=@DIM],AFU&XS@"!"R?BPR!4</@"S>7SM3OKR_DSGYI&5?^
M^0<5TUGIUG81A+2UBA &/D0"C0-3D_[(\2>(F#:M=C3[(\_9K9OG(]W'^%=)
MI6AZ?HL'E6-ND>?O-CYF]R>]:-%*X[!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M <;X&7R-0\06A_Y978P/JH/]:[*N,T,F#XA:]!T$VV4#Z*HKLZ;$@HHHI#.-
MUXF#X@Z#/VDC:'/U;/\ 2NRKD/&@$&H>'[W_ )YWZ*3[8-=<IRH/J*8A:***
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AN[:.
M\LYK:504D0J0?<5R_@.9H+*\T:1RSZ?<-$F?^>8X7^5==7&:5BR^)>KV_1;B
MVBD7ZY8FF([.N-\36%UI&J1^)]+C9VC7;>0+_P M4]?KP*[*D(# @C(/44AE
M32]3MM7T^*]M) \4@R,=O:KE</:Q_P#"*^./L<61IVK?,B=DE[X]L+7974ZV
MMG-<-]V*-G/X#- &9K?B?3M"VI<.7N'^Y!&,NU9EMX^L'N4AOK2ZT_S#A'N%
M&#^1-0>"+#[:MSXBO5\R[NY6\MG_ (8@3M _ UU%_IMIJ=G):W<"2PN,,K"F
M+42_U&"PTN:_=QY4:;]V>#Z5S7@S39+P2>)=17-[??-&C?\ +&/LH_6N2U5M
M1TRZ@\%7#R2VUY./LLI_YY#G:??(->MQHL42H@"JHP .U ;CZ***0PHHHH *
M1E#*58 @]012T4 <CJ_A.2&Z_M3P]-]COEY:,?ZN;V([?A5WP]XGCU8R6=W$
M;34X.)K=^OU'M70US7BOPNNMV_VFSE-KJD*GR;A.#]#^M,1F7T@\4^-X-.C&
MZQTO][.XZ-(>B_4%1^==Q7&_#Z>UBTM],:(P:I;L?MB/]YW[O[@X_2NRH8(*
M***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MFE$;JBGZBG44 ,\F+_GDG_?(I0BKT4#Z"G44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!Q[@6GQ/B/:YL&_/>/\*["N,\19A\=^'YQTD)
MA)^N3_2NSIB04444AG(_$52/#:W ZV\RR_EG_&NIMFW6L3>J _I6'XYA\_P7
MJBXR?))%:&@S_:M"LILYW1#_  I]!=31HHHI#"BBB@ HJK>ZC9Z?$9+NXCB4
M?WFY/X52L?$^CZC-Y5M>QM)V5OES^= &O1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<7XJ)T/Q%IGB((S0*3!<D=@V%4_09-=I5#6I[&WT>YEU
M+8;4(=X<9SQT^M"!ER&:.XA26)U>-QE64Y!%/KS+PUI7BF+3Y+W2KD6]K*Y:
MWL[D;ODR<'<>1D8XK;_M'QS!Q)HUA-_M+=$?^RT["N)XM83^*O#-K'_KEN6D
M..R[&&:G\=ZFT&E1Z9:G=>W\@B1%Y.TD!C],$US]OIGCFX\17&KRVMA#)(GE
M1;I=WDIG/ *\GK74:)X5%E?MJNHW37NI.,&1AA4]E7H.O:@#9TNR73M+M;-<
M8@B5..^!BK=%%(9QGBM5/C#PL6 _X^CS_P  >NSKC?'P:W;1=2 XM+S>Y] 5
M*_UKL0<@&F(6BBBD,***"<#)[4 %%<QJ'C6SANGLM.@GU&\3ADMTW!3[D=*I
M?\)3XC3YYO#+^5_TS=F;\L4["N=I16'HWBK3M9E:WC9X;M/O6\R[7'X5N4AG
M'>+M+GL[B/Q+I* 7MMC[0H'^MB[@_0;B*Z72]1@U;38+ZW;,<J!@,]/8^]6V
M571D8 JPP0>XKBO#V?#OBN\\/L3]EN<W-IGWY<?@2*8CMJ***0PHHHH :DD<
MF=CJVTX.#G%.KC? CNUQKFYV8"ZXW'/K794 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./\
M')$%QH-YT,5^N3[;6KKU.4!]16-XHT0Z]HDMJC[)Q\T+_P!UA6);^,-2T^U\
MC5="OOM,2X9K>(NC8[@\4Q':T5Y]#\0=5U*'SM)\-W-Q$3@.X*C/Y&@^(/']
MS_J/#EK!GH7G/_Q-%@N=?KXB.@7HF8+'Y1W$]!5'P06;P9IA<$'RSU_WC7)Z
M9%KOC2:[T_7[M;6*UD"SVD*@%\C(&X8.,5Z1!!';6\<$2A8T7:H Z"@$2444
M4AA6;KVKPZ'H\]]-SY:_*HZL3P *TJXC6C_PDGC2RTB(AK73C]HNO0MR I_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLMH09#R\K\LY]36O3$<</"6MS?-<>*[S=Z)"F/Y4C>'?$]H,V?B62;'\$\:
M'\0*[*BBX6.,_P"$B\0Z*<:UI'GVZ];BS)8#W.<5T6DZYIVMV_G6-RDH'# '
ME3Z&M @,,$ CT-<QK'@V"ZG^WZ5*=.U)>1-'T;V8>E '44UD5U*L 01@URNB
M^*9EOO[(UZ$6M^.$D_@F'J#_ (UI:]XDM-"A4/F:ZEXAMX^6<TAW,KP2WD7.
MMV"\1PWTC*/0$_\ UJZ^N5\':9?P/?ZEJ,0@FOI3((>Z \X/O754V)'&6&8/
MB=?QKPL]OYC#U(VBNSKC];TC6+/Q#_PD&D>5<,(C&]L^<L..G;/'>M30/$]K
MKBO%M:WO(N);:3AE/]?PH!&Y12$@#)( ]ZY_6_%MCI0\F'-Y?-Q';P\DGZ]!
M^-(9-XGU]- TMI53SKN3Y+> =9'/05!X0T)](TUY[IM^H7C>=<N>[=A^6*I:
M'X>N[O4AKVOD/>8_<6X^[ O^/2NOIB"N8\<ZFUEH+6L)S<WS"VC7O\_RD_AF
MNCGGBM8'GF<)&@+,Q/ %<7HJ2^*_$C:_.C#3K7,=DC#[QZ%_QX(H0,ZG1M/7
M2]'M;-1@QQJ&]VQR?SJ_112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !28&<XY-+10 45!>230V<LEO$)9E4E(RV Q],URAN?'<QWI86,"GHIF#'^5
M '945QG_  E.LZ-(@\1:4([9C@W-N_F!?][CBNPAFCN(4FA=7C<95E.010 ^
MBBB@ K)\1:)#KVDR6D@Q(/GB<=4<<@_F!6M1T&30!R_A+79KI)-(U0[=5L_E
MDW<>:.SCUSC-=17FE[:7OB?Q=>ZCH\_D-IBA(I .)G&=R$^G 'XUU7ASQ-'J
MP:SNT^S:I#Q-;OP3_M+ZC_&FT),Z&N,\6Q3Z1K-EXFMXWDCA_=7:+U,?8_@3
MFNSILD:2QM'(H9&&""."*0R&RO;?4+2.ZM95EAD&593FK%<?+X1O=+N'N?#>
MHFT#')MI%WQY]@3A:8$\>2?NS)8Q#O( &_2G85S:\1Z_;:!ICS2G?,PVPPKR
MSMZ 56\&:1/I>B[[SF]NW\^?_>/'\@*BTKP@EO?#4=5NGU"^'*O)]Q/]U>0*
MZ>@ K)\3N(_"^IN>@MG/Z5K5R7CZ[/\ 8T>EQ-_I&H2K %[[3PQ_#-)#9H>#
MHVB\+62MU*;OSYK=JO8VXM+"WMQ_RRC5/R&*L4 %4=4TBPUFU-O?VR3Q]@PS
M@^HJ]10!R!\$26PVZ;KFI6T?:/S\J/H,5S,&D30>(/[(\7ZG?7*7#9LY?-Q$
MX_NL#GGKWKU6L7Q1HD6N:++ WRS(-\,@ZHP[BG<5BUI>AZ9HT6S3K.*W!ZE%
MQGZUH5@^#]7DUCP[!-<<74?[N<>CBMZD,**** "BBB@ HHHH **** "BBB@
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M8?)LK:."/^[&N!5FB@"I?Z98ZG#Y5]:Q7$?]V1<BJVG^&]%TJ7S+#3+:W?\
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M4]Q;'I%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!!6N2\+"31O%&I: LC26:KY]N&.?+' *_F2: .VHHHI#"BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2SC^ZB_,,_7!%"!FEX(L#8^%[4N/WMP/M$F>NYN3714V-%BC5$&%48 ':G4
M<E\1)67PO) #_KW5#^>?Z5U%NBQVT:*,*J@ 5S7Q!MVE\*7$R#+6Y$F/Q KH
MK"XCN[""XB.4= 013Z"ZEBBBBD,**** "BBB@#A/B$LNLM9^&;9BLEV?,D8=
MHQP?YBMGP3J9U'PW LA_TBW_ '4P/4,#_ABL_24-_P#$35KMCN6S18$]@P#'
M^50,X\(>-6=\C3=8;EOX8YL=_087]:8O,[FBBBD,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>[$#^M $>L^+=/TFX^QKYEU?L/EMH%W/^(["LH:AXWU$;K;3+2QB/0RRDO\
M]\E:T_"_AN/1[!9+D"?4I1NN)W&2S=\>@KH:8CA_ "WB:CX@74'1[P7$?F,@
MP/N5U.L:3:ZUILME=)E''![J>Q![5SFFL;#XCZE:L-JWT0G3WV@+_6NRH8(X
M:SUG5/"9&GZY!-=6,?RPW\2[B1VW^A_$UVEO<1W5O'/$<QR*&4^H-/>-)%VR
M(K+Z,,BE50JA5 "C@ #I2&+1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU_>D'[L^^37<6=]:ZA;K/:3I-$W(9#D&E8=RQ1110 4444 %1SJ9+>1%ZLI
M_*I** .5\)>'[O2K*_@OT3%Q,S *V<J2?\:H>$_"-]I.N7%W>E3"NY;90^<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB-2?+N'D56_')%/<5K&);7^IZG\7=/O-1M#:"2(^5"W4+\O)^O%7[B2?X?\
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M>"T7!HR? -K?6?@ZQAU'=]H"Y^;J >GZ5TM%%(84444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gou0qrw2itv5000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -J!NP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M17HNC/D;*HUE5ASH=17F'PFUK4M5N-66_O);@((V4.<X)W9_D*M>./$NJ_\
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MQ26!;NE)<RZ%/&)6;B^5]3V&BH;NYBLK2:ZG;;%"A=SZ #->30:MXL^(&IW
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M.XTR.^7_ %;Q>9^&,U5;#NFE).Z?45*NJC<6K-%JBO)+*\\2?$+5K[['J?\
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MPUXKUW0_%2^'?$,AG#,$61SDJ3T(/<&O3M3D>+2[J1#AEB8@^AQ7D#2'QO\
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M )$[_MNE<&%BUB8Q?<[<3*]"378W? \CS>"]+DD=G=HCEF.2?F-=!7.> _\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<C%PY,LJ_P!TGM^ Q7;B7*6&BZWQWT[V./#J*Q#5'X;:]KG"_"W_ )'+6/\
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M"*VU#!5'4J3D]]"S7DWQ8_Y&'0_P_P#0Z]9KR;XL?\C#H?X?^AUAEW\=?/\
M(VQW\%_+\ST'7_\ D4=0_P"O-_\ T&N.^#2J/#U^VT;C=8)QR1M'^)KL=?\
M^11U#_KS?_T&N/\ @W_R+E]_U]_^RK3I_P"Z3]4*?^]0]&=/XZ4-X(U8$9_<
M_P!16)\)"3X,QG@7#X_2MSQQ_P B3JW_ %P_J*P_A)_R)I_Z^'_I2C_N4O\
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M>'P@4B9?^6DN#C\<5S_B.9=#^,$.IZI&S63,KHQ&1MV;<CZ-S7:ZM\1-"M[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 4444 %%%% !1110 5HVW_'NOX_SK.K1MO\ CW7\?YT
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M.OF\5WMK#>"YVPI-="(E?8'K7OW@[PMX>\-6$I\.JOV>[*NSK)O#XSC!_$T
M:>KZ]I6@VXN-5OX+.(G :5\9K-T7Q[X8\0WOV/2]8M[BYP2(E/) [BO"&N=-
M^(7Q;U:Z\3ZG';Z!IK.L:RRA%*JVU0,^N"37K7A'P_\ #AM6CU+PI]@:\MU(
M)M;C>0#ZC)H ] HHKS7X@?%^Q\&:HFD6MB^HZF5#/$K;0F?N@GGD]<"@#=\9
M?$'2_!,]C#J$4\CWC83RQG'..:ZJ&59H(Y5^ZZAAGT-?*GQ'\?1>-[W1-VGS
MV%Y:R[9H9>V6'0U[YXH\;6O@CPQIUW/:7%W+<!(888%R6;;G^E '945XF_QX
MU#3;B)M=\&WEA9RMA92QR1WP& !_.NA\0_%ZUT'Q'I%B=/:;3]3BCEBO0^!M
M<XR![&@#TNBN6\=^-+?P3X8;6)(?M)+*D40;&\GW^G-8FH?%BRT?X?:=XFU&
MQEBFU $062L"S')YSZ8&<^] 'HE%>6>'OBKK>HZY8V6K>"[_ $ZVOGV07+!M
MIXR"<J/TKU.@ HHHH **** "BBB@ HHHH **** "L_193-I<;M<PW)+-^\A3
M:IY/:M"L_16+Z7&6EM)#N;YK08C/)Z?U]Z -"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH PX_\ C^U/_K['_HF*IJAC_P"/[4_^OL?^B8JFH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *?#_KD_P!X4RGP_P"N3_>% $NL;O[*GVK9L<#B\_U74?>_SUQ5Q/\
M5K]WH/N]/PJGK"&329U6&WF) _=W!Q&>1U-7$_U:\ <#@=* *5W_ *_\*@J>
M[_U_X5!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6C;?\>Z_C_.LZM&V_P"/
M=?Q_G0!+1110 4444 %%%% !1110 4444 %%%8WBG1[G7O#EWIMG?/8SSJ M
MPG5.0: /"_B=_P G!:#_ +UI_P"AU]%NZQHSNP5%&68G  KPB?\ 9^U6ZO$O
M)_%K27*8VRO&2PQTYS7=Z'X U/3?!FKZ%?>()KV6^R$N'!S$" ,#- 'F_C[Q
M9J7Q0\11^"_":E[!9/\ 2+@?=DP>I/9!^IKV7P7X2L?!7AJWTBR^8K\\TQ&#
M+(>K'^0]@*\GL?V?M5TUF:Q\6M;L_#&*,KG]:[3P+\.]9\*Z[)?W_B:?4H6@
M:(0/G )*G=R?8_G0!W&LEUT/4&C^^+:0K]=IQ7AO[.2VSWNORRA3?Y7!/WMI
M)S^N*]^90RE6 ((P0>]>*ZI\"[V/Q)/J?AKQ"VF13L69 &W+GJ 0>E '-WT=
ME%^U!:+8K"J&X4R"+&-YC.[IW]:[OQQ\2M0TGQI!X6\,Z1;7FMS*JM+<_=7(
MW <$'ISR?PJIHWP070_&>D:[;:N9%M!ON5F4EYI3NRP/8<CCVK0\>_"B?Q)X
MEA\2:)JQTW58PH9\$@E1@$8Y!QQ0!Y)\4&\7'Q7H#>+(].CN./)^PYQMWC.[
M/?-=-\<-/G\,>.=#\:6*8)D428X!DC.X9^HR/H*U[_X&ZMJ]S::AJ?BM[S4H
MY5:629"R[!SM7GBNJ^-EK87'POU)KYPC0E)+=N_F[@ !]<D?0F@#S:SNHOB?
M\?8;R$F33-/173(_A0#^;DFNO^)OPUUS5O$EMXL\+7B1ZI;JN8W.TDKT*GIG
MV-4?V=?#WV3P[?:[*F)+V7RHB1_ G_V1/Y5TGC#P%XEU/Q')K7ASQ1-IDDL:
MQRP\[3M&,\&@#)^&OQ/UK5_$TWA+Q59)%JL2MME1=I)49(91QTYR./:O7:\V
M\!?"QO"^N7'B#5M4;4]8G!'FD$!<]3SR3VKTF@ HHHH **** "BBB@ HHHH
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M_I5_QGX=.J? 3PQJ\*DW&FVL1)'7RRH!_(X_.MF]^"OB+7=(^SZ]XQENY8%
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M_#<=G,8UN]16&8 ?>3!XKKJ\?\3Z-K&B>)?"T$NKRZEI+ZDK1&[P9XGP>-P
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MV-HWPXT6<VT1E,;Y<H,_?;O7<LJNI5@"I&"#WJ&RLK;3K..TLX4AMXAA(T&
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M\4ZKIE_I'@:^TJ]M&X>*#&XY!7H.Q'ZU]/Q%C$A<8<J-P]#0 ^BBB@ HHHH
M**** "BBB@ K.T.$0:5'&MI): ,W[F1][#D]_?K6C6=H:"/2HU6"Y@ 9ODN6
MRXY/6@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,./_C^U/\
MZ^Q_Z)BJ:H8_^/[4_P#K['_HF*IJ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/=ZSJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"#W!(KV*B@#Q^PU+XTZK?V\%UI&F:9;+*OGSY7)4'G'SMV]!7L%%% !1110
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M!4]W_K_PJ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH PX_P#C^U/_ *^Q_P"B8JFJ&/\
MX_M3_P"OL?\ HF*IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU5=(B,.E6\9MH[8JI_<QON5>3T/>@"Q<?\>[UG5HW'_'N]9U !1110 4444
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MC_X_M3_Z^Q_Z)BJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Q]8T-=1831.(Y@,'(X852T_PP\5PLMW(C*IR$3)S]372T5S2P
ME*4^=K4ATXMW#H,4445TEE.XTNRNI/,FMU9_7D9_*K$,$5O&(X8U1!V J2BI
M4(IW2U%9;A1115#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I\/^N3_ 'A3*?#_ *Y/]X4 2:S#]HTFXB^Q?;=P'^C^9Y>_D?Q=
MO7\*NH,1J-NW '&<XJEK40GTBXC:UDN@P'[F-]K-R.A[>M78QB-1@C '![4
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MJ*]''+%\B]MMY'#@WAN=^RW\S7HHHKRST0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 9*-T,@V;\J1MSC/M531X?(TFWB^Q_8]JG_1_,W[.3QN[U;F&8
M9!M+94C:#C/M531XA#I-O&+9[8*I_<R/N9.3U/>@"S<?\>[UG5HW'_'N]9U
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MN.+[!]APS?N/-\S;R>=WOUK1K.T.$0:5'&MI): ,W[J1][#D]_?K0!HT444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ,F_U,G+#Y3RO7\/>JFCL&TFW(DN9 5/S7
M0_>'D_>JW,<0R'<5PIY'454T>02Z3;N)Y;@%3^]F7:[<GJ* +-Q_Q[O6=6C<
M?\>[UG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5/:_Z\?0U!4]K_KQ]#0!?
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.T-@VE1E9;N0;F^:['[SJ>O
M]/:M&L[0Y1-I4;K<SW(+-^\G7:QY/:@#1HHHH *\RN=0U[PW\0-7GTOPKJ=_
MI=]L><QA /.5 N^/GD$  @XY7-;^K:!XFCU2;4] \2.AD.YK"^C$L!XZ+T9!
M]#5)?'6K:,PC\5^&[FV4<&]T_P#TB ^Y'WE'U!H 7_A.]<_Z$'7?RC_^*KM;
M69KBUBF>%X7= QC?[R'T/O5'2/$6CZ]")=+U&WN@1G"/\P^J]1^5:= !1110
M 4444 %5M0OK?3-/N+ZZD$<$"%W8]@*LUPOB MXN\4P^&823IMD5N-3<=&/5
M(OQZF@"IX$\9:[XA\5:C9ZI;PV]I]E2[M(PA$BQLQ"[CGJ1S^->BUP&CJ%^-
M.N*H 4:5  !V^<UW] $%S=):(&D29@3C]U"TA_)0:J_VS;_\\+__ , 9O_B:
MT:* .?M)EN+C4I4615:[&!)&4;_4Q=B 15JH8_\ C^U/_K['_HF*IJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "GP_ZY/\ >%,I\/\ KD_WA0!)K4PM](N)6O&LPH'[]8]Y3D=N_I^-78SF
M-3NW9 YQUJGK$QM])GE6\6S*@?OVCWA.1V[^GXU<0YC4[MV0.<=: *5W_K_P
MJ"I[O_7_ (5!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6C;?\>Z_C_.LZM&
MV_X]U_'^= $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F.V&0[MF%)W8
MSCWJIH\PN-)MY1=M=AE/[]DV%^3SCM5N4[87.[9A2=V,X]ZJZ1,;C2K>4W:W
M993^_5-@?D]NU %BX_X]WK.K1N/^/=ZSJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *GM?]>/H:@K#?Q6MG>.ALR^PE<^9C/Z5E5KTZ2O-V-J.'JUVU35['94
M5R'_  G2?] ]O^_O_P!:C_A.D_Z![?\ ?W_ZU8?7\/\ S?@SI_LS%?R?BO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW@BM;>.W@0)%&H5%'0 4 24444 %%%% !1110 4444 %%%% &''_ ,?VI_\
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M.U_Z!Q_[_?\ V-'_  G:_P#0./\ W^_^QK,'@_52 0L//_32C_A#M6_NP_\
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MM+LMO^ :M%%%>F>.%%%% %+49M2A1#IUE;W3$G>)[DPA?3&$;/Z5G_;?$_\
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M]O=^(7N(UN-'T^*$L [IJ+.RCU \D9^F16Q110 4444 %%%% !1110 4444
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MPF5YBB!?,?JV.YH FHHHH **** "BBB@ HHHH **** ,./\ X_M3_P"OL?\
MHF*IJAC_ ./[4_\ K['_ *)BJ:@ HHHH **** "BBB@ HHHH **** "BBB@
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MM %FX_X]WK.K1N/^/=ZSJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVO(XVD9HG.TJ3FNWI8*=.5/]VK"I.+6@4445V&H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !3X?]<G^\*93X?]<G^\* )-:Q_8]QN6\88'%G_K
M>H^[_GIFKL?^K7[W0?>Z_C5+6F"Z1<,TEU& !\]J/W@Y'W:NQ_ZM>2>!UZT
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MBB@ HHHH **** $(!&",@UD-X5T%KO[4=)M3/G._9WK8HJHSE'X78EQC+="
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M22YMREY/B;_G_P!(_P# *3_X[1Y/B;_G_P!(_P# *3_X[6U17L'48OD^)O\
MG_TC_P  I/\ X[6M;B<0(+EXWFQ\[1J54GV!)(_.I** "BBB@ HHHH ****
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M>:?Q8^A]'DW\"7K^AZY'_JU^@IU-C_U:_04ZO;6Q\Z]PHHHIB"BBB@ HHHH
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MY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]J +%Q_Q[O6=6C<?\>[UG4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y[J/_
M "$KC_?->A5Y[J/_ "$KC_?->5FOP1]3V\D_B2]#N_"/_(!3_?:MVL+PC_R
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MA_UR?[PH EUA#)I,Z+#;S$@?N[@X0\CJ:N)Q&HP!P.!TJGK$1GTF>-;6.Z+
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M% !1110!AQ_\?VI_]?8_]$Q5-4,?_']J?_7V/_1,534 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 C'"D^@S7GE]=R7EW)+(Q.2=H]!7HAY&#7
M'ZEX>NDN7>V3S(V.0!U%>=F%.I.*Y=48UDVM"/PY>20ZBL&XF.7@KVSZUVE<
MYH6B2VT_VJY&U@,*G]:Z.M<#"<*5ICI)J.IRWBJUE,T5R 3'MVDCL:YP L0
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MAY'0U=C_ -6O!' X/6J6M;?['N-RWA&!D6?^MZC[O^>F:NQ_ZM?O=!][K^-
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M'3Y=(N9'$5Y-(PD@C<Y*E>Y&2 :]&TBP72M'L[!6+"WA6/<>^!C- %VBBB@
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MZ?\ ^ R?X4?\(]HG_0'T_P#\!D_PK2HH S?^$>T4'(T?3_\ P&3_  K1
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MT!4K(),XV$'H<U4T/QCK$FL6FF^(]#73'OT+V<D=P)5? R4;T;':@#M:***
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M!2N_]?\ A4%3W?\ K_PJ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG"_P8^AX&,_WB?JPHHHK<Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?A5/6$,FDSHL-O,2!^[N#A&Y'4U<3_5KP!P.!TH I7?^O_"H*GN_]?\ A4%
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MAV+Z;H-A8R-ND@@2-CG/('-.MQI5IG[,+.'/7R]JY_*KH((R#D'H: %HHHH
M**** "BBB@ HHHH **** ,./_C^U/_K['_HF*IJAC_X_M3_Z^Q_Z)BJ:@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJW-S#(,,?E/"]3]*J:.@32;=1%/$ I^2X.9!R>M %FX_X]WK.K1N/^/=ZSJ
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *GM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!DIVPN=VS"D[L9Q[U5TB8SZ5;RF[6[+*?WZIL#\GMVJU*
M<0N=P7"GD]!572)#+I5NYGAG)4_O(5VHW)Z"@"Q<?\>[UG5HW'_'N]9U !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %3VO^O'T-05/:_Z\?0T 7Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *S]%G-SI<<K7JWI+-^^6/8#R>,>W2M"L_19
M#+I<;M<P7!+-^\@7:IY/04 :%%%% '%>/K6\MI-(\2V-J]U)H]P99H(^7>%E
M*OM'<@'/X5I:7X]\*ZO;+/:ZY9?,,F.24(Z_53@C\:Z.L#4O _A;5[AKB_T#
M3IIW.YY3;J'8^[ 9/XT <QXW\;:9J.F2^&] NHM3U?45\F..U;S!&#U9B.
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M]?>M"L_10PTR/<MDIW-Q9?ZKJ>GOZ^] &A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8<?_ !_:G_U]C_T3%4U0Q_\ ']J?_7V/_1,534 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %/A_UR?[PIE/A_P!<G^\* )=80R:3.BPP3$@?N[@X1N1U-7$_U:\ <#@=
M*IZQ$9])GC6U2Z+ ?N9'V*W(ZGMZU<08C48Q@#@=J *5W_K_ ,*@J>[_ -?^
M%04 %%%% !1110 4444 %%%% !1110 4444 %%%% %:YT^SO"#<VT4I'3>N:
MEA@BMXQ'#&L:#H%&!4E% !1U&#110!3_ +)T_P _SOL</F9SNV#-7*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K1MO^/=?Q_G6=6C;?\>Z_C_.@
M"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &2C,+C .5/#=#]:JZ0ACTJW
M0PP0D*?W<!RB\GH:M2C,+C:&RI&TG&?:JND1&'2K>,VJ6I53^Y1]P3D]#WH
ML7'_ ![O6=6C<?\ 'N]9U !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ,DC29"DB!U/4$9%5[?3+&T<O;VL4;'NJX-6Z* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *GM?\ 7CZ&H*GM?]>/H: +]%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9^BQF/2XU:"W@(9OW=NV4')Z&M"L_183;Z7
M'&UG':$,W[F-]X')[^_6@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]>/H:@J>U_UX^AH OT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:)!]
MFTN.(6'V'#,?(\WS-O)YW>_6M&L[0X1!I4<:VDMJ S?NI7WL.3W]^M &C111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 8<?\ Q_:G_P!?8_\ 1,53
M5#'_ ,?VI_\ 7V/_ $3%4U !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !3X?]<G^\*93X?]<G^\* )-:02:1<
M*T-Q,"!\EL<2'D=*NQ_ZM>".!P>M4M:V_P!CW&X7A&!D6?\ K>H^[_GIFKL?
M^K7[W0?>Z_C0!2N_]?\ A4%3W?\ K_PJ"@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?];U/7V]/:@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,./\
MX_M3_P"OL?\ HF*IJAC_ ./[4_\ K['_ *)BJ:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I\/^N3_>%,I\
M/^N3_>% $FM,$TBX9I+F, #Y[49D'(^[5V/_ %:\D\#KUJEK4@BTBXD:XEMP
M /WL*[F7D=!5V,YC4Y)X')[T 4KO_7_A4%3W?^O_  J"@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "M&V_P"/=?Q_G6=6C;?\>Z_C_.@"6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &3?ZF3EA\IY7K^'O531V#:3;L)+F0%3\]R,2'D_>
MJW,<0R'<5PIY'454T>02Z3;N+B6X!4_O95VLW)ZB@"S<?\>[UG5HW'_'N]9U
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6^T7/_0+O?R3_P"*H^T7/_0+O?R3_P"*H LT56^T7/\ T"[W\D_^*H^T7/\
MT"[W\D_^*H LT56^T7/_ $"[W\D_^*H^T7/_ $"[W\D_^*H LT56^T7/_0+O
M?R3_ .*H^T7/_0+O?R3_ .*H LT56^T7/_0+O?R3_P"*H^T7/_0+O?R3_P"*
MH LT56^T7/\ T"[W\D_^*H^T7/\ T"[W\D_^*H LT56^T7/_ $"[W\D_^*H^
MT7/_ $"[W\D_^*H LT56^T7/_0+O?R3_ .*H^T7/_0+O?R3_ .*H LT56^T7
M/_0+O?R3_P"*H^T7/_0+O?R3_P"*H LT56^T7/\ T"[W\D_^*H^T7/\ T"[W
M\D_^*H LT56^T7/_ $"[W\D_^*H^T7/_ $"[W\D_^*H LT56^T7/_0+O?R3_
M .*H^T7/_0+O?R3_ .*H LT56^T7/_0+O?R3_P"*H^T7/_0+O?R3_P"*H LT
M^'_7)_O"J?VBY_Z!=[^2?_%4Z.ZN5D5CI=[@'/1/_BJ +VM3"WTBXE:\-F%
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MH T:*SO[3E_Z!5__ -\I_P#%4?VG+_T"K_\ [Y3_ .*H T:*SO[3E_Z!5_\
M]\I_\51_:<O_ $"K_P#[Y3_XJ@#1HK._M.7_ *!5_P#]\I_\51_:<O\ T"K_
M /[Y3_XJ@#1HK._M.7_H%7__ 'RG_P 51_:<O_0*O_\ OE/_ (J@#1HK._M.
M7_H%7_\ WRG_ ,51_:<O_0*O_P#OE/\ XJ@#1HK._M.7_H%7_P#WRG_Q5']I
MR_\ 0*O_ /OE/_BJ -&BL[^TY?\ H%7_ /WRG_Q5']IR_P#0*O\ _OE/_BJ
M-&BL[^TY?^@5?_\ ?*?_ !5']IR_] J__P"^4_\ BJ -&BL[^TY?^@5?_P#?
M*?\ Q5']IR_] J__ .^4_P#BJ -&BL[^TY?^@5?_ /?*?_%4?VG+_P! J_\
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MM]HN?^@7>_DG_P 51]HN?^@7>_DG_P 50!9HJM]HN?\ H%WOY)_\51]HN?\
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M?EEN3QCVZ4?VG+_T"K__ +Y3_P"*J'P]?O?Z/'.\KSL68>8T0CS@GL#^'X4
M:]%%% !1110 4444 %%%% !1110 5Y[J5MJ?A+QU=>(;/39]0TS4H52ZBMAF
M2)U_CQW!KT*B@#SN7^T?'OB/1Y&TNZL-$TRX%ZSW:;6N)5!V!5] >37HE%%
M!1110!G:;_Q_ZO\ ]?:_^B8ZT:SM-_X_]7_Z^U_]$QUHT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M'6)#%I,[K<0VY '[V==R+R.HJXG,:G(/ Y'>J>L,5TF<K):QD ?-=_ZH<C[W
M^>M7$_U:]#P/N]* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ,E.(7.0N%/)Z"JND2&72K=S/#.
M2I_>0KM1N3T%6I?]2_*CY3RW3\?:JND$MI5N2]LY*GYK7_5GD_=H NT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #)?]2_W3\I^_T_'VJKI((TJW#+:J=IXM/]4.3]VK4H
MS"XP#E3PW0_6JND(8]*MT,,$)"G]W <HO)Z&@"[1110 4444 %%%% !1110
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M^SUWP%-XHLK=L0Q,SV[MRK+U7/\ 7%>>P_M"_;-'7['X<FN-9>1@+6)RZJ@
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M3D]#WJU*-T,@V;\J1MSC/M531X?L^DV\0L_L>U3_ */YF_9R>-W>@"]1110
M4444 %%%% !1110 4444 %%%% !1110 5S'B?X@^&?"$BQ:QJ213L,B%%+OC
MUVKD@5T]?)TEWI4'QQO9?'$+RV0N75PX)"\?(2.I4<=/UH ^@?#/Q.\*^+;T
M66F:AF[()$,L;(S8],CG\*["N*T3P9X'GU6R\3>'K:U6:#=LELI?W;94@@J#
MC.#Z UC3?%I[+XH?\(A?Z0+>%I?+2Z,^2<C*MMV]#]: /3J*XOXD>/X_ &B0
MWOV07<\\OEQPF39VR3G!K'\2_%2Y\._#[1?$LFB*TVI.H-LT^!&"K,#NV\Y
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MI>)+76[K3U_L"]AM;V-PP\]-R./[IQ0!R*>+/$7@R2TM/%]I#/ISNL":M:G
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M?#?X7:AX4N-<.JW%O-#J,9C A)R 3WS7.:7\)_'OA'4KR/POKUM#8W1Y=SR
M,XR,=1GM0!SGPY;4!\?KHZHD<=^TEQ]I6+[H?/S8]LU>^)VU?CUI!. N8*ZO
MP=\(=6\,_$-=>N-4BO(/+)=VSYCNP&X_GFK?Q4^%=_XOU:UUG1KN*"]A0(RR
M$C.#P0?6@#H_BR /A?KN !^X_J*\^^%LLT/P"\120#]X#=8QV_=KD_E746G@
MGQ9>?#76-$UW5X[K4[T8BD=LK&!C ) K3^&?@BY\(^#+C1-5>"X,\\CN(\E2
MC*!@Y^AH X/]FV.U;3]:F(4WGG*">^S'^.:]RBCMTEE,2QK(V#)M R?3->$7
M'P7\5^'=<N+SP;KJP0S$X!?8Z@]CV->B_#?PAJ_A:SOY=<U4ZA?WTBO(V20F
MT$8!/UH [>O-M#ROQW\4B3JUC;%/IMKTFO.=<7^POC%HNK-\MMJELUE(>WF#
ME<_A0!T/BOQ9_P (ZUE9VMD]]J=_)Y=M;JVT$]R3V KSWXJ3^-9OAKJS:O9:
M/!9 PE_(=VE7]ZF,$G'7';I7;^-/"E_K-[I>L:-=10:KIDA:+SP2DBGJIQ7.
M^*?!_C;QOH%S8ZIJ%A91D QVMMN(D<,"/,8CH.H [XH O_%]1)\-)$;.&FA!
MP?>GV?PG\+R65N[+J.YHU)QJ$OI_O5L>./#=UXF\)G2K66..;S(WW29Q\IYK
MH[:,PVD,3$$HBJ<>PH ;9VD5C90VD.[RH4")O8L<#IDGDUP _P"3@S_V O\
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M2O#P*AOX7N3Z?[M '?V5L+.PM[53D0Q+&#] !_2IZ** "BBB@ HHHH ****
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MT >QUX[XB4ZW^T3X?L).8=.MC<C_ 'OF;^:K7L5>3-']G_:4B9QQ<:6=A/J
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M:;_Q_P"K_P#7VO\ Z)CK1JI:6SP7-](Q&V><2+CT\M%_FIJW0 4444 %%%%
M!1110 4444 %%%% !1110 4444 (P)1@&VDC /I6'X4\+VOA/2#8VTTD[22M
M-+/+C=(['))Q6[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !61;^';*T\2W6NPM,ES=0K%-&&'EM@Y#8QG=[YK7HH **
M** "BBB@ K)U3P[9ZQJ6FWMV\S-I\IEAB# (7QC+#&3CZUK44 %%%% !1110
M!0UK;_9%QN%X1@9%G_K>H^[_ )Z9J['_ *M?O=!][K^-0WMLUY9R0+<2V[.!
MB6(X9><\&IU&U0,DX&,GO0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5P7C#X5:9XV\16NJZG?W@2WC$8MH]H4@')YQW[UWM% #418T5$ "J,
M #L*=110 4444 5-4T^+5M*NM/F9ECN(S&S+U /I7.> O %CX!L;JULKN>Y%
MS('9I@!C&<8Q]:ZZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "LGQ!X=LO$MC%:WIE013)/')"P5T=3D$$@UK44 (HVJ!DG QD]32T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!'/'YUO)$)'CWJ5WH<,N1
MU&>]9_A_0+'PUI2:?8!_+4EF>0@O(Q.2S' R36I10 4444 %%%% !1110 44
M44 %%%% !1110 R;_42?>^Z?N=?P]ZJ:-C^R+?:+L#:<"\_UO4_>]ZNNNY&7
M<5R,9'45#9V[6EI' T\LY08,DIRS?4T 3T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6'XN\-1>+O#L^CS7<UK%,1N>'&2!VY[5N44 <[X,\&Z=
MX(T3^S-.:61"YD>24C<Q/T%=%110 4444 %<)-\+M,F^(R^,S>W0NE8/Y V[
M-P7;UQG&*[NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L&_
M\):?J/BK3?$4CW$=]IZND?EL KAA@AAC)_ CK6]10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !6/HGANRT*:^GMWFFN+Z<SSS3L&=B>W & .P
MK8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[0]O]E1[1>@;FXO?
M];U/7V]/:M&JUC:M9VBP-<S7!!)\R9LL<G/6@"S1110 4444 %%%% !1110
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MR.H9&&"I'!%<H?AGX0-T9SHT.2VXH,["?]WI0!A>$Y#XD\=ZMXU=3'I4%O\
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MAW3UTKPWIM@@PMO;H@_ 5<O8II[*>&WN#;S.A5)@H)0XX.#P<5,   !P!2T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 1?9H/-\WR(_,_O[!G\ZEHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "F"*,2-($42,,%@.3^-/HH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gou0qrw2itv5000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gou0qrw2itv5000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,<!S0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %.3_ %TGU'\A11)_KI/J/Y"B
M@"Y1110 4444 <=\4/\ D1;O_?3_ -"KSGPE-X\31L>'8]UCYAYVQ'YN_P![
MFO1OBA_R(MW_ +Z?^A55^$O_ ")G_;=Z]6C4]G@W*R?O=3S:M/VF+2NUIT/,
M?&<GBJ2>U_X2=-L@4^3Q&.,\_<_K7I'C76I](^'=FMLY2:Z1(MP."%VY./\
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M;7XG=SV%UH/P9S &2:Z99)BO4*Q_EC^=95MI?A!_AQ)=R3Q#5A&QYE_>>9V
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MW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6+?W7GR;%/[M>GN:M:C=;%\E#\S#YCZ"LF@ HHHH Z&V_X]8?]
MP?RJ6HK;_CUA_P!P?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3PS<W.,K-GG'PP\)ZAHTEUJ6H1FW:=-B0GJ!G.3Z5WUYIMCJ"@7EI!.!T\Q
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M*]3H;&D-C#"-0[;G ^8@8R:=114E!1110 4444 %%%% !1110 4444 %%%%
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MS7HK)\0^(;+PUIR7MZ)&62588TB7<SNW0 5-K.M:?H&G/?:E<+# IP,\ECV
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MEY;6K$6MY:)O#QDD@$=B,TQ#M*CUB]^*$&LCP]=Z7:26;P7;2LN'(Y4\'KG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS4KK_E@A_P!X_P!*
MM7ER+>+C[YX K#)+$DG)/6@!**** "BBB@ HHHH **** .AMO^/6'_<'\JEJ
M*V_X]8?]P?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *<G^ND^H_D**)/]=)]1
M_(44 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0 #H,
M4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%0W,ZV\1<]>P]: *VH77EIY2'YFZ^PK(ISNTCEV.2:;0 4
M444 %%%% !1110 4444 %%%% '0VW_'K#_N#^52U%;?\>L/^X/Y5+0 4444
M%%%% !1110 4444 %%%% %746F2R<P6RW+C_ )9-_$*X?_A&=4DN;K5HK5+:
M0SI)%9 \87K[ FO0J*%H[ATL8&A6%TM[?:E>1>1)=D8BSDJ!ZU5\1Z/%:Z'?
MWD,]RLR1EU(D/!KJ:Q_%7_(JZE_UP:@"_ISL^F6CN26:%"2>YVBK-5-+_P"0
M39?]<$_]!%6Z "BBB@ J-YX8CB25$/HS 5)7$MH]EK?CC4H]0B,R101E%+D
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M_KI/J/Y"B@"Y1110 4444 %%<QX^\4/X1\*S:E#$))RZQ1!N@8YY/MP:\R\
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M* "BBB@ HHHH Z&V_P"/6'_<'\JEJ*V_X]8?]P?RJ6@ HHHH **** "BBB@
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M/XAU*:VT"^BF1(KV01RQ[><]^::5Q-V.XHHHI#"BBB@ HHHH **** "BBB@
MHHHH *SK""2+4=0E=<)*ZE#ZX&*T:0#% "T444 %%%% !1110 4444 %%%%
M!1110 4444 4Y/\ 72?4?R%%$G^ND^H_D** +E%%% !1110!FZ[H=EXBTB?3
M-0C+P2CG!P5(Z$>]<GX5^$VB^%]7&II/-=7"9\KS0 $SW]S7?44[BL@HHHI#
M"BBB@ K \;_\B3K'_7LU;]4-:TT:QHMYIQD\O[1$8]^,XS0!G^"/^1(T;_KU
M3^58?Q3NQ+X>CT*#Y[[5)EACC'7&<D_A4-EX/\86.GP6%OXLBBMX4")LM@6
M'UK6T'P-;:5J;:M?WUQJFJD8^TW'\ _V5' IDZVL<W\2+*:WTKPK;)<&W2&[
M2-Y@H.P[0 >>.M;W_"*^)",CQO=_^ B?XUOZ[HEGXATF;3KY28I.05.&4CH0
M?45S$/AOQK8QK:VGBBW>U0;5:XM\R!?J.#1<+:FOX3\*_P#"+P7BMJ$E[)=S
M>=)(Z!>?H*P_A9_R#]:_["<W\S76:)IUWIFGB"]U&74+@L6:>10O7L .U4?"
MGAMO#=M>Q-<";[3=/<9 QMW'.*!F#X@_Y*]X7_Z])_Z5J_$C_DGFM_\ 7LU6
M=0\-M?>,=*UT7 5;&&2,Q8Y;=WS5OQ+HYU_PY?:4LHB-S$8PY&=N: [G%>,E
ME?X+6_EL1BWMBQQG"C;G]*T-.\-:_/IEK+!XVNA$\*,@6T0@# P.M=1!H\'_
M  CL6CW0$\*VZP29'# +BN5M_"'B?1(OLFA>(XA8*?W45Y#O:,>@(ZT7%8T_
M#G@^71-;O=6NM8FU"ZNXUC<R1!  #[5E>%?^2H>,/K#_ .@BND\/Z5J>G+.^
MJ:P^HSS$'F,(D>.R@5#I/AMM-\4ZSK)N XU'9B/'W-HQ0.Q@_%G_ )%RQ/IJ
M$./SK:^('_)/]=_Z\I/_ $$U)XN\-MXGTV"T6X$'E7"3;B,YVG.*UM2L(=4T
MRZL+@$PW,31/CT(P: *7A4@^#]%(.?\ 0(/_ $6*YCPU_P E9\8?]<[?_P!
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MD41E^HR*ZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"G)_KI/J/Y"BB3_72?4?R%% %RBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\6^(V96"M(F"1UXKKZ:$0,6"@$]2!UIU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %.3_72?4?R%%$G^ND^H_D**
M +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-=UC0NQ
MP!0!#=W(MX2?XCPHK"9BS%B<D]:DN)VN)BYZ=AZ5%0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% '0VW_'K#_N#^52U%;?\>L/^X/Y5+0 4444
M%%%% !1110 4444 %%%% !1147VF J["9-J'#'<./K0!+6/XJ_Y%74O^N#5J
MQ313IOBD5U]5.:RO%7_(JZE_UP:@"[I?_()LO^N"?^@BK=5-+_Y!-E_UP3_T
M$5;H **** "BDS1F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q)O\
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M* +>]?[P_.C>O]X?G52B@"WO7^\/SHWK_>'YU4HH M[U_O#\Z-Z_WA^=5**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLZ\_X^#]!6C6=>?\?!^@H KT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!T-M_QZP_[@_E4M16W_'K#_N#^52T %%%% !1110 4444 %%%%
M !1110 4444 %8_BK_D5=2_ZX-6Q6/XJ_P"15U+_ *X-0!=TO_D$V7_7!/\
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MM/L8Y/,(VE5X[#@9)]JS474P_P"\TLM&GOY6-')0K_N];O56_&Y[#7COA/\
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MEQD#MD[C^AK'!5/:8GG:2T>QKBX<F'Y+MZK<];MSFVB)[H/Y5)3479&JC^$
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MV$#;DUV'COP.GC:RM[9[MK<0OO#*N<UX)XE^'&LZ/K,MG865W>P* 1,L9PU
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M!:?=?=_P3*_X2&P_N7__ (+Y_P#XBC_A(;#^Y?\ _@OG_P#B*U:*+P[/[_\
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_(3U7_KLO\ Z#6K65I?_(3U7_KLO_H-:M74^+[OR(I_#]_YA1114%A1110
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M!>P_\"4_QJ[Y$7_/)/\ OD4>1%_SR3_OD47AV?\ 7R"T^Z_KYE+_ (2#1?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/I=L)8XH2K$G'.:V_A%X9U3PSH=Y;:I"(I))MZ@'.10!Z,.E+2#I2T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07O_ !XS_P#7-OY5
M/4%[_P >,_\ US;^5..XI;$&B_\ ("T__KVC_P#015ZJ.B_\@+3_ /KVC_\
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MX/T%:-9UY_Q\'Z"@"O1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '0VW_'K#_N#^52U%;?\>L/^X/Y5+0 4444 %%%% !1110 4'IQ12'[I
MR<<4 <1KFIZWIDK)#J<,]PY_=6L4.YSZ9]*Z/P]_:YTF-M;,7VQN2(QP!Z5Y
MOY6@P:M>7BZCK,(EE91<@Y5WSRJUZ%X62=-('G_:N6)4W+9<CWHCL$MS;HHH
MH *Q_%7_ "*NI?\ 7!JV*Q_%7_(JZE_UP:@"[I?_ "";+_K@G_H(JUFJNE_\
M@FR_ZX)_Z"*YCXA>-7\%:=!=I:"X\U]NTG&* .EU2Z:RTNZND +0Q,X![X%>
M%)\=]9:=8S86_+[<UN:1\78_%4\VDWMM#80SPLIN'?A<BN7@^%VD-<!D\7V+
M$-NQF@#Z%T^X-UIUO<,,-+&KD#W%6,UX]\2/&$V@^'-,AT#6(_.0B.1H6!R
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MT+0#,CD#:#Z9'>NEJNA/4****0PK$F_Y'*V_Z\W_ /0A6W6)-_R.5M_UYO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'\A11)_KI/J/Y"B@!**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *SKS_CX/T%:-9UY_P ?!^@H KT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!T-M_QZP_[@_E4M16W_ !ZP_P"X/Y5+0 4444 %%%%
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M,,^AKY?'PI\6BX#?V<<;\_>]Z^FM(ADMM'LX)1B2.)58>A H NT444 %%%%
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MQP-1LES@>KKU%,5SK=7U2VT72;K4KMML%O&7;U/L/<GBN1M+SQUKMDFIV?\
M9VG6\P\R&WN$+NR'ID]B>M/\=2Q>*?AAJ,VBS"Z1E60>5SN".K,/K@'BM;0O
M%NB:AH5K<I?V\0$2AXW<*8R!RI'L: ZD7A#Q/-K@O;'4;86NK:?(([F$'(.>
MC#V-5]7\2:G=>(F\/>'(8FNH%#W=S."8X 1E1CN36)H>J65_\:=1ETR=9H)M
M*'FNGW2ZNHS[X'%7OAL1<S^*=0;F6;694+'^ZH&T?AN- A+GQ#XE\*7=FWB,
M6=WIEQ*(7N[92GDL>F0>U;/B;7KRRN],TK24B?4-1=A&\OW(T499CZU!\2;=
M+GX>ZPC@';$''L0P-8]XE]Y7A'Q3;6TMVEM;;;F*,9?9(@^8#O@T :^CZWJ]
MMXG;P]KOV>29[?[3;W-NI574'!!!Z$5-XMUVYLA:Z3I.&UB_;;"",B)/XI#[
M"L-]2,_B*3Q=>VD]EI>FV+0Q_:%VO,[-G@?I]:FT&:VTZ27Q-XGNX;74=2_U
M,<S8\B'^%!_,T#.XMTDCMHTED\R15 9\8W'N:DJ*VN8+RW2>VE26)QE70Y!J
M6D,**\K\)?\ "2^+M/FBN-6EM+""XD0S1X,LQW'C/8#I6FDVJ^#/%.FV-UJ<
MVH:3J1,2-./GAD'OZ&G85ST&BN4\8:W?6MQI^BZ0RIJ6HN565AD1(.K?6LZ^
M\*:[IMC+J%AXGOIKZ%#(4G ,<N!D@CM18+G>45SNF:\VM^!VU9!Y4S6KE@/X
M'"G/ZUR?A"U\2>+?#UO<ZCK,]I9A=J" CS)C_>9J+!<].HKA_#=]J>E>,+OP
MQJ-Z]]$(1/:SR#Y]O=34_B;5M2NM?M/#.C3_ &:XG0RW%SC)BC'I[FBP7.QJ
M&ZN%M+2:X<$K$A<@=P!FN$U?1-<\+Z=)K.G>(+R[:V'F36]S@K*HZ_0UJZS'
M_P )/X.CU"WO[FT1K9IL0D#?E?NGVHL%S<T+5X=>T2UU2!&2*Y3>JOU'./Z5
MH5YS\._#L[^%]%U$:U?JFS?]F##R_O'CZ4S7]0\0S?$AM#TBZ:*.>R0LYY6
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M!B_S-7[#P):Z9J"S6>I7\5JLOG"S63]WN_P]JUET"U7Q.VO;Y/M+0" KGY<
MT 5?&FMS>'O"UUJ%LH:==J1[N@+' )^E8\/@_P"U:6E]K'B'4YIGB$CO'<>4
MBY&> .U==J6G6NK:?-8WL0DMYEVNIKEX/AU91HEO/JFIW%C&?EM9)_DQZ'N1
M[4 RO\)Q&/"ER(G+QC4)]KDY+#(P<]Z3X;?>\2?]A67^==-X?T"T\.6$EG9%
MO)>=YL-_"6[#VI-$T"UT+[;]F>1OMEPUP^\]&;L*+A8YOQM_R-_@_P#Z_OZ5
M'XW=++QMX0U*?Y;:.>2%G/12X&,_E74:IH%MJVHZ;>S.ZR:?-YL84\$^]3ZQ
MHUCKVG26.H0B6!^W0J>Q![&BX6+CRQQQ&21U6,#)8G  KSGXDV]O=:MX4O;F
M:1=--R8Y)HG*[1(!M;<.G3K6H/AQ:.JP7>KZI<V2=+:2?Y3[$]Q737VBZ?J.
MDG2[JU22SV!!$>@ Z8],4!N8 ^'FCL 1>:J0>A%\];6@:%I_A[3FL]-#"%I&
MD8L^XECC//X5SZ?#Q(D\B'Q!JZ6HZ1"?H/3/6NHTO3+?1].BL;7S#%%G!D<L
MQR<DDGKR: 1<HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH Z&V_X]8?]P?RJ6HK;_CUA_P!P?RJ6@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !14<]Q#;1^9/*D:9"[G.!D]!4E
M!1110 4444 %%%-=UC1G=@JJ,DGH!0 ZBHX9HKB%989%DC895E.0:DH ****
M "BBB@ HHHH ***BCN8)99(HY4>2(X=5;)7ZT 2T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6=>?\ 'P?H*T:SKS_CX/T% %>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .AMO\ CUA_W!_*I:BMO^/6'_<'\JEH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Q_%7_(JZE_UP:MBL?Q5_R*NI?]<&H
MNZ7_ ,@FR_ZX)_Z"*MU4TO\ Y!-E_P!<$_\ 015N@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D 9)P!0 M9MWK,$$WV>!)
M+JZ_YXP#)'U/1?QJ%IKC66,=JS06(.&N!PTOLGH/?\JT;2SM[&'RK:)8TZG'
M4GU)[FINWL:\L8?'OV_S,WRM=O>9)[?3XS_!&OFO^). #],T?\(\DG_'SJ6H
M7!_VIMH_\= K9HHY5U#VTE\.GI_5S&_X1FQ[37H/K]J?_&C^Q;J'FTUF\0]E
MF"R+^6 ?UK9HHY4'MZG5W]=3&^V:O8?\?EHEW".LUIG</<H>?RS6A9W]M?Q>
M9;2AP.".A4^A':K-9]YI:3R_:K=OL]X.DRC[WLP_B%%F@YH3W5G_ %T_R^XT
M**H66H/+*;2[C\F[09*YRKC^\I[C^57Z:=R)1<79A1113)"BBB@ HHHH ***
M* "L2;_D<K;_ *\W_P#0A6W6)-_R.5M_UYO_ .A"@#;HHHH **** "BBB@ H
MHHH **** "BBB@ HHIK4 -D"LI1C@,,=:Y.'X:^&(=274([)A=!_,$GF'.?6
MN"^)GQ NM/\ %MA::<7,5DX>?:#ASZ5V'C3Q9<6?P\&MZ0I,DZKM;'W,]30!
MW@ QBH9[J"V*>?,D>]MJ[FQD^E>!_"[QSX@OO%T5A>7,MW;SYW!OX?>M'XLZ
M)XKO/$5K-:F6:S+ 6ZQ9_=O[_P"- 'N6:*QO#%KJ5IH%G%J\PFO50>8P'Z5L
MT %%%% $-U=16=L\\S;409-9]M92WTJ7NH@\'=#;'[L?H6]6_E3+?_B;ZDUR
MW-E:N4A7L\@ZM^'0>^?2MFIW-G^[5EO_ %I_F%%%!Z51B)D>HI&(QG(P.M>)
M_%F/Q-I6O6MUI.H7*VEZ1&$0\))7H5KI.M6O@)=.BNO.U:2'#33-T9NOY4 7
M?#WBJP\0W>HV]I)E[*7RW&>ON/:M^O'_  )\./$WA'Q(-0DN[:6"4%;A0_+9
M[UZ^HP*  @$$$9!Z@UCR0OH9-Q;!FT_.9K<#/E#^\GL.Z^G3TK9HI-7+A/E]
M!J.DL:R1L&1AE6!X(IU8UO\ \2C55LNEE=DM;>D<@Y:/Z$98?1AZ5LT)W"<>
M5Z;,****9 4444 %%%% !1110!3D_P!=)]1_(442?ZZ3ZC^0HH 2BBB@ HHH
MH 1F"J68@ <DGM5:UU&ROBPM+N&<I]X1N&Q^5<K\4X]2D\!W8TWS"VY3,(^I
MB_B_IGVS7C?PLBU,^.[)K%91&I/V@@';Y>#G=^./QII:$N5G8^F****10444
M4 <G\1[VZL/!ES-9SO!*71?,C.& )YP:I0^!;MK6.6W\6:S'*Z!LO(' )'H:
MF^*7_(CW'_7:/_T*NLL_^/&W_P"N2_RI]!=3C-(\0:QHOB.'PYXE>.<W"DV=
M^@V^;C^%AV-=T2 ,DX%<#\41Y=IH=VH'G0ZE&$_$@&D^(.KK]MTG0IK]=/M;
MUB]W.9 A$8_ASVR:+7"]CM8]1LI9S!'=P-*.J"0$_E5DD $DX ZFO,=1TSX;
M-I,D=CJ&EVUU&A:">&[ D5P.#G//-;_A?5Y];^')NKE]\XMY8W?^^5!&:+!<
MZB2^M(;<3R7,20GH[. /SJ2.>&6$31RH\9&0ZMD?G7F7P[\'V.J^&;74-9S?
MY!6""4_NX5SV'K[U7M?#9'CW4/"L%[/!H)C2\>UC8\Y_@!Z@>M%A7/4;>_M+
MMF6VN892IPP1P<58KS3QCH.G^$DTS7-#MELIX+J.)Q$2!(C'&&'>MOXBZY+I
M'AZ)+>X6VEO9E@$[-CRU/5L_2BP[G3-J5BMP(&NX!,>B&09_*K76O-(]*^&
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M10 4444 %%%% !1110 4444 %9UY_P ?!^@K1K.O/^/@_04 5Z*** "BBB@
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MH **** "L2;_ )'*V_Z\W_\ 0A6W6)-_R.5M_P!>;_\ H0H VZ*** "BBB@
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M)J&G6UY%G9/&L@!ZC(SBK-8WAW]U!?6?:VO944>BLV]1^ <5/VC5>]2:[/\
M/^D;-%%%49!1110 4444 %%%% %.3_72?4?R%%$G^ND^H_D** $HHHH ****
M "H8+6WMMWD011;CEO+0+GZXJ:B@ HHHH **** .+^*9 \#7!/ $L>?^^JU(
M?%WAVWT^$RZWIZ;8U!S<+G./K6S=V=M?VSVUW!'/ _WHY%#*?PK*3P=X:C<.
MNA:?N!R/]'4_TIBUN<F]R_Q"\56#64<G]@:9)YKW#IM$\G8+GJ*F\?P16/B+
M0_$-W;+<:?;L8+H,F\(K=&(QTS7H$<:0QK'$BHBC"JHP!^%$D:2QM'(BNC##
M*PR"/<47"QS@G\%M:_:A_8GD$9WE8L5>,MA/X7N)M,\G[&]O(8S"H"D;3R *
MKCP3X8$_G#0K'?G/^J&/RZ5MB"%;?[.L2+#MV^6%PN/3'I0!RGPQ_P"1!T_Z
M-_.JEG_R6?4O^P;%_,UV=G96VGVJ6UI D,"?=1!@"FKI]HNH/?K;QB[=!&TV
M/F*CH,T7"QR'Q5_Y%.'_ *_H/_0Q1\2M/EN?#UG?16_VC^S[A+AXMN=R=&X[
M\5U][I]IJ4 AO;>.>(,'"N,C(Y!JS@8QCCTHN%CEK"]\%:C8I=P)H_ELH8AH
MXP5]B".#6OHMQH]U:R2:*;4VX<JS6R@*6'TX-5)_!?AJYN#/-HEDTA.2?* R
M?<"M>VM;>R@6"U@B@A7HD2!5'X"@#B_AK]WQ#_V%9?YT>-?^1Q\'_P#7Z?Y5
MV-II]I8"7[);QP^<YDDV+C<QZD^]%QI]I=SV\]Q;QR2V[;X789*'U%%]0MH<
MI\5(GD\"7+(I;RYHI&QV4."3^5=-8:QI^I)$;6\@E:2,2*J2 G;ZX_&K<L4<
M\312HLD;C#*PR"/0BL[3?#FC://)/IVFV]M+(,,\:8)'I]* ZG+_  \)$GBH
MK]X:M-BL?P1'X>U&UO\ 4?$C6D^M"YD%R+X@F$ \ *W 7\*]+M-/M+ S&UMX
MX3/(99=@QO8]2?>J%[X4T#4;S[7>:1:37!ZR/$,GZ^OXT7"QQ7A*ZTF[^*VI
MOHL$45DNF!5,,01)")!EEQU';/M7=7OB#3K#6;'2;B8K>7V[R$"$YQUR>@_&
MK$.F6-O=BZ@M(8IQ"( Z( 1&#D+QVS7-VFC7.J^/+C7M1@:*WT]3;:?&XP6)
M^_+^.<#\Z V.OKSOP_>V_AGQ[XCTK4I4MUU&<7UI)(<+*&SN )[@_P C7HE4
M=2T;3=9B6+4K&"Z1?NB5 VWZ'M^%(&>??$[Q+87>GP:38O\ :IENX9)WA^9(
M &XW$< D]!6[\3-+GU+P<SVT/G2V4\=V(L9WA,Y'Y$UO0^&]%M]/-A%I=JEJ
M7$AB6,8+ Y!/J:U*=PL<EI.H>"]6TZ.[@CTE0R@NDD4:LA[A@1P<UL:)<Z)=
M1SMHALVC239*UJJA=P&<9'7K4%UX-\-WMRUQ<:+9/*QRS>4!D^IQUK5M+*UT
M^W$%G;0V\(Z)$@5?R% 'F7@V/0=4EU6_\3FUFUI+IUF2^(/DH#P K< ?A4OA
MVZT>Z^+D[:'!#'9IIC)N@B"1R,'&2N.".V?:NXO_  MH.IW?VJ]TFTGG[R/&
M,GZ^OXU;ATK3[>ZCN8+.&*:.+R49$"[8\YVC';-%PL<AXXF2P\7^#]1N&"6L
M5S,DDC<*I9,#)KH]6O;6\\.:O]FN8IMEK*'\MPVT["><5?OM/L]3M6M;ZVBN
M(&ZI*H85!8:%I6F6<MG8V$$%O+GS(T7 ?(P<^O% &+\./^1!TG_KC6>G_):)
M/^P8/YBNTM+2WL+6.VM(4A@C&$C08 %,_L^T_M#[?]GC^UE/+\['S;?3-%PL
M6:X'Q],- UG1?%(!\NW=K>XQW1AD#\Z[ZJU]I]IJ=HUK?6\=Q WWHY!D&D#.
M T+0SJ_PRU-YES<:L9;K..3SE/T JAX+U"3Q;XCTN68$KHMEMEST\\\?F *]
M3@@BMH$@@C6.)!M5%& !Z56L-(T_2VF-C9PVYF;?(8T W'U-.X6.6^*?_(H)
M_P!?L'_H57/'$$EQ\.-2CB4LYM 0 .3TKHKVPM-1@\B\MXYXMP;8XR,CH:F*
M*4V%04QC:1QBBX6,3PUK6G7VAZ8L%[ \CVZ@1B0;LA0#Q6#X1_Y'_P 7_P#7
M=/\ T&NELO#&AZ;?->V6EVL%R<_O(XP#SUQZ5=@T^TMKJ>Y@MXXY[@@RR*N"
MY'K0!QWQ/_Y!ND_]A"+^=3?%/_D2)O\ KXA_]#%=7>:?::@B)>6\<ZQN'0.,
MX8=#2WMC:ZC;&WO($GA)!*.,C(Y%%PL<;\1_^2<_\#M__0A79V?_ !XV_P#U
MS7^5-N]/M+^T^RW=O'-;Y!\MUR..E6% 50J@  8 ':@#AO '_(<\6?\ 7^/Y
M&NZJM:Z?:64L\EM;QQ/</OE9!C>WJ:LT@1S'CS7'T/PO.UN<WMR1;VRCJ7;C
MCZ=?PJ]X4T-/#OAJRTU0-\:9E;^\YY8_G_*K]UIUG?2V\MU;1S/;OYD1=<[&
M]1[U:H#J%07-E:7JJMW:PSJIRHEC#8_.IZ*!E6VTS3[.3S+6QMH)",%HH54X
M],@5:HHH J7.IV%G)Y5S>V\,F,[9) IQ^-<)\,]5T^VTK65GOK>-FUBX90\@
M&0=N#]*[._\ #FBZI<?:+_2[2YFVA=\L08X';-5?^$+\,?\ 0!T__OPM,6IS
MOQ&2;3=0\/>*(HV>+2[HK<[!DB*3 )_#!'XUT<WC#P]#I;:B=6M&MPNX%902
M?8#KGVK:>-)(VC=%:-AM*D9!'IBL./P5X9BNA<IH=B)0VX'RA@'Z=* ,GX<V
M=P=/U#7+N)HIM8NWNEC88*QG[H_+G\:[2@<# HI#/)?$6HR^"/$FOPP*VS7+
M82VBJ/\ EX)V,![\Y_ 5Z'X7T=="\-V.G+C=%$-Y'\3GEC^))KE];B7Q%\4-
M*T[R@UOH\1NYV*_QMC:N?R-=_38D>6^$5T30M3U7P_K]M91727+2V\EU&N)8
MVY&&8?I78I/X2AU&WMH1I(O9&Q$D:)OR.>,#(Z5IZEHNF:Q&J:E86]TJ_=\U
M 2OT/:H--\-:)I$GF:?I5K;R?WTC&[\^M%PL<AX[D@F\8:#I^L2F+0Y59I S
M;8Y)1T5CZ=*R_B(WA"Q\,36>FV>G&_?;L^RPH7C&1EBP&0*].U#3;'5;8VU_
M:0W,).=DJ!AFJ4'A70;6SEM(-(M(X)@!(JQCYP.1D]31<+&/XV_Y)=J'_7FG
M_LM;?AS_ )%O3?\ KW3^57;BRMKNR>SN($DMG7:T3#*D>E2111P1)%$@2-!M
M55' %(# N]1\*Z\MQ87T]C<>0Q26&<@,A'7KR/J*Y_X?;8-?UVQTNY>?08&7
M[.2Y=4<_>53Z5U6H>%- U6Y^T7VDVD\QZR-&-Q^I[UHV=E:Z?;+;V=O%;PKT
M2) H'X"F%B>BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K.O/^/@_05HUG7G_'P?H* *]%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 =#;?\ 'K#_ +@_E4M1
M6W_'K#_N#^52T %%%% !1110 4444 %%%% !1110!!>)/):2);&,2LI"F0''
MZ5RL'A74QH\=I->6PFMYO.@DC1L9SG!SVKL:* ,?1](FLY[J[O)8Y;JY(W^6
MI"@#L,UF^*/#^C)X=U&X72[,3")F$@A7=GUSBNJK'\5?\BKJ7_7!J +NE_\
M()L_^N"?^@BK=5-+_P"039?]<$_]!%6Z "BBB@ HHHH **** "BBB@ HHHH
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MH:DI!@5#=7<%G&))Y5C0L%W,<<G@"@">BD!R*,T +6-HW_(5\08Z?;EQ_P"
M\.?US6S6-X=_>P7UYVN;V5U/JJML4_B$%2]T:PTA)^B_&_Z&S1115&04444
M%%%% !1110!3D_UTGU'\A11)_KI/J/Y"B@!**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@"G)_KI/J/Y"BB3_72?4?R%% "4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5G7G_ !\'Z"M&LZ\_X^#]!0!7HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#H;;_ (]8?]P?RJ6HK;_C
MUA_W!_*I: "BBB@ HHHH **** "BBB@ HHHH **** "L?Q5_R*NI?]<&K8K'
M\5?\BKJ7_7!J +NE_P#()LO^N"?^@BK=5-+_ .039?\ 7!/_ $$5;H ****
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MT]U:)-':3NGF3@[8V_B'>K38[]J\$\8W_BR]^(,.IZ?I-[]EL'"PXC.''?\
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MXF"U++IN<37(./.'=(_8]W].!D\A?[/O=4YU=TCMC_RXP-E6_P"NCD M_N@
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MR4]/UH JT5:\E/3]:/)3T_6@"K15KR4]/UH\E/3]: *M%6O)3T_6CR4]/UH
MJT5:\E/3]:/)3T_6@"K15KR4]/UH\E/3]: *M%6O)3T_6CR4]/UH JT5:\E/
M3]:/)3T_6@"K15KR4]/UH\E/3]: *M%6O)3T_6CR4]/UH JT5:\E/3]:/)3T
M_6@"K15KR4]/UH\E/3]: *M%6O)3T_6CR4]/UH JT5:\E/3]:/)3T_6@"K15
MKR4]/UH\E/3]: *M%6O)3T_6CR4]/UH JT5:\E/3]:/)3T_6@"K15KR4]/UH
M\E/3]: *M%6O)3T_6CR4]/UH JT5:\E/3]:/)3T_6@"K15KR4]/UH\E/3]:
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M,DJ%!(!DKD=15FB@#RW1/@U#H6N0:M;ZW<M/&^YLH/G]0:]148%+10 4444
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M110 4444 %%%% %.3_72?4?R%%$G^ND^H_D** +E%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4Y/\
M72?4?R%%$G^ND^H_D** +E%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:/L7B#_H+P?^ H_QK;HH Q/L7B#_ *"\'_@*/\:/L7B#_H+P?^ H_P :VZ*
M,3[%X@_Z"\'_ ("C_&C[%X@_Z"\'_@*/\:VZ* .7U-O$&G6HF_M.W?+JF#;
M=3CUJ[]C\08_Y"\'_@*/\:TKVRBOX!%-NVA@W!QR#5GM0!B?8O$'_07@_P#
M4?XT?8O$'_07@_\  4?XUMT4 8GV+Q!_T%X/_ 4?XT?8O$'_ $%X/_ 4?XUM
MT4 9=I:ZQ'<HUUJ4,L(SN18 I/XYK4HHH **** "BBB@ HHHH **** *<G^N
MD^H_D**)/]=)]1_(44 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-BLD_?(Z\]@*6(P<76Y:>BM=^0Z&*:I<U376R\STVBO(K_6/%W@/4K1]5O\
M^T+*<X.XYSCJ/8UTWCOQE-H>AV<NG!3<7W^K<C.Q<#GZ\U@\'/FBHM-2V9LL
M7#EDY*W+NCMZ*\:UY?'.@:/%JUSKLCQRE0R(Y^0GD5O:+J'B"+X=:EJ]]?\
MFRO'YEL^[+*..M5+!-14E).[L*.+3DXN+5E<]'HK@_A=K>HZWH][)J-R]P\<
MX56?J!M!K(N?$VL)\6(]+6]<61G"&'^'&*GZG/VDJ=]8JY7UJ/)&=OB)/&_B
MC5]+\;6-C9W;16[F/<@ YRPS7I]>,?$?_DHVG?6'_P!"%=]XP;Q.YM;7PZJK
MYN?-G;'R?X5M6HQE"DE976YC2JM3JMW=F=33)9%AA>5_NHI8X]!7C^M_\)WX
M0MH]1N=9-Q$7 92^X ^A![5U6H:AK/B7X?07^CR+!<R+F8;L<#[P%92P;7++
MF3BW:YI'%)W7*TTKV-GP]XRTKQ-<3P:?Y^^ ;F\Q-O&<<<UT%?.O@VT\1W5[
M=+X>N/)F5 93OVY&?\:]1\9>+[KPKHEE NR359XP"3R 0.6]^:UQ."4:RITG
M>_3_ #,\/C.:DYU%:QW-%>/&U^(XTO\ MK^T7V%/-\CS.=O7[N,5U7@/QG-X
METJZCNPHOK5<EE&-XQUK*I@Y0@YQDFEO;H:T\5&4E%IIO:YV]%>%V'C+Q;J-
MS=:58SRSW4\I"/WC4$YQZ5NZO-XRT7P''=75].EY#=$2MNW$QD#'/UJY9?*,
ME&4E=D1QT91<E%V1ZO17,>#_ !'_ &MX-CU*ZD!FA5EG8^J]_P L5S'P\U_6
M_$?B34+BXNY&T^,$B(] 2?E'Y?RK'ZK.TV_LFOUB-X)?:/3J*I:Q/);:+>SQ
M-MDC@=E/H0*\>T#Q5XTUZW?3--E:6XW;WN7_ (%[#/;FBAA95HN::27<*V)C
M2DHM-M]CVZBO#[/QOXK\.ZQ<:7J!>]N/]6L4IW$.?ND'N.1Q3]8U;Q]X;DM]
M3U*[=8YWXCW H#UVE>@XKH_LV?-;F6NWF8?7X6ORO3?R/;:*Y#6?$,\WPSDU
MVR<P3R6Z.I'\#%@#C]:A^&&L7^M>&9[C4+AIYDNVC5VZ[=B''YDUS/#R5-U'
MT=CH5>+J*"ZJYVM<[X@\:Z3X:OH;._\ /\V9 Z^6FX 9(YY]JXZS\3ZQ)\7G
MTI[US8_:)(_)_AP$)'\JXWQ];ZU!XFQJ\PED<%K<ALXCWMM'MWKKH8!.HHU'
MNKG+6QK5-RIK9V/H0'(SZTM<9X1M?%EC;:B^N3BY;RP;5"^[Y@#D?RK!&D?$
MC5LW4NJ"Q)Y6%7V_@0*YEADY-.:LNIT/$/E3Y'=GJ-<]X@\::3X:O(+6_P#/
M\R9=Z^6FX8SCGGVKDOA_XNU>YU^XT#6I/.EC#;7;[RLIP03W_P#K5Q7Q"M]:
M@\2?\3:82%\M;$-G$>XX'M710P*=?V=1]+^IA6QMJ/M*:_X![W=2RKI\TULF
M^41,T:G^)L9 KCO FM^)]5O+U-=MFCAC \MFA\OG)X'K1X6M_%>GZ?J4VN70
ME46^ZV^?<5(!/^%9_P +_$6J:W=ZLFHW;SK"$*;OX<EL_P JA4>6E4M9VMK_
M )%NKS5*=[J]]/\ ,])HKR34O%_B'Q3XDDT?PS(((8R1YH."0."Q/:JMUK_C
M+P-J5N-8N?MEM+_>;>&'?!Z@T+ 3=E=<SZ=0>-@M;.W?H>RT5Y_\0_$EY9^&
M=.O])NFA^TN#N7J1C-<X=6\?>(=*.I6):VLX4R-K;6DQU/O44\%*<%-M);:E
M3Q<8R<$FWY'L=%>?_#?QA>:[:7EMJ3>9/: /YF.67W]^*YVUUSQ/XV\07EKI
MVK#3HH<E$4[21G'U)H6"GSRC)I<N[!XN'+&45?FV1[%2$@ DG '6N>\)6WB&
MSMKB#7[E+AE<>3*IR2N.]7_$5T;+PYJ%P.J0,1^6*YW3M/D3N;J=X<[5CS_0
M];U/Q+\39C#>S)IUJ6/E*WRD#CD>YKN]9\4:/H#(FHWBQ2/RJ8)./7 K@O@S
M;AHM4NSRY98\_K6Q=> 6U?QK=:IJQCGT]TQ%&&.1QQ7?B(4?;N$W:,5TZG%0
ME5]BI1U<G]QUUIK6G7VFMJ%M=QR6J@EI >%QUS6??>+]+MO#4VN6\OVNUC.T
M&/(W-Z<UPEW\-_$5C/=6NA:BJZ9<_?1Y"IQZ$=Z[S0/#%KI'AN#2)U2Y53OD
MWKD,_7.*QJ4L/!*2ES:[>7F;0J5YMQ<;:;^?D>>7'Q;UQ2)TT:*.U)^4R*_/
MX]*[SP=XPM_%EE(ZQ>3<PD"2+.>O<>U5?B)<V-AX+O(YDC#3+Y<*X'WCT(^E
M<M\(=/G@M-3U1U*Q,FR//\1')-=$X4:F&=51Y6GIYF$9U:>(5-RYD]S8\5_$
MAM)U4Z3I-D+R\4X?() /H .2:HZ/\4;I=6CT_P 1:<+/>0/,"LI7/0D'M6+\
M,PNI>/M0O9_GD5))5)YY+8_D:M_&:W1+K2[I5 <JZ,P[XP1_6M50H*JL,XZM
M;^9FZU9TWB%+1/;R.Q\6^,7T&XL["PM5N]0O#B*,G"@9P,_6J_AWQI>7OB*7
M0-:L$L[]5W)Y;$JV!G'/MS7*Z]#>PWWA3Q.MM-=6\5O#YPC4L05P?UYI(-0%
MUXZN?&$UM/:Z59PG#3+M,AVD  >I)K..&I^RM:^CU\[Z(MXB?M+WZK3RMN=O
MXU\6KX9T]! JS:A<';!%U_$CTK8T1]1DT>WDU41K>NNZ18Q@+GH/KBO/?"MM
M_;NMOXP\0RQ0QEL644SA5 '<9]/YUZ?%-%/&)(9$D0]&1@0?Q%<F(A&E%4TM
M>K\^WR.JA.523FWIT7ZC;J;[/:338SY:%L>N!7&>!/'-UXLN[R&YM(81 @=3
M&3SDXYS77:E_R"[O_KB_\C7DWP8_Y"NJ?]<%_P#0JJA2A+#U)M:JUB:U24:]
M.*>CN>Q$A5+,0 !DD]J\TUGXK[-0:RT#3_MK*=OF,"0Y_P!E1S72?$2^>P\#
M:C)$Y6215B!'^TP!_0FN:^#NDVZZ/=ZJ\:M<23F%6(Y55 /'U)_056'I4XT9
M5ZBO9V2)KU*DJJHTW;JV4D^*VLZ?,B:QH8C4GJ%9"?IGBO3-(U:TUO3(=0LG
MW0RC(SU![@^XK,\;Z7;ZIX1U)9HU9X8&FC;'*LHW<?EC\:XOX+WCM!JMDS$I
M&T<B+V&<@_R%5.%*MAW5A'E<7J3"=2E75*<KIA??%?4(M8NK*TTB.80RLBXW
M%B <9P*TO#OC_6=8UZUL+G0F@AE)#2['&W"D]^.U<-X?U:RT7XD7E[?OL@66
M92=N>23BO6=(\:Z!K6H+96-P6N&!*J4QG%;XFE"G&T:5]-]3'#U9U'>52VNV
MAQUWKFI^'/BL+:ZO9I=/NW&V-W)50_3 ]CQ7JE>1_&:#RKS2;U.)&5TR.ORD
M$?\ H5>H:5<_;-)L[G_GK"K_ )BN7%14J-.JNJL_D=.'DU5J4WT=_O+E%%%<
M)V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-?VOD
MR>8H^1OT-4JZ.2-98RC#(-8,\+02E&_ ^M $5%%% !1110 4444 %%%% !11
M10 4444 =#;?\>L/^X/Y5+45M_QZP_[@_E4M !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %,FBCGA>&50T;J593W!I]<QKSRZEXAL-!^TR6UK-
M"\\K1-M:4*0-@/;KDX]* *0>X\%2_9KHR7'AR4[4E/+6>>S>J>_:F7/AK1].
MTPS7VKW\NCK\T5L)B8P&.0!MY8<\47.GR^%;^U$4\MUH=],MM<6MRYD\MG.
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M:_#;P[!,")$"A@>OW:[SPM_R3O3_ /KQ_P#934GBSPI#XJL(;66X> 1/N!0
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M/&=R!Q\H/K[UI]9H.HL0W[R6WF1]7K*#H):-[^1UVEVWV'0[.VEP/(MT1\]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$=U T4T=[811%[JWD*-\^["$CK@*#@_WA6CK'AG3=;ECGN$DCN8QA+B"0QR
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M-)HVCD171AAE89!%4M/T32]*=WL+"WMW?[S1H 35^B@ HHHH **** "BBB@
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M"96,?S_2NJU?1[#7M.DL-2MUGMG(+(?4'(JQ9VD%A90V=K&(X($$<:#HJ@8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF32;"5;B59+JYF:XN&087>V!@#T  %:H !)  )Z^] 6%HHHI#"BBB@ HHHH
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M6.")I975(T&69C@ 5QWBJ^LFURRMM6N&CTC[))<A48@7$@8 +D<G .0!US0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)8EFC9&'!K GA:"
M4HW;H?6NBJK>VHN(LC[Z]* ,.B@@@X/444 %%%% '0VW_'K#_N#^52U%;?\
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M'H>DB*Y:95EDNQRMJO9@?[_H*8F5?$5U8GQ7<6^M0/=JEM'_ &=8\D3NQ(;
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M2=R,9QU"CWZUV%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX5F"#)+D8.<'GO5GQQ;06?PWUJWMHDAA2SD"H@P%X/05J>%_^12T;_KQ@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVS_\]4_[]G_&@"6BHML__/5/^_9_QHVS_P#/5/\ OV?\: ):*BVS_P#/5/\
MOV?\:-L__/5/^_9_QH @D_UTGU'\A14OV=B2SN"2>RX_K10!/1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>30
<FILENAME>alec-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T23:12:00.6402922+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6dc947f9232049b49804e807205611da -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:alec="http://www.alector.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="alec-20201231.xsd" />
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001653087_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20210215">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207_20190207">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-07</xbrli:startDate>
      <xbrli:endDate>2019-02-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20190207_20190207">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-07</xbrli:startDate>
      <xbrli:endDate>2019-02-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200129_20200130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-29</xbrli:startDate>
      <xbrli:endDate>2020-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200129_20200130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-29</xbrli:startDate>
      <xbrli:endDate>2020-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20171001_20171031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-01</xbrli:startDate>
      <xbrli:endDate>2017-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20180101_20180131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_srtRangeAxis_srtMaximumMember_20171031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtCounterpartyNameAxis_alecInnoventBiologicsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:InnoventBiologicsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecLabEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecLabEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20180601_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201001_20201031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20190501_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-05</xbrli:startDate>
      <xbrli:endDate>2019-02-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-05</xbrli:startDate>
      <xbrli:endDate>2019-02-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190206">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEmployeeStockPurchasePlanMember_20190205_20190206">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-05</xbrli:startDate>
      <xbrli:endDate>2019-02-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEmployeeStockPurchasePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeTaxAuthorityAxis_alecDomesticAndStateTaxAuthorityMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">alec:DomesticAndStateTaxAuthorityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeTaxAuthorityNameAxis_us-gaapCaliforniaFranchiseTaxBoardMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecTwoThousandFourteenAdimabAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200129_20200130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-29</xbrli:startDate>
      <xbrli:endDate>2020-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001653087_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001653087_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001653087_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001653087_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001653087_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001653087_20200101_20201231">ALEC</dei:TradingSymbol>
  <dei:EntityFileNumber id="F_000006" contextRef="C_0001653087_20200101_20201231">001-38792</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000007" contextRef="C_0001653087_20200101_20201231">82-2933343</dei:EntityTaxIdentificationNumber>
  <dei:EntityPublicFloat id="F_000008" contextRef="C_0001653087_20200630" decimals="-5" unitRef="U_iso4217USD">1375600000</dei:EntityPublicFloat>
  <dei:EntityAddressAddressLine1 id="F_000009" contextRef="C_0001653087_20200101_20201231">131 Oyster Point Blvd</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000010" contextRef="C_0001653087_20200101_20201231">Suite 600</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000011" contextRef="C_0001653087_20200101_20201231">South San Francisco</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000012" contextRef="C_0001653087_20200101_20201231">CA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000013" contextRef="C_0001653087_20200101_20201231">94080</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000014" contextRef="C_0001653087_20200101_20201231">415</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000015" contextRef="C_0001653087_20200101_20201231">231-5660</dei:LocalPhoneNumber>
  <dei:DocumentTransitionReport id="F_000016" contextRef="C_0001653087_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:DocumentAnnualReport id="F_000017" contextRef="C_0001653087_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:EntityRegistrantName id="F_000018" contextRef="C_0001653087_20200101_20201231">Alector, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000019" contextRef="C_0001653087_20200101_20201231">0001653087</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000020" contextRef="C_0001653087_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000021" contextRef="C_0001653087_20200101_20201231">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000022" contextRef="C_0001653087_20200101_20201231">false</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000023" contextRef="C_0001653087_20200101_20201231">false</dei:EntityEmergingGrowthCompany>
  <dei:IcfrAuditorAttestationFlag id="F_000024" contextRef="C_0001653087_20200101_20201231">true</dei:IcfrAuditorAttestationFlag>
  <dei:EntityShellCompany id="F_000025" contextRef="C_0001653087_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntityCurrentReportingStatus id="F_000026" contextRef="C_0001653087_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="F_000027" contextRef="C_0001653087_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityCommonStockSharesOutstanding id="F_000028" contextRef="C_0001653087_20210215" decimals="INF" unitRef="U_xbrlishares">79584442</dei:EntityCommonStockSharesOutstanding>
  <dei:SecurityExchangeName id="F_000029" contextRef="C_0001653087_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:Security12bTitle id="F_000030" contextRef="C_0001653087_20200101_20201231">Common Stock</dei:Security12bTitle>
  <dei:EntityInteractiveDataCurrent id="F_000031" contextRef="C_0001653087_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityWellKnownSeasonedIssuer id="F_000032" contextRef="C_0001653087_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityIncorporationStateCountryCode id="F_000033" contextRef="C_0001653087_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000034" contextRef="C_0001653087_20200101_20201231">&lt;p&gt;Portions of the registrant&amp;#8217;s Definitive Proxy Statement relating to the registrant&amp;#8217;s Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">49969000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">89641000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:MarketableSecuritiesCurrent id="F_000037" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">363339000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent id="F_000038" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">263432000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000039" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">8203000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000040" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">4364000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000041" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">421511000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000042" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">357437000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000043" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">30181000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000044" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">33852000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000045" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">32470000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000046" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">28476000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:RestrictedCashNoncurrent id="F_000047" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">1472000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000048" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">1472000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000049" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">2617000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000050" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">676000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000051" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">488251000</us-gaap:Assets>
  <us-gaap:Assets id="F_000052" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">421913000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000053" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">3004000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000054" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">278000</us-gaap:AccountsPayableCurrent>
  <alec:AccruedClinicalSupplyCost id="F_000055" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">11148000</alec:AccruedClinicalSupplyCost>
  <alec:AccruedClinicalSupplyCost id="F_000056" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">6706000</alec:AccruedClinicalSupplyCost>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000057" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">22538000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000058" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">18256000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000059" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">23886000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000060" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">30165000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000061" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">7512000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000062" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">6565000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000063" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">68088000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000064" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">61970000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000065" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">108417000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000066" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">123236000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000067" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">43744000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000068" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">41471000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000069" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">472000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000070" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">493000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000071" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">220721000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000072" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">227170000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000073" xsi:nil="true" contextRef="C_0001653087_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000074" xsi:nil="true" contextRef="C_0001653087_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000075" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000076" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="F_000077" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">676956000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000078" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">414414000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000079" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">614000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000080" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000081" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">-410048000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000082" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">-219820000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000083" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">267530000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000084" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">194743000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000085" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">488251000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000086" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">421913000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000087" contextRef="C_0001653087_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000088" contextRef="C_0001653087_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000089" contextRef="C_0001653087_20201231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000090" contextRef="C_0001653087_20191231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000091" contextRef="C_0001653087_20201231" decimals="INF" unitRef="U_xbrlishares">79316261</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000092" contextRef="C_0001653087_20191231" decimals="INF" unitRef="U_xbrlishares">69052873</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000093" contextRef="C_0001653087_20201231" decimals="INF" unitRef="U_xbrlishares">79316261</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000094" contextRef="C_0001653087_20191231" decimals="INF" unitRef="U_xbrlishares">69052873</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000095" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">21098000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000096" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000097" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">27508000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:TypeOfRevenueExtensibleList id="F_000098" contextRef="C_0001653087_20190101_20191231">alec:CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
  <us-gaap:TypeOfRevenueExtensibleList id="F_000099" contextRef="C_0001653087_20180101_20181231">alec:CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
  <alec:RevenueFromGrant id="F_000100" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">169000</alec:RevenueFromGrant>
  <us-gaap:Revenues id="F_000101" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">21098000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000102" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21219000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000103" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">27677000</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000104" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">156869000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000105" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">100528000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000106" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">73031000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000107" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">59403000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000108" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">35095000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000109" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">11934000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000110" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">216272000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000111" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">135623000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000112" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">84965000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000113" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-195174000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000114" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-114404000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000115" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-57288000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000116" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4946000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000117" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9019000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000118" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">5040000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000119" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-190228000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000120" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-105385000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000121" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-52248000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax id="F_000122" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">472000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax id="F_000123" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">184000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax id="F_000124" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-42000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000125" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-189756000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000126" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-105201000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000127" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-52290000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000128" contextRef="C_0001653087_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.45</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000129" contextRef="C_0001653087_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.71</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000130" contextRef="C_0001653087_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.62</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000131" contextRef="C_0001653087_20200101_20201231" decimals="0" unitRef="U_xbrlishares">77758806</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000132" contextRef="C_0001653087_20190101_20191231" decimals="0" unitRef="U_xbrlishares">61734492</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000133" contextRef="C_0001653087_20180101_20181231" decimals="0" unitRef="U_xbrlishares">11302788</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000134" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">36001203</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000135" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">77485000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockSharesOutstanding id="F_000136" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">13776153</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000137" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000138" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" unitRef="U_iso4217USD">10153000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000139" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" unitRef="U_iso4217USD">-62187000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000140" contextRef="C_0001653087_20171231" decimals="-3" unitRef="U_iso4217USD">-52033000</us-gaap:StockholdersEquity>
  <alec:TemporaryStockIssuedDuringPeriodSharesNewIssues id="F_000141" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">9373633</alec:TemporaryStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000142" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">133035000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited id="F_000143" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">11324</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000144" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">6925000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000145" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">6925000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000146" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-42000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000147" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-42000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:NetIncomeLoss id="F_000148" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-52248000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000149" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">45374836</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000150" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">210520000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockSharesOutstanding id="F_000151" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">13764829</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000152" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000153" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">17078000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000154" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" unitRef="U_iso4217USD">-42000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000155" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-114435000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000156" contextRef="C_0001653087_20181231" decimals="-3" unitRef="U_iso4217USD">-97398000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000157" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">45374836</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000158" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">210520000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000159" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-45374836</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000160" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000161" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-210516000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000162" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-210521000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000163" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">9739541</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000164" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000165" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">168222000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000166" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">168223000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000167" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">180287</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000168" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1519000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000169" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1519000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000170" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">50353</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000171" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">798000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000172" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">798000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited id="F_000173" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">56973</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000174" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16281000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000175" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16281000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000176" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">184000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000177" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">184000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:NetIncomeLoss id="F_000178" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-105385000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000179" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">69052873</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000180" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000181" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">414414000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000182" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000183" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-219820000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000184" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">9602500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000185" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000186" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">224510000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000187" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">224511000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000188" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">655772</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000189" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000190" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000191" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">86870</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000192" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1179000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000193" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1179000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited id="F_000194" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">81754</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000195" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000196" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000197" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">472000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000198" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">472000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:NetIncomeLoss id="F_000199" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-190228000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000200" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">79316261</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000201" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000202" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">676956000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000203" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217USD">614000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000204" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-410048000</us-gaap:StockholdersEquity>
  <alec:IssuanceCostOfPreferredStock id="F_000205" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">214000</alec:IssuanceCostOfPreferredStock>
  <alec:IssuanceCostsOfCommonStock id="F_000206" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1148000</alec:IssuanceCostsOfCommonStock>
  <alec:IssuanceCostsOfCommonStock id="F_000207" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3874000</alec:IssuanceCostsOfCommonStock>
  <us-gaap:ProfitLoss id="F_000208" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-190228000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000209" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-105385000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000210" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-52248000</us-gaap:ProfitLoss>
  <us-gaap:DepreciationAndAmortization id="F_000211" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5870000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000212" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3775000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000213" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1019000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ShareBasedCompensation id="F_000214" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30522000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000215" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16281000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000216" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">6925000</us-gaap:ShareBasedCompensation>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000217" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-584000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000218" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4701000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000219" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2745000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <alec:AmortizationRightOfUseAsset id="F_000220" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1395000</alec:AmortizationRightOfUseAsset>
  <alec:AmortizationRightOfUseAsset id="F_000221" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1799000</alec:AmortizationRightOfUseAsset>
  <us-gaap:OperatingLeaseImpairmentLoss id="F_000222" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">238000</us-gaap:OperatingLeaseImpairmentLoss>
  <us-gaap:OperatingLeaseImpairmentLoss id="F_000223" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1158000</us-gaap:OperatingLeaseImpairmentLoss>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000224" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-107000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000225" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-39000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000226" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-151000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000227" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3839000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000228" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1596000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000229" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2245000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000230" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2498000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000231" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000232" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-106000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000233" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2409000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000234" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">152000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000235" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-809000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts id="F_000236" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">12232000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
  <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts id="F_000237" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9210000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
  <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts id="F_000238" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">4743000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000239" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-21098000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000240" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-21219000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000241" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">172492000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <alec:IncreaseDecreaseInLeaseLiabilities id="F_000242" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-2407000</alec:IncreaseDecreaseInLeaseLiabilities>
  <alec:IncreaseDecreaseInLeaseLiabilities id="F_000243" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">868000</alec:IncreaseDecreaseInLeaseLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000244" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-21000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000245" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">353000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000246" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">75000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000247" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-166734000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000248" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-99308000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000249" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">127464000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000250" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5032000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000251" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">15265000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000252" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1884000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000253" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">506809000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000254" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">529609000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000255" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">472235000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000256" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">406790000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000257" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">496000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000258" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">250000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000259" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-105051000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000260" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-48874000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000261" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-224119000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering id="F_000262" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-170128000</alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering>
  <alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering id="F_000263" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1904000</alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering>
  <alec:ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts id="F_000264" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">224603000</alec:ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts>
  <alec:ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts id="F_000265" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-92000</alec:ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts>
  <alec:ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock id="F_000266" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">133050000</alec:ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000267" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6331000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000268" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1519000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockPlans id="F_000269" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1179000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans id="F_000270" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">798000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000271" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">232113000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000272" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">172353000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000273" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">131146000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000274" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-39672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000275" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">24171000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000276" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">34491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000277" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">91113000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000278" contextRef="C_0001653087_20181231" decimals="-3" unitRef="U_iso4217USD">66942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000279" contextRef="C_0001653087_20171231" decimals="-3" unitRef="U_iso4217USD">32451000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000280" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">51441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000281" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">428000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000282" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3471000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000283" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">293000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <alec:DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities id="F_000284" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">465000</alec:DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities>
  <alec:DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities id="F_000285" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">792000</alec:DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PaymentsForTenantImprovements id="F_000286" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8286000</us-gaap:PaymentsForTenantImprovements>
  <us-gaap:PaymentsForTenantImprovements id="F_000287" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">7449000</us-gaap:PaymentsForTenantImprovements>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000288" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;a name="NOTES_TO_CONSOLIDATED_FINANCIALS"&gt;&lt;/a&gt;&lt;a name="NOTES_TO_CONSOLIDATED_FINANCIALS"&gt;&lt;/a&gt;The Company and Liquidity &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Initial Public and Follow-on Offerings&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 7, 2019, the Company completed an initial public offering (IPO) through issuing and selling 9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&amp;#8217; partial exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $168.2 million, after deducting underwriting discounts and commissions and offering costs. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 45,374,836 shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 30, 2020, the Company completed a follow-on offering through issuing and selling 9,602,500 shares of common stock at a public offering price of $25.00 per share, including 1,252,500 shares sold pursuant to the underwriters&amp;#8217; full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $224.5 million, after deducting underwriting discounts and commissions and estimated offering costs.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000289" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Summary of Significant Accounting Policies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates&lt;font style="font-style:italic;"&gt;.&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents, and Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. &lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash as of December 31, 2020 relates to a letter of credit established for a lease entered into in June 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,470&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All marketable securities have been classified as &amp;#8220;available-for-sale&amp;#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&amp;#8217; equity (deficit) until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&amp;#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&amp;#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, commercial paper, and overnight repurchase agreements collateralized by U.S. treasury securities. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s believes the carrying value of financial instruments, including cash and cash equivalents, receivables, accounts payable, and accrued liabilities, approximate fair value due to their short-term nature. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&lt;font style="font-style:normal;"&gt; &amp;#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&lt;font style="font-style:normal;"&gt; &amp;#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&lt;font style="font-style:normal;"&gt; &amp;#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted Accounting Standards Update No.&amp;#160;2016-02, &lt;font style="font-style:italic;"&gt;Leases &lt;/font&gt;on January 1, 2019. There was no material effect on the statement of operations upon adoption.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds is fair value. For the year ended December 31, 2020, the Company recognized a $0.2 million impairment loss on its right-of-use asset related to decision to no longer utilize certain property through the end of the lease term. For the year ended December 31, 2019, the Company recognized a $1.2 million impairment loss on its right of use assets related to the portion of its headquarters being subleased.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when control of promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i)&amp;#160;identify the contract(s) with a customer, (ii)&amp;#160;identify the performance obligations in the contract, (iii)&amp;#160;determine the transaction price, (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract, and (v)&amp;#160;recognize revenue when (or as) the entity satisfies the performance obligation. &lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaboration Revenue &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company signed an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $205.0 million in upfront payments, of which $5.0 million and $200.0 million was received by the Company in October 2017 and January 2018, respectively. The Company will perform research and development services for the antibodies to the two programs through the end of Phase 2 clinical trials which the Company expects to conduct through 2023. AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration agreement with the Company for one or both of the programs for $250.0 million each. If AbbVie exercises its option for the programs, AbbVie will take over the development of the product candidates for such program and costs will be split between the parties. The Company will also share in profits and losses upon commercialization of any products from such program. However, following AbbVie&amp;#8217;s exercise of its option for a program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $242.8 million in milestone payments per program related to the initiation of certain clinical studies and regulatory approval for up to three indications per program. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has determined that there are two research and development performance obligations as part of the agreement with AbbVie, one research and development performance obligation for each of the two research and development programs. The non-refundable upfront cash payments of $5.0&amp;#160;million and $200.0&amp;#160;million received in October 2017 and January 2018, respectively, were included in the transaction price. None of the remaining development and regulatory milestone and program opt-in payment amounts have been included in the transaction price, as all these amounts were fully constrained as of December&amp;#160;31, 2020 and 2019. As part of the Company&amp;#8217;s evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestone amounts is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to royalties on net product sales will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in the Company&amp;#8217;s forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of clinical trials. The Company has had changes to the overall expected costs to satisfy the performance obligations from period to period. For the year ended December 31, 2020, the Company had a 7% increase in the forecast of total expected costs due to changes to the clinical trial plans. For the year ended December 31, 2020, the increase in the overall expected costs to satisfy the performance obligation resulted in an approximately $6.7 million reduction in revenue compared to if the expected costs had remained the same, as a result of the cumulative catch up for the change in estimate. Collaboration revenue under the Company&amp;#8217;s collaboration agreement with AbbVie during 2020, 2019, and 2018 was $21.1 million, $21.2 million, and $27.5&amp;#160;million, respectively. Collaboration revenue recognized during the year ended December 31, 2020, was included in deferred revenue at the beginning of the period. The balance of deferred revenue was $132.3&amp;#160;million as of December&amp;#160;31, 2020. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of Phase 2 clinical trials. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&amp;#8217;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent may pay the Company up to $11.5 million in development milestones, $112.5 million in sales milestones, and future royalties for any sales. The Company retains the rights to develop and commercialize AL008 outside of China. The Company has determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement have not been included in the transaction price, as all these amounts were fully constrained as of December 31, 2020. As of December 31, 2020, no revenue has been recognized or payments received under the Innovent Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&amp;#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&amp;#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the grant agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A substantial portion of the Company&amp;#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, contract research organizations in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation for employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of options to purchase common stock are measured using the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&amp;#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&amp;#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&amp;#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employee 401(k) Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a qualified contributory savings plan under Section&amp;#160;401(k) of the Internal Revenue Code (the &amp;#8220;Code&amp;#8221;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section&amp;#160;401(k) of the Code. Eligible employees may defer up to 100% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&amp;#8217;s contributions to the plan are discretionary. For the year ended December&amp;#160;31, 2020, the Company made matching contributions of $0.7 million. The Company did not make any matching contributions for the years ended December 31, 2019 or 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment. The Company&amp;#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&amp;#8217;s operations on a consolidated basis for purposes of allocating resources. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January 1, 2020, the Company adopted Accounting Standards Update (ASU) No. 2016-13, &lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326)&lt;/font&gt;. This ASU implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any changes in estimated credit losses immediately in earnings. There was no material impact to the Company&amp;#8217;s consolidated financial statements from the adoption of ASU No. 2016-13.&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes.&lt;/font&gt; This ASU modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, and the methodology for calculating income taxes in an interim period. The Company has early adopted this ASU as of January 1, 2020. There was no material impact to the Company&amp;#8217;s consolidated financial statements. There was no material impact to the Company&amp;#8217;s consolidated financial statements from the adoption of ASU No. 2019-12.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000290" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value Measurements &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&amp;#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Market&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;357,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;358,339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;400,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;401,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Market&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,735&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,735&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,103&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s Level&amp;#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. There were no transfers between levels of the fair value hierarchy during the year ended December 31, 2020. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2020, the remaining contractual maturities of $336.9 million investments were less than one year and $64.4 million investments were after one year through two years. The Company does not intend to sell the investments that are in an unrealized loss position before recovery of their amortized cost basis, which may be maturity.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock id="F_000291" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Balance Sheet Components &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment, Net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consists of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,610&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,458&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,554&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,265&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,957&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accrued Liabilities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued employee compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,094&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,040&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,471&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000292" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Commitments and Contingencies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 18, 2019, the Company initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, the Company&amp;#8217;s former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of Alector&amp;#8217;s confidential information that he learned during the course of rendering services to the Company as consulting Chief Scientific Officer/Chief Innovation Officer. An independent arbitrator issued a confidential decision in favor of Alector, finding Dr. Abeliovich liable for breach of his confidentiality agreement and for spoliation based on his destruction of documents relevant to the proceeding. The arbitrator awarded damages for breach of the agreement and sanctions for the spoliation, as well as violation of orders during the proceeding, and the amount of such monetary damages will be determined in a pending further proceeding.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock id="F_000293" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Leases &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company signed a lease agreement to lease approximately 105,000 square feet in office and laboratory space in South San Francisco which serves as the Company&amp;#8217;s headquarters (the &amp;#8220;Headquarters&amp;#8221;). The lease expires in 2029 with an option to renew for a period of ten years. The landlord paid for $15.7 million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $1.5&amp;#160;million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements. The measurement of the lease liabilities for the leases excludes the options to extend the term of the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&amp;#8217;s leases consist of operating expenses for the spaces. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company entered into an agreement to sublease approximately 25,000 square feet of the Headquarters (the &amp;#8220;Sublease&amp;#8221;), which was amended to approximately 23,600 square feet in December 2020. The Sublease expires in November 2021. The sublessor has the option to extend the Sublease for one additional year subject to the consent of the Company. The sublessee is required to pay its proportionate share of operating expenses for the space. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, in connection with the Sublease, the Company evaluated the related right-of-use asset for impairment. The lease costs plus amortization expense of the leasehold improvements in the subleased space exceeded the sublease income over the remaining sublease term. As such, the Company recorded an impairment charge of $1.2 million in general and administrative expenses to write-down the right-of-use asset such that no loss is expected to be recognized over the sublease period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income and reimbursement of variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,263&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,556&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense under legacy guidance for the year ended December&amp;#160;31, 2018 was $1.1&amp;#160;million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the weighted-average remaining lease term for operating leases was 8.2 years and the weighted-average discount rate was 8.5%. Cash paid for amounts included in the measurement of lease liabilities for the year ended&amp;#160;December 31, 2020 and 2019&amp;#160;was&amp;#160;$6.9 million and $3.2 million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following are the lease payments owed under the Company&amp;#8217;s operating leases as of December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,171&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,130&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Present value adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000294" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Stock-based Compensation &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized stock-based compensation as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,980&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Determination of Fair Value &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated grant-date fair value of all the Company&amp;#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3-6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3 &amp;#8211; 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1 &amp;#8211; 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74%-78%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76% &amp;#8211; 82%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73% &amp;#8211; 81%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3% - 1.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4% &amp;#8211; 2.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5% &amp;#8211; 3.1%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Term&amp;#8212;&lt;font style="font-style:normal;"&gt;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Volatility&amp;#8212;&lt;font style="font-style:normal;"&gt;The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&amp;#8217;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-Free Interest Rate&amp;#8212;&lt;font style="font-style:normal;"&gt;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Dividend Rate&amp;#8212;&lt;font style="font-style:normal;"&gt;The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock underlying its stock options in the foreseeable future. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The restricted common stock generally vests over a four-year period with straight-line vesting with a 25% one-year cliff. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity for the restricted common stock is shown below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,917,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(866,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;994,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(726,659&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81,754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $0.9&amp;#160;million, which the Company expects to recognize over a remaining weighted-average period of 0.8 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2019 Equity Incentive Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&amp;#8217;s employees, directors, and consultants. The Company&amp;#8217;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options or shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing 10% or more of the outstanding shares, the exercise price of each share shall be at least 110% of the fair market value and the term of the award shall not exceed five years. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed ten years. The shares generally vest over a four-year period with straight-line vesting with a 25% one-year cliff. As of December 31, 2020, the Company had reserved 15,628,217 shares of common stock for issuance under the 2019 Plan, of which 2,973,219 shares were available for issuance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity for the options to purchase common stock shown below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,063,688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,738,071&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(178,648&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,442,824&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,597,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(655,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(729,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,654,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,588,568&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,393&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest as of December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,654,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&amp;#8217;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was $11.1 million and $1.8 million for the years ended December 31, 2020 and 2019. There were no options exercised in 2018. The weighted-average grant-date fair value per share of options granted was $10.14, $12.06, and $6.27, for the years ended December 31, 2020, 2019, and 2018, respectively. As of December&amp;#160;31, 2020, total unrecognized stock-based compensation related to unvested stock options was $82.9&amp;#160;million, which the Company expects to recognize over a remaining weighted-average period of 2.6 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2019 Employee Stock Purchase Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 6, 2019, the Company adopted the 2019 Employee Stock Option Plan (2019 ESPP). The 2019 ESPP will enable eligible employees of the Company to purchase shares of common stock at a discount. Each offering period will be approximately six months long beginning on the first trading day on or after December 1 and June 1 each year. ESPP participants purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. As of December 31, 2020, there was $0.4 million in unrecognized compensation expense related to the 2019 ESPP to be recognized over five months.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000295" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Income Taxes &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurred net operating losses for the years ended December&amp;#160;31, 2020, 2019, and 2018. The Company has not reflected a benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the federal statutory rate to the Company&amp;#8217;s effective tax rate is as follows for the years ended December&amp;#160;31, 2020, 2019, and 2018 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefit at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,972&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,694&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,387&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Uncertain tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,044&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;708&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nondeductible expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefit recognized on utilization of attributes previous reserved&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,582&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred adjustment from amended tax return&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,073&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,346&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Others&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effects of temporary differences that give rise to significant components of the Company&amp;#8217;s deferred tax assets consist of (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,129&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Others&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(105,226&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,990&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Others&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(150&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized.&amp;#160;The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December&amp;#160;31, 2020, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $58.2 million during the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the Company had federal and state net operating loss (NOL) carryforwards of approximately $195.3&amp;#160;million and $191.4&amp;#160;million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed 80% of taxable income. State NOL carryforwards will begin to expire as early as 2030, if not utilized, or have an indefinite life. As of December&amp;#160;31, 2020, the Company also had federal and California tax credit carryforward of approximately $14.4&amp;#160;million and $3.8&amp;#160;million, respectively. The federal tax credits will begin to expire in 2036 while the California tax credits have no expiration date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section&amp;#160;382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section&amp;#160;383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&amp;#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &amp;#8220;ownership change.&amp;#8221; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity related to the Company&amp;#8217;s unrecognized tax benefits for the years ended December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,507&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decreases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; prior year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,035&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decreases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; prior year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the unrecognized tax benefits for uncertain tax positions as of December&amp;#160;31, 2020, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&amp;#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company did not accrue any interest or penalties and does not have any tax positions for interest or penalties for the year ended December&amp;#160;31, 2020. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December&amp;#160;31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the year ended December 31, 2020, the Company recorded a tax reserve of $2.0 million as a reduction of the tax credit carryover. The Company&amp;#8217;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000296" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Related Party Transactions &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its AL001 and AL101 product candidates, and the Company is developing antibodies optimized by Adimab in its AL002 and AL003 product candidates (2014 Adimab Agreement). In August 2019, the Company signed a new collaboration agreement with Adimab for research and development of additional antibodies (2019 Adimab Agreement). The Chief Executive Officer of Adimab is a Co-founder and Chairperson of the board of directors of Alector. For the years ended December&amp;#160;31, 2020, 2019, and 2018, Alector incurred expenses of zero, $2.8&amp;#160;million, and $2.3&amp;#160;million for services provided by Adimab, respectively. The Company had no accrued liabilities due to Adimab as of December 31, 2020 and 2019. Under the 2014 Adimab Agreement, the Company will owe up to $3.5&amp;#160;million in milestone payments per program to Adimab for its product candidates. The Company will also owe low- to mid- single-digit royalty payments for commercial sales of such product candidates. Under the 2019 Adimab Agreement, the Company will owe certain milestone payments per program for its product candidates and low single-digit royalty payments for commercial sales of such product candidates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 30, 2020, in connection with the Company&amp;#8217;s follow-on offering, a member of the Company&amp;#8217;s board of directors purchased 20,000 shares of the Company&amp;#8217;s common stock at the public offering price of $25.00 per share.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000297" contextRef="C_0001653087_20200101_20201231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Net Loss Per Share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,374,836&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock subject to future vesting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;994,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,917,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,654,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,442,824&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,063,688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares committed under ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,677&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,928,100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,482,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,356,372&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000298" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000299" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates&lt;font style="font-style:italic;"&gt;.&lt;/font&gt; &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000300" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000301" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents, and Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. &lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash as of December 31, 2020 relates to a letter of credit established for a lease entered into in June 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,470&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:MarketableSecuritiesPolicy id="F_000302" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All marketable securities have been classified as &amp;#8220;available-for-sale&amp;#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&amp;#8217; equity (deficit) until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&amp;#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&amp;#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, commercial paper, and overnight repurchase agreements collateralized by U.S. treasury securities. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000303" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s believes the carrying value of financial instruments, including cash and cash equivalents, receivables, accounts payable, and accrued liabilities, approximate fair value due to their short-term nature. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&lt;font style="font-style:normal;"&gt; &amp;#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&lt;font style="font-style:normal;"&gt; &amp;#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&lt;font style="font-style:normal;"&gt; &amp;#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. &lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000304" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000305" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted Accounting Standards Update No.&amp;#160;2016-02, &lt;font style="font-style:italic;"&gt;Leases &lt;/font&gt;on January 1, 2019. There was no material effect on the statement of operations upon adoption.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000306" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds is fair value. For the year ended December 31, 2020, the Company recognized a $0.2 million impairment loss on its right-of-use asset related to decision to no longer utilize certain property through the end of the lease term. For the year ended December 31, 2019, the Company recognized a $1.2 million impairment loss on its right of use assets related to the portion of its headquarters being subleased.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock id="F_000307" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when control of promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i)&amp;#160;identify the contract(s) with a customer, (ii)&amp;#160;identify the performance obligations in the contract, (iii)&amp;#160;determine the transaction price, (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract, and (v)&amp;#160;recognize revenue when (or as) the entity satisfies the performance obligation. &lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaboration Revenue &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company signed an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $205.0 million in upfront payments, of which $5.0 million and $200.0 million was received by the Company in October 2017 and January 2018, respectively. The Company will perform research and development services for the antibodies to the two programs through the end of Phase 2 clinical trials which the Company expects to conduct through 2023. AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration agreement with the Company for one or both of the programs for $250.0 million each. If AbbVie exercises its option for the programs, AbbVie will take over the development of the product candidates for such program and costs will be split between the parties. The Company will also share in profits and losses upon commercialization of any products from such program. However, following AbbVie&amp;#8217;s exercise of its option for a program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $242.8 million in milestone payments per program related to the initiation of certain clinical studies and regulatory approval for up to three indications per program. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has determined that there are two research and development performance obligations as part of the agreement with AbbVie, one research and development performance obligation for each of the two research and development programs. The non-refundable upfront cash payments of $5.0&amp;#160;million and $200.0&amp;#160;million received in October 2017 and January 2018, respectively, were included in the transaction price. None of the remaining development and regulatory milestone and program opt-in payment amounts have been included in the transaction price, as all these amounts were fully constrained as of December&amp;#160;31, 2020 and 2019. As part of the Company&amp;#8217;s evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestone amounts is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to royalties on net product sales will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in the Company&amp;#8217;s forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of clinical trials. The Company has had changes to the overall expected costs to satisfy the performance obligations from period to period. For the year ended December 31, 2020, the Company had a 7% increase in the forecast of total expected costs due to changes to the clinical trial plans. For the year ended December 31, 2020, the increase in the overall expected costs to satisfy the performance obligation resulted in an approximately $6.7 million reduction in revenue compared to if the expected costs had remained the same, as a result of the cumulative catch up for the change in estimate. Collaboration revenue under the Company&amp;#8217;s collaboration agreement with AbbVie during 2020, 2019, and 2018 was $21.1 million, $21.2 million, and $27.5&amp;#160;million, respectively. Collaboration revenue recognized during the year ended December 31, 2020, was included in deferred revenue at the beginning of the period. The balance of deferred revenue was $132.3&amp;#160;million as of December&amp;#160;31, 2020. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of Phase 2 clinical trials. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&amp;#8217;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent may pay the Company up to $11.5 million in development milestones, $112.5 million in sales milestones, and future royalties for any sales. The Company retains the rights to develop and commercialize AL008 outside of China. The Company has determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement have not been included in the transaction price, as all these amounts were fully constrained as of December 31, 2020. As of December 31, 2020, no revenue has been recognized or payments received under the Innovent Agreement.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000308" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&amp;#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&amp;#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the grant agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A substantial portion of the Company&amp;#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, contract research organizations in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="F_000309" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation for employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of options to purchase common stock are measured using the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000310" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&amp;#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&amp;#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000311" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&amp;#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:PostemploymentBenefitPlansPolicy id="F_000312" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employee 401(k) Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a qualified contributory savings plan under Section&amp;#160;401(k) of the Internal Revenue Code (the &amp;#8220;Code&amp;#8221;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section&amp;#160;401(k) of the Code. Eligible employees may defer up to 100% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&amp;#8217;s contributions to the plan are discretionary. For the year ended December&amp;#160;31, 2020, the Company made matching contributions of $0.7 million. The Company did not make any matching contributions for the years ended December 31, 2019 or 2018. &lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000313" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment. The Company&amp;#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&amp;#8217;s operations on a consolidated basis for purposes of allocating resources. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000314" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January 1, 2020, the Company adopted Accounting Standards Update (ASU) No. 2016-13, &lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326)&lt;/font&gt;. This ASU implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any changes in estimated credit losses immediately in earnings. There was no material impact to the Company&amp;#8217;s consolidated financial statements from the adoption of ASU No. 2016-13.&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes.&lt;/font&gt; This ASU modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, and the methodology for calculating income taxes in an interim period. The Company has early adopted this ASU as of January 1, 2020. There was no material impact to the Company&amp;#8217;s consolidated financial statements. There was no material impact to the Company&amp;#8217;s consolidated financial statements from the adoption of ASU No. 2019-12.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock id="F_000315" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,641&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,470&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,472&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="F_000316" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&amp;#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Market&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;357,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;358,339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;400,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;401,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&amp;#160;Market&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227,587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,735&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,735&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,103&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000317" contextRef="C_0001653087_20200101_20201231">Property and equipment, net consists of the following:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,610&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,458&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,554&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,265&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,957&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000318" contextRef="C_0001653087_20200101_20201231">Accrued liabilities consist of the following:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued employee compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,094&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,040&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,471&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:LeaseCostTableTextBlock id="F_000319" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income and reimbursement of variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,263&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,556&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="F_000320" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following are the lease payments owed under the Company&amp;#8217;s operating leases as of December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,171&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,130&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Present value adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000321" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized stock-based compensation as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,980&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000322" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated grant-date fair value of all the Company&amp;#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3-6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3 &amp;#8211; 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1 &amp;#8211; 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74%-78%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76% &amp;#8211; 82%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73% &amp;#8211; 81%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3% - 1.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4% &amp;#8211; 2.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5% &amp;#8211; 3.1%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock id="F_000323" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity for the restricted common stock is shown below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,917,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(866,037&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;994,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(726,659&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(81,754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000324" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity for the options to purchase common stock shown below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,063,688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,738,071&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(178,648&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,442,824&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,597,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(655,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(729,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,654,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,588,568&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,393&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest as of December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,654,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000325" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the federal statutory rate to the Company&amp;#8217;s effective tax rate is as follows for the years ended December&amp;#160;31, 2020, 2019, and 2018 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefit at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,972&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,694&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,010&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,387&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Uncertain tax positions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,044&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;708&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nondeductible expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefit recognized on utilization of attributes previous reserved&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,582&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred adjustment from amended tax return&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,073&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,346&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Others&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000326" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effects of temporary differences that give rise to significant components of the Company&amp;#8217;s deferred tax assets consist of (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,129&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Others&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,538&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(105,226&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,990&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Others&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(150&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock id="F_000327" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity related to the Company&amp;#8217;s unrecognized tax benefits for the years ended December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,507&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decreases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; prior year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,035&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decreases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; prior year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(446&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases related to tax positions taken during the&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,592&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000328" contextRef="C_0001653087_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,374,836&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock subject to future vesting&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;994,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,917,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,654,998&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,442,824&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,063,688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares committed under ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,677&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,928,100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,482,126&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,356,372&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000329" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207_20190207" decimals="INF" unitRef="U_xbrlishares">9739541</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000330" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207" decimals="INF" unitRef="U_iso4217USD_xbrlishares">19.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000331" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207_20190207" decimals="-5" unitRef="U_iso4217USD">168200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000332" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000333" contextRef="C_0001653087_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190207" decimals="INF" unitRef="U_xbrlishares">45374836</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000334" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20190207_20190207" decimals="INF" unitRef="U_xbrlishares">489541</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000335" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200129_20200130" decimals="INF" unitRef="U_xbrlishares">9602500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000336" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200130" decimals="INF" unitRef="U_iso4217USD_xbrlishares">25.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000337" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200129_20200130" decimals="-5" unitRef="U_iso4217USD">224500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000338" contextRef="C_0001653087_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200129_20200130" decimals="INF" unitRef="U_xbrlishares">1252500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000339" contextRef="C_0001653087_20181231" decimals="-3" unitRef="U_iso4217USD">65470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashNoncurrent id="F_000340" contextRef="C_0001653087_20181231" decimals="-3" unitRef="U_iso4217USD">1472000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:MarketableSecuritiesGainLoss id="F_000341" contextRef="C_0001653087_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:MarketableSecuritiesGainLoss id="F_000342" contextRef="C_0001653087_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000343" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000344" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <alec:CollaborativeArrangementUpfrontPayments id="F_000345" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20171001_20171031" decimals="-5" unitRef="U_iso4217USD">205000000</alec:CollaborativeArrangementUpfrontPayments>
  <us-gaap:ProceedsFromCollaborators id="F_000346" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20171001_20171031" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="F_000347" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20180101_20180131" decimals="-5" unitRef="U_iso4217USD">200000000</us-gaap:ProceedsFromCollaborators>
  <alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram id="F_000348" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20171001_20171031" decimals="-5" unitRef="U_iso4217USD">250000000</alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram>
  <alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram id="F_000349" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_srtRangeAxis_srtMaximumMember_20171031" decimals="-5" unitRef="U_iso4217USD">242800000</alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram>
  <alec:NonRefundableUpfrontPaymentReceivedInCash id="F_000350" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20171001_20171031" decimals="-5" unitRef="U_iso4217USD">5000000</alec:NonRefundableUpfrontPaymentReceivedInCash>
  <alec:NonRefundableUpfrontPaymentReceivedInCash id="F_000351" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_20180101_20180131" decimals="-5" unitRef="U_iso4217USD">200000000</alec:NonRefundableUpfrontPaymentReceivedInCash>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000352" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">21100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000353" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">21200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000354" contextRef="C_0001653087_srtCounterpartyNameAxis_alecAbbVieBiotechnologyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">27500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiability id="F_000355" contextRef="C_0001653087_20201231" decimals="-5" unitRef="U_iso4217USD">132300000</us-gaap:ContractWithCustomerLiability>
  <alec:PercentageOfChangeInForecastOfExpectedCosts id="F_000356" contextRef="C_0001653087_20201231" decimals="2" unitRef="U_xbrlipure">0.07</alec:PercentageOfChangeInForecastOfExpectedCosts>
  <alec:ReductionInRevenueDueToIncreaseInBudgetDuringYear id="F_000357" contextRef="C_0001653087_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">6700000</alec:ReductionInRevenueDueToIncreaseInBudgetDuringYear>
  <alec:DevelopmentMilestone id="F_000358" contextRef="C_0001653087_srtCounterpartyNameAxis_alecInnoventBiologicsMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">11500000</alec:DevelopmentMilestone>
  <alec:SalesMilestone id="F_000359" contextRef="C_0001653087_srtCounterpartyNameAxis_alecInnoventBiologicsMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">112500000</alec:SalesMilestone>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000360" contextRef="C_0001653087_srtCounterpartyNameAxis_alecInnoventBiologicsMember_20200101_20201231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000361" contextRef="C_0001653087_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000362" contextRef="C_0001653087_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000363" contextRef="C_0001653087_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000364" contextRef="C_0001653087_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000365" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">37951000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AssetsFairValueDisclosure id="F_000366" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">37951000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000367" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">357725000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000368" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">620000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000369" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AssetsFairValueDisclosure id="F_000370" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">358339000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000371" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AssetsFairValueDisclosure id="F_000372" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000373" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">400676000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000374" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">620000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000375" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AssetsFairValueDisclosure id="F_000376" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">401290000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000377" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">61104000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000378" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">43735000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000379" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">10103000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000380" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000381" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AssetsFairValueDisclosure id="F_000382" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">61104000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000383" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">43735000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000384" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapCorporateBondSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">10104000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000385" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">227446000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000386" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000387" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AssetsFairValueDisclosure id="F_000388" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">227587000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000389" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">342388000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000390" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">152000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000391" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AssetsFairValueDisclosure id="F_000392" contextRef="C_0001653087_us-gaapFairValueByAssetClassAxis_alecCashEquivalentsAndMarketableSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">342530000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000393" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000394" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue id="F_000395" contextRef="C_0001653087_20201231" decimals="-5" unitRef="U_iso4217USD">336900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <alec:AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue id="F_000396" contextRef="C_0001653087_20201231" decimals="-5" unitRef="U_iso4217USD">64400000</alec:AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000397" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">25542000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000398" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">25222000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000399" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecLabEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">11610000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000400" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecLabEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">10458000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000401" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">2222000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000402" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">2031000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000403" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">1764000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000404" contextRef="C_0001653087_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">1554000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000405" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">41138000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000406" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">39265000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000407" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">10957000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000408" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">5413000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <alec:AccruedResearchAndDevelopmentCosts id="F_000409" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">13375000</alec:AccruedResearchAndDevelopmentCosts>
  <alec:AccruedResearchAndDevelopmentCosts id="F_000410" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">6400000</alec:AccruedResearchAndDevelopmentCosts>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000411" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">7288000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000412" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">5730000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000413" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">1094000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000414" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">2040000</us-gaap:AccruedProfessionalFeesCurrent>
  <alec:AccruedPropertyAndEquipmentCurrent id="F_000415" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">428000</alec:AccruedPropertyAndEquipmentCurrent>
  <alec:AccruedPropertyAndEquipmentCurrent id="F_000416" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">3471000</alec:AccruedPropertyAndEquipmentCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000417" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">353000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000418" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">615000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <alec:AreaOfPropertyInLease id="F_000419" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20180601_20180630" decimals="0" unitRef="U_utrsqft">105000</alec:AreaOfPropertyInLease>
  <us-gaap:PaymentsForProceedsFromTenantAllowance id="F_000420" contextRef="C_0001653087_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">15700000</us-gaap:PaymentsForProceedsFromTenantAllowance>
  <alec:LeaseExpirationYear id="F_000421" contextRef="C_0001653087_20200101_20201231">2029</alec:LeaseExpirationYear>
  <us-gaap:LesseeOperatingLeaseRenewalTerm id="F_000422" contextRef="C_0001653087_20201231">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="F_000423" contextRef="C_0001653087_20200101_20201231">The lease expires in 2029 with an option to renew for a period of ten years</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <us-gaap:AreaOfRealEstateProperty id="F_000424" contextRef="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201031" decimals="0" unitRef="U_utrsqft">18700</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000425" contextRef="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231">In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements</us-gaap:LesseeOperatingLeaseDescription>
  <us-gaap:LeaseExpirationDate1 id="F_000426" contextRef="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201001_20201031">2028-02-06</us-gaap:LeaseExpirationDate1>
  <us-gaap:LessorOperatingLeaseRenewalTerm id="F_000427" contextRef="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201031">P5Y</us-gaap:LessorOperatingLeaseRenewalTerm>
  <us-gaap:PaymentsForProceedsFromTenantAllowance id="F_000428" contextRef="C_0001653087_srtStatementGeographicalAxis_alecNewarkCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201001_20201031" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:PaymentsForProceedsFromTenantAllowance>
  <alec:AreaOfPropertyInSubleaseAgreement id="F_000429" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20190501_20190531" decimals="0" unitRef="U_utrsqft">25000</alec:AreaOfPropertyInSubleaseAgreement>
  <alec:AreaOfPropertyInLease id="F_000430" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20201201_20201231" decimals="0" unitRef="U_utrsqft">23600</alec:AreaOfPropertyInLease>
  <alec:SubleaseExpirationMonthAndYear id="F_000431" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231">2021-11</alec:SubleaseExpirationMonthAndYear>
  <us-gaap:LesseeOperatingSubleaseOptionToExtend id="F_000432" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231">The sublessor has the option to extend the Sublease for one additional year subject to the consent of the Company.</us-gaap:LesseeOperatingSubleaseOptionToExtend>
  <alec:LesseeOperatingSubleaseRenewalTerm id="F_000433" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20190501_20190531">P1Y</alec:LesseeOperatingSubleaseRenewalTerm>
  <us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend id="F_000434" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231">true</us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend>
  <us-gaap:OperatingLeaseImpairmentLoss id="F_000435" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:OperatingLeaseImpairmentLoss>
  <alec:OngoingLossOverSubleasePeriod id="F_000436" contextRef="C_0001653087_srtStatementGeographicalAxis_alecSouthSanFranciscoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_alecOfficesAndLaboratoryFacilitiesMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</alec:OngoingLossOverSubleasePeriod>
  <us-gaap:OperatingLeaseCost id="F_000437" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5589000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000438" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5875000</us-gaap:OperatingLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000439" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2255000</us-gaap:VariableLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000440" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1328000</us-gaap:VariableLeaseCost>
  <us-gaap:ShortTermLeaseCost id="F_000441" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">68000</us-gaap:ShortTermLeaseCost>
  <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1 id="F_000442" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2288000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
  <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1 id="F_000443" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1263000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
  <us-gaap:LeaseCost id="F_000444" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5556000</us-gaap:LeaseCost>
  <us-gaap:LeaseCost id="F_000445" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6008000</us-gaap:LeaseCost>
  <us-gaap:OperatingLeaseExpense id="F_000446" contextRef="C_0001653087_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000447" contextRef="C_0001653087_20201231">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000448" contextRef="C_0001653087_20201231" decimals="3" unitRef="U_xbrlipure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeasePayments id="F_000449" contextRef="C_0001653087_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">6900000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments id="F_000450" contextRef="C_0001653087_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">3200000</us-gaap:OperatingLeasePayments>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000451" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">7872000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000452" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">8171000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000453" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">8436000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000454" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">8732000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="F_000455" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">9037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="F_000456" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">30130000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000457" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">72378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000458" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">21122000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiability id="F_000459" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">51256000</us-gaap:OperatingLeaseLiability>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000460" contextRef="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">14980000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000461" contextRef="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8031000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000462" contextRef="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">4195000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000463" contextRef="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">15542000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000464" contextRef="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8250000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000465" contextRef="C_0001653087_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2730000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000466" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30522000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000467" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16281000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000468" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">6925000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000469" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000470" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000471" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000472" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000473" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000474" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000475" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000476" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000477" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000478" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000479" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000480" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000481" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000482" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000483" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000484" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000485" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000486" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000487" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000488" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000489" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000490" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000491" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000492" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">1917848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000493" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">866037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_000494" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">56973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000495" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">994838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000496" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">726659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_000497" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">81754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000498" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">186425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000499" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_000500" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="F_000501" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000502" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_000503" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="F_000504" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000505" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="F_000506" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000507" contextRef="C_0001653087_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">P9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000508" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">15628217</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <alec:PercentageOfStockOwnedByIndividual id="F_000509" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206" decimals="2" unitRef="U_xbrlipure">0.10</alec:PercentageOfStockOwnedByIndividual>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="F_000510" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206" decimals="INF" unitRef="U_xbrlipure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000511" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000512" contextRef="C_0001653087_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000513" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage id="F_000514" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206" decimals="INF" unitRef="U_xbrlipure">0.25</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage>
  <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod id="F_000515" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190205_20190206">P1Y</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000516" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190206" decimals="INF" unitRef="U_xbrlishares">2973219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000517" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20181231" decimals="INF" unitRef="U_xbrlishares">5063688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000518" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">3738071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000519" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">180287</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000520" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">178648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000521" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">8442824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000522" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">5597148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000523" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">655772</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000524" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">729202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000525" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">12654998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000526" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">3588568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000527" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">12654998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000528" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000529" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">17.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000530" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000531" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">11.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000532" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">12.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000533" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">15.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000534" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">9.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000535" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000536" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">13.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000537" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">12.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000538" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">13.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000539" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_000540" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000541" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000542" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000543" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000544" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000545" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">39633000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000546" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">13393000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="F_000547" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">39633000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000548" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="-5" unitRef="U_iso4217USD">11100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000549" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20191231" decimals="-5" unitRef="U_iso4217USD">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000550" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20181231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000551" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="-5" unitRef="U_iso4217USD">82900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000552" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000553" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000554" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000555" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEquityIncentivePlanMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate id="F_000556" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEmployeeStockPurchasePlanMember_20190205_20190206" decimals="INF" unitRef="U_xbrlipure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
  <alec:SubsequentOfferingPeriod id="F_000557" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEmployeeStockPurchasePlanMember_20190205_20190206">P6M</alec:SubsequentOfferingPeriod>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000558" contextRef="C_0001653087_us-gaapPlanNameAxis_alecTwoThousandNineteenEmployeeStockPurchasePlanMember_20201231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000559" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-39948000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000560" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-22081000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000561" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-10972000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000562" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">16570000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000563" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4694000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationTaxCredits id="F_000564" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8010000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <us-gaap:IncomeTaxReconciliationTaxCredits id="F_000565" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6530000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <us-gaap:IncomeTaxReconciliationTaxCredits id="F_000566" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2387000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease id="F_000567" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2003000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
  <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease id="F_000568" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2044000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
  <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease id="F_000569" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">708000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000570" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">353000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000571" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1493000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000572" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1251000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense id="F_000573" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">51000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense id="F_000574" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">124000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense id="F_000575" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">58000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <alec:IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved id="F_000576" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">13582000</alec:IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved>
  <alec:IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn id="F_000577" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1073000</alec:IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000578" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">62280000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000579" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">44748000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000580" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">11346000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000581" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-159000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000582" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-449000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000583" contextRef="C_0001653087_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-4000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000584" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">54382000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000585" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">2223000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000586" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">1201000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000587" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">370000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000588" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">13000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000589" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">7319000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000590" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">6493000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000591" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">2015000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000592" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">32129000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000593" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">37621000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <alec:DeferredTaxAssetsLeaseLiabilities id="F_000594" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">12457000</alec:DeferredTaxAssetsLeaseLiabilities>
  <alec:DeferredTaxAssetsLeaseLiabilities id="F_000595" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">11781000</alec:DeferredTaxAssetsLeaseLiabilities>
  <us-gaap:DeferredTaxAssetsOther id="F_000596" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">463000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000597" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">209000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross id="F_000598" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">120125000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000599" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">61538000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000600" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">105226000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000601" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">47053000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="F_000602" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">14899000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="F_000603" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">14485000</us-gaap:DeferredTaxAssetsNet>
  <alec:DeferredTaxLiabilitiesDepreciationAndAmortization id="F_000604" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">6815000</alec:DeferredTaxLiabilitiesDepreciationAndAmortization>
  <alec:DeferredTaxLiabilitiesDepreciationAndAmortization id="F_000605" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">7495000</alec:DeferredTaxLiabilitiesDepreciationAndAmortization>
  <alec:DeferredTaxLiabilitiesRightOfUseAssets id="F_000606" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">7934000</alec:DeferredTaxLiabilitiesRightOfUseAssets>
  <alec:DeferredTaxLiabilitiesRightOfUseAssets id="F_000607" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">6990000</alec:DeferredTaxLiabilitiesRightOfUseAssets>
  <us-gaap:DeferredTaxLiabilitiesOther id="F_000608" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">150000</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000609" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">14899000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000610" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">14485000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000611" contextRef="C_0001653087_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">58200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:OperatingLossCarryforwards id="F_000612" contextRef="C_0001653087_us-gaapIncomeTaxAuthorityAxis_alecDomesticAndStateTaxAuthorityMember_20201231" decimals="-5" unitRef="U_iso4217USD">195300000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther id="F_000613" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
  <alec:OperatingLossCarryforwardsBeginningExpirationYear id="F_000614" contextRef="C_0001653087_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2030</alec:OperatingLossCarryforwardsBeginningExpirationYear>
  <us-gaap:OperatingLossCarryforwards id="F_000615" contextRef="C_0001653087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">191400000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000616" contextRef="C_0001653087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">14400000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000617" contextRef="C_0001653087_us-gaapIncomeTaxAuthorityNameAxis_us-gaapCaliforniaFranchiseTaxBoardMember_20201231" decimals="-5" unitRef="U_iso4217USD">3800000</us-gaap:TaxCreditCarryforwardAmount>
  <alec:TaxCreditBeginningExpirationYear id="F_000618" contextRef="C_0001653087_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2036</alec:TaxCreditBeginningExpirationYear>
  <us-gaap:UnrecognizedTaxBenefits id="F_000619" contextRef="C_0001653087_20181231" decimals="-3" unitRef="U_iso4217USD">1507000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions id="F_000620" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">80000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000621" contextRef="C_0001653087_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1608000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefits id="F_000622" contextRef="C_0001653087_20191231" decimals="-3" unitRef="U_iso4217USD">3035000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions id="F_000623" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">446000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000624" contextRef="C_0001653087_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2003000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefits id="F_000625" contextRef="C_0001653087_20201231" decimals="-3" unitRef="U_iso4217USD">4592000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000626" contextRef="C_0001653087_20201231" decimals="-5" unitRef="U_iso4217USD">2000000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000627" contextRef="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20200101_20201231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000628" contextRef="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">2800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000629" contextRef="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000630" contextRef="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000631" contextRef="C_0001653087_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecAdimabMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrent>
  <alec:FutureMilestonePaymentsOwed id="F_000632" contextRef="C_0001653087_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alecTwoThousandFourteenAdimabAgreementMember_20201231" decimals="INF" unitRef="U_iso4217USD">3500000</alec:FutureMilestonePaymentsOwed>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000633" contextRef="C_0001653087_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200129_20200130" decimals="INF" unitRef="U_xbrlishares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000634" contextRef="C_0001653087_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapSubsidiarySaleOfStockAxis_alecFollowOnPublicOfferingMember_20200130" decimals="2" unitRef="U_iso4217USD_xbrlishares">25.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000635" contextRef="C_0001653087_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">45374836</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000636" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">186425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000637" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">994838</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000638" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">1917848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000639" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">12654998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000640" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">8442824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000641" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">5063688</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000642" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">86677</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000643" contextRef="C_0001653087_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">44464</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000644" contextRef="C_0001653087_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">12928100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000645" contextRef="C_0001653087_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">9482126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000646" contextRef="C_0001653087_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">52356372</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>alec-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T23:12:00.6402922+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6dc947f9232049b49804e807205611da -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:alec="http://www.alector.com/20201231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alector.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.alector.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidity" id="Role_DisclosureTheCompanyAndLiquidity">
        <link:definition>100070 - Disclosure - The Company and Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100100 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureCommitmentAndContingencies" id="Role_DisclosureCommitmentAndContingencies">
        <link:definition>100110 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100120 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100130 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100140 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100150 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100160 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100180 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100190 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100200 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100210 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100220 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100230 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100240 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" id="Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
        <link:definition>100250 - Disclosure - The Company and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100280 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100300 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
        <link:definition>100310 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" id="Role_DisclosureLeasesComponentsOfLeaseExpenseDetail">
        <link:definition>100330 - Disclosure - Leases - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" id="Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail">
        <link:definition>100340 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company&apos;s Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail2" id="Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail2">
        <link:definition>100350 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company&apos;s Operating Leases (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
        <link:definition>100360 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" id="Role_DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>100370 - Disclosure - Stock-based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails">
        <link:definition>100390 - Disclosure - Stock-based Compensation - Summary of Restricted Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" id="Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails">
        <link:definition>100400 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100410 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100420 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100440 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100460 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="alec_AccruedClinicalSupplyCost" name="AccruedClinicalSupplyCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_RevenueFromGrant" name="RevenueFromGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" name="TemporaryStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_IssuanceCostsOfCommonStock" name="IssuanceCostsOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_IssuanceCostOfPreferredStock" name="IssuanceCostOfPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_AmortizationRightOfUseAsset" name="AmortizationRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" name="IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" name="ProceedsFromPaymentsForIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" name="ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" name="DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_AbbVieBiotechnologyLimitedMember" name="AbbVieBiotechnologyLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_InnoventBiologicsMember" name="InnoventBiologicsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_CollaborativeArrangementUpfrontPayments" name="CollaborativeArrangementUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" name="CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" name="CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_NonRefundableUpfrontPaymentReceivedInCash" name="NonRefundableUpfrontPaymentReceivedInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_PercentageOfChangeInForecastOfExpectedCosts" name="PercentageOfChangeInForecastOfExpectedCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" name="ReductionInRevenueDueToIncreaseInBudgetDuringYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_DevelopmentMilestone" name="DevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_SalesMilestone" name="SalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_CashEquivalentsAndMarketableSecuritiesMember" name="CashEquivalentsAndMarketableSecuritiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_LabEquipmentMember" name="LabEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_AccruedResearchAndDevelopmentCosts" name="AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_AccruedPropertyAndEquipmentCurrent" name="AccruedPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_OngoingLossOverSubleasePeriod" name="OngoingLossOverSubleasePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_AreaOfPropertyInLease" name="AreaOfPropertyInLease" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_AreaOfPropertyInSubleaseAgreement" name="AreaOfPropertyInSubleaseAgreement" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_SubleaseExpirationMonthAndYear" name="SubleaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_LesseeOperatingSubleaseRenewalTerm" name="LesseeOperatingSubleaseRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_OfficesAndLaboratoryFacilitiesMember" name="OfficesAndLaboratoryFacilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_SouthSanFranciscoMember" name="SouthSanFranciscoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_NewarkCaliforniaMember" name="NewarkCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" name="SubleaseIncomeAndReimbursementOfVariableLeaseCost1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_PercentageOfStockOwnedByIndividual" name="PercentageOfStockOwnedByIndividual" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_SubsequentOfferingPeriod" name="SubsequentOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" name="IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" name="IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_DomesticAndStateTaxAuthorityMember" name="DomesticAndStateTaxAuthorityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_OperatingLossCarryforwardsBeginningExpirationYear" name="OperatingLossCarryforwardsBeginningExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_TaxCreditBeginningExpirationYear" name="TaxCreditBeginningExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alec_FutureMilestonePaymentsOwed" name="FutureMilestonePaymentsOwed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alec_AdimabMember" name="AdimabMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alec_TwoThousandFourteenAdimabAgreementMember" name="TwoThousandFourteenAdimabAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>32
<FILENAME>alec-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T23:12:00.6402922+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6dc947f9232049b49804e807205611da -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="alec-20201231.xsd#TemplateLink" roleURI="http://www.alector.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedClinicalSupplyCost" xlink:type="locator" xlink:label="alec_AccruedClinicalSupplyCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="alec_AccruedClinicalSupplyCost" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:href="alec-20201231.xsd#alec_RevenueFromGrant" xlink:type="locator" xlink:label="alec_RevenueFromGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="alec_RevenueFromGrant" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:type="locator" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AmortizationRightOfUseAsset" xlink:type="locator" xlink:label="alec_AmortizationRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_AmortizationRightOfUseAsset" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10250.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="alec-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alec-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="alec-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:href="alec-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:type="locator" xlink:label="alec_AccruedPropertyAndEquipmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:type="locator" xlink:label="alec_AccruedResearchAndDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alec_AccruedResearchAndDevelopmentCosts" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alec_AccruedPropertyAndEquipmentCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="alec-20201231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:type="locator" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" order="10040.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail2" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" xlink:type="locator" xlink:label="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" xlink:type="locator" xlink:label="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alec-20201231.xsd#Role_DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="locator" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>33
<FILENAME>alec-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T23:12:00.6412926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6dc947f9232049b49804e807205611da -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="alec-20201231.xsd#TemplateLink" roleURI="http://www.alector.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="alec-20201231.xsd#alec_IssuanceCostsOfCommonStock" xlink:type="locator" xlink:label="alec_IssuanceCostsOfCommonStock" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IssuanceCostOfPreferredStock" xlink:type="locator" xlink:label="alec_IssuanceCostOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostOfPreferredStock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostsOfCommonStock" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="alec-20201231.xsd#alec_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alec_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="locator" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10590.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SalesMilestone" xlink:type="locator" xlink:label="alec_SalesMilestone" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DevelopmentMilestone" xlink:type="locator" xlink:label="alec_DevelopmentMilestone" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" xlink:type="locator" xlink:label="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" />
    <link:loc xlink:href="alec-20201231.xsd#alec_PercentageOfChangeInForecastOfExpectedCosts" xlink:type="locator" xlink:label="alec_PercentageOfChangeInForecastOfExpectedCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="alec-20201231.xsd#alec_NonRefundableUpfrontPaymentReceivedInCash" xlink:type="locator" xlink:label="alec_NonRefundableUpfrontPaymentReceivedInCash" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:type="locator" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:type="locator" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:type="locator" xlink:label="alec_CollaborativeArrangementUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:loc xlink:href="alec-20201231.xsd#alec_InnoventBiologicsMember" xlink:type="locator" xlink:label="alec_InnoventBiologicsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:type="locator" xlink:label="alec_AbbVieBiotechnologyLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_InnoventBiologicsMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_CollaborativeArrangementUpfrontPayments" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_NonRefundableUpfrontPaymentReceivedInCash" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_PercentageOfChangeInForecastOfExpectedCosts" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_DevelopmentMilestone" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SalesMilestone" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="11650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alec-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:type="locator" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="13310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="13390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="13470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="13550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="alec-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_LabEquipmentMember" xlink:type="locator" xlink:label="alec_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_LabEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OngoingLossOverSubleasePeriod" xlink:type="locator" xlink:label="alec_OngoingLossOverSubleasePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="alec-20201231.xsd#alec_LesseeOperatingSubleaseRenewalTerm" xlink:type="locator" xlink:label="alec_LesseeOperatingSubleaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:type="locator" xlink:label="alec_SubleaseExpirationMonthAndYear" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:type="locator" xlink:label="alec_AreaOfPropertyInSubleaseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="alec-20201231.xsd#alec_LeaseExpirationYear" xlink:type="locator" xlink:label="alec_LeaseExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AreaOfPropertyInLease" xlink:type="locator" xlink:label="alec_AreaOfPropertyInLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_NewarkCaliforniaMember" xlink:type="locator" xlink:label="alec_NewarkCaliforniaMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SouthSanFranciscoMember" xlink:type="locator" xlink:label="alec_SouthSanFranciscoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:type="locator" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_SouthSanFranciscoMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_NewarkCaliforniaMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInLease" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LeaseExpirationYear" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInSubleaseAgreement" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_SubleaseExpirationMonthAndYear" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LesseeOperatingSubleaseRenewalTerm" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_OngoingLossOverSubleasePeriod" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SubsequentOfferingPeriod" xlink:type="locator" xlink:label="alec_SubsequentOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:type="locator" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:type="locator" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:type="locator" xlink:label="alec_PercentageOfStockOwnedByIndividual" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_PercentageOfStockOwnedByIndividual" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_SubsequentOfferingPeriod" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10990.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="13390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="alec-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="alec-20201231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:type="locator" xlink:label="alec_TaxCreditBeginningExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:type="locator" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="locator" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:type="locator" xlink:label="alec_DomesticAndStateTaxAuthorityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="alec_DomesticAndStateTaxAuthorityMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxCreditBeginningExpirationYear" order="10650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="alec-20201231.xsd#alec_FutureMilestonePaymentsOwed" xlink:type="locator" xlink:label="alec_FutureMilestonePaymentsOwed" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alec_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:type="locator" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AdimabMember" xlink:type="locator" xlink:label="alec_AdimabMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_AdimabMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alec_FutureMilestonePaymentsOwed" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="alec-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>34
<FILENAME>alec-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T23:12:00.6412926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6dc947f9232049b49804e807205611da -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedClinicalSupplyCost" xlink:type="locator" xlink:label="alec_AccruedClinicalSupplyCost" />
    <link:label xml:lang="en-US" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical supply cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedClinicalSupplyCost" xlink:to="alec_AccruedClinicalSupplyCost_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical supply costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Supply Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, long-term portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, long-term portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 5)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 200,000,000 shares authorized; 79,316,261 and 69,052,873 shares issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_RevenueFromGrant" xlink:type="locator" xlink:label="alec_RevenueFromGrant" />
    <link:label xml:lang="en-US" xlink:label="alec_RevenueFromGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue earned during the period money awarded to an entity to carry out a specific purpose as provided in grants agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_RevenueFromGrant" xlink:to="alec_RevenueFromGrant_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_RevenueFromGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_RevenueFromGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used in computing net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under employee stock purchase plan (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E convertible preferred stock, net of costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture/Cancellation of restricted common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture/Cancellation of restricted common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Forfeited</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_IssuanceCostsOfCommonStock" xlink:type="locator" xlink:label="alec_IssuanceCostsOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="alec_IssuanceCostsOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance cost of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IssuanceCostsOfCommonStock" xlink:to="alec_IssuanceCostsOfCommonStock_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IssuanceCostOfPreferredStock" xlink:type="locator" xlink:label="alec_IssuanceCostOfPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="alec_IssuanceCostOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance cost of preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IssuanceCostOfPreferredStock" xlink:to="alec_IssuanceCostOfPreferredStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IssuanceCostOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost of convertible preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IssuanceCostOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Cost Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IssuanceCostsOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IssuanceCostsOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Common Stock</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_AmortizationRightOfUseAsset" xlink:type="locator" xlink:label="alec_AmortizationRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization right of use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AmortizationRightOfUseAsset" xlink:to="alec_AmortizationRightOfUseAsset_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:type="locator" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" />
    <link:label xml:lang="en-US" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in accrued liabilities and accrued clinical supply costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInLeaseLiabilities" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from (payments for) issuance of common stock as part of an initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" xlink:to="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from (payments for) issuance of convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" xlink:to="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs for public offerings included in accounts payable and accrued liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss on right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from disposal of property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and accrued clinical supply costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon follow-on public offering, net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Upon Follow On Public Offering Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments To Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of options to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of stock from employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs in accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs For Public Offerings Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:type="locator" xlink:label="us-gaap_PaymentsForTenantImprovements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements paid by landlord</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForTenantImprovements" xlink:to="us-gaap_PaymentsForTenantImprovements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Tenant Improvements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company and Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment or Disposal of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee 401 (K) Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefit Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Payments Owed Under Company&apos;s Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Recognized Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Options to Purchase Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="locator" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alec_FollowOnPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow On Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_FollowOnPublicOfferingMember" xlink:to="alec_FollowOnPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on-offering</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offerings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:type="locator" xlink:label="alec_AbbVieBiotechnologyLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AbbVie biotechnology, limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AbbVieBiotechnologyLimitedMember" xlink:to="alec_AbbVieBiotechnologyLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AbbVie Biotechnology Limited</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Abb Vie Biotechnology Limited [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Transaction With Party To Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_InnoventBiologicsMember" xlink:type="locator" xlink:label="alec_InnoventBiologicsMember" />
    <link:label xml:lang="en-US" xlink:label="alec_InnoventBiologicsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Innovent Biologics.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_InnoventBiologicsMember" xlink:to="alec_InnoventBiologicsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_InnoventBiologicsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innovent</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_InnoventBiologicsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Innovent Biologics [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains or loss on money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit losses on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Gain Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant, and equipment useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:type="locator" xlink:label="alec_CollaborativeArrangementUpfrontPayments" />
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, upfront payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementUpfrontPayments" xlink:to="alec_CollaborativeArrangementUpfrontPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Upfront Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:type="locator" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" />
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, milestone payments on option rights exercised per program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:type="locator" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" />
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, additional milestone payments receivable per program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive option rights exercised for each program</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payments On Option Rights Exercised Per Program</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Milestone Payments Receivable Per Program</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_NonRefundableUpfrontPaymentReceivedInCash" xlink:type="locator" xlink:label="alec_NonRefundableUpfrontPaymentReceivedInCash" />
    <link:label xml:lang="en-US" xlink:label="alec_NonRefundableUpfrontPaymentReceivedInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payment received in cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_NonRefundableUpfrontPaymentReceivedInCash" xlink:to="alec_NonRefundableUpfrontPaymentReceivedInCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_NonRefundableUpfrontPaymentReceivedInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment received, non-refundable</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_NonRefundableUpfrontPaymentReceivedInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment Received In Cash</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_PercentageOfChangeInForecastOfExpectedCosts" xlink:type="locator" xlink:label="alec_PercentageOfChangeInForecastOfExpectedCosts" />
    <link:label xml:lang="en-US" xlink:label="alec_PercentageOfChangeInForecastOfExpectedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of change in forecast of expected costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PercentageOfChangeInForecastOfExpectedCosts" xlink:to="alec_PercentageOfChangeInForecastOfExpectedCosts_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" xlink:type="locator" xlink:label="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" />
    <link:label xml:lang="en-US" xlink:label="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in revenue due to increase in budget during the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" xlink:to="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_PercentageOfChangeInForecastOfExpectedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in the forecast of total expected costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_PercentageOfChangeInForecastOfExpectedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Change In Forecast Of Expected Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in revenue due to increase in budget during the year</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduction In Revenue Due To Increase In Budget During Year</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_DevelopmentMilestone" xlink:type="locator" xlink:label="alec_DevelopmentMilestone" />
    <link:label xml:lang="en-US" xlink:label="alec_DevelopmentMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DevelopmentMilestone" xlink:to="alec_DevelopmentMilestone_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SalesMilestone" xlink:type="locator" xlink:label="alec_SalesMilestone" />
    <link:label xml:lang="en-US" xlink:label="alec_SalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SalesMilestone" xlink:to="alec_SalesMilestone_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_DevelopmentMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DevelopmentMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum annual contributions per employee, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined matching contribution plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Government Treasury Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:type="locator" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash equivalents and marketable securities, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities, Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash equivalents and marketable securities, Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities, Fair Market Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:type="locator" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of assets transferred from level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of assets transferred from level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of investments were less than one year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of investments were less than one year through two years</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_LabEquipmentMember" xlink:type="locator" xlink:label="alec_LabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="alec_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_LabEquipmentMember" xlink:to="alec_LabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:type="locator" xlink:label="alec_AccruedResearchAndDevelopmentCosts" />
    <link:label xml:lang="en-US" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedResearchAndDevelopmentCosts" xlink:to="alec_AccruedResearchAndDevelopmentCosts_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:type="locator" xlink:label="alec_AccruedPropertyAndEquipmentCurrent" />
    <link:label xml:lang="en-US" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued property and equipment current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedPropertyAndEquipmentCurrent" xlink:to="alec_AccruedPropertyAndEquipmentCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Property And Equipment Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_LeaseExpirationYear" xlink:type="locator" xlink:label="alec_LeaseExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="alec_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_LeaseExpirationYear" xlink:to="alec_LeaseExpirationYear_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OngoingLossOverSubleasePeriod" xlink:type="locator" xlink:label="alec_OngoingLossOverSubleasePeriod" />
    <link:label xml:lang="en-US" xlink:label="alec_OngoingLossOverSubleasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount recognized in operating expense over the term of the sublease related to the sublease impairment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OngoingLossOverSubleasePeriod" xlink:to="alec_OngoingLossOverSubleasePeriod_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AreaOfPropertyInLease" xlink:type="locator" xlink:label="alec_AreaOfPropertyInLease" />
    <link:label xml:lang="en-US" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of property in lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AreaOfPropertyInLease" xlink:to="alec_AreaOfPropertyInLease_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:type="locator" xlink:label="alec_AreaOfPropertyInSubleaseAgreement" />
    <link:label xml:lang="en-US" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of property in sublease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AreaOfPropertyInSubleaseAgreement" xlink:to="alec_AreaOfPropertyInSubleaseAgreement_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:type="locator" xlink:label="alec_SubleaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubleaseExpirationMonthAndYear" xlink:to="alec_SubleaseExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_LesseeOperatingSubleaseRenewalTerm" xlink:type="locator" xlink:label="alec_LesseeOperatingSubleaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="alec_LesseeOperatingSubleaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease renewal term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_LesseeOperatingSubleaseRenewalTerm" xlink:to="alec_LesseeOperatingSubleaseRenewalTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:type="locator" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Offices and laboratory facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OfficesAndLaboratoryFacilitiesMember" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offices and Laboratory Facilities</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Offices And Laboratory Facilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_SouthSanFranciscoMember" xlink:type="locator" xlink:label="alec_SouthSanFranciscoMember" />
    <link:label xml:lang="en-US" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SouthSanFranciscoMember" xlink:to="alec_SouthSanFranciscoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco [Member]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_NewarkCaliforniaMember" xlink:type="locator" xlink:label="alec_NewarkCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Newark, California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_NewarkCaliforniaMember" xlink:to="alec_NewarkCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Newark California [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area under lease</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Property In Lease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Tenant Allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amount form letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extend for an additional lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseRenewalTerm" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area under sublease</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Property In Sublease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Expiration Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sublease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sublease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_LesseeOperatingSubleaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease renewal period</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_LesseeOperatingSubleaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sublease Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sublease, existence of option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sublease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating sublease, impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OngoingLossOverSubleasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ongoing loss over sublease period</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OngoingLossOverSubleasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ongoing Loss Over Sublease Period</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:type="locator" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" />
    <link:label xml:lang="en-US" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">SubleaseIncomeAndReimbursementOfVariableLeaseCost1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income and reimbursement of variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income And Reimbursement Of Variable Lease Cost1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included In measurement of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Present value adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value per Share, Unvested, ending balanc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:type="locator" xlink:label="alec_PercentageOfStockOwnedByIndividual" />
    <link:label xml:lang="en-US" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of stock owned by Individual.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PercentageOfStockOwnedByIndividual" xlink:to="alec_PercentageOfStockOwnedByIndividual_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:type="locator" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" />
    <link:label xml:lang="en-US" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, cliff vesting percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:type="locator" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" />
    <link:label xml:lang="en-US" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, cliff vesting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of stock owned by Individual</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Stock Owned By Individual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price per share from fair market value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cliff vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cliff vesting period</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable (In years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested or expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of option exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_SubsequentOfferingPeriod" xlink:type="locator" xlink:label="alec_SubsequentOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsequent offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubsequentOfferingPeriod" xlink:to="alec_SubsequentOfferingPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of common stock, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Offering Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Un-recognized compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" xlink:type="locator" xlink:label="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" />
    <link:label xml:lang="en-US" xlink:label="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax benefit recognized on utilization of attributes previous reserved.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" xlink:to="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" xlink:type="locator" xlink:label="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" />
    <link:label xml:lang="en-US" xlink:label="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred adjustment from amended tax return.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" xlink:to="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefit at federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Period Increase Decrease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nondeductible expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax benefit recognized on utilization of attributes previous reserved</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Benefit Recognized On Utilization Of Attributes Previous Reserved</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred adjustment from amended tax return</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Deferred Adjustment From Amended Tax Return</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Others</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxAssetsLeaseLiabilities" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="locator" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities Right-of-use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Others</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Others</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:type="locator" xlink:label="alec_DomesticAndStateTaxAuthorityMember" />
    <link:label xml:lang="en-US" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Domestic and state tax authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DomesticAndStateTaxAuthorityMember" xlink:to="alec_DomesticAndStateTaxAuthorityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State Tax Authorities</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic And State Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="locator" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance deferred tax asset change in amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:type="locator" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards beginning expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:type="locator" xlink:label="alec_TaxCreditBeginningExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit beginning expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TaxCreditBeginningExpirationYear" xlink:to="alec_TaxCreditBeginningExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward, deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deductions Other</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward beginning expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Beginning Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Beginning Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Beginning Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefits, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decreases related to tax positions taken during the prior year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to tax positions taken during the current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefits, ending balance</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_FutureMilestonePaymentsOwed" xlink:type="locator" xlink:label="alec_FutureMilestonePaymentsOwed" />
    <link:label xml:lang="en-US" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future milestone payments owed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_FutureMilestonePaymentsOwed" xlink:to="alec_FutureMilestonePaymentsOwed_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_AdimabMember" xlink:type="locator" xlink:label="alec_AdimabMember" />
    <link:label xml:lang="en-US" xlink:label="alec_AdimabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adimab</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AdimabMember" xlink:to="alec_AdimabMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_AdimabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adimab [Member]</link:label>
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:type="locator" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adimab Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandFourteenAdimabAgreementMember" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Fourteen Adimab Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Adimab Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities due to related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future milestone payments owed</link:label>
    <link:label xml:lang="en-US" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone Payments Owed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Committed Under ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>35
<FILENAME>alec-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T23:12:00.6412926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 6dc947f9232049b49804e807205611da -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alector.com/20201231/role/TemplateLink" xlink:href="alec-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="alec-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedClinicalSupplyCost" xlink:type="locator" xlink:label="alec_AccruedClinicalSupplyCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="alec_AccruedClinicalSupplyCost" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="alec-20201231.xsd#alec_RevenueFromGrant" xlink:type="locator" xlink:label="alec_RevenueFromGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenuesAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="alec_RevenueFromGrant" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="alec-20201231.xsd#alec_IssuanceCostsOfCommonStock" xlink:type="locator" xlink:label="alec_IssuanceCostsOfCommonStock" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IssuanceCostOfPreferredStock" xlink:type="locator" xlink:label="alec_IssuanceCostOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostOfPreferredStock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostsOfCommonStock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="alec-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:type="locator" xlink:label="us-gaap_PaymentsForTenantImprovements" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:type="locator" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AmortizationRightOfUseAsset" xlink:type="locator" xlink:label="alec_AmortizationRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alec_AmortizationRightOfUseAsset" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsForTenantImprovements" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidity" xlink:href="alec-20201231.xsd#Role_DisclosureTheCompanyAndLiquidity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="alec-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="alec-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="alec-20201231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureCommitmentAndContingencies" xlink:href="alec-20201231.xsd#Role_DisclosureCommitmentAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureCommitmentAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="alec-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="alec-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="alec-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="alec-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alec-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="alec-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="alec-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="alec-20201231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="alec-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="alec-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
    <link:loc xlink:href="alec-20201231.xsd#alec_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alec_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="locator" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SalesMilestone" xlink:type="locator" xlink:label="alec_SalesMilestone" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DevelopmentMilestone" xlink:type="locator" xlink:label="alec_DevelopmentMilestone" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" xlink:type="locator" xlink:label="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" />
    <link:loc xlink:href="alec-20201231.xsd#alec_PercentageOfChangeInForecastOfExpectedCosts" xlink:type="locator" xlink:label="alec_PercentageOfChangeInForecastOfExpectedCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="alec-20201231.xsd#alec_NonRefundableUpfrontPaymentReceivedInCash" xlink:type="locator" xlink:label="alec_NonRefundableUpfrontPaymentReceivedInCash" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:type="locator" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:type="locator" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:type="locator" xlink:label="alec_CollaborativeArrangementUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="alec-20201231.xsd#alec_InnoventBiologicsMember" xlink:type="locator" xlink:label="alec_InnoventBiologicsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:type="locator" xlink:label="alec_AbbVieBiotechnologyLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_InnoventBiologicsMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alec_SummaryOfSignificantAccountingPoliciesLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_CollaborativeArrangementUpfrontPayments" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_NonRefundableUpfrontPaymentReceivedInCash" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_PercentageOfChangeInForecastOfExpectedCosts" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_DevelopmentMilestone" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SalesMilestone" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="alec-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alec-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:type="locator" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="13300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="13540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="alec-20201231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:type="locator" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="alec-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_LabEquipmentMember" xlink:type="locator" xlink:label="alec_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_LabEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:href="alec-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:type="locator" xlink:label="alec_AccruedPropertyAndEquipmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:type="locator" xlink:label="alec_AccruedResearchAndDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="alec_AccruedResearchAndDevelopmentCosts" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="alec_AccruedPropertyAndEquipmentCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OngoingLossOverSubleasePeriod" xlink:type="locator" xlink:label="alec_OngoingLossOverSubleasePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="alec-20201231.xsd#alec_LesseeOperatingSubleaseRenewalTerm" xlink:type="locator" xlink:label="alec_LesseeOperatingSubleaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:type="locator" xlink:label="alec_SubleaseExpirationMonthAndYear" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:type="locator" xlink:label="alec_AreaOfPropertyInSubleaseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="alec-20201231.xsd#alec_LeaseExpirationYear" xlink:type="locator" xlink:label="alec_LeaseExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AreaOfPropertyInLease" xlink:type="locator" xlink:label="alec_AreaOfPropertyInLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_NewarkCaliforniaMember" xlink:type="locator" xlink:label="alec_NewarkCaliforniaMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SouthSanFranciscoMember" xlink:type="locator" xlink:label="alec_SouthSanFranciscoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:type="locator" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_SouthSanFranciscoMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_NewarkCaliforniaMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInLease" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LeaseExpirationYear" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInSubleaseAgreement" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_SubleaseExpirationMonthAndYear" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LesseeOperatingSubleaseRenewalTerm" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_OngoingLossOverSubleasePeriod" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:type="locator" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:href="alec-20201231.xsd#Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="alec-20201231.xsd#alec_SubsequentOfferingPeriod" xlink:type="locator" xlink:label="alec_SubsequentOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:type="locator" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" />
    <link:loc xlink:href="alec-20201231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:type="locator" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="alec-20201231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:type="locator" xlink:label="alec_PercentageOfStockOwnedByIndividual" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_PercentageOfStockOwnedByIndividual" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_SubsequentOfferingPeriod" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:href="alec-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" xlink:type="locator" xlink:label="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" />
    <link:loc xlink:href="alec-20201231.xsd#alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" xlink:type="locator" xlink:label="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alec-20201231.xsd#Role_DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="locator" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="alec-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="alec-20201231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:type="locator" xlink:label="alec_TaxCreditBeginningExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="alec-20201231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:type="locator" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="locator" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:type="locator" xlink:label="alec_DomesticAndStateTaxAuthorityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="alec_DomesticAndStateTaxAuthorityMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxCreditBeginningExpirationYear" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="alec-20201231.xsd#Role_DisclosureScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alec-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="alec-20201231.xsd#alec_FutureMilestonePaymentsOwed" xlink:type="locator" xlink:label="alec_FutureMilestonePaymentsOwed" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alec_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alec-20201231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:type="locator" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember" />
    <link:loc xlink:href="alec-20201231.xsd#alec_AdimabMember" xlink:type="locator" xlink:label="alec_AdimabMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_AdimabMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alec_FutureMilestonePaymentsOwed" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="alec-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323278156440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 15, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALEC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2933343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,375.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Oyster Point Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">231-5660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alector, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001653087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,584,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p>Portions of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323275445960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,969<span></span>
</td>
<td class="nump">$ 89,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">363,339<span></span>
</td>
<td class="nump">263,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,203<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">421,511<span></span>
</td>
<td class="nump">357,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30,181<span></span>
</td>
<td class="nump">33,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">32,470<span></span>
</td>
<td class="nump">28,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,617<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">488,251<span></span>
</td>
<td class="nump">421,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,004<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_AccruedClinicalSupplyCost', window );">Accrued clinical supply costs</a></td>
<td class="nump">11,148<span></span>
</td>
<td class="nump">6,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">22,538<span></span>
</td>
<td class="nump">18,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">23,886<span></span>
</td>
<td class="nump">30,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">7,512<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">68,088<span></span>
</td>
<td class="nump">61,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term portion</a></td>
<td class="nump">108,417<span></span>
</td>
<td class="nump">123,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term portion</a></td>
<td class="nump">43,744<span></span>
</td>
<td class="nump">41,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">220,721<span></span>
</td>
<td class="nump">227,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 79,316,261 and 69,052,873 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">676,956<span></span>
</td>
<td class="nump">414,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(410,048)<span></span>
</td>
<td class="num">(219,820)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">267,530<span></span>
</td>
<td class="nump">194,743<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 488,251<span></span>
</td>
<td class="nump">$ 421,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedClinicalSupplyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical supply cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedClinicalSupplyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323378537848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">79,316,261<span></span>
</td>
<td class="nump">69,052,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">79,316,261<span></span>
</td>
<td class="nump">69,052,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323282326136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 21,098<span></span>
</td>
<td class="nump">$ 21,219<span></span>
</td>
<td class="nump">$ 27,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">alec:CollaborationRevenueMember<span></span>
</td>
<td class="text">alec:CollaborationRevenueMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_RevenueFromGrant', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">21,098<span></span>
</td>
<td class="nump">$ 21,219<span></span>
</td>
<td class="nump">27,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">156,869<span></span>
</td>
<td class="nump">100,528<span></span>
</td>
<td class="nump">73,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">59,403<span></span>
</td>
<td class="nump">35,095<span></span>
</td>
<td class="nump">11,934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">216,272<span></span>
</td>
<td class="nump">135,623<span></span>
</td>
<td class="nump">84,965<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(195,174)<span></span>
</td>
<td class="num">(114,404)<span></span>
</td>
<td class="num">(57,288)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,946<span></span>
</td>
<td class="nump">9,019<span></span>
</td>
<td class="nump">5,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(190,228)<span></span>
</td>
<td class="num">(105,385)<span></span>
</td>
<td class="num">(52,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (189,756)<span></span>
</td>
<td class="num">$ (105,201)<span></span>
</td>
<td class="num">$ (52,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="num">$ (4.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">77,758,806<span></span>
</td>
<td class="nump">61,734,492<span></span>
</td>
<td class="nump">11,302,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_RevenueFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period money awarded to an entity to carry out a specific purpose as provided in grants agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_RevenueFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272673704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="num">$ (52,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 10,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (62,187)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,001,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,776,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series E convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_TemporaryStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series E convertible preferred stock, net of costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,373,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture/Cancellation of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(52,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,248)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="num">(97,398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">17,078<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(114,435)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,374,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,764,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">210,521<span></span>
</td>
<td class="num">$ (210,520)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">210,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,374,836)<span></span>
</td>
<td class="nump">45,374,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="nump">168,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">168,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,739,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture/Cancellation of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(105,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,385)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 194,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">414,414<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="num">(219,820)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">69,052,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,052,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="nump">$ 224,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">224,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,602,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture/Cancellation of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(190,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190,228)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 267,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 676,956<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="num">$ (410,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">79,316,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,316,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_TemporaryStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_TemporaryStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323364018984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_IssuanceCostsOfCommonStock', window );">Issuance cost of common stock</a></td>
<td class="nump">$ 1,148<span></span>
</td>
<td class="nump">$ 3,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_IssuanceCostOfPreferredStock', window );">Issuance cost of convertible preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IssuanceCostOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance cost of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IssuanceCostOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IssuanceCostsOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance cost of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IssuanceCostsOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323277991208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (190,228)<span></span>
</td>
<td class="num">$ (105,385)<span></span>
</td>
<td class="num">$ (52,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">30,522<span></span>
</td>
<td class="nump">16,281<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and accretion of discounts on marketable securities</a></td>
<td class="nump">584<span></span>
</td>
<td class="num">(4,701)<span></span>
</td>
<td class="num">(2,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_AmortizationRightOfUseAsset', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss on right-of-use assets</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property and equipment, net</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,839)<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
<td class="num">(2,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,498)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,409<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="num">(809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts', window );">Accrued liabilities and accrued clinical supply costs</a></td>
<td class="nump">12,232<span></span>
</td>
<td class="nump">9,210<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(21,098)<span></span>
</td>
<td class="num">(21,219)<span></span>
</td>
<td class="nump">172,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(2,407)<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(166,734)<span></span>
</td>
<td class="num">(99,308)<span></span>
</td>
<td class="nump">127,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5,032)<span></span>
</td>
<td class="num">(15,265)<span></span>
</td>
<td class="num">(1,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(506,809)<span></span>
</td>
<td class="num">(529,609)<span></span>
</td>
<td class="num">(472,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">406,790<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(105,051)<span></span>
</td>
<td class="num">(48,874)<span></span>
</td>
<td class="num">(224,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,128<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts', window );">Proceeds from issuance of common stock upon follow-on public offering, net of issuance cost</a></td>
<td class="nump">224,603<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options to purchase common stock</a></td>
<td class="nump">6,331<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock from employee stock purchase plan</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">232,113<span></span>
</td>
<td class="nump">172,353<span></span>
</td>
<td class="nump">131,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(39,672)<span></span>
</td>
<td class="nump">24,171<span></span>
</td>
<td class="nump">34,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">91,113<span></span>
</td>
<td class="nump">66,942<span></span>
</td>
<td class="nump">32,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">51,441<span></span>
</td>
<td class="nump">91,113<span></span>
</td>
<td class="nump">66,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">3,471<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities', window );">Deferred offering costs in accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid by landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,286<span></span>
</td>
<td class="nump">$ 7,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AmortizationRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AmortizationRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs for public offerings included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredOfferingCostsForPublicOfferingsIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in accrued liabilities and accrued clinical supply costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ProceedsFromIssuanceOfCommonStockUponFollowOnPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (payments for) issuance of common stock as part of an initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (payments for) issuance of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ProceedsFromPaymentsToIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323365160072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Liquidity</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="NOTES_TO_CONSOLIDATED_FINANCIALS"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIALS"></a>The Company and Liquidity </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public and Follow-on Offerings</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 7, 2019, the Company completed an initial public offering (IPO) through issuing and selling 9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $168.2 million, after deducting underwriting discounts and commissions and offering costs. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 45,374,836 shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the Company completed a follow-on offering through issuing and selling 9,602,500 shares of common stock at a public offering price of $25.00 per share, including 1,252,500 shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $224.5 million, after deducting underwriting discounts and commissions and estimated offering costs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323354929560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Summary of Significant Accounting Policies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates<font style="font-style:italic;">.</font> </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash, Cash Equivalents, and Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. <font style="font-size:12pt;">&#160;</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash as of December 31, 2020 relates to a letter of credit established for a lease entered into in June 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,969</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,470</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,441</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,942</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity (deficit) until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, commercial paper, and overnight repurchase agreements collateralized by U.S. treasury securities. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s believes the carrying value of financial instruments, including cash and cash equivalents, receivables, accounts payable, and accrued liabilities, approximate fair value due to their short-term nature. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;1<font style="font-style:normal;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;2<font style="font-style:normal;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;3<font style="font-style:normal;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Update No.&#160;2016-02, <font style="font-style:italic;">Leases </font>on January 1, 2019. There was no material effect on the statement of operations upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds is fair value. For the year ended December 31, 2020, the Company recognized a $0.2 million impairment loss on its right-of-use asset related to decision to no longer utilize certain property through the end of the lease term. For the year ended December 31, 2019, the Company recognized a $1.2 million impairment loss on its right of use assets related to the portion of its headquarters being subleased.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when control of promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies the performance obligation. <font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company signed an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $205.0 million in upfront payments, of which $5.0 million and $200.0 million was received by the Company in October 2017 and January 2018, respectively. The Company will perform research and development services for the antibodies to the two programs through the end of Phase 2 clinical trials which the Company expects to conduct through 2023. AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration agreement with the Company for one or both of the programs for $250.0 million each. If AbbVie exercises its option for the programs, AbbVie will take over the development of the product candidates for such program and costs will be split between the parties. The Company will also share in profits and losses upon commercialization of any products from such program. However, following AbbVie&#8217;s exercise of its option for a program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $242.8 million in milestone payments per program related to the initiation of certain clinical studies and regulatory approval for up to three indications per program. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that there are two research and development performance obligations as part of the agreement with AbbVie, one research and development performance obligation for each of the two research and development programs. The non-refundable upfront cash payments of $5.0&#160;million and $200.0&#160;million received in October 2017 and January 2018, respectively, were included in the transaction price. None of the remaining development and regulatory milestone and program opt-in payment amounts have been included in the transaction price, as all these amounts were fully constrained as of December&#160;31, 2020 and 2019. As part of the Company&#8217;s evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestone amounts is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to royalties on net product sales will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in the Company&#8217;s forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of clinical trials. The Company has had changes to the overall expected costs to satisfy the performance obligations from period to period. For the year ended December 31, 2020, the Company had a 7% increase in the forecast of total expected costs due to changes to the clinical trial plans. For the year ended December 31, 2020, the increase in the overall expected costs to satisfy the performance obligation resulted in an approximately $6.7 million reduction in revenue compared to if the expected costs had remained the same, as a result of the cumulative catch up for the change in estimate. Collaboration revenue under the Company&#8217;s collaboration agreement with AbbVie during 2020, 2019, and 2018 was $21.1 million, $21.2 million, and $27.5&#160;million, respectively. Collaboration revenue recognized during the year ended December 31, 2020, was included in deferred revenue at the beginning of the period. The balance of deferred revenue was $132.3&#160;million as of December&#160;31, 2020. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of Phase 2 clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&#8217;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent may pay the Company up to $11.5 million in development milestones, $112.5 million in sales milestones, and future royalties for any sales. The Company retains the rights to develop and commercialize AL008 outside of China. The Company has determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement have not been included in the transaction price, as all these amounts were fully constrained as of December 31, 2020. As of December 31, 2020, no revenue has been recognized or payments received under the Innovent Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the grant agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, contract research organizations in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation for employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of options to purchase common stock are measured using the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have<font style="font-size:12pt;">&#160;</font>been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee 401(k) Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a qualified contributory savings plan under Section&#160;401(k) of the Internal Revenue Code (the &#8220;Code&#8221;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section&#160;401(k) of the Code. Eligible employees may defer up to 100% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the year ended December&#160;31, 2020, the Company made matching contributions of $0.7 million. The Company did not make any matching contributions for the years ended December 31, 2019 or 2018. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, the Company adopted Accounting Standards Update (ASU) No. 2016-13, <font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</font>. This ASU implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any changes in estimated credit losses immediately in earnings. There was no material impact to the Company&#8217;s consolidated financial statements from the adoption of ASU No. 2016-13.<font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes.</font> This ASU modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, and the methodology for calculating income taxes in an interim period. The Company has early adopted this ASU as of January 1, 2020. There was no material impact to the Company&#8217;s consolidated financial statements. There was no material impact to the Company&#8217;s consolidated financial statements from the adoption of ASU No. 2019-12.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323357536552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,951</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,951</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357,725</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,339</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">401,290</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,446</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,587</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,735</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,735</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,103</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,388</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Level&#160;2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. There were no transfers between levels of the fair value hierarchy during the year ended December 31, 2020. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2020, the remaining contractual maturities of $336.9 million investments were less than one year and $64.4 million investments were after one year through two years. The Company does not intend to sell the investments that are in an unrealized loss position before recovery of their amortized cost basis, which may be maturity.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323355010648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Balance Sheet Components </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,542</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,222</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,610</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,458</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,222</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,554</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,265</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,957</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,181</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,852</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Liabilities </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,375</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,730</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,040</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued property and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,471</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,538</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,256</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323354916504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 18, 2019, the Company initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, the Company&#8217;s former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of Alector&#8217;s confidential information that he learned during the course of rendering services to the Company as consulting Chief Scientific Officer/Chief Innovation Officer. An independent arbitrator issued a confidential decision in favor of Alector, finding Dr. Abeliovich liable for breach of his confidentiality agreement and for spoliation based on his destruction of documents relevant to the proceeding. The arbitrator awarded damages for breach of the agreement and sanctions for the spoliation, as well as violation of orders during the proceeding, and the amount of such monetary damages will be determined in a pending further proceeding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279508952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Leases </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company signed a lease agreement to lease approximately 105,000 square feet in office and laboratory space in South San Francisco which serves as the Company&#8217;s headquarters (the &#8220;Headquarters&#8221;). The lease expires in 2029 with an option to renew for a period of ten years. The landlord paid for $15.7 million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $1.5&#160;million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements. The measurement of the lease liabilities for the leases excludes the options to extend the term of the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#8217;s leases consist of operating expenses for the spaces. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into an agreement to sublease approximately 25,000 square feet of the Headquarters (the &#8220;Sublease&#8221;), which was amended to approximately 23,600 square feet in December 2020. The Sublease expires in November 2021. The sublessor has the option to extend the Sublease for one additional year subject to the consent of the Company. The sublessee is required to pay its proportionate share of operating expenses for the space. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, in connection with the Sublease, the Company evaluated the related right-of-use asset for impairment. The lease costs plus amortization expense of the leasehold improvements in the subleased space exceeded the sublease income over the remaining sublease term. As such, the Company recorded an impairment charge of $1.2 million in general and administrative expenses to write-down the right-of-use asset such that no loss is expected to be recognized over the sublease period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,255</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income and reimbursement of variable lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,263</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,008</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense under legacy guidance for the year ended December&#160;31, 2018 was $1.1&#160;million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the weighted-average remaining lease term for operating leases was 8.2 years and the weighted-average discount rate was 8.5%. Cash paid for amounts included in the measurement of lease liabilities for the year ended&#160;December 31, 2020 and 2019&#160;was&#160;$6.9 million and $3.2 million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the lease payments owed under the Company&#8217;s operating leases as of December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,872</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,171</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,732</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,037</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,130</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,378</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Present value adjustment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,122</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,256</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279531272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Stock-based Compensation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,980</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,730</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,522</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Determination of Fair Value </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3-6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 &#8211; 6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1 &#8211; 6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74%-78%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76% &#8211; 82%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73% &#8211; 81%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3% - 1.8%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4% &#8211; 2.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5% &#8211; 3.1%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term&#8212;<font style="font-style:normal;">The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility&#8212;<font style="font-style:normal;">The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate&#8212;<font style="font-style:normal;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Rate&#8212;<font style="font-style:normal;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock underlying its stock options in the foreseeable future. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restricted common stock generally vests over a four-year period with straight-line vesting with a 25% one-year cliff. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity for the restricted common stock is shown below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,917,848</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(866,037</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,973</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(726,659</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,754</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $0.9&#160;million, which the Company expects to recognize over a remaining weighted-average period of 0.8 years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Equity Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#8217;s employees, directors, and consultants. The Company&#8217;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options or shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing 10% or more of the outstanding shares, the exercise price of each share shall be at least 110% of the fair market value and the term of the award shall not exceed five years. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed ten years. The shares generally vest over a four-year period with straight-line vesting with a 25% one-year cliff. As of December 31, 2020, the Company had reserved 15,628,217 shares of common stock for issuance under the 2019 Plan, of which 2,973,219 shares were available for issuance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity for the options to purchase common stock shown below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,063,688</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.94</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,738,071</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178,648</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.52</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,442,824</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,597,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(655,772</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(729,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.96</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,633</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,588,568</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,393</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,633</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was $11.1 million and $1.8 million for the years ended December 31, 2020 and 2019. There were no options exercised in 2018. The weighted-average grant-date fair value per share of options granted was $10.14, $12.06, and $6.27, for the years ended December 31, 2020, 2019, and 2018, respectively. As of December&#160;31, 2020, total unrecognized stock-based compensation related to unvested stock options was $82.9&#160;million, which the Company expects to recognize over a remaining weighted-average period of 2.6 years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 6, 2019, the Company adopted the 2019 Employee Stock Option Plan (2019 ESPP). The 2019 ESPP will enable eligible employees of the Company to purchase shares of common stock at a discount. Each offering period will be approximately six months long beginning on the first trading day on or after December 1 and June 1 each year. ESPP participants purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. As of December 31, 2020, there was $0.4 million in unrecognized compensation expense related to the 2019 ESPP to be recognized over five months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279627928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Income Taxes </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred net operating losses for the years ended December&#160;31, 2020, 2019, and 2018. The Company has not reflected a benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its net deferred tax assets due to the uncertainty surrounding realization of such assets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended December&#160;31, 2020, 2019, and 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefit at federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,081</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,972</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,570</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,694</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,387</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,251</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nondeductible expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefit recognized on utilization of attributes previous reserved</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,582</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred adjustment from amended tax return</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,073</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,280</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,346</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(449</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets consist of (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,382</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,319</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,129</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,621</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,457</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,781</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,125</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,538</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,226</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,053</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,899</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,815</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,495</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,934</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,990</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,899</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,485</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized.&#160;The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December&#160;31, 2020, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $58.2 million during the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had federal and state net operating loss (NOL) carryforwards of approximately $195.3&#160;million and $191.4&#160;million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed 80% of taxable income. State NOL carryforwards will begin to expire as early as 2030, if not utilized, or have an indefinite life. As of December&#160;31, 2020, the Company also had federal and California tax credit carryforward of approximately $14.4&#160;million and $3.8&#160;million, respectively. The federal tax credits will begin to expire in 2036 while the California tax credits have no expiration date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section&#160;382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section&#160;383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &#8220;ownership change.&#8221; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,507</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; prior year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; current year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; prior year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(446</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; current year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the unrecognized tax benefits for uncertain tax positions as of December&#160;31, 2020, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company did not accrue any interest or penalties and does not have any tax positions for interest or penalties for the year ended December&#160;31, 2020. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the year ended December 31, 2020, the Company recorded a tax reserve of $2.0 million as a reduction of the tax credit carryover. The Company&#8217;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279614600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Related Party Transactions </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its AL001 and AL101 product candidates, and the Company is developing antibodies optimized by Adimab in its AL002 and AL003 product candidates (2014 Adimab Agreement). In August 2019, the Company signed a new collaboration agreement with Adimab for research and development of additional antibodies (2019 Adimab Agreement). The Chief Executive Officer of Adimab is a Co-founder and Chairperson of the board of directors of Alector. For the years ended December&#160;31, 2020, 2019, and 2018, Alector incurred expenses of zero, $2.8&#160;million, and $2.3&#160;million for services provided by Adimab, respectively. The Company had no accrued liabilities due to Adimab as of December 31, 2020 and 2019. Under the 2014 Adimab Agreement, the Company will owe up to $3.5&#160;million in milestone payments per program to Adimab for its product candidates. The Company will also owe low- to mid- single-digit royalty payments for commercial sales of such product candidates. Under the 2019 Adimab Agreement, the Company will owe certain milestone payments per program for its product candidates and low single-digit royalty payments for commercial sales of such product candidates.</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, in connection with the Company&#8217;s follow-on offering, a member of the Company&#8217;s board of directors purchased 20,000 shares of the Company&#8217;s common stock at the public offering price of $25.00 per share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323354881576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Net Loss Per Share</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,374,836</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock subject to future vesting</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,917,848</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,442,824</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,063,688</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares committed under ESPP</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,677</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,464</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,928,100</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,482,126</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,356,372</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323278040552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates<font style="font-style:italic;">.</font> </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash, Cash Equivalents, and Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. <font style="font-size:12pt;">&#160;</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash as of December 31, 2020 relates to a letter of credit established for a lease entered into in June 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,969</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,470</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,441</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,942</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity (deficit) until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were no credit-related losses recognized for the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, commercial paper, and overnight repurchase agreements collateralized by U.S. treasury securities. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s believes the carrying value of financial instruments, including cash and cash equivalents, receivables, accounts payable, and accrued liabilities, approximate fair value due to their short-term nature. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;1<font style="font-style:normal;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;2<font style="font-style:normal;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Level&#160;3<font style="font-style:normal;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. </font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Update No.&#160;2016-02, <font style="font-style:italic;">Leases </font>on January 1, 2019. There was no material effect on the statement of operations upon adoption.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds is fair value. For the year ended December 31, 2020, the Company recognized a $0.2 million impairment loss on its right-of-use asset related to decision to no longer utilize certain property through the end of the lease term. For the year ended December 31, 2019, the Company recognized a $1.2 million impairment loss on its right of use assets related to the portion of its headquarters being subleased.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when control of promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i)&#160;identify the contract(s) with a customer, (ii)&#160;identify the performance obligations in the contract, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations in the contract, and (v)&#160;recognize revenue when (or as) the entity satisfies the performance obligation. <font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company signed an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $205.0 million in upfront payments, of which $5.0 million and $200.0 million was received by the Company in October 2017 and January 2018, respectively. The Company will perform research and development services for the antibodies to the two programs through the end of Phase 2 clinical trials which the Company expects to conduct through 2023. AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration agreement with the Company for one or both of the programs for $250.0 million each. If AbbVie exercises its option for the programs, AbbVie will take over the development of the product candidates for such program and costs will be split between the parties. The Company will also share in profits and losses upon commercialization of any products from such program. However, following AbbVie&#8217;s exercise of its option for a program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $242.8 million in milestone payments per program related to the initiation of certain clinical studies and regulatory approval for up to three indications per program. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that there are two research and development performance obligations as part of the agreement with AbbVie, one research and development performance obligation for each of the two research and development programs. The non-refundable upfront cash payments of $5.0&#160;million and $200.0&#160;million received in October 2017 and January 2018, respectively, were included in the transaction price. None of the remaining development and regulatory milestone and program opt-in payment amounts have been included in the transaction price, as all these amounts were fully constrained as of December&#160;31, 2020 and 2019. As part of the Company&#8217;s evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestone amounts is outside the control of the Company and contingent upon success in future clinical trials. Any consideration related to royalties on net product sales will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in the Company&#8217;s forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of clinical trials. The Company has had changes to the overall expected costs to satisfy the performance obligations from period to period. For the year ended December 31, 2020, the Company had a 7% increase in the forecast of total expected costs due to changes to the clinical trial plans. For the year ended December 31, 2020, the increase in the overall expected costs to satisfy the performance obligation resulted in an approximately $6.7 million reduction in revenue compared to if the expected costs had remained the same, as a result of the cumulative catch up for the change in estimate. Collaboration revenue under the Company&#8217;s collaboration agreement with AbbVie during 2020, 2019, and 2018 was $21.1 million, $21.2 million, and $27.5&#160;million, respectively. Collaboration revenue recognized during the year ended December 31, 2020, was included in deferred revenue at the beginning of the period. The balance of deferred revenue was $132.3&#160;million as of December&#160;31, 2020. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of Phase 2 clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&#8217;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent may pay the Company up to $11.5 million in development milestones, $112.5 million in sales milestones, and future royalties for any sales. The Company retains the rights to develop and commercialize AL008 outside of China. The Company has determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement have not been included in the transaction price, as all these amounts were fully constrained as of December 31, 2020. As of December 31, 2020, no revenue has been recognized or payments received under the Innovent Agreement.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the grant agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, contract research organizations in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation for employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of options to purchase common stock are measured using the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have<font style="font-size:12pt;">&#160;</font>been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Employee 401 (K) Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee 401(k) Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a qualified contributory savings plan under Section&#160;401(k) of the Internal Revenue Code (the &#8220;Code&#8221;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section&#160;401(k) of the Code. Eligible employees may defer up to 100% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the year ended December&#160;31, 2020, the Company made matching contributions of $0.7 million. The Company did not make any matching contributions for the years ended December 31, 2019 or 2018. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, the Company adopted Accounting Standards Update (ASU) No. 2016-13, <font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</font>. This ASU implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any changes in estimated credit losses immediately in earnings. There was no material impact to the Company&#8217;s consolidated financial statements from the adoption of ASU No. 2016-13.<font style="font-size:12pt;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes.</font> This ASU modifies ASC 740 to simplify several aspects of accounting for income taxes, including eliminating certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, and the methodology for calculating income taxes in an interim period. The Company has early adopted this ASU as of January 1, 2020. There was no material impact to the Company&#8217;s consolidated financial statements. There was no material impact to the Company&#8217;s consolidated financial statements from the adoption of ASU No. 2019-12.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279346600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,969</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,641</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,470</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,472</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,441</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,942</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279558440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,951</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,951</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357,725</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,339</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">401,290</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Market</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="16" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,104</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,446</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,587</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,735</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,735</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,103</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,388</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279568056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text">Property and equipment, net consists of the following:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,542</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,222</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,610</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,458</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,222</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,554</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,265</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,957</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,181</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,852</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text">Accrued liabilities consist of the following:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,375</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,730</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,040</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued property and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,471</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,538</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,256</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323279437352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.22%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,255</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income and reimbursement of variable lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,263</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,008</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Payments Owed Under Company's Operating Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the lease payments owed under the Company&#8217;s operating leases as of December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,872</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,171</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,732</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,037</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,130</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,378</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Present value adjustment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,122</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,256</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323282623496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,980</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,730</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,522</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,925</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3-6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 &#8211; 6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1 &#8211; 6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74%-78%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76% &#8211; 82%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73% &#8211; 81%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3% - 1.8%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4% &#8211; 2.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5% &#8211; 3.1%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity for the restricted common stock is shown below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.22%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,917,848</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(866,037</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,973</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(726,659</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,754</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Options to Purchase Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity for the options to purchase common stock shown below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,063,688</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.94</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,738,071</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(178,648</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.52</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,442,824</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,597,148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.35</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(655,772</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(729,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.96</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,633</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,588,568</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,393</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,633</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323282201000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended December&#160;31, 2020, 2019, and 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefit at federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,081</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,972</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,570</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,694</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,010</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,387</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,251</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nondeductible expense</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefit recognized on utilization of attributes previous reserved</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,582</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred adjustment from amended tax return</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,073</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,280</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,748</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,346</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(449</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets consist of (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,382</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,319</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,129</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,621</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,457</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,781</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,125</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,538</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105,226</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,053</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,899</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,815</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,495</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,934</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,990</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,899</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,485</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,507</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; prior year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; current year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,035</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; prior year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(446</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases related to tax positions taken during the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; current year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,592</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323276718616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,374,836</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock subject to future vesting</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,917,848</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,654,998</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,442,824</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,063,688</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares committed under ESPP</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,677</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,464</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,928,100</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,482,126</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,356,372</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323277956328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Liquidity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2020</div></th>
<th class="th"><div>Feb. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,602,500<span></span>
</td>
<td class="nump">9,739,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,739,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,374,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="nump">1,252,500<span></span>
</td>
<td class="nump">489,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember', window );">Follow-on-offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="nump">9,602,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 224.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323275783048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Credit losses on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss on right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="nump">1,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_PercentageOfChangeInForecastOfExpectedCosts', window );">Increase in the forecast of total expected costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear', window );">Reduction in revenue due to increase in budget during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum annual contributions per employee, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined matching contribution plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_CollaborativeArrangementUpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram', window );">Exclusive option rights exercised for each program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_NonRefundableUpfrontPaymentReceivedInCash', window );">Cash payment received, non-refundable</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100,000<span></span>
</td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_InnoventBiologicsMember', window );">Innovent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_DevelopmentMilestone', window );">Development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SalesMilestone', window );">Sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | AbbVie Biotechnology Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram', window );">Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, additional milestone payments receivable per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, milestone payments on option rights exercised per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_NonRefundableUpfrontPaymentReceivedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payment received in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_NonRefundableUpfrontPaymentReceivedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_PercentageOfChangeInForecastOfExpectedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of change in forecast of expected costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_PercentageOfChangeInForecastOfExpectedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in revenue due to increase in budget during the year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ReductionInRevenueDueToIncreaseInBudgetDuringYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_InnoventBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_InnoventBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323282393144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,969<span></span>
</td>
<td class="nump">$ 89,641<span></span>
</td>
<td class="nump">$ 65,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 51,441<span></span>
</td>
<td class="nump">$ 91,113<span></span>
</td>
<td class="nump">$ 66,942<span></span>
</td>
<td class="nump">$ 32,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272774008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">$ 37,951<span></span>
</td>
<td class="nump">$ 61,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">37,951<span></span>
</td>
<td class="nump">61,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S Government Treasury Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">357,725<span></span>
</td>
<td class="nump">227,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">358,339<span></span>
</td>
<td class="nump">227,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">10,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">400,676<span></span>
</td>
<td class="nump">342,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">$ 401,290<span></span>
</td>
<td class="nump">342,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=alec_CashEquivalentsAndMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=alec_CashEquivalentsAndMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323276703320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value of assets transferred from level 1 to level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value of assets transferred from level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Remaining contractual maturities of investments were less than one year</a></td>
<td class="nump">336,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue', window );">Remaining contractual maturities of investments were less than one year through two years</a></td>
<td class="nump">$ 64,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272771768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 41,138<span></span>
</td>
<td class="nump">$ 39,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(10,957)<span></span>
</td>
<td class="num">(5,413)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">30,181<span></span>
</td>
<td class="nump">33,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">11,610<span></span>
</td>
<td class="nump">10,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">25,542<span></span>
</td>
<td class="nump">25,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323355028024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">$ 13,375<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="nump">5,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_AccruedPropertyAndEquipmentCurrent', window );">Accrued property and equipment</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">3,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 22,538<span></span>
</td>
<td class="nump">$ 18,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued property and equipment current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272921320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Amount form letter of credit</a></td>
<td class="nump">$ 1,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,472,000<span></span>
</td>
<td class="nump">$ 1,472,000<span></span>
</td>
<td class="nump">$ 1,472,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease expires in 2029 with an option to renew for a period of ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating sublease, impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="nump">1,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included In measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember', window );">Offices and Laboratory Facilities | South San Francisco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_AreaOfPropertyInLease', window );">Area under lease | ft&#178;</a></td>
<td class="nump">23,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_AreaOfPropertyInSubleaseAgreement', window );">Area under sublease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SubleaseExpirationMonthAndYear', window );">Sublease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseOptionToExtend', window );">Operating sublease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The sublessor has the option to extend the Sublease for one additional year subject to the consent of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_LesseeOperatingSubleaseRenewalTerm', window );">Sublease renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend', window );">Operating sublease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_OngoingLossOverSubleasePeriod', window );">Ongoing loss over sublease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember', window );">Offices and Laboratory Facilities | South San Francisco | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating sublease, impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember', window );">Offices and Laboratory Facilities | South San Francisco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  06,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Extend for an additional lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AreaOfPropertyInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of property in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AreaOfPropertyInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AreaOfPropertyInSubleaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of property in sublease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AreaOfPropertyInSubleaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_LesseeOperatingSubleaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease renewal term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_LesseeOperatingSubleaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_OngoingLossOverSubleasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized in operating expense over the term of the sublease related to the sublease impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_OngoingLossOverSubleasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubleaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubleaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether sublessee has option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alec_SouthSanFranciscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alec_SouthSanFranciscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alec_NewarkCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alec_NewarkCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272472536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,589<span></span>
</td>
<td class="nump">$ 5,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1', window );">Sublease income and reimbursement of variable lease cost</a></td>
<td class="nump">2,288<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 5,556<span></span>
</td>
<td class="nump">$ 6,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SubleaseIncomeAndReimbursementOfVariableLeaseCost1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323278050712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 7,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">8,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">8,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">8,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">9,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">30,130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">72,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(21,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 51,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323275746072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 30,522<span></span>
</td>
<td class="nump">$ 16,281<span></span>
</td>
<td class="nump">$ 6,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">14,980<span></span>
</td>
<td class="nump">8,031<span></span>
</td>
<td class="nump">4,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 15,542<span></span>
</td>
<td class="nump">$ 8,250<span></span>
</td>
<td class="nump">$ 2,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272820216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Share-based Payment Arrangement, Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272853112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,628,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_PercentageOfStockOwnedByIndividual', window );">Percentage of stock owned by Individual</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price per share from fair market value</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage', window );">Cliff vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for issuance</a></td>
<td class="nump">2,973,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.14<span></span>
</td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of common stock, percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_SubsequentOfferingPeriod', window );">Subsequent offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Un-recognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_PercentageOfStockOwnedByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock owned by Individual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_PercentageOfStockOwnedByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, cliff vesting percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, cliff vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubsequentOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsequent offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubsequentOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323275418920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Restricted Common Stock (Details) - Restricted Common Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, beginning balance</a></td>
<td class="nump">994,838<span></span>
</td>
<td class="nump">1,917,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(726,659)<span></span>
</td>
<td class="num">(866,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(81,754)<span></span>
</td>
<td class="num">(56,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, ending balance</a></td>
<td class="nump">186,425<span></span>
</td>
<td class="nump">994,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="nump">$ 6.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Vested</a></td>
<td class="nump">6.95<span></span>
</td>
<td class="nump">6.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Forfeited</a></td>
<td class="nump">6.95<span></span>
</td>
<td class="nump">6.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, ending balanc</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="nump">$ 6.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323275761496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Options to Purchase Common Stock (Details) - 2019 Equity Incentive Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, beginning balance</a></td>
<td class="nump">8,442,824<span></span>
</td>
<td class="nump">5,063,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">5,597,148<span></span>
</td>
<td class="nump">3,738,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(655,772)<span></span>
</td>
<td class="num">(180,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(729,202)<span></span>
</td>
<td class="num">(178,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, ending balance</a></td>
<td class="nump">12,654,998<span></span>
</td>
<td class="nump">8,442,824<span></span>
</td>
<td class="nump">5,063,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">3,588,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="nump">12,654,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, beginning balance</a></td>
<td class="nump">$ 12.79<span></span>
</td>
<td class="nump">$ 8.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">15.35<span></span>
</td>
<td class="nump">17.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">9.65<span></span>
</td>
<td class="nump">8.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">14.96<span></span>
</td>
<td class="nump">11.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, ending balance</a></td>
<td class="nump">13.96<span></span>
</td>
<td class="nump">$ 12.79<span></span>
</td>
<td class="nump">$ 8.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">12.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 13.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable (In years)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 39,633<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">13,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested or expected to vest</a></td>
<td class="nump">$ 39,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272462232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at federal statutory rate</a></td>
<td class="num">$ (39,948)<span></span>
</td>
<td class="num">$ (22,081)<span></span>
</td>
<td class="num">$ (10,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">(16,570)<span></span>
</td>
<td class="num">(4,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(8,010)<span></span>
</td>
<td class="num">(6,530)<span></span>
</td>
<td class="num">(2,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Uncertain tax positions</a></td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nondeductible expense</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved', window );">Tax benefit recognized on utilization of attributes previous reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn', window );">Deferred adjustment from amended tax return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">62,280<span></span>
</td>
<td class="nump">44,748<span></span>
</td>
<td class="nump">11,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Others</a></td>
<td class="num">$ (159)<span></span>
</td>
<td class="num">$ (449)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred adjustment from amended tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncomeTaxReconciliationDeferredAdjustmentFromAmendedTaxReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit recognized on utilization of attributes previous reserved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncomeTaxReconciliationTaxBenefitRecognizedOnUtilizationOfAttributesPreviousReserved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323275661928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 54,382<span></span>
</td>
<td class="nump">$ 2,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued bonus</a></td>
<td class="nump">1,201<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">7,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,493<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">32,129<span></span>
</td>
<td class="nump">37,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">12,457<span></span>
</td>
<td class="nump">11,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">120,125<span></span>
</td>
<td class="nump">61,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(105,226)<span></span>
</td>
<td class="num">(47,053)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">14,899<span></span>
</td>
<td class="nump">14,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(6,815)<span></span>
</td>
<td class="num">(7,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(7,934)<span></span>
</td>
<td class="num">(6,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Others</a></td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">$ (14,899)<span></span>
</td>
<td class="num">$ (14,485)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities Right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323282416888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance deferred tax asset change in amount</a></td>
<td class="nump">$ 58.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=alec_DomesticAndStateTaxAuthorityMember', window );">Federal and State Tax Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">195.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">191.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 14.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_TaxCreditBeginningExpirationYear', window );">Tax Credit Beginning Expiration Year</a></td>
<td class="text">2036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Authority | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Operating loss carry forward, deductions</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_OperatingLossCarryforwardsBeginningExpirationYear', window );">Operating loss carry forward beginning expiration year</a></td>
<td class="text">2030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_OperatingLossCarryforwardsBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_OperatingLossCarryforwardsBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_TaxCreditBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_TaxCreditBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=alec_DomesticAndStateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=alec_DomesticAndStateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323276709736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning balance</a></td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 1,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to tax positions taken during the prior year</a></td>
<td class="num">(446)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to tax positions taken during the current year</a></td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, ending balance</a></td>
<td class="nump">$ 4,592<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323272733464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember', window );">Follow-on-offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="nump">9,602,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember', window );">Follow-on-offering | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_AdimabMember', window );">Adimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued liabilities due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_TwoThousandFourteenAdimabAgreementMember', window );">Two Thousand Fourteen Adimab Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alec_FutureMilestonePaymentsOwed', window );">Future milestone payments owed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_FutureMilestonePaymentsOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future milestone payments owed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_FutureMilestonePaymentsOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_AdimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_AdimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_TwoThousandFourteenAdimabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_TwoThousandFourteenAdimabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140323271837400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">12,928,100<span></span>
</td>
<td class="nump">9,482,126<span></span>
</td>
<td class="nump">52,356,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,374,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">186,425<span></span>
</td>
<td class="nump">994,838<span></span>
</td>
<td class="nump">1,917,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">12,654,998<span></span>
</td>
<td class="nump">8,442,824<span></span>
</td>
<td class="nump">5,063,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares Committed Under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">86,677<span></span>
</td>
<td class="nump">44,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M9'_)9G=OI]L@86JL2O;!X" 1<O>?O>P3<130]TX$T'T ?17@MT\$!/N H&Y
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M*-LWHE@W/X&X+X0HLN;EBD?05.L ^'Y9%.+E3?VKBMTO@2[^ U!+ P04
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MJASX49R8NT$,!_Q\4S,0' W]4]PYOTGHJ5OHOYF[:2P04(:(9!,_]$,SJ6'
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MW]?.O86U(F^%$($51&CG0Q*[PJ>+0 (N(+@8MNVD784IIPKN1I84T;A?@*
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MA8-B0/2\G=BH&#_<@QQ/A#GO8?[^'H+@+E[[D,1K7T94:6%*2Y[:BR4AL'*
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M4?,1WW]D*;@2%4[W7)L;--3(+*7(BHSB^;N94$0T.%@D9@6!)%FN?DW1DOD
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MYEMFA;E'H;@=1O7=-\LL7;RR; NFDR,GC&4O2((^9<FK]X,/?BE]]7+,?H%
M"%H\U-+ +GRCHY? -?S#O:X]'9&<$158B\&"W&MAI"Z0!'.B8GO!C6V-(2&E
M3<%J+@LO?);.Q@MP02FR$S0XRB5+5.G>EPZZJ'>NJZHEOW?NNM@.ZP]Y8=
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M?(0[^7S95'S6ZPZ6D<=DG;9/UWBG=ZA3Z#M@*?Z^EADLGJFESMFHS4<#;5&
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M UJ ]VNE;'M##+KONK?_!5!+ P04    " "!@EE20JY@ZE8$  !W"@  &0
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M0-MB?5V3/X";*?T4DP?] 6DQ@<0G$#_9RG\J<J?5(Q@G#A(\?PO&( )?>?U
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M.CF[H)9=,=R:2G-(/4!8#FST6I/=.-U3.(@1346VX1 .Y,0$R1]ML8XW\<3
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M$'B22U52@TNU#72E@&;.J>1!'(;#H*1,>+.)VUNJV436AC,!2T5T7994_5T
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M:1Z2LC-6-8,S,FBX[/_L8:C#D4.1O.! !P?J>?>!/,NWS++50JL]T<X:T=S
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MRMS(Y6]\=9[8XA6RTNZ)EMW>-!Z@HM5&UBMAL* 63??/GE9^V!#(@AT"="5
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MV2!X-@CP(+E]9-[AYP:9F6PU:TI]Y-UP#7+%#,$4TF,!:3^WCO-^]DB$\RR
M08:#D,!_A$D>>Y]XPQ6KG  K@>/"^M<FJT=B'$<4]M,85.(T#+P[:6#OK@,
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M'G^A14*AM1=)KK-?="SVNCT4I=K(I !#! D3^3]Y+ I1 ^"@!> 5 .]<@%\
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M%*TX$%590O[W 1%VF%FN]?[@$6\+J1_8\70'MVB-Y/-NQ=7,;E4R7"(J,*.
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MN6?L07>NYB/+T8X@ADCJ%$3]K6$"<:PS*1^/95*KFE,+F^V7[)=F\6HQ]T3
MA,6_Z%RN1E;?0G-8D#R6-VSS#<H%!3I?Q&)A?M&FC'4L%.5"LJ04*P<)38M_
M\E2": BPOT?@E@+WO0*O%'AFH84SLZP+(LEXR-D&<1VMLNF&86/4:C4TU:]Q
M)KEZ2I5.CL])3-((T,SLF0E+,I9"*@7Z@F;%FT5L@:9<[1LNGQ%)Y^CK8TXS
M]2;E,?JA-(<7( F-Q9&2W,TNT.'!$3I -$6W*Y8+)1!#6RJG>CX[*EV=%Z[<
M/:XN(#I!'CY&KN,Z+?+)N^5X\%IN*SX5)+>"Y)I\WIY\U?*G"I9$9TT(Z/>U
MBD97$A+QIV,NKYK+,W/Y;\VE44.->LF9:"59I M-.GUHUV,?8Z\_M-=-8+M1
MWL#M!574*Z]^Y=7O]'H-0JB#&.5)'A,)<W5^5"V)*"E.J%H 21B7]*\9:#-?
MY.\U;'W!SB (M]RWA 4^]MK=!Y7[H-/]+9,D1MD>WBG(-L/!CA//P7V\Y;<E
MRNL';KO?7N6WUTV;W-?;KF.GA56^\--W=;^:J_^QN[J_0Q#C'G:V.+=$.7[0
M;^<\J+P..KWJ(IA+X.^"C9VZT#J?CALWRCK^6.!EOE<LPYZ_!;PM*@C\=N"X
MKJ_8?:.0J"_QBL5S=)6H [D&;59T@:C+*?8^'WM=$'%W1?Q_[+NES55 W6WN
M;6&NNZ>BX+H$XNX:>)GSE,J<@S%\29]TNQ-\7:UP[_/!U[4,AQ\,/MSY(KI-
MH"7WEBC'PUO8[<;]2U]^OQ.^I*E ,2R4S#D)U4O@Q7VRZ$B6F2O9/9/J@F>:
M*W4'!ZX#U/,%8_*EHV]YU:U^_ ]02P,$%     @ @8)94MDMBN?. @  W <
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MAK(7 ,58J;-%8+T]IU"[<-$>1.PER0'I6!3&_A'2<" -3R)M.%N#T.</ID@
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MM5"X4EHDN3!HD/ T^TL?<T=4!$BO08#D F1;H-L@X.<"_I8 [C<(='.![K;
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M%T)C_[7#'&](D"8 OR^%T+N)*=#>N>._4$L#!!0    ( (&"65+Y7 :?O@(
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M:1>8^:40>M>Q1;V]D\>_ 5!+ P04    " "!@EE20=$R:/T"  "3"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6S-5LENVS 4_!5"R"$!FFBWY< V
M8%M= C2 82?MH>B!D9XM(A+IDK25].M+4K(BK\BAAUPDDGHS>O.&6[]D_%ED
M !*]%#D5 RN3<G5KVR+)H,#BAJV JB\+Q@LL59<O;;'B@%,#*G+;<YR.76!"
MK6'?C$WYL,_6,B<4IAR)=5%@_CJ&G)4#R[6V S.RS*0>L(?]%5["'.3C:LI5
MSVY84E( %811Q&$QL$;N;>PZ&F B?A H1:N-M)0GQIYUYRX=6([."')(I*;
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MY4KWC"C, GU_P;EZ&9@'5%WH^!=02P,$%     @ @8)94J'#IE%:!0  !A8
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M.")I5H,W<Y!F/[6&?/'8;)1[+>$N!SL]N]?"?[PPJ0[00D2P_Q1-*WB!KH*
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MR>,E%)CWZ0J(7$DI*["00[8P^8H!3K13D9N.905F@3-BC(=Z[H&-AW0M\HS
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MG#!E(/]?4"H^&FJ ZEIR^#]02P,$%     @ @8)94F%$#GK[ P  :@P  !D
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MK[^IN_!ZX/2NZGP?M<,^NGK,\<L%C%^ [S=:N^>!3]!\"RW^ 5!+ P04
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MV%.<&H6K#./,:(IED=<<B)R39Z$@DPO!?D).GN@;&8. .3.:G$[ 4,;U&?E
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MF93>DX(MS@D*ZCR;%*3[":P,*UKCX1:OY[QRMFB"-1M]YW@)N%5K<OUF1X)
MIA@;9W3!.'YD0)$P!:(%3A]5V.Q(C/Y!81[$Z#>DX?6AJS;G-O>YAXT@#VN1
M*AJ'Y$:D4@/$)"\N,EY) )R@-/:#.[IE41HU54'5X-SV!Q=<U=K<__2V5*?X
M:D:, \X=R)W0%Q.1(F(#8:T1G8,L^^VZ K'W)A0S@-Y1N6(X8W!8(M*Y[&(2
M9#[3Y0LMDFQH60B-(U!VN<8Y&*39@,^70NC=PLQ!Y60]^@=02P,$%     @
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MX;&\E+I<.M%]#)O"Q6&WF5.W6I]BV5=S:66U/<C='D)__!=02P,$%     @
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M_?7_IG:-:U4V1W_6_=2;?P)02P$"% ,4    " "!@EE2!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M (&"65)ABHSI[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( (&"65*97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ @8)94JU"
M*>55!@  0!H  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( (&"65*2>_PTUP4  ,H6   8
M  " @9D.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "!
M@EE2DV;C<6X"  "5!@  &               @(&F%   >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ @8)94ICAWJJJ!   L!   !@
M         ("!2A<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( (&"65*C/9S%&@<  !4D   8              " @2H<  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "!@EE2<+GJH(L"  !D!@
M&               @(%Z(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ @8)94A99I'[S!P  <"$  !@              ("!.R8  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( (&"65+6J!A%2 0
M "X*   8              " @60N  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " "!@EE2A@0=E, <   O6   &               @('B
M,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ @8)94FAO
M'@G!!   - L  !D              ("!V$\  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " "!@EE2A]^:)&$#  !9!P  &0
M    @('05   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M (&"65((' C1AP,  .D'   9              " @6A8  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ @8)94N!K6=KS!@  T!   !D
M             ("!)EP  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " "!@EE2$9W[$]L+  !F(   &0              @(%08P  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (&"65)7W[-6SPH
M .,=   9              " @6)O  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ @8)94D*N8.I6!   =PH  !D              ("!
M:'H  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "!@EE2
M\I<YK!H#   [!@  &0              @('U?@  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( (&"65)=8$]R*!X  ,=A   9
M      " @4:"  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ @8)94@2R?P'H @  8 8  !D              ("!I:   'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "!@EE2JM81C(P#  !@"
M&0              @('$HP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( (&"65*D'LS'>@,  ,\'   9              " @8>G  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ @8)94@T1()12
M P  20<  !D              ("!.*L  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " "!@EE2F6%=YW\%  #$#0  &0
M@('!K@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (&"
M65+QF\FFF@4  -D-   9              " @7>T  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ @8)94E34&)$T P  @ 8  !D
M         ("!2+H  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " "!@EE2^/$WD@ $  !I#P  &0              @(&SO0  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (&"65*&SN@UQ 4  (@7
M   9              " @>K!  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ @8)94B]'5L6N @  R <  !D              ("!Y<<
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "!@EE2JC%*
M0E $   <%0  &0              @('*R@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( (&"65*<X;,3=P(  !X&   9
M  " @5'/  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M@8)94OT:+2=$ P  X0L  !D              ("!_]$  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " "!@EE2V2V*Y\X"  #<!P  &0
M            @(%ZU0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( (&"65)85V(1K 8  "P;   9              " @7_8  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ @8)94M6FL#:Z @
M?P<  !D              ("!8M\  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " "!@EE2^5P&G[X"  "?!P  &0              @(%3
MX@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (&"65)!
MT3)H_0(  ),)   9              " @4CE  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ @8)94AN2&1IT P  D0X  !D
M     ("!?.@  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (&"65*1$7"/MP,  /L,   9              "
M@9/^  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ @8)9
M4BB\ S^$ P  %PT  !D              ("!@0(! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " "!@EE2X_:[)-,"  "#!P  &0
M        @($\!@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( (&"65+O&/M#/@,  &4+   9              " @48) 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ @8)94M" D1)W P  T0P
M !D              ("!NPP! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " "!@EE2" N:/58"  !>#   #0              @ %I$ $
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (&"65*7BKL<P    !,"   +
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4!08     -@ V +$.  #'&P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>381</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - The Company and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidity</Role>
      <ShortName>The Company and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureCommitmentAndContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - The Company and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureTheCompanyAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>The Company and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Leases - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Leases - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stock-based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-based Compensation - Summary of Restricted Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Restricted Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alec-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alector.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>alec-20201231.xml</File>
    <File>alec-20201231.xsd</File>
    <File>alec-20201231_cal.xml</File>
    <File>alec-20201231_def.xml</File>
    <File>alec-20201231_lab.xml</File>
    <File>alec-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001564590-21-008860-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-008860-xbrl.zip
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M1E*GX^KAX3>'O'?\B%A3SW?]Q\4G9^9$Q,["HZ'>82EE^*.9G%*V?.YXK$/
M42*CX:7>J9E+IJ](SDC9W@0X*XJ19-V4H#WIY&6D=99-J:DM4XRRV-1\_>W.
MH3=>=V)&'IY\6\PA;+D* D0?+CZ?+G==\\$/3&R *SSS#?X*30M#F7\YT?0+
MSO[-7_7TJ7AN24!7BC(Q@;T_I.U+.!JF_4_2'SV"P)W(G7$E<.=ZR;UQ G<:
MAYB4P,D9WQQ7X&X]SW^"Y0(F 8>.=3+W4M;PSXIU*\=H:4?HQG2"WTPW)N\7
M5V%(V!E(4=W^XGMD\8L9_$&BF]BSP[RF%EY/__PGT-@,K.GB$WDBKCA6^LBM
M-X^CD/ZNKQSP%];L&BEQ$Y _8^)9B]+1A ?#K\2*@\)>9A,9/%'<&^ CT_*;
M8&2?YX-6,D\&4CG[' B("A8L0=(R$QYE\_?%3GNO%?5?[[\%E'$6]\@S3N00
M)>Y*W.N(^VH64B(OH\A?^\$<_7SRWO?LPTF]H:3^E*6^DHMD$WSCO 4?XZ-K
M,YSBD>XG^("GN3V;>6CF@TLV4 )*9ALLLS0^KL, YRHHIQ+_-GLCH:EBIN+?
MC43])2O>;> ,SV8DL!RL+@%3-LX)5I)^7">XA'MD$_2C.;^2"?II1+U*X%74
MJP3_W#+<2NI5AELY]0U*="F!58FNHPO*E\"'@:+%%Q=F #P@5N:XCO<+/#LF
MLO4GH!V9^JY].YL'_A,CXHFD;3= 0\;-%8@X[:SHWIBEV:JON<PBFV9!9?S)
M?$A_.B=M0@W1\N*5!EG)%&>@-:1A"MDT1>):QX'G1.!!PF,WSG?\ZRQ=D-5X
M4/IC$U8Y U4B(ZM(JE6P@F$<D> L_1!AHZH,"4J?K&62,U(FTC#)BVB2,(C2
M6J?_(/YC8,ZGCF6ZJ9MZ[\?1]-[T;@+3LYS0\O,YPTV]W;O)Q+$(IJ$^L?MU
M?K"X,2W'%?.0]$[B("E>,FANI;7-'>%-\+*/M"%>&UM): [+"E*_%.<7KQP.
MZI=4&;Q Z;=J<?E,GLW@CVO3=28^."7F0:4%%MW &BS-%I)R A_'A7B)HBU2
ML7NC;^XJOC_M>\6R"0NO)ZB,Q)D+2]TBAT7+<AQA>>&X8]SI\^)#G;Z2EO.-
M.\:7G7[MVD+PRGF)"SI@RA-3XL+\J@:Z8B\M+BIP4>+2X,AEC;BP=K+I$)]\
MR\2Z:N+6PC^(1P(8T;.O[)GC.6'$:JQ]_#X'8A(E?DK\MCX*6\%^V;;.1@RH
ME,+2]N$&LOV5A 2/YP-N/^#Q>Y]R95ZR3T8*-V*V#3"B6.UPK'8BI82;S&JR
M%NG=.ZN=1A'=1K.:I.5I]^T<GY<)5?[:T=GMG,RHM.S6?$.Z,;N=D2F5E]TD
M-:;5/3<Y6J^>S< N'FK].)N[_H(0VNVTI+'K"1C4W+HS)ENY\GWE?E27T"V9
MU_RNF%<VYC557],7U+PGXEO*PKS'UKRR>JF'T;R*>4]*\S:&>?>C>4\CS)*%
M>8^N>9L2L.U'\RKF/2G-*RGSJI!LK^QY3N&2\BFE9QU9_3UE%.5GG08:K*\D
MC +'BHA-47@FQJITU<I0[<8R)ZE@CLHI0KF/T<O5A*E'])/V3*31$TWT2E:S
MC.*4@^F)%RPP5M.?4$0_%-%?M&"8:WI)5WEZS>;;L_]MZL>AZ=F?'8]$A'AX
M]R1:W'H6+N:)X"LGP@?BZOD5ECKK5ZQ1Q1K@2AB=?O+'0/'(BWH7QF6G7\^[
MP%<&Q]_C.G.VVW7;2;'V45A[G\S;.)YM&#_EW.L<:TAM3AN=CFD>:[Q@AF8/
M6N,4DC8-X9$&Y7%V9RS%3R>:[=D]\#^)#:6&\$B#]IAV]W-.8H.[@8PE^7[W
M1HPEGA_X$@?6U Q/*CU0D[VJT:$"^ ,QV5G81#EXZSBY<7;O]YOY_2J.IGX
ML*8,\P%^""/'NO)L>B]8?.A$&*1\]9Q5UJ__1%ECHT/P*QB'_YK@[MJ/O2A8
MG)JSO8IODM]+E[^/A+>,Q^$E=^.K&95*-I8<]"W3_>\X<$+;L4[Q=/PZEEV#
M",58-1EKM08\92[:2O$UU$RN9(/4[>9/9!T5:#G1J1/BX^]],[!/EBTRMSMY
M9BT6SHU-E+\DA]IHD,GY2EP8VOX"0"V^@12%)C71X?N%^$L:P5T!*<R'4V.F
MS9'  SD1#8JI]LQ4)[)EVSBFDGS#=D>F.HVMD^8QE=P;)[N:/\5+)^E:[VK
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MG#GNXLTW9P9B_YD\:U_]F>GQ1W$B "  5GF+^+Z, M,+)_ %?.L1]M23&3C
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M0.,&C0&7GKWE [7RRS7_(%F21B11-C_%F 6+H9L0?/L?LT^)$+!U8MZ)COF
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MY E]@XAL^"+80ML/2A]>=2HBHU;B&_,%Y-,J:U<A[%%S!DJN*3&*+44S-W&
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M7V%&3C4>X=;#HGL69LIG#*_05^EO\6%Z$N-?\KN,73\![0\")COBXPQ^ B#
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MNM%-"!/<TZA=31WL-4"ZE&'B8-/AV7J*I1'<<*M#$>H0JSY->IWK\E4&#TN
M.G7GU;EC0A@2?%[Q>A'!B H'OE@X?H@S\MY8PZCZD8<=ZW5&>GPZXJA8!WNR
MM^P;@9Y&@5<59Q]&SW</40^'23["*]XOED&TDE)\58/].8O=.: C/@=.>%S'
M1_1UWJ=0?)#3.'/BE1CE\[PZ>QP/9IW4^FG3,'U2<U(/TDM]P=?/GU]I 2[^
M%G<P/T&\5'(!"3:(KSZ81R5KZ@ZGZC(??B79ZHJ:X@,EYX#Z3=PH"]..>._
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MH1.L$A\O4H.K6ATE?NK?2G5!*&\<]8>\!>CP-<ZMXP?880M['&2HX(2;+;)
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MNG=4/?H.JPA8$6CN+@Y@?S<IP L#_R;SO3SR*G__6CX0=7H.@[+TVP"-?"\
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M;;) L0C1V^@\T1GP"X/L7;189JF,R6R!TCG\30FF!GA%N>1DD]'K50^9/A[
M2S<_;&L\XHJ334"*C.PQL9&&AXGM,M%C8CN0V(9#)K8F($5ZL?W$F[R-*!.\
M+2_N31PEQV[W<@!8>YAKCZ0_K/AH0M?;*V436QS8VX%MV7T.(2.&2@.$C)F*
M"A+,5(V%CIGJ@ (PUU9O-"0+)3,5O6!GWG3>G-HI283CNMDB"YQ4>L*3RUBZ
MOI/Z4:B6R\XBBE/_/^J+,T=YL-^^H=%2[+=O,GKLMS\LS:3=M:Z'8QJZDCWW
MC:C3RHS6,)W(C-9D])C1#F.TH36P^S14)1/:L81&,=S[R8J1-V);^EN4.H%8
M;B_:2B/Z8Y-UPE7D*;N2N8K\\? >FUV3R@8!5Y'?>Q.A:]F38T^N/76$'<DB
M\JQSF1))P\.4R)3(E/@(2NQ;D^&Q.4-:28D:CAR-7<"==Z_]I]2!P2NN\OS;
M(T:H-B _5@>@]\ (;&WSGW_*DJL;QUF^SH.T/P?0V;>A]SY?"G^#M_X21.X?
M?_GO_Q+BS_GU7]VY]+) ?IJ]==TXD]YOOC/U S_U9?(-.UO<)WSOYQ<?_@F8
M]>W)"^%".^&G+W+V\XMW^*T]&O:[D_$_L>!OU^[:ZH/=Z]LO_F(>+8+RV7A_
MXB>IB&8BG4LQBX(@NH,Y_/K91O.IYM.?[%&W@HWJ3W6FJ#EDI/+G%UT82AE@
M23L7>E_\;21:_6UTA2XF5V@&(]8@38&S3.3K_,,;H45_W*U&$W*%^E(!L9U'
M;=^L.LKD2^B1JT')I9(W(/FK=.5B*F/1MRT:<L8E*>F50J9,4XT"D0F+-#8%
M8?7.2EAV_QA7 Q,:]A674S3DCV#T !F42.O*HP2.E2DKTPM4IO8U#0%E9=K<
MU<-6T=R:%>2RI8H,^9WED'738*#EQ&J=L+S\&(IT'F6)$WK)L4<H+NH4+AEH
M2!_!/9QT+FQ[/=]-C&4BG=B=JY!?3][*(%([G:#8DI3K#S5]EXNSVA,+1.)Z
M$,^9M[)O]<?'YN9@T6FO4F-ZH8)$2V6$Z:4!((VL0??8W226G#/JM$O-@$P?
MG7S9*1?+(%I)"<O,Q5*&R6-R.C7:WTD)G 9XGEFI446&[8("K;'5FW#N8F*@
M-$"$F&:H(,$R0A49IID"K:$U[I\[F)%%B'<]&X1.OOQ<QM%,)@FL.9U )#*^
M]5W)FYT-$!WVJ3$R;!<\5*VO>WULM3X6H?:*$-,,%2181J@BPS13GOZPN@/>
M_20&"N]^4D:GLOS<D&>7K"N'#0,J2+!6HXH,&P8%6H,>;WX2@Z0! L0D0P4)
MEA&JR##)%&CUK<'XW G3682:M/G)55<W0?8IG<OXS%X<.AG)*"'3 &\HEYYK
M,GI<>NXPBV/(=>>:@!,9R6-:(PT/T]IEHL>T=M@A5OO<"1*8UAJ_L\MU57?6
M577NEVXYL^N*B\<UU 7,Q>.>/ZG&,SGVN7C<Z6+3>M:P?^Y=Z$85CV.=RY1(
M&AZF1*9$IL1'G J:6+WAB(:.;08E-KN>:EG-=/_JI/6JIK]))Y'OHB3=7L+T
M^K 2I@>@I@J/5F$;=GI S#7<?MPH-L\'U+>YSE\%5X5I@D58 QPR(;]C2BLI
M[F0LA9.8LJS):U'B><!(C(X8B*WS2+VWK754^YW^X[9B*AS!A52?!J1>ISNB
MAU%UW,DGU2=4E:+?&4ZXM"J75B6+ O7B2*29JU$H,H<U#"V72(' 8:<_X J!
M1_KAN=QJ U BIC[MSF3"Y599F[(VY7JK#42)^I)BJVR:54;KQ(H,_6U%1B\H
M&)@F.+M:AQ*78"4+#>GSN$?PT(5MR7]:RMA)80S,OB&67*5ZK&(K!5T8)@TX
MX-+2Y )T2^(-U)J6PXRPMT-K.#EVD<JBTUZEIGQ^C 0!)%HJ(TPO34!I:$VX
MH#<U4$@?3>5EYC_P2XSR?/0J\WR.S@N#A+[+F7496638'JALB5J]X;'V ,M0
M>V6(EYM4D& 9H8H,\TSE]*35YZSVU$#A[4W2\'R=1S%<+N,%[V^2 84=T(P,
M6P2G@NM/DY[=HXL72Q)59'C]204)EA&JR##;E'"-CEU\L@ U:?%)[=CXA6'V
M%;-,X4K4#]UH(57YU5CZBVD6)Q)+L&(.GUMRVZ4G.E5^86 VP(/*A02:C-Z@
M=E3U\0A>NHWRLF?U)N=VDM,]H$H)JG,?T]ITT)\9K0$ZD1FMR>@QHQW(:+;5
M&QU;]8T9C0BCG;OB[,95>(M3RJN:.&=V9^U84K<8F08XA3G9_^4><>)L_Z<\
MAGMTLO^GKNM',MD_Z]P=:W*FQ//#PY3(E,B4^)@M=*O;/?<N>J,H\5+JWVRI
M8[->["9)I"PR,JE[\CHYJ[\Y:1;#OUL+X?2ZSUH(9T"P$(XN<@-#)V#FBG2>
M[Y\OG=5"E\>YDY[(H,6Q^O5=M%@ZX:H(HQR_@4OJ";$2+)X3S42U5(+ 03RR
MDLZZ).PSDN0JZ8P(5-*9=%4-(FH9[IMN*IYZ=^WZ 6<_5R%H3M[L46?R@,2U
M-BWVRX^A9A%[U'U#)A,IIQUMV+D\0VJ7O^8%"\HFN^Q5I'7Y&!QH*RQ\SPLD
M.;<2NXQ((3:LV0B/1.W2W4%C:S+ND862#U70.U3!E@-8#ON)S%E2^K#E0 0)
M5EY4D=$6 AL V-N)98^/70>Q##7) &#7P0D-@&/#H=EU0(5F>/727F38 *@:
M (/^N6,D68;8 ] D>,  &)"UF=D H(($*R^JR+ !4#4 QGVZ_DR6(?8 T(,'
M# "Z]9?8 *""!"LOJLBP 5#"=6UU^V.R2+$,T?, G"K^_<(P^S:7L71FJ8QI
M1-T^-O3]PN!IP+J4$TLU&;WAWJ<3V/# WO:[EMWOTM"5G%B*_1';X+'[G3%Y
MA%0^*3Q9ZB=NE(6I]-:.GI*U\-E?02?>F@\[\&&'B[4WQCVK/]XO^06?=B"E
M%]G300LSS!/R6GR.98+E(@"#3 K'^U>6I&AJT+#HV?O1M/4S>S^:C!Y[/PY,
MV-"S+?OL)\G8_='LO-J;39,G2U79(%>(]GX$>?:R,[L_=A@EG%>TX3X1SBMZ
MJ7X3SBNZ=ZIMV^KMF6O[Z?#FQ*)/X&]Y.+'HP3E#ZTE'O[ISZ66!_#1[OU@&
MT4K*KS*^]5WY=0XH_0*/\S!-I@P3>$$4O@W@$>K3I]D7Z48W(0RD]UG&?N1A
M?M-D8VI2^\E2DX[6)@#1S*0FTZB(BR&#WL$@74UQ@&%PRA'&A*,ZD6GRB!RC
MVT>@]\ (D,LV.B&0;70X[G"R4;)ND=R\'YR]E%]UE,GG/ZRF%K6[9\TM.NAV
M^IQ:=".2_R>=6+R'EGFU)-0T1(Y3BQ[KEVHG8S4*1.8NTMA028MM=\:3P[T9
M3&[85USST1! @GLP9% BK2R/$CC6IJQ-+U&;VM<T))2U*6O3-H/'VK3Y4(,V
M/;96'VM34@)Y3F_,5MG4#IK62149]MMQ) H)D<6&WOY ZX3EY<=0D*DF1N+L
M#!EHFGDF=ROI7%A U!>92"=VYP($1WCR5@;1\A&'8Y[A&.[3<0XE7!J0G*JE
M!P'I5J'OJC4L!WIB;^V!=3TY=L>$9:>]6HWYA0H2+941YI<FH#2QNGVZA7E;
M*CH-4&I,+U20:*F,,+TT :6!95_33=W>4M%I0 J@1P<S7QAD?Y6AC)U >3<=
M;^&'?I+B <!;26/#FD T,R6X&K#GR=E_FHQ>MQ;FP]E_'G2C#JWA@)/_- $J
M,M+'U$8:'J:VRT2/J>U0#VYOR$>JFH 4&>%C9B,-#S/;9:+'S';@>8S_W]ZW
M];:-)&W?+[#_@?#N +. HN&95#()X-CQO/Z0Q(;MS")7 YILV=S0I)8'Q]Y?
M_W53)U('BJ0HLEJLFQE%EJBN>KH.755=-3!P7@T72(&NC2V(*&/C5F]K6[*.
MLS8%/@IV<(6=C\8.KL>:U,8.KDU.X]-JMZ/O90=75+IH$T'#@S81;2+:Q'VR
MM/I -KNN1D:;R)7219L(&AZTB6@3T2;N ;4^&,E=5U!S91*/9=#'P>9T;!L'
MLGSN]72&^>E/*W1N67CX:L(>'/UI><GTQZ(H>9J^EQ\UDIT!(O=]!@B)8O?)
M8J/A'^C7XC<.?2V,+3><C7 -QH+E>4*\'!>2[J%_F+)DO(N$8,I@(0Z$21+:
MCVR^FAT\/07^-&8O_+0BP;8\._'2'TDB*K;ITSYZEOWC#44V\,C\.<(D=-F<
M#N$I<(@W$*8!_\!/OS =/\+^:BV1Q6$D4(:1J/I0W&^Z[D&Z)O'NXS9=3B/M
M5TYSW)VMJO8?,SIM/Z9)0T/'^20\SB<!5Z@!!CCHG3-!&SNN4$2SAVB5#MEH
MV#*Z?HDBCC/A "4P0KA)91ZB ?]Q"QT8.%&GXE 3U*DPL$*=>AQPHD[%T2:H
M4P%>H]DJF+. S?%777QZF1";9=JH=G@2?G5]X9588>TQ#2TT:92P22,,)$K:
MKK;L$B3TM*'R1A]V7?595*?6RQ(S#H0*U1L4)%"]%:DW85'6([T34-6!@X@#
M 4-5!P4)5'4%JDY"50<;(M"MGS'"L(@P/ >>%;N>&[^"#<>B28*"Q-0D]='B
M&.HO;RCM8)%!*P,5&=1>4)#HL?;2?\GYRZ:,F@P81!S(#VHR*$CT6),I*YI,
M0DT&#"*L+0 -SXT;_7@S#@D17*8@2!0+H177G>Z$ 6DH5J>M@'0?K8XXI&;G
MC2 -:T< ,,[<7[E!#08%B?YJ,&FHYAUG>:BC+@,&$@<2A+H,"A+]U67R4,OK
M,F58.PJ NHRG* #F_YN"Y]Q]=NG*'.'5)9X#-H2&Y@8*$OTU-R)&F($APH&X
MH.*"@@0J+H"@H.*"B@PJ+BA(H.(""$JWBNOX.HXWT0I\6YOQKX'_3**8.#?T
MOZ'+RMW3!W_SW3@ZM6-Z!(Y?MW<55_K<57S.'H%^.&W<'2YXF&\-[D9"]!C\
M](5[X@4_]^CDO<(0N8@AW/7V-@#T]M;UH0&O?R;Z ?GF4L;Z[. J&#6 2);+
MX)O49!MYRYTV\I:4X0C[>&\$\FN2MNX.QMN,PW&3G_HX$0S]TJ+_"H;_J..Y
MQP9U/'0@_YVN@3C]5/&GSR2T'D@_B?^#S9SJ)^GG;-#6A>6&_23_SW2ZV(3T
ME/S4L8/A4Z!?Q\M%HVD8YO@S+-]FP=>MD4,K*C@1'ADS,EMU\2HWTTK8HV]R
M"U6_[,1R_%N6@ZK?$@W!,+,.$SHY>W;<$[V,7W64LZBEP4@R!J8*5R5B!0M4
M9-!804$"C=5FZ/X)%C&T4>51U(<C#2R0:)Z:"PD</*W03$A 4H8&>(#^3&,"
M8,O[T'> @@0J,*C(I#X"N@",VE]-71^(B@$6JYY*4=U!66A@^J/&>BH:'""#
M!J:),R9*$$]GS*8B @V5^A_?P?,B",?$K7_V;!8@"#6@D-#A*IA=5/>)&A$F
M>G+9PEWT.]*#K:8/1H8"0U<"'.0-":NNIT*C10.M$U&(>(1KI[VJCMBQVRP
M^5B4-4S2\HX.UFU7K=L>@8W08;8!"A)8"L<M=%@35Q[.T4@=F$K=JFU,6?17
MRM!404$"900J,I@8Q\0X8$Q )\:Q^'K/XFN\N 7%T.#MD?XB@R[ ,D=MR/I
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MJJC\0$(W*C?_%EV/].['0%7E@2GC)")@P,"7,S168)! &0&*#!;E9A*,\M"
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M>HP;%Y4<.X>K%>&)N4_0\)8<G]<<PL?N[$CR0-?4P6A4MS5HPPJWO+9%"04
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M'W$@/-.W-V1&E[@>-5,R&WGQ"N_'<H!6M_!@4KB?\&)2&._'HM\'0$+1/O(
M#TH3%FT?I]G"^[&<( 5-):+% @T/2A-/<*'IPONQ*&IHN! >E"8\:AVGO<+[
ML56AFL(Q1Z,(N&Z3PK_%[%;FXE..^UR#0SF&_))E@+R# UO7_/MO2?3FP;(F
M;V_M1^(D'KD:WSY27#]:$7'.@J<)\2,K=@/_-@[L'U<3]C(ZM6/WV8U?[QA1
M=W15'SWZQP]__YL@_+[^O$_C,6%?()>^'3R1.^OEQHK)#;$#WW8]-WUZ_DF"
MZ[P_N?B+HJS(VHE /\A(OR'C]R=G[%U)UQ31-/YBR4M1$J7TA20KTLF'"BQ-
MN9;===I05G\IX++8_CX[%<(<GUCJ.GXDPIA0R;0\2J<5)W$0O@HAY2G+<;._
M,MPL_S4%_!^F+!GO(H',41!BZV7Z:3=BR?!QX'G!3_;_,/WR*[%"^G'* &>1
M)9\^2=+%=_.+Q.R_TFB0IMCI*U/XU?7IUX,DHN]$_WK;2$Z]#"!;MW;ZNUE!
M2T5PIM3>GXAT7Q'/8VJ+*L#%OV<*,?WW3-7:](=)N%"L,ZU(E9%G32+R=O[B
MG3#5G(:8'6B_N1JD@SN>FC&4?SF08N;</3W\]>FA:AZ*]Y#\EY)(T"53L:-0
M2%3(.H1%%8?*1E@R?N94^)MP-+/\O@\\9ZL[8Y8Q,WN@])TJ>.%33K_GJZ"
M"<\O[7F88#!JINCPT*6C4YN" Y; 6:*LV4%XZIHGN5/K)$E#H^1P]MZ9,#BM
MC- X=8\!JCE4<T>JYJ01#!%#-=<]!AA$0/7%E0"QN# ,T0$X]Q(,2J#O-W82
MSH:D#>^L%^&>^&3LQH(5;\G[=)PQQK@WE *9LG?U-MHG+)8!A9B8<RSV1.W8
M*V=^54:#D=KUQ3H0.0Q(L/P++"!HF: @@98)+=,Q6R99'HAFW>YT:)G0,ATG
M &B9N(4.+=-1P/BK) Y&A@P63+1,>X=AN:XJA@3*;9P6S*<7&%@!/8G EDNB
M_P %B9XJ, Z0F?H)Z 9,W0!]H!E=E].A%#5T0$4#TQ\UUE/1X  9-# 9 Z,.
M]%'7<Z50B-"^P * RSK''JJOQ2UZ&:ZYZ:D.P])%R.BPTD4[)(X;UPV68;(-
MBL>,T?[^(H-GF<Q9QAR(4M<#4U"(L)@#%@ <:+&>B@8'R*!]R=@7?: I:%^
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M<Y+E\GW@.5OMH5E&I@^/S:*EF-YI2S%%'&IJN1J,MF0+#)+GQ"9/]R04%&D
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M@(EQ:R@> $;+^HL,N@(+M*2!+$I@@4(1@HH,FADH2*",0$4&S<P"+<7 :>#
M(,&L)G" [JP7P0Z)X\:8SN1 5C!JALB@&[#CM*D,Z"+ (H4R!!49M#-0D$ 9
M@8H,VID%6L9 Z?S2*(H0)CCY.G#>QH']X\V]%1$G[0A(_"AMX @V<H-> 10D
M4*5!10:]@@5:^D =U2U[0A'JKPBAF8&"!,H(5&30S&2J:T5) PL4BA!F.R$"
MM&AE%))GXB<$;/0&O0$H2* J@XH,>@/+RB=Y(,D8BP:&"@<RA'8&"A(H(U"1
M03N3J; =Z'+=FQPH0SP=.S'GV1Q GXD5$<&;#9I[!1NV06\ "A*HR: B@][
MLM!6'JB: 18IE"&HR*"=@8($R@A49-#.+.V,-#!,[!\ #!70R<Z&YC,>WU'T
M*GXD8==7/>',8X0$#0>AT'(S@U$=PD0OURA_?P"/W>U0]:[;%Y:2NJR21,D#
M !>:-9CPH%D[3O30K%6K'!:[+A1"LX99W6)T9&.H:. 1^B,,HDAPUL>C@@U5
M8> ="A(X;XY;Z'#>7)44L3B09+RH! P6#J0,3144)-!4<0L=FJH*C1ND@::8
M8*%$2X599FZRS)\)/1A3YB=I:R?!\KS@I^7;7=^WQ0 ]IR%>#-#SC!X&Z"LA
M^JLD:@-9UF$H2XS2%X+U+Q@HH4GC32FB2>,9/31IU4R::@Q$#<NI>,"JP*)U
MEFXN.&@[07+O$4$>-FWE^,A!WP6QY0',01?X)0=##+YL<1 R+A$O+L*SUXY+
MW;GT4!(!S0%[[ Z-I [,4=TZNH9U;'D%VTNA!*-ST22"A@=-(II$-(E[F435
M[+K2"TTB]TGU Y>6PT?G/'N8GS<-<TGT%FPT%&OUH""1MVCHAG $W9H_@KX&
MSW!BO1Y49-!:04$"K16WT*&U.BHXT5K!2WH?^"#,12'Y.9F$Q'9G9>2^(UA/
M01B[_\.1P0# X2)TWTN]!CSJCFY!6A2G#TR<X0@-E;H%W6A5T*H<.3)H53@
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M21"YK$TL]:6M'\07G"1,/>U'4MN3Y8XYF>V[>"5,0I<>"=AQ &IU";I,4)!
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MD6I,I(J_;=O)4^)9](SP1QA$T3>?\MMCCV-YM8]D3(\2=]9+%M<2*7#$=?V
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M40NG8F[:FOF-D)^59&HE*=JPIB**UH?:JH5#*&L/1UJ]G[%Y&1676CCRL>Z
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M6<>'Z.IGMHI?+QRB5"K84Y$'F<8&%T$2LL8&4[:</H0D[5-1<Q^DON B(%Y
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M+]Q;%(J'8O*U\&P0GO4WT>JS*0-2QO'.?""UB;T?.0R&^T]\L8 "3;[3V%?
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M+,>UB7TI^"+VP0"?C-@;;(H@]+PMEF&MRH7VS9F'+Y=7*%$@&9J":"C^^82
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MQB7T+ZFM=UE56G.RP#__%U!+ P04    " "!@EE2UP*3GDD0  !J\@  %0
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M\R7%S]/0^J?S/5<1\/H^\CRTM&ZP;_L.MCUKO$;Z;^O6=XZLH>=9#^RUP'I
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M.38N E6?[)#Y=Y>C258DCR086>%:,-M+WAL?R="!<9^BRCC%!#:"+3?&M!+
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MA47IRFRSTF."@H!WYANDQ'B9)!UHKJ%CD26",84/@-6:D("P*JTH._VK7#(
M$5$:6U$UOH5[:R-KR5*$1*).C+9(A*B0Z$1F^QADR"@;(HT^GBK=0PKG/J.3
MO$LUBC)+I?+I47U6. ^V"A*C<C3AW\3AM"L[4M+BEA'9!NM:2%\5JV$</7GQ
MZ7@R0WQ#&L^>(AKP[<+1Y%>;8N;KY,6Q::8O;$6HB-:3=Q#6J8^(SC8%RY@3
M66_KT#K%EHS2&2_KSQ\JJW36VSJT5E(V5\=&[NQ.(<@]X[)W4;V)AF,AVHR6
M;[1A6 @V:VPRVOC+1*L\N51//*+;YAD[4^1&[, 5_[P^:CYZ0>X7,"[X55BV
MOQSO]NF@@DE42XGML9BJP=$RV00!0KO%;TY<K-6]BM!P$B+Z7UCZW^"%5!24
M8@%Z)EHQU0X)N\6(240/AIC+;AOB1RCX8)4<"V\=YA=R,,1,=)OP?H81_O$%
M>0OTB?CA5&JC7+V,-C%P",3ML-,D\9,Z:M;P5<OA*=N, H8O>30QM9HA#%\P
MZ>%J94 8[4W71A6W+HU.UJB#JKWU1^5,C48MU0?ZU^J#75O$^,7Z0$L@478S
M5O=J"U\@J,%.!8[CA%DL58T#CPYG[%-M1FM^ 8UC_\M&5Q_$\ZOUFS70<SNY
M0>=TD]%XE20=IN65L_W1?F6ITW<S+R@FM*A21ALF+C4 >J[EC+7839#!HT+<
M/R*%NP2%16JZ=C1+F4N>V?_67Z=<@P=61ZW8,:O5^,'2J[-(Y1J@2Y6F>D%P
M5L'K A/:66K=X8RW;/YT&%&A>PCK**5.9/#%!?+1!(?L^V>?G:0;^5]"^'V=
MUG,8AA0_12$*[BE:8!*QK J(+L0N)#M@X0VV^\^$U4GD\*SW<510#0T\6VS+
M<&8GQ)4-X*BI0!W<L&.UZ^:9--F<:T]D.) 4W& [@"\N863"M<Q@V\(:Q#0.
MP6 8^NX=8/ VS\C=%"8MND&\FZ_C;A4WMV%X@\!(MCVF= 10ESL650ULJ!:L
ME:M=W910[XMH?DU5AHX<K.Z,7HI6IRU_ #!Z:Z@Z,=MCO]+.3VO2>TAP(3G/
M&[W-4[V)R)J 1F_U'(8NPV_>$B#E@,M*I6NY3!J6ZO!!*%W491))=;JBE*[K
M>CM<I3V62I=S->V63U4UL^^JIJ)0%=\N9[R@[AK6<RE->..36<[E25#RNJ:$
MI1/9"[I0!23I6"^GU%A_L>K[E8C>%]4('OC'WOTQVQ8GM.NU]5Z/&_0PY3?%
MW&IIQW-*3PA]L:DKY4T3%MF2EA';C)LK3VPO2)\ K[DU");9"$/)-CP)@OI:
M09'81G!6V]RL8??R0+BDT^GE2="L_5;+KS+=I\54G?.W).Y=^Z<T\1>*JU'7
MPJM *ZE=*%EGJ]DL52J.U-ER&NF]DNDCL]]O1/,M[JJ"V!?5_/I9%"TIJQJC
MMU0JL)#=Q:JGM6P#'87#$%$?2HT^5%,#.>GIT>A-%5%&A(P:H_=+"F>]HB$T
ME438P'T19?#%3FD3MSE*UBY%9!0M)Y6V-=X )\I^!J.W-JH1ENF9JKRS82X?
MU=V6"7EOP<(5)V_?\9WP8&",4#D/HOL9"0T&&[$J$]2>G=97M%AS-TGC']C_
MGH#TG_X/4$L#!!0    ( (&"65+(_4:'!",  ,EZ @ 5    86QE8RTR,#(P
M,3(S,5]D968N>&UL[5U9<^,XDG[?B/T/6L_+3NRZ;*ONBJF9D*]>;[@LA^WN
MF7GJH$E(XA9%J '2MN;7+T!*!"7Q $ 2!Z5^Z&Y+0B(S@4PD$E\"?_G;VSP8
MO "$?1A^/SI[=WHT *$+/3^<?C^*\;&#7=\_^MM?__W?_O(?Q\>#R^N;N\'(
MC?P7<.EC-X X1N _'W_\>?"/\X?;P:T?_GQV,!A<0C>>@S :' ]F4;3X=G+R
M^OKZSIOX(89!')'.\#L7SD\&Q\=KTA<(./2+P:43@4'RS[?!\'1X=GPZ/!Y^
M>!J^_W8V_'9Z^N[3A[/AU^&G_SH])7_E"/R62C'(_?-M\/'=Z;NS=Q\_G^5^
M>.^X/YTI&-Q<YG[XR7._?O@\^3I\/SS]\/7YP]<OIQ_ E]//P]./G\[./"?/
M*5PLD3^=18/_=/^<L$CD#4,0!& YN/9#)W1])Q@\KB7][\%-Z+X;C()@\$";
MX<$#P "] ._=BFI ]/8M6"N/#$F(DS^_'^6T]_:,@G<034^&IZ?O3]:_/EK]
MG'[K15F#_(\_GJ1?9C_=(?WZ/OGMV=>O7T^2;[.?8K_HAX3HV<D_?MP^NC,P
M=X[)J$9$:,H+]K_AY,-;Z";#R2'"H/07]*_C]<^.Z4?'9\/C]V?OWK!W1!0W
M&*2J<Y"+8  >P&20L/\M6B[ ]R/LSQ<!Y2KY;(; I)2;M8YH)Q\I^3\Y07 T
M6!'^]>%F5[-^&)UX_OQD]9N3I,%)QUR1#D%(I_FQ!R9.'$1B/!8T5\@QG#M^
M*,WPJG7G_";]',_!_!D@068WFW;-Z8R00&[\#(XS+8GQ6T@@SS4ORTX 7,+7
M\/1LF!KGGYX ^15QY+>),]GFB,I&VT00)<O NNE)PM9FVR)^N.E%SAL,X7R9
M$GZ,"%6Z+%U N@[Y'OG3RSX<3\C'9"F,_.< W!.Y $+T:^C^'(7I?V<P\,@J
M<_5'[$?+2S#Q73^JT\0#Z?GW3GO>')>\OHB1^Z%/W3#5Y<;/P5L$0@]X:R)4
M06;H,^%_+4$ W2+C2*;TQ,'/R;PF<<K4<18)FR<@B/#ZDV0DCD_/5DO&GU8?
M_WX'(K(DPSFXA1AOJC&@ZQ9$ZP\#YQD$2214U/!$ :_C: ;0!9PO$)A1&WT!
MC /"SGCRY+S=0T0'>11%R'^.(X<H_ G>.XB,@HATC;M2H8^1]W\QCN@$PT]P
MY'G)]':">\?W;L(+9^%'3O X(PS1F,&CTA!1DE#D 9!YAOT(/)+@RW?!/4 ^
M]!Z "Z>ID?SF!#$045CWO*C0:&**-QC'P+N,$8G\4V82QC$)5<E(N]':<E\=
MY%U#- &$=T]$5TUZT:B%9!PJV"/['R$/TJB;:CWLKCWTD]_I<@J1@Y:5(W '
M7I.ON(21HZMB%#.FTC6E2MM"$C>CK]V*KTAL )< )#^ZCY$[(P[I/G#"-N9N
M?1>Z[;>4M[8LMZ(#[6.??#E>)*F(JS<2\/NX1<]=0EWWB'<E=!5Q[2,MY=%,
M\MZMNVM;_'.Z4Z(;\(U=TR-PR4\CO\41Y>A)]TBK4 9O1RIT0?8%<Q@FC*9C
M-(XCFE"E27@14:OI:(B^+AR$EJ3ST1S&8=1T=RI!7$?$V60$ZVDIL\V-U(RP
MP6VU5F-%)<FF'ZMTK(@AU9!2(D_@8#R>)/U>KG+? B(4M+:1Z]^'JN;\.I69
M8V'TY@NN-:5$5,CP "*B,>!=.2@DS@*+3_PR"DKR>JX;SV.:]_?*\I#B @D0
M59.[+$P12LA534AQU"+C87<:J^!Y%3F020!#8J;B#JJ$@+V\*_>O6UQ@:1];
M3$BI+$\TVI1B?M52*;>WQ+/?D/^54W>N]2;7[(QQA-P-R@YRUU17)\Z<((JT
MS03!>34CJ\Y@N8(A(F'H]Z.ST].STW>GIT>#!=G\D;W=\OL1F?@Q)AS!1>I(
M";GD?/V;"\,(O$5704+H^Q$&TWFZ55E]'T ,O.]'$=H]H&E7&87G\Y7*V9R1
M18HI-ANFIP_U>NI2Y * 2J7 E>X$<C@_)OE'8R3?<.U=")X7^[-FL3<Q,T4R
M5Z]\L#*J8')^[8^<-=%?)O/9^Q[)S!_),_EUFW2+\I=MS9BPF@VYB\5J=Q_-
MQ/UBC+OF6JA*\PJP+OW!1-;MPL16*#F)<_(..6(VS>9;D>[:6)=J\HE,9/,]
M-F\@OIL%9E+JMMVVI*S/UV<ROS_MI\P\QS!,"<.>**'ZJ(W)JWLWU:HYRY^B
M9@KY\*G?"N$^8V<:Z8LOY(1:9()_ZKEM[ !H,LD_]V4ID,!(94KXTI>E0 8=
MQ[2P#]9? 8Y<*^+LM.<V48^19:KHRQHIAY7.]*!]A]]4#W(H^4S^8<]-@J_D
M(5/'^[Z819-"F$P;'_JR?'9?0I7I[&-?(L[&=7J92C[W91IM%69F G[E=J)_
M.=F2C_3WT_#:XW0\9R#R72<[-U=?B%S(1K^JDC=%E"G#HQZ?7I)Q 7&$*1=9
M!HD'CU%+0JHT,$]P/-G4AA17NT240%R(YR?!=5/8;R49&\&S!^CL =)5P?'M
M =+5"TA7Q2FY07 N)4?&%J"9^(Z,*]<BFT!-'"F2Z@""P1]LWZO4QG 2X):.
M=RWLDK^G&: [3B=<DC#YUB>Q,=FJ+]F&_2:<0#1/-N:7%*H49*)7[D?:Z$#;
M3J,1\PKBA'L$70 \?$TFZ7K>">\\!(AI+?-+\V=I7NW7!0S9(:Q0$"U#_E!F
MVM;LO*'6Z@3W\7/@N^,)T;^@: )$E43JN5ESC](D9?*94,!>3D3[Q04:KYPH
MR6E<PR" K^-P<[CYLP$<1 [E=?TKK^M3@=J8K$PC,H&38Y44?2 ^ARJ(J)#A
MYGXLSG.ND9(Y0WS%:B=WY\S)_SXA)\2.FX1YPI.?AUH?I5)6@AH_8Q*6TZ-X
MQI.P=9<3D5JMQFCJA/Z_DIT!.Z^@.]:0K/4 $]M+_AQ/LHO%,P>#<_L/WK1E
M!YWJE%LH =I1QTISI]TJ#W8R07J>L>W.CB&7WS$QV5M9$E7KAZ'H\F%;$6^[
M&K K_RT07L#"R,ZJ[+>4L!6AMS'%@(:X1<YK#;1C*?44]UM03MA*<?]0M]MO
MVQ-P)*%8D9FY9;*=1ZO2-3@?=#L$$Y16GE=F>C+WT%69G@3.%)C>=,?B!NA-
MH#K:X+I09>J2.GJTH8Y4JZ&602P^<L?/RB 6C_%\3JR%1 G^-/0GONN$T<AU
M:5T]7=&(QEP?X!8A%^UU:  $HP5A%"2A*9P\I'4L85J707JG]7\4#;2J7/F7
MV#L%G 15)-A+6/GAO/GS>#X*P]@)\E]B$F^L*R+)_[J"]X&WTIU4\IK&\OB'
M3_X5D4T+=^IYNYE4WY?@!01P0=VB. ?%C:7X> !>G&Q>;L('0C6,P64,GN!-
MZ"+@8!(?G<?>%$1I-/Y/X/"?O4M0EI)@-0><*5TC9DXX):2O(0*N0V&(5V\+
M0,OP$IP>-^]"-!7!I2)$=IE_]Z/914P&? [0K>\\^X'@M>XUA+3+LIHJ<DY4
ME++4?+NC)8N3./1H,NO7!8F-PNC>65)C)+2!_P*2BD<\XYYM A2E.+Z  >F.
MA/#TO><10G0^4^)L$<V\R*I;G/9+^2&F0.*Q*7+FW/*TUE^KTN[T.0[3G&SZ
MF'-VK4.+ LMTJ1JRQWB'2.@(O8)(J^.V:1#\/IR;GA(HSP)01L+I;;+VS1>.
MCQ* N>##I=5T%,T=PD.TI#%:1#9]-"F01"*_8N+#@EM_(@2*Y"*G0JX?#OH)
MDOIJ=K_3+V0K+#I"U7142/)K2 *L@*YPZW[') 9[ :OR?!%A:DG)E:N&(21K
M<73NPP!.?5?@A8OJ]FJBEV*WDCL'H.''O4,F]1,L71DDL*!M]JODE0S6+2:6
M3:(<IY!MB0=.A$GOE[RJH'A/A/7Q)!_A"<+P2@A(>971\_-O/B ^(0+N+*2>
M87GKS^E]*X+NI9Z0A&XQBG)Z)7]MZY1\1+;,B]5E4J,I JO+#^(P FA!S9H>
M./(C-P4)]D\F22O@DFJ[1]Z)7]ZV*TY7>31^&RAHU!EO?BC!VV:CSN8M=4EB
MG&TT,9.O+FTBZ4;$$'(-E$3X9".^3,/SZSCT));A,@IJ7H5;WRA&,T$D"*#_
MH;NE%[)HD;"@^%.9M^.:]'/0A-H(K)@'T3"LBHK<R0K7(9Y8M8,0S0ZYOA6N
M51"FJ[X4059T*#,X^U!((&,!D,\B;2L4X/!1L#VO:UD-@3KEV%5>T,HB#^M#
M-V.J$#IU*UO1-JL^T V?K?8@Q;L*6+BK83+IQE%7VCVO2'8\_U:V(86%6W4;
M'G2KDV@S,6+/JVU-O4=QTLJ69]QJ4W90(K=H3 U7O<=I578[GG:3RSU#[C,
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MX<>R-MH=2AYX>3N4/)A<\L"N*T]<M=0M,D4$C%C-+03L'^#Z![C^ :[/.#G
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MWH&(XFW7S+)(Y-(/8@I.3N6Z>G.#V ,>]7(73N#&:7"V^AGPMLC((1N5\&(
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MVTE5F=F/F>J9Z;5(/6IUH\J02<KJ[2M;:Z,8"(E3""*:9"BE_O2'!Q\@@P\
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M.?#Y"&\RROY_8U@^8D5^-%@F[-S[C-QKR,_Z@G(<*Y2/?<M<O0M$M.ZAB N
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M;*'FHAU1\@73<D**"(%&1QD-"?H90AP?7E2SDYRNF#Z*&*"X^&'/?HQB!EY
MT/[P0**0?8?%!2:::&#'GXB*IT.:9D!Z<)A!KSF#Z#_ "!-FW1D!8RO_#,1)
M+0X<FU+T%)@7XJ<+&[YMG%;GV#%0U+6'76A^*Z*)^-MZ+WK]7KS@)(Q2LVX@
M%L3]1.-69AZ./^6DN9M*CZ9[0)V2[;'6'%E[U+PX7'5'7/F%7 94"@'#C65T
M\>7'O=0]!>BY/7EAX^U8MQY4^O)@UAZ307NV"#X7NSVAKUB&P1NFB*<@Q3=,
M]:X&Z1X&?@)Z)T/W+EY0/YZ%QQN<()Q+DG^X+[Z]9\* =GQ-R] <T@< 6:05
MZ [MA1AY)"@-YJ;7!*8?WSO5Y6Z]W<?"TQ#0S1)4+%C8A$##5G1G!4, +=0N
MM.<'?>%AZF5\L]C*=<K<CKZ[XK'Y$^IWC",'O6]W#70N?92)]-0-3I%IG\\<
M.NL+763B-30P7UM,)XY@F*,&JXPC,UAH2O<6IUD2A5E^2F7U)4@VES39XB@[
M).YV40?9^%DW#+#U47E1D?_^C'L((?*6"6;[22G-PFJV=(U$<PFIA<H2#<)P
M.5D)DT</(0Y2Y($1*&3\ZE&=P^3Q !=/2XA>KK]%"3?8&:XF-3!9H#68KBG[
M8\3DR6?EKJ1[VM'(2DC^P!:^&][7!L>I,.U;S.;)*1.931>?HQ#+U[S%(7V,
M!141$TWBB']9QO3X\BN;CY.LS+I.A3CBKHI"'AAQ9S*[HU-C^-9M+(]TZB5K
M]Q3U=*:K1$:JS*@4&N52%Y%2D5M.K !=DUE<RW5#$W%7WLAC?J-9^;D\4(/U
M;Q=5.K45S>LGM8%9N%WD06;HJLCJZCJ4B^3SY*"/&Y?;[GWCMT:%AG<F@FB(
M<!$7RZ&+XOHCC8.ZH$Z;-U^D]T0REF]IW#0 ]AG=$2I8U '=(VL=<S:WX[JN
M(JU^QK/D_/Q/^6HZLX1!$I:7<'63]'+?5KFWP/<*FAOP$*[5TD"):JJN_SXB
M#2M9;^MMIJSLY)B( TMI$IW&5AH1!YJY=,+59C#M&ISD"BNQI7<QMA=>+YD1
MR;MNLA[R(L7NIGF'M4D3LQJ(40,5 D:'. $&1CAKW5.OQKVVF=3=\&X C'<C
MC=?BG/CRRZB3)(3YR0!(NGLT$%ZE#9-4'NS6N;U&;W["5AS,:O\I4XW\]MOU
M]G.*5VF*M9)=PS0L9R<]-+U,3E1^*.$,N<$<4HP"SA/"W$0'*JJK/KO);!PF
M.$CQ.9;_7L6K,$P.>',=!0\1$;F[5;S)/SQC!*,P('>'_9Z\"NO5G_&.YV0[
M+1[+V<_<.9<*%6+Q:\H#*0,BE60BP51\'N;"H51()^NY(%BR.SNB;E%SY!77
M_!^%\PBS/R;ES*Z;I/T:[K>;G/'ON.D2\9EBN##-LA/(;KMKUZJ58=TD-,1X
MDUXR$6^"5[$A=TF38D)P)7L-W(A6 ^N\TX"VJ=D1MS0^&V9>S+$0!''8T;?[
M7!:TI<GOJL+OYD&2($7[(!$S@J"SQP,$"QYE,70T6*.MO.!1FTU_WM/XDA)"
MOZSC.E>Q9U6;AEN9OP.N#OQBM!03.$RGAXCF)ULAZ"G[2:_]"32/<6=];:[D
M"%]G(\D]527JN EAU'"BR<'AF*+%<>Z!I7/+#9H_V%E*WS!B@(^5G9_G= HG
M$G[#QJZZ:Z5LUD8.&[P1JP2^XYHR ?EN:[5$L)F]>^)NZ1]>I/'B.X6DY7B1
MGSQBOM,<25(V^Y+RY@M@(3&;G0F1:ZM?8(L+OZ9)_8,^R5Y6<5\("P]!^G3)
MQL5T]9!F21 :U=[UTW%P74H+74\7I_!\+V.%!"_T2\$-RE:6#F!M-]AT*G *
M,V-S*\Z=C5#/$?."CZ^?4^X+ZSU.6$B*'U=A%CW+G)&%\=E0MS=)<VX>[A[C
M!KH5!BJF/[1@SH)QP?W/, QV!/1TO-*7!S.I"A@%RH4 Z.,KXB+P:O!2"%1)
MH16IO#@WDW ;9;R.T\1IU:?L4:JH^*LAA>%'+5JFW7J H]'<GB5946D\YZDL
M?APB#B.":_7']]3CZ.2'OZ.3,8[D\7#;N'(D)J,H*>04B2U1V<T^Y3^'/$@>
M4KD^ 3P.>C7#KH-93N%]BR9'CJWMGJ)21'$H0CTDP?ZXD%'Y'.^9TT1BQ<\7
MF4I]@DGTZB5C;Q$]9-W'$I69S%@H[&!$!QVTJ('Z "-#6D!AC-!*"Q0_61!^
M0.%C\R"H4?ZC@\*(S$<KQ:_M:/, ,E1/7S!1*#)/G 7Z>'2F=^II<A@F6#B]
MXH?K[7F4RGPE<]&;!.^BPRZ]BI]Q/EH:380M.8R8=UAQ]-'2I%;M*$]B"+9E
M AT7?]D4P@$_K#O27J@;E!9F&XU99XE[S3S66U1*(4;&0@ZD"#*^FMI[P6]M
M.=>P?U'P>TJWIV7![Q+>B+2\C&#$,6.LD. U=8>%8MDA"N&N=OL@2L0%\X8)
MN7XZ(\[ ]]#U< 2AI"^S!$5QN8FM3=;O0 <Y:J))R"CESE.MD@4GI  V0W+P
MQR"*.=MU?,=""#_JPU-(V2OO2ISQH^+[G6$7$EV*]E#I<? QBQ$I$+'AQ&8I
M>YH&1,YE)'\QE\$%?U&"!L//#$&F=JH&#FC="SE+F=%:QXASE6?/<B %8U1R
MGM@GCTN\RYB1MT&R2<.;4+6'4I^+ATWA)R8>3AMY<#'>"==4ZG. Y,0MD*;V
MNEX.JKF3'I]!JF69BYY@LZ68C]7"5BIL--\415$7+SR;P6N<1/,A,3LVFI/:
M<G )M0Y''X-MSA=AR5#Z,!5-G,)#PEO4@)K,CC2&7K_6AV!AP&OX>V$&9<UF
M+H?(#,B>7JL!,YAJE.;"5#MV#IR]G:+3.-["P8<S2Z!@^VLO?OWC;J<6@6.E
M,]X*Y)2]71C.UB@C'N=G1\1<PM8@[B&WV"A*A^I?79#UNE:K]L##T^=0)5PW
M.G MJ(- PR;-.P6\&4T,P"\TH$@DM__SSPNAD)1*-F&9/=R>T5@LL?X:94]G
MAS2C.YP4;_ Z+O@.D';IZ[VL?-3=Y%/6!#_CN*_U]+R!60_<WC"MH=F% =GG
MPP5[Q/FC0H#2I5]]!#(_S3-4<[UNMLA8SFOT@25?ZUKGM:9<*'YBGBK3&(8G
M/^WH.E^(M/)Q;Y1R^4%H_'C*/M[IF^?,Z\A^>(=7DSWJ71*4PRO+BOF,/JI_
MV,G$0TVH3G%0RY%WTBP@N7=^*@X@[(MZ\(=7]&U^&N%WK<<18'BM!>!6I_&F
M.X4W[^D[&/XJZ\-\G:?MI>X<XAYN_L_31@5S>.>(1D _[,&#2E\>S#H>70H!
MXN1.U;ME%?[C$"6X5@^RBC=6=4DF5$><'M7FXF7+M+A4OK,J"88/6R!,[76\
M #0;9X6+7D[\+C3)N%F;Q#.&<]4G'6GEI[)*_ZXLTA_EFNT$'>+8QL"W0P(^
MRV"&:)\K=BL6-GK##E@Q17<:\/GJ-%%V..-%BRP*_!1D7);7]7:T%YH3']5E
MP8R9^SEOSH]/=8![IS7J=+3"%X=PX<%%=T3.7A;X\B&SD(!7^T)P:/U%@9_U
MZS0+&H]YIZ+Q1=N"%8;W6D!LM4Z=;GTZ[[H4AH=>1G$0A[XR3;W4G4/<P\U_
MIFE;,%],IDD'^F$/'E3Z\F#6\>A2"--,D^Z.\PR-_SNJU_7;F'?T]^]H8KY(
M'?7-SLK5%I,!E9=/Y5(@*08JY'#[]D!:X*L!TF/_^S>INU:3*JVH<7D9XO(A
M*2 _^=<PKN(.\/H-:'X<;L+.\;KFU7,U\X21:$+%](>C>]JPHTH_VK<4^D\#
M<?[K/6_%D%Z\X"2,V$AKG?9I)^8H"=!&W+>!9T\8X9P9-V J^?/FB?LB-ZM_
M2>,L&9]>@+LR/-VZ!@]F>P9'1.^<(2HYSNUX?#/&/LFJ4'"(BJ XY< A)R3B
M8[S;$_J*<?Y9Z6)[)A-0UZI#V.=/BF)APM7C.8(+V-2)GY3)-&OHB8KJVO(D
M,#S* F:K],AT:9%YTR$3>RF7C?^/5Q,\LTDYF_G>XC1+HC##&_Z'5;RI?Z!\
M\X8MF^CFN*R87_;"WNKB)10].6Z##%^P-999<G1JR>Q-:UI)_42<J/W>5!Z(
M3F0XPI7,)Z*J*"E?27P!1CB:R9[IO-;P==DN4?82Q'\4D5 EK/P;W_=M?J9^
M7[X#:CNBD+\&*MX#\1=!\DV6%*8GB[JS&:(;N]H+4[C+@B13MJLTPQ\*,O2
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M46&+<KY0/%,?2&JAT06 1AIXK=KQFB==TW4J<,1XJ$UR5)\5'1:^#K ^ #W
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M/I[7VF#%FZ).W$W1M1_^7L.ZL3Q?6TFV5YLRFPI88O46[<=TBE KUN;3A/*
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M5V]/V E"2(>Z!Q@B3P[7HN_;8W8)\)RLLU\Q>HT62NN@A$1[*W;I^/YY',(
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M&<-RD-4\Q6S1>\SKO0>8\:0H3SFY,:NU=Q?$0O-F^S-F&D'<W\P</-M/D)K
MVVIS#ISM9TE-P!6V*33RI%PWCFGZPW ZVP3YR=^R6&'F?$U/UC\"A[:/Y29:
MWF-M,%C?7%D540Q8[M\!39H$WN2%L#3?/&\QG;&UG5G:YTX(7<+L)?3C/9"K
M;;GJ"";\EFU08VMU&XA92\J0?[D;XU+IW%1)QE@M<TG ;O+B0)_F-5TC_.AD
MRQ,FWO_$(;N[. <SA(GJ<WTG#-/WY_C?*_6S,LB4"8S):)Q_&1QV/C2V'NZ(
MBMW>*B<,;,HMI">Q@I+16G$U_ L_-\KW!BTUKOG')GC^%01D7)\HXHFWA %[
M>H8VQ558.K6D#'5* ,3+I25ME^ %^(B5A2A(4T.HD_6D$BJH(&)F/EY $,MM
M!?Z-4K>>S>?7Y#SS*WU'263HD@]-($0?99_.-F-?4?<ZA,10WD*Q]D)"9 S.
M-$6O*%/LZLWU8^K(TBH)\G^>I'>A1-[D"E?9G/O?&HY&)B9R]Y2U^6FSP*08
MZ3X%.J3 0%6SR.,<=L<F2]?^/CIR&Y?W,; [UT $P$K-SH&R.QY9!52)\>:M
M'NR.<4MLPFQQ8@N-'/J48:%!KU>XSAQ%NS-ZZH\@2/C(Q,OR[5954IC5'IJ'
M4G\NA5I!L(27"H]Z352O90-D;99:VX9?38R45UW;[;QJ@'(G5LZ1L[L"1=<B
M-'/;PBN][39!&F:E\F:PS0)PRU9W[6TQQ])N!UP#EJH)!FW61/<M66<Z(S\F
M^$0TLG*_E86E,17FV.^\:-4@<Z?AR+U-XU&5RY*\]3]\>.R?&KI! DOZPB)>
M)TAN.W=.EK3+S22*,'R.6:?*)Y34"$C=*\D2[U#R1K-91\ND7+I? #3)^\'E
MS=04/M[39]J)O6^XCQH/9>;UO]3]?T(E];1L8SP[(6!^"!&%69@'0!9:""-R
MUL OT*5Y^A!YY'B!Y@&C(MW^O7U>C.WD)'G\DIS!@GG"3*)=>-?)Q"Z^.M@C
M1[89V$_4%=CQBJ-TB *;APKV8BR7.-)H&*5<D]1H5,[ '7AE?R4DC!K=+JQM
M!=I2$C>CW_DNOB*^-UH#D-0KQ=A=$(5$.Q/K6+OU0W2]?TMYT[5S*P;H?.[9
M7T[9*3B\>@/8A:%&S5U"O>L9;TOH*N*=S[221NN3]M:NK@]%/R=QB) LJ%Q,
M@@?%M<VHP$A=S[0),$0'ZJ0R_F![%/0KRF-??.<P(SN&,X9O80!NR+]*JHG]
MKPV]DEP<@/X.Z!6(W/:O(65$'GI5.YVQ<2_1TH%2+G;1UT;73I:!R1M46T+[
M1,SD^.>;?,DOH#(*AEY_KNOT)B^0!%$SD<O" *&"7-6$#/LL*IIJ[V,CE>*)
MWT 6 0K(-I573R4$C&JH'1Y"92U53,BH+$_46U-B?O.EX4HD/0^B"Q+L4UJ'
M;-/$_"SQ?C2GP\B#R:_K(F2*-Q\':B!)F97*#-4J7H[7%ZOQJC9<Q9V-MH:5
M8_33B)& \\3+(NU65N)XB3O1'+NS$;NJ$Q4'RF[%)6$1]P_->6MX:C](I<$'
M5!TAX?6UQU:OIHK8$I((@W&X[-;P$ILO$_3DZ Q$->V'BP7[OQ^?:D_K7R47
M=9&#H\/"J?[BHL4F +:@)G*CQ1L&:*_/.5@8!?NYZG_PZ& 1:W@ISCL+Z"NV
M^Y9 &H Y/6E8 :=PPD4;G1HLQ',W:X>W'1A(N$Q]$1:B9G>+B^9+K23-CQ>
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MONJ325[]G5J'L=Q)#]6>2GFO,CO-L=BI'E5&'3A&9U9C)*?P!$),O ?9L97
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M!I?Q4CQ.7?!1:[R18Y \;_F/VN+M@<Z='&>Y3UKE2^;=KLP')G;>%7'_T!J
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MLT@V_(.T")257W6W:,7X.01D,_NL.S@KF#B$/5ZOPG:<E@= ;^O(SR]0P-(
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ML*HYS79F/HUY$+WT[4M[,Z43]\G Q)GLO)9F#EW-9N0[^$)$)U^")^?M@>!
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MN>IHXXFS?F82ZT$R:V9XE8B^8CPKL)-T05JLMK%P+\LZLVV\MC8L=-MY!.V
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G+3(P,C Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  S@\"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
